JPH07194384A - 免疫グロブリンｄｎａ含有発現ベクター及び組換え宿主細胞 - Google Patents
免疫グロブリンｄｎａ含有発現ベクター及び組換え宿主細胞Info
- Publication number
- JPH07194384A JPH07194384A JP6241576A JP24157694A JPH07194384A JP H07194384 A JPH07194384 A JP H07194384A JP 6241576 A JP6241576 A JP 6241576A JP 24157694 A JP24157694 A JP 24157694A JP H07194384 A JPH07194384 A JP H07194384A
- Authority
- JP
- Japan
- Prior art keywords
- chain
- antibody
- dna
- fragment
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013604 expression vector Substances 0.000 title claims abstract description 33
- 108060003951 Immunoglobulin Proteins 0.000 title claims description 38
- 102000018358 immunoglobulin Human genes 0.000 title claims description 38
- 239000000427 antigen Substances 0.000 claims description 40
- 102000036639 antigens Human genes 0.000 claims description 40
- 108091007433 antigens Proteins 0.000 claims description 40
- 108090000623 proteins and genes Proteins 0.000 abstract description 104
- 238000000034 method Methods 0.000 abstract description 68
- 239000013598 vector Substances 0.000 abstract description 33
- 210000004408 hybridoma Anatomy 0.000 abstract description 25
- 239000013600 plasmid vector Substances 0.000 abstract description 7
- 210000001236 prokaryotic cell Anatomy 0.000 abstract description 2
- 230000003044 adaptive effect Effects 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 description 123
- 210000004027 cell Anatomy 0.000 description 101
- 239000013612 plasmid Substances 0.000 description 60
- 108020004414 DNA Proteins 0.000 description 53
- 230000002494 anti-cea effect Effects 0.000 description 49
- 241000588724 Escherichia coli Species 0.000 description 44
- 235000018102 proteins Nutrition 0.000 description 42
- 102000004169 proteins and genes Human genes 0.000 description 42
- 239000002299 complementary DNA Substances 0.000 description 31
- 241001529936 Murinae Species 0.000 description 30
- 125000003275 alpha amino acid group Chemical group 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 24
- 230000027455 binding Effects 0.000 description 23
- 238000010276 construction Methods 0.000 description 23
- 150000001413 amino acids Chemical class 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 21
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 239000002773 nucleotide Substances 0.000 description 20
- 125000003729 nucleotide group Chemical group 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 108091008146 restriction endonucleases Proteins 0.000 description 17
- 239000004098 Tetracycline Substances 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 16
- 229960002180 tetracycline Drugs 0.000 description 16
- 229930101283 tetracycline Natural products 0.000 description 16
- 235000019364 tetracycline Nutrition 0.000 description 16
- 150000003522 tetracyclines Chemical class 0.000 description 16
- 108091026890 Coding region Proteins 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 210000003719 b-lymphocyte Anatomy 0.000 description 14
- 238000004113 cell culture Methods 0.000 description 14
- 239000000499 gel Substances 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 239000013615 primer Substances 0.000 description 13
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 229960000723 ampicillin Drugs 0.000 description 11
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 11
- 230000008707 rearrangement Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229940072221 immunoglobulins Drugs 0.000 description 9
- 229920002401 polyacrylamide Polymers 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- PLVPPLCLBIEYEA-WAYWQWQTSA-N (z)-3-(1h-indol-3-yl)prop-2-enoic acid Chemical compound C1=CC=C2C(\C=C/C(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-WAYWQWQTSA-N 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 238000011065 in-situ storage Methods 0.000 description 8
- PLVPPLCLBIEYEA-UHFFFAOYSA-N indoleacrylic acid Natural products C1=CC=C2C(C=CC(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-UHFFFAOYSA-N 0.000 description 8
- 150000007523 nucleic acids Chemical group 0.000 description 8
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 102000004594 DNA Polymerase I Human genes 0.000 description 7
- 108010017826 DNA Polymerase I Proteins 0.000 description 7
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000013613 expression plasmid Substances 0.000 description 7
- 238000001502 gel electrophoresis Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000006798 recombination Effects 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000012410 DNA Ligases Human genes 0.000 description 4
- 108010061982 DNA Ligases Proteins 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241001646716 Escherichia coli K-12 Species 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000013599 cloning vector Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000012869 ethanol precipitation Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000016784 immunoglobulin production Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 230000017854 proteolysis Effects 0.000 description 4
- 239000010409 thin film Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000617590 Escherichia coli K1 Species 0.000 description 3
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000003519 mature b lymphocyte Anatomy 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 108091027963 non-coding RNA Proteins 0.000 description 3
- 102000042567 non-coding RNA Human genes 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000004513 sizing Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020001019 DNA Primers Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 2
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 2
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 2
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 101150016222 SNAT1 gene Proteins 0.000 description 2
- 101150006914 TRP1 gene Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000003277 amino acid sequence analysis Methods 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000004754 hybrid cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 102220201851 rs143406017 Human genes 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 229940043517 specific immunoglobulins Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- WBQJTPDOGLYTBE-VIFPVBQESA-N 1-nitroso-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CN(N=O)C2=C1 WBQJTPDOGLYTBE-VIFPVBQESA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 102100040193 ADP-ribosylation factor-binding protein GGA3 Human genes 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
- 101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 241000908115 Bolivar Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019776 Hepatitis H Diseases 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 101001037079 Homo sapiens ADP-ribosylation factor-binding protein GGA3 Proteins 0.000 description 1
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- OOSPRDCGTLQLBP-NHCYSSNCSA-N Met-Glu-Val Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OOSPRDCGTLQLBP-NHCYSSNCSA-N 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100436483 Mus musculus Atp7a gene Proteins 0.000 description 1
- 101100205189 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-5 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150010978 PRKCE gene Proteins 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 101710088839 Replication initiation protein Proteins 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000010856 establishment of protein localization Effects 0.000 description 1
- NTNZTEQNFHNYBC-UHFFFAOYSA-N ethyl 2-aminoacetate Chemical compound CCOC(=O)CN NTNZTEQNFHNYBC-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 239000004247 glycine and its sodium salt Substances 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- -1 isocytochrome C Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000007169 ligase reaction Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010405 reoxidation reaction Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940081969 saccharomyces cerevisiae Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940029258 sodium glycinate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- HAEPBEMBOAIUPN-UHFFFAOYSA-L sodium tetrathionate Chemical compound O.O.[Na+].[Na+].[O-]S(=O)(=O)SSS([O-])(=O)=O HAEPBEMBOAIUPN-UHFFFAOYSA-L 0.000 description 1
- WUWHFEHKUQVYLF-UHFFFAOYSA-M sodium;2-aminoacetate Chemical compound [Na+].NCC([O-])=O WUWHFEHKUQVYLF-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/40—Liliopsida [monocotyledons]
- A01N65/44—Poaceae or Gramineae [Grass family], e.g. bamboo, lemon grass or citronella grass
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/30—Signal or leader sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
(57)【要約】
【目的】 有効な構成成分を有する免疫グロブリンを生
産し得る発現ベクターを提供する。 【構成】 第１の抗体クラス又は第１の哺乳動物種の抗
体の不変領域にホモローガスな不変領域と、第２の異な
った抗体クラス又は哺乳動物種の抗体の可変領域にホモ
ローガスな可変領域を有する免疫グロブリンをコードし
ているＤＮＡを含有している発現ベクター。
産し得る発現ベクターを提供する。 【構成】 第１の抗体クラス又は第１の哺乳動物種の抗
体の不変領域にホモローガスな不変領域と、第２の異な
った抗体クラス又は哺乳動物種の抗体の可変領域にホモ
ローガスな可変領域を有する免疫グロブリンをコードし
ているＤＮＡを含有している発現ベクター。
Description
【０００１】本発明は、免疫グロブリン産生の分野及び
天然に生ずる免疫グロブリンアミノ酸配列の改変に関す
るものである。詳細には、本発明は、組換技術を使用し
て、脊椎動物系に通常見られるものと同類(analogous)
である双方の免疫グロブリンを産生すると共に、これら
遺伝子改変技術を利用してキメラ型又はその他の改変型
を作成することに関するものである。
天然に生ずる免疫グロブリンアミノ酸配列の改変に関す
るものである。詳細には、本発明は、組換技術を使用し
て、脊椎動物系に通常見られるものと同類(analogous)
である双方の免疫グロブリンを産生すると共に、これら
遺伝子改変技術を利用してキメラ型又はその他の改変型
を作成することに関するものである。
【０００２】Ａ．免疫グロブリン及び抗体 抗体は、外来蛋白質,糖蛋白質,細胞又はその他の抗原性
外来物質による攻撃に反応して脊椎動物免疫系により産
生される特異的な免疫グロブリンポリペプチドである。
生物が外来細胞による侵入を克服し或るいは外来物質を
その生物系から除去し得る一連の過程は、少なくとも部
分的に理解されている。この過程の重要な部分は、特定
の外来物質に対して特異的に結合する抗体の製造であ
る。特定抗原に対するこの種のポリペプチドの結合特異
性は極めて精巧なものであり、個々の脊椎動物により発
生し得る特異性の多様性は著しく複雑で変化に富むもの
である。多数の抗原が反応を誘発し得るが、それらの反
応は殆んどそれを誘発した特定抗原のみに対するもので
ある。
外来物質による攻撃に反応して脊椎動物免疫系により産
生される特異的な免疫グロブリンポリペプチドである。
生物が外来細胞による侵入を克服し或るいは外来物質を
その生物系から除去し得る一連の過程は、少なくとも部
分的に理解されている。この過程の重要な部分は、特定
の外来物質に対して特異的に結合する抗体の製造であ
る。特定抗原に対するこの種のポリペプチドの結合特異
性は極めて精巧なものであり、個々の脊椎動物により発
生し得る特異性の多様性は著しく複雑で変化に富むもの
である。多数の抗原が反応を誘発し得るが、それらの反
応は殆んどそれを誘発した特定抗原のみに対するもので
ある。
【０００３】免疫グロブリンは、上記したような抗体と
抗原特異性を欠如した同類の蛋白物質との両者を包含す
る。後者はリンパ系では低レベルで産生されるが骨髄腫
では高レベルで産生される。
抗原特異性を欠如した同類の蛋白物質との両者を包含す
る。後者はリンパ系では低レベルで産生されるが骨髄腫
では高レベルで産生される。
【０００４】Ａ．１．起源及び用途 現在、脊椎動物抗体の２種の主な起源が利用されてい
る:即ち、哺乳動物Ｂリンパ球によるin situ生成及びＢ
細胞ハイブリッドによる細胞培養物(cell culture)にお
ける生成である。抗体は未熟のＢリンパ球がプラズマ細
胞(形質細胞)へ分化する結果としてin situで生成さ
れ、これは特異抗原による刺激に反応して生ずる。未分
化のＢ細胞では、免疫グロブリン鎖上の種々の領域をコ
ードしているＤＮＡ部分はゲノムＤＮＡ内で隔てられて
存在している。これら配列は転写前に順次再配列され
る。この過程の概略はＧough, Ｔrends in Ｂiochem．
Ｓci．,６:２０３(１９８１)に記載されている。得られ
る再配列ゲノムは、成熟Ｂリンパ球内で発現し所望の抗
体を産生することができる。然しながら、単一の抗原の
みが特定哺乳動物の免疫系圏内に入る場合でさえ、均一
な抗体群が生じるわけではない。特定抗原に対するin s
ituでの免疫反応は、抗原に存在する各種決定因子に対
する反応のモザイクにより規定される。単一群(single
population)のＢ細胞が相同抗体(homologous antibody)
の各サブセットに寄与し、従ってin situでの抗体の生
成は「ポリクローナル」である。
る:即ち、哺乳動物Ｂリンパ球によるin situ生成及びＢ
細胞ハイブリッドによる細胞培養物(cell culture)にお
ける生成である。抗体は未熟のＢリンパ球がプラズマ細
胞(形質細胞)へ分化する結果としてin situで生成さ
れ、これは特異抗原による刺激に反応して生ずる。未分
化のＢ細胞では、免疫グロブリン鎖上の種々の領域をコ
ードしているＤＮＡ部分はゲノムＤＮＡ内で隔てられて
存在している。これら配列は転写前に順次再配列され
る。この過程の概略はＧough, Ｔrends in Ｂiochem．
Ｓci．,６:２０３(１９８１)に記載されている。得られ
る再配列ゲノムは、成熟Ｂリンパ球内で発現し所望の抗
体を産生することができる。然しながら、単一の抗原の
みが特定哺乳動物の免疫系圏内に入る場合でさえ、均一
な抗体群が生じるわけではない。特定抗原に対するin s
ituでの免疫反応は、抗原に存在する各種決定因子に対
する反応のモザイクにより規定される。単一群(single
population)のＢ細胞が相同抗体(homologous antibody)
の各サブセットに寄与し、従ってin situでの抗体の生
成は「ポリクローナル」である。
【０００５】この限られてはいるが固有の異質性は、多
くの特定の場合に、ハイブリドーマ技術を用いて「モノ
クローナル」抗体を生成させることにより克服された(Ｋ
ohleret al．,Ｅur．Ｊ．Ｉmmunol．,６:５１１(１９７
６))。この方法に於いては、抗原を注射した哺乳動物に
由来する脾細胞又はリンパ球を腫瘍細胞系(セルライン)
と融合させてハイブリッド細胞即ち「ハイブリドーマ」を
作製する。これらハイブリッド細胞は、不滅(永久的に
増殖可能)であると共にＢ細胞の遺伝学的にコードされ
た抗体を産生することができる。このように生成された
ハイブリッドを選択、希釈及び再増殖により遺伝的に単
一の株に分離すると、各株は単一の遺伝系を示す。従っ
て、これらは所望の抗原に対し免疫反応性の抗体を産生
し、これら抗体は同質であることが確証され、その純粋
な遺伝起源(genetic parentage)に基いて「モノクローナ
ル」と呼ばれる。細胞融合技術は現在まで主としてネズ
ミ系の融合に集中しているが、ヒト−ヒトハイブリドー
マ(Ｌ．Ｏlsson et al．,Ｐroc．Ｎatl．Ａcad．Ｓci．
ＵＳＡ,７７:５４２９(１９８０))、並びにヒト−ネズ
ミハイブリドーマ(Ｊ．Ｓchlom et al．,同上,７７:６
８４１(１９８０))及びその他数種の異種間ハイブリッ
ド組合せも同様に作成されている。或いは抗体産生一次
Ｂ細胞(primary Ｂ cell)が、ウィルスＤＮＡでの形質
転換によるin vitroで永久株化されている。
くの特定の場合に、ハイブリドーマ技術を用いて「モノ
クローナル」抗体を生成させることにより克服された(Ｋ
ohleret al．,Ｅur．Ｊ．Ｉmmunol．,６:５１１(１９７
６))。この方法に於いては、抗原を注射した哺乳動物に
由来する脾細胞又はリンパ球を腫瘍細胞系(セルライン)
と融合させてハイブリッド細胞即ち「ハイブリドーマ」を
作製する。これらハイブリッド細胞は、不滅(永久的に
増殖可能)であると共にＢ細胞の遺伝学的にコードされ
た抗体を産生することができる。このように生成された
ハイブリッドを選択、希釈及び再増殖により遺伝的に単
一の株に分離すると、各株は単一の遺伝系を示す。従っ
て、これらは所望の抗原に対し免疫反応性の抗体を産生
し、これら抗体は同質であることが確証され、その純粋
な遺伝起源(genetic parentage)に基いて「モノクローナ
ル」と呼ばれる。細胞融合技術は現在まで主としてネズ
ミ系の融合に集中しているが、ヒト−ヒトハイブリドー
マ(Ｌ．Ｏlsson et al．,Ｐroc．Ｎatl．Ａcad．Ｓci．
ＵＳＡ,７７:５４２９(１９８０))、並びにヒト−ネズ
ミハイブリドーマ(Ｊ．Ｓchlom et al．,同上,７７:６
８４１(１９８０))及びその他数種の異種間ハイブリッ
ド組合せも同様に作成されている。或いは抗体産生一次
Ｂ細胞(primary Ｂ cell)が、ウィルスＤＮＡでの形質
転換によるin vitroで永久株化されている。
【０００６】ポリクローナル又は特に好ましくはモノク
ローナル抗体は、本発明の抗体と同様な多くの有用な性
質を有する。例えばこれらは、Ｂ細胞ゲノムの初期プロ
セッシングを誘発する抗原の存在を、この抗原−抗体反
応を適当な検出技術、例えば検定(ＲＩＡ,ＥＭＩＴ及び
ＥＬＩＳＡ)を可能にする放射性同位元素又は酵素によ
る標識と組合せることによって、検出するための特異的
免疫沈澱試薬として使用することができる。このよう
に、抗体は多くの抗原物質に対する免疫診断試験の基礎
となる。他の重要な用途において、抗体は問題とする抗
原を含有する物質又は有機体による攻撃を受けた対象被
検体に直接注射して、この攻撃に対処することができ
る。この方法は現在その実験段階にあるが、その有力性
は明らかである。第３に、全身診断及び処置も可能とな
る。何故なら、注射された抗体は特定の標的病気組織に
指向させられ、従って、これらと共に適当な標識を運ぶ
ことにより病気の存在を決定し、或いは適当な薬剤を運
ぶことにより病気組織を攻撃するために使用することが
できる。
ローナル抗体は、本発明の抗体と同様な多くの有用な性
質を有する。例えばこれらは、Ｂ細胞ゲノムの初期プロ
セッシングを誘発する抗原の存在を、この抗原−抗体反
応を適当な検出技術、例えば検定(ＲＩＡ,ＥＭＩＴ及び
ＥＬＩＳＡ)を可能にする放射性同位元素又は酵素によ
る標識と組合せることによって、検出するための特異的
免疫沈澱試薬として使用することができる。このよう
に、抗体は多くの抗原物質に対する免疫診断試験の基礎
となる。他の重要な用途において、抗体は問題とする抗
原を含有する物質又は有機体による攻撃を受けた対象被
検体に直接注射して、この攻撃に対処することができ
る。この方法は現在その実験段階にあるが、その有力性
は明らかである。第３に、全身診断及び処置も可能とな
る。何故なら、注射された抗体は特定の標的病気組織に
指向させられ、従って、これらと共に適当な標識を運ぶ
ことにより病気の存在を決定し、或いは適当な薬剤を運
ぶことにより病気組織を攻撃するために使用することが
できる。
【０００７】ハイブリドーマにより産生されるモノクロ
ーナル抗体は、理論的には上記したように有効であり且
つその特異性によりポリクローナル抗体よりも明らかに
好適であるが、或る種の欠点を有する。第１に、これら
はハイブリドーマ(従って、哺乳動物)起源の他の蛋白質
及び細胞物質で汚染される傾向がある。これらの細胞は
更に、発癌性を高め、発生し又は媒介し得る物質、特に
核酸断片を含有し、更に蛋白質断片も含有する。第２
に、モノクローナル抗体を産生するハイブリドーマ系は
不安定な傾向があり、産生される抗体の構造が変化した
り、抗体産生が完全に停止したりする(Ｇ．Ｋohler et
al．,Ｐroc．Ｎatl．Ａcad．Ｓci．,ＵＳＡ,７７:２１
９７(１９８０);Ｓ．Ｌ．Ｍorrison,Ｊ．Ｉmmunol．１
２３:７９３(１９７９))。細胞系ゲノムは、現在その性
質が未知であるような刺激に反応してそれ自体で変化(a
lteration)すると思われ、その結果誤った配列を産生し
得る。第３に、ハイブリドーマ及びＢ細胞は共に或る種
の抗体をグリコシル化型で産生することが避けられず
(Ｆ．Ｍelchers, Ｂiochemistry,１０:６５３(１９７
１))、これは或る場合には望ましくないものである。第
４に、モノクローナル抗体及びポリクローナル抗体の産
生はいずれも比較的高価である。第５に、恐らく最も重
要なことであるが、現在の技術(ハイブリドーマ又はＢ
細胞反応)による産生では、成熟Ｂ細胞由来抗原に反応
してin situで通常誘発されるものよりも有効な構成成
分を有する抗体を産生すべくゲノムを操作することがで
きない。本発明の抗体は上記の欠点をもたず、更に優秀
な分子を提供する機会を与える。
ーナル抗体は、理論的には上記したように有効であり且
つその特異性によりポリクローナル抗体よりも明らかに
好適であるが、或る種の欠点を有する。第１に、これら
はハイブリドーマ(従って、哺乳動物)起源の他の蛋白質
及び細胞物質で汚染される傾向がある。これらの細胞は
更に、発癌性を高め、発生し又は媒介し得る物質、特に
核酸断片を含有し、更に蛋白質断片も含有する。第２
に、モノクローナル抗体を産生するハイブリドーマ系は
不安定な傾向があり、産生される抗体の構造が変化した
り、抗体産生が完全に停止したりする(Ｇ．Ｋohler et
al．,Ｐroc．Ｎatl．Ａcad．Ｓci．,ＵＳＡ,７７:２１
９７(１９８０);Ｓ．Ｌ．Ｍorrison,Ｊ．Ｉmmunol．１
２３:７９３(１９７９))。細胞系ゲノムは、現在その性
質が未知であるような刺激に反応してそれ自体で変化(a
lteration)すると思われ、その結果誤った配列を産生し
得る。第３に、ハイブリドーマ及びＢ細胞は共に或る種
の抗体をグリコシル化型で産生することが避けられず
(Ｆ．Ｍelchers, Ｂiochemistry,１０:６５３(１９７
１))、これは或る場合には望ましくないものである。第
４に、モノクローナル抗体及びポリクローナル抗体の産
生はいずれも比較的高価である。第５に、恐らく最も重
要なことであるが、現在の技術(ハイブリドーマ又はＢ
細胞反応)による産生では、成熟Ｂ細胞由来抗原に反応
してin situで通常誘発されるものよりも有効な構成成
分を有する抗体を産生すべくゲノムを操作することがで
きない。本発明の抗体は上記の欠点をもたず、更に優秀
な分子を提供する機会を与える。
【０００８】抗体特異性を欠如している免疫グロブリン
でさえ、抗体自身よりは小さい範囲の潜在的用途である
が有用である。現在まで理解されたこの種の免疫グロブ
リンの用途としては、グロブリン関連貧血に対する蛋白
質補充治療がある。この意味で、抗原に結合し得ないこ
とは実際に有益である。何故ならこれら蛋白質の治療価
値はこのような機能により阻害されるからである。現
在、この種の非特異性抗体は、適当に誘発された骨髄腫
細胞培養物からのみ少量で誘導することができる。本発
明は、それに代わる一層経済的な起源を提供する。更
に、本発明は四元体(tetramer)の４つの鎖を別々に処理
することにより特異性を消却する機会を与える。
でさえ、抗体自身よりは小さい範囲の潜在的用途である
が有用である。現在まで理解されたこの種の免疫グロブ
リンの用途としては、グロブリン関連貧血に対する蛋白
質補充治療がある。この意味で、抗原に結合し得ないこ
とは実際に有益である。何故ならこれら蛋白質の治療価
値はこのような機能により阻害されるからである。現
在、この種の非特異性抗体は、適当に誘発された骨髄腫
細胞培養物からのみ少量で誘導することができる。本発
明は、それに代わる一層経済的な起源を提供する。更
に、本発明は四元体(tetramer)の４つの鎖を別々に処理
することにより特異性を消却する機会を与える。
【０００９】Ａ．２．一般的構造特性 脊椎動物系に於ける基本的な免疫グロブリン構造単位は
現在充分に理解されている(Ｇ．Ｍ．Ｅdelman, Ａnn．
Ｎ．Ｙ．Ａcad．Ｓci．,１９０:５(１９７１))。これら
の単位は、分子量約２３,０００ダルトンの２つの同一
のＬポリペプチド鎖と分子量５３,０００〜７０,０００
の２つの同一なＨ鎖とから構成されている。これら４つ
の鎖はジスルフィド結合により「Ｙ」形状で結合され、こ
こでＬ鎖は、図１に示すように、Ｙの口部から出発し分
岐領域を通って連続するＨ鎖を包囲する。「枝」部分は、
図に示したようにＦab領域と呼ばれる。Ｈ鎖はγ,μ,
α,δ又はεとして更にこれらのいくつかのサブクラス
に分類され、この鎖の性質はこれが長い不変領域を有す
るためＩgＧ,ＩgＭ,ＩgＡ,ＩgＤ又はＩgＥとしての抗体
の「クラス」を決定する。Ｌ鎖はκ又はλとして分類され
る。各Ｈ鎖のクラスはκ又はλのいずれのＬ鎖とも組合
せて作成することができる。Ｌ鎖とＨ鎖とは互いに共有
結合され、免疫グロブリンがハイブリドーマ又はＢ細胞
により生成される際に２つのＨ鎖の「テイル(尾部)」部分
は共有ジスルフィド結合により互いに結合される。然し
ながら、正確な配置に於いて、鎖の非共有的会合が起こ
っても、集合体は抗原との反応が同様に可能であり、或
いは非特異的免疫グロブリンとして蛋白質補充に有用で
ある。
現在充分に理解されている(Ｇ．Ｍ．Ｅdelman, Ａnn．
Ｎ．Ｙ．Ａcad．Ｓci．,１９０:５(１９７１))。これら
の単位は、分子量約２３,０００ダルトンの２つの同一
のＬポリペプチド鎖と分子量５３,０００〜７０,０００
の２つの同一なＨ鎖とから構成されている。これら４つ
の鎖はジスルフィド結合により「Ｙ」形状で結合され、こ
こでＬ鎖は、図１に示すように、Ｙの口部から出発し分
岐領域を通って連続するＨ鎖を包囲する。「枝」部分は、
図に示したようにＦab領域と呼ばれる。Ｈ鎖はγ,μ,
α,δ又はεとして更にこれらのいくつかのサブクラス
に分類され、この鎖の性質はこれが長い不変領域を有す
るためＩgＧ,ＩgＭ,ＩgＡ,ＩgＤ又はＩgＥとしての抗体
の「クラス」を決定する。Ｌ鎖はκ又はλとして分類され
る。各Ｈ鎖のクラスはκ又はλのいずれのＬ鎖とも組合
せて作成することができる。Ｌ鎖とＨ鎖とは互いに共有
結合され、免疫グロブリンがハイブリドーマ又はＢ細胞
により生成される際に２つのＨ鎖の「テイル(尾部)」部分
は共有ジスルフィド結合により互いに結合される。然し
ながら、正確な配置に於いて、鎖の非共有的会合が起こ
っても、集合体は抗原との反応が同様に可能であり、或
いは非特異的免疫グロブリンとして蛋白質補充に有用で
ある。
【００１０】アミノ酸配列は、Ｙの頂部のＮ−末端から
各鎖の底部のＣ−末端まで延在する。Ｎ−末端は、抗体
を誘発した抗原に対し特異的で且つ長さ約１００個のア
ミノ酸から成る可変領域であり、この可変領域はＬ鎖と
Ｈ鎖との間及び抗体毎に僅かの変動がある。各鎖の可変
領域は、鎖の残余の長さに亘って延在する不変領域と結
合している。Ｌ鎖とＨ鎖の結合は、ゲノムレベルで見
て、約１２個のアミノ酸をコードするＬ鎖遺伝子内の
「Ｊ」領域として、並びに両方で約２５個のアミノ酸をコ
ードするＨ鎖遺伝子内の「Ｄ」領域と「Ｊ」領域との組合せ
として、現在知られている結合配列を介して生ずるもの
と思われる。
各鎖の底部のＣ−末端まで延在する。Ｎ−末端は、抗体
を誘発した抗原に対し特異的で且つ長さ約１００個のア
ミノ酸から成る可変領域であり、この可変領域はＬ鎖と
Ｈ鎖との間及び抗体毎に僅かの変動がある。各鎖の可変
領域は、鎖の残余の長さに亘って延在する不変領域と結
合している。Ｌ鎖とＨ鎖の結合は、ゲノムレベルで見
て、約１２個のアミノ酸をコードするＬ鎖遺伝子内の
「Ｊ」領域として、並びに両方で約２５個のアミノ酸をコ
ードするＨ鎖遺伝子内の「Ｄ」領域と「Ｊ」領域との組合せ
として、現在知られている結合配列を介して生ずるもの
と思われる。
【００１１】鎖の残余の部分は不変領域と呼ばれ、特定
のクラス内では、抗体の特異性(即ち、これを誘発する
抗原)と共に変化しない。上記したように、５種の主要
な公知クラスの不変領域が存在し、これらは免疫グロブ
リン分子のクラス(Ｈ鎖不変領域のγ,μ,α,δ及びεに
対応するＩgＧ,ＩgＭ,ＩgＡ,ＩgＤ及びＩgＥ)を決定す
る。不変領域もしくはクラスは、補体の活性化(Ｅ．
Ａ．Ｋabat,“Ｓtructural Ｃoncepts in Ｉmmunology
and Ｉmmunochemistry",第２版,p．４１３−４３６, Ｈ
olt, Ｒinehart, Ｗinston(１９７６))及びその他の細
胞反応(Ｄ．Ｗ．Ａndrews et al．,Ｃlinical Ｉmmunob
iology,p．１−１８,Ｗ．Ｂ．Ｓanders(１９８０);Ｓ．
Ｋohl et al．,Ｉmmunology,４８:１８７(１９８３))を
含め、抗体のその後のエフェクター機能を決定する一
方、可変領域はこれが反応する抗原を決定する。
のクラス内では、抗体の特異性(即ち、これを誘発する
抗原)と共に変化しない。上記したように、５種の主要
な公知クラスの不変領域が存在し、これらは免疫グロブ
リン分子のクラス(Ｈ鎖不変領域のγ,μ,α,δ及びεに
対応するＩgＧ,ＩgＭ,ＩgＡ,ＩgＤ及びＩgＥ)を決定す
る。不変領域もしくはクラスは、補体の活性化(Ｅ．
Ａ．Ｋabat,“Ｓtructural Ｃoncepts in Ｉmmunology
and Ｉmmunochemistry",第２版,p．４１３−４３６, Ｈ
olt, Ｒinehart, Ｗinston(１９７６))及びその他の細
胞反応(Ｄ．Ｗ．Ａndrews et al．,Ｃlinical Ｉmmunob
iology,p．１−１８,Ｗ．Ｂ．Ｓanders(１９８０);Ｓ．
Ｋohl et al．,Ｉmmunology,４８:１８７(１９８３))を
含め、抗体のその後のエフェクター機能を決定する一
方、可変領域はこれが反応する抗原を決定する。
【００１２】Ｂ．組換ＤＮＡ技術 組換ＤＮＡ技術は、遺伝子配列のクローニング及び発現
に関する技術が集積されて充分高度な状態に達してい
る。各種のＤＮＡ配列をかなり容易に組換えて、形質転
換微生物及び細胞培養物に於いて異種蛋白質産物を産生
し得る新規なＤＮＡ配列を創成することができる。ＤＮ
Ａの各種の平滑末端断片又は「粘着(付着性)」末端断片を
in vitroで結合して発現ベクターを産生させ且つ生物を
形質転換させる一般的手段及び方法が現在使用できる。
に関する技術が集積されて充分高度な状態に達してい
る。各種のＤＮＡ配列をかなり容易に組換えて、形質転
換微生物及び細胞培養物に於いて異種蛋白質産物を産生
し得る新規なＤＮＡ配列を創成することができる。ＤＮ
Ａの各種の平滑末端断片又は「粘着(付着性)」末端断片を
in vitroで結合して発現ベクターを産生させ且つ生物を
形質転換させる一般的手段及び方法が現在使用できる。
【００１３】必須要素(即ち、複製のオリジン、１種も
しくはそれ以上の表現型選択特性、発現制御配列、異種
遺伝子挿入物(インサート))及び残余のベクターのＤＮ
Ａ組換えは、一般に宿主細胞の外部で行なわれる。得ら
れる複製可能な組換発現ベクター即ちプラスミドを形質
転換により細胞中へ導入し、多量の組換ベヒクルを形質
転換体の増殖によって得る。コードされているＤＮＡメ
ッセージの転写及び翻訳を支配する部分に関し、遺伝子
が適正に挿入された場合、得られる発現ベクターは挿入
遺伝子がコードするポリプペチド配列を産生するのに有
用であり、この過程を「発現」と呼ぶ。得られる産物は、
必要に応じ、宿主細胞の溶菌及び適当な精製による他の
蛋白質からの産物の回収によって得ることができる。
しくはそれ以上の表現型選択特性、発現制御配列、異種
遺伝子挿入物(インサート))及び残余のベクターのＤＮ
Ａ組換えは、一般に宿主細胞の外部で行なわれる。得ら
れる複製可能な組換発現ベクター即ちプラスミドを形質
転換により細胞中へ導入し、多量の組換ベヒクルを形質
転換体の増殖によって得る。コードされているＤＮＡメ
ッセージの転写及び翻訳を支配する部分に関し、遺伝子
が適正に挿入された場合、得られる発現ベクターは挿入
遺伝子がコードするポリプペチド配列を産生するのに有
用であり、この過程を「発現」と呼ぶ。得られる産物は、
必要に応じ、宿主細胞の溶菌及び適当な精製による他の
蛋白質からの産物の回収によって得ることができる。
【００１４】実際上、組換ＤＮＡ技術の使用は、全く異
種のポリプペチドを発現することができ(所謂直接的発
現)、或いは同種(homologous)ポリプペチドのアミノ酸
配列の一部に融合した異種ポリプペチドを発現すること
もできる。後者の場合、目的とする生物活性産物は、し
ばしばそれが細胞外環境で開裂されるまで融合した同種
／異種ポリプペチド内で生物不活性にされている。
種のポリプペチドを発現することができ(所謂直接的発
現)、或いは同種(homologous)ポリプペチドのアミノ酸
配列の一部に融合した異種ポリプペチドを発現すること
もできる。後者の場合、目的とする生物活性産物は、し
ばしばそれが細胞外環境で開裂されるまで融合した同種
／異種ポリプペチド内で生物不活性にされている。
【００１５】遺伝学及び細胞生理学の研究のための細胞
もしくは組織培養物並びに微生物系を維持する技術は充
分確立されている。単離した細胞から順次トランスファ
ーすることにより作成された永久細胞系を維持するため
の手段及び方法が使用できる。研究に使用する目的に
は、この種の細胞系は液体媒体中の個体支持体上に維持
され、或いは支持栄養源を含有する懸濁物中での増殖に
より維持される。大量生産への規模拡大は、単に機械的
問題を提起するだけと思われる。
もしくは組織培養物並びに微生物系を維持する技術は充
分確立されている。単離した細胞から順次トランスファ
ーすることにより作成された永久細胞系を維持するため
の手段及び方法が使用できる。研究に使用する目的に
は、この種の細胞系は液体媒体中の個体支持体上に維持
され、或いは支持栄養源を含有する懸濁物中での増殖に
より維持される。大量生産への規模拡大は、単に機械的
問題を提起するだけと思われる。
【００１６】本発明は、適当な宿主細胞培養物を用いる
組換技術により生成される抗体及び非特異性免疫グロブ
リン(ＮＳＩ)に関するものである。これらの抗体及びＮ
ＳＩは、純粋な「モノクローナル」形態で容易に製造する
ことができる。これらをゲノムレベルで処理して互いに
異なる種からの相同性(homology)を引き出す変種のキメ
ラを生成することができる。更に、４つの鎖全部を同じ
細胞で生成する必要はないので、蛋白質レベルで処理す
ることもできる。従って、多くの「タイプ」の免疫グロブ
リンが本発明に包含される。
組換技術により生成される抗体及び非特異性免疫グロブ
リン(ＮＳＩ)に関するものである。これらの抗体及びＮ
ＳＩは、純粋な「モノクローナル」形態で容易に製造する
ことができる。これらをゲノムレベルで処理して互いに
異なる種からの相同性(homology)を引き出す変種のキメ
ラを生成することができる。更に、４つの鎖全部を同じ
細胞で生成する必要はないので、蛋白質レベルで処理す
ることもできる。従って、多くの「タイプ」の免疫グロブ
リンが本発明に包含される。
【００１７】第１に、哺乳動物Ｂ細胞によりin situで
又は適当な永続性腫瘍系と融合したＢ細胞、即ちハイブ
リドーマにより産生される天然に存在する抗体のアミノ
酸配列に類似する免疫グロブリン特に抗体は、組換技術
を用いて産生される。第２に、本発明方法により、従来
性質が互いに関連するとは思われていなかったポリプペ
チドから成る免疫グロブリンが産生され、本発明はこの
ような免疫グロブリンに係る。この種の再編成は、２種
以上の抗原を結合し得る「ハイブリッド」抗体を産生する
のに特に有用であり、且つ異なる起源のＨ鎖とＬ鎖とが
実質的に特異性を減弱化する「複合」免疫グロブリンを産
生するのに有用である。第３に、遺伝子操作によって、
例えば可変領域は１種の哺乳動物モデル系からのアミノ
酸配列に対応し、不変領域は他の哺乳動物モデル系のア
ミノ酸配列に類似するような「キメラ」抗体を生成するこ
とができる。更に、これら２種の類似配列は、異なる種
から誘導することができる。第４に、遺伝子操作によ
り、特異性及びその他の特性が向上した「改変」抗体を生
成することもできる。
又は適当な永続性腫瘍系と融合したＢ細胞、即ちハイブ
リドーマにより産生される天然に存在する抗体のアミノ
酸配列に類似する免疫グロブリン特に抗体は、組換技術
を用いて産生される。第２に、本発明方法により、従来
性質が互いに関連するとは思われていなかったポリプペ
チドから成る免疫グロブリンが産生され、本発明はこの
ような免疫グロブリンに係る。この種の再編成は、２種
以上の抗原を結合し得る「ハイブリッド」抗体を産生する
のに特に有用であり、且つ異なる起源のＨ鎖とＬ鎖とが
実質的に特異性を減弱化する「複合」免疫グロブリンを産
生するのに有用である。第３に、遺伝子操作によって、
例えば可変領域は１種の哺乳動物モデル系からのアミノ
酸配列に対応し、不変領域は他の哺乳動物モデル系のア
ミノ酸配列に類似するような「キメラ」抗体を生成するこ
とができる。更に、これら２種の類似配列は、異なる種
から誘導することができる。第４に、遺伝子操作によ
り、特異性及びその他の特性が向上した「改変」抗体を生
成することもできる。
【００１８】２つの他のタイプの免疫グロブリン様の部
分が産生され得る:即ち、標的組織に対するホーミング
キャリア(homing carrier)として有用な「単一価(unival
ent)」抗体及び免疫グロブリン分子の「Ｆab」領域、即ち
「Ｙ」の枝のみを含む「Ｆab蛋白質」である。これらの単一
価の抗体及びＦab断片も「哺乳動物性(哺乳動物由来)」と
することができ、即ち哺乳動物由来のアミノ酸配列に類
似する。例えば、不変配列パターン及び可変配列パター
ンが異なる起源であるような哺乳動物鎖もしくはキメラ
の新規な組立ても可能である。最後に、組換技術により
産生されるＬ鎖もしくはＨ鎖のみ、或いはその部分のい
ずれも本発明に包含され、哺乳動物性であってもキメラ
であってもよい。
分が産生され得る:即ち、標的組織に対するホーミング
キャリア(homing carrier)として有用な「単一価(unival
ent)」抗体及び免疫グロブリン分子の「Ｆab」領域、即ち
「Ｙ」の枝のみを含む「Ｆab蛋白質」である。これらの単一
価の抗体及びＦab断片も「哺乳動物性(哺乳動物由来)」と
することができ、即ち哺乳動物由来のアミノ酸配列に類
似する。例えば、不変配列パターン及び可変配列パター
ンが異なる起源であるような哺乳動物鎖もしくはキメラ
の新規な組立ても可能である。最後に、組換技術により
産生されるＬ鎖もしくはＨ鎖のみ、或いはその部分のい
ずれも本発明に包含され、哺乳動物性であってもキメラ
であってもよい。
【００１９】他の面に於いて、本発明は、上記のＮＳ
Ｉ,抗体及びその部分をコードするＤＮＡ並びに適当な
宿主細胞に於いてこの種の免疫グロブリンの産生を行な
い得る発現ベクター又はプラスミドに向けられる。本発
明は、これらベクターにより形質転換して得られる宿主
細胞及び細胞培養物も包含する。最後に本発明はこれら
ＮＳＩ及び抗体の製造方法並びにＤＮＡ配列、プラスミ
ド及びそれらによる形質転換細胞に向けられる。
Ｉ,抗体及びその部分をコードするＤＮＡ並びに適当な
宿主細胞に於いてこの種の免疫グロブリンの産生を行な
い得る発現ベクター又はプラスミドに向けられる。本発
明は、これらベクターにより形質転換して得られる宿主
細胞及び細胞培養物も包含する。最後に本発明はこれら
ＮＳＩ及び抗体の製造方法並びにＤＮＡ配列、プラスミ
ド及びそれらによる形質転換細胞に向けられる。
【００２０】詳細な説明 Ａ．定義 本明細書中に使用する「抗体」という用語は、特異的免疫
反応活性を有する四元体(tetramer)又はその集合体(agg
regate)を意味し、通常図１の「Ｙ」形状に合体されたＬ
鎖とＨ鎖とから成り、これら連鎖の間に共有結合を有し
又は持たない。「免疫グロブリン」という用語は、特異的
免疫反応活性があるかないかに拘らず、この種の集合体
(assembly)又はその一部を意味する。「非特異的免疫グ
ロブリン」(「ＮＳＩ」)という用語は、特異性を持たない
免疫グロブリン、即ち抗体でないものを意味する。
反応活性を有する四元体(tetramer)又はその集合体(agg
regate)を意味し、通常図１の「Ｙ」形状に合体されたＬ
鎖とＨ鎖とから成り、これら連鎖の間に共有結合を有し
又は持たない。「免疫グロブリン」という用語は、特異的
免疫反応活性があるかないかに拘らず、この種の集合体
(assembly)又はその一部を意味する。「非特異的免疫グ
ロブリン」(「ＮＳＩ」)という用語は、特異性を持たない
免疫グロブリン、即ち抗体でないものを意味する。
【００２１】「哺乳動物抗体」という用語は、鎖のアミノ
酸配列がin situで又はハイブリドーマに於いて哺乳動
物系により産生される抗体に見られるような配列と相同
(homologous)である抗体を意味する。これらの抗体は、
不純な形態であるが慣用の系においても生成され得るよ
うな抗体に類似する。
酸配列がin situで又はハイブリドーマに於いて哺乳動
物系により産生される抗体に見られるような配列と相同
(homologous)である抗体を意味する。これらの抗体は、
不純な形態であるが慣用の系においても生成され得るよ
うな抗体に類似する。
【００２２】「ハイブリッド抗体」という用語は、鎖が個
別に対応の哺乳動物抗体の鎖と相同である新規な集合体
を示し、従って２つの異なる抗原が四元体により沈澱し
得るような抗体を意味する。ハイブリッド抗体に於いて
一方のＨ鎖とＬ鎖との対は１つの抗原に対して生じた抗
体と相同であり、Ｈ鎖とＬ鎖との他方の対は他の抗原に
対して生じた抗体と相同である。この結果、「二価(deva
lence)」の性質が生じ、即ち２つの抗原に同時に結合す
る能力が生ずる。勿論、この種のハイブリッドは下記す
るようなキメラ鎖を用いて生成することもできる。
別に対応の哺乳動物抗体の鎖と相同である新規な集合体
を示し、従って２つの異なる抗原が四元体により沈澱し
得るような抗体を意味する。ハイブリッド抗体に於いて
一方のＨ鎖とＬ鎖との対は１つの抗原に対して生じた抗
体と相同であり、Ｈ鎖とＬ鎖との他方の対は他の抗原に
対して生じた抗体と相同である。この結果、「二価(deva
lence)」の性質が生じ、即ち２つの抗原に同時に結合す
る能力が生ずる。勿論、この種のハイブリッドは下記す
るようなキメラ鎖を用いて生成することもできる。
【００２３】「複合(composite)」免疫グロブリンという
用語は、Ｈ鎖とＬ鎖とが異なる種の起源又は特異性のも
のに類似し、従って得られたものが非特異的免疫グロブ
リン(ＮＳＩ)になると思われ、即ち抗体特性を欠如する
と思われるようなものを意味する。
用語は、Ｈ鎖とＬ鎖とが異なる種の起源又は特異性のも
のに類似し、従って得られたものが非特異的免疫グロブ
リン(ＮＳＩ)になると思われ、即ち抗体特性を欠如する
と思われるようなものを意味する。
【００２４】「キメラ抗体」という用語は、Ｈ鎖とＬ鎖と
の各アミノ酸配列の１部が特定種に由来する又は特定ク
ラスに属する抗体の対応配列と相同であり、且つ鎖の残
部が他の対応配列と相同であるような抗体を意味する。
典型的には、これらキメラ抗体に於いて、Ｌ鎖とＨ鎖と
の両者の可変領域は哺乳動物の１種に由来する抗体の可
変領域に類似し、不変部分は他の哺乳動物に由来する抗
体の配列と相同である。この種のキメラ型に対する１つ
の明らかな利点は、例えば容易に入手し得るハイブリド
ーマ又はヒト以外の宿主生物由来Ｂ細胞を、例えばヒト
細胞調製物に由来する不変領域と組合せて使用すること
により、現在公知の起源から可変領域を便利に誘導し得
ることである。可変領域は製造が容易であるという利点
を有し且つ特異性はその起源により影響されないが、不
変領域がヒト由来であるために、抗体を注射した場合、
ヒト以外の起源に由来する不変領域よりもヒト被験者に
対する免疫反応を誘発しにくいと思われる。
の各アミノ酸配列の１部が特定種に由来する又は特定ク
ラスに属する抗体の対応配列と相同であり、且つ鎖の残
部が他の対応配列と相同であるような抗体を意味する。
典型的には、これらキメラ抗体に於いて、Ｌ鎖とＨ鎖と
の両者の可変領域は哺乳動物の１種に由来する抗体の可
変領域に類似し、不変部分は他の哺乳動物に由来する抗
体の配列と相同である。この種のキメラ型に対する１つ
の明らかな利点は、例えば容易に入手し得るハイブリド
ーマ又はヒト以外の宿主生物由来Ｂ細胞を、例えばヒト
細胞調製物に由来する不変領域と組合せて使用すること
により、現在公知の起源から可変領域を便利に誘導し得
ることである。可変領域は製造が容易であるという利点
を有し且つ特異性はその起源により影響されないが、不
変領域がヒト由来であるために、抗体を注射した場合、
ヒト以外の起源に由来する不変領域よりもヒト被験者に
対する免疫反応を誘発しにくいと思われる。
【００２５】然しながら、この定義はこの特定例に限定
されない。即ち、Ｈ鎖もしくはＬ鎖の一方又は双方が異
なる起源の抗体の配列に類似した配列の組合せから成る
任意の抗体を包含し、これらの起源は異なるクラスであ
っても、異なる抗原反応であっても、或いは異なる種の
起源があってもよく、融合点(fusion point)が可変／不
変領域の境界に存在するかどうかに関係ない。従って、
不変領域も可変領域も公知の抗体配列に類似しないよう
な抗体を産生することができる。このようにして、例え
ば可変領域が特定抗原に対しより高度の特異親和性を有
するか、又は不変領域が向上した補体固定反応(complem
ent fixation)を誘発させ得るような抗体を作成するこ
とができ、或いは特定の不変領域が有する性質を更に改
善することができる。
されない。即ち、Ｈ鎖もしくはＬ鎖の一方又は双方が異
なる起源の抗体の配列に類似した配列の組合せから成る
任意の抗体を包含し、これらの起源は異なるクラスであ
っても、異なる抗原反応であっても、或いは異なる種の
起源があってもよく、融合点(fusion point)が可変／不
変領域の境界に存在するかどうかに関係ない。従って、
不変領域も可変領域も公知の抗体配列に類似しないよう
な抗体を産生することができる。このようにして、例え
ば可変領域が特定抗原に対しより高度の特異親和性を有
するか、又は不変領域が向上した補体固定反応(complem
ent fixation)を誘発させ得るような抗体を作成するこ
とができ、或いは特定の不変領域が有する性質を更に改
善することができる。
【００２６】「改変(変容)抗体(altered antibody)」とい
う用語は、アミノ酸配列が哺乳動物の抗体又はその他の
脊椎動物の抗体とは変化している抗体を意味する。本発
明に対して組換ＤＮＡ技術が適切であるため、天然抗体
に見られるアミノ酸の配列に制限する必要はない。抗体
を再設計して所望の特性を得ることができる。可能な変
化は数多く、僅か１個もしくは数個のアミノ酸の変化か
ら例えば不変領域の完全な再設計に至る範囲とすること
ができる。一般に、不変領域に於ける変化は例えば補体
固定、膜との相互作用及びその他の作用機能のような細
胞処理特性(cellular process characteristics)を改良
させるために行なわれる。可変領域に於ける変化は、抗
原結合特性を改良するために行なわれる。更に、抗体を
工学的に処理して「魔法玉(magic bullet)」概念に従って
毒性剤(toxic agent)を特異的に放出する役に立てるこ
ともできる。改変(alteration)は標準的組換技術により
行なうことができ、又オリゴヌクレオチド−指向突然変
異誘発技術(aligonucleotide−directed mutagenesis t
echniques)によっても行なうことができる(Ｄalbadie−
ＭcＦarland et al．,Ｐroc．Ｎatl．Ａcad．Ｓci．,Ｕ
ＳＡ,７９:６４０９(１９８２))。
う用語は、アミノ酸配列が哺乳動物の抗体又はその他の
脊椎動物の抗体とは変化している抗体を意味する。本発
明に対して組換ＤＮＡ技術が適切であるため、天然抗体
に見られるアミノ酸の配列に制限する必要はない。抗体
を再設計して所望の特性を得ることができる。可能な変
化は数多く、僅か１個もしくは数個のアミノ酸の変化か
ら例えば不変領域の完全な再設計に至る範囲とすること
ができる。一般に、不変領域に於ける変化は例えば補体
固定、膜との相互作用及びその他の作用機能のような細
胞処理特性(cellular process characteristics)を改良
させるために行なわれる。可変領域に於ける変化は、抗
原結合特性を改良するために行なわれる。更に、抗体を
工学的に処理して「魔法玉(magic bullet)」概念に従って
毒性剤(toxic agent)を特異的に放出する役に立てるこ
ともできる。改変(alteration)は標準的組換技術により
行なうことができ、又オリゴヌクレオチド−指向突然変
異誘発技術(aligonucleotide−directed mutagenesis t
echniques)によっても行なうことができる(Ｄalbadie−
ＭcＦarland et al．,Ｐroc．Ｎatl．Ａcad．Ｓci．,Ｕ
ＳＡ,７９:６４０９(１９８２))。
【００２７】「単一価の抗体(univalent antibody)」とい
う用語は、第２のＨ鎖のＦc(もしくはステム)領域に結
合したＨ鎖／Ｌ鎖ダイマーから成る集合体(aggregatio
n)を意味する。この種の抗体は抗原に対し特異的である
が、特異抗原表面を有する組織を標的とする所望の性質
を更に有し、その抗原有効性(antigenic effectivenes
s)を損うことがなく、即ち抗原変調(antigenic modulat
ion)がない。この点に関する単一価の抗体の現象及び性
質はＭ．Ｊ．Ｇlennie et al．,Ｎature,２９５:７１２
(１９８２)に示されている。従来、単一価の抗体は蛋白
質分解により形成されていた。
う用語は、第２のＨ鎖のＦc(もしくはステム)領域に結
合したＨ鎖／Ｌ鎖ダイマーから成る集合体(aggregatio
n)を意味する。この種の抗体は抗原に対し特異的である
が、特異抗原表面を有する組織を標的とする所望の性質
を更に有し、その抗原有効性(antigenic effectivenes
s)を損うことがなく、即ち抗原変調(antigenic modulat
ion)がない。この点に関する単一価の抗体の現象及び性
質はＭ．Ｊ．Ｇlennie et al．,Ｎature,２９５:７１２
(１９８２)に示されている。従来、単一価の抗体は蛋白
質分解により形成されていた。
【００２８】「Ｆab」領域とは、Ｈ鎖のＹ枝部分から成る
配列に対し、及び全体的にＬ鎖に対しほぼ均等又は同様
(analogous)であり且つ全体(集合体)として抗体活性を
有することが示されている鎖の部分を意味する。「Ｆab
蛋白質」(この蛋白質は本発明の一面を構成する)は、１
つのＨ鎖と１つのＬ鎖との集合体(aggregate)(一般にＦ
ab'として知られる)並びに抗体Ｙの２つの枝部分に対応
する四元体(一般にＦ(ab)2として知られる)を包含し、
これらはいずれも共有的に又は非共有的に集合される。
但し、この集合は特定抗原又は抗原群(antigen family)
と選択的に反応することができる。Ｆab抗体は単一価の
抗体と同様に、従来蛋白質分解により生成されており、
標的組織に対する抗原変調を誘発しないという性質を有
する。然しながら、これらは「エフェクター」Ｆc部分を
欠如するので例えばマクロファージによる標的細胞の溶
菌を行なうことができない。
配列に対し、及び全体的にＬ鎖に対しほぼ均等又は同様
(analogous)であり且つ全体(集合体)として抗体活性を
有することが示されている鎖の部分を意味する。「Ｆab
蛋白質」(この蛋白質は本発明の一面を構成する)は、１
つのＨ鎖と１つのＬ鎖との集合体(aggregate)(一般にＦ
ab'として知られる)並びに抗体Ｙの２つの枝部分に対応
する四元体(一般にＦ(ab)2として知られる)を包含し、
これらはいずれも共有的に又は非共有的に集合される。
但し、この集合は特定抗原又は抗原群(antigen family)
と選択的に反応することができる。Ｆab抗体は単一価の
抗体と同様に、従来蛋白質分解により生成されており、
標的組織に対する抗原変調を誘発しないという性質を有
する。然しながら、これらは「エフェクター」Ｆc部分を
欠如するので例えばマクロファージによる標的細胞の溶
菌を行なうことができない。
【００２９】「Ｆab蛋白質」は、一般的用語「抗体」もしく
は「免疫グロブリン」と同様に本発明の定義に従う同様な
サブセットを有する。即ち、「哺乳動物」Ｆab蛋白質、
「ハイブリッド」Ｆab蛋白質、「キメラ」Ｆab及び「改変(al
tered)」Ｆab蛋白質が種々のタイプの抗体につき上記に
示した対応の定義と同様に規定される。
は「免疫グロブリン」と同様に本発明の定義に従う同様な
サブセットを有する。即ち、「哺乳動物」Ｆab蛋白質、
「ハイブリッド」Ｆab蛋白質、「キメラ」Ｆab及び「改変(al
tered)」Ｆab蛋白質が種々のタイプの抗体につき上記に
示した対応の定義と同様に規定される。
【００３０】勿論、個々のＨ鎖もしくはＬ鎖は、上記に
従って「哺乳動物」、「キメラ」又は「改変」とすることがで
きる。発明の詳細な説明から明らかとなるように、開示
技術を使用して特定的に定義したもの以外に、例えば、
キメラＬ鎖及び哺乳動物Ｈ鎖を含有するハイブリッド抗
体、哺乳動物Ｌ鎖と共にＨ鎖のキメラＦab蛋白質を含有
するハイブリッドＦab蛋白質、等のような４ペプチド鎖
の集合体のその他の組合せを製造することができる。
従って「哺乳動物」、「キメラ」又は「改変」とすることがで
きる。発明の詳細な説明から明らかとなるように、開示
技術を使用して特定的に定義したもの以外に、例えば、
キメラＬ鎖及び哺乳動物Ｈ鎖を含有するハイブリッド抗
体、哺乳動物Ｌ鎖と共にＨ鎖のキメラＦab蛋白質を含有
するハイブリッドＦab蛋白質、等のような４ペプチド鎖
の集合体のその他の組合せを製造することができる。
【００３１】「発現ベクター」という用語は、そこに含有
されるＤＮＡ配列を発現し得るベクターを包含し、即ち
コード配列は発現を行ない得るその他の配列に有効に発
現するように結合される。これは必ずしも明確に規定さ
れないが、これらの発現ベクターは宿主生物に於いてエ
ピソームとして、又は染色体ＤＮＡの一体的部分として
複製し得るものでなければならないことを意味する。明
らかに、複製可能性が欠如することは、有効に機能し得
なくなる。有効な発現ベクターの有用であるが必ずしも
必要でない要素は、マーカーコード配列であり、即ち容
易に細胞を固定し得る蛋白質を含有する細胞の表現型特
性(たとえばテトラサイクリン耐性)をもたらすような蛋
白質をコードする配列である。要するに、「発現ベクタ
ー」には機能的定義が与えられ、特定の含有ＤＮＡコー
ドを発現し得る全てのＤＮＡ配列がこの用語に包含さ
れ、同様に特定の配列に適用される。現在この種のベク
ターはしばしばプラスミドの形態であるので、「プラス
ミド」と「発現ベクター」とはしばしば互換的に使用され
る。然しながら、本発明は均等な機能を有し且つ時と共
に当業界で公知となり得るような他の形態の発現ベクタ
ーをも包含することを意図する。
されるＤＮＡ配列を発現し得るベクターを包含し、即ち
コード配列は発現を行ない得るその他の配列に有効に発
現するように結合される。これは必ずしも明確に規定さ
れないが、これらの発現ベクターは宿主生物に於いてエ
ピソームとして、又は染色体ＤＮＡの一体的部分として
複製し得るものでなければならないことを意味する。明
らかに、複製可能性が欠如することは、有効に機能し得
なくなる。有効な発現ベクターの有用であるが必ずしも
必要でない要素は、マーカーコード配列であり、即ち容
易に細胞を固定し得る蛋白質を含有する細胞の表現型特
性(たとえばテトラサイクリン耐性)をもたらすような蛋
白質をコードする配列である。要するに、「発現ベクタ
ー」には機能的定義が与えられ、特定の含有ＤＮＡコー
ドを発現し得る全てのＤＮＡ配列がこの用語に包含さ
れ、同様に特定の配列に適用される。現在この種のベク
ターはしばしばプラスミドの形態であるので、「プラス
ミド」と「発現ベクター」とはしばしば互換的に使用され
る。然しながら、本発明は均等な機能を有し且つ時と共
に当業界で公知となり得るような他の形態の発現ベクタ
ーをも包含することを意図する。
【００３２】「組換宿主細胞」という用語は、組換ＤＮＡ
技術を用いて作成されたベクターにより形質転換された
細胞を意味する。本明細書に定義したように、組換宿主
細胞により産生される抗体又はその改変物(modificatio
n)は、この形態転換のため未形質転換宿主で産生される
ような少量でなく、より一般的には検出量以下のもので
ない。
技術を用いて作成されたベクターにより形質転換された
細胞を意味する。本明細書に定義したように、組換宿主
細胞により産生される抗体又はその改変物(modificatio
n)は、この形態転換のため未形質転換宿主で産生される
ような少量でなく、より一般的には検出量以下のもので
ない。
【００３３】組換宿主から抗体を単離する方法の説明に
於いて、「細胞」及び「細胞培養物」という用語は、特記し
ない限り抗体の起源を示すために互換的に使用される。
換言すれば、「細胞」からの抗体の回収は、遠心分離され
た全細胞からの回収又は培地と懸濁細胞との両者を含有
する細胞培養物からの回収のいずれをも意味する。
於いて、「細胞」及び「細胞培養物」という用語は、特記し
ない限り抗体の起源を示すために互換的に使用される。
換言すれば、「細胞」からの抗体の回収は、遠心分離され
た全細胞からの回収又は培地と懸濁細胞との両者を含有
する細胞培養物からの回収のいずれをも意味する。
【００３４】Ｂ．宿主細胞培養物及びベクター 本明細書中に開示したベクター及び方法は、広範囲の原
核生物及び真核生物に亘る宿主細胞に使用するのに適し
ている。
核生物及び真核生物に亘る宿主細胞に使用するのに適し
ている。
【００３５】一般的には勿論、本発明に有用なベクター
を作成する際、ＤＮＡ配列をクローン化(クローニング)
するには原核生物が好適である。例えばＥ．coli Ｋ１
２菌株２９４(ＡＴＣＣ Ｎo．３１４４６)が特に有用
である。使用し得るその他の微生物菌株はＥ．coli菌
株、例えばＥ．coliＢ及びＥ．coliＸ１７７６(ＡＴＣ
Ｃ Ｎo．３１５３７)を包含する。これらの例は、勿論
例示であって限定を意味するものでない。
を作成する際、ＤＮＡ配列をクローン化(クローニング)
するには原核生物が好適である。例えばＥ．coli Ｋ１
２菌株２９４(ＡＴＣＣ Ｎo．３１４４６)が特に有用
である。使用し得るその他の微生物菌株はＥ．coli菌
株、例えばＥ．coliＢ及びＥ．coliＸ１７７６(ＡＴＣ
Ｃ Ｎo．３１５３７)を包含する。これらの例は、勿論
例示であって限定を意味するものでない。
【００３６】発現用にも原核生物を使用することができ
る。上記の菌株並びにＥ．coli Ｗ３１１０(Ｆ-,λ-,
原始栄養性(prototrophic)、ＡＴＣＣ Ｎo．２７３２
５)、桿菌例えばＢacillus subtilus、及び他の腸内細
菌例えばＳalmonella typhimurium又はＳerratia marce
sans及び各種のＰscudomonas種を使用することができ
る。
る。上記の菌株並びにＥ．coli Ｗ３１１０(Ｆ-,λ-,
原始栄養性(prototrophic)、ＡＴＣＣ Ｎo．２７３２
５)、桿菌例えばＢacillus subtilus、及び他の腸内細
菌例えばＳalmonella typhimurium又はＳerratia marce
sans及び各種のＰscudomonas種を使用することができ
る。
【００３７】一般に、レプリコン及び制御配列を含有し
宿主細胞に適合性の種由来のプラスミドベクターを、こ
れら宿主と関連して使用する。通常、ベクターは複製部
位並びに形質転換細胞に表現型選択を与え得るマーカー
配列を有する。例えばＥ．coliは、典型的にはpＢＲ３
２２即ちＥ．coli種から得られるプラスミド(Ｂolivare
t al．,Ｇene２:９５(１９７７))を用いて形質転換され
る。pＢＲ３２２はアンピシリン耐性及びテトラサイク
リン耐性遺伝子を有し、従って形質転換細胞を同定する
ための便利な手段を与える。pＢＲ３２２プラスミド又
はその他の微生物プラスミドは、又、微生物がそれ自身
の蛋白質を発現するように使用し得るプロモーターを含
有し又は含有するよう改変されなければならない。組換
ＤＮＡの作成に最も一般的に使用されるプロモーター
は、β−ラクタマーゼ(ペニシリナーゼ)及び乳糖プロモ
ーター系(Ｃhang et al．,Ｎature．２７５:６１５(１
９７８);Ｉtakura et al．,Ｓcience,１９８:１０５６
(１９７７);Ｇoeddel et al．,Ｎature,２８１:５４４
(１９７９))並びにトリプトファン(trp)プロモーター系
(Ｇoeddel et al．,Ｎucleic Ａcids Ｒes．,８:４０５
７(１９８０);ＥＰＯ出願公開第００３６７７６号)を包
含する。これらが特に一般的に使用されるが、他の微生
物プロモーターも見出され且つ利用されており、これら
ヌクレオチド配列に関する詳細が公開されており、当業
者はこれらをプラスミドベクターと機能的に結合させる
ことができる(Ｓiebenlist et al．,Ｃell,２０:２６９
(１９８０))。
宿主細胞に適合性の種由来のプラスミドベクターを、こ
れら宿主と関連して使用する。通常、ベクターは複製部
位並びに形質転換細胞に表現型選択を与え得るマーカー
配列を有する。例えばＥ．coliは、典型的にはpＢＲ３
２２即ちＥ．coli種から得られるプラスミド(Ｂolivare
t al．,Ｇene２:９５(１９７７))を用いて形質転換され
る。pＢＲ３２２はアンピシリン耐性及びテトラサイク
リン耐性遺伝子を有し、従って形質転換細胞を同定する
ための便利な手段を与える。pＢＲ３２２プラスミド又
はその他の微生物プラスミドは、又、微生物がそれ自身
の蛋白質を発現するように使用し得るプロモーターを含
有し又は含有するよう改変されなければならない。組換
ＤＮＡの作成に最も一般的に使用されるプロモーター
は、β−ラクタマーゼ(ペニシリナーゼ)及び乳糖プロモ
ーター系(Ｃhang et al．,Ｎature．２７５:６１５(１
９７８);Ｉtakura et al．,Ｓcience,１９８:１０５６
(１９７７);Ｇoeddel et al．,Ｎature,２８１:５４４
(１９７９))並びにトリプトファン(trp)プロモーター系
(Ｇoeddel et al．,Ｎucleic Ａcids Ｒes．,８:４０５
７(１９８０);ＥＰＯ出願公開第００３６７７６号)を包
含する。これらが特に一般的に使用されるが、他の微生
物プロモーターも見出され且つ利用されており、これら
ヌクレオチド配列に関する詳細が公開されており、当業
者はこれらをプラスミドベクターと機能的に結合させる
ことができる(Ｓiebenlist et al．,Ｃell,２０:２６９
(１９８０))。
【００３８】原核生物の他に、酵母培養物のような真核
微生物も使用することができる。Ｓaccharomyces cerev
isiae即ち一般的なパン酵母が真核微生物として最も一
般的に使用されるが、他の多くの菌株も一般的に使用し
得る。Ｓaccharomycesに於ける発現については例えばプ
ラスミドＹＲp７(Ｓtinchcomb et al．,Ｎature,２８
２:３９(１９７９);Ｋingsman et al．,Ｇene,７:１４
１(１９７９);Ｔschemperet al．, Ｇene,１０:１５７
(１９８０))が一般的に使用される。このプラスミドは
既にトリプトファン中で増殖する能力を欠如した酵母の
突然変異菌株、例えばＡＴＣＣ Ｎo．４４０７６即ち
ＰＥＰ４−１(Ｊones,Ｇenetics,８５:１２(１９７７))
に対し選択マーカーを与えるtrp１遺伝子を含有する。
酵母宿主細胞ゲノムの特性としてtrp１欠陥(lesion)が
存在するため、トリプトファンの不在下での増殖による
形質転換の検出用に有効な環境が得られる。
微生物も使用することができる。Ｓaccharomyces cerev
isiae即ち一般的なパン酵母が真核微生物として最も一
般的に使用されるが、他の多くの菌株も一般的に使用し
得る。Ｓaccharomycesに於ける発現については例えばプ
ラスミドＹＲp７(Ｓtinchcomb et al．,Ｎature,２８
２:３９(１９７９);Ｋingsman et al．,Ｇene,７:１４
１(１９７９);Ｔschemperet al．, Ｇene,１０:１５７
(１９８０))が一般的に使用される。このプラスミドは
既にトリプトファン中で増殖する能力を欠如した酵母の
突然変異菌株、例えばＡＴＣＣ Ｎo．４４０７６即ち
ＰＥＰ４−１(Ｊones,Ｇenetics,８５:１２(１９７７))
に対し選択マーカーを与えるtrp１遺伝子を含有する。
酵母宿主細胞ゲノムの特性としてtrp１欠陥(lesion)が
存在するため、トリプトファンの不在下での増殖による
形質転換の検出用に有効な環境が得られる。
【００３９】酵母ベクターに於ける適当なプロモーター
配列は３−ホスホグリセレートキナーゼ(Ｈitzeman et
al．,Ｊ．Ｂiol．Ｃhem．,２５５:２０７３(１９８０))
又はその他の糖分解酵素(Ｈess et al．,Ｊ．Ａdv．Ｅn
zymc Ｒeg．,７:１４９(１９６８);Ｈolland et al．,
Ｂiochemistry,１７:４９００(１９７８))例えばエノラ
ーゼ、グリセルアルデヒド−３−ホスフェートデヒドロ
ゲナーゼ、ヘキソキナーゼ、ピルベートデカルボキシラ
ーゼ、ホスホフルクトキナーゼ、グルコース−６−ホス
フェートイソメラーゼ、３−ホスホグリセレートムター
ゼ、ピルベートキナーゼ、トリオースホスフェートイソ
メラーゼ、ホスホグルコースイソメラーゼ及びグルコキ
ナーゼに対するプロモーターを包含する。適する発現プ
ラスミドを作成する際、これら遺伝子に関連する停止配
列も、mＲＮＡのポリアデニル化及び停止を行なうよう
に発現させたり配列の発現ベクター３'中へ結合させ
る。増殖条件により制御される転写の付加的利点を更に
有する他のプロモーターは、アルコールデヒドロゲナー
ゼ２、イソチトクロームＣ、酸ホスファターゼ、窒素代
謝に関連する分解酵素並びに上記のグリセルアルデヒド
−３−ホスフェートデヒドロゲナーゼ及びマルトースと
ガラクトースとの利用に関する酵素(Ｈolland,上記)に
対するプロモーター領域である。酵母適合性のプロモー
ターと複製のオリジンと停止配列とを有するプラスミド
ベクターが適している。
配列は３−ホスホグリセレートキナーゼ(Ｈitzeman et
al．,Ｊ．Ｂiol．Ｃhem．,２５５:２０７３(１９８０))
又はその他の糖分解酵素(Ｈess et al．,Ｊ．Ａdv．Ｅn
zymc Ｒeg．,７:１４９(１９６８);Ｈolland et al．,
Ｂiochemistry,１７:４９００(１９７８))例えばエノラ
ーゼ、グリセルアルデヒド−３−ホスフェートデヒドロ
ゲナーゼ、ヘキソキナーゼ、ピルベートデカルボキシラ
ーゼ、ホスホフルクトキナーゼ、グルコース−６−ホス
フェートイソメラーゼ、３−ホスホグリセレートムター
ゼ、ピルベートキナーゼ、トリオースホスフェートイソ
メラーゼ、ホスホグルコースイソメラーゼ及びグルコキ
ナーゼに対するプロモーターを包含する。適する発現プ
ラスミドを作成する際、これら遺伝子に関連する停止配
列も、mＲＮＡのポリアデニル化及び停止を行なうよう
に発現させたり配列の発現ベクター３'中へ結合させ
る。増殖条件により制御される転写の付加的利点を更に
有する他のプロモーターは、アルコールデヒドロゲナー
ゼ２、イソチトクロームＣ、酸ホスファターゼ、窒素代
謝に関連する分解酵素並びに上記のグリセルアルデヒド
−３−ホスフェートデヒドロゲナーゼ及びマルトースと
ガラクトースとの利用に関する酵素(Ｈolland,上記)に
対するプロモーター領域である。酵母適合性のプロモー
ターと複製のオリジンと停止配列とを有するプラスミド
ベクターが適している。
【００４０】微生物の他に、多細胞生物由来細胞の培養
物も宿主として使用することができる。原則として、任
意のこの種の細胞培養物は、脊椎動物由来であっても、
或いは無脊椎動物の培養物であっても使用可能である。
然しながら、最も興味があるものは脊椎動物細胞であ
り、脊椎動物細胞の培養(組織培養)による増殖が、近年
日常の手法となった(Ｔissue Ｃulture, Ａcademic Ｐr
ess, Ｋruse and Ｐatterson編(１９７３))。この種の
有用な宿主細胞系の例は、ＶＥＲＯ細胞及びＨeＬa細
胞、チャイニーズハムスター卵巣(ＣＨＯ)細胞系並びに
Ｗ１３８,ＢＨＫ,ＣＯＳ−７及びＭＤＣＫ細胞系であ
る。この種の細胞に対する発現ベクターは一般に、(必
要に応じ)複製のオリジン、発現すべき遺伝子の前方に
位置するプロモーター並びに任意の必要なリポソーム結
合部位、ＲＮＡスプライス部位、ポリアデニル化部位及
び転写停止配列を含む。
物も宿主として使用することができる。原則として、任
意のこの種の細胞培養物は、脊椎動物由来であっても、
或いは無脊椎動物の培養物であっても使用可能である。
然しながら、最も興味があるものは脊椎動物細胞であ
り、脊椎動物細胞の培養(組織培養)による増殖が、近年
日常の手法となった(Ｔissue Ｃulture, Ａcademic Ｐr
ess, Ｋruse and Ｐatterson編(１９７３))。この種の
有用な宿主細胞系の例は、ＶＥＲＯ細胞及びＨeＬa細
胞、チャイニーズハムスター卵巣(ＣＨＯ)細胞系並びに
Ｗ１３８,ＢＨＫ,ＣＯＳ−７及びＭＤＣＫ細胞系であ
る。この種の細胞に対する発現ベクターは一般に、(必
要に応じ)複製のオリジン、発現すべき遺伝子の前方に
位置するプロモーター並びに任意の必要なリポソーム結
合部位、ＲＮＡスプライス部位、ポリアデニル化部位及
び転写停止配列を含む。
【００４１】哺乳動物細胞に於いて使用するには、発現
ベクターに対する制御機能がしばしばウィルス性材料に
より与えられる。例えば一般的に使用されるプロモータ
ーはポリオーマ、アデノウィルス２及び特にしばしばサ
ルウィルス４０(ＳＶ４０)から得られる。ＳＶ４０ウィ
ルスの初期及び後期プロモーターが特に有用である。何
故なら、これら両者は複製のＳＶ４０ウィルスオリジン
をも含有する断片としてウィルスから容易に得られるか
らである。(Ｆiers et al．,Ｎature,２７３:１１３(１
９７８),これを引用して本明細書に包含する)。より小
さい又はより大きいＳＶ４０断片も使用し得るが、但し
ＨindＩＩＩから複製のウィルスオリジン内に存在する
ＢglＩ部位まで延びる約２５０bp配列が含まれることが
必要である。更に一般に所望の遺伝子配列に関連するプ
ロモーター又は制御配列を使用することもでき、且つ使
用するのがしばしば望ましい。但し、この種の制御配列
は、宿主細胞系に対し適合性であるものとする。
ベクターに対する制御機能がしばしばウィルス性材料に
より与えられる。例えば一般的に使用されるプロモータ
ーはポリオーマ、アデノウィルス２及び特にしばしばサ
ルウィルス４０(ＳＶ４０)から得られる。ＳＶ４０ウィ
ルスの初期及び後期プロモーターが特に有用である。何
故なら、これら両者は複製のＳＶ４０ウィルスオリジン
をも含有する断片としてウィルスから容易に得られるか
らである。(Ｆiers et al．,Ｎature,２７３:１１３(１
９７８),これを引用して本明細書に包含する)。より小
さい又はより大きいＳＶ４０断片も使用し得るが、但し
ＨindＩＩＩから複製のウィルスオリジン内に存在する
ＢglＩ部位まで延びる約２５０bp配列が含まれることが
必要である。更に一般に所望の遺伝子配列に関連するプ
ロモーター又は制御配列を使用することもでき、且つ使
用するのがしばしば望ましい。但し、この種の制御配列
は、宿主細胞系に対し適合性であるものとする。
【００４２】複製のオリジンは、例えばＳＶ４０又はそ
の他のウィルス(例えばポリオーマ、アデノ、ＶＳＶ、
ＢＰＶ等)源から得られるような外来オリジンを含むよ
うにベクターを作成して供給するか、或いは宿主細胞の
染色体複製メカニズムにより供給することができる。ベ
クターが宿主細胞の染色体中に組み込まれれば、これで
しばしば充分である。
の他のウィルス(例えばポリオーマ、アデノ、ＶＳＶ、
ＢＰＶ等)源から得られるような外来オリジンを含むよ
うにベクターを作成して供給するか、或いは宿主細胞の
染色体複製メカニズムにより供給することができる。ベ
クターが宿主細胞の染色体中に組み込まれれば、これで
しばしば充分である。
【００４３】本発明を好適具体例につき本明細書中に説
明するが、ここに記載したような宿主細胞、ベクター及
び発現系のみに限定されるものでないことが了解されよ
う。
明するが、ここに記載したような宿主細胞、ベクター及
び発現系のみに限定されるものでないことが了解されよ
う。
【００４４】Ｃ．使用方法 Ｃ．１．形質転換: 強固な細胞壁バリヤーを持たない細胞を宿主細胞として
使用する場合、トリンスフェクションはＧraham及びＶa
n der ＥbによりＶirology,５２:５４６(１９７８)に記
載された燐酸カルシウム沈澱法により行なわれる。然し
ながら、例えば核注入又はプロトプラスト融合によるよ
うな細胞中へのＤＮＡの他の導入法も使用することがで
きる。
使用する場合、トリンスフェクションはＧraham及びＶa
n der ＥbによりＶirology,５２:５４６(１９７８)に記
載された燐酸カルシウム沈澱法により行なわれる。然し
ながら、例えば核注入又はプロトプラスト融合によるよ
うな細胞中へのＤＮＡの他の導入法も使用することがで
きる。
【００４５】原核細胞又は実質の細胞壁構造を含有する
細胞を使用する場合、好適なトランスフェクション方法
はＦ．Ｎ．Ｃohen et al．,によりＰroc．Ｎatl．Ａca
d．Ｓci．,ＵＳＡ,６９:２１１０(１９７２)に記載され
たように塩化カルシウムを使用するカルシウム処理であ
る。
細胞を使用する場合、好適なトランスフェクション方法
はＦ．Ｎ．Ｃohen et al．,によりＰroc．Ｎatl．Ａca
d．Ｓci．,ＵＳＡ,６９:２１１０(１９７２)に記載され
たように塩化カルシウムを使用するカルシウム処理であ
る。
【００４６】Ｃ．２．ベクターの作成 所望のコード配列と制御配列とを含有する適するベクタ
ーの作成は、標準的結合技術を使用する。単離されたプ
ラスミド又はＤＮＡ断片を開裂し、適当に処理し且つ所
望の形態に再結合して、所要のプラスミドを生成する。
使用する方法は、ＤＮＡ源又は使用する宿主に依存しな
い。
ーの作成は、標準的結合技術を使用する。単離されたプ
ラスミド又はＤＮＡ断片を開裂し、適当に処理し且つ所
望の形態に再結合して、所要のプラスミドを生成する。
使用する方法は、ＤＮＡ源又は使用する宿主に依存しな
い。
【００４７】開裂は、適当な緩衝液中で１種又はそれ以
上の制限酵素により処理して行なわれる。一般に、約１
μgのプラスミド又はＤＮＡ断片を約２０μlの緩衝溶液
中で約１ユニットの酵素と共に使用する(特定制限酵素
に対する適当な緩衝液及び基質の量は製造業者により特
定されている)。３７℃にて約１時間インキュベーショ
ンする。培養後、フェノール及びクロロホルムでの抽出
により蛋白質を除去し、且つ核酸をエタノールでの沈澱
により水性フラクションから回収する。
上の制限酵素により処理して行なわれる。一般に、約１
μgのプラスミド又はＤＮＡ断片を約２０μlの緩衝溶液
中で約１ユニットの酵素と共に使用する(特定制限酵素
に対する適当な緩衝液及び基質の量は製造業者により特
定されている)。３７℃にて約１時間インキュベーショ
ンする。培養後、フェノール及びクロロホルムでの抽出
により蛋白質を除去し、且つ核酸をエタノールでの沈澱
により水性フラクションから回収する。
【００４８】平滑末端が必要ならば、この調製物を１０
ユニットのＥ．coliＤＮＡポリメラーゼＩ(Ｋlenow)と
共に１５℃にて１５分間処理し、フェノール−クロロホ
ルム抽出し、エタノール沈澱する。
ユニットのＥ．coliＤＮＡポリメラーゼＩ(Ｋlenow)と
共に１５℃にて１５分間処理し、フェノール−クロロホ
ルム抽出し、エタノール沈澱する。
【００４９】開裂した断片のサイズ分画はＤ．Ｇoeddel
et al．によりＮucleic Ａcids Ｒes．,８:４０５７
(１９８０)(引用して本明細書に包含する)に記載された
６％ポリアクリルアミドゲルを用いて行なわれる。
et al．によりＮucleic Ａcids Ｒes．,８:４０５７
(１９８０)(引用して本明細書に包含する)に記載された
６％ポリアクリルアミドゲルを用いて行なわれる。
【００５０】結合には、正確な整合性を与えるために適
当に末端処理した所望の成分のほぼ等モル量を０．５μ
gのＤＮＡ当り約１０ユニットのＴ４ＤＮＡリガーゼで
処理する。(開裂したベクターを成分として使用する場
合、細菌のアルカリ性ホスファターゼで予備処理するこ
とにより開裂ベクターの再結合を防止するのが有用であ
る。)
当に末端処理した所望の成分のほぼ等モル量を０．５μ
gのＤＮＡ当り約１０ユニットのＴ４ＤＮＡリガーゼで
処理する。(開裂したベクターを成分として使用する場
合、細菌のアルカリ性ホスファターゼで予備処理するこ
とにより開裂ベクターの再結合を防止するのが有用であ
る。)
【００５１】下記の実施例に於いて、プラスミド作成に
対する正確な結合は、Ｅ．coli Ｋ１２菌株２９４(Ａ
ＴＣＣ Ｎo．３１４４６)を結合混合物で形質転換する
ことにより確認される。成功した形質転換体は、プラス
ミドの作成様式に応じてアンピシリン耐性又はテトラサ
イクリン耐性により選択した。次いで、形質転換体から
のプラスミドを調製し、制限分析し及び／又はＭessing
等の方法(Ｎucleic Ａcids Ｒes．,９:３０９(１９８
１))又はＭaxam et al．の方法(Ｍethods in Ｅnzymolo
gy,６５:４９９(１９８０))によって配列決定した。
対する正確な結合は、Ｅ．coli Ｋ１２菌株２９４(Ａ
ＴＣＣ Ｎo．３１４４６)を結合混合物で形質転換する
ことにより確認される。成功した形質転換体は、プラス
ミドの作成様式に応じてアンピシリン耐性又はテトラサ
イクリン耐性により選択した。次いで、形質転換体から
のプラスミドを調製し、制限分析し及び／又はＭessing
等の方法(Ｎucleic Ａcids Ｒes．,９:３０９(１９８
１))又はＭaxam et al．の方法(Ｍethods in Ｅnzymolo
gy,６５:４９９(１９８０))によって配列決定した。
【００５２】Ｄ．方法の概略 Ｄ．１．哺乳動物抗体 本発明の一部を構成し且つその方法により製造される第
１のタイプの抗体は、「哺乳動物抗体」であり、Ｈ鎖とＬ
鎖とが成熟哺乳動物Ｂリンパ球によりin situで、或い
はハイブリドーマ培養物の部分として永久株化細胞と融
合した場合に産生される抗体のアミノ酸配列に類似する
ものである。要するに、これらの抗体は次のようにして
産生される。
１のタイプの抗体は、「哺乳動物抗体」であり、Ｈ鎖とＬ
鎖とが成熟哺乳動物Ｂリンパ球によりin situで、或い
はハイブリドーマ培養物の部分として永久株化細胞と融
合した場合に産生される抗体のアミノ酸配列に類似する
ものである。要するに、これらの抗体は次のようにして
産生される。
【００５３】Ｈ鎖もしくはＬ鎖をコードするメッセンジ
ャーＲＮＡを適当な起源、即ち成熟Ｂ細胞又はハイブリ
ドーマ培養物から単離する。その際ＲＮＡ単離の標準技
術及びポリ−Ａ mＲＮＡを分離するためのオリゴ−dＴ
セルロースクロマトグラフィーを使用する。更にポリ−
Ａ mＲＮＡを分画して、場合により所望抗体のＬ鎖も
しくはＨ鎖に於けるアミノ酸配列をコードするのに充分
なサイズの配列を得る。
ャーＲＮＡを適当な起源、即ち成熟Ｂ細胞又はハイブリ
ドーマ培養物から単離する。その際ＲＮＡ単離の標準技
術及びポリ−Ａ mＲＮＡを分離するためのオリゴ−dＴ
セルロースクロマトグラフィーを使用する。更にポリ−
Ａ mＲＮＡを分画して、場合により所望抗体のＬ鎖も
しくはＨ鎖に於けるアミノ酸配列をコードするのに充分
なサイズの配列を得る。
【００５４】次いで、所望のcＤＮＡに特徴的である適
当なプライマー好ましくは核酸配列を用いて、mＲＮＡ
の混合物からcＤＮＡライブラリーを作成する。配列が
公知であれば、この種のプライマーを抗体のアミノ酸配
列に基いて推定し且つ合成することができる。或いは、
所望の抗体を産生する細胞系からの未分画ポリ−Ａ m
ＲＮＡのcＤＮＡ又はポリ−dＴを使用することもでき
る。得られたcＤＮＡを必要に応じポリアクリルアミド
ゲルでサイズ分画し、次いで適当な制限酵素(例えばＰs
tＩ)により開裂し且つdＧ残部で延長したpＢＲ３２２又
はその他の適当なクローニングベクターとアニールする
ために例えばdＣ残基で延長する。勿論、他のテイル及
び他のクローニングベクター残部を用いてcＤＮＡ含有
クローニングベクターを形成するその他の手段も使用し
得るが、前記のものが標準的且つ好適な選択である。適
する宿主細胞菌株、典型的にはＥ．coliをアニールした
クローニングベクターで形質転換し、得られた形質転換
体を例えばテトラサイクリン耐性により、或いはクロー
ニングベクタープラスミド上に存在する他の表現型特性
により同定する。
当なプライマー好ましくは核酸配列を用いて、mＲＮＡ
の混合物からcＤＮＡライブラリーを作成する。配列が
公知であれば、この種のプライマーを抗体のアミノ酸配
列に基いて推定し且つ合成することができる。或いは、
所望の抗体を産生する細胞系からの未分画ポリ−Ａ m
ＲＮＡのcＤＮＡ又はポリ−dＴを使用することもでき
る。得られたcＤＮＡを必要に応じポリアクリルアミド
ゲルでサイズ分画し、次いで適当な制限酵素(例えばＰs
tＩ)により開裂し且つdＧ残部で延長したpＢＲ３２２又
はその他の適当なクローニングベクターとアニールする
ために例えばdＣ残基で延長する。勿論、他のテイル及
び他のクローニングベクター残部を用いてcＤＮＡ含有
クローニングベクターを形成するその他の手段も使用し
得るが、前記のものが標準的且つ好適な選択である。適
する宿主細胞菌株、典型的にはＥ．coliをアニールした
クローニングベクターで形質転換し、得られた形質転換
体を例えばテトラサイクリン耐性により、或いはクロー
ニングベクタープラスミド上に存在する他の表現型特性
により同定する。
【００５５】成功した形質転換体を釣り上げて、マイク
ロタイター皿又はその他の支持体に移し、更に増殖及び
保存する。次いで、これら増殖する培養物のニトロセル
ロースフィルターのプリント物(imprint)をcＤＮＡ中の
所望配列に相補的であることが知られた塩基を含有する
適当なヌクレオチド配列でプローブする。数種のプロー
ブを使用することができ、好ましくはＡＴＰ32でキナー
ゼ処理することにより標識した合成単一鎖ＤＮＡ配列を
使用する。ニトロセルロースフィルターに固定された細
胞を溶菌し、ＤＮＡを変性し、固定した後にキナーゼ処
理したプローブと反応させる。うまくハイブリダイズす
るクローンをフォトプレートへ接触させて検出し、プラ
スミドを増殖するコロニーから単離し、遺伝子の所望部
分が存在することを証明するために当業界で知られた手
段により配列決定する。
ロタイター皿又はその他の支持体に移し、更に増殖及び
保存する。次いで、これら増殖する培養物のニトロセル
ロースフィルターのプリント物(imprint)をcＤＮＡ中の
所望配列に相補的であることが知られた塩基を含有する
適当なヌクレオチド配列でプローブする。数種のプロー
ブを使用することができ、好ましくはＡＴＰ32でキナー
ゼ処理することにより標識した合成単一鎖ＤＮＡ配列を
使用する。ニトロセルロースフィルターに固定された細
胞を溶菌し、ＤＮＡを変性し、固定した後にキナーゼ処
理したプローブと反応させる。うまくハイブリダイズす
るクローンをフォトプレートへ接触させて検出し、プラ
スミドを増殖するコロニーから単離し、遺伝子の所望部
分が存在することを証明するために当業界で知られた手
段により配列決定する。
【００５６】所望の遺伝子断片を切断処理して、適当な
発現ベクター中へ挿入した場合の制御セグメントとの適
当な解読枠を確保する。典型的には、ヌクレオチドを
５'末端へ付加して開始信号と適当に位置する制限エン
ドヌクレアーゼ部位とを含むようにする。
発現ベクター中へ挿入した場合の制御セグメントとの適
当な解読枠を確保する。典型的には、ヌクレオチドを
５'末端へ付加して開始信号と適当に位置する制限エン
ドヌクレアーゼ部位とを含むようにする。
【００５７】次いで、適当に処理した遺伝子配列を、遺
伝子と共に解読枠にあるプロモーターを含有し且つ使用
する宿主に対し適合性であるベクター中に配置する。例
えば米国特許出願第３０７４７３号、第２９１８９２号
及び第３０５６５７号(ＥＰＯ特許公開第００３６７７
６号、第００４８９７０号及び第００５１８７３号)明
細書に記載されたような多数のプラスミドは、適当なプ
ロモーターと制御配列とリボソーム結合部位と転写停止
部位と便利なマーカーとを既に含有する。
伝子と共に解読枠にあるプロモーターを含有し且つ使用
する宿主に対し適合性であるベクター中に配置する。例
えば米国特許出願第３０７４７３号、第２９１８９２号
及び第３０５６５７号(ＥＰＯ特許公開第００３６７７
６号、第００４８９７０号及び第００５１８７３号)明
細書に記載されたような多数のプラスミドは、適当なプ
ロモーターと制御配列とリボソーム結合部位と転写停止
部位と便利なマーカーとを既に含有する。
【００５８】本発明に於いては、Ｌ鎖をコードする遺伝
子及びＨ鎖をコードする遺伝子を上記の手法により別々
に回収する。即ち、これらは、それぞれ適当なプロモー
ター及び翻訳制御の下にある限り、別々の発現プラスミ
ド中へ挿入することができ、或いは一緒に同じプラスミ
ドに挿入することができる。
子及びＨ鎖をコードする遺伝子を上記の手法により別々
に回収する。即ち、これらは、それぞれ適当なプロモー
ター及び翻訳制御の下にある限り、別々の発現プラスミ
ド中へ挿入することができ、或いは一緒に同じプラスミ
ドに挿入することができる。
【００５９】次いで、上記のように作成した発現ベクタ
ーを使用して適当な細胞を形質転換する。Ｌ鎖及びＨ鎖
を同一種又は異なる種の別々の細胞培養物中に形質転換
することができ、Ｌ鎖及びＨ鎖に対する別々のプラスミ
ドを使用して単一の細胞培養物を同時形質転換すること
ができ、或いは両遺伝子を含有し且つＬ鎖とＨ鎖との両
者に対する遺伝子を発現し得る単一の発現プラスミドを
単一の細胞培養物に形質転換することができる。
ーを使用して適当な細胞を形質転換する。Ｌ鎖及びＨ鎖
を同一種又は異なる種の別々の細胞培養物中に形質転換
することができ、Ｌ鎖及びＨ鎖に対する別々のプラスミ
ドを使用して単一の細胞培養物を同時形質転換すること
ができ、或いは両遺伝子を含有し且つＬ鎖とＨ鎖との両
者に対する遺伝子を発現し得る単一の発現プラスミドを
単一の細胞培養物に形質転換することができる。
【００６０】上記３つの選択のどれを選択するかに関係
なく、細胞を所望蛋白質の産生に適する条件下で増殖さ
せる。この種の条件は、主として所望蛋白質の性質では
なく、発現ベクター中に使用されるプロモーター及び制
御系のタイプにより支配される。次いで、このように産
生された蛋白質を当業界で公知の方法により細胞培養物
から回収するが、方法の選択は必然的に蛋白質の発現さ
れた形態に依存する。例えばＥ．coliで発現された成熟
異種蛋白質を不溶性粒子として細胞内に沈着させるのが
一般的であり、これは回収を可能にするための細胞の溶
菌と変性剤(denaturant)中への可溶化とを必要とする。
他方、酵母及び細菌の菌株中の適切な合成条件下の蛋白
質は培地中(酵母及びク゛ラム陽性菌)又はペリプラズム空
間(グラム陰性菌)へ分泌することができ、それほど激し
くない方法により回収することができる。一般に、宿主
としての組織培養細胞は異種蛋白質の便利な回収を可能
にすると思われる。
なく、細胞を所望蛋白質の産生に適する条件下で増殖さ
せる。この種の条件は、主として所望蛋白質の性質では
なく、発現ベクター中に使用されるプロモーター及び制
御系のタイプにより支配される。次いで、このように産
生された蛋白質を当業界で公知の方法により細胞培養物
から回収するが、方法の選択は必然的に蛋白質の発現さ
れた形態に依存する。例えばＥ．coliで発現された成熟
異種蛋白質を不溶性粒子として細胞内に沈着させるのが
一般的であり、これは回収を可能にするための細胞の溶
菌と変性剤(denaturant)中への可溶化とを必要とする。
他方、酵母及び細菌の菌株中の適切な合成条件下の蛋白
質は培地中(酵母及びク゛ラム陽性菌)又はペリプラズム空
間(グラム陰性菌)へ分泌することができ、それほど激し
くない方法により回収することができる。一般に、宿主
としての組織培養細胞は異種蛋白質の便利な回収を可能
にすると思われる。
【００６１】Ｈ鎖とＬ鎖とを同一宿主中で同時発現させ
る場合、単離法は再編成抗体を回収するように設計され
る。これは下記するようにin vitroで行なうことがで
き、或いは細胞質の還元環境からＩgＧ鎖を分泌する微
生物中in vivoで行なうことも可能である。より詳細な
説明は下記Ｄ．２．に示す。
る場合、単離法は再編成抗体を回収するように設計され
る。これは下記するようにin vitroで行なうことがで
き、或いは細胞質の還元環境からＩgＧ鎖を分泌する微
生物中in vivoで行なうことも可能である。より詳細な
説明は下記Ｄ．２．に示す。
【００６２】Ｄ．２．鎖組換技術 Ｈ鎖及びＬ鎖又はその部分を互いに分離して産生する本
発明の方法の能力は、独特且つ先例のない免疫グロブリ
ン、Ｆab領域及び単一価の抗体の集合体を得る機会を与
える。このような製造は、単離した鎖を再組立てする技
術の使用を必要とする。この種の手段は当業界で公知で
あり、従ってこれらにつきここで再検討するのが適当で
ある。
発明の方法の能力は、独特且つ先例のない免疫グロブリ
ン、Ｆab領域及び単一価の抗体の集合体を得る機会を与
える。このような製造は、単離した鎖を再組立てする技
術の使用を必要とする。この種の手段は当業界で公知で
あり、従ってこれらにつきここで再検討するのが適当で
ある。
【００６３】単一鎖のジスルフィド結合を含有する蛋白
質を還元し且つ再酸化して天然構造及び活性を高収率で
再生させているが(Ｒ．Ｂ．Ｆreedman et al．,Ｅnzymo
logyof Ｐost Ｔranslational Ｍodification of Ｐrot
eins,１:１５７−２１２(１９８０)Ａcademic Ｐress
社、ＮＹ．)、ジスルフィド結合により結合されている
不連続ポリペプチド鎖より成る蛋白質は還元開裂の後に
in vitroで再編成するのが困難である。精巧な場合であ
るインシュリンは永年に亘り多くの実験的注目を集めて
おり、現在ではこれに関し工業的方法が確立されている
ほど効率的に再編成することができる(Ｒ．Ｅ．Ｃhance
et al．,Ｐeptides:第７回米国ペプチドシンポジウム
のＰroceedings(Ｄ．Ｈ．Ｒich及びＥ．Ｇross編)７２
１−７２８．Ｐierce Ｃhemical Ｃo．,Ｒockford,Ｉ
Ｌ．(１９８１))。
質を還元し且つ再酸化して天然構造及び活性を高収率で
再生させているが(Ｒ．Ｂ．Ｆreedman et al．,Ｅnzymo
logyof Ｐost Ｔranslational Ｍodification of Ｐrot
eins,１:１５７−２１２(１９８０)Ａcademic Ｐress
社、ＮＹ．)、ジスルフィド結合により結合されている
不連続ポリペプチド鎖より成る蛋白質は還元開裂の後に
in vitroで再編成するのが困難である。精巧な場合であ
るインシュリンは永年に亘り多くの実験的注目を集めて
おり、現在ではこれに関し工業的方法が確立されている
ほど効率的に再編成することができる(Ｒ．Ｅ．Ｃhance
et al．,Ｐeptides:第７回米国ペプチドシンポジウム
のＰroceedings(Ｄ．Ｈ．Ｒich及びＥ．Ｇross編)７２
１−７２８．Ｐierce Ｃhemical Ｃo．,Ｒockford,Ｉ
Ｌ．(１９８１))。
【００６４】免疫グロブリンは、インシュリンよりも困
難な問題を含むことが判明している。四元体は１５個も
しくはそれ以上のジスルフィド結合により分子内及び分
子間で安定化されている。鎖間ジスルフィドのみの開裂
により分解されたＨ鎖とＬ鎖とを再結合して、鎖間ジス
ルフィドを復帰させなくても抗体活性を再取することが
可能であった(Ｇ．Ｍ．Ｅdelman et al．,Ｐroc．Ｎat
l．Ａcad．Ｓci．,ＵＳＡ,５０:７５３(１９６３)）。
更に、蛋白質分解により生成される活性なＩgＧの断片
(約５０,０００ＭＷのＦab断片)をそれらの完全に還元
したＨ鎖成分とＬ鎖成分とに開裂させ、これらをかなり
効率的に再編成して活性抗体を与えることができる
(Ｅ．Ｈaber,Ｐroc．Ｎatl．Ａcad．Ｓci．,ＵＳＡ,５
２:１０９９(１９６４);Ｐ．Ｌ．Ｗhitney et al．,Ｐr
oc．Ｎatl．Ａcad．Ｓci．,ＵＳＡ,５３:５２４(１９６
５))。完全還元された天然ＩgＧから活性抗体を再編成
する試みは、恐らく還元鎖及び副産物又は中間物が再編
成過程に於いて不溶解性であるため、完全に不成功であ
った(Ｍ．Ｈ．Ｆreedman et al．,Ｊ．Ｂiol．Ｃhem．,
２４１:５２２５(１９６６))。然しながら、免疫グロブ
リンを完全還元の前にリジンのポリアデニル化によりラ
ンダムに改変すれば、分離される鎖は再酸化の際に抗原
結合性の活性を回収する能力を有する(上記)。
難な問題を含むことが判明している。四元体は１５個も
しくはそれ以上のジスルフィド結合により分子内及び分
子間で安定化されている。鎖間ジスルフィドのみの開裂
により分解されたＨ鎖とＬ鎖とを再結合して、鎖間ジス
ルフィドを復帰させなくても抗体活性を再取することが
可能であった(Ｇ．Ｍ．Ｅdelman et al．,Ｐroc．Ｎat
l．Ａcad．Ｓci．,ＵＳＡ,５０:７５３(１９６３)）。
更に、蛋白質分解により生成される活性なＩgＧの断片
(約５０,０００ＭＷのＦab断片)をそれらの完全に還元
したＨ鎖成分とＬ鎖成分とに開裂させ、これらをかなり
効率的に再編成して活性抗体を与えることができる
(Ｅ．Ｈaber,Ｐroc．Ｎatl．Ａcad．Ｓci．,ＵＳＡ,５
２:１０９９(１９６４);Ｐ．Ｌ．Ｗhitney et al．,Ｐr
oc．Ｎatl．Ａcad．Ｓci．,ＵＳＡ,５３:５２４(１９６
５))。完全還元された天然ＩgＧから活性抗体を再編成
する試みは、恐らく還元鎖及び副産物又は中間物が再編
成過程に於いて不溶解性であるため、完全に不成功であ
った(Ｍ．Ｈ．Ｆreedman et al．,Ｊ．Ｂiol．Ｃhem．,
２４１:５２２５(１９６６))。然しながら、免疫グロブ
リンを完全還元の前にリジンのポリアデニル化によりラ
ンダムに改変すれば、分離される鎖は再酸化の際に抗原
結合性の活性を回収する能力を有する(上記)。
【００６５】免疫グロブリンの再編成に対して特に適し
た方法は、現在では古典的となったインシュリン組換技
術から得られるものであり、ここでは出発物質を酸化ス
ルフィトリシス(Ｏxidative sulfitolysis)により調製
し、蛋白質に於ける全てのシステインのチオール不安定
性Ｓ−スルホン酸基を発生させ、ジスルフィドを非還元
的に破壊する(Ｃhance et al．,上記)。酸化スルフィ
トリシスは緩和なジスルフィド開裂反応であり(Ｇ．
Ｅ．Ｍeans et al．,Ｃhemical Ｍodificationof
Ｐroteins,Ｈolden−Ｄay,Ｓan Ｆrancisco(１９７
１))、これはしばしば還元より緩和であり、且つジスル
フィド再生成がチオール−ジスルフィド相互交換を介し
て生じ得る緩和な還元剤に露呈されるまで安定であるよ
うな誘導体を生成する。本発明に於いて、酸化スルフィ
トリシスにより生成されるＨ鎖及びＬ鎖のＳ−スルホネ
ートは、ジスルフィド結合生成を行なうために空気酸化
とチオール−ジスルフィド相互交換との両者を用いて再
編成された。一般的手順は、１９８２年１２月２２日付
で出願された米国特許出願第４５２１８７号(ＥＰＯ出
願第８３．３０７８４０．５号)明細書に詳細に示され
ており、これを参考のためここに引用して本明細書に包
含する。
た方法は、現在では古典的となったインシュリン組換技
術から得られるものであり、ここでは出発物質を酸化ス
ルフィトリシス(Ｏxidative sulfitolysis)により調製
し、蛋白質に於ける全てのシステインのチオール不安定
性Ｓ−スルホン酸基を発生させ、ジスルフィドを非還元
的に破壊する(Ｃhance et al．,上記)。酸化スルフィ
トリシスは緩和なジスルフィド開裂反応であり(Ｇ．
Ｅ．Ｍeans et al．,Ｃhemical Ｍodificationof
Ｐroteins,Ｈolden−Ｄay,Ｓan Ｆrancisco(１９７
１))、これはしばしば還元より緩和であり、且つジスル
フィド再生成がチオール−ジスルフィド相互交換を介し
て生じ得る緩和な還元剤に露呈されるまで安定であるよ
うな誘導体を生成する。本発明に於いて、酸化スルフィ
トリシスにより生成されるＨ鎖及びＬ鎖のＳ−スルホネ
ートは、ジスルフィド結合生成を行なうために空気酸化
とチオール−ジスルフィド相互交換との両者を用いて再
編成された。一般的手順は、１９８２年１２月２２日付
で出願された米国特許出願第４５２１８７号(ＥＰＯ出
願第８３．３０７８４０．５号)明細書に詳細に示され
ており、これを参考のためここに引用して本明細書に包
含する。
【００６６】Ｄ．３．組換技術により可能な変種 上記Ｄ．１及びＤ．２に記載した技術を用いて、哺乳動
物抗体の効率的産生を得るために用いた他の操作を全く
簡潔に変化させて、この基本的抗体型の多くの変種を産
生させることができる。これらの変種は組換技術の使用
に本質的であり、通常見られる哺乳動物免疫グロブリン
鎖に於けるアミノ酸配列の遺伝子レベルでの改変を可能
にし、この方法の真価はこれら変種を得る能力を有する
こと並びに所望の珍しく、しばしば汚染された分子を経
済的且つ特異的に産生する能力を有することにある。更
に、これらの変種は個々の鎖を単離する能力を特徴と
し、従って新規な集合体をもたらす。
物抗体の効率的産生を得るために用いた他の操作を全く
簡潔に変化させて、この基本的抗体型の多くの変種を産
生させることができる。これらの変種は組換技術の使用
に本質的であり、通常見られる哺乳動物免疫グロブリン
鎖に於けるアミノ酸配列の遺伝子レベルでの改変を可能
にし、この方法の真価はこれら変種を得る能力を有する
こと並びに所望の珍しく、しばしば汚染された分子を経
済的且つ特異的に産生する能力を有することにある。更
に、これらの変種は個々の鎖を単離する能力を特徴と
し、従って新規な集合体をもたらす。
【００６７】要するに、遺伝子操作は発現ベクターの作
成過程でゲノム材料の再編成を可能にするので、この種
の再編成を行なって「天然」抗体、もしくは免疫グロブリ
ンの成分に対し新規なコード配列を産生することができ
る。下記に詳細に説明するように、哺乳動物Ｈ鎖に対す
るコード配列は、単一起源又は単一クラスからは完全に
は得ることができず、配列の部分を例えばネズミ−ネズ
ミハイブリドーマ、ヒト−ネズミハイブリドーマ或いは
一連の抗原処理に呼応して分化させたＢ細胞のような種
々異なるmＲＮＡプールからＤ．１に記載した技術によ
り回収することができる。各々の場合に於ける配列の所
望の部分は、Ｄ．１に記載したプローブ及び分析技術を
用いて回収され且つ同じモデル配列の部分について使用
されると同じ結合法を用いて発現ベクターに組換えるこ
とができる。この種のキメラ鎖は任意所望の長さで作成
することができ、例えば完全なＨ鎖を作成することがで
き、そのＦab領域に対する配列のみを作成することもで
きる。
成過程でゲノム材料の再編成を可能にするので、この種
の再編成を行なって「天然」抗体、もしくは免疫グロブリ
ンの成分に対し新規なコード配列を産生することができ
る。下記に詳細に説明するように、哺乳動物Ｈ鎖に対す
るコード配列は、単一起源又は単一クラスからは完全に
は得ることができず、配列の部分を例えばネズミ−ネズ
ミハイブリドーマ、ヒト−ネズミハイブリドーマ或いは
一連の抗原処理に呼応して分化させたＢ細胞のような種
々異なるmＲＮＡプールからＤ．１に記載した技術によ
り回収することができる。各々の場合に於ける配列の所
望の部分は、Ｄ．１に記載したプローブ及び分析技術を
用いて回収され且つ同じモデル配列の部分について使用
されると同じ結合法を用いて発現ベクターに組換えるこ
とができる。この種のキメラ鎖は任意所望の長さで作成
することができ、例えば完全なＨ鎖を作成することがで
き、そのＦab領域に対する配列のみを作成することもで
きる。
【００６８】組換技術の使用により生ずる付加的な融通
性は、別々の培養物に於いてＨ鎖とＬ鎖もしくはその断
片或いは同じ培養物に於けるＨ鎖とＬ鎖との独特な組合
せを産生し、且つ適当な成分が組立てられるまで抗体又
は免疫グロブリン集合体の再編成を防止する能力から生
ずる。例えば、通常の抗体産生はＬ鎖及びＨ鎖の部分が
同じ細胞に於ける特定の決定子に呼応して作成されるの
で、自動的に「哺乳動物の交代」の生成をもたらすが、本
発明の方法は完全に新規な混合物を組立てる機会を提供
する。若干制限された量の「ハイブリッド」抗体が「クワ
ドローマ(quadroma)」、即ちこのように産生されたＨ鎖
とＬ鎖とのランダム集合を可能にする２種のハイブリド
ーマ細胞培養物の融合体により産生されている。
性は、別々の培養物に於いてＨ鎖とＬ鎖もしくはその断
片或いは同じ培養物に於けるＨ鎖とＬ鎖との独特な組合
せを産生し、且つ適当な成分が組立てられるまで抗体又
は免疫グロブリン集合体の再編成を防止する能力から生
ずる。例えば、通常の抗体産生はＬ鎖及びＨ鎖の部分が
同じ細胞に於ける特定の決定子に呼応して作成されるの
で、自動的に「哺乳動物の交代」の生成をもたらすが、本
発明の方法は完全に新規な混合物を組立てる機会を提供
する。若干制限された量の「ハイブリッド」抗体が「クワ
ドローマ(quadroma)」、即ちこのように産生されたＨ鎖
とＬ鎖とのランダム集合を可能にする２種のハイブリド
ーマ細胞培養物の融合体により産生されている。
【００６９】本発明は、所望鎖をin vitroで混合するこ
とにより、或いは同じ培養物を所望鎖に対するコード配
列で形質転換させることにより一層制御された所望鎖の
組立てを可能にする。
とにより、或いは同じ培養物を所望鎖に対するコード配
列で形質転換させることにより一層制御された所望鎖の
組立てを可能にする。
【００７０】Ｄ．４．複合免疫グロブリン 哺乳動物抗体の組換体産生につき詳細に説明した上記の
方法を若干改変して使用することにより、本発明に包含
される他の種類の抗体又はＮＳＩを作成することができ
る。鎖の相同性が種々異なる特異性の免疫グロブリン配
列に対応するような特定具体例の非特異性複合免疫グロ
ブリンを作成するには勿論、Ｈ鎖とＬ鎖とを別々の培養
物で作成し、これらを所望に応じて再組立てすることの
みを必要とする。
方法を若干改変して使用することにより、本発明に包含
される他の種類の抗体又はＮＳＩを作成することができ
る。鎖の相同性が種々異なる特異性の免疫グロブリン配
列に対応するような特定具体例の非特異性複合免疫グロ
ブリンを作成するには勿論、Ｈ鎖とＬ鎖とを別々の培養
物で作成し、これらを所望に応じて再組立てすることの
みを必要とする。
【００７１】例えば、抗−ＣＥＡＬ鎖／抗−肝炎Ｈ鎖の
複合抗体を作成するには、Ｌ鎖クローンのための鋳型と
して使用するmＲＮＡの適する原料は、例えばＥ．１に
記載する抗−ＣＥＡ産生細胞系である。Ｈ鎖に対応する
mＲＮＡは肝炎感染に反応して生じたＢ細胞から、或い
はＢ細胞がこの種の起源であるようなハイブリドーマか
ら得られるであろう。この種の複合体は本発明の方法を
用いて殆んど任意に組立てることができ、且つ各鎖に対
する鋳型として使用するのに適したmＲＮＡの入手し得
る起源によってのみ制約されることが明らかである。こ
の方法の他の特徴は、全て上記のものと同様である。
複合抗体を作成するには、Ｌ鎖クローンのための鋳型と
して使用するmＲＮＡの適する原料は、例えばＥ．１に
記載する抗−ＣＥＡ産生細胞系である。Ｈ鎖に対応する
mＲＮＡは肝炎感染に反応して生じたＢ細胞から、或い
はＢ細胞がこの種の起源であるようなハイブリドーマか
ら得られるであろう。この種の複合体は本発明の方法を
用いて殆んど任意に組立てることができ、且つ各鎖に対
する鋳型として使用するのに適したmＲＮＡの入手し得
る起源によってのみ制約されることが明らかである。こ
の方法の他の特徴は、全て上記のものと同様である。
【００７２】Ｄ．５．ハイブリッド抗体 ハイブリッド抗体は、２種以上の抗原と同時に反応し得
るので特に有用である。例えば上記Ｄ．４に示したよう
な種々異なる抗原に対する抗体の鎖に対応するＨ鎖とＬ
鎖との対は、４つの別々の培養物で作成され、四元体の
時期尚早な組立てを防止する。この後、別々に作成され
た４種のペプチドを混合することにより、所望の四元体
まで組立てることができる。ランダムな集合は極めて望
ましくない産生物の生成をもたらし得るが、同質(相同)
のＬ鎖及びＨ鎖が互いに結合されて他の対とは一致しな
いような産生物のその部分は所望のハイブリッド抗体を
与える。
るので特に有用である。例えば上記Ｄ．４に示したよう
な種々異なる抗原に対する抗体の鎖に対応するＨ鎖とＬ
鎖との対は、４つの別々の培養物で作成され、四元体の
時期尚早な組立てを防止する。この後、別々に作成され
た４種のペプチドを混合することにより、所望の四元体
まで組立てることができる。ランダムな集合は極めて望
ましくない産生物の生成をもたらし得るが、同質(相同)
のＬ鎖及びＨ鎖が互いに結合されて他の対とは一致しな
いような産生物のその部分は所望のハイブリッド抗体を
与える。
【００７３】Ｄ．６．キメラ抗体 キメラ抗体(例えば可変配列が不変配列とは別に誘導さ
れる)を作成するには、上記Ｄ．１及びＤ．２の手順を
適当に改変及び付加して応用することができる。好適手
順は、Ｈ鎖及びＬ鎖の部分をコードする遺伝子の所望部
分を適当な種々異なる起源から回収し、これら断片を制
限エンドヌクレアーゼにより再結合して各鎖をコードす
る遺伝子を再編成することである。
れる)を作成するには、上記Ｄ．１及びＤ．２の手順を
適当に改変及び付加して応用することができる。好適手
順は、Ｈ鎖及びＬ鎖の部分をコードする遺伝子の所望部
分を適当な種々異なる起源から回収し、これら断片を制
限エンドヌクレアーゼにより再結合して各鎖をコードす
る遺伝子を再編成することである。
【００７４】例えば、特に好適なキメラ構造に於いて、
ネズミハイブリドーマ培養物により産生される抗体の可
変配列をコードするＨ鎖遺伝子及びＬ鎖遺伝子の部分を
この培養物から回収し且つクローニングし、そしてヒト
抗体に対するＨ鎖及びＬ鎖の不変領域をコードする遺伝
子断片を例えばヒト骨髄腫細胞から回収しクローニング
する。次いで適する制限酵素を使用して、ネズミ遺伝子
の可変部分をヒト遺伝子の不変領域へ２つの鎖のそれぞ
れにつき結合させることができる。キメラ鎖はＤ．１に
示したように産生し、Ｄ．２に示したように合体させ、
非キメラ型と同様に使用する。勿論、鎖に於ける任意の
接合点を選択することができる。
ネズミハイブリドーマ培養物により産生される抗体の可
変配列をコードするＨ鎖遺伝子及びＬ鎖遺伝子の部分を
この培養物から回収し且つクローニングし、そしてヒト
抗体に対するＨ鎖及びＬ鎖の不変領域をコードする遺伝
子断片を例えばヒト骨髄腫細胞から回収しクローニング
する。次いで適する制限酵素を使用して、ネズミ遺伝子
の可変部分をヒト遺伝子の不変領域へ２つの鎖のそれぞ
れにつき結合させることができる。キメラ鎖はＤ．１に
示したように産生し、Ｄ．２に示したように合体させ、
非キメラ型と同様に使用する。勿論、鎖に於ける任意の
接合点を選択することができる。
【００７５】Ｄ．７．改変抗体 改変抗体は、本質的にキメラ抗体の範囲内にある。ここ
でも、Ｄ．１及びＤ．２の技術を応用することができ
る。然しながら鎖の接合部分ではなく適するアミノ酸の
改変、欠失又は付加を例えば突然変異のような可能な技
術により作成する(上記)。例えば、減少した補体固定
(結合)性を有する抗体をコードする遺伝子、或いは向上
した金属結合能力を有する遺伝子をこの種の技術を用い
て作成する。例えば、後者のクラスはメタロチオネイン
ＩＩをコードする公知の遺伝子配列を利用することがで
きる(Ｍ．Ｋarin et al．,Ｎature．２９９:７９７(１
９８２))。この分子断片のキレート化特性は、重金属を
腫瘍部位まで運ぶ際、腫瘍造影に於ける助剤として有用
である(Ｄ．Ａ．Ｓcheinberg et al．,Ｓcience,２１
５:１９(１９８２))。
でも、Ｄ．１及びＤ．２の技術を応用することができ
る。然しながら鎖の接合部分ではなく適するアミノ酸の
改変、欠失又は付加を例えば突然変異のような可能な技
術により作成する(上記)。例えば、減少した補体固定
(結合)性を有する抗体をコードする遺伝子、或いは向上
した金属結合能力を有する遺伝子をこの種の技術を用い
て作成する。例えば、後者のクラスはメタロチオネイン
ＩＩをコードする公知の遺伝子配列を利用することがで
きる(Ｍ．Ｋarin et al．,Ｎature．２９９:７９７(１
９８２))。この分子断片のキレート化特性は、重金属を
腫瘍部位まで運ぶ際、腫瘍造影に於ける助剤として有用
である(Ｄ．Ａ．Ｓcheinberg et al．,Ｓcience,２１
５:１９(１９８２))。
【００７６】Ｄ．８．単一価の抗体 他の好適具体例に於いて、第３の(Ｈ)鎖のＦc領域と結
合した一対のＨ鎖及びＬ鎖から成る抗体を生成させる。
これらの抗体は特に有用な性質を有する。これらは、通
常の抗体と同様に、例えば腫瘍のような組織の抗原表面
を標的として使用することができるが、通常の抗体とは
異なり、これらは標的組織の抗原表面を後退させて非受
容性とはならない。通常の抗体の使用は、数時間でこの
種の表面抗原の集合及びその後の失活をもたらす。
合した一対のＨ鎖及びＬ鎖から成る抗体を生成させる。
これらの抗体は特に有用な性質を有する。これらは、通
常の抗体と同様に、例えば腫瘍のような組織の抗原表面
を標的として使用することができるが、通常の抗体とは
異なり、これらは標的組織の抗原表面を後退させて非受
容性とはならない。通常の抗体の使用は、数時間でこの
種の表面抗原の集合及びその後の失活をもたらす。
【００７７】単一価の抗体の作成方法は、本発明の簡潔
な応用である。所望のＦc領域のＨ鎖に対する遺伝子を
制限酵素により開裂させ、所望のＦc領域をコードする
その部分のみを発現する。次いで、この部分をＤ．２の
技術を用いて別々に作成したＨ鎖に結合し、所望対をＨ
／Ｈ及びＦc／Ｆc組合せ物から分離し、別々に産生した
Ｌ鎖を付加する。このようにして、２つのＨ鎖部分の予
備結合は、通常の抗体が生成される可能性を減少させ
る。
な応用である。所望のＦc領域のＨ鎖に対する遺伝子を
制限酵素により開裂させ、所望のＦc領域をコードする
その部分のみを発現する。次いで、この部分をＤ．２の
技術を用いて別々に作成したＨ鎖に結合し、所望対をＨ
／Ｈ及びＦc／Ｆc組合せ物から分離し、別々に産生した
Ｌ鎖を付加する。このようにして、２つのＨ鎖部分の予
備結合は、通常の抗体が生成される可能性を減少させ
る。
【００７８】Ｄ．９．Ｆab蛋白質 同様にして、Ｈ鎖部分に対する完全遺伝子を含む必要は
ない。上記の変種を全てＦab蛋白質の産生に対する方法
に積み重ねることができ、全体的手順はアミノ末端２２
０個のアミノ酸をコードするＨ鎖の部分を適当な発現ベ
クターで使用する点のみ相違する。
ない。上記の変種を全てＦab蛋白質の産生に対する方法
に積み重ねることができ、全体的手順はアミノ末端２２
０個のアミノ酸をコードするＨ鎖の部分を適当な発現ベ
クターで使用する点のみ相違する。
【００７９】Ｅ．好適具体例の特定例 上記に本発明を一般的意味に於いて記載したが、所望抗
体を産生させる実験手順の詳細を説明するために以下い
くつかの特定具体例を示す。
体を産生させる実験手順の詳細を説明するために以下い
くつかの特定具体例を示す。
【００８０】例Ｅ．１は抗ＣＥＡ抗体成分を作成するた
めの即ち「哺乳動物抗体」を作成するための一般的手順を
示している。
めの即ち「哺乳動物抗体」を作成するための一般的手順を
示している。
【００８１】例Ｅ．３は再編成方法を示しており、従っ
て哺乳動物性複合ハイブリッド及びキメラ免疫グロブリ
ン並びにＦab蛋白質及び単一価の抗体を製造するために
応用できる。
て哺乳動物性複合ハイブリッド及びキメラ免疫グロブリ
ン並びにＦab蛋白質及び単一価の抗体を製造するために
応用できる。
【００８２】例Ｅ．４は、可変領域と不変領域とが種々
異なる起源から得られるようにＨ鎖もしくはＬ鎖を処理
するための手順を示している。
異なる起源から得られるようにＨ鎖もしくはＬ鎖を処理
するための手順を示している。
【００８３】例Ｅ．５は短くしたＨ鎖ゲノムを得る方法
を示しており、これはＦab領域の産生を可能にし且つ同
様にしてＦc領域の産生も可能にする。
を示しており、これはＦab領域の産生を可能にし且つ同
様にしてＦc領域の産生も可能にする。
【００８４】以下、実施例により本発明を説明するが、
これらのみに限定されない。
これらのみに限定されない。
【００８５】Ｅ．１．ネズミ抗−ＣＥＡ抗体鎖に対する
発現ベクターの作成及びペプチド合成 胎生期癌の抗原(ＣＥＡ)は、ヒトオリジンの或る種の腫
瘍細胞の表面に関連する(Ｐ．Ｇold et al．,Ｊ．Ｅx
p．Ｍed．,１２２:４６７(１９６５))。ＣＥＡに結合す
る抗体(抗−ＣＥＡ抗体)は、これら腫瘍の早期発見に有
用であり(Ｔ．Ｒ．Ｖan Ｎagell et al．,Ｃancer Ｒe
s．,４０:５０２(１９８０))、表面にＣＥＡを支持する
と思われるヒト腫瘍の処置に使用できる能力を有する。
Ｉgγ1型(クラス)の抗−ＣＥＡ抗体を分泌するネズミハ
イブリドーマ細胞系(ＣＥＡ．６６−Ｅ３)がＣ．Ｗagen
er et al．,Ｊ．Ｉmmunol．,１３０:２３０８(１９８
３)(この文献を引用して本明細書に包含する)に記載さ
れているように調製されて、mＲＮＡ源として使用され
た。この細胞系による抗ＣＥＡ抗体の産生を決定した。
これら細胞により産生された抗体のＮ−末端配列を次の
ようにしてモノクローナル抗−ＣＥＡのそれと比較し
た。精製したＩgＧをＰＣＡ酵素で処理し(Ｄ．Ｎ．Ｐod
ell et al．,Ｂiochem．Ｂiophys．Ｒes．Ｃommun．,８
１:１７６(１９７８)、次いで６Ｍグアニジン塩酸塩と
１０mＭ２−メルカプトエタノールに於いて解離させた
(１．０mgの免疫グロブリン、５分間、１００℃の水
浴)。解離した鎖をアルキルフェニルカラム(Ｗaters Ａ
ssociates社製)に於いて１００％Ａ(０．１％、ＴＦＡ
−水)〜９０％Ｂ(ＴＦＡ／Ｈ2Ｏ／ＭeＣＮ:０．１／
９．９／９０)の直線勾配を用いて０．８ml／min．の流
速で分離した。３つの主たるピークを溶出させ、銀染色
によってＳＤＳゲルで分析した。最初の２つのピークは
純粋なＬ鎖(ＭＷ２５,０００ダルトン)であり、第３の
ピークはＨ鎖とＬ鎖との７:３混合物であった。１．２n
Ｍ(ナノモル)のＬ鎖をＪ．Ｅ．Ｓhively, Ｍethods in
Ｅnzymology,７９:３１(１９８１)の方法により０．４n
ＭのＮＨ2末端収率にて配列決定した。Ｈ鎖とＬ鎖との
混合物(３nＭ)も配列決定し、Ｌ鎖の配列を二重配列か
ら推定してＨ鎖の配列を得た。
発現ベクターの作成及びペプチド合成 胎生期癌の抗原(ＣＥＡ)は、ヒトオリジンの或る種の腫
瘍細胞の表面に関連する(Ｐ．Ｇold et al．,Ｊ．Ｅx
p．Ｍed．,１２２:４６７(１９６５))。ＣＥＡに結合す
る抗体(抗−ＣＥＡ抗体)は、これら腫瘍の早期発見に有
用であり(Ｔ．Ｒ．Ｖan Ｎagell et al．,Ｃancer Ｒe
s．,４０:５０２(１９８０))、表面にＣＥＡを支持する
と思われるヒト腫瘍の処置に使用できる能力を有する。
Ｉgγ1型(クラス)の抗−ＣＥＡ抗体を分泌するネズミハ
イブリドーマ細胞系(ＣＥＡ．６６−Ｅ３)がＣ．Ｗagen
er et al．,Ｊ．Ｉmmunol．,１３０:２３０８(１９８
３)(この文献を引用して本明細書に包含する)に記載さ
れているように調製されて、mＲＮＡ源として使用され
た。この細胞系による抗ＣＥＡ抗体の産生を決定した。
これら細胞により産生された抗体のＮ−末端配列を次の
ようにしてモノクローナル抗−ＣＥＡのそれと比較し
た。精製したＩgＧをＰＣＡ酵素で処理し(Ｄ．Ｎ．Ｐod
ell et al．,Ｂiochem．Ｂiophys．Ｒes．Ｃommun．,８
１:１７６(１９７８)、次いで６Ｍグアニジン塩酸塩と
１０mＭ２−メルカプトエタノールに於いて解離させた
(１．０mgの免疫グロブリン、５分間、１００℃の水
浴)。解離した鎖をアルキルフェニルカラム(Ｗaters Ａ
ssociates社製)に於いて１００％Ａ(０．１％、ＴＦＡ
−水)〜９０％Ｂ(ＴＦＡ／Ｈ2Ｏ／ＭeＣＮ:０．１／
９．９／９０)の直線勾配を用いて０．８ml／min．の流
速で分離した。３つの主たるピークを溶出させ、銀染色
によってＳＤＳゲルで分析した。最初の２つのピークは
純粋なＬ鎖(ＭＷ２５,０００ダルトン)であり、第３の
ピークはＨ鎖とＬ鎖との７:３混合物であった。１．２n
Ｍ(ナノモル)のＬ鎖をＪ．Ｅ．Ｓhively, Ｍethods in
Ｅnzymology,７９:３１(１９８１)の方法により０．４n
ＭのＮＨ2末端収率にて配列決定した。Ｈ鎖とＬ鎖との
混合物(３nＭ)も配列決定し、Ｌ鎖の配列を二重配列か
ら推定してＨ鎖の配列を得た。
【００８６】以下の説明に於いて、ＣＥＡ．６６−Ｅ３
により産生された抗ＣＥＡ抗体に対するＨ鎖及びＬ鎖の
遺伝子の単離及び発現につき記載する。これら鎖の不変
領域はそれぞれγ及びκ型(family)に属するので、「Ｌ
鎖」と「κ鎖」及び「Ｈ鎖」と「γ鎖」とをそれぞれ以下では
互換的に使用する。
により産生された抗ＣＥＡ抗体に対するＨ鎖及びＬ鎖の
遺伝子の単離及び発現につき記載する。これら鎖の不変
領域はそれぞれγ及びκ型(family)に属するので、「Ｌ
鎖」と「κ鎖」及び「Ｈ鎖」と「γ鎖」とをそれぞれ以下では
互換的に使用する。
【００８７】Ｅ．１．１．抗ＣＥＡのＬ鎖及びＨ鎖(κ
及びγ鎖)に対するメッセンジャーＲＮＡの単離 ＣＥＡ．６６−Ｅ３細胞から全ＲＮＡをＬynch et a
l．,Ｖirology,９８:２５１(１９７９)により報告され
たように抽出した。これら細胞を遠心分離によりペレッ
ト化し、約１g部分のペレットを１０mＭ ＮaＣl,１０m
ＭトリスＨＣl(pＨ７．４)、１．５mＭ ＭgＣl2の１０
ml中に再懸濁した。この再懸濁した細胞を最終濃度１％
まで非イオン性表面活性剤ＮＰ−４０を添加して溶菌
し、核を遠心分離により除去した。１％最終濃度までＳ
ＤＳ(pＨ７．４)を添加した後、上清を３mlずつのフェ
ノール(再蒸溜)／クロロホルム:イソアミルアルコール
２５:１にて４℃で２回抽出した。水相をＮaＣl中で
０．２Ｍとし、２倍容量の１００％エタノールを添加
し、−２０℃で１晩貯蔵することにより全ＲＮＡを沈澱
した。遠心分離後、ポリ−Ａ mＲＮＡをＡviv及びＬed
er,Ｐroc．Ｎatl．Ａcad．Ｓci．,ＵＳＡ,６９:１４０
８(１９７２)により記載されたオリゴ−dＴセルロース
クロマトグラフィーにより全ＲＮＡから精製した。１g
の細胞から１４２μgのポリ−Ａ mＲＮＡが得られた。
及びγ鎖)に対するメッセンジャーＲＮＡの単離 ＣＥＡ．６６−Ｅ３細胞から全ＲＮＡをＬynch et a
l．,Ｖirology,９８:２５１(１９７９)により報告され
たように抽出した。これら細胞を遠心分離によりペレッ
ト化し、約１g部分のペレットを１０mＭ ＮaＣl,１０m
ＭトリスＨＣl(pＨ７．４)、１．５mＭ ＭgＣl2の１０
ml中に再懸濁した。この再懸濁した細胞を最終濃度１％
まで非イオン性表面活性剤ＮＰ−４０を添加して溶菌
し、核を遠心分離により除去した。１％最終濃度までＳ
ＤＳ(pＨ７．４)を添加した後、上清を３mlずつのフェ
ノール(再蒸溜)／クロロホルム:イソアミルアルコール
２５:１にて４℃で２回抽出した。水相をＮaＣl中で
０．２Ｍとし、２倍容量の１００％エタノールを添加
し、−２０℃で１晩貯蔵することにより全ＲＮＡを沈澱
した。遠心分離後、ポリ−Ａ mＲＮＡをＡviv及びＬed
er,Ｐroc．Ｎatl．Ａcad．Ｓci．,ＵＳＡ,６９:１４０
８(１９７２)により記載されたオリゴ−dＴセルロース
クロマトグラフィーにより全ＲＮＡから精製した。１g
の細胞から１４２μgのポリ−Ａ mＲＮＡが得られた。
【００８８】Ｅ．１．２．Ｈ鎖及びＬ鎖のＤＮＡ配列挿
入物を有するプラスミドを含有したＥ．coliコロニーラ
イブラリーの作成 上記Ｅ．１．１で調製した未分画ポリ−Ａ mＲＮＡの
５μgをＧoeddel et al．,Ｎature,２８１:５４４(１
９７９)及びＷickens et al．,Ｊ．Ｂiol．Ｃhem．,２
５３:２４８３(１９７８)(この文献を引用して本明細書
に包含する)により、二重鎖(ds)cＤＮＡのオリゴ−dＴ
プライム処理調製物に対する鋳型として使用した。この
cＤＮＡを６％ポリアクリルアミドゲル電気泳動によっ
て寸法(サイズ)分画し、長さ６００塩基対より大きいds
cＤＮＡの１２４ngを電気溶出によって回収した。２０
ngのds cＤＮＡをＣhang et al．,Ｎature,２７５:６１
７(１９７８)(この文献を引用して本明細書に包含する)
に記載された末端(ターミナル)デオキシヌクレオチジル
トランスフェラーゼを用いてデオキシＣ残基で延長さ
せ、予めＰstＩにより開裂させ、デオキシＧで処理した
２００ngのプラスミドpＢＲ３２２(Ｂolivar et al．,
Ｇene,２:９５(１９７７))と共にアニールした。それぞ
れアニールした混合物をＥ．coli Ｋ１２菌株２９４
(ＡＴＣＣ Ｎo．３１４４６)に形質転換した。約８,５
００種のアンピシリン感受性且つテトラサイクリン耐性
の形質転換体が得られた。
入物を有するプラスミドを含有したＥ．coliコロニーラ
イブラリーの作成 上記Ｅ．１．１で調製した未分画ポリ−Ａ mＲＮＡの
５μgをＧoeddel et al．,Ｎature,２８１:５４４(１
９７９)及びＷickens et al．,Ｊ．Ｂiol．Ｃhem．,２
５３:２４８３(１９７８)(この文献を引用して本明細書
に包含する)により、二重鎖(ds)cＤＮＡのオリゴ−dＴ
プライム処理調製物に対する鋳型として使用した。この
cＤＮＡを６％ポリアクリルアミドゲル電気泳動によっ
て寸法(サイズ)分画し、長さ６００塩基対より大きいds
cＤＮＡの１２４ngを電気溶出によって回収した。２０
ngのds cＤＮＡをＣhang et al．,Ｎature,２７５:６１
７(１９７８)(この文献を引用して本明細書に包含する)
に記載された末端(ターミナル)デオキシヌクレオチジル
トランスフェラーゼを用いてデオキシＣ残基で延長さ
せ、予めＰstＩにより開裂させ、デオキシＧで処理した
２００ngのプラスミドpＢＲ３２２(Ｂolivar et al．,
Ｇene,２:９５(１９７７))と共にアニールした。それぞ
れアニールした混合物をＥ．coli Ｋ１２菌株２９４
(ＡＴＣＣ Ｎo．３１４４６)に形質転換した。約８,５
００種のアンピシリン感受性且つテトラサイクリン耐性
の形質転換体が得られた。
【００８９】Ｅ．１．３．合成プローブの作成 可変領域ＤＮＡ配列の２５塩基対３'で始まるネズミＭ
ＯＰＣ２１κ鎖に対する不変領域のコード配列に補完
(相補)的な１４元体、即ち５'ＧＧＴＧＧＧＡＡＧＡＴ
ＧＧＡ３'をκ鎖プローブとして使用した。ネズミＭＯ
ＰＣ２１γ鎖に対する可変領域ＤＮＡ配列の７２塩基対
３'に位置するコード配列に補完的な１５元体、即ち５'
ＧＡＣＣＡＧＧＣＡＴＣＣＣＡＧ３'をγ鎖遺伝子プロ
ーブとして使用した。
ＯＰＣ２１κ鎖に対する不変領域のコード配列に補完
(相補)的な１４元体、即ち５'ＧＧＴＧＧＧＡＡＧＡＴ
ＧＧＡ３'をκ鎖プローブとして使用した。ネズミＭＯ
ＰＣ２１γ鎖に対する可変領域ＤＮＡ配列の７２塩基対
３'に位置するコード配列に補完的な１５元体、即ち５'
ＧＡＣＣＡＧＧＣＡＴＣＣＣＡＧ３'をγ鎖遺伝子プロ
ーブとして使用した。
【００９０】両プローブは、ドイツ公開公報第２６４４
４３２号(この文献を引用して本明細書に包含する)に記
載されたホスホトリエステル法により合成し、次のよう
にキナーゼ処理して放射能活性にした。２５０ngのデオ
キシオリゴヌクレオチドを６０mＭトリスＨＣl(pＨ
８)、１０mＭ ＭgＣl2、１５mＭ β−メルカプトエタ
ノール及び１００μＣi(γ−Ｐ32)ＡＴＰ(Ａmersham,
５,０００Ｃi／mＭ)の２５μl中に入れた。５ユニット
のＴ４ポリヌクレオチドキナーゼを加え、反応を３７℃
にて３０分間進行させ、ＥＤＴＡを２０mＭまで加える
ことにより停止させた。
４３２号(この文献を引用して本明細書に包含する)に記
載されたホスホトリエステル法により合成し、次のよう
にキナーゼ処理して放射能活性にした。２５０ngのデオ
キシオリゴヌクレオチドを６０mＭトリスＨＣl(pＨ
８)、１０mＭ ＭgＣl2、１５mＭ β−メルカプトエタ
ノール及び１００μＣi(γ−Ｐ32)ＡＴＰ(Ａmersham,
５,０００Ｃi／mＭ)の２５μl中に入れた。５ユニット
のＴ４ポリヌクレオチドキナーゼを加え、反応を３７℃
にて３０分間進行させ、ＥＤＴＡを２０mＭまで加える
ことにより停止させた。
【００９１】Ｅ．１．４．κ鎖又はγ鎖配列に対するコ
ロニーライブラリーの選別 上記Ｅ．１．２に記載したように、調製した約２,００
０個のコロニーをＬＢ(Ｍiller, Ｅxperiments in Ｍol
ecular Ｇenetics,p．４３１−３,Ｃold Ｓpring Ｈar
bor Ｌab．,Ｃold Ｓpring Ｈarbor, Ｎew Ｙork(１９
７２)＋５μg／mlのテトラサイクリンを含有するマイク
ロタイター皿の穴に個々に接種し、ＤＭＳＯを７％まで
添加した後に−２０℃で貯蔵した。このライブラリーか
らの個々のコロニーを２組のＳchleicher及びＳchuell
ＢＡ８５／２０のニトロセルロースフィルターに移
し、ＬＢ＋５μg／mlテトラサイクリンを含有する寒天
板で増殖した。３７℃にて約１０時間増殖した後、これ
らのコロニーフィルターをＬＢ＋５μg／mlテトラサイ
クリンと１２．５μg／mlのクロラムフェニコールとを
含有する寒天板に移し、３７℃にて１晩再培養した。次
いで、各コロニーからのＤＮＡを変性させ、Ｇrunstein
et al．,Ｐroc．Ｎatl．Ａcad．Ｓci．,ＵＳＡ,７２:
３９６１(１９７５)(この文献を引用して本明細書に包
含する)に記載されたＧrunstein−Ｈogness法の変法に
よってフィルターに固定した。各フィルターを０．５Ｎ
ＮaＯＨと１．５Ｍ ＮaＣlとの上に３分間浮遊させ
てコロニーを溶菌し、ＤＮＡを変性させ、次いで３Ｍ
ＮaＣlと０．５ＭトリスＨＣl(pＨ７．５)の上に１５分
間浮遊させて中和した。次いでこれらフィルターを２×
ＳＳＣ上に更に１５分間浮遊させ、８０℃の減圧オーブ
ン内で２時間焼成した。これらフィルターを０．９Ｍ
ＮaＣl、１×Ｄenhardts,１００mＭトリスＨＣl(pＨ
７．５)、５mＭ Ｎa−ＥＤＴＡ、１mＭ ＡＴＰ、１Ｍ
燐酸ナトリウム(二塩基性)、１mＭピロ燐酸ナトリウ
ム、０．５％ＮＰ−４０及び２００μg／mlＥ．colit−
ＲＮＡに於いて室温で２時間予備ハイブリゼーションし
た後、同じ溶液で１晩ハイブリゼーションし(実質的に
Ｗellace et al．,Ｎucleic Ａcids Ｒesearch,９:８７
９(１９８１)に記載されている)、この場合、上記のキ
ナーゼ処理したκプローブ又はγプローブの約４０×１
０6cpmを使用した。６×ＳＳＣ、０．１％ＳＤＳ中に於
いて、３７℃で激しく洗浄した後、これらフィルターを
ＤupontＬightning−Ｐlusg強化スクリーンを用いてＫo
dak ＸＲ−５ Ｘ線フィルムに−８０℃で１６〜２４時
間露出した。κ鎖プローブとハイブリダイズした約２０
種のコロニー及びγ鎖プローブとハイブリダイズした２
０種のコロニーを特性化した。
ロニーライブラリーの選別 上記Ｅ．１．２に記載したように、調製した約２,００
０個のコロニーをＬＢ(Ｍiller, Ｅxperiments in Ｍol
ecular Ｇenetics,p．４３１−３,Ｃold Ｓpring Ｈar
bor Ｌab．,Ｃold Ｓpring Ｈarbor, Ｎew Ｙork(１９
７２)＋５μg／mlのテトラサイクリンを含有するマイク
ロタイター皿の穴に個々に接種し、ＤＭＳＯを７％まで
添加した後に−２０℃で貯蔵した。このライブラリーか
らの個々のコロニーを２組のＳchleicher及びＳchuell
ＢＡ８５／２０のニトロセルロースフィルターに移
し、ＬＢ＋５μg／mlテトラサイクリンを含有する寒天
板で増殖した。３７℃にて約１０時間増殖した後、これ
らのコロニーフィルターをＬＢ＋５μg／mlテトラサイ
クリンと１２．５μg／mlのクロラムフェニコールとを
含有する寒天板に移し、３７℃にて１晩再培養した。次
いで、各コロニーからのＤＮＡを変性させ、Ｇrunstein
et al．,Ｐroc．Ｎatl．Ａcad．Ｓci．,ＵＳＡ,７２:
３９６１(１９７５)(この文献を引用して本明細書に包
含する)に記載されたＧrunstein−Ｈogness法の変法に
よってフィルターに固定した。各フィルターを０．５Ｎ
ＮaＯＨと１．５Ｍ ＮaＣlとの上に３分間浮遊させ
てコロニーを溶菌し、ＤＮＡを変性させ、次いで３Ｍ
ＮaＣlと０．５ＭトリスＨＣl(pＨ７．５)の上に１５分
間浮遊させて中和した。次いでこれらフィルターを２×
ＳＳＣ上に更に１５分間浮遊させ、８０℃の減圧オーブ
ン内で２時間焼成した。これらフィルターを０．９Ｍ
ＮaＣl、１×Ｄenhardts,１００mＭトリスＨＣl(pＨ
７．５)、５mＭ Ｎa−ＥＤＴＡ、１mＭ ＡＴＰ、１Ｍ
燐酸ナトリウム(二塩基性)、１mＭピロ燐酸ナトリウ
ム、０．５％ＮＰ−４０及び２００μg／mlＥ．colit−
ＲＮＡに於いて室温で２時間予備ハイブリゼーションし
た後、同じ溶液で１晩ハイブリゼーションし(実質的に
Ｗellace et al．,Ｎucleic Ａcids Ｒesearch,９:８７
９(１９８１)に記載されている)、この場合、上記のキ
ナーゼ処理したκプローブ又はγプローブの約４０×１
０6cpmを使用した。６×ＳＳＣ、０．１％ＳＤＳ中に於
いて、３７℃で激しく洗浄した後、これらフィルターを
ＤupontＬightning−Ｐlusg強化スクリーンを用いてＫo
dak ＸＲ−５ Ｘ線フィルムに−８０℃で１６〜２４時
間露出した。κ鎖プローブとハイブリダイズした約２０
種のコロニー及びγ鎖プローブとハイブリダイズした２
０種のコロニーを特性化した。
【００９２】Ｅ．１．５．κＤＮＡ配列プローブにハイ
ブリダイズしたコロニーの特性化 κ鎖プローブにハイブリダイズした数種の異なる形質転
換体から単離したプラスミドＤＮＡをＰstＩにより開裂
し、ポリアクリルアミドゲル電気泳動(ＰＡＧＥ)により
分画した。この分析により、多数のプラスミドＤＮＡが
充分な長さのκ鎖をコード化するのに充分な大きさのc
ＤＮＡ挿入物を含有することが示された。これらプラス
ミドの１種に於けるcＤＮＡ挿入物の完全ヌクレオチド
配列をＳmith, Ｍethods Ｅnzymol．,６５:５６０(１９
８０)(この文献を引用して本明細書に包含する)に記載
されたジデオキシヌクレオチド鎖停止法により、制限エ
ンドヌクレアーゼ開裂断片をＭ１３ベクター中へサブク
ローニングした後に決定した(Ｍessing et al．,Ｎucle
ic Ａcids Ｒesearch,９:３０９(１９８１))。図２、図
３、図４および図５はpＫ１７Ｇ４のcＤＮＡ挿入物のヌ
クレオチド配列を示し、図６、図７および図８は対応す
るアミノ酸配列を有する遺伝子配列を示している。ネズ
ミ抗−ＣＥＡκ鎖の全コード領域を、この１種の大型Ｄ
ＮＡ断片につき単離した。κ鎖のアミノ酸配列は、pＫ
１７Ｇ４ cＤＮＡ挿入物のヌクレオチド配列から推定
して、成熟ネズミ抗−ＣＥＡκ鎖の最初の２３個のＮ−
末端アミノ酸と完全に一致し、これは精製したネズミ抗
−ＣＥＡκ鎖のアミノ酸配列分析により決定された。p
Ｋ１７Ｇ４のコード領域は、予備配列の２７塩基対もし
くは９個のアミノ酸と成熟蛋白質の６４２塩基対もしく
は２１４個のアミノ酸を含有する。グリコシル化してい
ない成熟蛋白質(ＭＷ２４,５５３)は、１２個のアミノ
酸のＪ１結合領域を含め１１９個のアミノ酸から成る可
変領域と１０７個のアミノ酸から成る不変領域とを有す
る。アミノ酸２１５の後の停止コドンの後にポリ−Ａ付
加に至るまで３'未翻訳配列の２１２塩基対が始まる。p
Ｋ１７Ｇ４を同定するために使用したκ鎖プローブは、
ヌクレオチド３７４−３８８にハイブリダイズする
(図、図３、図４および図５)。
ブリダイズしたコロニーの特性化 κ鎖プローブにハイブリダイズした数種の異なる形質転
換体から単離したプラスミドＤＮＡをＰstＩにより開裂
し、ポリアクリルアミドゲル電気泳動(ＰＡＧＥ)により
分画した。この分析により、多数のプラスミドＤＮＡが
充分な長さのκ鎖をコード化するのに充分な大きさのc
ＤＮＡ挿入物を含有することが示された。これらプラス
ミドの１種に於けるcＤＮＡ挿入物の完全ヌクレオチド
配列をＳmith, Ｍethods Ｅnzymol．,６５:５６０(１９
８０)(この文献を引用して本明細書に包含する)に記載
されたジデオキシヌクレオチド鎖停止法により、制限エ
ンドヌクレアーゼ開裂断片をＭ１３ベクター中へサブク
ローニングした後に決定した(Ｍessing et al．,Ｎucle
ic Ａcids Ｒesearch,９:３０９(１９８１))。図２、図
３、図４および図５はpＫ１７Ｇ４のcＤＮＡ挿入物のヌ
クレオチド配列を示し、図６、図７および図８は対応す
るアミノ酸配列を有する遺伝子配列を示している。ネズ
ミ抗−ＣＥＡκ鎖の全コード領域を、この１種の大型Ｄ
ＮＡ断片につき単離した。κ鎖のアミノ酸配列は、pＫ
１７Ｇ４ cＤＮＡ挿入物のヌクレオチド配列から推定
して、成熟ネズミ抗−ＣＥＡκ鎖の最初の２３個のＮ−
末端アミノ酸と完全に一致し、これは精製したネズミ抗
−ＣＥＡκ鎖のアミノ酸配列分析により決定された。p
Ｋ１７Ｇ４のコード領域は、予備配列の２７塩基対もし
くは９個のアミノ酸と成熟蛋白質の６４２塩基対もしく
は２１４個のアミノ酸を含有する。グリコシル化してい
ない成熟蛋白質(ＭＷ２４,５５３)は、１２個のアミノ
酸のＪ１結合領域を含め１１９個のアミノ酸から成る可
変領域と１０７個のアミノ酸から成る不変領域とを有す
る。アミノ酸２１５の後の停止コドンの後にポリ−Ａ付
加に至るまで３'未翻訳配列の２１２塩基対が始まる。p
Ｋ１７Ｇ４を同定するために使用したκ鎖プローブは、
ヌクレオチド３７４−３８８にハイブリダイズする
(図、図３、図４および図５)。
【００９３】Ｅ．１．６．γ１ＤＮＡプローブにハイブ
リダイズしたコロニーの特性化 Ｈ鎖γ１プローブとのハイブリダイズに対し陽性である
数種の形質転換体から単離されたプラスミドＤＮＡを、
上記Ｅ．１．５．に記載したようにＰstＩ制限エンドヌ
クレアーゼ分析にかけた。最も大きいcＤＮＡ挿入物断
片を示すプラスミドＤＮＡを後の試験用に選択した。ネ
ズミＨ鎖(γ−１鎖)をコード化するヌクレオチド配列
は、可変領域と不変領域との間の接合部近くにＮcoＩ制
限エンドヌクレアーゼ開裂部位を有する。選択したプラ
スミドＤＮＡをＰstＩとＮcoＩとの両者により消化し、
ポリアクリルアミドで寸法分画した。この分析はＮcoＩ
制限エンドヌクレアーゼ部位を有する多数のプラスミド
ＤＮＡの同定を可能にするが、このいずれもネズミ抗−
ＣＥＡＨ鎖の全コード化領域をコードするのに充分大き
いcＤＮＡ挿入物断片を示さない。
リダイズしたコロニーの特性化 Ｈ鎖γ１プローブとのハイブリダイズに対し陽性である
数種の形質転換体から単離されたプラスミドＤＮＡを、
上記Ｅ．１．５．に記載したようにＰstＩ制限エンドヌ
クレアーゼ分析にかけた。最も大きいcＤＮＡ挿入物断
片を示すプラスミドＤＮＡを後の試験用に選択した。ネ
ズミＨ鎖(γ−１鎖)をコード化するヌクレオチド配列
は、可変領域と不変領域との間の接合部近くにＮcoＩ制
限エンドヌクレアーゼ開裂部位を有する。選択したプラ
スミドＤＮＡをＰstＩとＮcoＩとの両者により消化し、
ポリアクリルアミドで寸法分画した。この分析はＮcoＩ
制限エンドヌクレアーゼ部位を有する多数のプラスミド
ＤＮＡの同定を可能にするが、このいずれもネズミ抗−
ＣＥＡＨ鎖の全コード化領域をコードするのに充分大き
いcＤＮＡ挿入物断片を示さない。
【００９４】単離した１種のプラスミド(即ちpγ２９
８)に於いて、約１３００bpのcＤＮＡ挿入物は５'未翻
訳領域、信号配列及びＨ鎖のＮ−末端部分に対する配列
情報を有する。pγ２９８はネズミ抗−ＣＥＡγ１鎖に
対するＣ−末端配列をコードしなかったので、プラスミ
ドＤＮＡを他のコロニーから単離してＰstＩ及びＮcoＩ
で選別した。pγ１１のcＤＮＡ挿入物に於けるＣ−末端
領域を配列決定して、停止コドンと３'未翻訳配列とpγ
２９８から喪失されたコード配列の部分とを含有するこ
とが示された。
８)に於いて、約１３００bpのcＤＮＡ挿入物は５'未翻
訳領域、信号配列及びＨ鎖のＮ−末端部分に対する配列
情報を有する。pγ２９８はネズミ抗−ＣＥＡγ１鎖に
対するＣ−末端配列をコードしなかったので、プラスミ
ドＤＮＡを他のコロニーから単離してＰstＩ及びＮcoＩ
で選別した。pγ１１のcＤＮＡ挿入物に於けるＣ−末端
領域を配列決定して、停止コドンと３'未翻訳配列とpγ
２９８から喪失されたコード配列の部分とを含有するこ
とが示された。
【００９５】図９、図１０、図１１、図１２、図１３及
び図１４はネズミ抗−ＣＥＡＨ鎖の全ヌクレオチド配列
を示し(Ｓmith, Ｍethods Ｅnzymol．,６５:５６０(１
９８０)のジデオキシヌクレオチド鎖停止法により決定
する)、図１５、図１６、図１７、図１８および図１９
は翻訳配列を含んでいる。
び図１４はネズミ抗−ＣＥＡＨ鎖の全ヌクレオチド配列
を示し(Ｓmith, Ｍethods Ｅnzymol．,６５:５６０(１
９８０)のジデオキシヌクレオチド鎖停止法により決定
する)、図１５、図１６、図１７、図１８および図１９
は翻訳配列を含んでいる。
【００９６】pγ２９８ cＤＮＡ挿入物のヌクレオチド
配列から推定したγ１(Ｈ鎖)のアミノ酸配列は、精製ネ
ズミ抗−ＣＥＡγ１鎖のアミノ酸配列分析により決定し
て成熟ネズミ抗−ＣＥＡγ１鎖の最初の２３個のＮ−末
端アミノ酸に完全に一致する。コード領域は予備配列の
５７塩基対もしくは１９個のアミノ酸と、成熟蛋白質の
１３４６塩基対もしくは４４７個のアミノ酸とより成っ
ている。グリコシル化されていない成熟蛋白質(ＭＷ５
２,２５８)は、１２個のアミノ酸のＤ領域を含め１３５
個のアミノ酸より成る可変領域と、１３個のアミノ酸よ
り成るＪ４結合領域とを有する。不変領域は３２４個の
アミノ酸である。アミノ酸４４７の後の停止コドンに続
いて、ポリ−Ａ付加まで９６bpの３未翻訳配列が開始す
る。pγ２９８及びpγ１１を同定するために使用したプ
ローブは、ヌクレオチド５２８−５４２にハイブリダイ
ズした(図９、図１０、図１１、図１２、図１３及び図
１４)。
配列から推定したγ１(Ｈ鎖)のアミノ酸配列は、精製ネ
ズミ抗−ＣＥＡγ１鎖のアミノ酸配列分析により決定し
て成熟ネズミ抗−ＣＥＡγ１鎖の最初の２３個のＮ−末
端アミノ酸に完全に一致する。コード領域は予備配列の
５７塩基対もしくは１９個のアミノ酸と、成熟蛋白質の
１３４６塩基対もしくは４４７個のアミノ酸とより成っ
ている。グリコシル化されていない成熟蛋白質(ＭＷ５
２,２５８)は、１２個のアミノ酸のＤ領域を含め１３５
個のアミノ酸より成る可変領域と、１３個のアミノ酸よ
り成るＪ４結合領域とを有する。不変領域は３２４個の
アミノ酸である。アミノ酸４４７の後の停止コドンに続
いて、ポリ−Ａ付加まで９６bpの３未翻訳配列が開始す
る。pγ２９８及びpγ１１を同定するために使用したプ
ローブは、ヌクレオチド５２８−５４２にハイブリダイ
ズした(図９、図１０、図１１、図１２、図１３及び図
１４)。
【００９７】Ｅ．１．７．ネズミ成熟抗−ＣＥＡ κ鎖
遺伝子を直接発現させるためのプラスミドの作成、pＫ
ＣＥＡtrp２０７−１＊ 図２０、図２１および図２２はpＫＣＥＡtrp２０７−１
＊の作成を示している。
遺伝子を直接発現させるためのプラスミドの作成、pＫ
ＣＥＡtrp２０７−１＊ 図２０、図２１および図２２はpＫＣＥＡtrp２０７−１
＊の作成を示している。
【００９８】まず、単一のtrpプロモーターを有する中
間プラスミドpＨＧＨ２０７−１＊を次のように作成し
た:プラスミドpＨＧＨ２０７(１９８１年１０月１日付
出願の米国特許出願第３０７,４７３号(ＥＰＯ公開第０
０３６７７６号)に記載)は、二重lacプロモーターに続
いてＥcoＲＩ部位に整列(フランキング)するtrpプロモ
ーターを有し、これを使用してpＨＣＨ２０７−１を作
成した。pＨＧＨ２０７をＢamＨＩで消化し、ＥcoＲＩ
で部分消化した。完全trpプロモーターを含有する最も
大きい断片を単離し、これをpＢＲ３２２からの最も大
きいＥcoＲＩ−ＢamＨＩ断片に結合し、この結合混合物
を使用してＥ．coli２９４を形質転換した。ＴetR Ａmp
Rのコロニーを単離し、これらの殆んどはpＨＧＨ２０７
−１を含有した。ampR遺伝子とtrpプロモーターの間に
ＥcoＲＩ部位を欠如するpＨＧＨ２０７−１＊をＥcoＲ
ＩでのpＨＧＨ２０７−１の部分消化、末端に於けるＫl
enow及びdＮＴＰの充填及び再結合によって得た。
間プラスミドpＨＧＨ２０７−１＊を次のように作成し
た:プラスミドpＨＧＨ２０７(１９８１年１０月１日付
出願の米国特許出願第３０７,４７３号(ＥＰＯ公開第０
０３６７７６号)に記載)は、二重lacプロモーターに続
いてＥcoＲＩ部位に整列(フランキング)するtrpプロモ
ーターを有し、これを使用してpＨＣＨ２０７−１を作
成した。pＨＧＨ２０７をＢamＨＩで消化し、ＥcoＲＩ
で部分消化した。完全trpプロモーターを含有する最も
大きい断片を単離し、これをpＢＲ３２２からの最も大
きいＥcoＲＩ−ＢamＨＩ断片に結合し、この結合混合物
を使用してＥ．coli２９４を形質転換した。ＴetR Ａmp
Rのコロニーを単離し、これらの殆んどはpＨＧＨ２０７
−１を含有した。ampR遺伝子とtrpプロモーターの間に
ＥcoＲＩ部位を欠如するpＨＧＨ２０７−１＊をＥcoＲ
ＩでのpＨＧＨ２０７−１の部分消化、末端に於けるＫl
enow及びdＮＴＰの充填及び再結合によって得た。
【００９９】５μgのpＨＧＨ２０７−１＊をＥcoＲＩで
消化し、これら末端を６０mＭ ＮaＣl,７mＭ ＭgＣ
l2,７mＭトリスＨＣl(pＨ７．４)及び１mＭの各dＮＴＰ
を含有する５０μlの反応液中で１２ユニットのＤＮＡ
ポリメラーゼを用いて３７℃にて１時間延長し、次いで
フェノール／ＣＨＣl3で抽出しエタノールで沈澱させ
た。沈澱したＤＮＡをＢamＨＩで消化し、大ベクター断
片(断片１)を５％ポリアクリルアミドゲル電気泳動、電
気溶出、フェノール／ＣＨＣl3抽出及びエタノール沈澱
によって精製した。
消化し、これら末端を６０mＭ ＮaＣl,７mＭ ＭgＣ
l2,７mＭトリスＨＣl(pＨ７．４)及び１mＭの各dＮＴＰ
を含有する５０μlの反応液中で１２ユニットのＤＮＡ
ポリメラーゼを用いて３７℃にて１時間延長し、次いで
フェノール／ＣＨＣl3で抽出しエタノールで沈澱させ
た。沈澱したＤＮＡをＢamＨＩで消化し、大ベクター断
片(断片１)を５％ポリアクリルアミドゲル電気泳動、電
気溶出、フェノール／ＣＨＣl3抽出及びエタノール沈澱
によって精製した。
【０１００】このＤＮＡを１０mＭトリス(pＨ８)、１m
Ｍ ＥＤＴＡの５０μl中に再懸濁し、５００ユニット
の細菌性アルカリホスファターゼ(ＢＡＰ)で６５℃にて
３０秒間処理し、フェノールＣＨＣl3抽出し、エタノー
ル沈澱させた。
Ｍ ＥＤＴＡの５０μl中に再懸濁し、５００ユニット
の細菌性アルカリホスファターゼ(ＢＡＰ)で６５℃にて
３０秒間処理し、フェノールＣＨＣl3抽出し、エタノー
ル沈澱させた。
【０１０１】Ｌ鎖配列１部を含有するＤＮＡ断片を次の
ように作成した:７μgのpＫ１７ＫＧ４ＤＮＡをＰstＩ
で消化しcＤＮＡ挿入物を含有するκ鎖を６％ゲル電気
泳動及び電気溶出によって単離した。フェノール／ＣＨ
Ｃl3抽出、エタノール沈澱及び水中への再懸濁の後、こ
の断片をＡvaＩＩによって消化した。３３３bpのＰstＩ
−ＡvaＩＩ ＤＮＡ断片を単離し、６％ポリアクリルア
ミドゲルから精製した。
ように作成した:７μgのpＫ１７ＫＧ４ＤＮＡをＰstＩ
で消化しcＤＮＡ挿入物を含有するκ鎖を６％ゲル電気
泳動及び電気溶出によって単離した。フェノール／ＣＨ
Ｃl3抽出、エタノール沈澱及び水中への再懸濁の後、こ
の断片をＡvaＩＩによって消化した。３３３bpのＰstＩ
−ＡvaＩＩ ＤＮＡ断片を単離し、６％ポリアクリルア
ミドゲルから精製した。
【０１０２】１５ヌクレオチドＤＮＡプライマーをホス
ホトリエステル法(Ｇ．Ｏ．２,６４４,４３２(上記))に
より合成し、次の配列を有した:
ホトリエステル法(Ｇ．Ｏ．２,６４４,４３２(上記))に
より合成し、次の配列を有した:
【０１０３】５'メチオニンは開始コドンとして作用す
る。５００ngのこのプライマーを０．５mＭ ＡＴＰを
含有する２０μlの反応液中で１０ユニットのＴ４ＤＮ
Ａキナーゼにより５'末端で燐酸化した。約２００ngの
ＰstＩ−ＡvaＩＩ ＤＮＡ断片を２０μlの燐酸化した
プライマーと混合し、９５℃まで３分間加熱し、ドライ
アイスエタノール浴中で急速に凍結させた。変性したＤ
ＮＡ溶液を６０mＭ ＮaＣl,７mＭ ＭgＣl2,７mＭトリ
スＨＣl(pＨ７．４),１２mＭの各dＮＴＰと成し、１２
ユニットのＤＮＡポリメラーゼＩ−大断片を加えた。３
７℃にて２時間培養した後、このプライマー修復反応物
をフェノール／ＣＨＣl3で抽出し、エタノール沈澱させ
てＳau３Ａで完全に消化した。次いで、反応混合物を６
％ポリアクリルアミドゲルで電気泳動にかけ、電気溶出
の後にＳau３Ａに対し平滑末端の１８２塩基対アミノ末
端断片(断片２)の約５０ngを得た。
る。５００ngのこのプライマーを０．５mＭ ＡＴＰを
含有する２０μlの反応液中で１０ユニットのＴ４ＤＮ
Ａキナーゼにより５'末端で燐酸化した。約２００ngの
ＰstＩ−ＡvaＩＩ ＤＮＡ断片を２０μlの燐酸化した
プライマーと混合し、９５℃まで３分間加熱し、ドライ
アイスエタノール浴中で急速に凍結させた。変性したＤ
ＮＡ溶液を６０mＭ ＮaＣl,７mＭ ＭgＣl2,７mＭトリ
スＨＣl(pＨ７．４),１２mＭの各dＮＴＰと成し、１２
ユニットのＤＮＡポリメラーゼＩ−大断片を加えた。３
７℃にて２時間培養した後、このプライマー修復反応物
をフェノール／ＣＨＣl3で抽出し、エタノール沈澱させ
てＳau３Ａで完全に消化した。次いで、反応混合物を６
％ポリアクリルアミドゲルで電気泳動にかけ、電気溶出
の後にＳau３Ａに対し平滑末端の１８２塩基対アミノ末
端断片(断片２)の約５０ngを得た。
【０１０４】１００ngの断片１(上記)と５０ngの断片２
とを２０mＭトリスＨＣl(pＨ７．５),１０mＭ ＭgＣ
l2,１０mＭ ＤＴＴ,２．５mＭ ＡＴＰ及び１ユニット
のＴ４ＤＮＡリガーゼの２０μlに於いて合せた。１４
℃にて１晩結合させた後、この反応物をＥ．coli Ｋ１
２菌株２９４で形質転換した。多数のアンピシリン耐性
形質転換体からのプラスミドＤＮＡの制限エンドヌクレ
アーゼ消化は適正な作成を示し、ＤＮＡ配列分析はこの
新規なプラスミドpＫＣＥＡＩnt１の開始コドンを介し
て所望のヌクレオチド配列を証明した(図２０、図２１
および図２２)。
とを２０mＭトリスＨＣl(pＨ７．５),１０mＭ ＭgＣ
l2,１０mＭ ＤＴＴ,２．５mＭ ＡＴＰ及び１ユニット
のＴ４ＤＮＡリガーゼの２０μlに於いて合せた。１４
℃にて１晩結合させた後、この反応物をＥ．coli Ｋ１
２菌株２９４で形質転換した。多数のアンピシリン耐性
形質転換体からのプラスミドＤＮＡの制限エンドヌクレ
アーゼ消化は適正な作成を示し、ＤＮＡ配列分析はこの
新規なプラスミドpＫＣＥＡＩnt１の開始コドンを介し
て所望のヌクレオチド配列を証明した(図２０、図２１
および図２２)。
【０１０５】κＬ鎖遺伝子のコード化配列の残部は次の
ように作成した:７μgのＫ１７Ｇ７ＤＮＡからのＰstＩ
cＤＮＡ挿入物断片をＡvaＩＩで部分消化させ、ＡvaＩ
Ｉ付着末端をＤＮＡポリメラーゼＩ大断片反応に於いて
平滑末端部まで延長させた。６％ポリアクリルアミドゲ
ル電気泳動に続き、６８６塩基対のＰstＩ−平滑末端Ａ
vaＩＩＤＮＡ断片を単離し、精製し、ＨpaＩＩ制限エン
ドヌクレアーゼ消化にかけた。４９７塩基対のＨpaＩＩ
−平滑末端ＡvaＩＩ ＤＮＡ断片(断片３)を単離し、ゲ
ル電気泳動の後に精製した。
ように作成した:７μgのＫ１７Ｇ７ＤＮＡからのＰstＩ
cＤＮＡ挿入物断片をＡvaＩＩで部分消化させ、ＡvaＩ
Ｉ付着末端をＤＮＡポリメラーゼＩ大断片反応に於いて
平滑末端部まで延長させた。６％ポリアクリルアミドゲ
ル電気泳動に続き、６８６塩基対のＰstＩ−平滑末端Ａ
vaＩＩＤＮＡ断片を単離し、精製し、ＨpaＩＩ制限エン
ドヌクレアーゼ消化にかけた。４９７塩基対のＨpaＩＩ
−平滑末端ＡvaＩＩ ＤＮＡ断片(断片３)を単離し、ゲ
ル電気泳動の後に精製した。
【０１０６】１０μgのpＫＣＥＡＩnt１ＤＮＡをＡvaＩ
で消化し、ＤＮＡポリメラーゼＩ大断片で延長化し、Ｘ
baＩで消化した。大平滑末端ＡvaＩ−ＸbaＩベクター断
片と、小平滑末端ＡvaＩ−ＸbaＩ断片とを単離し、６％
ポリアクリルアミドゲルから電気泳動の後に精製した。
大ベクター断片(断片４)を細菌性アルカリホスファター
ゼ(ＢＡＰ)で処理し、小断片をＨpaＩＩで消化させ、６
％ポリアクリルアミドゲルで電気泳動にかけ、１６９塩
基対のＸbaＩ−ＨpaＩＩＤＮＡ断片(断片５)を精製し
た。約７５ngの断片４と約５０ngの断片３と約５０ngの
断片５とをＴ４ＤＮＡリガーゼ反応物中であわせ、１４
℃にて１晩培養し、反応混合物をＥ．coliＫ１２菌株２
９４で形質転換した。６種のアンピシリン耐性形質転換
体からのプラスミドＤＮＡを制限エンドヌクレアーゼ消
化により分析した１種のプラスミドＤＮＡは適正な作成
を示し、これをpＫＣＥＡＩnt２と命名した。
で消化し、ＤＮＡポリメラーゼＩ大断片で延長化し、Ｘ
baＩで消化した。大平滑末端ＡvaＩ−ＸbaＩベクター断
片と、小平滑末端ＡvaＩ−ＸbaＩ断片とを単離し、６％
ポリアクリルアミドゲルから電気泳動の後に精製した。
大ベクター断片(断片４)を細菌性アルカリホスファター
ゼ(ＢＡＰ)で処理し、小断片をＨpaＩＩで消化させ、６
％ポリアクリルアミドゲルで電気泳動にかけ、１６９塩
基対のＸbaＩ−ＨpaＩＩＤＮＡ断片(断片５)を精製し
た。約７５ngの断片４と約５０ngの断片３と約５０ngの
断片５とをＴ４ＤＮＡリガーゼ反応物中であわせ、１４
℃にて１晩培養し、反応混合物をＥ．coliＫ１２菌株２
９４で形質転換した。６種のアンピシリン耐性形質転換
体からのプラスミドＤＮＡを制限エンドヌクレアーゼ消
化により分析した１種のプラスミドＤＮＡは適正な作成
を示し、これをpＫＣＥＡＩnt２と命名した。
【０１０７】最終的な作成は、pＫＣＥＡＩnt２からのt
rpプロモーターを含むＫ−ＣＥＡ断片をpＢＲ３２２(Ｘ
ＡＰ)中へ結合することにより行なった(pＢＲ３２２(Ｘ
ＡＰ)は１９８２年１２月２２日付出願の米国特許出願
第４５２,２２７号明細書に記載されたように、pＢＲ３
２２からＡvaＩ−ＰvaＩＩ断片の削除(欠失)に続く結合
によって作成した)。
rpプロモーターを含むＫ−ＣＥＡ断片をpＢＲ３２２(Ｘ
ＡＰ)中へ結合することにより行なった(pＢＲ３２２(Ｘ
ＡＰ)は１９８２年１２月２２日付出願の米国特許出願
第４５２,２２７号明細書に記載されたように、pＢＲ３
２２からＡvaＩ−ＰvaＩＩ断片の削除(欠失)に続く結合
によって作成した)。
【０１０８】Ｋ−ＣＥＡ断片は、pＫＣＥＡＩnt２をＡv
aＩで処理し、ＤＮＡポリメラーゼＩ(Ｋlenow断片)によ
りdＮＴＰの存在下で平滑末端化させ、ＰstＩで消化
し、ゲル電気泳動と電気溶出とにより所望断片を単離し
て作成した。
aＩで処理し、ＤＮＡポリメラーゼＩ(Ｋlenow断片)によ
りdＮＴＰの存在下で平滑末端化させ、ＰstＩで消化
し、ゲル電気泳動と電気溶出とにより所望断片を単離し
て作成した。
【０１０９】pＢＲ３２２(ＸＡＰ)からの大型ベクター
断片は、ＥcoＲＩによる処理、ポリメラーゼによる平滑
末端化及びＰstＩによる再消化に続いて、電気泳動と電
気溶出とによる大型ベクター断片の単離という順序の処
理によって作成した。
断片は、ＥcoＲＩによる処理、ポリメラーゼによる平滑
末端化及びＰstＩによる再消化に続いて、電気泳動と電
気溶出とによる大型ベクター断片の単離という順序の処
理によって作成した。
【０１１０】上記のように作成したＫ−ＣＥＡ断片とを
Ｔ４ＤＮＡリガーゼにより結合させ、結合混合物をＥ．
coliに上記のように形質転換させた。数種のアンピシリ
ン耐性形質転換体からのプラスミドＤＮＡを分析用に選
択し、１種のプラスミドＤＮＡが適正な作成を示し、こ
れをpＫＣＥＡtrp２０７−１＊と命名した。
Ｔ４ＤＮＡリガーゼにより結合させ、結合混合物をＥ．
coliに上記のように形質転換させた。数種のアンピシリ
ン耐性形質転換体からのプラスミドＤＮＡを分析用に選
択し、１種のプラスミドＤＮＡが適正な作成を示し、こ
れをpＫＣＥＡtrp２０７−１＊と命名した。
【０１１１】Ｅ．１．８．ネズミ成熟抗体−ＣＥＡＨ鎖
(γＩ鎖)遺伝子を直接発現するためのプラスミドベクタ
ーの作成、pγＣＥＡtrp２０７−１＊ 図２３、図２４および図２５はpγＣＥＡtrp２０７−１
＊の作成を示している。このプラスミドは、γ１遺伝子
のＣ−末端領域の作成で始まる２つの部分に於いて作成
した。
(γＩ鎖)遺伝子を直接発現するためのプラスミドベクタ
ーの作成、pγＣＥＡtrp２０７−１＊ 図２３、図２４および図２５はpγＣＥＡtrp２０７−１
＊の作成を示している。このプラスミドは、γ１遺伝子
のＣ−末端領域の作成で始まる２つの部分に於いて作成
した。
【０１１２】５μgのプラスミドpＨＧＨ２０７−１＊を
ＡvaＩで消化し、ＤＮＡポリメラーゼＩ大型断片(Ｋlen
ow断片)で平滑末端まで延長化し、フェノール／ＣＨＣl
3で抽出し、エタノール沈澱させた。ＤＮＡをＢamＨＩ
で消化し、ＢＡＰで処理し大型断片(断片Ａ)を６％ポリ
アクリルアミドゲル電気泳動及び電気溶出により精製し
た。
ＡvaＩで消化し、ＤＮＡポリメラーゼＩ大型断片(Ｋlen
ow断片)で平滑末端まで延長化し、フェノール／ＣＨＣl
3で抽出し、エタノール沈澱させた。ＤＮＡをＢamＨＩ
で消化し、ＢＡＰで処理し大型断片(断片Ａ)を６％ポリ
アクリルアミドゲル電気泳動及び電気溶出により精製し
た。
【０１１３】約５μgのpγ１１をＰstＩにより消化し、
そして遺伝子のＣ末端部分を有するγ鎖cＤＮＡ挿入物
切断片を精製し、ＡvaＩＩで消化し、次いでＡvaＩＩ付
着端部をクノールで延長化し、次いでＴaqＩの消化を行
なった。３７５塩基対の平滑端ＡvaＩＩ−ＴaqＩ断片
(断片Ｂ)を単離し、そしてゲル電気泳動および電気溶出
により精製した。
そして遺伝子のＣ末端部分を有するγ鎖cＤＮＡ挿入物
切断片を精製し、ＡvaＩＩで消化し、次いでＡvaＩＩ付
着端部をクノールで延長化し、次いでＴaqＩの消化を行
なった。３７５塩基対の平滑端ＡvaＩＩ−ＴaqＩ断片
(断片Ｂ)を単離し、そしてゲル電気泳動および電気溶出
により精製した。
【０１１４】９μgのpγ２９８をＴaqＩ及びＢamＨＩで
消化して４９６塩基対断片(断片Ｃ)を単離した。
消化して４９６塩基対断片(断片Ｃ)を単離した。
【０１１５】ほぼ等モル量の断片Ａ,Ｂ及びＣを２０μl
の反応混合物中で１４℃にて１晩結合させ、Ｅ．coli菌
株２９４に形質転換させた。６種のアンピシリン耐性形
質転換体からのプラスミドＤＮＡを制限エンドヌクレア
ーゼ分析にかけ、pγＣＥＡＩntと命名した１種のプラ
スミドＤＮＡはγ１のＣ−末端部分の正確な作成を示し
た(図１５、図１６、図１７、図１８および図１９)。
の反応混合物中で１４℃にて１晩結合させ、Ｅ．coli菌
株２９４に形質転換させた。６種のアンピシリン耐性形
質転換体からのプラスミドＤＮＡを制限エンドヌクレア
ーゼ分析にかけ、pγＣＥＡＩntと命名した１種のプラ
スミドＤＮＡはγ１のＣ−末端部分の正確な作成を示し
た(図１５、図１６、図１７、図１８および図１９)。
【０１１６】Ｎ−末端配列を得るため、３０μgのpγ２
９８をＰstＩで消化し、ネズミ抗−ＣＥＡγ鎖のＮ−末
端領域をコード化する６２８塩基対のＤＮＡ断片を単離
し、精製した。この断片を更にＡluＩ及びＲsaＩで消化
して２８０塩基対断片を単離した。１５ヌクレオチドＤ
ＮＡプライマー、即ち met glu val met leu ５' ＡＴＧ ＧＡＡ ＧＴＧ ＡＴＧ ＣＴＧ ３' をホスホトリエステル法(上記)により合成した。
９８をＰstＩで消化し、ネズミ抗−ＣＥＡγ鎖のＮ−末
端領域をコード化する６２８塩基対のＤＮＡ断片を単離
し、精製した。この断片を更にＡluＩ及びＲsaＩで消化
して２８０塩基対断片を単離した。１５ヌクレオチドＤ
ＮＡプライマー、即ち met glu val met leu ５' ＡＴＧ ＧＡＡ ＧＴＧ ＡＴＧ ＣＴＧ ３' をホスホトリエステル法(上記)により合成した。
【０１１７】５メチオニンは開始コドンとして作用す
る。５００ngのこの合成オリゴマーであるプライマーを
０．５mＭ ＡＴＰを２０μlの反応混合物中に含有する
１０ユニットのＴ４ＤＮＡキナーゼと反応させて５末端
で燐酸化した。５００ngの２８０塩基対ＡluＩ−ＲsaＩ
ＤＮＡ断片を燐酸化したプライマーと混合した。この
混合物を９５℃で３分間熱変性させ、ドライアイスエタ
ノール中で急冷した。変性したＤＮＡ溶液を６０mＭ
ＮaＣl,７mＭ ＭgＣl2,７mＭトリスＨＣl(pＨ７．４),
１２mＭの各dＮＴＰとなし、１２ユニットのＤＮＡポリ
メラーゼＩ−大型断片を加えた。３７℃で２時間培養し
た後、このプライマー修復反応物をフェノール／ＣＨＣ
l3で抽出し、エタノール沈澱させ、ＨpaＩＩで完全消化
させた。予想された１２５塩基対の平滑末端−ＨpaＩＩ
ＤＮＡ断片(断片Ｄ)５０ngをゲルから精製した。
る。５００ngのこの合成オリゴマーであるプライマーを
０．５mＭ ＡＴＰを２０μlの反応混合物中に含有する
１０ユニットのＴ４ＤＮＡキナーゼと反応させて５末端
で燐酸化した。５００ngの２８０塩基対ＡluＩ−ＲsaＩ
ＤＮＡ断片を燐酸化したプライマーと混合した。この
混合物を９５℃で３分間熱変性させ、ドライアイスエタ
ノール中で急冷した。変性したＤＮＡ溶液を６０mＭ
ＮaＣl,７mＭ ＭgＣl2,７mＭトリスＨＣl(pＨ７．４),
１２mＭの各dＮＴＰとなし、１２ユニットのＤＮＡポリ
メラーゼＩ−大型断片を加えた。３７℃で２時間培養し
た後、このプライマー修復反応物をフェノール／ＣＨＣ
l3で抽出し、エタノール沈澱させ、ＨpaＩＩで完全消化
させた。予想された１２５塩基対の平滑末端−ＨpaＩＩ
ＤＮＡ断片(断片Ｄ)５０ngをゲルから精製した。
【０１１８】第２の部分のpγ２９８ＤＮＡをＰstＩで
消化し、６２８塩基対のＤＮＡ断片をポリアクリルアミ
ドゲル電気泳動で精製し、更にＢamＨＩ及びＨpaＩＩで
消化した。得られた３８０塩基対断片(断片Ｅ)をゲル電
気泳動により精製した。
消化し、６２８塩基対のＤＮＡ断片をポリアクリルアミ
ドゲル電気泳動で精製し、更にＢamＨＩ及びＨpaＩＩで
消化した。得られた３８０塩基対断片(断片Ｅ)をゲル電
気泳動により精製した。
【０１１９】５μgのpγＣＥＡＩnt１をＥcoＲＩで消化
し、付着末端をＤＮＡポリメラーゼＩ(Ｋlenow)と整列
させ、ＢamＨＩで消化し、ＢＡＰで処理し、６％ポリア
クリルアミドゲル電気泳動にかけた。大型ベクター断片
(断片Ｆ)を単離し、精製した。
し、付着末端をＤＮＡポリメラーゼＩ(Ｋlenow)と整列
させ、ＢamＨＩで消化し、ＢＡＰで処理し、６％ポリア
クリルアミドゲル電気泳動にかけた。大型ベクター断片
(断片Ｆ)を単離し、精製した。
【０１２０】３つの断片の結合に於いて、５０ngの断片
Ｄと１００ngの断片Ｅと１００ngの断片Ｆとを４℃にて
２０μlの反応混合物中で１晩結合させ、これを使用し
てＥ．coli Ｋ１２菌株２９４を形質転換させた。１２
種のアンピシリン耐性形質転換体からのプラスミドＤＮ
Ａを正確な作成につき分析し、開始コドンを包囲するヌ
クレオチド配列がpγＣＥＡＩnt２と命名したプラスミ
ドにつき正確であることが証明された。
Ｄと１００ngの断片Ｅと１００ngの断片Ｆとを４℃にて
２０μlの反応混合物中で１晩結合させ、これを使用し
てＥ．coli Ｋ１２菌株２９４を形質転換させた。１２
種のアンピシリン耐性形質転換体からのプラスミドＤＮ
Ａを正確な作成につき分析し、開始コドンを包囲するヌ
クレオチド配列がpγＣＥＡＩnt２と命名したプラスミ
ドにつき正確であることが証明された。
【０１２１】Ｈ鎖遺伝子の発現に使用した発現プラスミ
ドpγＣＥＡtrp２０７−１は、pＢＲ３２２(ＸＡＰ)(上
記)からの大型ベクター断片と、pγＣＥＡＩnt２から作
成した２種の断片とを用いて３つの結合により作成す
る。
ドpγＣＥＡtrp２０７−１は、pＢＲ３２２(ＸＡＰ)(上
記)からの大型ベクター断片と、pγＣＥＡＩnt２から作
成した２種の断片とを用いて３つの結合により作成す
る。
【０１２２】pＢＲ３２２(ＸＡＰ)を上記のようにＥco
ＲＩで消化し、ＤＮＡポリメラーゼ(Ｋlenow)によりdＮ
ＴＰの存在下で平滑末端化させ、次いでＰstＩにより処
理し、ゲル電気泳動で大型ベクター断片を単離すること
により処理した。Ｈ鎖遺伝子のＮ−末端コード化領域と
結合したtrpプロモーターを含有するpγＣＥＡＩnt２か
らの１５４３塩基対断片を単離し、その際pγＣＥＡＩn
t２をＰstＩに続き、ＢamＨＩで処理し、所望の断片を
ＰＡＧＥにより単離した。遺伝子のＣ−末端コード化部
分を含有する８６９塩基対断片をＡvaＩによるpγＣＥ
ＡＩnt２の部分消化、Ｋlenowによる平滑末端化及びＢa
mＨＩによる消化、次いでゲル電気泳動による所望断片
の精製によって作成した。
ＲＩで消化し、ＤＮＡポリメラーゼ(Ｋlenow)によりdＮ
ＴＰの存在下で平滑末端化させ、次いでＰstＩにより処
理し、ゲル電気泳動で大型ベクター断片を単離すること
により処理した。Ｈ鎖遺伝子のＮ−末端コード化領域と
結合したtrpプロモーターを含有するpγＣＥＡＩnt２か
らの１５４３塩基対断片を単離し、その際pγＣＥＡＩn
t２をＰstＩに続き、ＢamＨＩで処理し、所望の断片を
ＰＡＧＥにより単離した。遺伝子のＣ−末端コード化部
分を含有する８６９塩基対断片をＡvaＩによるpγＣＥ
ＡＩnt２の部分消化、Ｋlenowによる平滑末端化及びＢa
mＨＩによる消化、次いでゲル電気泳動による所望断片
の精製によって作成した。
【０１２３】上記３種の断片を標準条件下でＴ４ＤＮＡ
リガーゼを用いて結合させ、結合混合物を使用してＥ．
coli菌株２９４を形質転換させた。数種のテトラサイク
リン耐性形質転換体からのプラスミドＤＮＡを分析し、
そのうち１種のプラスミドＤＮＡが適正な作成を示し、
これをpγＣＥＡtrp２０７−１と命名した。
リガーゼを用いて結合させ、結合混合物を使用してＥ．
coli菌株２９４を形質転換させた。数種のテトラサイク
リン耐性形質転換体からのプラスミドＤＮＡを分析し、
そのうち１種のプラスミドＤＮＡが適正な作成を示し、
これをpγＣＥＡtrp２０７−１と命名した。
【０１２４】Ｅ．１．９．Ｅ．coliによる免疫グロブリ
ンの鎖の産生 Ｅ．coli 菌株(Ｗ３１１０−ＡＴＣＣ Ｎo．２７３２
５)を標準技術によりpγＣＥＡtrp２０７−１又はpＫＣ
ＥＡtrp２０７−１で形質転換させた。
ンの鎖の産生 Ｅ．coli 菌株(Ｗ３１１０−ＡＴＣＣ Ｎo．２７３２
５)を標準技術によりpγＣＥＡtrp２０７−１又はpＫＣ
ＥＡtrp２０７−１で形質転換させた。
【０１２５】二重形質転換体を得るため、Ｅ．coli菌株
Ｗ３１１０細胞を予めamp遺伝子からのＰstＩ−ＰvuＩ
断片の開裂及び再結合によって改変させた改変pＫＣＥ
Ａtrp２０７−１及びpＫＣＥＡtrp２０７−１△で形質
転換させた。pＫＣＥＡtrp２０７−１△で形質転換させ
た細胞はアンピシリンに対し感受性であるが、テトラサ
イクリンに対し耐性である。成功した形質転換体をアン
ピシリンに対する耐性を付与するがテトラサイクリンに
対する耐性を付与しないpγＣＥＡＩnt２を用いて再び
形質転換させた。pＫＣＥＡtrp２０７−１△及びpγＣ
ＥＡＩnt２の両者を含有する細胞は、アンピシリンとテ
トラサイクリンとの両者を含有する培地中での増殖によ
り同定した。
Ｗ３１１０細胞を予めamp遺伝子からのＰstＩ−ＰvuＩ
断片の開裂及び再結合によって改変させた改変pＫＣＥ
Ａtrp２０７−１及びpＫＣＥＡtrp２０７−１△で形質
転換させた。pＫＣＥＡtrp２０７−１△で形質転換させ
た細胞はアンピシリンに対し感受性であるが、テトラサ
イクリンに対し耐性である。成功した形質転換体をアン
ピシリンに対する耐性を付与するがテトラサイクリンに
対する耐性を付与しないpγＣＥＡＩnt２を用いて再び
形質転換させた。pＫＣＥＡtrp２０７−１△及びpγＣ
ＥＡＩnt２の両者を含有する細胞は、アンピシリンとテ
トラサイクリンとの両者を含有する培地中での増殖によ
り同定した。
【０１２６】形質転換細胞に於けるＨ鎖及び／又はＬ鎖
の産生を確認するため、細胞試料を１０μg／mlのテト
ラサイクリンを含有し、トリプトファンを含有しないＭ
９培地に接種し、ＯＤ５５０が０．５の読みとなるまで
インドールアクリル酸(ＩＡＡ)で誘発させた。誘発細胞
を種々の時間に亘り、３７℃で増殖させ、次いで遠心分
離し、２％ＳＤＳと０．１Ｍ β−メルカプトエタノー
ルとを含有するＴＥ緩衝液中に懸濁させ、５分間煮沸し
た。１０倍容量のアセトンを加え、細胞を２２℃に１０
分間保ち、次いで１２,０００rpmにて遠心分離した。沈
澱物をＰ．Ｈ．ＯＦarrell,Ｊ．Ｂiol．Ｃhem．,２５
０:４００７(１９７５)によるＳＤＳ試料緩衝液に懸濁
させた。３分間煮沸し、再び遠心分離し、ＳＤＳのＰＡ
ＧＥ(１０％)を用いて分画し、銀染色剤により染色し
(Ｄ．Ｇoldman et al．,Ｓcience,２１１:１４３７(１
９８１)）、又はＬ鎖とＨ鎖とを同定するため、ウサギ
抗−ネズミＩgＧを用いてウェスタンプロット(Ｗestern
blot)にかけた(Ｗ．Ｎ．Ｂurnett et al．,Ａnal．Ｂi
ochem．,１１２:１９５(１９８１))。
の産生を確認するため、細胞試料を１０μg／mlのテト
ラサイクリンを含有し、トリプトファンを含有しないＭ
９培地に接種し、ＯＤ５５０が０．５の読みとなるまで
インドールアクリル酸(ＩＡＡ)で誘発させた。誘発細胞
を種々の時間に亘り、３７℃で増殖させ、次いで遠心分
離し、２％ＳＤＳと０．１Ｍ β−メルカプトエタノー
ルとを含有するＴＥ緩衝液中に懸濁させ、５分間煮沸し
た。１０倍容量のアセトンを加え、細胞を２２℃に１０
分間保ち、次いで１２,０００rpmにて遠心分離した。沈
澱物をＰ．Ｈ．ＯＦarrell,Ｊ．Ｂiol．Ｃhem．,２５
０:４００７(１９７５)によるＳＤＳ試料緩衝液に懸濁
させた。３分間煮沸し、再び遠心分離し、ＳＤＳのＰＡ
ＧＥ(１０％)を用いて分画し、銀染色剤により染色し
(Ｄ．Ｇoldman et al．,Ｓcience,２１１:１４３７(１
９８１)）、又はＬ鎖とＨ鎖とを同定するため、ウサギ
抗−ネズミＩgＧを用いてウェスタンプロット(Ｗestern
blot)にかけた(Ｗ．Ｎ．Ｂurnett et al．,Ａnal．Ｂi
ochem．,１１２:１９５(１９８１))。
【０１２７】pγＣＥＡtrp２０７−１で形質転換させた
細胞は、ＳＤＳ ＰＡＧＥに於いてＨ鎖の分子量に相当
するバンドを示し、これは銀染色により展開された。p
ＫＣＥＡtrp２０７−１で形質転換させた細胞はＬ鎖に
対する適正な分子量バンドを示し、ウェスタンブロット
により同定された。二重形質転換細胞は、ウェスタンブ
ロットによりウサギ抗−ネズミＩgＧを用いて展開した
場合、Ｈ鎖とＬ鎖との両者の分子量蛋白質に対するバン
ドを示した。これらを図２６、図２７及び図２８に示
す。
細胞は、ＳＤＳ ＰＡＧＥに於いてＨ鎖の分子量に相当
するバンドを示し、これは銀染色により展開された。p
ＫＣＥＡtrp２０７−１で形質転換させた細胞はＬ鎖に
対する適正な分子量バンドを示し、ウェスタンブロット
により同定された。二重形質転換細胞は、ウェスタンブ
ロットによりウサギ抗−ネズミＩgＧを用いて展開した
場合、Ｈ鎖とＬ鎖との両者の分子量蛋白質に対するバン
ドを示した。これらを図２６、図２７及び図２８に示
す。
【０１２８】図２６は、pγＣＥＡtrp２０７−１で形質
転換させた細胞から銀染色により展開した結果を示して
いる。レーン１はＣＥＡ．６６−Ｅ３からのモノクロー
ナル抗−ＣＥＡＨ鎖(標準)である。レーン２b−５bはＩ
ＡＡ添加後２時間、４時間、６時間及び２４時間の経時
試料である。レーン２a−５aは対応する未形質転換比較
であり、レーン２c−５cは対応する未誘発形質転換体で
ある。
転換させた細胞から銀染色により展開した結果を示して
いる。レーン１はＣＥＡ．６６−Ｅ３からのモノクロー
ナル抗−ＣＥＡＨ鎖(標準)である。レーン２b−５bはＩ
ＡＡ添加後２時間、４時間、６時間及び２４時間の経時
試料である。レーン２a−５aは対応する未形質転換比較
であり、レーン２c−５cは対応する未誘発形質転換体で
ある。
【０１２９】図２７は、pＫＣＥＡtrp２０７−１で形質
転換させた細胞からウェスタンブロットにより展開した
結果を示している。レーン１b−６bはＩＡＡ添加直後、
１時間、３．５時間、５時間、８時間及び２４時間後の
誘発細胞からの抽出物であり、１a−６aは対応する未誘
発比較であり、レーン７はpγＣＥＡtrp２０７−１比較
からの抽出物であり、レーン８、９及び１０はＣＥＡ．
６６−Ｅ３細胞からの種々な量の抗ＣＥＡ−κ鎖であ
る。
転換させた細胞からウェスタンブロットにより展開した
結果を示している。レーン１b−６bはＩＡＡ添加直後、
１時間、３．５時間、５時間、８時間及び２４時間後の
誘発細胞からの抽出物であり、１a−６aは対応する未誘
発比較であり、レーン７はpγＣＥＡtrp２０７−１比較
からの抽出物であり、レーン８、９及び１０はＣＥＡ．
６６−Ｅ３細胞からの種々な量の抗ＣＥＡ−κ鎖であ
る。
【０１３０】図２８は、ＩＡＡ添加後２４時間の二重形
質転換細胞の４種のコロニーからウェスタンブロットに
より展開した結果を示している(レーン４−７)。レーン
１−３は種々の量のモノクローナルγ鎖比較であり、レ
ーン８及び９はそれぞれ未形質転換細胞抽出物及びpγ
ＣＥＡtrp２０７−１形質転換細胞抽出物である。他の
定量分析に於いて、Ｅ．１．１０(下記)に従って増殖さ
せた凍結形質転換Ｅ．coli細胞をドデシル硫酸ナトリウ
ム(ＳＤＳ)／β−メルカプトエタノール細胞溶菌緩衝液
中で１００℃にて加熱することにより溶菌させた。１部
を種々の量のハイブリドーマ抗−ＣＥＡを加えたレーン
に隣接するＳＤＳポリアクリルアミドゲルに加えた。こ
のゲルをＮew Ｅngland Ｎuclear社からのＩ125−標識
したヒツジ抗−ネズミＩgＧ抗体を用いてウェスタンブ
ロット(Ｂurnett,上記)により展開させた。これら結果
を図２９に示す。この図は、Ｅ．coli産生物が標準ハイ
ブリドーマ鎖と共に移動することを示し、Ｅ．coliに於
ける検出し得る蛋白質分解を示さない。哺乳動物細胞か
らのＨ鎖はＥ．coli材料よりも前者がグリコシル化され
ているため僅かに重いと予想される。ハイブリドーマレ
ーンを標準として使用し、Ｈ鎖及びＬ鎖の産生につき次
の推定を行なった:
質転換細胞の４種のコロニーからウェスタンブロットに
より展開した結果を示している(レーン４−７)。レーン
１−３は種々の量のモノクローナルγ鎖比較であり、レ
ーン８及び９はそれぞれ未形質転換細胞抽出物及びpγ
ＣＥＡtrp２０７−１形質転換細胞抽出物である。他の
定量分析に於いて、Ｅ．１．１０(下記)に従って増殖さ
せた凍結形質転換Ｅ．coli細胞をドデシル硫酸ナトリウ
ム(ＳＤＳ)／β−メルカプトエタノール細胞溶菌緩衝液
中で１００℃にて加熱することにより溶菌させた。１部
を種々の量のハイブリドーマ抗−ＣＥＡを加えたレーン
に隣接するＳＤＳポリアクリルアミドゲルに加えた。こ
のゲルをＮew Ｅngland Ｎuclear社からのＩ125−標識
したヒツジ抗−ネズミＩgＧ抗体を用いてウェスタンブ
ロット(Ｂurnett,上記)により展開させた。これら結果
を図２９に示す。この図は、Ｅ．coli産生物が標準ハイ
ブリドーマ鎖と共に移動することを示し、Ｅ．coliに於
ける検出し得る蛋白質分解を示さない。哺乳動物細胞か
らのＨ鎖はＥ．coli材料よりも前者がグリコシル化され
ているため僅かに重いと予想される。ハイブリドーマレ
ーンを標準として使用し、Ｈ鎖及びＬ鎖の産生につき次
の推定を行なった:
【０１３１】 (細胞１g当り)Ｅ．coli (Ｗ３１１０／pγＣＥＡtrp２０７−１＊) ５mgγＥ．coli (Ｗ３１１０／pＫＣＥＡtrp２０７−１＊) １．５mgκＥ．coli (Ｗ３１１０／pＫＣＥＡtrp２０７−１＊△, pγＣＥＡＩnt２) ０．５mgκ,１．０mgγ
【０１３２】Ｅ．１．１０．組換κ鎖及びγ鎖からの抗
体の再編成 再編成用のＨ鎖及びＬ鎖調製物を得るため、形質転換細
胞を大型バッチで増殖させ、収穫し、凍結させた。種々
形質転換させた細胞の増殖条件は次の通りとした:
体の再編成 再編成用のＨ鎖及びＬ鎖調製物を得るため、形質転換細
胞を大型バッチで増殖させ、収穫し、凍結させた。種々
形質転換させた細胞の増殖条件は次の通りとした:
【０１３３】Ｅ．coli(Ｗ３１１０／pγＣＥＡtrp２０
７−１＊)を５μg／mlのテトラサイクリンを含有する５
００mlのＬＢ培地に接種し、回転振盪器で８時間増殖さ
せた。次いで、培養物を酵母栄養分、塩、グルコース及
び２μg／mlのテトラサイクリンを含有する１０lの発酵
培地に移した。増殖の際にグルコースを追加し、ＯＤ５
５０＝２０にてインドールアクリル酸(ＩＡＡ)、即ち、
trpデプレッサーを５０μg／mlの濃度まで加えた。細胞
に追加グルコースを最終ＯＤ５５０＝４０まで供給し、
これはＩＡＡを加えてから約６時間で達成された。
７−１＊)を５μg／mlのテトラサイクリンを含有する５
００mlのＬＢ培地に接種し、回転振盪器で８時間増殖さ
せた。次いで、培養物を酵母栄養分、塩、グルコース及
び２μg／mlのテトラサイクリンを含有する１０lの発酵
培地に移した。増殖の際にグルコースを追加し、ＯＤ５
５０＝２０にてインドールアクリル酸(ＩＡＡ)、即ち、
trpデプレッサーを５０μg／mlの濃度まで加えた。細胞
に追加グルコースを最終ＯＤ５５０＝４０まで供給し、
これはＩＡＡを加えてから約６時間で達成された。
【０１３４】pＫＣＥＡtrp２０７−１＊で形質転換させ
たＥ．coli(Ｗ３１１０)細胞とpＫＣＥＡtrp２０７−１
＊△及びpγＣＥＡＩnt２で二重形質転換させたものと
を上記と同様に増殖させた。但し、ＩＡＡ添加後６時間
に於ける収穫時のＯＤ５５０は２５−３０であった。次
いで、これらの細胞を遠心分離により収穫し凍結した。
たＥ．coli(Ｗ３１１０)細胞とpＫＣＥＡtrp２０７−１
＊△及びpγＣＥＡＩnt２で二重形質転換させたものと
を上記と同様に増殖させた。但し、ＩＡＡ添加後６時間
に於ける収穫時のＯＤ５５０は２５−３０であった。次
いで、これらの細胞を遠心分離により収穫し凍結した。
【０１３５】Ｅ．２．再編成抗体の分析方法 抗−ＣＥＡ活性を再編成の成功に対する基準としてＥＬ
ＩＳＡにより測定した。マイクロタイタープレート(Ｄy
natech Ｉmmulon社製)のウェルにＣＥＡを飽和させ、
０．１Ｍ炭酸塩緩衝液(pＨ９．３)中の２〜５μgＣＥＡ
／ml溶液１００μlを室温で１２時間培養することによ
り行なった。次いで、これらのウェルを燐酸塩緩衝液
(ＰＢＳ)で４回洗浄し、ＰＢＳに於ける０．５％ＢＳＡ
２００μlを３７℃で２時間培養し、ＰＢＳで４回洗浄
することによりＢＳＡで飽和させた。５０μlの各試料
を各ウェルに加えた。ＰＢＳに於ける０．５％ＢＳＡ中
１０μg,５μg、５００ng、１００ng、５０ng、１０n
g、５ng及び１ngの抗−ＣＥＡ／mlの５０μl試料と、ブ
ランクとしてのＰＢＳに於ける０．５％ＢＳＡ５０μl
のみとから成る標準曲線(図３０に示す)を作成した。全
ての試料をプレート中で３７℃にて９０分間培養した。
ＩＳＡにより測定した。マイクロタイタープレート(Ｄy
natech Ｉmmulon社製)のウェルにＣＥＡを飽和させ、
０．１Ｍ炭酸塩緩衝液(pＨ９．３)中の２〜５μgＣＥＡ
／ml溶液１００μlを室温で１２時間培養することによ
り行なった。次いで、これらのウェルを燐酸塩緩衝液
(ＰＢＳ)で４回洗浄し、ＰＢＳに於ける０．５％ＢＳＡ
２００μlを３７℃で２時間培養し、ＰＢＳで４回洗浄
することによりＢＳＡで飽和させた。５０μlの各試料
を各ウェルに加えた。ＰＢＳに於ける０．５％ＢＳＡ中
１０μg,５μg、５００ng、１００ng、５０ng、１０n
g、５ng及び１ngの抗−ＣＥＡ／mlの５０μl試料と、ブ
ランクとしてのＰＢＳに於ける０．５％ＢＳＡ５０μl
のみとから成る標準曲線(図３０に示す)を作成した。全
ての試料をプレート中で３７℃にて９０分間培養した。
【０１３６】次いで、これらのプレートをＰＢＳで４回
洗浄し、ヒツジ抗−ネズミＩgＧ−アルカリホスフェー
ト(ＴＡＧＯ,Ｉnc．)をＰＢＳに於ける０．５％ＢＳＡ
中の２４ユニット／mlの酵素濃度１０μlを加えること
により各ウェルに施した。この溶液を３７℃にて９０分
間培養した。これらプレートをＰＢＳで４回洗浄した
後、基質へエタノールアミン緩衝塩(pＨ９．５)に於け
るp−ニトロフェニルホスフェート(Ｓigma社製)の０．
４mg／ml溶液１００μlを加えた。この基質を３７℃に
て９０分間培養した発色させた。
洗浄し、ヒツジ抗−ネズミＩgＧ−アルカリホスフェー
ト(ＴＡＧＯ,Ｉnc．)をＰＢＳに於ける０．５％ＢＳＡ
中の２４ユニット／mlの酵素濃度１０μlを加えること
により各ウェルに施した。この溶液を３７℃にて９０分
間培養した。これらプレートをＰＢＳで４回洗浄した
後、基質へエタノールアミン緩衝塩(pＨ９．５)に於け
るp−ニトロフェニルホスフェート(Ｓigma社製)の０．
４mg／ml溶液１００μlを加えた。この基質を３７℃に
て９０分間培養した発色させた。
【０１３７】各ウェルのＡ450を１．５の閾域、１．０
の較正値及び０．０００１に設定したＰＢＳ(Ｂlank)ウ
ェルに於ける０．５％ＢＳＡにセットしたマイクロエリ
サ・オート・リーダー(Ｍicroelisa Ａuto Ｒeader,Ｄy
natech社製)により読み取った。Ａ450のデータをＶＡＸ
系に於けるＲＳ−１で表にし、標準曲線データを４パラ
メータのロジスチックモデルに当てはめた。未知試料の
濃度をＡ450データに基いて算出した。
の較正値及び０．０００１に設定したＰＢＳ(Ｂlank)ウ
ェルに於ける０．５％ＢＳＡにセットしたマイクロエリ
サ・オート・リーダー(Ｍicroelisa Ａuto Ｒeader,Ｄy
natech社製)により読み取った。Ａ450のデータをＶＡＸ
系に於けるＲＳ−１で表にし、標準曲線データを４パラ
メータのロジスチックモデルに当てはめた。未知試料の
濃度をＡ450データに基いて算出した。
【０１３８】Ｅ．３．組換抗体の再編成及び分析 上記Ｅ．１．１０に記載したように、作成した凍結細胞
を冷溶菌緩衝液(１０mＭトリスＨＣl(pＨ７．５),１mＭ
ＥＤＴＡ,０．１Ｍ ＮaＣl,１mＭ弗化フェニルメチ
ルスルホニル(ＰＭＳＦ))に於いて解凍させ、音波処理
で溶菌させた。溶菌物を３,０００rpmにて２０分間の遠
心分離により部分清澄化させた。１mＭＰＭＳＦを追加
して蛋白質分解酵素から上清を保護し、直ちに使用する
か又は−８０℃で凍結保存した。凍結溶菌物は、決して
２回以上解凍させなかった。
を冷溶菌緩衝液(１０mＭトリスＨＣl(pＨ７．５),１mＭ
ＥＤＴＡ,０．１Ｍ ＮaＣl,１mＭ弗化フェニルメチ
ルスルホニル(ＰＭＳＦ))に於いて解凍させ、音波処理
で溶菌させた。溶菌物を３,０００rpmにて２０分間の遠
心分離により部分清澄化させた。１mＭＰＭＳＦを追加
して蛋白質分解酵素から上清を保護し、直ちに使用する
か又は−８０℃で凍結保存した。凍結溶菌物は、決して
２回以上解凍させなかった。
【０１３９】Ｅ．coliで産生した抗−ＣＥＡＨ鎖(γ)の
Ｓ−スルホン化物を次のように作成した:不溶性物体と
してＨ鎖を含有するpγＣＥＡtrp２０７−１＊で形質転
換させた組換Ｅ．coli細胞を溶菌し、上記と同様に遠心
分離した。ペレットを同じ緩衝液中に再懸濁させ、音波
処理し、再遠心分離した。このペレットを緩衝液で１回
洗浄し、６Ｍグアニジン塩酸塩,０．１ＭトリスＨＣl(p
Ｈ８),１mＭ ＥＤＴＡ,２０mg／ml亜硫酸ナトリウム及
び１０mg／mlテトラチオン酸ナトリウムに懸濁させ、２
５℃にて約１６時間反応させた。反応混合物を８Ｍ尿
素,０．１ＭトリスＨＣl(pＨ８)に対し、透析し、４℃
で貯蔵してγ−ＳＳＯ3の３mg／ml溶液を得た。
Ｓ−スルホン化物を次のように作成した:不溶性物体と
してＨ鎖を含有するpγＣＥＡtrp２０７−１＊で形質転
換させた組換Ｅ．coli細胞を溶菌し、上記と同様に遠心
分離した。ペレットを同じ緩衝液中に再懸濁させ、音波
処理し、再遠心分離した。このペレットを緩衝液で１回
洗浄し、６Ｍグアニジン塩酸塩,０．１ＭトリスＨＣl(p
Ｈ８),１mＭ ＥＤＴＡ,２０mg／ml亜硫酸ナトリウム及
び１０mg／mlテトラチオン酸ナトリウムに懸濁させ、２
５℃にて約１６時間反応させた。反応混合物を８Ｍ尿
素,０．１ＭトリスＨＣl(pＨ８)に対し、透析し、４℃
で貯蔵してγ−ＳＳＯ3の３mg／ml溶液を得た。
【０１４０】各種のＩgＧ鎖を産生する各種のＥ．coli
菌株の細胞から得られる細胞溶菌物６５０μlを５００m
gの尿素に加えた。これに２０mＭまでのβ−メルカプト
エタノールと５０mＭまでのトリスＨＣl(pＨ８．５)
と、１mＭまでのＥＤＴＡとを加え、また或る実験では
γ−ＳＳＯ3を０．１mg／mlまで加えた。２５℃で３０
〜９０分間静置した後、この反応混合物を４℃にて０．
１Ｍグリシン酸ナトリウム(pＨ１０．８),０．５Ｍ尿
素,１０mＭグリシンエチルエステル,５mＭ還元グルタチ
オン,０．１mＭ酸化グルタチオンから成り、緩衝液に対
して透析した。この緩衝液をＮ飽和した水から調製し、
透析を蓋付ウィートン瓶にて行なった。１６〜４８時間
後、透析袋を１mＭ ＰＭＳＦを含有する４℃の燐酸塩
緩衝液に移し、更に１６〜２４時間透析を続けた。透析
物をＥ．２に記載したようにＣＥＡを結合する能力につ
きＥＬＩＳＡによって分析した。下記の結果は標準曲線
と比較して得られた数値をng／ml抗−ＣＥＡとして示
す。更に、ＥＬＩＳＡ反応マイナスκ鎖のみを産生する
細胞のバックグラウンド(１０８ng／ml)から、及び反応
混合物に於けるγ及びκ鎖のレベルの推定値から計算し
た再編成効率をも示す。
菌株の細胞から得られる細胞溶菌物６５０μlを５００m
gの尿素に加えた。これに２０mＭまでのβ−メルカプト
エタノールと５０mＭまでのトリスＨＣl(pＨ８．５)
と、１mＭまでのＥＤＴＡとを加え、また或る実験では
γ−ＳＳＯ3を０．１mg／mlまで加えた。２５℃で３０
〜９０分間静置した後、この反応混合物を４℃にて０．
１Ｍグリシン酸ナトリウム(pＨ１０．８),０．５Ｍ尿
素,１０mＭグリシンエチルエステル,５mＭ還元グルタチ
オン,０．１mＭ酸化グルタチオンから成り、緩衝液に対
して透析した。この緩衝液をＮ飽和した水から調製し、
透析を蓋付ウィートン瓶にて行なった。１６〜４８時間
後、透析袋を１mＭ ＰＭＳＦを含有する４℃の燐酸塩
緩衝液に移し、更に１６〜２４時間透析を続けた。透析
物をＥ．２に記載したようにＣＥＡを結合する能力につ
きＥＬＩＳＡによって分析した。下記の結果は標準曲線
と比較して得られた数値をng／ml抗−ＣＥＡとして示
す。更に、ＥＬＩＳＡ反応マイナスκ鎖のみを産生する
細胞のバックグラウンド(１０８ng／ml)から、及び反応
混合物に於けるγ及びκ鎖のレベルの推定値から計算し
た再編成効率をも示す。
【０１４１】 ng／ml 組換 抗−ＣＥＡ ％ ＩＦＮ−αＡを産生するＥ．coli Ｗ３１１０(比較) ０ −Ｅ．coli (Ｗ３１１０／pＫＣＥＡtrp２０７−１＊) １０８ −Ｅ．coli (Ｗ３１１０／pＫＣＥＡtrp２０７−１＊) ＋γ−ＳＳＯ3 ８４８ ０．３３Ｅ．coli (Ｗ３１１０／pＫＣＥＡtrp２０７−１＊△, pγＣＥＡＩnt２) １５８０ ０．７６ ハイブリドーマ抗−ＣＥＡ κ−ＳＳＯ3 及びγ−ＳＳＯ3 ５４０ ０．４０
【０１４２】Ｅ．４．キメラ抗体の作成 図３１及び図３２はネズミ抗ＣＥＡ可変領域とヒトγ２
不変領域とから成るキメラＨ(γ)鎖のための発現ベクタ
ーの作成を示している。
不変領域とから成るキメラＨ(γ)鎖のための発現ベクタ
ーの作成を示している。
【０１４３】ヒトγ２Ｈ鎖をコード化するＤＮＡ配列は
次のように作成される:ヒト多発性骨髄腫細胞系から標
準技術により得たcＤＮＡライブラリーを５'ＧＧＧＣＡ
ＣＴＣＧＡＣＡＣＡＡ３'で検索して、ヒトγ２鎖に対
するcＤＮＡ挿入物を含有するプラスミドを得(Ｔakahas
hi et al．,Ｃell,２９:６７１(１９８２))(この文献を
引用して本明細書に包含する)、分析してヒトγ２に於
ける公知配列によりこれを同定する(Ｊ．Ｅllison et a
l．,Ｐroc．Ｎatl．Ａcad．ＵＳＡ,７９:１９８４(１９
８２)）(この文献を引用して本明細書に包含する)。
次のように作成される:ヒト多発性骨髄腫細胞系から標
準技術により得たcＤＮＡライブラリーを５'ＧＧＧＣＡ
ＣＴＣＧＡＣＡＣＡＡ３'で検索して、ヒトγ２鎖に対
するcＤＮＡ挿入物を含有するプラスミドを得(Ｔakahas
hi et al．,Ｃell,２９:６７１(１９８２))(この文献を
引用して本明細書に包含する)、分析してヒトγ２に於
ける公知配列によりこれを同定する(Ｊ．Ｅllison et a
l．,Ｐroc．Ｎatl．Ａcad．ＵＳＡ,７９:１９８４(１９
８２)）(この文献を引用して本明細書に包含する)。
【０１４４】図３１に示したように、クローン化ヒトγ
２プラスミド(pγ２)から２つの断片が得られる。第１
の断片は、ＰvuＩＩによる消化に続きＡvaＩＩＩでの消
化及び不変領域の部分を勧誘する小さいＤＮＡ断片の６
％ＰＡＧＥを用いる精製によって生ぜしめる。第２の断
片は、pγ２をγ２の３'未翻訳領域に於いて開裂する
(ヌクレオチド配列から推定される)制限酵素で消化し、
Ｋlenow及びdＮＴＰを充填し、ＡvaＩＩＩで開裂させ
て、６％ＰＡＧＥを用いて小さい方の断片を単離するこ
とにより得られる。(ＰvuＩＩ−３'未翻訳断片を供給す
るための２工程且つ２断片の組成物の選択は、３末端に
対しＡvaＩＩＩ部位が近接するため産生物に対する明確
な経路を与え、従って３'未翻訳領域部位に適合する遺
伝子配列に於ける制限部位を更に必要としない。)pγＣ
ＥＡ２０７−１をＥcoＲＩで消化し、Ｋlenow及びdＮＴ
Ｐで処理して付着性末端充填し、ＰvuＩＩで消化し、こ
の場合大きいベクター断片は６％ＰＡＧＥにより単離さ
れたプロモーターを含有する。
２プラスミド(pγ２)から２つの断片が得られる。第１
の断片は、ＰvuＩＩによる消化に続きＡvaＩＩＩでの消
化及び不変領域の部分を勧誘する小さいＤＮＡ断片の６
％ＰＡＧＥを用いる精製によって生ぜしめる。第２の断
片は、pγ２をγ２の３'未翻訳領域に於いて開裂する
(ヌクレオチド配列から推定される)制限酵素で消化し、
Ｋlenow及びdＮＴＰを充填し、ＡvaＩＩＩで開裂させ
て、６％ＰＡＧＥを用いて小さい方の断片を単離するこ
とにより得られる。(ＰvuＩＩ−３'未翻訳断片を供給す
るための２工程且つ２断片の組成物の選択は、３末端に
対しＡvaＩＩＩ部位が近接するため産生物に対する明確
な経路を与え、従って３'未翻訳領域部位に適合する遺
伝子配列に於ける制限部位を更に必要としない。)pγＣ
ＥＡ２０７−１をＥcoＲＩで消化し、Ｋlenow及びdＮＴ
Ｐで処理して付着性末端充填し、ＰvuＩＩで消化し、こ
の場合大きいベクター断片は６％ＰＡＧＥにより単離さ
れたプロモーターを含有する。
【０１４５】ネズミγ１遺伝子に於けるＰvuＩＩ部位を
包囲する位置及びＤＮＡ配列は、ヒトγ２遺伝子に於け
るＰvuＩＩ部位を包囲する位置及びＤＮＡ配列と同一で
ある。
包囲する位置及びＤＮＡ配列は、ヒトγ２遺伝子に於け
るＰvuＩＩ部位を包囲する位置及びＤＮＡ配列と同一で
ある。
【０１４６】上記断片の３方向結合から得られるプラス
ミド(pＣhim１)は、trpプロモーターの影響下で、ネズ
ミ抗−ＣＥＡγ１鎖の可変領域及び不変領域の１部並び
にγ２ヒト鎖の１部を含有する。事実、pＣhim１は、
Ｅ．coliに形質転換させた場合、キメラＨ鎖を発現する
が、ネズミからヒトへの変化は可変領域対不変領域の接
合部に於いて生じないものである。
ミド(pＣhim１)は、trpプロモーターの影響下で、ネズ
ミ抗−ＣＥＡγ１鎖の可変領域及び不変領域の１部並び
にγ２ヒト鎖の１部を含有する。事実、pＣhim１は、
Ｅ．coliに形質転換させた場合、キメラＨ鎖を発現する
が、ネズミからヒトへの変化は可変領域対不変領域の接
合部に於いて生じないものである。
【０１４７】図３２は発現により生ずる蛋白質がネズミ
抗−ＣＥＡ抗体からの可変領域とヒトγ２鎖からの不変
領域とを含有するようにpＣhim２を作成するためのpＣh
im１の改変を示している。まず、ＮcoＩで処理し、Ｋle
now及びdＮＴＰで平滑末端化させ、ＰvuＩＩにより開裂
させ、ネズミ抗−ＣＥＡに対する一定コード化領域に於
ける短セグメントを除き、殆んど完全プラスミドである
大型ベクター断片を単離することにより、pＣhim１から
断片を作成する。ＰvuＩＩで処理し、可変領域で開裂す
る任意の制限酵素で処理し、Ｋlenow及びdＮＴＰで平滑
末端化し、この連鎖の可変領域と不変領域との間の接合
部から成る短い断片を単離することにより、上記のpγ
２から第２の断片を作成する。
抗−ＣＥＡ抗体からの可変領域とヒトγ２鎖からの不変
領域とを含有するようにpＣhim２を作成するためのpＣh
im１の改変を示している。まず、ＮcoＩで処理し、Ｋle
now及びdＮＴＰで平滑末端化させ、ＰvuＩＩにより開裂
させ、ネズミ抗−ＣＥＡに対する一定コード化領域に於
ける短セグメントを除き、殆んど完全プラスミドである
大型ベクター断片を単離することにより、pＣhim１から
断片を作成する。ＰvuＩＩで処理し、可変領域で開裂す
る任意の制限酵素で処理し、Ｋlenow及びdＮＴＰで平滑
末端化し、この連鎖の可変領域と不変領域との間の接合
部から成る短い断片を単離することにより、上記のpγ
２から第２の断片を作成する。
【０１４８】上記２つの断片を結合すれば、中間的プラ
スミドが得られ、このプラスミドはネズミ抗−ＣＥＡ抗
原の不変領域の小部分と、ヒトγ鎖の可変領域の小部分
とを含有する外来ＤＮＡ断片以外には正確である。この
修復はＸbaＩ−ＰvuＩＩの断片を切断しＭessing et a
l．,Ｎucleic acids Ｒes．,９:３０９(１９８１)に記
載されたＭ１３ファージ中へクローン化させ、次いでＡ
delman et al．,ＤＮＡ,２:１８３(１９８３)に記載さ
れたように試験管内に於ける部位指向性の削除突然変異
によって行なった。このように改変させたＸbaＩ−Ｐvu
ＩＩ断片を再び中間プラスミドに結合してpＣhim２を生
成させる。このプラスミドは適当な宿主に於いて、明確
に作成されたネズミ可変領域／ヒト不変領域キメラＨ鎖
を発現することができる。
スミドが得られ、このプラスミドはネズミ抗−ＣＥＡ抗
原の不変領域の小部分と、ヒトγ鎖の可変領域の小部分
とを含有する外来ＤＮＡ断片以外には正確である。この
修復はＸbaＩ−ＰvuＩＩの断片を切断しＭessing et a
l．,Ｎucleic acids Ｒes．,９:３０９(１９８１)に記
載されたＭ１３ファージ中へクローン化させ、次いでＡ
delman et al．,ＤＮＡ,２:１８３(１９８３)に記載さ
れたように試験管内に於ける部位指向性の削除突然変異
によって行なった。このように改変させたＸbaＩ−Ｐvu
ＩＩ断片を再び中間プラスミドに結合してpＣhim２を生
成させる。このプラスミドは適当な宿主に於いて、明確
に作成されたネズミ可変領域／ヒト不変領域キメラＨ鎖
を発現することができる。
【０１４９】同様にして、γ鎖でなくヒトκ鎖に対する
cＤＮＡ作成のためのmＲＮＡ鋳型を使用してキメラＬ鎖
のための発現プラスミドを作成する。
cＤＮＡ作成のためのmＲＮＡ鋳型を使用してキメラＬ鎖
のための発現プラスミドを作成する。
【０１５０】次いで、上記２つのプラスミドをＥ．coli
Ｗ３１１０に二重形質転換させ、これら細胞を増殖さ
せ、上記Ｅ．１−Ｅ．３に示したように連鎖を再編成す
る。
Ｗ３１１０に二重形質転換させ、これら細胞を増殖さ
せ、上記Ｅ．１−Ｅ．３に示したように連鎖を再編成す
る。
【０１５１】Ｅ．５．改変ネズミ抗−ＣＥＡ抗体の作成 Ｅ．５．１．改変ネズミ抗−ＣＥＡＨ鎖遺伝子の直接発
現用プラスミドベクターの作成 ネズミ抗−ＣＥＡＨ鎖の不変領域に於けるアミノ酸２１
６−２３０の区域のシステイン残基及び得られるジスル
フィド結合は、補体結合に対し重要であると思われる
(Ｋlein et al．,Ｐroc．Ｎatl．Ａcad．Ｓci．,ＵＳ
Ａ,７８:５２４(１９８１))が、得られる抗体の抗原結
合性にとっては重要でない。本発明の方法による再編成
の際、不正確なジスルフィド結合形成の可能性を減少さ
せるため、３個のシステインに対するコドンを含むアミ
ノ酸残基２３６−２３２をコードするヌクレオチドを次
のようにして欠失する:
現用プラスミドベクターの作成 ネズミ抗−ＣＥＡＨ鎖の不変領域に於けるアミノ酸２１
６−２３０の区域のシステイン残基及び得られるジスル
フィド結合は、補体結合に対し重要であると思われる
(Ｋlein et al．,Ｐroc．Ｎatl．Ａcad．Ｓci．,ＵＳ
Ａ,７８:５２４(１９８１))が、得られる抗体の抗原結
合性にとっては重要でない。本発明の方法による再編成
の際、不正確なジスルフィド結合形成の可能性を減少さ
せるため、３個のシステインに対するコドンを含むアミ
ノ酸残基２３６−２３２をコードするヌクレオチドを次
のようにして欠失する:
【０１５２】「デリーター(deleter,欠失剤)」デオキシオ
リゴヌクレオチド即ち５'ＣＴＡＡＣＡＣＣＡＴＧＴＣ
ＡＧＧＧＴを使用して、Ｗallace et al．,Ｓcience,２
０９:１３９６(１９８０)の方法又はＡdelman et al．,
ＤＮＡ,２:１８３(１９８３)の方法によってpγＣＥＡt
rp２０７−１＊から遺伝子の適切な部分を欠失させる。
要するに、「デリーター」デオキシオリゴヌクレオチドを
変性pγＣＥＡtrp２０７−１＊ＤＮＡと共にアニール
し、プライマー修復合成をin vitroで行ない、次いでＰ
32標識したデリーター配列と推定欠失クローンとのハイ
ブリゼーションにより選別(screening)する。
リゴヌクレオチド即ち５'ＣＴＡＡＣＡＣＣＡＴＧＴＣ
ＡＧＧＧＴを使用して、Ｗallace et al．,Ｓcience,２
０９:１３９６(１９８０)の方法又はＡdelman et al．,
ＤＮＡ,２:１８３(１９８３)の方法によってpγＣＥＡt
rp２０７−１＊から遺伝子の適切な部分を欠失させる。
要するに、「デリーター」デオキシオリゴヌクレオチドを
変性pγＣＥＡtrp２０７−１＊ＤＮＡと共にアニール
し、プライマー修復合成をin vitroで行ない、次いでＰ
32標識したデリーター配列と推定欠失クローンとのハイ
ブリゼーションにより選別(screening)する。
【０１５３】Ｅ．５．２．システイン欠如改変抗体の産
生 Ｅ．５．１．で作成したプラスミドを用いて、上記のよ
うに予めpＫＣＥＡtrp２０７−１＊で形質転換したＥ．
coli菌株を形質転換する。これら細胞を増殖させ、組換
抗体鎖を抽出し、Ｅ．１．１０．に記載したように改変
抗体を再編成する。
生 Ｅ．５．１．で作成したプラスミドを用いて、上記のよ
うに予めpＫＣＥＡtrp２０７−１＊で形質転換したＥ．
coli菌株を形質転換する。これら細胞を増殖させ、組換
抗体鎖を抽出し、Ｅ．１．１０．に記載したように改変
抗体を再編成する。
【０１５４】Ｅ．６．Ｆabの作成 Ｅ．６．１．ネズミ抗−ＣＥＡγ１Ｆab断片遺伝子の直
接発現用プラスミドベクターの作成:pγＣＥＡＦabtrp
２０７−１＊ 図３３はpγＣＥＡＦabtrp２０７−１＊の作成を示して
いる。５μgのpＢＲ３２２をＨindＩＩＩで消化し、Ｋl
enow及びdＮＴＰで処理して付着性末端を平滑化し、Ｐs
tＩで消化し、ＢＡＰで処理した。大ベクター断片、即
ち断片Ｉを６％ＰＡＧＥを用い、電気溶出することによ
り回収した。
接発現用プラスミドベクターの作成:pγＣＥＡＦabtrp
２０７−１＊ 図３３はpγＣＥＡＦabtrp２０７−１＊の作成を示して
いる。５μgのpＢＲ３２２をＨindＩＩＩで消化し、Ｋl
enow及びdＮＴＰで処理して付着性末端を平滑化し、Ｐs
tＩで消化し、ＢＡＰで処理した。大ベクター断片、即
ち断片Ｉを６％ＰＡＧＥを用い、電気溶出することによ
り回収した。
【０１５５】５μgのpγＣＥＡtrp２０７−１をＢamＨ
Ｉ及びＰstＩの両者で消化し、trpプロモーターと、可
変領域をコードし不変領域まで続き更に抗−ＣＥＡγ１
鎖のヒンジ領域まで続く遺伝子配列とを含有する約１５
７０bpのＤＮＡ断片(断片ＩＩ)を単離し、電気泳動の後
に精製した。
Ｉ及びＰstＩの両者で消化し、trpプロモーターと、可
変領域をコードし不変領域まで続き更に抗−ＣＥＡγ１
鎖のヒンジ領域まで続く遺伝子配列とを含有する約１５
７０bpのＤＮＡ断片(断片ＩＩ)を単離し、電気泳動の後
に精製した。
【０１５６】完全Ｈ鎖でなく、抗−ＣＥＡγ１鎖Ｆab断
片が発現されるためには、停止コドンが遺伝子中の適当
な位置に作成されることが必要である。このため、２０
μgのpγ２９８から２６０bpのＮcoＩ−ＮdeＩ ＤＮＡ
断片を単離し、精製した。１３ヌクレオチドＤＮＡプラ
イマー、即ちその相補鎖がＦab遺伝子の最後の３個のＣ
−末端アミノ酸と停止コドンに対し必要とされる３個の
うち２個の塩基とをコードするものをホスホトリエステ
ル法(上記)によって合成した。このプローブはヌクレオ
チド７５４−７６７(図９、図１０、図１１、図１２、
図１３および図１４)にハイブリダイズし、これは次の
配列を有する:
片が発現されるためには、停止コドンが遺伝子中の適当
な位置に作成されることが必要である。このため、２０
μgのpγ２９８から２６０bpのＮcoＩ−ＮdeＩ ＤＮＡ
断片を単離し、精製した。１３ヌクレオチドＤＮＡプラ
イマー、即ちその相補鎖がＦab遺伝子の最後の３個のＣ
−末端アミノ酸と停止コドンに対し必要とされる３個の
うち２個の塩基とをコードするものをホスホトリエステ
ル法(上記)によって合成した。このプローブはヌクレオ
チド７５４−７６７(図９、図１０、図１１、図１２、
図１３および図１４)にハイブリダイズし、これは次の
配列を有する:
【０１５７】停止コドンの第３塩基を上記のpＢＲ３２
２開裂物の充填ＨindＩＩＩ部位の末端ヌクレオチドに
より供給する。このプライマー５００ngを、２０μl中
に０．５mＭのＡＴＰを含有する１０ユニットのＴ４Ｄ
ＮＡキナーゼを用いる反応液中の５'末端の燐酸化によ
りプライマー修復反応に使用し、これを約２００ngのＮ
coＩ−ＮdeＩ ＤＮＡ断片と混合した。混合物を９５℃
で３分間加熱変性させ、ドライアイスエタノール中で急
冷した。この変性したＤＮＡ溶液を６０mＭ ＮaＣl,７
mＭ ＭgＣl2,７mＭトリスＨＣl(pＨ７．４),１２mＭの
各dＮＴＰとなし、１２ユニットのＤＮＡポリメラーゼ
Ｉ−大断片を加えた。３７℃で２時間インキュベーショ
ンした後、このプライマー修復反応物をフェノール／Ｃ
ＨＣl3で抽出し、エタノール沈澱し、ＢamＨＩで消化
し、反応物を６％ポリアクリルアミドゲルで電気泳動に
かけた。１８１bp平滑末端−ＢamＨＩのＤＮＡ断片、即
ち断片ＩＩＩの約５０ngを単離し、精製した。
２開裂物の充填ＨindＩＩＩ部位の末端ヌクレオチドに
より供給する。このプライマー５００ngを、２０μl中
に０．５mＭのＡＴＰを含有する１０ユニットのＴ４Ｄ
ＮＡキナーゼを用いる反応液中の５'末端の燐酸化によ
りプライマー修復反応に使用し、これを約２００ngのＮ
coＩ−ＮdeＩ ＤＮＡ断片と混合した。混合物を９５℃
で３分間加熱変性させ、ドライアイスエタノール中で急
冷した。この変性したＤＮＡ溶液を６０mＭ ＮaＣl,７
mＭ ＭgＣl2,７mＭトリスＨＣl(pＨ７．４),１２mＭの
各dＮＴＰとなし、１２ユニットのＤＮＡポリメラーゼ
Ｉ−大断片を加えた。３７℃で２時間インキュベーショ
ンした後、このプライマー修復反応物をフェノール／Ｃ
ＨＣl3で抽出し、エタノール沈澱し、ＢamＨＩで消化
し、反応物を６％ポリアクリルアミドゲルで電気泳動に
かけた。１８１bp平滑末端−ＢamＨＩのＤＮＡ断片、即
ち断片ＩＩＩの約５０ngを単離し、精製した。
【０１５８】約１００ngの断片Ｉとそれぞれ約１００ng
の断片ＩＩ及びＩＩＩを１晩結合させ、Ｅ．coli Ｋ１
２菌株２９４に形質転換した。数種のテトラサイクリン
耐性形質転換体からのプラスミドＤＮＡを適正な構成の
ものにつき分析し、修復平滑末端充填ＨindＩＩＩ接合
部を介するヌクレオチド配列を決定してＴＧＡ停止コド
ンを証明した。
の断片ＩＩ及びＩＩＩを１晩結合させ、Ｅ．coli Ｋ１
２菌株２９４に形質転換した。数種のテトラサイクリン
耐性形質転換体からのプラスミドＤＮＡを適正な構成の
ものにつき分析し、修復平滑末端充填ＨindＩＩＩ接合
部を介するヌクレオチド配列を決定してＴＧＡ停止コド
ンを証明した。
【０１５９】Ｅ．６．２．Ｆab蛋白質の産生 Ｅ．６．１で作成したプラスミドを上記のように予めp
ＫＣＥＡtrp２０７−１＊で形質転換したＥ．coli菌株
を形質転換する。これら細胞を増殖させ、組換抗体鎖に
つき抽出し、Ｆab蛋白質をＥ．１．１０に記載したよう
に再編成する。
ＫＣＥＡtrp２０７−１＊で形質転換したＥ．coli菌株
を形質転換する。これら細胞を増殖させ、組換抗体鎖に
つき抽出し、Ｆab蛋白質をＥ．１．１０に記載したよう
に再編成する。
【図１】 免疫グロブリンの一般的構造図を示す図であ
る。
る。
【図２】 κ抗ＣＥＡ鎖をコードするpＫ１７Ｇ４のcＤ
ＮＡ挿入物の詳細な配列を示す図である。
ＮＡ挿入物の詳細な配列を示す図である。
【図３】 κ抗ＣＥＡ鎖をコードするpＫ１７Ｇ４のcＤ
ＮＡ挿入物の詳細な配列を示す図である。
ＮＡ挿入物の詳細な配列を示す図である。
【図４】 κ抗ＣＥＡ鎖をコードするpＫ１７Ｇ４のcＤ
ＮＡ挿入物の詳細な配列を示す図である。
ＮＡ挿入物の詳細な配列を示す図である。
【図５】 κ抗ＣＥＡ鎖をコードするpＫ１７Ｇ４のcＤ
ＮＡ挿入物の詳細な配列を示す図である。
ＮＡ挿入物の詳細な配列を示す図である。
【図６】 対応するアミノ酸配列と共に示した図２、図
３、図４および図５の断片のコード配列を示す図であ
る。
３、図４および図５の断片のコード配列を示す図であ
る。
【図７】 対応するアミノ酸配列と共に示した図２、図
３、図４および図５の断片のコード配列を示す図であ
る。
３、図４および図５の断片のコード配列を示す図であ
る。
【図８】 対応するアミノ酸配列と共に示した図２、図
３、図４および図５の断片のコード配列を示す図であ
る。
３、図４および図５の断片のコード配列を示す図であ
る。
【図９】 γ抗ＣＥＡ鎖をコードするpγ２９８及びpγ
１１のcＤＮＡ挿入物の結合詳細配列を示す図である。
１１のcＤＮＡ挿入物の結合詳細配列を示す図である。
【図１０】 γ抗ＣＥＡ鎖をコードするpγ２９８及びp
γ１１のcＤＮＡ挿入物の結合詳細配列を示す図であ
る。
γ１１のcＤＮＡ挿入物の結合詳細配列を示す図であ
る。
【図１１】 γ抗ＣＥＡ鎖をコードするpγ２９８及びp
γ１１のcＤＮＡ挿入物の結合詳細配列を示す図であ
る。
γ１１のcＤＮＡ挿入物の結合詳細配列を示す図であ
る。
【図１２】 γ抗ＣＥＡ鎖をコードするpγ２９８及びp
γ１１のcＤＮＡ挿入物の結合詳細配列を示す図であ
る。
γ１１のcＤＮＡ挿入物の結合詳細配列を示す図であ
る。
【図１３】 γ抗ＣＥＡ鎖をコードするpγ２９８及びp
γ１１のcＤＮＡ挿入物の結合詳細配列を示す図であ
る。
γ１１のcＤＮＡ挿入物の結合詳細配列を示す図であ
る。
【図１４】 γ抗ＣＥＡ鎖をコードするpγ２９８及びp
γ１１のcＤＮＡ挿入物の結合詳細配列を示す図であ
る。
γ１１のcＤＮＡ挿入物の結合詳細配列を示す図であ
る。
【図１５】 図９、図１０、図１１、図１２、図１３お
よび図１４の断片によりコードされた対応アミノ酸配列
を示す図である。
よび図１４の断片によりコードされた対応アミノ酸配列
を示す図である。
【図１６】 図９、図１０、図１１、図１２、図１３お
よび図１４の断片によりコードされた対応アミノ酸配列
を示す図である。
よび図１４の断片によりコードされた対応アミノ酸配列
を示す図である。
【図１７】 図９、図１０、図１１、図１２、図１３お
よび図１４の断片によりコードされた対応アミノ酸配列
を示す図である。
よび図１４の断片によりコードされた対応アミノ酸配列
を示す図である。
【図１８】 図９、図１０、図１１、図１２、図１３お
よび図１４の断片によりコードされた対応アミノ酸配列
を示す図である。
よび図１４の断片によりコードされた対応アミノ酸配列
を示す図である。
【図１９】 図９、図１０、図１１、図１２、図１３お
よび図１４の断片によりコードされた対応アミノ酸配列
を示す図である。
よび図１４の断片によりコードされた対応アミノ酸配列
を示す図である。
【図２０】 κ及びγ抗−ＣＥＡ鎖に対する発現ベクタ
ーの作成概略を示す図である。
ーの作成概略を示す図である。
【図２１】 κ及びγ抗−ＣＥＡ鎖に対する発現ベクタ
ーの作成概略を示す図である。
ーの作成概略を示す図である。
【図２２】 κ及びγ抗−ＣＥＡ鎖に対する発現ベクタ
ーの作成概略を示す図である。
ーの作成概略を示す図である。
【図２３】 κ及びγ抗−ＣＥＡ鎖に対する発現ベクタ
ーの作成概略を示す図である。
ーの作成概略を示す図である。
【図２４】 κ及びγ抗−ＣＥＡ鎖に対する発現ベクタ
ーの作成概略を示す図である。
ーの作成概略を示す図である。
【図２５】 κ及びγ抗−ＣＥＡ鎖に対する発現ベクタ
ーの作成概略を示す図である。
ーの作成概略を示す図である。
【図２６】 γ鎖,κ鎖及びこれら両者に対する遺伝子
を発現するＥ．coli抽出物につき行なったサイジングゲ
ル操作の結果を示す薄膜上に形成された微細なパターン
を表している写真である。
を発現するＥ．coli抽出物につき行なったサイジングゲ
ル操作の結果を示す薄膜上に形成された微細なパターン
を表している写真である。
【図２７】 γ鎖,κ鎖及びこれら両者に対する遺伝子
を発現するＥ．coli抽出物につき行なったサイジングゲ
ル操作の結果を示す薄膜上に形成された微細なパターン
を表している写真である。
を発現するＥ．coli抽出物につき行なったサイジングゲ
ル操作の結果を示す薄膜上に形成された微細なパターン
を表している写真である。
【図２８】 γ鎖,κ鎖及びこれら両者に対する遺伝子
を発現するＥ．coli抽出物につき行なったサイジングゲ
ル操作の結果を示す薄膜上に形成された微細なパターン
を表している写真である。
を発現するＥ．coli抽出物につき行なったサイジングゲ
ル操作の結果を示す薄膜上に形成された微細なパターン
を表している写真である。
【図２９】 図２６、図２７および図２８と同様に形質
転換された細胞抽出物のウェスタンブロットの結果を示
す薄膜上に形成された微細なパターンを表している写真
である。
転換された細胞抽出物のウェスタンブロットの結果を示
す薄膜上に形成された微細なパターンを表している写真
である。
【図３０】 抗ＣＥＡ活性のＥＬＩＳＡ分析に対する標
準曲線図である。
準曲線図である。
【図３１】 キメラＨ鎖をコードする遺伝子の発現に対
するプラスミドの作成図である。
するプラスミドの作成図である。
【図３２】 キメラＨ鎖をコードする遺伝子の発現に対
するプラスミドの作成図である。
するプラスミドの作成図である。
【図３３】 Ｈ鎖のＦab領域をコードする遺伝子の発現
に対するプラスミドの作成図である。
に対するプラスミドの作成図である。
フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 ＦＩ 技術表示箇所 // Ａ６１Ｋ 39/395 Ｖ Ｇ０１Ｎ 33/577 Ｂ (Ｃ１２Ｎ 1/21 Ｃ１２Ｒ 1:19） (Ｃ１２Ｐ 21/08 Ｃ１２Ｒ 1:19） (72)発明者 シュミュエル・カビリィ アメリカ合衆国、カリフォルニア・91006、 アーカーディア、サウス・セカンド・アヴ ェニュー・325 (72)発明者 ヘルベルト・ルイス・ヒンケル アメリカ合衆国、カリフォルニア・94010、 バーリンゲイム、イーストン・ドライヴ・ 2621 (72)発明者 ウィリアム・エバンス・ホウムズ アメリカ合衆国、カリフォルニア・94044、 パシフィカ、イーストレイク・29 (72)発明者 アーサー・デイル・リッグス アメリカ合衆国、カリフォルニア・91750、 ラ・ヴァーン、セント・アンドレス・アヴ ェニュー・4852 (72)発明者 ロナルド・バーネル・ウェッゼル アメリカ合衆国、カリフォルニア・94127、 サン・フランシスコ、アーバノ・ドライ ヴ・455
Claims (3)
- 【請求項１】 特定の同定された抗原に対して特異性を
有する免疫グロブリンであって、第１の抗体クラスまた
は第１の哺乳動物種の抗体の不変領域にホモローガスな
不変領域と、第２の異なった抗体クラスまたは哺乳動物
種の抗体の可変領域にホモローガスな可変領域を有する
免疫グロブリン、をコードしているＤＮＡであって、適
切な原核性または真核性宿主細胞に適合し得るプロモー
ターと機能的に結合しているＤＮＡ、を含有している複
製可能な発現ベクター。 - 【請求項２】 不変領域および可変領域が、それぞれ異
なった哺乳動物種の不変領域および可変領域とホモロー
ガスである請求項１に記載の発現ベクター。 - 【請求項３】 特定の同定された抗原に対して特異性を
有する免疫グロブリンであって、第１の抗体クラスまた
は第１の哺乳動物種の抗体の不変領域にホモローガスな
不変領域と、第２の異なった抗体クラスまたは哺乳動物
種の抗体の可変領域にホモローガスな可変領域を有する
免疫グロブリン、をコードしているＤＮＡであって、適
切な原核性または真核性宿主細胞に適合し得るプロモー
ターと機能的に結合しているＤＮＡ、を含有している複
製可能な発現ベクターで形質転換された組換え宿主細
胞。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US483457 | 1983-04-08 | ||
| US06/483,457 US4816567A (en) | 1983-04-08 | 1983-04-08 | Recombinant immunoglobin preparations |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP06987484A Division JP3162055B2 (ja) | 1983-04-08 | 1984-04-06 | 組換免疫グロブリン |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001104857A Division JP2001346592A (ja) | 1983-04-08 | 2001-04-03 | 免疫グロブリンｄｎａ含有発現ベクター及び組換え宿主細胞 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH07194384A true JPH07194384A (ja) | 1995-08-01 |
Family
ID=23920101
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP06987484A Expired - Lifetime JP3162055B2 (ja) | 1983-04-08 | 1984-04-06 | 組換免疫グロブリン |
| JP6241576A Pending JPH07194384A (ja) | 1983-04-08 | 1994-10-05 | 免疫グロブリンｄｎａ含有発現ベクター及び組換え宿主細胞 |
| JP24156594A Expired - Lifetime JP3559795B2 (ja) | 1983-04-08 | 1994-10-05 | 組換免疫グロブリンの調製方法 |
| JP2001104856A Pending JP2001346591A (ja) | 1983-04-08 | 2001-04-03 | 組換免疫グロブリンの調製方法 |
| JP2001104857A Pending JP2001346592A (ja) | 1983-04-08 | 2001-04-03 | 免疫グロブリンｄｎａ含有発現ベクター及び組換え宿主細胞 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP06987484A Expired - Lifetime JP3162055B2 (ja) | 1983-04-08 | 1984-04-06 | 組換免疫グロブリン |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP24156594A Expired - Lifetime JP3559795B2 (ja) | 1983-04-08 | 1994-10-05 | 組換免疫グロブリンの調製方法 |
| JP2001104856A Pending JP2001346591A (ja) | 1983-04-08 | 2001-04-03 | 組換免疫グロブリンの調製方法 |
| JP2001104857A Pending JP2001346592A (ja) | 1983-04-08 | 2001-04-03 | 免疫グロブリンｄｎａ含有発現ベクター及び組換え宿主細胞 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US4816567A (ja) |
| EP (1) | EP0125023B2 (ja) |
| JP (5) | JP3162055B2 (ja) |
| KR (2) | KR840008264A (ja) |
| AT (1) | ATE64151T1 (ja) |
| AU (2) | AU598441B2 (ja) |
| CA (1) | CA1218613A (ja) |
| CY (1) | CY1793A (ja) |
| DE (1) | DE3484664D1 (ja) |
| DK (2) | DK174048B1 (ja) |
| ES (1) | ES531372A0 (ja) |
| HK (1) | HK129394A (ja) |
| IE (1) | IE57198B1 (ja) |
| IL (1) | IL71455A (ja) |
| NZ (3) | NZ222543A (ja) |
| ZA (1) | ZA842583B (ja) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009119794A1 (ja) | 2008-03-27 | 2009-10-01 | タカラバイオ株式会社 | 感染症予防、治療剤 |
| WO2010013498A1 (ja) | 2008-08-01 | 2010-02-04 | 学校法人聖マリアンナ医科大学 | 変形性関節症治療剤又は予防剤 |
| JP2010539911A (ja) * | 2007-09-24 | 2010-12-24 | ウーデ ゲゼルシャフト ミット ベシュレンクテル ハフツング | アミンでの発酵及び抽出により乳酸を製造する方法 |
| WO2011093081A1 (ja) | 2010-01-29 | 2011-08-04 | Ａｘｉｓ株式会社 | 変形性関節症治療剤を含有する注射剤 |
| WO2011093082A1 (ja) | 2010-01-29 | 2011-08-04 | Ａｘｉｓ株式会社 | 変形性関節症治療剤または予防剤を製造するための使用 |
| WO2011093083A1 (ja) | 2010-01-29 | 2011-08-04 | Ａｘｉｓ株式会社 | 変形性関節症治療又は予防用医薬組成物及びその製造方法 |
| WO2012005076A1 (ja) | 2010-07-08 | 2012-01-12 | 本田技研工業株式会社 | 高周波加熱用コイル |
| WO2014021339A1 (ja) | 2012-07-30 | 2014-02-06 | 国立大学法人名古屋大学 | ヒトミッドカインに対するモノクローナル抗体 |
| WO2014042251A1 (ja) | 2012-09-13 | 2014-03-20 | 中外製薬株式会社 | 遺伝子ノックイン非ヒト動物 |
Families Citing this family (7097)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6630328B2 (en) | 1909-07-15 | 2003-10-07 | Genencor International, Inc. | Increasing production of proteins in gram-positive microorganisms |
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5639639A (en) * | 1983-11-02 | 1997-06-17 | Genzyme Corporation | Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof |
| DE3486474T2 (de) * | 1983-11-02 | 2000-08-03 | Applied Research Systems | Produkte und Methoden für die Herstellung einer heterodimerer menschlicher LH mit einem Met42 Val55 alpha Untereinheit |
| US5229272A (en) * | 1989-04-25 | 1993-07-20 | Igen, Inc. | Catalytic antibody components |
| JPS6147500A (ja) * | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| EP0173494A3 (en) * | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) * | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) * | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US5169939A (en) * | 1985-05-21 | 1992-12-08 | Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College | Chimeric antibodies |
| US5672502A (en) * | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
| US5369010A (en) * | 1985-08-16 | 1994-11-29 | Genetic Systems Corporation | Monoclonal antibody to polymorphic HLA determinant -B27 |
| EP0536566A1 (en) * | 1985-11-01 | 1993-04-14 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5576195A (en) * | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
| DE3689123T2 (de) * | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| JPS62153300A (ja) * | 1985-12-26 | 1987-07-08 | Teijin Ltd | ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法 |
| EP0234592A1 (en) * | 1986-02-28 | 1987-09-02 | Teijin Limited | Plasmid containing DNA fragment coding for human immunoglobulin G Fc region protein and use thereof for production of said protein |
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) * | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8607679D0 (en) * | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5811248A (en) * | 1986-03-31 | 1998-09-22 | Charter Ventures | Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof |
| US6025477A (en) * | 1986-03-31 | 2000-02-15 | Calenoff; Emanuel | Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof |
| US5955584A (en) * | 1986-03-31 | 1999-09-21 | Charter Ventures | Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof |
| US4859609A (en) * | 1986-04-30 | 1989-08-22 | Genentech, Inc. | Novel receptors for efficient determination of ligands and their antagonists or agonists |
| JPS63112995A (ja) * | 1986-07-07 | 1988-05-18 | セントコ−・インコ−ポレ−テッド | 腫瘍関連抗原に特異的なキメラ齧歯類／ヒト免疫グロブリン |
| JPH0698021B2 (ja) * | 1986-08-01 | 1994-12-07 | 帝人株式会社 | マウス−ヒトキメラ抗体、それをコ−ドする発現型キメラｄｎａ配列、プラスミド及び細胞 |
| JPS6336786A (ja) * | 1986-07-31 | 1988-02-17 | Teijin Ltd | 抗体ｌ鎖発現型核酸塩基配列，プラスミド，細胞及びキメラ抗体ｌ鎖 |
| US5958678A (en) * | 1986-08-21 | 1999-09-28 | The Trustees Of Columbia University In The City Of New York | DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS |
| US6673896B1 (en) * | 1986-08-21 | 2004-01-06 | The Trustees Of Columbia University In The City Of New York | Derivatives of soluble T-4 |
| US6121424A (en) * | 1991-11-25 | 2000-09-19 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5869620A (en) * | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| EP0281604B1 (en) * | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| IL84285A (en) * | 1986-10-27 | 1993-03-15 | Int Genetic Engineering | Chimeric antibody with specificity to human tumor antigen |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| CA1339445C (en) * | 1986-11-12 | 1997-09-09 | The General Hospital Corporation | Recombinant hybrid immunoglobulin molecules and method of use |
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5217895A (en) * | 1987-02-19 | 1993-06-08 | Nissin Shokuhin Kabushiki Kaisha | Monoclonal anti-idiotypic antibodies specific for anti-T4 antibodies and cross-reactive with HIV |
| US5140105A (en) * | 1987-02-19 | 1992-08-18 | Nissin Shokuhin Kabushiki Kaisha | Methods and materials for HIV detection |
| ES2102347T3 (es) | 1987-02-20 | 1997-08-01 | Genentech Inc | Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv. |
| JP3101690B2 (ja) * | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5610034A (en) * | 1987-04-29 | 1997-03-11 | Alko Group Ltd. | Immunoglobulin production by trichoderma |
| US5132405A (en) * | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) * | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US5834599A (en) * | 1987-05-29 | 1998-11-10 | Tanox Biosystems, Inc. | Immunoconjugates which neutralize HIV-1 infection |
| US6657050B1 (en) | 1987-05-29 | 2003-12-02 | Tanox, Inc. | Chimeric viral-neutralizing immunoglobulins |
| US5981278A (en) * | 1987-05-29 | 1999-11-09 | Tanox, Inc. | Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS |
| CA1341235C (en) * | 1987-07-24 | 2001-05-22 | Randy R. Robinson | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5677425A (en) * | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| EP0393045B1 (en) * | 1987-09-09 | 1995-03-29 | Celltech Therapeutics Limited | Fv antibody fragment production |
| US5336603A (en) * | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| US6710169B2 (en) * | 1987-10-02 | 2004-03-23 | Genentech, Inc. | Adheson variants |
| NZ226694A (en) * | 1987-10-28 | 1994-04-27 | Oncogen | Human immunoglobulin produced by recombinant dna techniques |
| US4978745A (en) * | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
| AU625613B2 (en) * | 1988-01-05 | 1992-07-16 | Novartis Ag | Novel chimeric antibodies |
| GB8800077D0 (en) * | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel chimeric antibodies |
| US5843708A (en) * | 1988-01-05 | 1998-12-01 | Ciba-Geigy Corporation | Chimeric antibodies |
| US6004781A (en) * | 1988-01-22 | 1999-12-21 | The General Hospital Corporation | Nucleic acid encoding Ig-CD4 fusion proteins |
| US5750375A (en) * | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
| US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
| PT89484B (pt) * | 1988-01-22 | 1994-03-31 | Gen Hospital Corp | Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao |
| US5567584A (en) * | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| JP2646007B2 (ja) | 1988-01-30 | 1997-08-25 | 財団法人 化学及血清療法研究所 | 抗ｈｉｖ抗体可変領域をコードする遺伝子断片およびこれらを用いて発現された抗ｈｉｖキメラ抗体ならびにその製法 |
| JP3095168B2 (ja) * | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| IL89489A0 (en) * | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
| WO1989009393A1 (en) * | 1988-03-24 | 1989-10-05 | Igen, Inc. | Luminescent chimeric proteins |
| US5582862A (en) * | 1988-04-04 | 1996-12-10 | General Hospital Corporation | Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin |
| US5372812A (en) * | 1988-04-04 | 1994-12-13 | The General Hospital Corporation | Composition and method for acceleration of clot lysis |
| KR900700134A (ko) * | 1988-04-15 | 1990-08-11 | 원본미기재 | Il-2 수용체-특이적 키메릭 항체 |
| US4975369A (en) * | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| US5171666A (en) * | 1988-04-22 | 1992-12-15 | Eli Lilly And Company | Monoclonal antibodies reactive with a cell-surface gylcoprotein expressed on human carcinomas |
| US5770198A (en) * | 1988-05-18 | 1998-06-23 | The Research Foundation Of The State Of New York | Platelet-specific chimeric 7E3 immunoglobulin |
| EP0420937B1 (en) | 1988-06-21 | 1994-11-09 | Genentech, Inc. | Therapeutic compositions for the treatment of myocardial infarction |
| US5609869A (en) * | 1988-08-19 | 1997-03-11 | The General Hospital Corporation | Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use |
| US5811265A (en) * | 1988-08-19 | 1998-09-22 | The General Hospital Corporation | Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use |
| ATE154364T1 (de) | 1988-09-02 | 1997-06-15 | Univ Rockefeller | Makrophagenabgeleiteter entzündungsmediator(mip- 2) |
| CA1341351C (en) * | 1988-09-06 | 2002-03-26 | Marc D. Better | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
| DE3835350A1 (de) * | 1988-10-17 | 1990-04-19 | Boehringer Mannheim Gmbh | Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern |
| US6051225A (en) | 1988-10-19 | 2000-04-18 | The Dow Chemical Company | Family of high affinity, modified antibodies for cancer treatment |
| ATE102631T1 (de) * | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| US20040049014A1 (en) * | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2006878A1 (en) * | 1988-12-29 | 1990-06-29 | John D. Rodwell | Molecular recognition units |
| US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US6406697B1 (en) | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| JP3355351B2 (ja) * | 1989-02-24 | 2002-12-09 | ユーロジェン・ホールディング・ソシエテ・アノニム | 遺伝的に工作されたイムノグロブリン |
| US6048717A (en) * | 1989-04-25 | 2000-04-11 | Igen International, Inc. | Inhibitors of catalytic antibodies |
| US5236836A (en) * | 1989-04-25 | 1993-08-17 | Igen, Inc. | Autoantibodies which enhance the rate of a chemical reaction |
| US5602015A (en) * | 1989-04-25 | 1997-02-11 | Igen, Inc. | Autoantibodies which enhance the rate of a chemical reaction |
| US5658753A (en) * | 1989-04-25 | 1997-08-19 | Paul; Sudhir | Catalytic antibody components |
| US5599538A (en) * | 1989-04-25 | 1997-02-04 | Igen, Inc. | Autoantibodies which enhance the rate of a chemical reaction |
| US5318897A (en) * | 1989-04-25 | 1994-06-07 | Igen, Inc. | Monoclonal antibody and antibody components elicited to a polypeptide antigen ground state |
| US6291158B1 (en) * | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US6291159B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
| US6291160B1 (en) * | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
| US6680192B1 (en) | 1989-05-16 | 2004-01-20 | Scripps Research Institute | Method for producing polymers having a preselected activity |
| US6969586B1 (en) | 1989-05-16 | 2005-11-29 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US6291161B1 (en) * | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertiore |
| US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| US5081235A (en) * | 1989-07-26 | 1992-01-14 | City Of Hope | Chimeric anti-cea antibody |
| US7247475B2 (en) * | 1989-07-28 | 2007-07-24 | Wyeth | Method for producing monoclonal antibodies |
| US6475787B1 (en) * | 1989-07-28 | 2002-11-05 | Wyeth | Method for producing monoclonal antibodies |
| US5580774A (en) * | 1989-07-31 | 1996-12-03 | Eli Lilly And Company | Chimeric antibodies directed against a human glycoprotein antigen |
| US5959087A (en) * | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
| US20030225254A1 (en) * | 1989-08-07 | 2003-12-04 | Rathjen Deborah Ann | Tumour necrosis factor binding ligands |
| AU632843B2 (en) * | 1989-08-10 | 1993-01-14 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin |
| US5843693A (en) * | 1989-08-16 | 1998-12-01 | Chiron Corporation | Assay method for screening for inhibitors of proTNF conversion |
| US5998378A (en) * | 1989-08-16 | 1999-12-07 | Chiron Corporation | Compositions for the inhibition of TNF hormone formation and uses thereof |
| AU5940090A (en) | 1989-08-16 | 1991-04-03 | Cetus Oncology Corporation | Compositions for the inhibition of protein hormone formation and uses thereof |
| JPH05500611A (ja) * | 1989-08-23 | 1993-02-12 | ザ・ジェネラル・ホスピタル・コーポレーション | 非ヒト霊長類ｃｄ４ポリペプチド、グリコシル化可能なヒトｃｄ４分子、その断片、その融合タンパク質、その遺伝子配列および使用 |
| US5672683A (en) * | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| US6329508B1 (en) | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
| ATE236249T1 (de) * | 1989-09-12 | 2003-04-15 | Hoffmann La Roche | Tfn-bindende proteine |
| ES2100892T3 (es) * | 1989-09-15 | 1997-07-01 | Tanox Biosystems Inc | Tratamiento de enfermedades autoinmunitarias. |
| JPH05500608A (ja) * | 1989-09-19 | 1993-02-12 | セントカー・インコーポレーテツド | ヒトモノクローナル抗体の産生を改良する方法 |
| US5196320A (en) * | 1989-09-20 | 1993-03-23 | Abbott Biotech, Inc. | Method of producing engineered binding proteins |
| US6018031A (en) * | 1989-10-20 | 2000-01-25 | Trustees Of Dartmouth College | Binding agents specific for IgA receptor |
| US5202422A (en) * | 1989-10-27 | 1993-04-13 | The Scripps Research Institute | Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use |
| US7037722B1 (en) | 1989-10-27 | 2006-05-02 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5959177A (en) * | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US7005560B1 (en) | 1989-10-27 | 2006-02-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6995014B1 (en) | 1989-10-27 | 2006-02-07 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| PT95809A (pt) * | 1989-11-07 | 1991-09-13 | Bristol Myers Squibb Co | Processo para a preparacao de imunoglobulinas oligomericas, nomeadamente anticorpos monoclonais oligomericos |
| CA2044590A1 (en) * | 1989-11-13 | 1991-05-14 | Marc D. Better | Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen |
| US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US7037496B2 (en) | 1989-12-27 | 2006-05-02 | Centocor, Inc. | Chimeric immunoglobulin for CD4 receptors |
| US6232444B1 (en) * | 1990-01-29 | 2001-05-15 | The Regents Of The University Of California | Conserved anti-DNA antibody idiotype associated with nephritis in murine and human lupus |
| CA2078689C (en) * | 1990-03-20 | 2003-02-11 | Sherie L. Morrison | Chimeric antibodies with receptor binding ligands in place of their constant region |
| GB9009549D0 (en) * | 1990-04-27 | 1990-06-20 | Celltech Ltd | Recombinant antibody and method |
| GB9009548D0 (en) * | 1990-04-27 | 1990-06-20 | Celltech Ltd | Chimeric antibody and method |
| WO1991017177A1 (en) * | 1990-05-04 | 1991-11-14 | Baxter Diagnostics Inc. | High affinity antibodies to small peptides |
| US6395888B1 (en) * | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
| US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
| US20030064480A1 (en) * | 1990-06-28 | 2003-04-03 | Leander Lauffer | Fusion proteins with immunoglobulin portions, the preparation and use thereof |
| US7063943B1 (en) | 1990-07-10 | 2006-06-20 | Cambridge Antibody Technology | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6916605B1 (en) | 1990-07-10 | 2005-07-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| JP3283041B2 (ja) * | 1990-07-13 | 2002-05-20 | 学校法人藤田学園 | 人工抗体 |
| CA2084189A1 (en) * | 1990-07-16 | 1992-01-17 | Alko Group Limited | Immunoglobulin production by trichoderma |
| DE4107154A1 (de) * | 1990-10-11 | 1992-04-16 | Boehringer Mannheim Gmbh | Monoklonale antikoerper gegen melanom |
| GB9022543D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| EP0556328A4 (en) * | 1990-11-09 | 1994-06-08 | Abbott Lab | Bridging antibody fusion constructs |
| CZ96893A3 (en) * | 1990-11-23 | 1993-12-15 | Gen Hospital Corp | Inhibition of adhesive protein cells and their carbohydrates interaction |
| US5709859A (en) * | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
| US5571894A (en) * | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| MX9203138A (es) * | 1991-03-12 | 1992-09-01 | Biogen Inc | Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos. |
| AU660981B2 (en) * | 1991-03-12 | 1995-07-13 | Astellas Us Llc | CD2-binding domain of lymphocyte function associated antigen 3 |
| US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| US20040120952A1 (en) * | 2000-08-07 | 2004-06-24 | Centocor, Inc | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US6582959B2 (en) * | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US20030206899A1 (en) * | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| US20020032313A1 (en) * | 1991-03-29 | 2002-03-14 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| US5223396A (en) * | 1991-05-03 | 1993-06-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for detecting organ transplant rejection |
| US20050196400A1 (en) * | 1991-05-06 | 2005-09-08 | Xoma Technology Ltd. | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
| US6797492B2 (en) * | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| US5834229A (en) | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5939531A (en) * | 1991-07-15 | 1999-08-17 | Novartis Corp. | Recombinant antibodies specific for a growth factor receptor |
| US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| MX9204374A (es) * | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| DE69230545T2 (de) * | 1991-08-21 | 2000-07-06 | Novartis Ag | Antikörperderivate |
| EP0861893A3 (en) * | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
| US20070031409A1 (en) * | 1991-09-26 | 2007-02-08 | Stichting Rega Vzw | Recombinant DNA-molecule complex for the expression of anti-human-interferon-gamma chimeric antibodies or antibody fragments |
| US6764681B2 (en) * | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| ES2341666T3 (es) * | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| DE69233204T2 (de) * | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| US5869619A (en) * | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| CA2127462C (en) † | 1992-01-13 | 1999-03-23 | Roy R. Lobb | Treatment for asthma |
| US5635177A (en) | 1992-01-22 | 1997-06-03 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
| EP0671920B1 (en) * | 1992-03-09 | 2003-12-10 | San Diego Regional Cancer Center | An anti-idiotypic antibody and its use in diagnosis and in therapy in hiv-related disease |
| US5518887A (en) * | 1992-03-30 | 1996-05-21 | Abbott Laboratories | Immunoassays empolying generic anti-hapten antibodies and materials for use therein |
| US6599505B1 (en) * | 1992-04-10 | 2003-07-29 | Research Development Foundation | Immunotoxins directed against CD33 related surface antigens |
| US7754211B2 (en) * | 1992-04-10 | 2010-07-13 | Research Development Foundation | Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens |
| AU4283793A (en) * | 1992-04-16 | 1993-11-18 | Albert Einstein College Of Medicine Of Yeshiva University | Monocyte adhesion protein and monoclonal antibody thereto |
| US5851787A (en) * | 1992-04-20 | 1998-12-22 | The General Hospital Corporation | Nucleic acid encoding amyloid precursor-like protein and uses thereof |
| AU4382193A (en) * | 1992-05-19 | 1993-12-13 | Xoma Corporation | BPI-immunoglobulin fusion proteins |
| US6274348B1 (en) | 1992-05-19 | 2001-08-14 | Xoma Corporation | Methods for the preparation of positively charged proteins |
| US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US6765087B1 (en) * | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5437951A (en) * | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
| US5573924A (en) * | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
| US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DE69233739D1 (de) | 1992-10-28 | 2008-08-07 | Genentech Inc | Verwendung von Antagonisten des Zellwachstumsfaktors VEGF |
| US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
| ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| ES2293635T3 (es) * | 1992-11-16 | 2008-03-16 | Centocor Inc. | Metodo para reducir la inmunogenicidad de la region variable de anticuerpos. |
| AU5670194A (en) * | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
| DK0678122T3 (da) * | 1993-01-12 | 2000-03-06 | Biogen Inc | Rekombinante anti-VLA4 antistofmolekyler |
| WO1994015969A1 (en) * | 1993-01-14 | 1994-07-21 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Recombinant anti-hiv antibody and preparation thereof |
| US20050260201A1 (en) * | 1993-01-29 | 2005-11-24 | Centocor, Inc. | Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins |
| EP0621338A3 (en) * | 1993-04-21 | 1997-10-29 | Ajinomoto Kk | The interleukin-2 response blocking immunosuppressor. |
| DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
| EP1421951A3 (en) | 1993-05-12 | 2005-10-05 | Chiron Corporation | Conserved motif of hepatitis C virus E2/NS1 region |
| US6562333B1 (en) | 1993-06-14 | 2003-05-13 | Schering Corporation | Purified mammalian CTLA-8 antigens and related reagents |
| US20040067157A1 (en) * | 1993-07-22 | 2004-04-08 | Clearant, Inc. | Methods for sterilizing biological materials |
| US5684144A (en) * | 1993-07-28 | 1997-11-04 | University Of North Texas | Escherichia coli csrA gene, protein encoded thereby, and methods of use thereof |
| US5491071A (en) * | 1993-08-03 | 1996-02-13 | Abbott Laboratories | Reagents and methods for the detection and quantification of testosterone in fluid samples |
| US5780028A (en) * | 1993-09-20 | 1998-07-14 | Anadis Ltd. | Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition |
| WO1995008336A1 (en) * | 1993-09-22 | 1995-03-30 | Nichols Institute Diagnostics | Graves' ophthalmopathy associated antibodies, graves' ophthalmopathy orbital antigen, and methods of use thereof |
| US5827690A (en) * | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| DK145493D0 (da) * | 1993-12-23 | 1993-12-23 | Dako As | Antistof |
| US5476939A (en) * | 1993-12-30 | 1995-12-19 | Abbott Laboratories | Certain pyridyl and isoquinolyl carbinolamine derivatives |
| US6660256B1 (en) | 1994-01-03 | 2003-12-09 | Genetech, Inc. | Porcine mpl ligand |
| US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US6395547B1 (en) | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6165793A (en) * | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US6995017B1 (en) | 1994-02-17 | 2006-02-07 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5874080A (en) * | 1994-03-03 | 1999-02-23 | Genentech, Inc. | Anti-IL-8 monoclonal antibodies for treatment of asthma |
| US5677426A (en) * | 1994-03-03 | 1997-10-14 | Genentech, Inc. | Anti-IL-8 antibody fragments |
| CA2185162A1 (en) | 1994-03-07 | 1995-09-14 | Robert F. Halenback (Deceased) | Compositions for the inhibition of tnf formation and uses thereof |
| WO1995024483A1 (en) * | 1994-03-08 | 1995-09-14 | Scotgen Biopharmaceuticals, Inc. | Recombinant humanized anti-fb5 antibodies |
| US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| US6992175B1 (en) * | 1994-04-15 | 2006-01-31 | Amgen Inc. | Nucleic acids encoding Eph-like receptor tyrosine kinases |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5708142A (en) | 1994-05-27 | 1998-01-13 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
| GB9412230D0 (en) | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
| USRE39548E1 (en) | 1994-06-17 | 2007-04-03 | Celltech R&D Limited | Interleukin-5 specific recombinant antibodies |
| US5686600A (en) * | 1994-06-28 | 1997-11-11 | Novartis Finance Corporation | Antibodies which bind to insect gut proteins and their use |
| US6576236B1 (en) | 1994-07-01 | 2003-06-10 | Dana Farber Cancer Institute | Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain |
| US6080560A (en) * | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
| US6140075A (en) * | 1994-07-25 | 2000-10-31 | Monsanto Company | Method for producing antibodies and protein toxins in plant cells |
| US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
| US8771694B2 (en) * | 1994-08-12 | 2014-07-08 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells |
| DE69524182T3 (de) | 1994-08-12 | 2009-07-09 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Nukleinsäuresonden umfassend ein Fragment des 17Q-verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens |
| AU3272695A (en) * | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| US6124439A (en) * | 1994-08-17 | 2000-09-26 | The Rockefeller University | OB polypeptide antibodies and method of making |
| US6124448A (en) * | 1994-08-17 | 2000-09-26 | The Rockfeller University | Nucleic acid primers and probes for the mammalian OB gene |
| US6350730B1 (en) | 1994-08-17 | 2002-02-26 | The Rockefeller University | OB polypeptides and modified forms as modulators of body weight |
| US6048837A (en) * | 1994-08-17 | 2000-04-11 | The Rockefeller University | OB polypeptides as modulators of body weight |
| US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| US6471956B1 (en) | 1994-08-17 | 2002-10-29 | The Rockefeller University | Ob polypeptides, modified forms and compositions thereto |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| NZ296748A (en) | 1994-11-02 | 1999-11-29 | Univ New York State Res Found | Peripheral nervous system specific sodium channel proteins, DNA coding therefor, compositions and methods |
| US7820798B2 (en) * | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US7597886B2 (en) | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US6017697A (en) | 1994-11-14 | 2000-01-25 | Eli Lilly And Company | Excitatory amino acid receptor protein and related nucleic acid compounds |
| US5633149A (en) * | 1994-12-07 | 1997-05-27 | Incyte Pharmaceuticals, Inc. | Polynucleotide encoding novel chemokine expressed in inflamed adenoid |
| US6692920B1 (en) * | 1994-12-07 | 2004-02-17 | Incyte Corporation | Antibodies to a chemokine expressed in inflamed adenoid |
| IL114615A0 (en) | 1995-07-16 | 1995-11-27 | Yeda Res & Dev | Modulators of the function of fas receptors and other proteins |
| US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| US7005509B1 (en) | 1995-02-17 | 2006-02-28 | Incyte Corporation | Chemokine PANEC-1 polynucleotides and compositions and methods related thereto |
| US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| US6130364A (en) * | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| IL117645A (en) * | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US20060193862A1 (en) * | 1995-03-30 | 2006-08-31 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| US5646036A (en) * | 1995-06-02 | 1997-07-08 | Genentech, Inc. | Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies |
| US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| US6214344B1 (en) | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| US7153508B2 (en) * | 1995-06-07 | 2006-12-26 | Biogen Idec Inc. | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 |
| AU701106B2 (en) | 1995-06-07 | 1999-01-21 | Promega Biosciences, Inc. | Novel carbamate-based cationic lipids |
| US7175847B1 (en) * | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
| GB0112226D0 (en) * | 2001-05-18 | 2001-07-11 | Danisco | Method of improving dough and bread quality |
| US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| ATE266726T1 (de) * | 1995-06-07 | 2004-05-15 | Ortho Pharma Corp | CDR-TRANSPLANTIERTE ANTIKÖRPER GEGEN ßTISSUE FACTORß UND VERFAHREN ZUR DEREN VERWENDUNG |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| CA2245835A1 (en) | 1995-06-14 | 1997-01-03 | The Regents Of The University Of California | Novel high affinity human antibodies to tumor antigens |
| US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| PT1516628E (pt) | 1995-07-27 | 2013-09-24 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
| US20040197326A1 (en) * | 1995-07-27 | 2004-10-07 | Genentech, Inc. | Method for treatment of allergic asthma |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6248555B1 (en) | 1995-08-31 | 2001-06-19 | The General Hospital Corporation | Genetic alterations related to familial alzheimer's disease |
| EP1416280A3 (en) * | 1995-09-14 | 2005-08-10 | The Regents of the University of California | Antibodies specific for native PrPsc |
| CA2230957A1 (en) | 1995-09-29 | 1997-04-10 | Universita'degli Studi Di Siena | Regulated genes and uses thereof |
| US7368111B2 (en) | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
| JPH09124509A (ja) * | 1995-10-27 | 1997-05-13 | Sumitomo Electric Ind Ltd | 肝炎治療剤 |
| US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| NZ326525A (en) | 1995-12-18 | 1999-11-29 | Endorecherche Inc | Chromosome 13-linked breast cancer susceptibility gene |
| US20050089958A1 (en) * | 1996-01-09 | 2005-04-28 | Genentech, Inc. | Apo-2 ligand |
| US6046048A (en) * | 1996-01-09 | 2000-04-04 | Genetech, Inc. | Apo-2 ligand |
| US6998116B1 (en) * | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
| US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
| US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
| JP2001508642A (ja) * | 1996-02-12 | 2001-07-03 | セダーズ―シナイ メディカル センター | ビタミンｄ応答エレメント結合タンパク質 |
| US20040006018A1 (en) * | 1996-02-14 | 2004-01-08 | Genentech, Inc. | Cardiotrophin and uses therefor |
| US6730300B2 (en) * | 1996-03-20 | 2004-05-04 | Immunomedics, Inc. | Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications |
| US5714352A (en) * | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US7964190B2 (en) * | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
| US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
| US6506602B1 (en) | 1996-03-25 | 2003-01-14 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US20020165157A1 (en) * | 1996-04-01 | 2002-11-07 | Genentech, Inc. | Apo-2LI and Apo-3 polypeptides |
| WO1997037020A1 (en) * | 1996-04-01 | 1997-10-09 | Genentech, Inc. | Apo-2li and apo-3 apoptosis polypeptides |
| US7241568B2 (en) * | 1996-04-03 | 2007-07-10 | Kyowa Hakko Kogyo Co., Ltd. | Anti-fibroblast growth factor-8 monoclonal antibody |
| US6497878B1 (en) | 1996-04-23 | 2002-12-24 | Chugai Seiyaku Kabushiki Kaisha | Treatment of cerebral disorders by inhibition of IL-8 binding to receptor |
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| CA2253942A1 (en) * | 1996-05-10 | 1997-11-20 | Biogen, Inc. | Common gamma chain blocking agents |
| GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| WO1997045143A1 (en) | 1996-05-31 | 1997-12-04 | The National American Red Cross | Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids |
| US6716974B1 (en) | 1996-05-31 | 2004-04-06 | Maine Medical Center Research Institute | Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids |
| ATE248192T1 (de) * | 1996-06-07 | 2003-09-15 | Neorx Corp | HUMANISIERTE ANTIKÖRPER DIE AN DAS GLEICHE ANTIGEN WIE ANTIKÖRPER NR-LU-13 BINDEN UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN |
| GB9712818D0 (en) | 1996-07-08 | 1997-08-20 | Cambridge Antibody Tech | Labelling and selection of specific binding molecules |
| DE69740057D1 (de) | 1996-07-12 | 2010-12-30 | Bristol Myers Squibb Co | Transkriptionaler Intermediärfaktor 2 |
| US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| ATE397660T1 (de) | 1996-08-16 | 2008-06-15 | Schering Corp | Zelloberflächen-antigen aus säugetieren und verwandte reagenzien |
| AU731123B2 (en) | 1996-08-16 | 2001-03-22 | Human Genome Sciences, Inc. | Human endokine alpha |
| US20030044859A1 (en) * | 1996-08-19 | 2003-03-06 | Henslee Jerry G. | Reagents and methods useful for detecting diseases of the breast |
| CA2266341A1 (en) * | 1996-09-20 | 1998-03-26 | The General Hospital Corporation | Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin |
| US6462176B1 (en) * | 1996-09-23 | 2002-10-08 | Genentech, Inc. | Apo-3 polypeptide |
| AU744146B2 (en) * | 1996-09-26 | 2002-02-14 | Chugai Seiyaku Kabushiki Kaisha | Antibody against human parathormone related peptides |
| US6136958A (en) | 1996-09-30 | 2000-10-24 | Genentech, Inc. | Antibodies to vertebrate smoothened proteins |
| US5990281A (en) * | 1996-09-30 | 1999-11-23 | Genentech, Inc. | Vertebrate smoothened proteins |
| US6808880B2 (en) * | 1996-10-01 | 2004-10-26 | Geron Corporation | Method for detecting polynucleotides encoding telomerase |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| US7585622B1 (en) * | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
| US6093809A (en) | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
| US6610839B1 (en) | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
| US6475789B1 (en) * | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
| CN1291231B (zh) * | 1996-10-01 | 2010-06-02 | 杰龙公司 | 人类的端粒酶催化亚单位 |
| US6420140B1 (en) * | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
| US5916771A (en) * | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| US5977319A (en) * | 1996-10-21 | 1999-11-02 | Cambridge Antibody Technology Limited | Specific binding members for estradiol; materials and methods |
| US7255854B1 (en) * | 1996-10-25 | 2007-08-14 | Biogen, Inc. | Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases |
| US6348581B1 (en) | 1996-10-31 | 2002-02-19 | The Dow Chemical Company | High affinity humanized anti-TAG-72 monoclonalantibodies |
| US20040146507A1 (en) * | 1996-11-27 | 2004-07-29 | Genentech, Inc. | Antibody mutants |
| US6037454A (en) * | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| PT1114864E (pt) | 1996-12-13 | 2008-10-08 | Schering Corp | Antigénios de superfície de células de mamífero, reagentes relacionados |
| US20070009930A1 (en) * | 1996-12-18 | 2007-01-11 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| SI1019500T1 (sl) | 1997-01-15 | 2007-02-28 | Yeda Res & Dev | Proteini, ki vezejo receptor 1 za ifn, dna, ki jih kodira, in postopki za regulacijo celicnega odziva na interferone |
| US6100076A (en) | 1997-01-31 | 2000-08-08 | Genentech, Inc. | O-fucosyltransferase |
| US20040241645A1 (en) * | 1997-01-31 | 2004-12-02 | Genentech, Inc. | O-fucosyltransferase |
| EP0966533B1 (en) | 1997-02-07 | 2009-09-16 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Activity dependent neurotrophic factor iii (adnf iii) |
| US7528239B1 (en) * | 1997-02-13 | 2009-05-05 | Immunex Corporation | Receptor that binds trail |
| US7033589B1 (en) * | 1997-02-20 | 2006-04-25 | Biogen Idec Ma Inc. | γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
| US6893636B2 (en) * | 1997-02-20 | 2005-05-17 | Biogen Idec Ma Inc. | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
| US7749498B2 (en) * | 1997-03-10 | 2010-07-06 | Genentech, Inc. | Antibodies for inhibiting blood coagulation and methods of use thereof |
| US20030109680A1 (en) * | 2001-11-21 | 2003-06-12 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
| US5986065A (en) * | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
| US20060235209A9 (en) * | 1997-03-10 | 2006-10-19 | Jin-An Jiao | Use of anti-tissue factor antibodies for treating thromboses |
| US7541034B1 (en) * | 1997-03-20 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors |
| CA2284271C (en) | 1997-03-21 | 2012-05-08 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for sensitized t cell-mediated diseases comprising il-6 antagonist as an active ingredient |
| US5955355A (en) * | 1997-03-27 | 1999-09-21 | Millennium Pharmaceuticals, Inc. | Chromosome 18 marker |
| US5866412A (en) * | 1997-03-27 | 1999-02-02 | Millennium Pharmaceuticals, Inc. | Chromosome 18 marker |
| US5939316A (en) * | 1997-03-27 | 1999-08-17 | Millennium Pharmaceuticals, Inc. | Chromosome 18 marker |
| US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7083786B2 (en) | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| US20070059302A1 (en) * | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
| US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| SI1325932T1 (ja) * | 1997-04-07 | 2005-08-31 | Genentech Inc | |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| DK1695985T3 (da) | 1997-04-07 | 2011-06-14 | Genentech Inc | Fremgangsmåde til dannelse af humaniserede antistoffer ved tilfældig mutagenese |
| DE69839808D1 (de) | 1997-04-09 | 2008-09-11 | Intellect Neurosciences Inc | Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung |
| ATE426018T1 (de) | 1997-04-10 | 2009-04-15 | Stichting Katholieke Univ | Pca3, pca3-gene und verfahren zu ihrer verwendung |
| WO1998046265A1 (en) | 1997-04-11 | 1998-10-22 | G.D. Searle & Co. | Methods for using antagonistic anti-avb3 integrin antibodies |
| AU6954398A (en) | 1997-04-11 | 1998-11-11 | G.D. Searle & Co. | Antagonistic anti-avb3 integrin antibodies |
| PT975755E (pt) | 1997-04-16 | 2007-06-26 | Millennium Pharm Inc | Proteínas crsp (proteínas segregadas ricas em cisteínas), moléculas de ácido nucleico que as codificam e suas utilizações |
| US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| WO1998046751A1 (en) | 1997-04-16 | 1998-10-22 | Amgen Inc. | Osteoprotegerin binding proteins and receptors |
| US7413864B2 (en) * | 1997-04-18 | 2008-08-19 | Geron Corporation | Treating cancer using a telomerase vaccine |
| US20050013825A1 (en) * | 1997-04-18 | 2005-01-20 | Geron Corporation | Vaccine containing the catalytic subunit of telomerase for treating cancer |
| US7622549B2 (en) | 1997-04-18 | 2009-11-24 | Geron Corporation | Human telomerase reverse transcriptase polypeptides |
| WO1998049313A2 (en) | 1997-04-25 | 1998-11-05 | Aquila Biopharmaceuticals, Inc. | Characterization of granulocytic ehrlichia and methods of use |
| CA2288943C (en) * | 1997-04-30 | 2011-02-01 | De Novo Enzyme Corporation | Ricin-like toxin variants for treatment of cancer, viral or parasitic infections |
| US20030207346A1 (en) * | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| WO1998050431A2 (en) | 1997-05-02 | 1998-11-12 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| EP0975674B1 (en) * | 1997-05-02 | 2005-08-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services | Immunotoxins, comprising an onc protein, directed against malignant cells |
| EP1798288B1 (en) | 1997-05-07 | 2009-09-16 | Schering Corporation | Human Toll-like receptor proteins, related reagents and methods |
| ATE516354T1 (de) * | 1997-05-15 | 2011-07-15 | Genentech Inc | Apo-2-rezeptor |
| US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| US20100152426A1 (en) * | 1997-05-15 | 2010-06-17 | Ashkenazi Avi J | Apo-2 receptor fusion proteins |
| DE69841994D1 (de) | 1997-05-30 | 2010-12-23 | Human Genome Sciences Inc | 32 Humane sekretierte Proteine |
| US6528271B1 (en) * | 1997-06-05 | 2003-03-04 | Duke University | Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia |
| US7541151B2 (en) | 1997-06-05 | 2009-06-02 | Duke University | Single-cell biosensor for the measurement of GPCR ligands in a test sample |
| US5891646A (en) * | 1997-06-05 | 1999-04-06 | Duke University | Methods of assaying receptor activity and constructs useful in such methods |
| US6291643B1 (en) | 1997-06-05 | 2001-09-18 | Board Of Reports, The University Of Texas System | Apaf-1 an activator of caspase-3 |
| ES2287976T3 (es) | 1997-06-13 | 2007-12-16 | Genentech, Inc. | Recuperacion de proteinas mediante cromatografia seguida de filtracion sobre una capa cargada. |
| CA2206774A1 (en) | 1997-06-16 | 1998-12-16 | Rick E. Preddie | "prionins", highly specific markers for noninvasive presymptomatic defection of tse diseases, and targets for therapeutic reagents to prevent and control tse diseases in animals and humans |
| CA2293740A1 (en) * | 1997-06-18 | 1998-12-23 | Genentech, Inc. | Apo-2dcr, a tnf-related receptor |
| EP1754490A3 (en) | 1997-06-20 | 2010-01-20 | Biogen Idec MA Inc. | CD 154 blockage therapy for pancreatic islet tissue transplantation in primates |
| US7147854B2 (en) * | 1997-06-23 | 2006-12-12 | Yes Biotech Laboratories Ltd. | Topical treatment of psoriasis using neutralizing antibodies to interleukin-8 |
| US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
| US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| US6242570B1 (en) | 1997-07-10 | 2001-06-05 | Beth Israel Deaconess Medical Center | Production and use of recombinant protein multimers with increased biological activity |
| US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| JP2001500391A (ja) * | 1997-07-11 | 2001-01-16 | ユニバーシティ オブ ノース テキサス | Ｅｓｃｈｅｒｉｃｈｉａ ｃｏｌｉ ｃｓｒＢ遺伝子、それによりコードされるＲＮＡ、および使用方法 |
| ES2547858T3 (es) | 1997-07-14 | 2015-10-09 | Université de Liège | Doble musculación en mamíferos |
| US6103466A (en) * | 1997-07-14 | 2000-08-15 | University Of Liege | Double-muscling in mammals |
| US20070067859A1 (en) * | 1997-07-14 | 2007-03-22 | Michel Georges | Double-muscling in mammals |
| US6506579B1 (en) | 1997-07-15 | 2003-01-14 | Genencor International, Inc. | Increasing production of proteins in gram-positive microorganisms using SecG |
| US6762039B2 (en) * | 1997-07-15 | 2004-07-13 | Genencor International, Inc. | Bacillus subtillis with an inactivated cysteine protease-1 |
| US6723550B1 (en) | 1997-07-15 | 2004-04-20 | Genencor International, Inc. | Proteases from gram-positive organisms |
| US20030157642A1 (en) | 1997-07-15 | 2003-08-21 | Caldwell Robert M. | Increasing production of proteins in gram-positive microorganisms |
| US6521421B1 (en) | 1997-07-16 | 2003-02-18 | Genencor International, Inc. | Expression vectors encoding Bacillus subtilis disulfide bond isomerase and methods of secreting proteins in gram-positive microorganisms using the same |
| ZA986596B (en) | 1997-07-25 | 1999-02-08 | Schering Corp | Mammalian cytokine related reagents |
| EP1003861B1 (en) | 1997-08-01 | 2006-10-04 | Schering Corporation | Mammalian cell membrane proteins; related reagents |
| KR20080027967A (ko) | 1997-08-15 | 2008-03-28 | 츄가이 세이야꾸 가부시키가이샤 | 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는전신성 홍반성 낭창의 예방 및/또는 치료제 |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| CA2301847A1 (en) * | 1997-08-26 | 1999-03-04 | Genentech, Inc. | Rtd receptor |
| US20030175856A1 (en) * | 1997-08-26 | 2003-09-18 | Genetech, Inc. | Rtd receptor |
| NZ503850A (en) * | 1997-09-12 | 2002-12-20 | Apotech S | April - a novel protein with growth effects |
| US6300117B1 (en) | 1997-09-15 | 2001-10-09 | Genencor International, Inc. | Proteases from gram-positive organisms |
| US6521440B1 (en) * | 1997-09-15 | 2003-02-18 | Genencor International, Inc. | Proteases from gram-positive organisms |
| US20020192209A1 (en) * | 1997-09-17 | 2002-12-19 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| DK1015587T3 (da) * | 1997-09-18 | 2008-08-25 | Genentech Inc | DcR3 polypeptid, en TNFR-homolog |
| US20030166110A1 (en) * | 1997-09-18 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20040231011A1 (en) * | 2001-06-28 | 2004-11-18 | Genentech, Inc. | DcR3 polypeptide, a TNFR homolog |
| US7378244B2 (en) * | 1997-10-01 | 2008-05-27 | Geron Corporation | Telomerase promoters sequences for screening telomerase modulators |
| WO1999019490A1 (en) | 1997-10-10 | 1999-04-22 | Genentech, Inc. | Apo-3 ligand |
| WO1999018997A1 (fr) | 1997-10-14 | 1999-04-22 | Chugai Seiyaku Kabushiki Kaisha | Potentialisateur pour anticorps anti-tumeur lymphoide |
| ATE314471T1 (de) | 1997-10-17 | 2006-01-15 | Genentech Inc | Menschliche toll homologen |
| US6639051B2 (en) * | 1997-10-20 | 2003-10-28 | Curis, Inc. | Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto |
| WO1999020752A1 (en) | 1997-10-21 | 1999-04-29 | The University Court Of The University Of Glasgow | JMY, A CO-ACTIVATOR FOR p300/CBP, NUCLEIC ACID ENCODING JMY AND USES THEREOF |
| DK1029046T3 (da) | 1997-10-29 | 2009-02-02 | Genentech Inc | WNT-1 inducerbare gener |
| DK1027437T3 (da) | 1997-10-29 | 2008-11-24 | Genentech Inc | Anvendelse af det WNT-1 inducerede udskilte polypeptid WISP-1 |
| KR20010031713A (ko) | 1997-11-03 | 2001-04-16 | 벤슨 로버트 에이치. | 맥관형성 및 종양 성장 억제제인 맥관 내피 세포 성장억제제 |
| EP1029049A2 (en) * | 1997-11-07 | 2000-08-23 | Biogen, Inc. | Bmog, a protein member of the myelin-oligodendrocyte glycoprotein family and its use |
| GB9724627D0 (en) | 1997-11-20 | 1998-01-21 | Genencor Int Bv | Gram positive microorganism formate pathway |
| ATE472599T1 (de) | 1997-11-21 | 2010-07-15 | Human Genome Sciences Inc | Chemokin alpha-5 |
| US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
| ES2288649T3 (es) | 1997-11-21 | 2008-01-16 | Genentech, Inc. | Antigenos tipo a-33 y sus utilizaciones farmacologicas. |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7790856B2 (en) * | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US20080050367A1 (en) * | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| EP1036198B1 (en) | 1997-12-08 | 2012-09-26 | California Institute Of Technology | Method for creating polynucleotide and polypeptide sequences |
| WO1999029732A2 (en) | 1997-12-08 | 1999-06-17 | Lexigen Pharmaceuticals Corporation | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
| US6248542B1 (en) * | 1997-12-09 | 2001-06-19 | Massachusetts Institute Of Technology | Optoelectronic sensor |
| EP1947119A3 (en) | 1997-12-12 | 2012-12-19 | Genentech, Inc. | Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent |
| US6599731B1 (en) * | 1997-12-30 | 2003-07-29 | Genencor International, Inc. | Proteases from gram positive organisms |
| US6465186B1 (en) * | 1997-12-30 | 2002-10-15 | Genecor International, Inc. | Proteases from gram positive organisms |
| GB9727470D0 (en) * | 1997-12-30 | 1998-02-25 | Genencor Int Bv | Proteases from gram positive organisms |
| US6528255B1 (en) * | 1997-12-30 | 2003-03-04 | Genencor International, Inc. | Proteases from gram positive organisms |
| AU2451199A (en) * | 1998-01-07 | 1999-07-26 | Human Genome Sciences, Inc. | 36 human secreted proteins |
| DE69939732D1 (de) | 1998-01-15 | 2008-11-27 | Genentech Inc | Apo-2 ligand |
| US6673914B1 (en) | 1998-01-22 | 2004-01-06 | John Wayne Cancer Institute | Human tumor-associated gene |
| US6764830B1 (en) | 1998-01-23 | 2004-07-20 | The Regents Of The University Of California | Thermomyces lanuginosus kinesin motor protein and methods of screening for modulators of kinesin proteins |
| US7060667B1 (en) | 1998-01-30 | 2006-06-13 | Biogen Idec Ma, Inc. | Treatment of follicular lymphomas using inhibitors of the LT pathway |
| US7794946B1 (en) | 1998-02-04 | 2010-09-14 | Life Technologies Corporation | Microarray and uses therefor |
| US20020136721A1 (en) * | 1998-02-17 | 2002-09-26 | Schwall Ralph H. | Hepatocyte growth factor receptor antagonists and uses thereof |
| US6051228A (en) * | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| US6727079B1 (en) * | 1998-02-25 | 2004-04-27 | The United States Of America As Represented By The Department Of Health And Human Services | cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product |
| US6617171B2 (en) * | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
| US7449320B2 (en) | 1998-03-04 | 2008-11-11 | Genencor International, Inc. | Truncated forms of pullulanase |
| NZ525914A (en) | 1998-03-10 | 2004-03-26 | Genentech Inc | Novel polypeptides and nucleic acids encoding the same |
| US6342351B1 (en) | 1998-03-16 | 2002-01-29 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating chromosome-18p related disorders |
| DK1064382T3 (da) * | 1998-03-17 | 2008-12-08 | Genentech Inc | Homologe polypeptider til VEGF og BMP1 |
| US20030224001A1 (en) * | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
| DE69943022D1 (de) | 1998-03-19 | 2011-01-20 | Human Genome Sciences Rockville | Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor |
| ES2268854T3 (es) | 1998-03-24 | 2007-03-16 | Chugai Seiyaku Kabushiki Kaisha | Inhibidores de la vascularizacion. |
| US6337200B1 (en) * | 1998-03-31 | 2002-01-08 | Geron Corporation | Human telomerase catalytic subunit variants |
| AU3548799A (en) * | 1998-04-03 | 1999-10-25 | Invitrogen Corporation | Libraries of expressible gene sequences |
| US20050059802A1 (en) * | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
| ES2267263T3 (es) * | 1998-04-15 | 2007-03-01 | Emd Lexigen Research Center Corp. | Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo. |
| US6348575B1 (en) | 1998-04-15 | 2002-02-19 | Genentech, Inc. | Patched-2 |
| US7157083B2 (en) * | 1998-04-17 | 2007-01-02 | Surrogate Pharmaceutical Pathways, Llc | Compositions and methods for treating retroviral infections |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| EP1865061A3 (en) | 1998-05-15 | 2007-12-19 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
| US6197947B1 (en) | 1998-06-01 | 2001-03-06 | The Rockefeller University | Translation initiation factor 4AIII and methods of use thereof |
| EP1086138B1 (en) * | 1998-06-12 | 2009-09-23 | Genentech, Inc. | Monoclonal antibodies, cross-reactive antibodies and method for producing the same |
| US6252050B1 (en) * | 1998-06-12 | 2001-06-26 | Genentech, Inc. | Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method |
| JP2000000097A (ja) | 1998-06-15 | 2000-01-07 | Nippon Zoki Pharmaceut Co Ltd | Ｎｅｆ結合蛋白質、該蛋白質をコードするＤＮＡ並びに該蛋白質に対するモノクローナル抗体 |
| US6406921B1 (en) * | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
| US20020119579A1 (en) * | 1998-07-14 | 2002-08-29 | Peter Wagner | Arrays devices and methods of use thereof |
| US6780582B1 (en) * | 1998-07-14 | 2004-08-24 | Zyomyx, Inc. | Arrays of protein-capture agents and methods of use thereof |
| DK1098988T4 (da) | 1998-07-21 | 2007-09-03 | Danisco | Födevare |
| US6727349B1 (en) * | 1998-07-23 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Recombinant anti-CCR2 antibodies and methods of use therefor |
| US6696550B2 (en) * | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
| US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
| CA2340091C (en) | 1998-08-11 | 2013-02-05 | Idec Pharmaceuticals Corporation | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
| US20020172678A1 (en) | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
| TR200100607T2 (tr) * | 1998-08-31 | 2001-06-21 | Biogen, Inc. | Bellek efektör T-hücrelerinin modülasyonu için yöntem ve bileşimler |
| AU6246199A (en) | 1998-09-21 | 2000-04-10 | Schering Corporation | Human interleukin-b50, therapeutic uses |
| EP0997476A3 (en) | 1998-09-25 | 2000-07-19 | Schering-Plough | Antibodies to a mammalian Langerhans cell antigen and their uses |
| JP2003523166A (ja) * | 1998-09-29 | 2003-08-05 | ガミダ セル リミテッド | 幹細胞および前駆細胞の増殖と分化を制御する方法 |
| US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| US20030027998A1 (en) * | 1998-10-30 | 2003-02-06 | Holtzman Douglas A. | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
| US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| KR20010099788A (ko) * | 1998-11-09 | 2001-11-09 | 케네쓰 제이. 울코트 | Ｂｍｔ 또는 ｐｂｓｃ 이식을 받은 환자의 키메라항-ｃｄ２０ 항체 치료법 |
| MXPA01004648A (es) | 1998-11-09 | 2002-05-06 | Idec Pharma Corp | Tratamientro de enfermedades hematologicas malignas asociadas con celulas tumorales de la circulacion usando el anticuerpo quimerico anti-cd20. |
| EP1950300A3 (en) | 1998-11-18 | 2011-03-23 | Genentech, Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| US6773911B1 (en) | 1998-11-23 | 2004-08-10 | Amgen Canada Inc. | Apoptosis-inducing factor |
| EP2075335A3 (en) | 1998-12-22 | 2009-09-30 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| ATE300957T1 (de) | 1998-12-22 | 2005-08-15 | Genentech Inc | Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung |
| EP2330198A1 (en) | 1998-12-23 | 2011-06-08 | Genentech, Inc. | IL-1 related polypeptides |
| IL143600A0 (en) | 1999-01-11 | 2002-04-21 | Schering Corp | Interleukin-17 related mammalian cytokines, polynucleotides encoding them and their uses |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| EP2298332B1 (en) | 1999-01-25 | 2015-07-08 | Biogen MA Inc. | BAFF, inhibitors thereof and their use in the modulation of the B-cell response |
| US6303749B1 (en) | 1999-01-29 | 2001-10-16 | Amgen Inc. | Agouti and agouti-related peptide analogs |
| US8624010B1 (en) | 1999-02-03 | 2014-01-07 | Steven K. Yoshinaga | Nucleic acids encoding B7RP1 |
| US7435796B1 (en) | 1999-02-03 | 2008-10-14 | Amgen Inc. | Antibodies which bind B7RP1 |
| EP2796465A1 (en) * | 1999-02-03 | 2014-10-29 | Amgen, Inc | Polypeptides involved in immune response |
| US7708993B2 (en) * | 1999-02-03 | 2010-05-04 | Amgen Inc. | Polypeptides involved in immune response |
| BR0008209A (pt) * | 1999-02-12 | 2002-02-19 | Genetics Inst | Imunoglobulina humanizada reativa com moléculas b7 e processos de tratamento com as mesmas |
| US6972125B2 (en) | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
| EP1179000A4 (en) | 1999-02-26 | 2005-10-12 | Millennium Pharm Inc | DECISION PROTEINS AND THEIR USE |
| ATE296839T1 (de) * | 1999-03-01 | 2005-06-15 | Genentech Inc | Antikörper zur krebsbehandlung und -diagnose |
| MY133346A (en) * | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| US6531125B1 (en) | 1999-03-02 | 2003-03-11 | Twinstrand Therapeutics Inc. | Antiviral ricin-like proteins |
| WO2000051637A1 (en) * | 1999-03-02 | 2000-09-08 | Centocor, Inc. | ANTI-TNFα ANTIBODIES IN THERAPY OF ASTHMA |
| US6599710B1 (en) | 1999-03-10 | 2003-07-29 | The General Hospital Corporation | Treatment of autoimmune disease |
| IL145480A0 (en) | 1999-03-19 | 2002-06-30 | Genentech Inc | Treatment of lfa-1 associated disorders with increasing doses of lfa-1 |
| WO2000058479A1 (en) | 1999-03-26 | 2000-10-05 | Amgen Inc. | Beta secretase genes and polypeptides |
| DE19915057A1 (de) | 1999-04-01 | 2000-10-19 | Forschungszentrum Borstel | Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung |
| ES2571230T3 (es) * | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| GB9908533D0 (en) | 1999-04-14 | 1999-06-09 | Novartis Ag | Organic compounds |
| US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| CN100358577C (zh) | 1999-05-07 | 2008-01-02 | 杰南技术公司 | 抗体在制备治疗哺乳动物自身免疫病的试剂中的用途 |
| US6831060B2 (en) | 1999-05-07 | 2004-12-14 | Genentech, Inc. | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
| EP1645289A1 (en) | 1999-05-07 | 2006-04-12 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
| US8119101B2 (en) * | 1999-05-10 | 2012-02-21 | The Ohio State University | Anti-CD74 immunoconjugates and methods of use |
| US8383081B2 (en) * | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
| US7829064B2 (en) | 1999-05-10 | 2010-11-09 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods |
| KR20100123890A (ko) | 1999-05-13 | 2010-11-25 | 메디칼 리서취 카운실 | Ｏｘ2 수용체 동족체 |
| US20040023874A1 (en) * | 2002-03-15 | 2004-02-05 | Burgess Catherine E. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| US6974684B2 (en) * | 2001-08-08 | 2005-12-13 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| US20040229779A1 (en) * | 1999-05-14 | 2004-11-18 | Ramesh Kekuda | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| PL365999A1 (en) | 1999-05-14 | 2005-01-24 | Imclone Systems Incorporated | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| US6221597B1 (en) | 1999-05-21 | 2001-04-24 | Rosetta Inpharmatics, Inc. | Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs |
| US6197517B1 (en) | 1999-05-21 | 2001-03-06 | Rosetta Inpharmatics, Inc. | Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs |
| US6200803B1 (en) | 1999-05-21 | 2001-03-13 | Rosetta Inpharmatics, Inc. | Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs |
| CA2370466C (en) | 1999-06-25 | 2011-02-08 | Sharon Erickson | Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
| CA2305716A1 (en) | 1999-05-28 | 2000-11-28 | University Of Guelph | Method for assay of wbpm |
| US7166573B1 (en) * | 1999-05-28 | 2007-01-23 | Ludwig Institute For Cancer Research | Breast, gastric and prostate cancer associated antigens and uses therefor |
| IL130225A0 (en) | 1999-05-31 | 2000-06-01 | Yissum Res Dev Co | Novel uses of antibodies against ache and peptides thereof |
| EP2258849A1 (en) | 1999-06-01 | 2010-12-08 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
| US20040067490A1 (en) * | 2001-09-07 | 2004-04-08 | Mei Zhong | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| US7534605B2 (en) | 1999-06-08 | 2009-05-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases |
| AU5152700A (en) | 1999-06-15 | 2001-01-02 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| GB9914210D0 (en) | 1999-06-17 | 1999-08-18 | Danisco | Promoter |
| US20030166561A1 (en) * | 1999-06-18 | 2003-09-04 | Cooper Garth J. S. | Peptide |
| GEP20104998B (en) | 1999-06-25 | 2010-06-10 | Genentech Inc | Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer |
| US7291714B1 (en) * | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
| US20040001826A1 (en) * | 1999-06-30 | 2004-01-01 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
| AU5632500A (en) | 1999-06-30 | 2001-01-31 | Ludwig Institute For Cancer Research | Cancer associated antigens and uses therefor |
| FR2797402B1 (fr) | 1999-07-15 | 2004-03-12 | Biomerieux Stelhys | Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune |
| US7001766B2 (en) * | 1999-07-20 | 2006-02-21 | Curagen Corporation | Nucleic acid sequences encoding human angiopoietin-like polypeptides |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| JP2003506026A (ja) | 1999-07-30 | 2003-02-18 | シェーリング コーポレイション | 哺乳動物サイトカイン；関連試薬 |
| MXPA02001417A (es) * | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
| US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
| US6927203B1 (en) * | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| US7192698B1 (en) * | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
| CN1370076A (zh) | 1999-08-23 | 2002-09-18 | 中外制药株式会社 | Hm1.24抗原的表达增强剂 |
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US6627196B1 (en) | 1999-08-27 | 2003-09-30 | Genentech, Inc. | Dosages for treatment with anti-ErbB2 antibodies |
| KR20050004240A (ko) * | 1999-08-31 | 2005-01-12 | 제넨테크, 인크. | 종양 치료용 조성물 및 방법 |
| US7459540B1 (en) * | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| US7408047B1 (en) * | 1999-09-07 | 2008-08-05 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| EP1905832A3 (en) | 1999-09-09 | 2009-09-09 | Schering Corporation | Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions |
| US6900043B1 (en) | 1999-09-21 | 2005-05-31 | Amgen Inc. | Phosphatases which activate map kinase pathways |
| US7297478B1 (en) | 2000-09-22 | 2007-11-20 | Large Scale Biology Corporation | Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules |
| EP2333049A1 (en) | 1999-09-24 | 2011-06-15 | ABT Holding Company | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof |
| ATE321857T1 (de) | 1999-09-29 | 2006-04-15 | Diagnocure Inc | Pca3 mrna in gutartigen und bösartigen prostatageweben |
| US7892541B1 (en) | 1999-09-30 | 2011-02-22 | Tumor Biology Investment Group, Inc. | Soluble epidermal growth factor receptor isoforms |
| MXPA02003278A (es) | 1999-10-01 | 2002-09-02 | Chugai Pharmaceutical Co Ltd | Prevencion y tratamiento de enfermedades relacionadas con la coagulacion sanguinea. |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| US7947496B2 (en) | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US6855806B1 (en) * | 1999-10-15 | 2005-02-15 | Curagen Corporation | Thymosin beta 10-like proteins and nucleic acids encoding same |
| AU784660B2 (en) * | 1999-10-19 | 2006-05-18 | Curagen Corporation | Genes associated with obesity and methods for using the same |
| CN1402782A (zh) | 1999-10-19 | 2003-03-12 | 路德维哥癌症研究院 | Mage－a12抗原肽及其应用 |
| KR20080068767A (ko) * | 1999-10-20 | 2008-07-23 | 제넨테크, 인크. | Ｔ 헬퍼 세포 매개 질환의 치료를 위한 ｔ 세포 분화의조절 |
| US6342587B1 (en) | 1999-10-22 | 2002-01-29 | Ludwig Institute For Cancer Research | A33 antigen specific immunoglobulin products and uses thereof |
| US6346249B1 (en) | 1999-10-22 | 2002-02-12 | Ludwig Institute For Cancer Research | Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products |
| US7078382B1 (en) | 1999-11-02 | 2006-07-18 | Genentech, Inc. | Modulation of eNOS activity and therapeutic uses thereof |
| US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| EP2261256A3 (en) | 1999-11-24 | 2011-03-02 | Schering Corporation | Methods of inhibiting metastasis |
| US7425437B2 (en) * | 1999-11-26 | 2008-09-16 | Crucell Holland B.V. | Vaccines against West Nile Virus |
| ES2629683T3 (es) | 1999-11-30 | 2017-08-14 | Mayo Foundation For Medical Education And Research | B7-H1, una nueva molécula inmunorreguladora |
| CA2492070A1 (en) | 1999-12-01 | 2001-06-07 | Kevin P. Baker | Lung tumor marker pro4329 polypeptides and nucleic acids encoding the same |
| US6544792B1 (en) * | 1999-12-21 | 2003-04-08 | Genencor International, Inc. | Production of secreted polypeptides |
| EP2258848B1 (en) | 1999-12-23 | 2014-03-05 | Genentech, Inc. | Il-17 homologous polypeptide and therapeutic uses thereof |
| KR20020073491A (ko) | 1999-12-30 | 2002-09-26 | 제넨코 인터내셔날 인코포레이티드 | 트리코데르마 레제이 자일란 분해효소 |
| US6979537B2 (en) * | 2000-01-10 | 2005-12-27 | Scios, Inc. | Methods for identifying inhibitors of neuronal degeneration |
| CA2397207C (en) * | 2000-01-13 | 2013-12-03 | Genentech, Inc. | Novel stra6 polypeptides |
| US20020009728A1 (en) * | 2000-01-18 | 2002-01-24 | Quantum Dot Corporation | Oligonucleotide-tagged semiconductor nanocrystals for microarray and fluorescence in situ hybridization |
| US7091321B2 (en) | 2000-02-11 | 2006-08-15 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of antibody-based fusion proteins |
| WO2001058949A2 (en) | 2000-02-11 | 2001-08-16 | Biogen, Inc. | Heterologous polypeptide of the tnf family |
| ATE511857T1 (de) | 2000-02-16 | 2011-06-15 | Genentech Inc | Anti-april monoklonaler antikörper und deren verwendung zur behandlung von immunerkrankungen oder krebs |
| WO2001061351A1 (fr) | 2000-02-17 | 2001-08-23 | Laboratory Of Molecular Biophotonics | Detection d'antigene par voie quantitative |
| MXPA02007761A (es) * | 2000-02-17 | 2002-10-11 | Cv Therapeutics Inc | Metodo para identificar y utilizar antagonistas del receptor a2b de adenosina para mediar la proliferacion celular en mamiferos. |
| US20030103978A1 (en) | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
| EP1719528B1 (en) * | 2000-02-24 | 2011-09-28 | Philogen S.p.A. | Compositions and methods for treatment of angiogenesis in pathological lesions |
| JP2003524018A (ja) | 2000-02-24 | 2003-08-12 | アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ | フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用 |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| CA2401342C (en) * | 2000-03-03 | 2010-08-03 | Cambridge Antibody Technology Limited | Human antibodies against eotaxin and their use |
| EP1790725A2 (en) * | 2000-03-03 | 2007-05-30 | Curagen Corporation | Proteins named after FCTRX and nucleic acids encoding same |
| US6630584B1 (en) * | 2000-03-16 | 2003-10-07 | Ramot At Tel-Aviv University Ltd. | Single chain antibody against mutant p53 |
| US6740520B2 (en) * | 2000-03-21 | 2004-05-25 | Genentech, Inc. | Cytokine receptor and nucleic acids encoding the same |
| US6653080B2 (en) | 2000-03-22 | 2003-11-25 | Quantum Dot Corporation | Loop probe hybridization assay for polynucleotide analysis |
| US20040086970A1 (en) * | 2000-03-22 | 2004-05-06 | Genentech, Inc. | Novel cytokine receptors and nucleic acids encoding the same |
| WO2001070672A2 (en) | 2000-03-23 | 2001-09-27 | Elan Pharmaceuticals, Inc. | Compounds and methods to treat alzheimer's disease |
| US6992081B2 (en) | 2000-03-23 | 2006-01-31 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
| US20030212022A1 (en) * | 2001-03-23 | 2003-11-13 | Jean-Marie Vogel | Compositions and methods for gene therapy |
| US8697137B2 (en) | 2000-03-24 | 2014-04-15 | Biosphere Medical, Inc. | Methods of using microspheres for active embolization |
| US20030144236A1 (en) * | 2000-03-29 | 2003-07-31 | Weiss Robert H | Novel specific inhibitor of the cyclin kinase inhibitor p21 (wafl/cip1) |
| US20050043262A1 (en) * | 2000-03-29 | 2005-02-24 | Weiss Robert H. | Novel specific inhibitor of the cyclin kinase inhibitor p21Waf1/Cip1 and methods of using the inhibitor |
| US20030108927A1 (en) * | 2000-04-03 | 2003-06-12 | Kathryn Leishman | Compositions and methods for the prevention, treatment and detection of tuberculosis and other diseases |
| MXPA02010011A (es) * | 2000-04-11 | 2003-04-25 | Genentech Inc | Anticuerpos multivalentes y usos para los mismos. |
| JP2003530847A (ja) | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
| EP1272526A4 (en) | 2000-04-13 | 2004-10-13 | Univ Rockefeller | REINFORCING ANTIBODY-IMMUNE RESPONSE |
| US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| SI1274450T1 (sl) | 2000-04-18 | 2009-04-30 | Schering Corp | Medicinske uporabe agonistov in antagonistov IL-174 |
| US7632929B2 (en) | 2000-04-20 | 2009-12-15 | The Board Of Trustees Of The University Of Arkansas | Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof |
| CN1437478A (zh) * | 2000-04-25 | 2003-08-20 | Idec药物公司 | 瑞图希单抗的鞘内施用,用于中枢神经系统淋巴瘤的治疗 |
| US20030092086A1 (en) * | 2000-04-25 | 2003-05-15 | Kouichirou Hirata | Method for detecting streptococcus sobrinus and antibody therefor |
| US20040013674A1 (en) * | 2001-04-27 | 2004-01-22 | Christine Ambrose | Taci as an anti-tumor agent |
| WO2001082968A1 (fr) | 2000-04-28 | 2001-11-08 | Chugai Seiyaku Kabushiki Kaisha | Inhibiteurs de proliferation cellulaire |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
| US6696620B2 (en) | 2000-05-02 | 2004-02-24 | Epicyte Pharmaceutical, Inc. | Immunoglobulin binding protein arrays in eukaryotic cells |
| KR20040010041A (ko) | 2000-05-04 | 2004-01-31 | 예일 유니버시티 | 단백질 활성의 스크리닝을 위한 고밀도 단백질 어레이 |
| US6835545B2 (en) * | 2000-05-08 | 2004-12-28 | President And Fellows Of Harvard College | Methods, products and treatments for diabetes |
| US7439330B2 (en) * | 2000-05-08 | 2008-10-21 | President And Fellows Of Harvard College | Anti-glycated CD59 antibodies and uses thereof |
| US7560534B2 (en) | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
| US20040005554A1 (en) * | 2000-05-08 | 2004-01-08 | Tayar Nabil El | Novel glycoproteins and methods of use thereof |
| US20030219786A1 (en) * | 2000-08-11 | 2003-11-27 | Applied Research Systems Ars Holding N.V. | Novel glycoproteins and methods of use thereof |
| ES2609494T3 (es) | 2000-05-10 | 2017-04-20 | Mayo Foundation For Medical Education And Research | Anticuerpos IgM humanos con la capacidad de inducir remielinización y usos diagnósticos y terapéuticos de los mismos, particularmente en el sistema nervioso central |
| AU2001261351B2 (en) | 2000-05-10 | 2007-03-01 | Merck Sharp & Dohme Corp. | Mammalian receptor proteins; related reagents and methods |
| US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
| MXPA02011130A (es) | 2000-05-12 | 2003-03-10 | Amgen Inc | Metodos y composiciones de materia que se refieren a april/g70, bcma, blys/agp-3, y taci. |
| EP1935431A3 (en) | 2000-05-15 | 2008-08-13 | Health Research, Inc. | Cancer treatments by using a combination of an antibody against her2 and interleukin-2 |
| EP1714661A3 (en) | 2000-05-19 | 2012-03-14 | The Center for Blood Research, INC. | Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity |
| US20030009016A1 (en) * | 2000-05-25 | 2003-01-09 | Shimkets Richard A. | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| WO2001092338A1 (en) | 2000-06-01 | 2001-12-06 | The Brigham And Women's Hospital, Inc. | Diagnosis of endometrial precancers |
| EP1299542A2 (en) * | 2000-06-06 | 2003-04-09 | Idec Pharmaceuticals Corporation | Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| CN1443074A (zh) | 2000-06-08 | 2003-09-17 | 血液研究中心 | 抑制免疫球蛋白介导的再灌注损伤的方法和组合物 |
| CA2413160A1 (en) | 2000-06-15 | 2001-12-20 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
| EP2281843B1 (en) | 2000-06-16 | 2016-10-12 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to BLyS |
| AU2001268633A1 (en) * | 2000-06-21 | 2002-01-02 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| CA2648051A1 (en) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| DK2042597T3 (da) | 2000-06-23 | 2014-08-11 | Genentech Inc | Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese |
| MXPA02012747A (es) | 2000-06-28 | 2003-09-25 | Amgen Inc | Moleculas del receptor de linfopoietina estromica timica y sus usos. |
| US20060034828A1 (en) * | 2000-06-28 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform |
| US20060257399A1 (en) * | 2000-06-28 | 2006-11-16 | Glycofi, Inc. | Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform |
| US20060024304A1 (en) * | 2000-06-28 | 2006-02-02 | Gerngross Tillman U | Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform |
| US20060034830A1 (en) * | 2000-06-28 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform |
| EP1294882A2 (en) * | 2000-06-28 | 2003-03-26 | Amgen, Inc. | B7-like molecules and uses thereof |
| ATE368475T1 (de) * | 2000-06-29 | 2007-08-15 | Emd Lexigen Res Ct Corp | Steigerung von durch antikörper-zytokin- fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme |
| PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
| AU2001273113A1 (en) * | 2000-06-30 | 2002-01-14 | Elan Pharmaceuticals, Inc | Compounds to treat alzheimer's disease |
| US20030096864A1 (en) * | 2000-06-30 | 2003-05-22 | Fang Lawrence Y. | Compounds to treat alzheimer's disease |
| US6846813B2 (en) | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
| US6852510B2 (en) * | 2000-07-03 | 2005-02-08 | Gala Design Inc | Host cells containing multiple integrating vectors |
| AU2001270252B2 (en) * | 2000-07-03 | 2007-02-08 | Catalent Pharma Solutions, Llc | Expression vectors |
| US20040235173A1 (en) * | 2000-07-03 | 2004-11-25 | Gala Design, Inc. | Production of host cells containing multiple integrating vectors by serial transduction |
| US20030224415A1 (en) * | 2001-06-29 | 2003-12-04 | Gala Design, Inc. | Selection free growth of host cells containing multiple integrating vectors |
| FR2811323B1 (fr) * | 2000-07-07 | 2006-10-06 | Fuma Tech Gmbh | Materiau hybride, utilisation dudit materiau hybride et procede de sa fabrication |
| US7176037B2 (en) | 2000-07-13 | 2007-02-13 | The Scripps Research Institute | Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation |
| US6951947B2 (en) * | 2000-07-13 | 2005-10-04 | The Scripps Research Institute | Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation |
| US20040023259A1 (en) * | 2000-07-26 | 2004-02-05 | Luca Rastelli | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| US6891030B2 (en) | 2000-07-27 | 2005-05-10 | Mayo Foundation For Medical Education And Research | T-cell immunoregulatory molecule |
| US6984522B2 (en) * | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| US20050249735A1 (en) * | 2000-08-07 | 2005-11-10 | Centocor, Inc. | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
| US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
| US20060018907A1 (en) * | 2000-08-07 | 2006-01-26 | Centocor, Inc. | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| US20110195063A1 (en) * | 2000-08-07 | 2011-08-11 | Centocor, Inc. | Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor |
| ATE360640T1 (de) | 2000-08-08 | 2007-05-15 | St Jude Childrens Res Hospital | Gruppe-b streptococcus polypeptide, nukleinsäure, therapeutische zusammensetzungen und impfstoffe davon |
| US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
| US6911204B2 (en) | 2000-08-11 | 2005-06-28 | Favrille, Inc. | Method and composition for altering a B cell mediated pathology |
| CA2418802C (en) | 2000-08-11 | 2012-10-23 | Kirin Beer Kabushiki Kaisha | Polypeptide regulating phosphate metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same |
| CA2416794A1 (en) * | 2000-08-11 | 2002-02-21 | Favrille, Inc. | Method and composition for altering a t cell mediated pathology |
| EP2014298A3 (en) | 2000-08-24 | 2009-10-07 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| ATE497007T1 (de) | 2000-08-25 | 2011-02-15 | Basf Plant Science Gmbh | Polynukleotide, die für prenylproteasen aus pflanzen kodieren |
| US6803211B2 (en) | 2000-08-25 | 2004-10-12 | Pfizer Inc. | Methods and compositions for diagnosing and treating disorders involving angiogenesis |
| EP1315812B1 (en) | 2000-09-01 | 2009-11-11 | The Center for Blood Research, INC. | Modified polypeptides stabilized in a desired conformation and methods for producing same |
| AU8867501A (en) * | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| EP1315743B1 (en) | 2000-09-08 | 2012-11-07 | Merck Sharp & Dohme Corp. | Mammalian genes; related reagents and methods |
| US6673623B1 (en) | 2000-09-12 | 2004-01-06 | Novocure, Inc. | Methods and compositions that control lipid production |
| US7101976B1 (en) | 2000-09-12 | 2006-09-05 | Purdue Research Foundation | EphA2 monoclonal antibodies and methods of making and using same |
| US20040077043A1 (en) * | 2000-09-12 | 2004-04-22 | Hiroshi Watarai | Novel dendritic cell wall membrane and use thereof |
| ATE373717T1 (de) * | 2000-09-12 | 2007-10-15 | Univ Washington | Pde8a und seine verwendung |
| AU2001289019B2 (en) | 2000-09-14 | 2006-07-27 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
| UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
| CA2422076A1 (en) * | 2000-09-18 | 2002-03-21 | Idec Pharmaceutical Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| ATE312932T1 (de) | 2000-09-18 | 2005-12-15 | Genencor Int | Zwillingsarginin translokation in bacillus |
| GB0022978D0 (en) | 2000-09-19 | 2000-11-01 | Oxford Glycosciences Uk Ltd | Detection of peptides |
| US20020115058A1 (en) * | 2000-09-22 | 2002-08-22 | Pedersen Finn Skou | Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1 |
| US20020164576A1 (en) * | 2000-09-22 | 2002-11-07 | Pedersen Finn Skou | Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2 |
| US20030044803A1 (en) * | 2000-09-22 | 2003-03-06 | Pedersen Finn Skou | Methods for diagnosis and treatment of diseases associated with altered expression of JAK1 |
| AU2001293187A1 (en) * | 2000-09-28 | 2002-04-08 | Uab Research Foundation | Chimeric retroviral gag genes and screening assays |
| DE60143535D1 (de) | 2000-10-02 | 2011-01-05 | Novartis Vaccines & Diagnostic | Humane antikörper gegen cd40 |
| US20030022247A1 (en) * | 2000-10-03 | 2003-01-30 | Masabumi Shibuya | Substance which inhibits binding of information transfer molecule for 1175-tyrosine phosphorylated KDR/FLK-1 and usages of the same |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US20050059031A1 (en) | 2000-10-06 | 2005-03-17 | Quantum Dot Corporation | Method for enhancing transport of semiconductor nanocrystals across biological membranes |
| EP1327145B1 (en) | 2000-10-06 | 2009-03-11 | Life Technologies Corporation | Cells having a spectral signature, and methods of preparation and use thereof |
| ES2483991T3 (es) | 2000-10-10 | 2014-08-08 | Genentech, Inc. | Anticuerpos contra C5 que inhibe la activación de las células endoteliales de tipo II |
| EP1326892A2 (en) | 2000-10-12 | 2003-07-16 | University of Rochester | Compositions that inhibit proliferation of cancer cells |
| IL155002A0 (en) | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| ES2338757T3 (es) | 2000-10-18 | 2010-05-12 | The Brigham And Women's Hospital, Inc. | Polipeptidos ligandos para selectina-e/selectina-l de la celula hematopoyetica y metodos de utilizacion de los mismos. |
| US7393532B1 (en) | 2000-10-18 | 2008-07-01 | Genentech, Inc. | Modulation of T cell differentiation for the treatment of T helper cell mediated diseases |
| US20020128448A1 (en) * | 2000-10-20 | 2002-09-12 | Idec Pharmaceuticals Corporation | Variant IgG3 Rituxan and therapeutic use thereof |
| US7259232B1 (en) | 2000-10-27 | 2007-08-21 | Nymox Pharmaceutical Corporation | Preferred segments of neural thread protein |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| AU2002241556B2 (en) * | 2000-11-01 | 2007-07-19 | Elusys Therapeutics, Inc. | Method of producing bispecific molecules by protein trans-splicing |
| US7163800B2 (en) * | 2000-11-03 | 2007-01-16 | Molecular Devices Corporation | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity |
| US7018812B2 (en) * | 2000-11-03 | 2006-03-28 | Duke University | Modified G-protein coupled receptors |
| US6992234B2 (en) * | 2000-11-06 | 2006-01-31 | The Jackson Laboratory | FcRn-based therapeutics for the treatment of auto-immune disorders |
| WO2002040874A1 (en) * | 2000-11-16 | 2002-05-23 | California Institute Of Technology | Apparatus and methods for conducting assays and high throughput screening |
| JP4368196B2 (ja) * | 2000-11-17 | 2009-11-18 | ユニバーシティー オブ ロチェスター | 真核細胞において免疫グロブリン分子を製造および同定するインビトロにおける方法 |
| US20050196755A1 (en) * | 2000-11-17 | 2005-09-08 | Maurice Zauderer | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| IL155952A0 (en) | 2000-11-28 | 2003-12-23 | Wyeth Corp | Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| BR0115728A (pt) | 2000-11-28 | 2003-09-23 | Wyeth Corp | Análise da expressão de ácidos nucléicos kiaa e polipeptìdeos úteis no diagnóstico e tratamento de cáncer de próstata |
| CA2429599A1 (en) | 2000-11-28 | 2002-06-06 | Amgen Inc. | Use of b7rp1 antagonists in ige-mediated disorders |
| TWI327600B (en) | 2000-11-28 | 2010-07-21 | Medimmune Llc | Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
| US7534429B2 (en) * | 2000-11-29 | 2009-05-19 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| CA2430082A1 (en) * | 2000-11-29 | 2002-06-06 | Lynkeus Biotech Gmbh | Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379 |
| PE20020574A1 (es) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| EP1415005B1 (en) | 2000-12-07 | 2012-11-21 | Novartis Vaccines and Diagnostics, Inc. | Endogenous retroviruses up-regulated in prostate cancer |
| DE60144493D1 (de) | 2000-12-08 | 2011-06-01 | Curagen Corp | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen |
| DE60120500T2 (de) * | 2000-12-08 | 2007-06-06 | Genentech, Inc., South San Francisco | In Knorpelgeweben stark exprimiertes Gen |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US6979556B2 (en) * | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
| RU2287574C2 (ru) * | 2000-12-14 | 2006-11-20 | Дженентек, Инк. | БАКТЕРИЯ Е.coli, ПРОДУЦИРУЮЩАЯ ГЕТЕРОЛОГИЧНЫЙ ПОЛИПЕПТИД, И СПОСОБ ПРОДУЦИРОВАНИЯ ПОЛИПЕПТИДА |
| US20020187100A1 (en) * | 2000-12-21 | 2002-12-12 | David Rizzieri | Anti-tenascin monoclonal antibody therapy for lymphoma |
| US7700274B2 (en) * | 2000-12-22 | 2010-04-20 | Sagres Discovery, Inc. | Compositions and methods in cancer associated with altered expression of KCNJ9 |
| US7645441B2 (en) * | 2000-12-22 | 2010-01-12 | Sagres Discovery Inc. | Compositions and methods in cancer associated with altered expression of PRLR |
| US20030087252A1 (en) * | 2000-12-22 | 2003-05-08 | Morris David W. | Novel compositions and methods in cancer associated with altered expression of PRDM11 |
| US7892730B2 (en) | 2000-12-22 | 2011-02-22 | Sagres Discovery, Inc. | Compositions and methods for cancer |
| US20030232334A1 (en) * | 2000-12-22 | 2003-12-18 | Morris David W. | Novel compositions and methods for cancer |
| US20060063152A1 (en) | 2000-12-22 | 2006-03-23 | Osamu Ohara | Novel gene and protein encoded by the gene |
| US7820447B2 (en) * | 2000-12-22 | 2010-10-26 | Sagres Discovery Inc. | Compositions and methods for cancer |
| US20030165878A1 (en) * | 2000-12-22 | 2003-09-04 | Morris David W. | Novel compositions and methods in cancer associated with altered expression of MCM3AP |
| US7445802B2 (en) * | 2000-12-26 | 2008-11-04 | Yeda Research And Development Co. Ltd | Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases |
| US6964849B2 (en) | 2001-01-11 | 2005-11-15 | Curagen Corporation | Proteins and nucleic acids encoding same |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2433877C (en) | 2001-01-17 | 2014-11-18 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7279324B2 (en) * | 2001-01-23 | 2007-10-09 | Duke University | Nucleic acid encoding G-protein coupled receptor with modified DRY motif |
| WO2002059337A1 (en) * | 2001-01-26 | 2002-08-01 | Georgetown University School Of Medicine | Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof |
| US20020159996A1 (en) | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
| WO2002060485A2 (en) | 2001-01-31 | 2002-08-08 | Idec Pharmaceuticals Corporation | Use of immunoregulatory antibodies in the treatment of neoplastic disorders |
| WO2002062850A2 (en) * | 2001-02-02 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Hybrid antibodies and uses thereof |
| US7422860B2 (en) * | 2001-02-07 | 2008-09-09 | Massachusetts Institute Of Technology | Optoelectronic detection system |
| US8216797B2 (en) * | 2001-02-07 | 2012-07-10 | Massachusetts Institute Of Technology | Pathogen detection biosensor |
| US20040077081A1 (en) * | 2001-02-07 | 2004-04-22 | Egbert Oosterwijk | Hybridoma cell line g250 and its use for producing monoclonal antibodies |
| AU2002256992B2 (en) * | 2001-02-07 | 2007-06-07 | Massachusetts Institute Of Technology | Optoelectronic detection system |
| ES2531909T3 (es) * | 2001-02-07 | 2015-03-20 | Wilex Ag | Método de producción de anticuerpos recombinantes contra tumores |
| JP3986439B2 (ja) | 2001-02-07 | 2007-10-03 | 中外製薬株式会社 | 造血器腫瘍の治療剤 |
| CA2438433A1 (en) * | 2001-02-14 | 2002-08-22 | Tularik Inc. | Methods for the diagnosis and treatment of tumors employing the hepsin gene |
| AU2002253981B2 (en) * | 2001-02-20 | 2008-02-21 | Abeome Corporation | Rapid production of monoclonal antibodies |
| US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| US6815166B2 (en) | 2001-02-23 | 2004-11-09 | Dana-Farber Cancer Institute, Inc. | HIN-1, a tumor suppressor gene |
| US20030044406A1 (en) * | 2001-03-02 | 2003-03-06 | Christine Dingivan | Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents |
| HUP0303428A2 (hu) | 2001-03-07 | 2004-01-28 | Merck Patent Gmbh. | Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez |
| JP2004533815A (ja) | 2001-03-14 | 2004-11-11 | ミリアド・ジェネティックス・インコーポレイテッド | Ｔｓｇ１０１−ｇａｇ相互作用およびその使用 |
| EP2368904A1 (en) | 2001-03-14 | 2011-09-28 | Genencor International, Inc. | Regulatable growth of filamentous fungi |
| EP2295064B1 (en) * | 2001-03-15 | 2017-02-22 | Precision Biologics, Inc. | Monoclonal antibody therapy for pancreas cancer |
| US20020177239A1 (en) * | 2001-03-16 | 2002-11-28 | Thomas Gregory Brian | Anti-GPE antibodies, their uses, and analytical methods for GPE |
| US20080008704A1 (en) * | 2001-03-16 | 2008-01-10 | Mark Rubin | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| US8231878B2 (en) * | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| CN1509328A (zh) * | 2001-03-23 | 2004-06-30 | Opg配体调节免疫应答的作用 | |
| CA2441228A1 (en) | 2001-03-23 | 2002-10-03 | Aphton Corporation | Combination treatment of pancreatic cancer |
| US6992174B2 (en) * | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| WO2002079499A1 (en) | 2001-04-02 | 2002-10-10 | Wyeth | Pd-1, a receptor for b7-4, and uses therefor |
| UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| US20030148298A1 (en) * | 2001-04-03 | 2003-08-07 | O''toole Margot | Methods for diagnosing and treating systemic lupus erythematosus disease and compositions thereof |
| WO2002081640A2 (en) * | 2001-04-06 | 2002-10-17 | Georgetown University | Gene shinc-1 and diagnostic and therapeutic uses thereof |
| WO2002081641A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene scc-112 and diagnostic and therapeutic uses thereof |
| WO2002081639A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene brcc2 and diagnostic and therapeutic uses thereof |
| DE60236646D1 (de) | 2001-04-13 | 2010-07-22 | Human Genome Sciences Inc | Anti-VEGF-2 Antikörper |
| WO2002083855A2 (en) | 2001-04-16 | 2002-10-24 | Wyeth Holdings Corporation | Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| ES2366775T3 (es) | 2001-04-24 | 2011-10-25 | Merck Patent Gmbh | POLITERAPIA UTILIZANDO AGENTES ANTIANGIOGÉNICOS Y TNF(alfa). |
| PL207087B1 (pl) | 2001-04-26 | 2010-10-29 | Biogen | Przeciwciało, które wiąże się swoiście z białkiem Cripto, zawierająca je kompozycja farmaceutyczna i zastosowanie przeciwciała |
| US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
| DE10121255A1 (de) * | 2001-04-30 | 2002-11-07 | Switch Biotech Ag | Verwendung von alpha 1-Antichymotrypsin Polypeptiden oder diese kodierende Nukleinsäuren, oder einer ein ACT Polypeptid oder diese kodierende Nukleinsäure exprimierende Zelle, zur Behandlung und/oder Prävention von diabetes-assoziierten und/oder arteriellen schlecht heilenden Wunden und zur Identifizierung von pharmakologisch aktiven Substanzen |
| US7256257B2 (en) * | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20030017159A1 (en) * | 2001-05-02 | 2003-01-23 | Jerome Ritz | Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof |
| BR0209177A (pt) * | 2001-05-03 | 2004-10-05 | Merck Patent Gmbh | Anticorpo especìfico a tumor recombinante e uso do mesmo |
| US20090191232A1 (en) * | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
| US6794501B2 (en) * | 2001-05-04 | 2004-09-21 | Ludwig Institute For Cancer Research | Colon cancer antigen panel |
| US7803382B2 (en) * | 2001-05-04 | 2010-09-28 | Ludwig Institute For Cancer Research Ltd. | Method for inducing immune response to NY-CO-58 |
| US20110313230A1 (en) | 2001-05-11 | 2011-12-22 | Terrance Grant Johns | Specific binding proteins and uses thereof |
| ES2334494T5 (es) | 2001-05-11 | 2013-05-29 | Ludwig Institute For Cancer Research Ltd. | Proteínas de unión específicas y usos de las mismas |
| ES2527471T3 (es) * | 2001-05-11 | 2015-01-26 | Amgen Inc. | Péptidos y moléculas relacionadas que se unen a TALL-1 |
| GB0111628D0 (en) * | 2001-05-11 | 2001-07-04 | Scancell Ltd | Binding member |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| US6972324B2 (en) * | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
| US20030138429A1 (en) * | 2001-05-22 | 2003-07-24 | Pizzo Salvatore V. | Compositions and methods for inhibiting metastasis |
| US7132401B2 (en) | 2001-05-22 | 2006-11-07 | Merck & Co., Inc. | Beta-secretase substrates and uses thereof |
| US20020197253A1 (en) * | 2001-05-22 | 2002-12-26 | Cheek Dennis J. | Compositions and methods for promoting or inhibiting NDPK |
| GB0112844D0 (en) * | 2001-05-25 | 2001-07-18 | Psimei Pharmaceuticals Plc | Neutron capture therapy |
| US7064189B2 (en) | 2001-05-25 | 2006-06-20 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| US7279274B2 (en) * | 2001-05-29 | 2007-10-09 | Pride Proteomics A/S | Method for diagnosing diabetes in a mammal |
| US20030007974A1 (en) * | 2001-05-30 | 2003-01-09 | Nanus David M. | Endopeptidase/anti-PSMA antibody fusion proteins for treatment of cancer |
| US7745398B2 (en) | 2001-05-31 | 2010-06-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 and treatment of cancer |
| US7744882B2 (en) | 2001-05-31 | 2010-06-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 methods of detection and antibodies |
| WO2002096910A1 (en) * | 2001-05-31 | 2002-12-05 | Medarex, Inc. | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
| EP1392360B1 (en) | 2001-06-01 | 2011-11-30 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| US20090324612A1 (en) * | 2001-06-05 | 2009-12-31 | Kaufman Daniel L | Modulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule |
| US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| US7553484B2 (en) * | 2001-06-05 | 2009-06-30 | The Regents Of The University Of California | Modulating neuronal outgrowth via the major histocompatibility complex class I (MHC I) molecule |
| EP2305699B1 (de) | 2001-06-05 | 2014-08-13 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose |
| EP1392845A4 (en) * | 2001-06-07 | 2005-10-05 | Wyeth Corp | G-PROTEIN-COUPLED RECEPTOR AND USES THEREOF |
| JP4233092B2 (ja) * | 2001-06-07 | 2009-03-04 | ケモセントリックス， インコーポレイテッド | 細胞移動アッセイ |
| EP2320233A1 (en) * | 2001-06-15 | 2011-05-11 | Inhibitex, Inc. | Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus |
| EP2000482A1 (en) * | 2001-06-20 | 2008-12-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| JP2005500034A (ja) * | 2001-06-20 | 2005-01-06 | プロション バイオテク リミテッド | 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用 |
| US20030148408A1 (en) | 2001-09-18 | 2003-08-07 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| AU2002345743A1 (en) * | 2001-06-21 | 2003-01-08 | Sierra Sciences, Inc. | Telomerase expression repressor proteins and methods of using the same |
| EP3492100B1 (en) | 2001-06-26 | 2021-12-08 | Amgen Inc. | Antibodies to opgl |
| US20030013081A1 (en) | 2001-06-26 | 2003-01-16 | Olson William C. | Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
| JP2005500319A (ja) * | 2001-06-27 | 2005-01-06 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病の治療に有用なβ−ヒドロキシアミン誘導体 |
| WO2003002608A1 (en) | 2001-06-28 | 2003-01-09 | Kyowa Hakko Kogyo Co., Ltd. | Humanized antibody against fibroblast growth factor-8 and fragment of the antibody |
| US20030087274A1 (en) * | 2001-07-05 | 2003-05-08 | Anderson David W. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| US20030129613A1 (en) * | 2001-07-05 | 2003-07-10 | Fernandes Elma R. | Novel human proteins and polynucleotides encoding them |
| NZ530949A (en) * | 2001-07-05 | 2005-09-30 | Wyeth Corp | Aggrecanase molecules |
| US20030021786A1 (en) * | 2001-07-09 | 2003-01-30 | Gevas Philip C. | Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
| US7393656B2 (en) | 2001-07-10 | 2008-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for risk stratification |
| US20030113940A1 (en) * | 2001-07-16 | 2003-06-19 | Erlanger Bernard F. | Antibodies specific for nanotubes and related methods and compositions |
| EP1417342A4 (en) | 2001-07-17 | 2005-07-06 | Gen Hospital Corp | METHODS FOR DIAGNOSING AND TREATING DISEASES AND DISORDERS OF THE DIGESTIVE SYSTEM AND CANCER |
| BR0211342A (pt) | 2001-07-20 | 2005-05-03 | Univ Georgia Res Found | Vìrus de raiva atenuado com mutação de nucleoproteìna no sìtio de fosforilação para vacinação contra raiva e terapia de gene na cns |
| US7858095B2 (en) * | 2001-07-24 | 2010-12-28 | Astellas Us Llc | Method for treating or preventing sclerotic disorders using CD-2 binding agents |
| AUPR673001A0 (en) * | 2001-07-31 | 2001-08-23 | Prince Henry's Institute Of Medical Research | Pregnancy-related enzyme activity |
| TWI327597B (en) * | 2001-08-01 | 2010-07-21 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| US7413870B2 (en) | 2001-08-01 | 2008-08-19 | Rigel Pharmaceuticals, Incorporated | SAK: modulation of cellular proliferation for treatment of cancer |
| US20040030096A1 (en) * | 2001-08-02 | 2004-02-12 | Linda Gorman | Novel human proteins, polynucleotides encoding them and methods of using the same |
| WO2003014703A2 (en) * | 2001-08-09 | 2003-02-20 | Curagen Corporation | Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof |
| US20030035802A1 (en) * | 2001-08-14 | 2003-02-20 | Dewan Zeng | Localization of A2B AdoR on human normal and diseased tissue: the use of anti-A2B antibody to diagnose and treat human tumors |
| EP1878441B1 (en) | 2001-08-17 | 2018-01-24 | Genentech, Inc. | Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b |
| US6861231B2 (en) * | 2001-08-17 | 2005-03-01 | Qiagen Gmbh | Suppression of cross-reactivity and non-specific binding by antibodies using protein A |
| DK1567641T3 (da) * | 2001-08-24 | 2012-08-27 | Uvic Industry Partnerships Inc | Proaerolysin indeholdende proteaseaktiveringssekvenser og fremgangsmåder til anvendelse til behandling af prostatacancer. |
| EP1421214A4 (en) * | 2001-08-27 | 2005-11-02 | Tularik Inc | AMPLIFIED ONCOGENE AND THEIR ROLE IN CANCER |
| KR100968664B1 (ko) * | 2001-08-27 | 2010-07-06 | 제넨테크, 인크. | 항체 발현 및 조립을 위한 시스템 |
| US20030099985A1 (en) * | 2001-08-27 | 2003-05-29 | Jing Li | Amplified gene involved in cancer |
| US7270960B2 (en) | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
| US20040235068A1 (en) * | 2001-09-05 | 2004-11-25 | Levinson Arthur D. | Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders |
| US20060068405A1 (en) * | 2004-01-27 | 2006-03-30 | Alex Diber | Methods and systems for annotating biomolecular sequences |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US7981863B2 (en) | 2001-09-19 | 2011-07-19 | Neuronova Ab | Treatment of Parkinson's disease with PDGF |
| WO2003035887A1 (en) | 2001-09-20 | 2003-05-01 | Immunex Corporation | Selection of cells expressing heteromeric polypeptides |
| US6982159B2 (en) * | 2001-09-21 | 2006-01-03 | Genencor International, Inc. | Trichoderma β-glucosidase |
| NZ531818A (en) | 2001-09-25 | 2005-10-28 | Fujisawa Pharmaceutical Co | Recombinant anti-osteopontin antibody and use in the treatment of autoimmune diseases such as rheumatoid arthritis and osteoarthritis |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| WO2003028537A2 (en) | 2001-10-01 | 2003-04-10 | The General Hospital Corporation | Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer |
| WO2003028630A2 (en) | 2001-10-04 | 2003-04-10 | Genetics Institute Llc. | Methods and compositions for modulating interleukin-21 receptor activity |
| US20030199442A1 (en) * | 2001-10-09 | 2003-10-23 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| EP1439857B1 (en) | 2001-10-12 | 2009-02-25 | Schering Corporation | USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES |
| PL374426A1 (en) * | 2001-10-15 | 2005-10-17 | Immunomedics, Inc. | Affinity enhancement agents |
| JP4347694B2 (ja) * | 2001-10-16 | 2009-10-21 | レイベン バイオテクノロジーズ，インコーポレイティド | 癌関連抗原ｃｄ４６に結合する抗体およびその使用方法 |
| DE10151511A1 (de) | 2001-10-18 | 2003-05-08 | Basf Lynx Bioscience Ag | ee3-Proteinfamilie und zugrundeliegende DNA-Sequenzen |
| US20050123925A1 (en) | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US20040151721A1 (en) | 2001-10-19 | 2004-08-05 | O'keefe Theresa | Humanized anti-CCR2 antibodies and methods of use therefor |
| US20110045005A1 (en) | 2001-10-19 | 2011-02-24 | Craig Crowley | Compositions and methods for the treatment of tumor of hematopoietic origin |
| US20040166490A1 (en) * | 2002-12-17 | 2004-08-26 | Morris David W. | Novel therapeutic targets in cancer |
| US20040126762A1 (en) * | 2002-12-17 | 2004-07-01 | Morris David W. | Novel compositions and methods in cancer |
| US7445925B2 (en) * | 2001-10-27 | 2008-11-04 | Sanofi-Aventis Deutschland Gmbh | Aequorin as a reporter gene in yeast |
| US20030190705A1 (en) * | 2001-10-29 | 2003-10-09 | Sunol Molecular Corporation | Method of humanizing immune system molecules |
| US7282205B2 (en) | 2001-11-07 | 2007-10-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anti-hepatitis A virus antibodies |
| WO2004039826A1 (en) | 2001-11-14 | 2004-05-13 | Centocor, Inc. | Anti-il-6 antibodies, compositions, methods and uses |
| AU2002334746B2 (en) * | 2001-11-15 | 2007-10-11 | Becton, Dickinson And Company | Methods and devices for the integrated discovery of cell culture environments |
| WO2003044161A2 (en) * | 2001-11-15 | 2003-05-30 | Tularik Inc. | Gene amplification and overexpression in cancer |
| EP2298717B1 (en) | 2001-11-30 | 2015-10-28 | Biogen MA Inc. | Antibodies against monocyte chemotactic proteins |
| TW200408407A (en) * | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
| US7871619B2 (en) | 2001-11-30 | 2011-01-18 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| US20040180344A1 (en) * | 2003-03-14 | 2004-09-16 | Morris David W. | Novel therapeutic targets in cancer |
| US20040197778A1 (en) * | 2002-12-26 | 2004-10-07 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
| US20060040262A1 (en) * | 2002-12-27 | 2006-02-23 | Morris David W | Novel compositions and methods in cancer |
| CN100390282C (zh) | 2001-12-04 | 2008-05-28 | 默克专利有限公司 | 具有调节的选择性的il-2融合蛋白 |
| WO2003049673A2 (en) | 2001-12-05 | 2003-06-19 | Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of sympathetic tone |
| US8178128B2 (en) * | 2001-12-05 | 2012-05-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Nanoparticles containing polymeric nucleic acid homologs |
| GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
| WO2003050258A2 (en) * | 2001-12-07 | 2003-06-19 | Chiron Corporation | Endogenous retrovirus polypeptides linked to oncogenic transformation |
| US20060275747A1 (en) * | 2001-12-07 | 2006-12-07 | Hardy Stephen F | Endogenous retrovirus up-regulated in prostate cancer |
| EP1465634B1 (en) | 2001-12-12 | 2014-10-22 | The Government of the United States of America, as represented by the Secretary Department of Health and Human Services | Methods for using adenosine receptor inhibitors to enhance immune response and inflammation |
| CA2471777A1 (en) * | 2001-12-18 | 2003-06-26 | Endocube Sas | Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control |
| US7045331B2 (en) | 2001-12-18 | 2006-05-16 | Genencor International, Inc. | EGVII endoglucanase and nucleic acids encoding the same |
| US7858297B2 (en) | 2001-12-18 | 2010-12-28 | Centre National De La Recherche Scientifique Cnrs | Chemokine-binding protein and methods of use |
| US7005289B2 (en) * | 2001-12-18 | 2006-02-28 | Genencor International, Inc. | BGL5 β-glucosidase and nucleic acids encoding the same |
| US7045332B2 (en) * | 2001-12-18 | 2006-05-16 | Genencor International, Inc. | BGL4 β-glucosidase and nucleic acids encoding the same |
| US7056721B2 (en) * | 2001-12-18 | 2006-06-06 | Genencor International, Inc. | EGVI endoglucanase and nucleic acids encoding the same |
| US7049125B2 (en) | 2001-12-18 | 2006-05-23 | Genencor International, Inc. | EGVIII endoglucanase and nucleic acids encoding the same |
| DE10162480A1 (de) * | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| AU2002359721A1 (en) * | 2001-12-19 | 2003-07-09 | Bristol-Myers Squibb Company | Pichia pastoris formate dehydrogenase and uses therefor |
| EP1463834A4 (en) * | 2001-12-20 | 2005-08-10 | Tularik Inc | IDENTIFICATION OF AN AMPLIFIED GENE AND TARGET FOR A DRUG INTERVENTION |
| GB0130543D0 (en) | 2001-12-20 | 2002-02-06 | Univ Cambridge Tech | Human antibodies and their use |
| EP1463751B1 (en) | 2001-12-21 | 2013-05-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050171339A1 (en) | 2001-12-28 | 2005-08-04 | Izumi Sugo | Method of stabilizing protein |
| AU2003202472B2 (en) | 2001-12-28 | 2009-11-26 | Kyowa Kirin Co., Ltd. | Antibodies against fibroblast growth factor 23 |
| US7465553B2 (en) | 2001-12-31 | 2008-12-16 | Dana-Farber Cancer Institute, Inc. | Psoriasin expression by breast epithelial cells |
| NZ556415A (en) | 2002-01-02 | 2009-02-28 | Genentech Inc | Compositions and methods for the diagnosis and treatment of glioma tumor |
| US20040009498A1 (en) * | 2002-01-14 | 2004-01-15 | Diversa Corporation | Chimeric antigen binding molecules and methods for making and using them |
| WO2003062395A2 (en) * | 2002-01-18 | 2003-07-31 | Bristol-Myers Squibb Company | Predictor sets for tyrosine kinase pathways |
| IL152904A0 (en) * | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
| WO2003062404A1 (en) * | 2002-01-25 | 2003-07-31 | Gamida-Cell Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
| US7781396B2 (en) * | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
| WO2003064622A2 (en) * | 2002-01-31 | 2003-08-07 | Wyeth | Aggrecanase molecules |
| US20040052928A1 (en) * | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
| PT2311869E (pt) | 2002-02-01 | 2013-03-04 | Merck Sharp & Dohme | Utilização de reagentes relacionados com citoquinas de mamíferos |
| PL373396A1 (en) | 2002-02-05 | 2005-08-22 | Wyeth | Truncated aggrecanase molecules |
| EP1472275B1 (en) | 2002-02-05 | 2008-12-17 | Genentech, Inc. | Protein purification |
| CA2475112A1 (en) | 2002-02-06 | 2003-08-14 | Vicor Technologies, Inc. | Anti-infarction molecules |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| EP2360476B1 (en) | 2002-02-13 | 2017-10-25 | BioMedica Diagnostics Inc. | Methods for selecting treatment regimens and predicting outcomes in cancer patients |
| KR20040094705A (ko) * | 2002-02-21 | 2004-11-10 | 듀크 유니버시티 | 자가면역질환에 대한 시약 및 치료 방법 |
| SI3031910T1 (en) | 2002-02-21 | 2018-05-31 | Institute Of Virology Slovak Academy Of Sciences | MN / CA IX-SPECIFIC MONOCLONIC PROTECTOR GENERATED FROM MN / CA- DEFROSTABLE MICE AND METHOD OF APPLICATION |
| US20040025194A1 (en) * | 2002-02-22 | 2004-02-05 | Board Of Trustees Of The University Of Illinois | Beta chain-associated regulator of apoptosis |
| US7662924B2 (en) * | 2002-02-22 | 2010-02-16 | The Board Of Trustees Of The University Of Illinois | Beta chain-associated regulator of apoptosis |
| EP1575480A4 (en) | 2002-02-22 | 2008-08-06 | Genentech Inc | COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM |
| WO2003093452A2 (en) * | 2002-02-26 | 2003-11-13 | University Of Utah Research Foundation | Variants of nedd4l associated with hypertension and viral budding |
| US20100311954A1 (en) * | 2002-03-01 | 2010-12-09 | Xencor, Inc. | Optimized Proteins that Target Ep-CAM |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| CN1649902B (zh) * | 2002-03-01 | 2011-04-13 | 免疫医疗公司 | 内在化抗-cd74抗体和使用方法 |
| US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| US20090042291A1 (en) * | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
| US8361464B2 (en) | 2002-03-01 | 2013-01-29 | Immunomedics, Inc. | Anthracycline-Antibody Conjugates for Cancer Therapy |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7332276B2 (en) | 2002-03-01 | 2008-02-19 | Celltech R&D, Inc. | Methods to increase or decrease bone density |
| US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| GB0205022D0 (en) | 2002-03-04 | 2002-04-17 | Univ Cambridge Tech | Materials and methods for the treatment of cns damage |
| EP1480666B1 (en) | 2002-03-05 | 2012-06-13 | Ramot at Tel-Aviv University Ltd. | Immunizing composition and method for inducing an immune response against the beta-secretase cleavage site of amyloid precursor protein |
| PL374386A1 (en) | 2002-03-11 | 2005-10-17 | Philogen S.P.A. | Selective targeting of tumor vasculature using antibody molecules |
| MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| US6703216B2 (en) | 2002-03-14 | 2004-03-09 | The Regents Of The University Of California | Methods, compositions and apparatuses for detection of gamma-hydroxybutyric acid (GHB) |
| WO2003079982A2 (en) * | 2002-03-19 | 2003-10-02 | Tularik Inc. | Gene amplification in cancer |
| WO2003081211A2 (en) * | 2002-03-19 | 2003-10-02 | Cengent Therapeutics, Inc. | Discrete bayesian analysis of data |
| EP1494711A4 (en) * | 2002-03-19 | 2008-05-28 | Abgenix Inc | METHODS FOR TREATING CHRONIC OBSTRUCTIVE BRONCHO PNEUMOPATHY (COPD) |
| US20030182669A1 (en) * | 2002-03-19 | 2003-09-25 | Rockman Howard A. | Phosphoinositide 3-kinase mediated inhibition of GPCRs |
| AU2003218350A1 (en) | 2002-03-21 | 2003-10-08 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
| CA2480404A1 (en) * | 2002-03-25 | 2003-10-30 | Uab Research Foundation | Fc receptor homolog, reagents, and uses thereof |
| US7384738B2 (en) * | 2002-03-28 | 2008-06-10 | Bremel Robert D | Retrovirus-based genomic screening |
| US20040038304A1 (en) * | 2002-03-28 | 2004-02-26 | Gala Design, Inc. | Antibody libraries |
| EP1497445A2 (en) * | 2002-04-01 | 2005-01-19 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
| GB0207533D0 (en) | 2002-04-02 | 2002-05-08 | Oxford Glycosciences Uk Ltd | Protein |
| US7718776B2 (en) * | 2002-04-05 | 2010-05-18 | Amgen Inc. | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
| US7244565B2 (en) | 2002-04-10 | 2007-07-17 | Georgetown University | Gene shinc-3 and diagnostic and therapeutic uses thereof |
| US7138512B2 (en) * | 2002-04-10 | 2006-11-21 | Georgetown University | Gene SHINC-2 and diagnostic and therapeutic uses thereof |
| DK1501856T3 (da) | 2002-04-10 | 2013-03-25 | Genentech Inc | Anti-HER2 antistofvarianter |
| US20040048312A1 (en) * | 2002-04-12 | 2004-03-11 | Ronghao Li | Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof |
| EP1571968A4 (en) | 2002-04-16 | 2007-10-17 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS |
| US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
| ATE514707T1 (de) | 2002-04-19 | 2011-07-15 | Univ Toronto | Immunologisches verfahren und zusammensetzungen für die behandlung der krankheit von alzheimer |
| EP1501369B1 (en) | 2002-04-26 | 2015-06-24 | Genentech, Inc. | Non-affinity purification of proteins |
| AU2003221575B2 (en) | 2002-05-02 | 2010-06-10 | Dalia Barsyte | Teneurin C-terminal associated peptides (TCAP) and uses thereof |
| EP1501544A4 (en) * | 2002-05-03 | 2006-06-21 | Raven Biotechnologies Inc | ALCAM AND ALCAM MODULATORS |
| EP1504034B1 (en) | 2002-05-06 | 2012-12-12 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies |
| US20090068178A1 (en) * | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| HUE027779T2 (en) | 2002-05-09 | 2016-11-28 | Brigham & Womens Hospital Inc | 1L1RL-1 is a marker of cardiovascular disease |
| ATE530577T1 (de) * | 2002-05-10 | 2011-11-15 | Purdue Research Foundation | Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren |
| US20050152899A1 (en) * | 2002-05-10 | 2005-07-14 | Kinch Michael S. | EphA2 agonistic monoclonal antibodies and methods of use thereof |
| ATE525398T1 (de) * | 2002-05-10 | 2011-10-15 | Medimmune Inc | Epha2 monoklonale antikörper und deren anwendungsverfahren |
| US20030228317A1 (en) * | 2002-05-22 | 2003-12-11 | Prafulla Gokhale | Gene BRCC-1 and diagnostic and therapeutic uses thereof |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| EP2316921B1 (en) | 2002-05-24 | 2014-05-14 | Merck Sharp & Dohme Corp. | Neutralizing human anti-IGFR antibody |
| US7351803B2 (en) * | 2002-05-30 | 2008-04-01 | Macrogenics, Inc. | CD16A binding proteins and use for the treatment of immune disorders |
| EP1513879B1 (en) * | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
| EP2305710A3 (en) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetic antibody phage libraries |
| JP4643255B2 (ja) * | 2002-06-10 | 2011-03-02 | バクシネックス インコーポレーティッド | 乳癌および膀胱癌において差次的に発現される遺伝子ならびにコードされるポリペプチド |
| AU2003231912A1 (en) * | 2002-06-12 | 2003-12-31 | Tel Aviv Medical Center Research Development Fund | Methods of detecting and treating prostate cancer |
| AU2003276679A1 (en) * | 2002-06-13 | 2003-12-31 | Chiron Corporation | Vectors for expression of hml-2 polypeptides |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| EP2801616A1 (en) | 2002-06-17 | 2014-11-12 | Thrasos Innovation, Inc. | Single domain TDF-related compounds and analogs thereof |
| EP2277917A3 (en) * | 2002-06-19 | 2012-07-11 | Raven Biotechnologies, Inc. | B7-H3L cell surface target and a family of antibodies recognizing that target |
| US8029803B2 (en) | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| US8025873B2 (en) | 2002-06-20 | 2011-09-27 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| US7144950B2 (en) | 2003-09-17 | 2006-12-05 | The Regents Of The University Of California | Conformationally flexible cationic conjugated polymers |
| US7582313B2 (en) * | 2002-06-27 | 2009-09-01 | The General Hospital Corporation | Methods of organ regeneration using Hox 11-expressing pluripotent cells |
| US7628988B2 (en) * | 2002-06-27 | 2009-12-08 | The General Hospital Corporation | Methods and compositions for treating type 1 diabetes |
| WO2004003155A2 (en) | 2002-06-28 | 2004-01-08 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors |
| US7455834B2 (en) | 2002-06-29 | 2008-11-25 | Genentech, Inc. | Methods and compositions for modulating and detecting WISP activity |
| AU2003280442B2 (en) * | 2002-07-01 | 2009-02-05 | Wilex Ag | Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas |
| AU2003247806B2 (en) * | 2002-07-08 | 2009-11-12 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| KR20050037552A (ko) | 2002-07-15 | 2005-04-22 | 와이어쓰 | Ｔ 헬퍼(ｔｈ) 세포 발생 및 기능을 조절하는 방법 및조성물 |
| JP4827411B2 (ja) | 2002-07-15 | 2011-11-30 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 陰イオン性リン脂質およびアミノリン脂質に結合する選択された抗体およびデュラマイシンペプチド、ならびにウイルス感染の処置におけるそれらの使用 |
| CN102295703A (zh) | 2002-07-15 | 2011-12-28 | 健泰科生物技术公司 | 鉴定对用抗ErbB2抗体处理响应的肿瘤的方法 |
| CA2965865C (en) * | 2002-07-18 | 2021-10-19 | Merus N.V. | Recombinant production of mixtures of antibodies |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| US7435419B2 (en) | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
| EP1525311A2 (en) * | 2002-07-19 | 2005-04-27 | Cellzome Ag | Protein complexes of the tip60 transcriptional activator protein as well as components, fragments and derivatives thereof and methods for using the same |
| US20040132058A1 (en) | 2002-07-19 | 2004-07-08 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
| ES2534294T3 (es) | 2002-07-19 | 2015-04-21 | Beth Israel Deaconess Medical Center | Métodos para tratar la preeclampsia |
| US7250551B2 (en) * | 2002-07-24 | 2007-07-31 | President And Fellows Of Harvard College | Transgenic mice expressing inducible human p25 |
| US7794716B2 (en) | 2002-07-25 | 2010-09-14 | Glenveigh Pharmaceuticals, Llc | Antibody composition and passive immunization against pregnancy-induced hypertension |
| US20040018497A1 (en) * | 2002-07-26 | 2004-01-29 | Warden Craig H | Human obesity LIPIN3 polynucleotide and polypeptide sequences and methods of use thereof |
| WO2004011637A2 (en) * | 2002-07-29 | 2004-02-05 | Wyeth | Modified adamts4 molecules and method of use thereof |
| EP2357006B1 (en) | 2002-07-31 | 2015-09-16 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| EP1572121B1 (en) | 2002-08-01 | 2012-01-11 | The Regents of The University of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| EP1575992A4 (en) | 2002-08-05 | 2007-02-21 | Univ Rochester | CHIMERIC PROTEINS WITH PROTEIN TRANSDUCTION FIELD / DOMAINE DESAMINASE, ASSOCIATED COMPOUNDS AND CORRESPONDING USES |
| WO2004013290A2 (en) * | 2002-08-05 | 2004-02-12 | Invitrogen Corporation | Compositions and methods for molecular biology |
| WO2004015063A2 (en) * | 2002-08-07 | 2004-02-19 | Tularik Inc. | Amplification and overexpression of oncogenes |
| DK1534736T3 (da) * | 2002-08-10 | 2010-09-20 | Biogen Idec Inc | Nogo-receptorantagonister |
| US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
| AU2003262650B2 (en) | 2002-08-14 | 2009-10-29 | Macrogenics, Inc. | FcgammaRIIB-specific antibodies and methods of use thereof |
| AU2003264009A1 (en) * | 2002-08-15 | 2004-03-03 | Epitomics, Inc. | Humanized rabbit antibodies |
| DK2305800T3 (en) | 2002-08-16 | 2015-08-24 | Danisco Us Inc | NOVEL Hypocrea JECORINA CBH CELLULASEVARIANTER |
| WO2004016643A2 (en) | 2002-08-16 | 2004-02-26 | Yeda Research And Development Co. Ltd. | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines |
| US20050233473A1 (en) * | 2002-08-16 | 2005-10-20 | Zyomyx, Inc. | Methods and reagents for surface functionalization |
| AU2003265556A1 (en) | 2002-08-20 | 2004-03-11 | Millenium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| GB0219524D0 (en) | 2002-08-21 | 2002-10-02 | Queen Mary & Westfield College | Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor |
| WO2004019861A2 (en) * | 2002-08-28 | 2004-03-11 | Pharmacia Corporation | Stable ph optimized formulation of a modified antibody |
| US20040247588A1 (en) * | 2002-08-28 | 2004-12-09 | Johnson Robert E. | Formulations of modified antibodies and methods of making the same |
| EP1575515A4 (en) * | 2002-08-29 | 2007-08-08 | Genentech Inc | ACHAETE-SCUTE-SIMILAR 2 POLYPEPTIDES AND CODING NUCLEIC ACIDS AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF A TUMOR |
| US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
| WO2004022595A1 (ja) | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | MRL/lprマウスを用いた抗体の作製 |
| WO2004022097A1 (en) * | 2002-09-05 | 2004-03-18 | Medimmune, Inc. | Methods of preventing or treating cell malignancies by administering cd2 antagonists |
| CA2497884C (en) | 2002-09-06 | 2013-10-22 | Brian Varnum | Therapeutic human anti-il-1r1 monoclonal antibody |
| US20080260744A1 (en) | 2002-09-09 | 2008-10-23 | Omeros Corporation | G protein coupled receptors and uses thereof |
| US20040171809A1 (en) | 2002-09-09 | 2004-09-02 | Korsmeyer Stanley J. | BH3 peptides and method of use thereof |
| US20060134109A1 (en) * | 2002-09-09 | 2006-06-22 | Nura Inc. | G protein coupled receptors and uses thereof |
| DE60335552D1 (de) | 2002-09-11 | 2011-02-10 | Genentech Inc | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen |
| ES2629602T5 (es) | 2002-09-11 | 2021-06-08 | Genentech Inc | Purificación de proteínas |
| EP1578373A4 (en) | 2002-09-11 | 2007-10-24 | Genentech Inc | NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM |
| AU2003295330A1 (en) * | 2002-09-16 | 2004-05-04 | Elusys Therapeutics, Inc. | Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment |
| US20040053359A1 (en) * | 2002-09-18 | 2004-03-18 | Thomas Ryll | Method for production of a multimeric protein by cell fusion |
| US20040053363A1 (en) * | 2002-09-18 | 2004-03-18 | Thomas Ryll | Method for production of a multimeric protein by cell fusion |
| EP1545575A4 (en) | 2002-09-19 | 2006-04-05 | Us Gov Health & Human Serv | POLYPEPTIDES OF P. ARIASI POLYPEPTIDES P. PERNICIOSUS AND METHODS OF USE |
| WO2004028479A2 (en) | 2002-09-25 | 2004-04-08 | Genentech, Inc. | Nouvelles compositions et methodes de traitement du psoriasis |
| EP2371955A1 (en) | 2002-09-26 | 2011-10-05 | K.U. Leuven Research & Development | Integrase cofactor |
| EP2042517B1 (en) | 2002-09-27 | 2012-11-14 | Xencor, Inc. | Optimized FC variants and methods for their generation |
| KR20050046751A (ko) * | 2002-09-27 | 2005-05-18 | 오리디스 비오메드 포르슝스-운트 엔트비크룽스 게엠베하 | 폴리펩티드 및 이들을 암호화하는 핵산 및 간질환 및 상피세포암을 예방, 진단 또는 치료하기 위한 이들의 용도 |
| US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| US7541440B2 (en) * | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
| AU2003283995A1 (en) * | 2002-09-30 | 2004-04-19 | Protein Design Labs, Inc. | Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes |
| EP1556403A4 (en) * | 2002-10-03 | 2006-06-28 | Large Scale Biology Corp | ENGINEERING MULTIMERIC PROTEINS |
| WO2004032852A2 (en) * | 2002-10-04 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists |
| EP1570045A4 (en) * | 2002-10-04 | 2007-09-05 | Univ Minnesota | NUCLEIC ACID AND POLYPEPTIDE SEQUENCES FROM LAWSONIA INTRACELLULARIS AND METHOD OF USE |
| US7255860B2 (en) | 2002-10-08 | 2007-08-14 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| PT1556083E (pt) * | 2002-10-08 | 2011-03-17 | Rinat Neuroscience Corp | Métodos para tratar a dor pós-cirúrgica pela administração de um anticorpo contra o factor de crescimento nervoso e composições que contêm o mesmo |
| WO2004032868A2 (en) * | 2002-10-09 | 2004-04-22 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
| GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| US7396913B2 (en) * | 2002-10-14 | 2008-07-08 | Abbott Laboratories | Erythropoietin receptor binding antibodies |
| US7229762B2 (en) * | 2002-10-15 | 2007-06-12 | Duke University Medical Center | Proteomic screening for redox state dependent protein—protein interactions |
| AU2003294232A1 (en) | 2002-10-16 | 2004-05-04 | Euro-Celtique S.A. | Antibodies that bind cell-associated CA 125/O722P and methods of use thereof |
| JP2006515318A (ja) * | 2002-10-29 | 2006-05-25 | ファルマシア・コーポレーション | 特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法 |
| EP2322201A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004039958A2 (en) | 2002-10-29 | 2004-05-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Lutzomyia longipalpis polypeptides and methods of use |
| EP1578447A4 (en) | 2002-10-31 | 2009-06-03 | Genentech Inc | METHODS AND COMPOSITIONS THAT CAN INCREASE ANTIBODY PRODUCTION |
| EP1629090B1 (en) * | 2002-11-06 | 2014-03-05 | iBio, Inc. | Expression of foreign sequences in plants using trans-activation system |
| US8278079B2 (en) | 2002-11-07 | 2012-10-02 | Danisco Us Inc. | BGL6 β-glucosidase and nucleic acids encoding the same |
| US7582462B2 (en) * | 2002-11-07 | 2009-09-01 | Danisco Us Inc., Genencor Division | BGL6 beta-glucosidase and nucleic acids encoding the same |
| JP2006516094A (ja) | 2002-11-08 | 2006-06-22 | ジェネンテック・インコーポレーテッド | ナチュラルキラー細胞関連疾患の治療のための組成物と方法 |
| US7491509B2 (en) | 2003-02-03 | 2009-02-17 | Fraunhofer Usa, Inc. | System for expression of genes in plants |
| US7692063B2 (en) | 2002-11-12 | 2010-04-06 | Ibio, Inc. | Production of foreign nucleic acids and polypeptides in sprout systems |
| US7683238B2 (en) * | 2002-11-12 | 2010-03-23 | iBio, Inc. and Fraunhofer USA, Inc. | Production of pharmaceutically active proteins in sprouted seedlings |
| AU2003295474B2 (en) * | 2002-11-13 | 2009-07-30 | Macrogenics West, Inc. | Antigen PIPA and antibodies that bind thereto |
| US20060009378A1 (en) | 2002-11-14 | 2006-01-12 | Itshak Golan | Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases |
| WO2004045532A2 (en) | 2002-11-15 | 2004-06-03 | Chiron Corporation | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| US9233120B2 (en) | 2002-11-15 | 2016-01-12 | Jyant Technologies | Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration |
| US8658377B2 (en) | 2002-11-15 | 2014-02-25 | Morehouse School Of Medicine | Detecting cancer with anti-CCL25 and anti-CCR9 antibodies |
| US20040229785A1 (en) * | 2002-11-15 | 2004-11-18 | Denise Faustman | Screening methods to identify treatments for autoimmune disease |
| US8512701B2 (en) | 2002-11-15 | 2013-08-20 | Morehouse School Of Medicine | Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration |
| AU2003294315A1 (en) * | 2002-11-19 | 2004-06-15 | Amgen Inc. | Amplified genes involved in cancer |
| WO2004048552A2 (en) | 2002-11-21 | 2004-06-10 | Celltech R & D, Inc. | Modulating immune responses |
| US7407788B2 (en) * | 2002-11-21 | 2008-08-05 | Danisco A/S, Genencor Division | BGL7 beta-glucosidase and nucleic acids encoding the same |
| EP2112229A3 (en) | 2002-11-25 | 2009-12-02 | Sequenom, Inc. | Methods for identifying risk of breast cancer and treatments thereof |
| US7597936B2 (en) | 2002-11-26 | 2009-10-06 | University Of Utah Research Foundation | Method of producing a pigmented composite microporous material |
| KR20050089151A (ko) | 2002-11-26 | 2005-09-07 | 프로테인 디자인 랩스 인코포레이티드 | 혈관형성을 조절하는 α5β1 인테그린에 대한 키메라성 및인간화 항체 |
| WO2004048936A2 (en) * | 2002-11-26 | 2004-06-10 | University Of Utah Research Foundation | Microporous materials, methods, and articles for localizing and quantifying analytes |
| AU2003302386B2 (en) | 2002-11-26 | 2010-04-01 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| CA2537263C (en) | 2002-11-27 | 2017-05-30 | Minerva Biotechnologies Corporation | Techniques and compositions for the diagnosis and treatment of cancer (muc1) |
| WO2004053066A2 (en) | 2002-12-06 | 2004-06-24 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy |
| US7491699B2 (en) | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
| US8420086B2 (en) | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
| US7056702B2 (en) * | 2002-12-16 | 2006-06-06 | Kimberly Clark Co | Detecting lipocalin |
| DK1572748T3 (da) | 2002-12-17 | 2010-08-23 | Merck Patent Gmbh | Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2 |
| AU2002953431A0 (en) * | 2002-12-19 | 2003-01-09 | Murdoch University | BmpB Novel Nucleotide and Amino Acid Sequences and Diagnostic and Therapeutic Uses Thereof |
| US7482117B2 (en) | 2002-12-20 | 2009-01-27 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
| US9487823B2 (en) | 2002-12-20 | 2016-11-08 | Qiagen Gmbh | Nucleic acid amplification |
| DE60333035D1 (de) | 2002-12-23 | 2010-07-29 | Vical Inc | Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden |
| US7332156B2 (en) | 2002-12-23 | 2008-02-19 | Schering Corporation | Methods of treating wounds using IL-23 |
| AU2003300397A1 (en) * | 2002-12-23 | 2004-07-22 | Rinat Neuroscience Corp. | Methods for treating taxol-induced sensory neuropathy |
| PL215171B1 (pl) | 2002-12-24 | 2013-10-31 | Rinat Neuroscience Corp | Przeciwcialo przeciw czynnikowi wzrostu nerwów (NGF) lub jego fragment, kompozycja farmaceutyczna, zestaw, sposób wytwarzania przeciwciala lub jego fragmentu, zastosowanie skutecznej ilosci antagonistycznego przeciwciala anty-NGF lub jego fragmentu, zastosowanie antagonistycznego przeciwciala anty-NGF lub jego fragmentu, izolowany polinukleotyd zawierajacy sekwencje nukleotydowa kodujaca przeciwcialo lub jego fragment, wektor oraz komórka gospodarza zawierajaca polinukleotyd |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| US7569364B2 (en) * | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| CA2511823A1 (en) | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
| US20050265992A1 (en) | 2003-01-03 | 2005-12-01 | The Research Foundation Of State University Of New York | F11 receptor (F11R) antagonists as therapeutic agents |
| US8557957B2 (en) | 2003-01-03 | 2013-10-15 | Elizabeth Kornecki | Methods of treating disorders by administration of F11 receptor antagonists |
| WO2004060791A1 (en) | 2003-01-07 | 2004-07-22 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures encapsulating a foreign material and method of manufacturing same |
| ES2897506T3 (es) | 2003-01-09 | 2022-03-01 | Macrogenics Inc | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos |
| CA2513025A1 (en) * | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | Dual expression vector system for antibody expression in bacterial and mammalian cells |
| EP1585767A2 (en) * | 2003-01-16 | 2005-10-19 | Genentech, Inc. | Synthetic antibody phage libraries |
| MXPA05007653A (es) * | 2003-01-17 | 2005-09-30 | Danisco | Metodo. |
| US20050196766A1 (en) * | 2003-12-24 | 2005-09-08 | Soe Jorn B. | Proteins |
| SI1619961T1 (sl) | 2003-01-17 | 2011-03-31 | Danisco | Postopek za proizvodnjo in situ emulgatorja v Ĺľivilu |
| JP2006525792A (ja) | 2003-01-17 | 2006-11-16 | ザ ジョンズ ホプキンス ユニバーシティー | Ｇｔｒａｐ３−１８を用いた細胞グリコシル化のモジュレーターを同定する方法 |
| US7955814B2 (en) * | 2003-01-17 | 2011-06-07 | Danisco A/S | Method |
| US20040197629A1 (en) * | 2003-01-20 | 2004-10-07 | Yasuo Arishima | Electric power generating element for fuel cell and fuel cell using the same |
| WO2004065551A2 (en) * | 2003-01-21 | 2004-08-05 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (mgat3), and uses thereof |
| AU2004205684A1 (en) * | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| RS20050577A (en) * | 2003-01-27 | 2007-09-21 | Biogen Idec Ma Inc., | Compositions and methods for treating cancer using igsf9 and liv-1 |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| CN1745175A (zh) * | 2003-02-01 | 2006-03-08 | 神经实验室有限公司 | 自动免疫产生针对可溶性A－β的抗体 |
| WO2004070011A2 (en) | 2003-02-01 | 2004-08-19 | Tanox, Inc. | HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES |
| ES2427853T3 (es) | 2003-02-07 | 2013-11-04 | Diagnocure Inc. | Procedimiento para detectar cáncer de próstata en una muestra |
| CN110496230A (zh) | 2003-02-11 | 2019-11-26 | 夏尔人类遗传性治疗公司 | 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗 |
| US7767387B2 (en) * | 2003-06-13 | 2010-08-03 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
| EP1638587A4 (en) | 2003-02-14 | 2007-04-18 | Univ Missouri | RECIPROCAL PROCEDURES AND COMPOSITIONS CONCERNING PROTEASOMAL INTERFERENCE |
| US8795672B2 (en) * | 2003-02-14 | 2014-08-05 | University Of Southern California | Compositions and methods for cancer immunotherapy |
| US20070218071A1 (en) * | 2003-09-15 | 2007-09-20 | Morris David W | Novel therapeutic targets in cancer |
| BRPI0407375A (pt) * | 2003-02-19 | 2006-02-07 | Rinat Neuroscience Corp | Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos |
| EP2289559B1 (en) | 2003-02-20 | 2014-02-12 | Seattle Genetics, Inc. | Anit-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| WO2004075837A2 (en) | 2003-02-21 | 2004-09-10 | Tanox, Inc. | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| EP1594541A4 (en) * | 2003-02-21 | 2007-03-28 | Rikshospitalet Radiumhospitale | METHOD AND COMPOSITIONS FOR TREATING MECONIUM ASPIRATION SYNDROME |
| AU2004214977B2 (en) * | 2003-02-21 | 2008-05-08 | The Queen's Medical Center | Methods of screening for TRPM5 modulators |
| US8388955B2 (en) * | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US20070275460A1 (en) * | 2003-03-03 | 2007-11-29 | Xencor.Inc. | Fc Variants With Optimized Fc Receptor Binding Properties |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| WO2004081229A2 (en) | 2003-03-12 | 2004-09-23 | Genentech, Inc. | Use of bv8 and/or eg-vegf to promote hematopoiesis |
| US8017113B2 (en) | 2003-03-12 | 2011-09-13 | Rappaport Family Institute For Research In The Medical Sciences | Compositions and methods for diagnosing and treating an inflammation |
| US7741065B2 (en) * | 2003-03-13 | 2010-06-22 | Ramot At Tel Aviv University Ltd. | Non-invasive marker for liver function and disease |
| US20040180387A1 (en) * | 2003-03-13 | 2004-09-16 | Fujirebio Diagnostics, Inc. | Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer |
| BRPI0408315A (pt) | 2003-03-14 | 2006-03-07 | Wyeth Corp | anticorpo isolado, composição farmacêutica, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos de produzir um anticorpo, de gerar um anticorpo ou fragmento de ligação de antìgeno, de regular uma resposta imune, de tratar ou prevenir um distúrbio associado com célula imune em um paciente, de tratar ou prevenir um distúrbio hiperproliferativo em um paciente, e, kit de diagnóstico |
| DE10311248A1 (de) * | 2003-03-14 | 2004-09-30 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper |
| EP2248899B8 (en) | 2003-03-19 | 2015-07-15 | Biogen MA Inc. | NOGO receptor binding protein |
| WO2004083865A2 (en) | 2003-03-20 | 2004-09-30 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Materials and methods for modulating cell motility |
| EP1622941A2 (en) * | 2003-03-20 | 2006-02-08 | ImClone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
| EP1620127A4 (en) * | 2003-03-20 | 2007-04-04 | Rinat Neuroscience Corp | METHOD FOR TREATING TAXOL-INDUCED ANTI-FERROUS DISORDER |
| WO2004088326A2 (en) | 2003-03-28 | 2004-10-14 | Aphton Corporation | Gastrin hormone immunoassays |
| US8043834B2 (en) * | 2003-03-31 | 2011-10-25 | Qiagen Gmbh | Universal reagents for rolling circle amplification and methods of use |
| AU2003237792A1 (en) | 2003-04-01 | 2004-11-23 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| JPWO2004089419A1 (ja) | 2003-04-04 | 2006-07-06 | 国立大学法人 東京大学 | 抗ｍｔ−ｍｍｐモノクローナル抗体含有脂質膜構造体 |
| SI2335725T1 (sl) | 2003-04-04 | 2017-01-31 | Genentech, Inc. | Visokokoncentrirane formulacije protiteles in proteinov |
| EP1610678B1 (en) | 2003-04-04 | 2011-07-27 | Yeda Research And Development Co., Ltd. | Antibodies for inhibiting the activity of mmp-2 and mmp-9 |
| ZA200507805B (en) | 2003-04-09 | 2006-12-27 | Genentech Inc | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor |
| US20050059592A1 (en) * | 2003-04-11 | 2005-03-17 | Kiener Peter A. | EphA2 and hyperproliferative cell disorders |
| EP2316487B1 (en) | 2003-04-11 | 2014-06-11 | MedImmune, LLC | Recombinant IL-9 antibodies & uses thereof |
| US20050049176A1 (en) * | 2003-04-11 | 2005-03-03 | Kiener Peter A. | EphA2, hypoproliferative cell disorders and epithelial and endothelial reconstitution |
| SE0301087D0 (sv) | 2003-04-14 | 2003-04-14 | Cartela Ab | New monoclonal antibody |
| US20060140963A1 (en) * | 2003-04-14 | 2006-06-29 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
| US20080213169A1 (en) * | 2003-04-14 | 2008-09-04 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
| AT500650B1 (de) | 2003-04-17 | 2009-11-15 | Altropus Gmbh | Immunogener rekombinanter antikörper |
| BRPI0410495A (pt) * | 2003-04-23 | 2006-06-13 | Medarex Inc | composição para o tratamento de uma doença inflamatória dos intestinos e uso de um antagonista de interferon tipo i para preparar um medicamento |
| ES2368737T3 (es) * | 2003-04-23 | 2011-11-21 | Medarex, Inc. | Anticuerpos humanizados contra el receptor de interferon alfa 1 (ifnar-1). |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| WO2004098634A2 (en) * | 2003-04-30 | 2004-11-18 | Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health | Protein arginine n-methyltransferase 2 (prmt-2) |
| PL2382990T3 (pl) | 2003-04-30 | 2015-04-30 | Univ Zuerich | Sposoby leczenia raka z zastosowaniem immunotoksyny |
| US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| NZ568403A (en) | 2003-05-09 | 2009-10-30 | Univ Duke | CD20-specific antibodies and methods of employing same |
| WO2004106384A1 (en) | 2003-05-12 | 2004-12-09 | Natimmune A/S | Antibodies to masp-2 |
| US7566447B2 (en) | 2003-05-15 | 2009-07-28 | Iogenetics, Llc | Biocides |
| MXPA05011886A (es) | 2003-05-15 | 2006-02-17 | Tanox Inc | Metodos y composiciones para la prevencion y tratamiento de septicemia. |
| US20050014932A1 (en) * | 2003-05-15 | 2005-01-20 | Iogenetics, Llc | Targeted biocides |
| US8394379B2 (en) | 2003-05-15 | 2013-03-12 | Iogenetics, Llc | Targeted cryptosporidium biocides |
| US8703134B2 (en) | 2003-05-15 | 2014-04-22 | Iogenetics, Llc | Targeted cryptosporidium biocides |
| US8080642B2 (en) | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
| US7892563B2 (en) | 2003-05-20 | 2011-02-22 | Wyeth Holdings Corporation | Methods for treatment of severe acute respiratory syndrome (SARS) |
| CA2526720C (en) | 2003-05-22 | 2013-10-22 | Fraunhofer Usa, Inc. | Recombinant carrier molecule for expression, delivery and purification of target polypeptides |
| WO2004111192A2 (en) | 2003-05-29 | 2004-12-23 | The Scripps Research Institute | Targeted delivery to legumain-expressing cells |
| TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
| EP2395017A3 (en) | 2003-05-30 | 2012-12-19 | Merus B.V. | Design and use of paired variable regions of specific binding molecules |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| RS20050885A (sr) | 2003-05-30 | 2008-04-04 | Genentech | Lečenje sa anti-vegf antitelima |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| JP4644663B2 (ja) * | 2003-06-03 | 2011-03-02 | セル ジェネシス インコーポレイテッド | ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法 |
| US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| US7485291B2 (en) | 2003-06-03 | 2009-02-03 | Cell Genesys, Inc. | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof |
| US7405274B2 (en) | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
| US20050163775A1 (en) * | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
| JP2007526220A (ja) * | 2003-06-05 | 2007-09-13 | ジェネンテック・インコーポレーテッド | Ｂ細胞疾患の併用療法 |
| CN1279056C (zh) * | 2003-06-06 | 2006-10-11 | 马菁 | 肿瘤相关抗原sm5－1的特异性抗体及其应用 |
| KR20110117728A (ko) | 2003-06-06 | 2011-10-27 | 제넨테크, 인크. | Ｈｇｆ 베타 쇄와 ｃ-ｍｅｔ 사이의 상호작용의 변조 |
| US20050232926A1 (en) * | 2003-06-06 | 2005-10-20 | Oncomax Acquisition Corp. | Antibodies specific for cancer associated antigen SM5-1 and uses thereof |
| GB0313259D0 (en) | 2003-06-09 | 2003-07-16 | Consejo Superior Investigacion | Magnetic nanoparticles |
| US20040248323A1 (en) | 2003-06-09 | 2004-12-09 | Protometrix, Inc. | Methods for conducting assays for enzyme activity on protein microarrays |
| CA2542232A1 (en) | 2003-06-09 | 2005-01-20 | Alnylam Pharmaceuticals, Inc. | Method for treating neurodegenerative disease by inhibiting alpha-synuclein |
| KR20060015646A (ko) | 2003-06-13 | 2006-02-17 | 유니버시티 오브 피츠버그 | 면역, 혈액 및 염증성 질환의 모니터링 방법 |
| IL156495A0 (en) * | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
| ES2527102T3 (es) * | 2003-06-19 | 2015-01-20 | Genentech, Inc. | Composiciones y métodos para el tratamiento de trastornos relacionados con la coagulación |
| EP2657248B1 (en) | 2003-06-19 | 2017-03-22 | Genzyme Corporation | AAV virions with decreased immunoreactivity and uses therefor |
| US20050026194A1 (en) * | 2003-06-20 | 2005-02-03 | Tularik Inc. | Gene amplification and overexpression in cancer |
| US20050163782A1 (en) * | 2003-06-27 | 2005-07-28 | Biogen Idec Ma Inc. | Modified binding molecules comprising connecting peptides |
| GB0315450D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| KR101444717B1 (ko) | 2003-07-02 | 2014-09-26 | 노보 노르디스크 에이/에스 | Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법 |
| US20090191213A9 (en) | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
| EP3594228A1 (en) | 2003-07-08 | 2020-01-15 | Genentech, Inc. | Il-17a/f heterologous polypedtides and therapeutic uses thereof |
| WO2005010163A2 (en) * | 2003-07-15 | 2005-02-03 | Barros Research Institute | Compositions and methods for immunotherapy of human immunotherapy of human immunodeficiency virus (hiv) |
| GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| EP1644408A1 (en) * | 2003-07-15 | 2006-04-12 | Barros Research Institute | Eimeria tenella antigen for immunotherapy of coccidiosis |
| IL161903A0 (en) * | 2003-07-17 | 2005-11-20 | Gamida Cell Ltd | Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs |
| ES2523837T3 (es) | 2003-07-18 | 2014-12-01 | Amgen Inc. | Agentes de unión específica al factor de crecimiento de hepatocitos |
| US20050085420A1 (en) * | 2003-07-22 | 2005-04-21 | Stanley Korsmeyer | Method of modulating apoptosis and compositions thereof |
| KR101299599B1 (ko) | 2003-07-24 | 2013-08-23 | 위니베르시따 데글리 스뚜디 디 뻬루지아 | Ｎｋ 세포 강화 화합물을 사용하여 치료용 항체의 효율을 높이는 방법 및 조성물 |
| EP3722309A1 (en) | 2003-07-28 | 2020-10-14 | Genentech, Inc. | Reducing protein a leaching during protein a affinity chromatography |
| WO2005032582A2 (en) | 2003-07-31 | 2005-04-14 | Chiron Corporation | Immunogenic compositions for streptococcus pyogenes |
| US20050026881A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease |
| US20090263381A1 (en) * | 2003-07-31 | 2009-10-22 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
| EP1939779A3 (en) | 2003-08-01 | 2009-04-01 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
| AU2004261980A1 (en) * | 2003-08-01 | 2005-02-10 | Genentech, Inc. | Antibody CDR polypeptide sequences with restricted diversity |
| JP5576010B2 (ja) | 2003-08-04 | 2014-08-20 | ザ・ホスピタル・フォー・シック・チルドレン | ラフォラ病遺伝子 |
| US8007805B2 (en) | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
| US20050221383A1 (en) | 2003-08-08 | 2005-10-06 | Choong-Chin Liew | Osteoarthritis biomarkers and uses thereof |
| US20080153104A1 (en) | 2003-08-08 | 2008-06-26 | Hiroyuki Aburantai | Gene Overexpressed in Cancer |
| US20050079131A1 (en) * | 2003-08-08 | 2005-04-14 | Lanza Gregory M. | Emulsion particles for imaging and therapy and methods of use thereof |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20060035242A1 (en) | 2004-08-13 | 2006-02-16 | Michelitsch Melissa D | Prion-specific peptide reagents |
| CA2535901A1 (en) | 2003-08-14 | 2005-02-24 | Exelixis, Inc. | Ups as modifiers of the beta catenin pathway and methods of use |
| DE602004031024D1 (de) | 2003-08-15 | 2011-02-24 | Univ Florida | Die identifikation von polynukleotiden von porphyromonas gingivalis-virulenz zur diagnose, behandlung und beobachtung von periodontalerkrankungen |
| CA2536062A1 (en) * | 2003-08-18 | 2005-03-03 | Tethys Bioscience, Inc. | Methods for reducing complexity of a sample using small epitope antibodies |
| WO2005035575A2 (en) * | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| BRPI0413977A (pt) | 2003-08-27 | 2006-11-07 | Osi Eyetech Inc | método para suprimir um distúrbio neovascular, e para tratar um paciente diagnosticado com ou em risco de desenvolver um distúrbio neovascular, composição farmacêutica, e, embalagem farmacêutica |
| US7589181B2 (en) | 2003-08-29 | 2009-09-15 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use |
| US20050152894A1 (en) * | 2003-09-05 | 2005-07-14 | Genentech, Inc. | Antibodies with altered effector functions |
| TR200600945T1 (tr) * | 2003-09-05 | 2006-10-26 | The Scripps Research Institute | Terapötik usuller. |
| CA2537984A1 (en) * | 2003-09-05 | 2005-03-17 | The Scripps Research Institute | Detection of cholesterol ozonation products |
| US7046714B2 (en) * | 2003-09-10 | 2006-05-16 | Intel Corporation | Method and apparatus for Raman ring resonator based laser/wavelength converter |
| EP1514561A1 (en) | 2003-09-10 | 2005-03-16 | Philogen S.p.A. | Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B |
| GB0321997D0 (en) | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
| BRPI0414446A (pt) | 2003-09-18 | 2006-11-14 | Genmab As | métodos para triar um agente terapêutico, para a supressão da sequência de polinucleotìdeo, para o tratamento de um cáncer não dependente de esteróide, para triar a ligação de um agente especificamente a um polinucleotìdeo e para determinar se um paciente está em risco de desenvolver ou ter um cáncer não dependente de esteróide, composição farmacêutica, usos de um agente terapêutico, de uma molécula anti-sentido ou de uma célula que expressa e/ou contém a molécula anti-sentido, de pelo menos uma das proteìnas de membrana imunogênicas, fragmentos, derivados ou homólogos destas ou de uma célula que contém e/ou que expressa pelo menos uma das proteìnas de membranas imunogênicas ou fragmentos, derivados ou homólogos destas e de um agente ou anticorpo, agente, e, kit para identificar um paciente em risco de desenvolver ou ter cáncer não dependente de esteróide |
| SG146644A1 (en) * | 2003-09-18 | 2008-10-30 | Raven Biotechnologies Inc | Kid3 and kid3 antibodies that bind thereto |
| US20050282177A1 (en) * | 2003-09-22 | 2005-12-22 | Aichi Prefecture | Types of lymphoma and method for prognosis thereof |
| EP1673394A4 (en) * | 2003-09-23 | 2008-03-26 | Favrille Inc | MODIFICATION OF A LYMPHOCYTE B PATHOLOGY USING AUTODERATED ANTIGENS IN CONJUGATION WITH A SPECIFICALLY BINDING CYTOREDUCING AGENT |
| DK1842920T4 (da) | 2003-09-23 | 2017-08-21 | Univ North Carolina Chapel Hill | Celler der co-udtrykker K-vitaminreduktase og K-vitaminafhængigt protein, samt anvendelse deraf til at forbedre produktiviteten af det K-vitaminafhængige protein |
| US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US8101720B2 (en) * | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| US20070281896A1 (en) * | 2003-09-30 | 2007-12-06 | Morris David W | Novel compositions and methods in cancer |
| US7803624B2 (en) | 2003-09-30 | 2010-09-28 | Cytyc Corporation | Automated cytological sample classification |
| WO2005031362A2 (en) * | 2003-10-02 | 2005-04-07 | Ramot At Tel Aviv University Ltd. | Novel antibacterial agents and methods of identifying and utilizing same |
| KR20060120652A (ko) | 2003-10-07 | 2006-11-27 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 난소암의 확인, 평가, 예방 및 치료를 위한 핵산 분자 및단백질 |
| IL158287A0 (en) | 2003-10-07 | 2004-05-12 | Yeda Res & Dev | Antibodies to nik, their preparation and use |
| US20050287138A1 (en) * | 2003-10-08 | 2005-12-29 | Kyowa Hakko Kogyo Co., Ltd. | CCR4-specific antibody composition |
| US20050226867A1 (en) * | 2003-10-08 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | IL-5R-specific antibody composition |
| US20060021071A1 (en) * | 2003-10-09 | 2006-01-26 | Kyowa Hakko Kogyo Co., Ltd. | Cell in which genome is modified |
| US7691810B2 (en) * | 2003-10-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Method of producing recombinant antithrombin III composition |
| PL1673450T3 (pl) * | 2003-10-14 | 2010-10-29 | Baxalta Inc | Polipeptyd przekształcający epoksyd witaminy K VKORC1, obiekt działania leczniczego kumaryny i jej pochodnych |
| EP3412686A1 (en) | 2003-10-17 | 2018-12-12 | AlJamal-Naylor, Rehab | Tissue repair by modulation of beta-1 integrin biological function |
| IL158599A0 (en) * | 2003-10-26 | 2004-05-12 | Yeda Res & Dev | Methods of modulating hematopoiesis |
| US7304139B2 (en) * | 2003-10-28 | 2007-12-04 | University Of Florida Research Foundation, Inc. | Polynucleotides and polypeptides of Anaplasma phagocytophilum and methods of using the same |
| JP4765039B2 (ja) | 2003-11-04 | 2011-09-07 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Ｃｄ４０抗原を発現する癌に対する治療方法。 |
| PT1682177E (pt) | 2003-11-04 | 2010-11-29 | Xoma Technology Lt | Utilização de anticorpos antagonistas anti-cd40 para o tratamento da leucemia linfocítica crónica |
| PL1684805T3 (pl) | 2003-11-04 | 2010-12-31 | Novartis Vaccines & Diagnostics Inc | Sposoby leczenia szpiczaka mnogiego z zastosowaniem antagonistycznych monoklonalnych przeciwciał przeciwko CD40 |
| EP1844815B1 (en) | 2003-11-04 | 2011-09-14 | Novartis Vaccines and Diagnostics, Inc. | Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers |
| US20070098717A1 (en) | 2003-11-04 | 2007-05-03 | Chiron Corporation | Methods of therapy for solid tumors expressing the cd40 cell-surface antigen |
| WO2005044998A2 (en) | 2003-11-05 | 2005-05-19 | Palingen, Inc. | Enhanced b cell cytotoxicity of cdim binding antibody |
| EA025962B1 (ru) * | 2003-11-05 | 2017-02-28 | Роше Гликарт Аг | АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ |
| EP1725249B1 (en) | 2003-11-06 | 2014-01-08 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| US20060199194A1 (en) * | 2003-11-10 | 2006-09-07 | Q-Rna, Inc. | Methods of detection using immuno-Q-Amp technology |
| PE20090047A1 (es) | 2003-11-10 | 2009-01-26 | Schering Corp | Anticuerpo recombinante humanizado anti-interleuquina 10 |
| US20070276049A1 (en) | 2003-11-11 | 2007-11-29 | Schlievert Patrick M | Regulation of Cell Membrane-Mediated Effects |
| EP1687325A4 (en) * | 2003-11-12 | 2008-11-12 | Progenics Pharm Inc | NOVEL GLYCOPROTEIN CODING SEQUENCES OF HEPATITIS C VIRUS |
| EP1691836B1 (en) * | 2003-11-13 | 2012-02-22 | Sutter West Bay Hospitals | Anti-pecam therapy for metastasis suppression |
| JP5027512B2 (ja) | 2003-11-14 | 2012-09-19 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 免疫調節法 |
| DK2161283T3 (da) | 2003-11-17 | 2014-09-01 | Genentech Inc | SAMMENSÆTNINGER OMFATTENDE ANTISTOFFER MOD CD79b, SOM ER KONJUGERET TIL ET VÆKSTINHIBERENDE MIDDEL ELLER ET CYTOTOKSISK MIDDEL, OG FREMGANGSMÅDER TIL BEHANDLING AF TUMOR AF HÆMATOPOIETISK OPRINDELSE |
| CN1914226B (zh) * | 2003-11-25 | 2012-02-01 | 达纳-法伯癌症研究院有限公司 | SARS-CoV抗体及其使用方法 |
| CA2832293C (en) | 2003-11-26 | 2015-08-04 | Celera Corporation | Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof |
| DE10355904A1 (de) | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Feste Formen von anti-EGFR-Antikörpern |
| CA2547459C (en) | 2003-11-30 | 2013-10-08 | Yeda Research And Development Co. Ltd | Modulators of nik-siva complex formation for treating immune disorders |
| EP1694829B1 (fr) | 2003-12-02 | 2010-08-04 | Institut Pasteur | Nouvelle souche de coronavirus associe au sras et ses applications. |
| ATE526037T1 (de) * | 2003-12-04 | 2011-10-15 | Vaccinex Inc | Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen |
| US20060047436A1 (en) * | 2004-08-25 | 2006-03-02 | Ishikawa Muriel Y | System and method for magnifying an immune response |
| US20060122784A1 (en) * | 2004-12-03 | 2006-06-08 | Ishikawa Muriel Y | System and method for augmenting a humoral immune response |
| US20060095211A1 (en) * | 2003-12-05 | 2006-05-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | System and method for modulating a cell mediated immune response |
| US20060047437A1 (en) * | 2004-08-25 | 2006-03-02 | Ishikawa Muriel Y | System and method for heightening an immune response |
| US20060116824A1 (en) * | 2004-12-01 | 2006-06-01 | Ishikawa Muriel Y | System and method for modulating a humoral immune response |
| US20060122783A1 (en) * | 2004-08-24 | 2006-06-08 | Ishikawa Muriel Y | System and method for heightening a humoral immune response |
| US20060047434A1 (en) * | 2004-08-24 | 2006-03-02 | Ishikawa Muriel Y | System and method related to improving an immune system |
| US20060182742A1 (en) * | 2004-08-24 | 2006-08-17 | Ishikawa Muriel Y | System and method for magnifying a humoral immune response |
| US20060047435A1 (en) * | 2004-08-24 | 2006-03-02 | Ishikawa Muriel Y | System and method related to augmenting an immune system |
| US20070249809A1 (en) * | 2003-12-08 | 2007-10-25 | Xencor, Inc. | Protein engineering with analogous contact environments |
| AU2004299833B2 (en) | 2003-12-10 | 2009-05-07 | E. R. Squibb & Sons, L.L.C. | Interferon alpha antibodies and their uses |
| SI2383295T1 (sl) | 2003-12-10 | 2015-07-31 | E.R. Squibb & Sons, L.L.C. | Protitelesa IP-10 in njihova uporaba |
| US7312320B2 (en) | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
| EP1631311A4 (en) | 2003-12-10 | 2007-04-11 | Millennium Pharm Inc | HUMANIZED ANTI-CCR2 ANTIBODIES AND METHOD OF USE |
| AU2004298483A1 (en) | 2003-12-11 | 2005-06-30 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
| WO2005058961A2 (en) * | 2003-12-12 | 2005-06-30 | Amgen Inc. | Antibodies specific for human galanin, and uses thereof |
| US7427670B2 (en) * | 2003-12-19 | 2008-09-23 | Cytochroma Inc. | Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof |
| ZA200604864B (en) * | 2003-12-19 | 2007-10-31 | Genentech Inc | Monovalent antibody fragments useful as therapeutics |
| AU2004308439A1 (en) * | 2003-12-22 | 2005-07-14 | Centocor, Inc. | Methods for generating multimeric molecules |
| US8586357B2 (en) | 2003-12-23 | 2013-11-19 | Viacyte, Inc. | Markers of definitive endoderm |
| US20050266554A1 (en) * | 2004-04-27 | 2005-12-01 | D Amour Kevin A | PDX1 expressing endoderm |
| EA200601220A1 (ru) | 2003-12-23 | 2006-12-29 | Ринат Ньюросайенс Корп. | Анти-trkc антитела-агонисты и способы их применения |
| US7985585B2 (en) | 2004-07-09 | 2011-07-26 | Viacyte, Inc. | Preprimitive streak and mesendoderm cells |
| EP2722387B1 (en) * | 2003-12-23 | 2019-12-11 | Viacyte, Inc. | Definitive endoderm |
| US7625753B2 (en) * | 2003-12-23 | 2009-12-01 | Cythera, Inc. | Expansion of definitive endoderm cells |
| US7541185B2 (en) | 2003-12-23 | 2009-06-02 | Cythera, Inc. | Methods for identifying factors for differentiating definitive endoderm |
| US8647873B2 (en) | 2004-04-27 | 2014-02-11 | Viacyte, Inc. | PDX1 expressing endoderm |
| ATE552850T1 (de) | 2003-12-23 | 2012-04-15 | Genentech Inc | Neue anti-il 13-antikörper und verwendungen dafür |
| US7718408B2 (en) * | 2003-12-24 | 2010-05-18 | Danisco A/S | Method |
| DK2119771T3 (en) | 2003-12-24 | 2018-12-10 | Dupont Nutrition Biosci Aps | PROTEINS |
| GB0716126D0 (en) * | 2007-08-17 | 2007-09-26 | Danisco | Process |
| ES2387028T3 (es) * | 2003-12-31 | 2012-09-12 | Merck Patent Gmbh | Proteína de fusión de Fc-eritropoyetina con farmacocinética mejorada |
| US20090324604A1 (en) | 2004-01-07 | 2009-12-31 | Chiron Corporation | M-csf specific monoclonal antibody and uses thereof |
| US20050221429A1 (en) * | 2004-01-16 | 2005-10-06 | Cardinal Health Pts, Llc | Host cells containing multiple integrating vectors comprising an amplifiable marker |
| NZ548828A (en) | 2004-01-20 | 2009-07-31 | Merus B V | Mixtures of binding proteins |
| CA2554239C (en) | 2004-01-20 | 2015-05-12 | Sunnybrook And Women's College Health Sciences Centre | High frequency ultrasound imaging using contrast agents |
| US20060014211A1 (en) * | 2004-01-21 | 2006-01-19 | Fujirebio Diagnostics, Inc. | Detection of mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of the peritoneum and the peritoneal cavity |
| US7670771B2 (en) | 2004-01-21 | 2010-03-02 | University Of Utah Research Foundation | Mutant sodium channel Nav1.7 nucleic acid methods |
| JP2007535913A (ja) * | 2004-01-21 | 2007-12-13 | ノボザイムス アクティーゼルスカブ | ヘテロカリオン菌類又は菌類宿主細胞におけるモノクローナル抗体の生成 |
| JP4987484B2 (ja) | 2004-01-22 | 2012-07-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 補体結合が低下した抗癌抗体 |
| US7323551B2 (en) * | 2004-01-27 | 2008-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inhibiting squamous cell carcinoma |
| ATE546158T1 (de) * | 2004-01-27 | 2012-03-15 | Univ Southern California | Therapeutisches krebsmittel mit polymergebundenem antikörper |
| US7875277B2 (en) * | 2004-01-27 | 2011-01-25 | The Dept. of Veterans Affairs Office of The General Counsel | Compositions and methods for inhibiting squamous cell carcinoma |
| WO2005071059A2 (en) * | 2004-01-27 | 2005-08-04 | Compugen Ltd. | Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby |
| CN1934251A (zh) * | 2004-01-29 | 2007-03-21 | 塞尔卓姆股份公司 | 使用atp7a－调控剂治疗神经变性疾病 |
| DK1713501T3 (da) * | 2004-01-29 | 2008-05-26 | Cellzome Ag | Behandling af neurodegenerative sygdomme ved anvendelse af GPR49 |
| US20070249530A1 (en) * | 2004-01-29 | 2007-10-25 | Genentech, Inc. | Bcma Polypeptides and Uses Thereof |
| WO2005075647A1 (en) * | 2004-02-06 | 2005-08-18 | Nymox Corporation | Humanized antibody |
| PT2857418T (pt) | 2004-02-06 | 2017-10-20 | Univ Massachusetts | Anticorpos contra toxinas de clostridium difficile e utilizações dos mesmos |
| US7481997B1 (en) | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
| US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| US9550838B2 (en) | 2004-02-13 | 2017-01-24 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
| US8883160B2 (en) * | 2004-02-13 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
| CA2555208A1 (en) * | 2004-02-18 | 2005-09-01 | Merck & Co., Inc. | Nucleic acid molecules encoding novel murine low-voltage activated calcium channel proteins, designated-alpha 1h, encoded proteins and methods of use thereof |
| CA2555820C (en) | 2004-02-19 | 2016-01-19 | Genentech, Inc. | Cdr-repaired antibodies |
| EP1717250A4 (en) | 2004-02-20 | 2008-10-01 | Immuno Biological Lab Co Ltd | MONOCLONAL ANTIBODY AND ITS USE |
| WO2005081905A2 (en) * | 2004-02-20 | 2005-09-09 | Fraunhofer Usa Inc. | Systems and methods for clonal expression in plants |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| WO2005085288A2 (en) | 2004-03-01 | 2005-09-15 | The Cbr Institute For Biomedical Research | Natural igm antibodies and inhibitors thereof |
| EP1730196B1 (en) | 2004-03-12 | 2010-12-22 | Vasgene Therapeutics, Inc. | Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth |
| WO2005088308A2 (en) * | 2004-03-12 | 2005-09-22 | The Scripps Research Institute | Fluorescent signal emitting live cell biosensor molecules and dyes for detection and quantification of protein activities |
| GB0405637D0 (en) | 2004-03-12 | 2004-04-21 | Danisco | Protein |
| AU2005224267B2 (en) * | 2004-03-19 | 2011-07-21 | Imclone Llc | Human anti-epidermal growth factor receptor antibody |
| KR20060132006A (ko) * | 2004-03-23 | 2006-12-20 | 비오겐 아이덱 엠에이 아이엔씨. | 수용체 커플링제 및 이의 치료적 용도 |
| AU2005227326B2 (en) * | 2004-03-24 | 2009-12-03 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
| WO2005092443A1 (en) * | 2004-03-26 | 2005-10-06 | Cellzome Ag | Treatment of neurodegenerative diseases by the use of laptm4b |
| EP1786463A4 (en) * | 2004-03-26 | 2009-05-20 | Human Genome Sciences Inc | ANTIBODY AGAINST NOGO RECEPTOR |
| CA2561405C (en) * | 2004-03-29 | 2014-01-21 | Receptor Biologix, Inc. | Monoclonal antibodies to gastrin hormone |
| US20050260710A1 (en) * | 2004-03-31 | 2005-11-24 | Sekisui Chemical Co. Ltd. | Methods for producing recombinant polyclonal immunoglobulins |
| US7479379B2 (en) | 2004-03-31 | 2009-01-20 | Centocor, Inc. | Methods for altering protein production rates |
| ZA200608130B (en) | 2004-03-31 | 2008-12-31 | Genentech Inc | Humanized anti-TGF-beta antibodies |
| CA2562038C (en) | 2004-04-02 | 2017-04-25 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin |
| CA2562024C (en) * | 2004-04-07 | 2014-05-27 | Rinat Neuroscience Corp. | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
| US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| AU2005241415A1 (en) | 2004-04-09 | 2005-11-17 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Real time method of detecting acute inflammatory conditions |
| US20060018902A1 (en) * | 2004-04-09 | 2006-01-26 | Reilly Edward B | Antibodies to erythropoietin receptor and uses thereof |
| US20080038265A1 (en) * | 2004-04-09 | 2008-02-14 | Reilly Edward B | Antibodies to Erythropoietin Receptor and Uses Thereof |
| US7785903B2 (en) * | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| ES2482142T3 (es) | 2004-04-15 | 2014-08-01 | University Of Florida Research Foundation, Inc. | Proteínas neurales como biomarcadores para lesiones del sistema nervioso y otros trastornos neurales |
| MXPA06011824A (es) * | 2004-04-16 | 2006-12-15 | Genentech Inc | Ensayo para anticuerpos. |
| JP2007532680A (ja) * | 2004-04-16 | 2007-11-15 | ジェネンテック・インコーポレーテッド | 疾患の治療方法 |
| US20050276803A1 (en) * | 2004-04-16 | 2005-12-15 | Genentech, Inc. | Method for augmenting B cell depletion |
| JP2008501638A (ja) | 2004-04-23 | 2008-01-24 | ドイツ連邦共和国 | ＩＣＯＳ陽性細胞のｉｎｖｉｖｏ枯渇によるＴ細胞介在病態の治療方法 |
| EP1753449A4 (en) * | 2004-04-30 | 2009-09-23 | Corthera Inc | METHOD AND COMPOSITIONS FOR CONTROLLING FEDERAL GROWTH BY RELAXIN MODULATION |
| US7311906B2 (en) * | 2004-04-30 | 2007-12-25 | Brigham Young University | Anti-viral activity of an anti-thymidine kinase monoclonal antibody |
| KR20070011558A (ko) * | 2004-05-04 | 2007-01-24 | 제네상스 파머슈티컬스, 아이엔씨. | 일배체형 마커 및 치료에 대한 반응을 측정하기 위해 이를이용하는 방법 |
| WO2005115436A1 (en) * | 2004-05-07 | 2005-12-08 | Astellas Us Llc | Soluble lfa-3 polypeptide for treating viral disorders |
| EP1745154B1 (en) | 2004-05-07 | 2012-08-01 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof |
| GB0410627D0 (en) | 2004-05-12 | 2004-06-16 | Scancell Ltd | Specific binding members |
| CA2562800A1 (en) | 2004-05-15 | 2005-12-01 | Genentech, Inc. | Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule |
| EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| US20060292554A1 (en) * | 2004-05-18 | 2006-12-28 | Genentech, Inc. | Major coat protein variants for C-terminal and bi-terminal display |
| WO2005113838A2 (en) | 2004-05-18 | 2005-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of protein translocation by beta-galactosidase reporter fragment complementation |
| WO2005116270A2 (en) | 2004-05-18 | 2005-12-08 | Vical Incorporated | Influenza virus vaccine composition and method of use |
| US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
| JP4806680B2 (ja) * | 2004-05-19 | 2011-11-02 | メダレックス インコーポレイテッド | 自己犠牲リンカー及び薬剤複合体 |
| US8551486B2 (en) * | 2004-05-21 | 2013-10-08 | Savoy Pharmaceuticals, Inc. | Monoclonal antibodies to human thymidine kinase to treat cancer |
| US7837998B2 (en) * | 2004-05-21 | 2010-11-23 | Nathaniel Lallatin | Anti-cancer activity of an anti-thymidine kinase monoclonal antibody |
| WO2005112978A2 (en) * | 2004-05-21 | 2005-12-01 | University Of Utah Research Foundation | Methods and compositions related to delivery of chemical compounds to invertebrate embryos |
| US20100266495A1 (en) * | 2004-05-21 | 2010-10-21 | Brigham Young University | Anti-Cancer Activity of an Anti-Thymidine Kinase Monoclonal Antibody |
| CA2567449C (en) | 2004-05-28 | 2014-03-11 | Agensys, Inc. | Antibodies and related molecules that bind to psca proteins |
| JP5234734B2 (ja) | 2004-06-01 | 2013-07-10 | ジェネンテック， インコーポレイテッド | 抗体−薬物結合体および方法 |
| MXPA06014031A (es) | 2004-06-01 | 2007-10-08 | Domantis Ltd | Anticuerpos de fusion biespecificos con vida media de serica mejorada. |
| EP1767633B1 (en) | 2004-06-02 | 2010-08-18 | TSS Biotech Inc. | Novel polypeptide useful for diagnosis and treatment of cancer |
| TW201422238A (zh) | 2004-06-04 | 2014-06-16 | Genentech Inc | Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品 |
| AU2005252699B2 (en) * | 2004-06-07 | 2010-12-23 | Macrogenics West, Inc. | Transferrin receptor antibodies |
| US7604947B2 (en) * | 2004-06-09 | 2009-10-20 | Cornell Research Foundation, Inc. | Detection and modulation of cancer stem cells |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8951522B2 (en) | 2011-04-08 | 2015-02-10 | University Of Leicester | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US20060018896A1 (en) * | 2004-06-10 | 2006-01-26 | University Of Leicester | Methods for treating conditions associated with lectin-dependent complement activation |
| EP3530288A3 (en) | 2004-06-10 | 2019-12-18 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
| WO2005121168A2 (en) * | 2004-06-10 | 2005-12-22 | Enkam Pharmaceuticals A/S | Heparin binding peptide |
| GB0412966D0 (en) | 2004-06-10 | 2004-07-14 | Univ Leicester | Genetically modified non-human mammals and cells |
| US20100316653A1 (en) * | 2004-06-12 | 2010-12-16 | Oregon Health & Science University | Compositions and methods for diagnosis and treatment of orthopoxviruses |
| EP2789342A1 (en) | 2004-06-17 | 2014-10-15 | Thrasos Innovation, Inc. | TDF-related compounds and analogs thereof |
| CA2570267A1 (en) * | 2004-06-18 | 2005-12-29 | Enkam Pharmaceuticals A/S | Fgfr binding peptides |
| KR101541658B1 (ko) | 2004-06-21 | 2015-08-07 | 메다렉스, 엘.엘.시. | 인터페론 알파 수용체 1 항체 및 그의 용도 |
| JP5058792B2 (ja) | 2004-06-21 | 2012-10-24 | プロティオーム・サイエンシィズ・ピーエルシー | スクリーニング方法 |
| GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
| US8486893B2 (en) * | 2004-06-24 | 2013-07-16 | Biogen Idec Ma Inc. | Treatment of conditions involving demyelination |
| PL2287195T3 (pl) | 2004-07-01 | 2019-10-31 | Novo Nordisk As | Przeciwciała pan-kir2dl receptora nk i ich zastosowanie w diagnostyce i terapii |
| US7973134B2 (en) * | 2004-07-07 | 2011-07-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways |
| US7919086B2 (en) | 2004-07-09 | 2011-04-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
| US7598071B2 (en) * | 2004-07-09 | 2009-10-06 | The United States Of America As Represented By The Department Of Health And Human Services | Infectious clone of human parvovirus B19 and methods |
| US8865171B2 (en) | 2004-07-09 | 2014-10-21 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Soluble forms of Hendra and Nipah virus G glycoprotein |
| DK2112162T3 (da) | 2004-07-10 | 2015-02-23 | Fox Chase Cancer Ct | Genetisk modificerede humane naturlige dræbercellelinjer |
| KR20070034621A (ko) * | 2004-07-12 | 2007-03-28 | 라파포트 패밀리 인스티튜트 포 리서치 인 더 메디칼 사이언시스 | 다형형 단백질의 표현형 확인방법 |
| JP2008506389A (ja) * | 2004-07-13 | 2008-03-06 | セル ジェネシス インコーポレイテッド | Ａａｖベクター組成物および免疫グロブリンの発現の増強のための方法ならびにその使用方法 |
| US20090087376A1 (en) * | 2004-07-15 | 2009-04-02 | The General Hospital Corporation | Heterocyclic Dye Compounds For In Vivo Imaging And Diagnosis Of Alzheimer's Disease |
| CN103351434B (zh) | 2004-07-15 | 2015-09-30 | 赞科股份有限公司 | 优化的Fc变体 |
| US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
| US6986264B1 (en) * | 2004-07-15 | 2006-01-17 | Carrier Corporation | Economized dehumidification system |
| CN1984982A (zh) * | 2004-07-16 | 2007-06-20 | 丹尼斯科公司 | 用酶使油脱胶的方法 |
| US8604185B2 (en) | 2004-07-20 | 2013-12-10 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| EP1771474B1 (en) * | 2004-07-20 | 2010-01-27 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| US20070264277A1 (en) | 2004-07-22 | 2007-11-15 | Dirk Behrens | Compositions and Methods of Use for Mgd-Csf in Disease Treatment |
| EP1784211A4 (en) | 2004-07-29 | 2010-06-30 | Novartis Vaccines & Diagnostic | IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE |
| EP2298807A3 (en) * | 2004-07-30 | 2011-05-18 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| WO2006013552A2 (en) | 2004-08-02 | 2006-02-09 | Ramot At Tel Aviv University Ltd. | Articles of peptide nanostructures and method of forming the same |
| JP5014130B2 (ja) | 2004-08-02 | 2012-08-29 | ズィナイス オペレーションズ ピーティーワイ．エルティーディー． | Ｖｅｇｆ−ｂアンタゴニストを含む癌治療方法 |
| CA2575607C (en) | 2004-08-03 | 2017-07-11 | Innate Pharma | Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor |
| EP2329714A1 (en) | 2004-08-03 | 2011-06-08 | Biogen Idec MA Inc. | Influence of TAJ in the neuronal functions |
| US8283122B2 (en) * | 2004-08-03 | 2012-10-09 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma |
| WO2006135382A2 (en) * | 2004-08-04 | 2006-12-21 | Chemocentryx, Inc. | Enzymatic activities in chemokine-mediated inflammation |
| JP4840939B2 (ja) | 2004-08-04 | 2011-12-21 | アムジェン インコーポレイテッド | Ｄｋｋ−１に対する抗体 |
| KR101397851B1 (ko) * | 2004-08-05 | 2014-05-22 | 제넨테크, 인크. | 인간화 항-ｃｍｅｔ 길항제 |
| MX2007001509A (es) * | 2004-08-05 | 2007-03-27 | Wyeth Corp | Antagonismo de la actividad del receptor de interleuquina 21. |
| AU2005271601A1 (en) | 2004-08-06 | 2006-02-16 | Genentech, Inc. | Assays and methods using biomarkers |
| CN101061238B (zh) | 2004-08-06 | 2013-11-20 | 健泰科生物技术公司 | 使用生物标志的测定法和方法 |
| US20090098105A1 (en) * | 2004-08-09 | 2009-04-16 | Carsten Hopf | Treatment of neurodegenerative diseases by the use of scd4 inhibitors |
| US20060073168A1 (en) * | 2004-08-11 | 2006-04-06 | Stephens David S | Neisseria meningitidis serogroup a capsular polysaccharide acetyltransferase, methods and compositions |
| US20080181892A1 (en) * | 2004-08-11 | 2008-07-31 | Trubion Pharmaceuticals | Binding Domain Fusion Protein |
| CA2478458A1 (en) * | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| US20070265818A1 (en) * | 2004-08-24 | 2007-11-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems for heightening cell-mediated immune response |
| US20070265817A1 (en) * | 2004-08-24 | 2007-11-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems and methods relating to fortifying an immune system |
| US20070207492A1 (en) * | 2004-08-24 | 2007-09-06 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems to adjust a humoral immune response |
| US20070265788A1 (en) * | 2004-08-24 | 2007-11-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems for augmenting cell-mediated immune response |
| US20060047439A1 (en) * | 2004-08-24 | 2006-03-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | System and method for improving a humoral immune response |
| US20070198196A1 (en) * | 2004-08-24 | 2007-08-23 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems and methods relating to ameliorating an immune system |
| TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
| US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
| ATE542140T1 (de) | 2004-08-27 | 2012-02-15 | Novartis Vaccines & Diagnostic | Nichtstrukturelle hcv-proteinmutanten und verwendungsmöglichkeiten dafür |
| TWI364458B (en) * | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
| US7655229B2 (en) * | 2004-09-02 | 2010-02-02 | Chan Andrew C | Anti-FC-gamma RIIB receptor antibody and uses therefor |
| AU2005282700A1 (en) * | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| US7662926B2 (en) | 2004-09-02 | 2010-02-16 | Genentech, Inc. | Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor |
| MX337423B (es) * | 2004-09-03 | 2016-03-04 | Genentech Inc | Antagonistas anti-beta7 humanizados y usos para los mismos. |
| US7432359B2 (en) | 2004-09-06 | 2008-10-07 | Kirin Pharma Kabushiki Kaisha | Anti-A33 antibody |
| KR100918746B1 (ko) | 2004-09-06 | 2009-09-24 | 교와 핫꼬 기린 가부시키가이샤 | 항 ａ３３ 항체 |
| US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| JP2008518586A (ja) * | 2004-09-09 | 2008-06-05 | ユニバーシティ オブ ワシントン | オールトランスレチノールすなわちオールトランス１３，１４−ジヒドロレチノールサチュラーゼ及びその使用方法 |
| WO2006031994A2 (en) * | 2004-09-14 | 2006-03-23 | Xencor, Inc. | Monomeric immunoglobulin fc domains |
| WO2006030442A2 (en) * | 2004-09-16 | 2006-03-23 | Gamida-Cell Ltd. | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells |
| US7700720B2 (en) | 2004-09-21 | 2010-04-20 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
| JP2008513536A (ja) | 2004-09-22 | 2008-05-01 | レセプター バイオロジックス インコーポレイテッド | プロガストリンに対するモノクローナル抗体 |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| ES2669510T3 (es) | 2004-09-23 | 2018-05-28 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| DK1804836T3 (da) | 2004-09-24 | 2011-01-24 | Beth Israel Hospital | Fremgangsmåder til diagnosticering og behandling af graviditetskomplikationer |
| US7935790B2 (en) * | 2004-10-04 | 2011-05-03 | Cell Singaling Technology, Inc. | Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways |
| WO2006041934A2 (en) * | 2004-10-05 | 2006-04-20 | Neuralab Limited | Methods and compositions for improving recombinant protein production |
| EP1810026B1 (en) | 2004-10-06 | 2018-04-18 | Mayo Foundation For Medical Education And Research | B7-h1 and pd-1 in treatment of renal cell carcinoma |
| KR101243577B1 (ko) | 2004-10-07 | 2013-03-20 | 아고스 쎄라퓨틱스, 인코포레이티드 | 성숙 수지상 세포 조성물 및 그의 배양 방법 |
| US8247371B2 (en) * | 2004-10-14 | 2012-08-21 | Yale University | Therapy with Clostridium perfringens enterotoxin to treat ovarian and uterine cancer |
| GB0423139D0 (en) | 2004-10-18 | 2004-11-17 | Danisco | Enzymes |
| US20080274095A1 (en) * | 2004-10-20 | 2008-11-06 | Jane Homan | Biocides |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| AU2005299701B2 (en) | 2004-10-21 | 2011-11-17 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
| WO2006047417A2 (en) | 2004-10-21 | 2006-05-04 | University Of Florida Research Foundation, Inc. | Detection of cannabinoid receptor biomarkers and uses thereof |
| US7928205B2 (en) * | 2004-10-22 | 2011-04-19 | Amgen Inc. | Methods for refolding of recombinant antibodies |
| SI1812058T1 (sl) | 2004-10-25 | 2013-02-28 | Statens Serum Institut | Antigeni chlamidia trachomatis za cepivo in diagnostiäśno rabo |
| AU2005299296A1 (en) | 2004-10-27 | 2006-05-04 | Vanderbilt University | Mammalian genes involved in infection |
| EP1809326A4 (en) | 2004-10-27 | 2009-11-04 | Medimmune Inc | MODULATION OF ANTIBODY SPECIFICITY BY MEASURING ADAPTATION OF ITS AFFINITY TO AN APPARENT ANTIGEN |
| TW200636064A (en) * | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
| CN101072578A (zh) | 2004-10-29 | 2007-11-14 | 南加州大学 | 用共刺激分子的联合癌症免疫疗法 |
| JP2008518947A (ja) * | 2004-10-29 | 2008-06-05 | エルシス セラピューティクス， インク． | 免疫応答のクリアランス及び誘導におけるｃｒ１結合分子の使用 |
| MX2007005378A (es) * | 2004-11-04 | 2008-02-14 | Genentech Inc | Polipeptidos que ligan a baff y/o april. |
| JP2008519028A (ja) * | 2004-11-04 | 2008-06-05 | フィブロン リミテッド | Ｂ細胞悪性腫瘍の治療 |
| KR20080007425A (ko) | 2004-11-05 | 2008-01-21 | 팔링겐, 인코포레이티드 | 항체 유도된 세포막 손상 |
| US20060099144A1 (en) | 2004-11-08 | 2006-05-11 | Schering Corporation | Tumor association of MDL-1 and methods |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| CN101090913B (zh) | 2004-11-09 | 2015-11-25 | 菲罗根股份公司 | 抗生腱蛋白c的抗体 |
| US20060135459A1 (en) * | 2004-11-09 | 2006-06-22 | Epstein Alan L | Targeted innate immunity |
| GB0424940D0 (en) | 2004-11-11 | 2004-12-15 | Danisco | Transcription factors |
| EP2845865A1 (en) | 2004-11-12 | 2015-03-11 | Xencor Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1817336B1 (en) | 2004-11-12 | 2019-01-09 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
| US20070135620A1 (en) * | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| WO2006050999A2 (en) * | 2004-11-15 | 2006-05-18 | Obe Therapy Biotechnology S.A.S | Methods of reducing body fat |
| US8173591B2 (en) * | 2004-11-16 | 2012-05-08 | Yeda Research And Development Co. | Variants of pigment epithelium derived factor and uses thereof |
| PT2343380T (pt) | 2004-11-16 | 2019-09-18 | Humanigen Inc | Permuta de cassetes da região variável de imunoglobulina |
| US20060115862A1 (en) * | 2004-11-17 | 2006-06-01 | Duke University | Anti-tenascin monoclonal antibody immunoassays and diagnostic kits |
| EP1824886B1 (en) | 2004-11-17 | 2010-12-22 | Amgen Inc. | Fully human monoclonal antibodies to il-13 |
| WO2006083355A2 (en) | 2004-11-19 | 2006-08-10 | Cornell Research Foundation, Inc. | Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics |
| AU2005306399B2 (en) * | 2004-11-19 | 2012-02-09 | Biogen Ma Inc. | Treatment for multiple sclerosis |
| US20060141504A1 (en) * | 2004-11-23 | 2006-06-29 | Willman Cheryl L | Molecular technologies for improved risk classification and therapy for acute lymphoblastic leukemia in children and adults |
| US7459529B2 (en) | 2004-11-24 | 2008-12-02 | Seoul National University Industry Foundation | AIMP2-DX2 and its uses |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| JP2008521420A (ja) * | 2004-11-30 | 2008-06-26 | ノボ ノルディスク アクティーゼルスカブ | 抗体を産生する方法 |
| TWI487535B (zh) | 2004-11-30 | 2015-06-11 | Centocor Inc | 類鐸受體３（ｔｏｌｌ ｌｉｋｅ ｒｅｃｅｐｔｏｒ３）拮抗劑，方法及用途 |
| EP2769990A3 (en) | 2004-12-02 | 2015-02-25 | Domantis Limited | Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY |
| MX2007006640A (es) | 2004-12-03 | 2007-06-19 | Schering Corp | Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina. |
| AU2005313026B2 (en) | 2004-12-06 | 2011-09-08 | Kyowa Hakko Kirin Co., Ltd. | Human monoclonal antibodies to influenza M2 protein and methods of making and using same |
| MX2007006867A (es) | 2004-12-08 | 2007-08-06 | Aventis Pharma Inc | Metodo para medir la reistencia o sensibilidad a docetaxel. |
| KR100890410B1 (ko) | 2004-12-08 | 2009-03-26 | 시리온 테라퓨틱스, 인크. | 레티놀-관련 질환의 치료 방법, 검정법 및 치료용 조성물 |
| US20060121574A1 (en) * | 2004-12-08 | 2006-06-08 | Icos Corporation | Recombinant method for making multimeric proteins |
| CA2590337C (en) * | 2004-12-15 | 2017-07-11 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
| EP1838854B1 (en) * | 2004-12-15 | 2012-10-31 | Janssen Alzheimer Immunotherapy | Antibodies that recognize Beta Amyloid Peptide |
| EP1838349A1 (en) * | 2004-12-15 | 2007-10-03 | Neuralab, Ltd. | Amyloid beta antibodies for use in improving cognition |
| BRPI0517202A (pt) * | 2004-12-16 | 2008-09-30 | Genentech Inc | método de tratamento de um distúrbio autoimune, uso de um agonista de tccr, métodos para aumentar a expressão de il-10 e de socs3 em linfócitos, método para a seleção de agonistas tccr, anticorpo monoclonal, linhagem celular de hibridoma, métodos de tratamento ou supressão de uma resposta imune e método de inibição da produção de il-17, il-6 ou gm-csf |
| US7504769B2 (en) * | 2004-12-16 | 2009-03-17 | E. I. Du Pont De Nemours + Company | Aromatic chalcogen compounds and their use |
| PE20061075A1 (es) * | 2004-12-17 | 2006-11-15 | Genentech Inc | Anticuerpos anti-vegf como agentes antiangiogenicos para tratar enfermedades autoinmunes en pacientes en quienes fallo una terapia anterior |
| AU2005318171B2 (en) * | 2004-12-20 | 2011-09-29 | Crucell Holland B.V. | Binding molecules capable of neutralizing West Nile virus and uses thereof |
| US7807789B2 (en) * | 2004-12-21 | 2010-10-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in EGFR-signaling pathways |
| WO2006067402A2 (en) * | 2004-12-22 | 2006-06-29 | Lipopeptide Ab | Agents inibiting the cathelin-like protein cap18/ll-37 |
| EP1833970A2 (en) | 2004-12-22 | 2007-09-19 | Genentech, Inc. | Methods for producing soluble multi-membrane-spanning proteins |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| WO2006066912A2 (en) * | 2004-12-23 | 2006-06-29 | F. Hoffmann-La Roche Ag | Detection of a therapeutic antibody in an experimental animal |
| CA2491067A1 (en) | 2004-12-24 | 2006-06-24 | Stichting Katholieke Universiteit | Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer |
| KR101564713B1 (ko) | 2004-12-28 | 2015-11-06 | 이나뜨 파르마 | Ｎｋｇ2ａ에 대한 단클론 항체 |
| CA2531616A1 (en) * | 2004-12-28 | 2006-06-28 | Kabushiki Kaisha Kobe Seiko Sho (Kobe Steel, Ltd.) | High strength thin steel sheet having high hydrogen embrittlement resisting property and high workability |
| US20060154285A1 (en) * | 2004-12-29 | 2006-07-13 | Robishaw Janet D | Zebrafish heterotrimer G-protein gamma 2 subunit (GNG2) |
| US7850960B2 (en) | 2004-12-30 | 2010-12-14 | University Of Washington | Methods for regulation of stem cells |
| WO2006074399A2 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| WO2006086098A2 (en) * | 2005-01-06 | 2006-08-17 | President And Fellows Of Harvard College | Mass spectrometric methods and products |
| EP1836225B1 (en) * | 2005-01-06 | 2011-11-02 | Novo Nordisk A/S | Kir-binding agents and methods of use thereof |
| JP4988599B2 (ja) | 2005-01-07 | 2012-08-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｇｆ−１融合ポリペプチドおよびその治療的使用 |
| ES2343746T3 (es) | 2005-01-07 | 2010-08-09 | Diadexus, Inc. | Composiciones de anticuerpo ovr110 y metodos de uso. |
| JP2008526256A (ja) | 2005-01-12 | 2008-07-24 | レイベン バイオテクノロジーズ，インコーポレイティド | Ｋｉｄ３１およびｋｉｄ３１に結合する抗体 |
| AU2006204791A1 (en) * | 2005-01-12 | 2006-07-20 | Xencor, Inc | Antibodies and Fc fusion proteins with altered immunogenicity |
| US20080102054A1 (en) * | 2005-01-18 | 2008-05-01 | Faustman Denise L | Compositions Containing Agm Cells And Methods Of Use Thereof |
| AU2005325200A1 (en) | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of HER antibodies |
| AU2006208226A1 (en) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
| CA2594297A1 (en) | 2005-01-27 | 2006-07-27 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| EP1846032A4 (en) * | 2005-01-31 | 2009-01-28 | Raven Biotechnologies Inc | LUCA2 AND ANTIBODY BINDING |
| US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
| WO2006084075A2 (en) | 2005-02-02 | 2006-08-10 | Raven Biotechnologies, Inc. | Adam-9 modulators |
| US20060171952A1 (en) * | 2005-02-02 | 2006-08-03 | Mather Jennie P | JAM-3 and antibodies that bind thereto |
| CA2597171A1 (en) | 2005-02-03 | 2006-08-10 | Raven Biotechnologies, Inc. | Antibodies to oncostatin m receptor |
| ZA200707275B (en) | 2005-02-04 | 2009-01-28 | Raven Biotechnologies Inc | Antibodies that bind to EphA2 and methods of use thereof |
| CN103981190A (zh) | 2005-02-07 | 2014-08-13 | 罗氏格黎卡特股份公司 | 结合egfr的抗原结合分子，编码它的载体，及其应用 |
| CA2599589A1 (en) | 2005-02-07 | 2006-08-17 | Genenews,Inc. | Mild osteoarthritis biomarkers and uses thereof |
| LT1850873T (lt) | 2005-02-08 | 2019-04-10 | Genzyme Corporation | Antikūnas prieš tgf beta |
| RU2007129263A (ru) * | 2005-02-14 | 2009-03-20 | Вайет (Us) | Антитела к интерлейкину-17f и другие антагонисты опосредуемой il-17f передачи сигналов и их применение |
| CN101160528A (zh) * | 2005-02-14 | 2008-04-09 | 惠氏公司 | Il17-f在诊断和治疗气道炎症中的用途 |
| US20080019905A9 (en) * | 2005-02-18 | 2008-01-24 | Strome Scott E | Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection |
| PT1853718E (pt) | 2005-02-15 | 2015-11-12 | Univ Duke | Anticorpos anti-cd19 e usos em oncologia |
| US7731965B2 (en) * | 2005-02-17 | 2010-06-08 | Abbott Lab | Human ring specific BNP antibodies |
| WO2006089141A2 (en) | 2005-02-18 | 2006-08-24 | Dana-Farber Cancer Institute | Antibodies against cxcr4 and methods of use thereof |
| JP2008531576A (ja) | 2005-02-23 | 2008-08-14 | ジェネンテック・インコーポレーテッド | Ｈｅｒ二量体化阻害剤を使用した、ガン患者における疾患の進行までの期間または生存の延長 |
| US20060193849A1 (en) * | 2005-02-25 | 2006-08-31 | Antisoma Plc | Biological materials and uses thereof |
| TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
| WO2006096565A2 (en) * | 2005-03-04 | 2006-09-14 | Curedm Inc. | Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions |
| EP1865986B1 (en) | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Anti-ctla-4 antibody compositions |
| TW200642695A (en) * | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
| WO2006098998A2 (en) | 2005-03-10 | 2006-09-21 | Genentech, Inc. | Methods and compositions for modulating vascular integrity |
| AU2006222204B2 (en) | 2005-03-11 | 2012-09-27 | Sanofi-Aventis | Use of MGC4504 |
| AU2005329450A1 (en) * | 2005-03-15 | 2006-09-28 | University Of North Carolina At Chapel Hill | Methods and compositions for producing active Vitamin K-dependent proteins |
| IL296666A (en) | 2005-03-23 | 2022-11-01 | Genmab As | Antibodies against 38cd for the treatment of multiple myeloma |
| US8323645B2 (en) | 2005-03-24 | 2012-12-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind OV064 and methods of use therefor |
| TW200720439A (en) * | 2005-03-25 | 2007-06-01 | Glycart Biotechnology Ag | Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function |
| DK1866339T3 (da) * | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
| EP1875244B1 (en) * | 2005-03-30 | 2019-01-23 | Minerva Biotechnologies Corporation | Proliferation of muc1 expressing cells |
| DK1875244T3 (en) | 2005-03-30 | 2019-04-29 | Minerva Biotechnologies Corp | Proliferation of MUC1-Expressing Cells |
| ES2592271T3 (es) | 2005-03-31 | 2016-11-29 | Chugai Seiyaku Kabushiki Kaisha | Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos |
| EP3300739A3 (en) | 2005-03-31 | 2018-07-18 | Agensys, Inc. | Antibodies and related molecules that bind to 161p2f10b proteins |
| US8309303B2 (en) * | 2005-04-01 | 2012-11-13 | Qiagen Gmbh | Reverse transcription and amplification of RNA with simultaneous degradation of DNA |
| ES2550140T3 (es) | 2005-04-04 | 2015-11-04 | Idexx Laboratories, Inc. | Antígenos DIVA (de Diferenciación entre Animales Vacunados e Infectados) de Erlichia canis |
| US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
| US8475794B2 (en) | 2005-04-06 | 2013-07-02 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
| EP1910557A2 (en) | 2005-04-07 | 2008-04-16 | Chiron Corporation | Cancer-related genes |
| AU2006235276A1 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | CACNA1E in cancer diagnosis, detection and treatment |
| EP2316859A1 (en) | 2005-04-09 | 2011-05-04 | Fusion Antibodies Limited | Cathepsin S antibody |
| ES2374419T3 (es) | 2005-04-11 | 2012-02-16 | National Research Council Of Canada | Identificación de una beta-1,3-n-acetilgalactosaminiltranferasa (cgte) de campylobacter jejuni lio87. |
| HUE052976T2 (hu) | 2005-04-11 | 2021-06-28 | Horizon Pharma Rheumatology Llc | Urát-oxidáz variáns formái és azok alkalmazása |
| US20090099340A1 (en) * | 2007-10-12 | 2009-04-16 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| GT200600148A (es) | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| EP1868649A4 (en) * | 2005-04-15 | 2011-06-29 | Immunogen Inc | ELIMINATION OF A POPULATION OF HETEROGENEOUS OR MIXED CELLS IN TUMORS |
| US9296816B2 (en) | 2005-04-15 | 2016-03-29 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US20090054320A1 (en) * | 2005-04-20 | 2009-02-26 | Protemix Discovery Limited | Vesiculins |
| AR054260A1 (es) * | 2005-04-26 | 2007-06-13 | Rinat Neuroscience Corp | Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos |
| US7595380B2 (en) | 2005-04-27 | 2009-09-29 | Tripath Imaging, Inc. | Monoclonal antibodies and methods for their use in the detection of cervical disease |
| DE602006018458D1 (de) | 2005-04-29 | 2011-01-05 | Univ California | Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose |
| UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| JO3058B1 (ar) | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها |
| US20060257317A1 (en) * | 2005-05-04 | 2006-11-16 | Duke University | Combination therapy in the treatment of cancer |
| EP1885396A2 (en) | 2005-05-04 | 2008-02-13 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against cd55 and cd59 and uses thereof |
| WO2006121852A2 (en) | 2005-05-05 | 2006-11-16 | Duke University | Anti-cd19 antibody therapy for autoimmune disease |
| WO2006122079A1 (en) | 2005-05-06 | 2006-11-16 | Zymogenetics, Inc. | Il-31 monoclonal antibodies and methods of use |
| RU2406760C3 (ru) | 2005-05-09 | 2017-11-28 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104815331A (zh) | 2005-05-09 | 2015-08-05 | 生物领域医疗公司 | 使用微球和非离子型造影剂的组合物和方法 |
| EP2377884A1 (en) | 2005-05-10 | 2011-10-19 | Neoloch Aps | Neuritogenic peptides |
| US7622560B2 (en) * | 2005-05-11 | 2009-11-24 | Dinona Inc. | Monoclonal antibody specific for CD43 epitope |
| EP1882044A1 (en) * | 2005-05-11 | 2008-01-30 | sanofi-aventis | Use of a gip promoter polymorphism |
| JP4722180B2 (ja) | 2005-05-11 | 2011-07-13 | ダイノナ インコーポレーテッド | 急性白血病及びリンパ芽球性リンパ腫特異ｃｄ４３抗原決定基及びその用途 |
| AR053272A1 (es) | 2005-05-11 | 2007-04-25 | Hoffmann La Roche | Determinacion de responsivos a la quimioterapia |
| AU2006245734C1 (en) | 2005-05-12 | 2012-05-24 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
| CN101175856A (zh) | 2005-05-12 | 2008-05-07 | 诺瓦提斯公司 | 猪痢疾短螺旋体的基因和蛋白质及其用于诊断和治疗的用途 |
| WO2006125117A2 (en) | 2005-05-18 | 2006-11-23 | Novartis Ag | Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component |
| EP2371843B1 (en) | 2005-05-19 | 2014-09-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services | Functional epitopes of streptococcus pneumoniae psaA antigen and uses thereof |
| EA013821B1 (ru) * | 2005-05-25 | 2010-08-30 | Кьюрдм, Инк. | Проостровковые пептиды человека, их производные и аналоги и способы их применения |
| US8355776B2 (en) | 2005-05-27 | 2013-01-15 | Board Of Regents, The University Of Texas System | Hemoglobin contrast in magneto-motive optical doppler tomography, optical coherence tomography, and ultrasound imaging methods and apparatus |
| WO2006130676A2 (en) | 2005-05-31 | 2006-12-07 | Duska Scientific Co. | Inhibition of neuronal damage |
| TW200643171A (en) | 2005-06-07 | 2006-12-16 | Temasek Life Sciences Lab Ltd | Porcine circovirus type 2 vaccines |
| TW200718780A (en) | 2005-06-10 | 2007-05-16 | Chugai Pharmaceutical Co Ltd | Sc(Fv)2 site-directed mutant |
| DE602006020867D1 (de) | 2005-06-14 | 2011-05-05 | Protox Therapeutics Inc | Verfahren zur behandlung oder prävention gutartiger prostatahyperplasie unter verwendung modifizierter porenbildender proteine |
| EP2364998A1 (en) | 2005-06-16 | 2011-09-14 | The Feinstein Institute for Medical Research | Antibodies against HMGB1 and fragments thereof |
| EP2937360A1 (en) | 2005-06-17 | 2015-10-28 | Merck Sharp & Dohme Corp. | Ilt3 binding molecules and uses therefor |
| JP5270337B2 (ja) | 2005-06-17 | 2013-08-21 | ヤンセン アルツハイマー イミュノセラピー | 抗Ａβ抗体を精製する方法 |
| AU2006261357A1 (en) * | 2005-06-17 | 2006-12-28 | Zimmer Spine Austin, Inc. | Improved method of treating degenerative spinal disorders |
| US20070225242A1 (en) * | 2005-06-21 | 2007-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for treating and preventing tumor metastasis in vivo |
| KR101502920B1 (ko) | 2005-06-21 | 2015-03-17 | 조마 (유에스) 엘엘씨 | ＩＬ-１β 결합성 항체 및 그의 단편 |
| WO2006136601A1 (en) * | 2005-06-23 | 2006-12-28 | Crucell Holland B.V. | Optimization of west nile virus antibodies |
| JP2008546805A (ja) | 2005-06-23 | 2008-12-25 | メディミューン，エルエルシー | 最適な凝集および断片化プロフィールを有する抗体製剤 |
| ES2410406T3 (es) | 2005-06-30 | 2013-07-01 | Janssen Biotech, Inc. | Anticuerpos anti-IL-23, composiciones, procedimientos y usos |
| CN103146708A (zh) | 2005-06-30 | 2013-06-12 | Abbvie公司 | Il-12/p40结合蛋白 |
| CN101248089A (zh) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | 抗程序性死亡配体1（pd-l1）的人单克隆抗体 |
| US20070009976A1 (en) | 2005-07-06 | 2007-01-11 | Helmut Lenz | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody |
| US8871720B2 (en) * | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
| EP1917020B1 (en) | 2005-07-07 | 2016-05-25 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
| US7482124B2 (en) * | 2005-07-08 | 2009-01-27 | Bristol-Myers Squibb Company | Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema |
| AU2006268227A1 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc | Optimized anti-Ep-CAM antibodies |
| EP1904104B1 (en) | 2005-07-08 | 2013-09-11 | Biogen Idec MA Inc. | Sp35 antibodies and uses thereof |
| US7780969B2 (en) | 2005-07-15 | 2010-08-24 | University Of Georgia Research Foundation, Inc. | Trypanosoma cruzi proteome compositions and methods |
| CA2616005C (en) | 2005-07-18 | 2015-09-22 | Seattle Genetics, Inc. | Beta-glucuronide-linker drug conjugates |
| US7632509B2 (en) * | 2005-07-19 | 2009-12-15 | Biosante Pharmaceuticals, Inc. | Methods to express recombinant proteins from lentiviral vectors |
| SG164379A1 (en) | 2005-07-21 | 2010-09-29 | Genmab As | Potency assays for antibody drug substance binding to an fc receptor |
| WO2007014162A2 (en) * | 2005-07-21 | 2007-02-01 | Abbott Laboratories | Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis |
| BRPI0613770A2 (pt) * | 2005-07-22 | 2009-05-19 | Y S Therapeutics Co Ltd | anticorpos anti-cd26 e métodos de uso destes |
| US8211648B2 (en) * | 2005-07-22 | 2012-07-03 | Kalobios Pharmaceuticals, Inc. | Secretion of antibodies without signal peptides from bacteria |
| JP2009514790A (ja) * | 2005-07-22 | 2009-04-09 | プロジェニクス・ファーマスーティカルズ・インコーポレイテッド | Ｈｉｖ−１−感染患者におけるウイルス負荷を減少させる方法 |
| DK2298815T3 (en) | 2005-07-25 | 2015-06-15 | Emergent Product Dev Seattle | B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES |
| ES2538036T3 (es) * | 2005-07-28 | 2015-06-16 | Novartis Ag | Uso de anticuerpo a M-CSF |
| WO2007016285A2 (en) | 2005-07-28 | 2007-02-08 | Novartis Ag | M-csf specific monoclonal antibody and uses thereof |
| WO2007016597A2 (en) * | 2005-07-29 | 2007-02-08 | The Regents Of The University Of California | Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy |
| US7411046B2 (en) | 2005-08-02 | 2008-08-12 | Arius Research Inc | Cancerous disease modifying antibodies |
| US7452979B2 (en) | 2005-08-02 | 2008-11-18 | Arius Research, Inc. | Cancerous disease modifying antibodies |
| US7456259B2 (en) | 2005-08-02 | 2008-11-25 | Arius Research, Inc. | Cancerous disease modifying antibodies |
| US7456258B2 (en) | 2005-08-02 | 2008-11-25 | Arius Research, Inc. | Cancerous disease modifying antibodies |
| US7494648B2 (en) * | 2005-08-02 | 2009-02-24 | Hoffmann-La Roche Inc. | Cancerous disease modifying antibodies |
| US7452978B2 (en) | 2005-08-02 | 2008-11-18 | Arius Research, Inc. | Cancerous disease modifying antibodies |
| WO2007117264A2 (en) * | 2005-08-03 | 2007-10-18 | Fraunhofer Usa, Inc. | Compositions and methods for production of immunoglobulins |
| US8642330B2 (en) | 2005-08-08 | 2014-02-04 | Onconon, Llc | Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility |
| SI2573114T1 (sl) | 2005-08-10 | 2016-08-31 | Macrogenics, Inc. | Identifikacija in inženiring protiteles z variantnimi fc regijami in postopki za njih uporabo |
| DE602006019262D1 (de) | 2005-08-11 | 2011-02-10 | Siemens Healthcare Diagnostics | QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN |
| AU2006281980A1 (en) * | 2005-08-15 | 2007-02-22 | Cephalon Australia Pty Ltd | Engineered antibodies with new world primate framework regions |
| JP2009504183A (ja) | 2005-08-15 | 2009-02-05 | ジェネンテック・インコーポレーテッド | 遺伝子破壊、それに関連する組成物および方法 |
| ATE540318T1 (de) | 2005-08-16 | 2012-01-15 | Genentech Inc | Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe |
| EP2500355A3 (en) | 2005-08-19 | 2012-10-24 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20090215992A1 (en) * | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
| US20070202512A1 (en) * | 2005-08-19 | 2007-08-30 | Bristol-Myers Squibb Company | Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof |
| AU2006283532B2 (en) | 2005-08-19 | 2012-04-26 | Abbvie Inc. | Dual variable domain immunoglobin and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| AR055137A1 (es) | 2005-08-26 | 2007-08-08 | Glycart Biotechnology Ag | Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada |
| MX2008003054A (es) | 2005-08-31 | 2008-03-25 | Centocor Inc | Lineas de celulas hospederas para la produccion de la region constante de anticuerpos, con fusion efectora mejorada. |
| JP5350793B2 (ja) | 2005-08-31 | 2013-11-27 | メルク・シャープ・アンド・ドーム・コーポレーション | 改変抗ｉｌ−２３抗体 |
| WO2007027867A2 (en) | 2005-08-31 | 2007-03-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| US20100151495A9 (en) * | 2005-08-31 | 2010-06-17 | Cell Signaling Technolgy, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| EP1934867A2 (en) * | 2005-08-31 | 2008-06-25 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
| WO2007028030A2 (en) * | 2005-09-02 | 2007-03-08 | Picobella, Llc | Oncogenic regulatory rnas for diagnostics and therapeutics |
| CA2620713A1 (en) * | 2005-09-09 | 2007-03-15 | Glycofi, Inc. | Immunoglobulin comprising predominantly a man7glcnac2, man8glcnac2 glycoform |
| CA2623415A1 (en) | 2005-09-20 | 2007-03-29 | Thrasos, Inc. | Tdf-related compounds and analogs thereof |
| US7799530B2 (en) | 2005-09-23 | 2010-09-21 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
| KR20080056167A (ko) | 2005-09-26 | 2008-06-20 | 메다렉스, 인코포레이티드 | 씨디70에 대한 인간 모노크로날 항체 |
| EP1940470B1 (en) | 2005-09-26 | 2013-04-17 | Medarex, Inc. | Antibody-drug conjugates and their use |
| US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| BRPI0616720A2 (pt) | 2005-09-28 | 2011-06-28 | Becton Dickinson Co | método para o diagnóstico ou prognóstico de sepse em um paciente, kit para diagnóstico ou prognóstico, ou monitoração, de sepse em um paciente, e, dispositivo para o diagnóstico ou prognóstico de sepse |
| BRPI0616602A2 (pt) | 2005-09-30 | 2011-06-28 | Seattle Biomedical Res Inst | polipeptìdeo isolado, composição imunogênica, molécula de ácido nucleico isolada, e, uso de uma composição imunogênica |
| EP1928905B1 (de) * | 2005-09-30 | 2015-04-15 | AbbVie Deutschland GmbH & Co KG | Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung |
| WO2007041635A2 (en) * | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| IL172297A (en) | 2005-10-03 | 2016-03-31 | Compugen Ltd | Soluble vegfr-1 variants for the diagnosis of preeclampsia |
| US7422899B2 (en) * | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
| WO2007044607A2 (en) * | 2005-10-06 | 2007-04-19 | Emthrax, Llc | Methods and compositions relating to anthrax spore glycoproteins as vaccines |
| WO2007044616A2 (en) | 2005-10-06 | 2007-04-19 | Xencor, Inc. | Optimized anti-cd30 antibodies |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| WO2007043048A2 (en) | 2005-10-11 | 2007-04-19 | Ramot At Tel Aviv University Ltd. | Self-assembled fmoc-ff hydrogels |
| DE102005048898A1 (de) | 2005-10-12 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| EP1948802A4 (en) * | 2005-10-13 | 2009-01-14 | Virexx Medical Corp | CHIMERIC ANTIGEN WITH HEPATITIS C VIRUS POLYPEPTIDE AND FC FRAGMENT FOR CALLING UP AN IMMUNE RESPONSE |
| US8461126B2 (en) | 2005-10-14 | 2013-06-11 | Phigenix, Inc. | Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions |
| CN101300272B (zh) | 2005-10-14 | 2013-09-18 | 依奈特制药公司 | 用于治疗增生性病症的组合物和方法 |
| US20100029504A1 (en) | 2007-01-16 | 2010-02-04 | Phigenix, Inc. | Detecting pax2 for the diagnosis of breast cancer |
| EP1941907B1 (en) | 2005-10-14 | 2016-03-23 | Fukuoka University | Inhibitor of transplanted islet dysfunction in islet transplantation |
| KR101323563B1 (ko) | 2005-10-18 | 2013-10-29 | 니토 보세키 가부시기가이샤 | 항체를 생산하는 트랜스제닉 누에와 그의 제조방법 |
| US7794951B2 (en) * | 2005-10-18 | 2010-09-14 | University Of Massachusetts Medical School | SREBP2gc transcription factors and uses thereof |
| AR058104A1 (es) | 2005-10-21 | 2008-01-23 | Novartis Ag | Compuestos organicos |
| DK1945666T3 (da) * | 2005-10-21 | 2013-07-01 | Genzyme Corp | Antistoffer med forøget antistofafhængig cellulær cytotoksicitetsaktivitet, fremgangsmåder til fremstilling af disse og anvendelse heraf |
| EP1945816B1 (en) | 2005-10-21 | 2011-07-27 | GeneNews Inc. | Method and apparatus for correlating levels of biomarker products with disease |
| BRPI0617664B8 (pt) | 2005-10-21 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio |
| PE20070796A1 (es) * | 2005-10-24 | 2007-08-15 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
| WO2007050793A2 (en) | 2005-10-25 | 2007-05-03 | The Johns Hopkins University | Methods and compositions for the treatment of marfan syndrome and associated disorders |
| US20080213274A1 (en) * | 2005-10-28 | 2008-09-04 | Sabbadini Roger A | Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye |
| US20090074720A1 (en) * | 2005-10-28 | 2009-03-19 | Sabbadini Roger A | Methods for decreasing immune response and treating immune conditions |
| HUE025908T2 (en) | 2005-10-31 | 2016-04-28 | Oncomed Pharm Inc | Preparations and procedures for the diagnosis and treatment of cancer |
| RS53055B (en) | 2005-11-01 | 2014-04-30 | Abbvie Biotechnology Ltd | PROCEDURES FOR DETERMINING THE EFFICIENCY OF ADALIMUMAB IN RESPONDENTS WHO HAVE ANKILLOSATIVE SPONDILITIS USING CTX-II AND MMP3 AS BIOMARKERS |
| FR2892724B1 (fr) | 2005-11-02 | 2008-01-04 | Lab Francais Du Fractionnement | Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii. |
| US7879212B2 (en) * | 2005-11-03 | 2011-02-01 | Ramot At Tel-Aviv University Ltd. | Peptide nanostructure-coated electrodes |
| US20070099246A1 (en) * | 2005-11-03 | 2007-05-03 | Sandy John D | Antibodies, assays and kits to quantitate cartilage destruction |
| BRPI0619657A2 (pt) | 2005-11-04 | 2011-11-08 | Genentech Inc | métodos de prevenção ou melhoria de doença ocular, uso de um inibidor de complemento, uso de um sirna especìfico para uma proteìna do sistema complemento e uso de um ácido nucleico que codifica um inibidor do sistema complemento |
| EP2510934A1 (en) | 2005-11-04 | 2012-10-17 | Biogen Idec MA Inc. | Methods for promoting neurite outgrowth and survival of dopaminergic neurons |
| ZA200804082B (en) | 2005-11-07 | 2010-02-24 | Scripps Research Inst | Compositions and methods for controlling tissue factor signaling specificity |
| WO2007055916A2 (en) | 2005-11-07 | 2007-05-18 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
| US8679490B2 (en) | 2005-11-07 | 2014-03-25 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
| UA96139C2 (uk) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
| US20070161089A1 (en) * | 2005-11-08 | 2007-07-12 | Genentech, Inc. | Method of Producing Pan-Specific Antibodies |
| JP5364378B2 (ja) | 2005-11-09 | 2013-12-11 | アボット・ラボラトリーズ | ヒトｂｎｐ免疫特異的抗体 |
| US7939069B2 (en) | 2005-11-09 | 2011-05-10 | Abbott Laboratories | Human BNP immunospecific antibodies |
| US9415107B2 (en) | 2005-11-10 | 2016-08-16 | Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College | Compositions and methods for the treatment of addiction and other neuropsychiatric disorders |
| US8106010B2 (en) * | 2005-11-14 | 2012-01-31 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Variants of pigment epithelium derived factor and uses thereof |
| WO2007055369A1 (ja) * | 2005-11-14 | 2007-05-18 | Riken | 活性化形質細胞様樹状細胞に特異的に発現する膜分子 |
| EP2365334A1 (en) | 2005-11-14 | 2011-09-14 | MetaMol Theranostics, LLC | Peptide sequence that promotes tumor invasion |
| US8128934B2 (en) | 2005-11-14 | 2012-03-06 | Ribomic, Inc. | Method for treatment or prevention of disease associated with functional disorder of regulatory T cell |
| EP3069731A1 (en) | 2005-11-14 | 2016-09-21 | Labrys Biologics Inc. | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| WO2007061679A1 (en) * | 2005-11-17 | 2007-05-31 | Millennium Pharmaceuticals, Inc. | HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN |
| CA2629715C (en) | 2005-11-18 | 2016-05-03 | Glenmark Pharmaceuticals S.A. | Anti-alpha2 integrin antibodies and their uses |
| CA2627446A1 (en) | 2005-11-21 | 2007-05-31 | Laboratoires Serono S.A. | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
| JP5215865B2 (ja) | 2005-11-22 | 2013-06-19 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | ノロウイルス抗原およびサポウイルス抗原 |
| TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| AR057941A1 (es) | 2005-11-25 | 2007-12-26 | Univ Keio | Agentes terapeuticos para el cancer de prostata |
| WO2007064759A2 (en) * | 2005-11-29 | 2007-06-07 | The Scripps Research Institute | Inhibiting tumour cell invasion, metastasis and angiogenesis through targetting legumain |
| US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
| JP5486808B2 (ja) | 2005-11-30 | 2014-05-07 | アッヴィ・インコーポレイテッド | アミロイドベータタンパク質に対するモノクローナル抗体及びその使用 |
| PL1954718T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał |
| CA2632094C (en) | 2005-12-02 | 2015-01-27 | Wayne A. Marasco | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
| JP5808070B2 (ja) * | 2005-12-02 | 2015-11-10 | ジェネンテック， インコーポレイテッド | 結合ポリペプチド及びその使用 |
| AU2006342792A1 (en) | 2005-12-02 | 2007-11-08 | Genentech, Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R |
| EP1973951A2 (en) * | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| WO2007065273A1 (en) * | 2005-12-08 | 2007-06-14 | The University Of British Columbia | Mucopolysaccharidosis (mps) diagnostic methods, systems, kits and assays associated therewith |
| PL1960434T3 (pl) | 2005-12-08 | 2012-12-31 | Squibb & Sons Llc | Ludzkie przeciwciała monoklonalne przeciw fozylowi-gm1 i sposoby zastosowania antyfukozylu-gm1 |
| US20070134249A1 (en) * | 2005-12-08 | 2007-06-14 | Genitope Corporation | Combination therapy and antibody panels |
| WO2007075308A2 (en) * | 2005-12-09 | 2007-07-05 | Wisconsin Alumni Research Foundation (W.A.R.F.) | Vaccine candidates against johne's disease |
| DOP2006000277A (es) | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
| PL2481753T3 (pl) | 2005-12-13 | 2018-09-28 | Eli Lilly And Company | Przeciwciała anty-IL-17 |
| AU2005339101B2 (en) | 2005-12-14 | 2013-01-10 | Herantis Pharma Plc. | Novel neurotrophic factor protein and uses thereof |
| AR057237A1 (es) | 2005-12-15 | 2007-11-21 | Genentech Inc | Metodos y composiciones para actuar sobre la poliubiquitina |
| US20070264687A1 (en) | 2005-12-15 | 2007-11-15 | Min-Yuan Chou | Recombinant triplex scaffold-based polypeptides |
| US10183986B2 (en) | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
| US7632498B2 (en) | 2005-12-19 | 2009-12-15 | Tripath Imaging, Inc. | MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease |
| US7625759B2 (en) * | 2005-12-19 | 2009-12-01 | Genentech, Inc. | Method for using BOC/CDO to modulate hedgehog signaling |
| EP1981535A2 (en) * | 2005-12-22 | 2008-10-22 | IQ Corporation | Compositions and methods of modulating the immune response |
| AU2006342119B8 (en) * | 2005-12-22 | 2013-05-09 | Novartis Ag | Soluble human M-CSF receptor and uses thereof |
| BRPI0620946B8 (pt) | 2005-12-29 | 2021-05-25 | Centocor Inc | anticorpo il-23p19 isolado, composição, método in vitro, artigo de fabricação, molécula e vetor de ácido nucleico, célula hospedeira procariótica |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| EP1966245B1 (en) | 2005-12-30 | 2011-05-18 | Merck Patent GmbH | Anti-cd19 antibodies with reduced immunogenicity |
| EP3026119B1 (en) | 2006-01-04 | 2019-09-18 | Fujirebio America, Inc. | Use of he4 and other biochemical markers for assessment of ovarian cancers |
| US8101365B2 (en) | 2006-01-05 | 2012-01-24 | Genentech, Inc. | Anti-EphB4 antibodies and methods using same |
| CN101534858A (zh) * | 2006-01-05 | 2009-09-16 | 诺华有限公司 | 预防和治疗癌症转移和癌症转移相关性骨丢失的方法 |
| RU2520088C2 (ru) | 2006-01-12 | 2014-06-20 | Алексион Фармасьютикалз, Инк. | Антитела к ох-2/сd200 и их применение |
| WO2007080597A2 (en) | 2006-01-16 | 2007-07-19 | Compugen Ltd. | Polynucleotide and polypeptide sequences and methods for diagnosis |
| US20070166306A1 (en) * | 2006-01-17 | 2007-07-19 | Fey Georg H M | Anti-CD19 antibody composition and method |
| EP1973569B1 (en) | 2006-01-18 | 2013-05-22 | Merck Patent GmbH | Specific therapy using integrin ligands for treating cancer |
| US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
| JP5554925B2 (ja) | 2006-01-20 | 2014-07-23 | セル・シグナリング・テクノロジー・インコーポレイテツド | ヒト非小細胞肺癌における転座及び変異体ｒｏｓキナーゼ |
| EP3135298B1 (en) | 2006-01-27 | 2018-06-06 | Keio University | Therapeutic agents for diseases involving choroidal neovascularization |
| ES2550099T3 (es) | 2006-01-27 | 2015-11-04 | Biogen Ma Inc. | Antagonistas del receptor Nogo |
| US20070178103A1 (en) * | 2006-01-30 | 2007-08-02 | Fey Georg H | CD19-specific immunotoxin and treatment method |
| US20080038761A1 (en) * | 2006-01-30 | 2008-02-14 | Invitrogen Corporation | Compositions and methods for detecting and quantifying toxic substances in disease states |
| US20070179094A1 (en) | 2006-01-31 | 2007-08-02 | Bayer Schering Pharma Ag | Modulation of MDL-1 activity for treatment of inflammatory disease |
| US7846439B2 (en) | 2006-02-01 | 2010-12-07 | Cephalon Australia Pty Ltd | Domain antibody construct |
| ATE491948T1 (de) * | 2006-02-06 | 2011-01-15 | Rhode Island Hospital | Gpr30-östrogenrezeptor bei mammakarzinomen |
| EP1994043A4 (en) | 2006-02-10 | 2009-05-20 | Univ Cincinnati | PROTEIN-A PHOSPHATASE INHIBITOR AS REGULATOR OF CARDIAC FUNCTION |
| US7790857B2 (en) * | 2006-02-10 | 2010-09-07 | Sanofi Pasteur Limited | Monoclonal antibodies and uses thereof |
| EP2623610B1 (en) | 2006-02-10 | 2015-04-29 | Life Technologies Corporation | Labeling and detection of post translationally modified proteins |
| CA2642056A1 (en) * | 2006-02-13 | 2007-08-23 | Fraunhofer Usa, Inc. | Hpv antigens, vaccine compositions, and related methods |
| US8277816B2 (en) * | 2006-02-13 | 2012-10-02 | Fraunhofer Usa, Inc. | Bacillus anthracis antigens, vaccine compositions, and related methods |
| AU2007215080A1 (en) * | 2006-02-13 | 2007-08-23 | Fraunhofer Usa, Inc. | Influenza antigens, vaccine compositions, and related methods |
| EP1989228B1 (en) | 2006-02-14 | 2015-04-29 | University Of Tasmania Through The Menzies Research Institute | Metallothionein-derived peptide fragments |
| CA2638821A1 (en) | 2006-02-17 | 2007-10-11 | Genentech, Inc. | Gene disruptons, compositions and methods relating thereto |
| US7750116B1 (en) * | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
| TWI417301B (zh) | 2006-02-21 | 2013-12-01 | Wyeth Corp | 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途 |
| US20080317710A1 (en) | 2006-02-22 | 2008-12-25 | University Of Zurich | Methods For Treating Autoimmune or Demyelinating Diseases |
| US7459280B2 (en) | 2006-02-27 | 2008-12-02 | Picobella, Llc | Methods for diagnosing and treating kidney cancer |
| EP1998792B1 (en) * | 2006-03-01 | 2015-02-18 | The University of Utah Research Foundation | Methods and compositions related to cyclic peptide synthesis |
| US8470965B2 (en) * | 2006-03-01 | 2013-06-25 | University Of Utah Research Foundation | Methods and compositions related to cyclic peptide synthesis |
| US7807364B2 (en) | 2006-03-03 | 2010-10-05 | University Of Southern California | Angiogenesis pathway gene polymorphisms for therapy selection |
| WO2007103470A2 (en) | 2006-03-06 | 2007-09-13 | Medimmune, Inc. | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| EP2540741A1 (en) | 2006-03-06 | 2013-01-02 | Aeres Biomedical Limited | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| DK2596807T3 (en) * | 2006-03-08 | 2016-03-07 | Archemix Llc | Complement aptamer AND ANTI-C5 FUNDS FOR USE IN THE TREATMENT OF EYE DISEASES |
| WO2008076139A1 (en) * | 2006-03-10 | 2008-06-26 | Tethys Bioscience, Inc. | Multiplex protein fractionation |
| US7504106B2 (en) * | 2006-03-14 | 2009-03-17 | Boris Skurkovich | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis |
| CA2649688A1 (en) | 2006-03-14 | 2007-09-20 | Oregon Health & Science University | Methods for detecting a mycobacterium tuberculosis infection |
| SI2359834T1 (sl) | 2006-03-15 | 2017-02-28 | Alexion Pharmaceuticals, Inc. | Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa |
| EP2374472B9 (en) | 2006-03-16 | 2019-06-12 | Dyax Corp. | Compositions and methods for treating ophthalmic disorders |
| AR059851A1 (es) | 2006-03-16 | 2008-04-30 | Genentech Inc | Anticuerpos de la egfl7 y metodos de uso |
| US9121853B2 (en) | 2006-03-20 | 2015-09-01 | Mayo Foundation For Medical Education And Research | B7-H4 expression on tumor vasculature |
| US20100278821A1 (en) | 2006-03-21 | 2010-11-04 | The Regents Of The University Of California | N-cadherin: target for cancer diagnosis and therapy |
| CA2646597A1 (en) | 2006-03-21 | 2007-09-27 | The Regents Of The University Of California | N-cadherin and ly6 e: targets for cancer diagnosis and therapy |
| HUE025989T2 (hu) | 2006-03-21 | 2016-05-30 | Genentech Inc | Alfa5béta1-antagonistákat magában foglaló kombinációs terápia |
| EP2004221A2 (en) | 2006-03-23 | 2008-12-24 | Novartis Pharma AG | Anti-tumor cell antigen antibody therapeutics |
| PL2423229T3 (pl) | 2006-03-27 | 2013-09-30 | Medimmune Ltd | Element wiążący dla receptora GM-CSF |
| CN101454446A (zh) | 2006-03-30 | 2009-06-10 | 明治制果株式会社 | 绿脓杆菌的外膜蛋白pa0427 |
| JP6092497B2 (ja) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物 |
| JP5624276B2 (ja) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | 抗体の血中動態を制御する方法 |
| US8221966B2 (en) | 2006-03-31 | 2012-07-17 | Dana Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| EP2016949A4 (en) | 2006-03-31 | 2009-12-09 | Riken | NEW USE OF G PROTEIN CONJUGATED RECEPTOR AND ITS LIGAND |
| EP2163563A1 (en) | 2006-03-31 | 2010-03-17 | Massachusetts Institute of Technology | Treatment of tumors expressing mutant EGF receptors |
| US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
| WO2007115207A2 (en) * | 2006-03-31 | 2007-10-11 | Regents Of The University Of Minnesota | Irf-5 haplotypes in systemic lupus erythematosus |
| CN105177091A (zh) | 2006-03-31 | 2015-12-23 | 中外制药株式会社 | 用于纯化双特异性抗体的抗体修饰方法 |
| US20070292922A1 (en) * | 2006-03-31 | 2007-12-20 | Cell Genesys, Inc. | Regulated expression of recombinant proteins from adeno-associated viral vectors |
| AU2007243946B2 (en) | 2006-04-05 | 2012-11-29 | Curis, Inc. | Method for using BOC/CDO to modulate hedgehog signaling |
| EP2738179A1 (en) | 2006-04-05 | 2014-06-04 | AbbVie Biotechnology Ltd | Antibody purification |
| NZ572379A (en) | 2006-04-05 | 2012-06-29 | Univ Rockefeller | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| US20070280935A1 (en) * | 2006-04-07 | 2007-12-06 | Bernd Bohrmann | Antibody that recognizes phosphorylated peptides |
| BRPI0710645A2 (pt) | 2006-04-07 | 2012-03-20 | The Procter & Gamble Company | Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos |
| WO2007117657A2 (en) | 2006-04-07 | 2007-10-18 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
| MX2008012754A (es) * | 2006-04-07 | 2009-04-27 | Us Gov Health & Human Serv | Composiciones de anticuerpos y metodos para tratamiento de enfermedad neoplastica. |
| EP2025346B1 (en) | 2006-04-07 | 2016-08-10 | Osaka University | Muscle regeneration promoter |
| EP2666479A3 (en) | 2006-04-10 | 2014-03-26 | Abbott Biotechnology Ltd | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| GB0620255D0 (en) * | 2006-10-12 | 2006-11-22 | Fusion Antibodies Ltd | Antibody and uses thereof |
| CA2648322C (en) | 2006-04-10 | 2017-11-28 | Genentech, Inc. | Disheveled pdz modulators |
| CA2564435A1 (en) | 2006-04-10 | 2007-10-10 | Abbott Biotechnology Ltd. | Methods for monitoring and treating intestinal disorders |
| JP5796267B2 (ja) * | 2006-04-10 | 2015-10-21 | フージョン アンティボディーズ リミテッド | 治療法 |
| WO2008063213A2 (en) | 2006-04-10 | 2008-05-29 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
| KR101288027B1 (ko) * | 2006-04-12 | 2013-07-22 | 새비언트 파마수티컬즈 인크. | 양이온 계면활성제를 이용한 단백질 정제 방법 |
| EP2447360A1 (en) | 2006-04-14 | 2012-05-02 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| US8784810B2 (en) * | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
| JP2009536022A (ja) | 2006-04-19 | 2009-10-08 | ジェネンテック・インコーポレーテッド | 新規の遺伝子破壊、それに関連する組成物および方法 |
| EP2420246A1 (en) | 2006-04-20 | 2012-02-22 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Methods and compositions based on shiga toxin type 1 protein |
| NZ571757A (en) | 2006-04-21 | 2012-01-12 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer |
| EP2013346B1 (en) | 2006-04-21 | 2014-11-26 | Intervet International B.V. | Pestivirus species |
| US20070254338A1 (en) * | 2006-04-24 | 2007-11-01 | Amgen Inc. | Method for making recombinant protein using complementation dependent DHFR mutants |
| DK2557180T3 (da) | 2006-04-24 | 2014-09-15 | Genentech Inc | Fremgangsmåder til påvisning af autoimmune lidelser |
| TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| US8492097B2 (en) * | 2006-04-24 | 2013-07-23 | Diagnostic Hybrids, Inc. | Compositions and methods for human metapneumovirus monoclonal antibodies |
| EP2011513B1 (en) | 2006-04-25 | 2016-10-19 | The University of Tokyo | Therapeutic agents for alzheimer's disease and cancer |
| US20070258908A1 (en) * | 2006-04-27 | 2007-11-08 | Lanza Gregory M | Detection and imaging of target tissue |
| WO2007127335A2 (en) * | 2006-04-27 | 2007-11-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways |
| WO2007128757A2 (en) | 2006-05-02 | 2007-11-15 | Actogenix N.V. | Microbial intestinal delivery of obesity related peptides |
| US20070258976A1 (en) * | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
| DE102006020885A1 (de) * | 2006-05-05 | 2007-11-08 | Qiagen Gmbh | Einführung von Sequenzelementen in Nukleinsäuren |
| WO2007134050A2 (en) * | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| US7727525B2 (en) * | 2006-05-11 | 2010-06-01 | City Of Hope | Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics |
| CA2651962A1 (en) | 2006-05-12 | 2007-12-21 | Oklahoma Medical Research Foundation | Anthrax compositions and methods of use and production |
| WO2007134132A2 (en) * | 2006-05-12 | 2007-11-22 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors |
| JP2009537536A (ja) * | 2006-05-15 | 2009-10-29 | ユニヴァーシティ・オヴ・ケンタッキー | 眼の血管形成および黄斑変性に対するＴｏｌｌ様受容体（ＴＬＲ）の刺激 |
| EP1918302A3 (en) * | 2006-05-18 | 2009-11-18 | AvantGen, Inc. | Methods for the identification and the isolation of epitope specific antibodies |
| EP2027284A2 (en) * | 2006-05-18 | 2009-02-25 | Sanofi-Aventis | Use of adamts4 gene and protein polymorphisms |
| CN107573445B (zh) | 2006-05-27 | 2021-05-25 | 富鲁达加拿大公司 | 聚合物骨架元素标签 |
| DK2032606T3 (da) | 2006-05-30 | 2014-02-03 | Genentech Inc | Antistoffer og immunkonjugater og anvendelser deraf |
| US7862812B2 (en) * | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
| US9274130B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
| US20080138334A1 (en) * | 2006-05-31 | 2008-06-12 | Sabbadini Roger A | Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same |
| US8796429B2 (en) | 2006-05-31 | 2014-08-05 | Lpath, Inc. | Bioactive lipid derivatives, and methods of making and using same |
| US9274129B2 (en) * | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Methods and reagents for detecting bioactive lipids |
| WO2007143121A2 (en) | 2006-06-01 | 2007-12-13 | President And Fellows Of Harvard College | Purification of a bivalently active antibody using a non-chromatographic method |
| EP2024391A2 (en) | 2006-06-01 | 2009-02-18 | Genentech, Inc. | Crystal structure of crig and c3b: crig complex |
| DK2027156T3 (da) | 2006-06-02 | 2011-04-26 | Aveo Pharmaceuticals Inc | Hepatocytvækstfaktor (HGF)bindingsprotein |
| AU2007257162A1 (en) | 2006-06-05 | 2007-12-13 | Cancer Care Ontario | Assessment of risk for colorectal cancer |
| RU2008152435A (ru) * | 2006-06-06 | 2010-07-20 | Дженентек, Инк. (Us) | Композиции и способы регулирования развития сосудов |
| CL2007001623A1 (es) | 2006-06-06 | 2008-01-18 | Genentech Inc | Anticuerpo anti-dll4; polinucleotido que lo codifica; vector y celula huesped que comprenden dicho polinucleotido; metodo para elaborar el anticuerpo e inmunojugado; metodo de deteccion de dll4 y metodo diagnostico de un trastorno asociado a dll4; composicion que comprende al anticuerpo. |
| GB0611116D0 (en) | 2006-06-06 | 2006-07-19 | Oxford Genome Sciences Uk Ltd | Proteins |
| EA031202B1 (ru) * | 2006-06-06 | 2018-11-30 | Янссен Вэксинс Энд Превеншн Б.В. | Антитело человека, обладающее фагоцитарной активностью против стафилококков, и его применение |
| NZ572561A (en) * | 2006-06-07 | 2012-05-25 | Bioalliance Cv | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
| US20110287010A1 (en) | 2006-06-07 | 2011-11-24 | Otago Innovation Limited | Diagnostic methods and markers |
| AT503690A1 (de) | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
| CA2654317A1 (en) * | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| US9056906B2 (en) | 2006-06-14 | 2015-06-16 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| KR20090021217A (ko) | 2006-06-14 | 2009-02-27 | 추가이 세이야쿠 가부시키가이샤 | 조혈 줄기세포 증가 촉진제 |
| US7858756B2 (en) | 2006-06-15 | 2010-12-28 | The Board Of Trustees Of The University Of Arkansas | Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds |
| CA2655504A1 (en) | 2006-06-15 | 2007-12-21 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| JP5597793B2 (ja) * | 2006-06-19 | 2014-10-01 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｉｌｔ３結合分子およびその使用 |
| KR101351208B1 (ko) | 2006-06-21 | 2014-01-14 | 온코세라피 사이언스 가부시키가이샤 | Ｆｚｄ10에 대한 종양-표적화 모노클로날 항체 및 이의 용도 |
| US8874380B2 (en) | 2010-12-09 | 2014-10-28 | Rutgers, The State University Of New Jersey | Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs |
| AU2007260817A1 (en) | 2006-06-23 | 2007-12-27 | Myriad Genetics, Inc. | DPYD gene variants and use thereof |
| HUE030269T2 (en) | 2006-06-26 | 2017-04-28 | Macrogenics Inc | FC RIIB-specific antibodies and methods for their use |
| WO2008000079A1 (en) * | 2006-06-26 | 2008-01-03 | The University Of British Columbia | Secreted protein acidic and rich in cysteine (sparc) as chemotherapeutic sensitizers |
| FR2902799B1 (fr) | 2006-06-27 | 2012-10-26 | Millipore Corp | Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide |
| PT2193801E (pt) | 2006-06-28 | 2012-02-28 | Yeda Res & Dev | Caspase-8 e tratamento de inflamação, infecção e cicatrização de ferida |
| CA2651992A1 (en) * | 2006-06-30 | 2008-01-10 | Abbott Biotechnology Ltd. | Automatic injection device |
| CA2655997A1 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Igfbp2 biomarker |
| DK2426150T3 (en) | 2006-06-30 | 2018-01-22 | Novo Nordisk As | ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF |
| US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
| AU2007269714A1 (en) | 2006-07-03 | 2008-01-10 | Charles David Adair | Composition for modulating the expression of cell adhesion molecules |
| EP2046383B1 (en) | 2006-07-04 | 2014-11-19 | Genmab A/S | Cd20 binding molecules for the treatment of copd |
| US20080026376A1 (en) | 2006-07-11 | 2008-01-31 | Huaming Wang | KEX2 cleavage regions of recombinant fusion proteins |
| US8198046B2 (en) * | 2006-07-11 | 2012-06-12 | Danisco Us Inc. | KEX2 cleavage regions of recombinant fusion proteins |
| WO2008007804A1 (fr) | 2006-07-12 | 2008-01-17 | Gene Techno Science Co., Ltd. | ANTICORPS ANTI-INTÉGRINE α-9 HUMAINE ET UTILISATION DE CELUI-CI |
| SI2495307T1 (en) | 2006-07-13 | 2018-05-31 | Wyeth Llc | Production of the calibration factor IX with an improved glycolization pattern |
| EP2447275B1 (en) | 2006-07-13 | 2015-04-01 | University of Iowa Research Foundation | Methods and reagents for treatment of age-related macular degeneration |
| WO2008010101A2 (en) | 2006-07-18 | 2008-01-24 | Sanofi-Aventis | Antagonist antibody against epha2 for the treatment of cancer |
| ES2612383T3 (es) | 2006-07-19 | 2017-05-16 | The Trustees Of The University Of Pennsylvania | WSX-1/IL-27 como una diana para respuestas antiinflamatorias |
| ATE465179T1 (de) | 2006-07-24 | 2010-05-15 | Pasteur Institut | Antikörper, antikörperfragmente und scfv die an posttranslational modifizierte neurotrophine binden |
| GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| CA2659012A1 (en) * | 2006-07-26 | 2008-01-31 | Diamedica Inc. | Methods of diagnosis and treatment for metabolic disorders |
| CN101626783A (zh) * | 2006-08-04 | 2010-01-13 | 诺华有限公司 | Ephb3-特异性抗体和其应用 |
| US20100112601A1 (en) | 2006-08-08 | 2010-05-06 | Kyoto University | Novel monoclonal antibody and use of the same |
| AU2007284651B2 (en) | 2006-08-09 | 2014-03-20 | Institute For Systems Biology | Organ-specific proteins and methods of their use |
| AR062223A1 (es) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
| US7939636B2 (en) * | 2006-08-11 | 2011-05-10 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in c-Src signaling pathways |
| AU2007283463B2 (en) | 2006-08-11 | 2012-04-26 | Csl Limited | Treatment of pulmonary disease conditions |
| JP5244785B2 (ja) | 2006-08-11 | 2013-07-24 | 小野薬品工業株式会社 | ストローマ由来因子−１（ｓｄｆ−１）に対するモノクローナル抗体 |
| US20090269342A1 (en) * | 2006-08-14 | 2009-10-29 | Massachusetts Institute Of Technology | Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto |
| PT2383297E (pt) | 2006-08-14 | 2013-04-15 | Xencor Inc | Anticorpos otimizados que visam cd |
| US9867530B2 (en) | 2006-08-14 | 2018-01-16 | Volcano Corporation | Telescopic side port catheter device with imaging system and method for accessing side branch occlusions |
| BRPI0715718A2 (pt) | 2006-08-18 | 2014-06-24 | Novartis Ag | Anticorpo, métodos de triar para um anticorpo para o domínio extracelular de uma proteína prlr, de alterar sistematicamente anticorpos e triar para um anticorpo para o domínio extracelular de uma proteína prlr, de tratar um indivíduo que sofre de câncer, de alvejar uma célula tumoral que expressa prlr, de usar uma célula hospedeira, de identificar um indivíduo com necessidade de tratamento com um anticorpo anti-prlr, e de monitorar terapia de câncer em um indivíduo, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, composição farmacêutica, e, kit |
| EP2423333A1 (en) | 2006-08-25 | 2012-02-29 | Oncotherapy Science, Inc. | Prognostic markers and therapeutic targets for lung cancer |
| EA021255B1 (ru) | 2006-08-28 | 2015-05-29 | Киова Хакко Кирин Ко., Лимитед | Антагонистические моноклональные антитела человека, специфичные в отношении light человека |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| US20090258442A1 (en) * | 2006-08-31 | 2009-10-15 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| PL2594586T3 (pl) | 2006-09-01 | 2015-02-27 | Zymogenetics Inc | Przeciwciała monoklonalne IL-31 i sposoby ich zastosowania |
| US7951776B2 (en) | 2006-09-01 | 2011-05-31 | American Type Culture Collection | Methods for treatment of type 1 diabetes |
| US20090203602A1 (en) | 2006-09-01 | 2009-08-13 | Cohava Gelber | Compositions and methods for diagnosis and treatment of type 2 diabetes |
| GB0617429D0 (en) | 2006-09-05 | 2006-10-18 | Electrophoretics Ltd | Markers of renal transplant rejection and renal damage |
| SI2061810T1 (sl) | 2006-09-05 | 2015-04-30 | Alexion Pharmaceuticals, Inc. | Postopki in sestavki za zdravljenje s protitelesi povezanih nevropatij |
| WO2008030122A1 (en) | 2006-09-07 | 2008-03-13 | University Of Otago | Biomarkers |
| US20080064045A1 (en) * | 2006-09-07 | 2008-03-13 | Huaiqin Wu | Biomarker fragments for the detection of human BNP |
| WO2008033333A2 (en) | 2006-09-08 | 2008-03-20 | Amgen Inc. | Il-1 family variants |
| PL3339445T3 (pl) | 2006-09-08 | 2020-12-14 | Abbvie Bahamas Ltd. | Białka wiążące interleukinę 13 |
| US20100008910A1 (en) | 2006-09-12 | 2010-01-14 | John Chant | Methods and compositions for the diagnosis and treatment of cancer |
| EP2500416A1 (en) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
| NZ597334A (en) | 2006-09-13 | 2014-02-28 | Abbott Lab | Cell culture improvements |
| EP2064240A2 (en) | 2006-09-18 | 2009-06-03 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
| EP2492278A1 (en) | 2006-09-18 | 2012-08-29 | Compugen Ltd. | Antibodies against an agonist of G-protein coupled receptors and its use indiagnosis and therapy |
| US20080076139A1 (en) | 2006-09-21 | 2008-03-27 | Sharat Singh | Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells |
| PL2081595T3 (pl) | 2006-09-26 | 2019-11-29 | Genmab As | Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych |
| FR2906533B1 (fr) | 2006-09-28 | 2013-02-22 | Pf Medicament | Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| HUE028379T2 (en) | 2006-09-29 | 2016-12-28 | Oncomed Pharm Inc | Preparations and procedures for the diagnosis and treatment of cancer |
| CA2664712C (en) | 2006-09-29 | 2019-07-09 | Translational Therapeutics, Inc. | Eif4e regulon-based diagnostics |
| BRPI0718197A2 (pt) | 2006-10-02 | 2014-09-30 | Medarex Inc | Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, e, métodos para preparar um anticorpo anti-cxcr4, para modular a atividade do cxcr4 em uma célula, e para estimular a mobilização de células tronco cd34+ da medula óssea para o sangue periférico em um indivíduo. |
| US20120282245A1 (en) | 2006-10-03 | 2012-11-08 | Biogen Idec Ma Inc. | Biomarkers and assays for the treatment of cancer |
| PL2069798T3 (pl) | 2006-10-04 | 2014-09-30 | Genentech Inc | Test ELISA dla VEGF |
| AU2007307536A1 (en) | 2006-10-06 | 2008-04-17 | Takeda Pharmaceutical Company Limited | Agent for preventing/treating cancer |
| CA2664630C (en) | 2006-10-10 | 2018-11-27 | Shiv Srivastava | Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations |
| US20100111965A1 (en) * | 2006-10-11 | 2010-05-06 | Fusion Antibodies Limited | Combination therapy |
| WO2008043566A2 (en) * | 2006-10-11 | 2008-04-17 | Janssen Pharmaceutica N.V. | Compositions and methods for treating and diagnosing irritable bowel syndrome |
| CA2665423A1 (en) * | 2006-10-12 | 2008-04-17 | Wyeth | Methods and compositions with reduced opalescence |
| WO2008063776A2 (en) * | 2006-10-12 | 2008-05-29 | Genentech, Inc. | Antibodies to lymphotoxin-alpha |
| JP5247106B2 (ja) * | 2006-10-13 | 2013-07-24 | キヤノン株式会社 | タンパク質、タンパク質の固定方法、構造体、バイオセンサー、核酸、ベクター及び標的物質検出用キット |
| WO2008048545A2 (en) | 2006-10-16 | 2008-04-24 | Medimmune, Llc. | Molecules with reduced half-lives, compositions and uses thereof |
| EP2068921B1 (en) | 2006-10-19 | 2014-07-09 | CSL Limited | High affinity antibody antagonists of interleukin-13 receptor alpha 1 |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US8613925B2 (en) | 2006-10-19 | 2013-12-24 | Csl Limited | Anti-IL-13Rα1 antibodies and their uses thereof |
| US8338376B2 (en) * | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
| US8108030B2 (en) | 2006-10-20 | 2012-01-31 | Board Of Regents, The University Of Texas System | Method and apparatus to identify vulnerable plaques with thermal wave imaging of heated nanoparticles |
| MX2009004134A (es) * | 2006-10-20 | 2009-08-12 | Biogen Idec Inc | Tratamiento de trastornos de desmielinizacion con el receptor de linfotoxina beta soluble. |
| WO2008051511A2 (en) | 2006-10-20 | 2008-05-02 | Applera Corporation | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof |
| CN101528777B (zh) | 2006-10-26 | 2013-03-27 | 株式会社遗传科技 | 抗胞外基质蛋白的rgd氨基酸序列的抗体及其制法与用途 |
| EP1916259A1 (en) | 2006-10-26 | 2008-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti-glycoprotein VI SCFV fragment for treatment of thrombosis |
| CN101687031B (zh) * | 2006-10-27 | 2014-05-14 | 勒帕斯公司 | 用于治疗眼疾和眼病的组合物及方法 |
| AU2007329759B2 (en) * | 2006-10-27 | 2013-05-30 | Lpath, Inc. | Compositions and methods for binding sphingosine-1-phosphate |
| US7745148B2 (en) | 2006-10-30 | 2010-06-29 | Functional Genetics, Inc. | Random homozygous gene perturbation to enhance antibody production |
| GB0621513D0 (en) * | 2006-10-30 | 2006-12-06 | Domantis Ltd | Novel polypeptides and uses thereof |
| WO2008070367A2 (en) * | 2006-11-01 | 2008-06-12 | Facet Biotech Corporation | Mammalian cell-based immunoglobulin display libraries |
| TWI472535B (zh) | 2006-11-02 | 2015-02-11 | Genentech Inc | 人類化之抗-因子ｄ抗體及其用途 |
| BRPI0716680A2 (pt) | 2006-11-02 | 2013-09-24 | Daniel J Capon | "composto, multÍmero, composiÇço, mÉtodo de afetar a atividade de um alvo, complexo, processo de produÇço do composto, mÉtodo de produÇço de um extensço de aminoÁcidos consecutivos, processo de produÇço de uma extensço de aminoacidos consecutivos , processo para a produÇço de um composto , mÉtodo de produÇço de uma proteina e polipeptÍdeo" |
| EP2982963B1 (en) | 2006-11-02 | 2019-08-21 | Fluidigm Canada Inc. | Particles containing detectable elemental code |
| JP5401319B2 (ja) | 2006-11-03 | 2014-01-29 | ワイス・エルエルシー | 細胞培養における解糖阻害物質 |
| EP2094733A1 (en) | 2006-11-03 | 2009-09-02 | U3 Pharma GmbH | Fgfr4 antibodies |
| US9457047B2 (en) | 2006-11-06 | 2016-10-04 | Whitehead Institute | Immunomodulating compositions and methods of use thereof |
| ES2397186T3 (es) * | 2006-11-06 | 2013-03-05 | Whitehead Institute | Composiciones inmunomoduladoras y métodos para su uso |
| EP2094307A4 (en) | 2006-11-08 | 2015-08-26 | Macrogenics West Inc | TES7 AND THEREO BINDING ANTIBODIES |
| ES2397637T3 (es) | 2006-11-10 | 2013-03-08 | Massachusetts Institute Of Technology | Inhibidores de PAK para uso en el tratamiento de trastornos del desarrollo neurológico |
| BRPI0718644A2 (pt) * | 2006-11-13 | 2013-11-26 | Arius Res Inc | Anticorpo monoclonal isolado, anticorpos humanizado e quimérico do anticorpo monoclonal isolado, linha de célula hibridoma isolada, método para iniciar a citotoxidez induzida por anticorpo de células cancerosas em uma amostra de tecido selecionada de um tumor humano, cdmab do anticorpo monoclonal isolado ou seu cdmab e usos de um anticorpo monoclonal ou seu cdmab, sozinho ou em conjução com pelo menos um agente quimioterapêutico, e composição |
| JP2010509245A (ja) * | 2006-11-13 | 2010-03-25 | エフ．ホフマン−ラ ロシュ アーゲー | 癌性疾患修飾抗体 |
| AU2007321665A1 (en) * | 2006-11-13 | 2008-05-22 | F. Hoffmann-La Roche Ag | Cancerous disease modifying antibodies |
| RU2447449C2 (ru) | 2006-11-14 | 2012-04-10 | Дженентек, Инк. | Модуляторы нейрональной регенерации |
| US7492312B2 (en) * | 2006-11-14 | 2009-02-17 | Fam Adly T | Multiplicative mismatched filters for optimum range sidelobe suppression in barker code reception |
| EA200970477A1 (ru) | 2006-11-15 | 2009-12-30 | Медарекс, Инк. | Человеческие моноклональные антитела к btla и способы применения |
| AU2007323799B2 (en) * | 2006-11-15 | 2013-07-18 | Eli Lilly And Company | Anti-TSG101 antibodies and their uses for treatment of viral infections |
| BRPI0718406A2 (pt) | 2006-11-17 | 2013-12-17 | Novartis Ag | Moléculas de ligação de lingo e uso farmacêutico das mesmas |
| CA2670320A1 (en) | 2006-11-21 | 2008-11-20 | The Regents Of The University Of California | Modulation of rhamm (cd168) for selective adipose tissue development |
| US20100062000A1 (en) * | 2006-11-21 | 2010-03-11 | The Regents Of The University Of California | Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations |
| ES2432173T3 (es) | 2006-11-21 | 2013-12-02 | Kalobios Pharmaceuticals, Inc. | Métodos de tratamiento de enfermedades inflamatorias crónicas usando un antagonista de GM-CSF |
| US8785400B2 (en) * | 2006-11-22 | 2014-07-22 | Curedm Group Holdings, Llc | Methods and compositions relating to islet cell neogenesis |
| JP5391073B2 (ja) | 2006-11-27 | 2014-01-15 | ディアデクサス インコーポレーテッド | Ｏｖｒ１１０抗体組成物および使用方法 |
| AU2007355108B2 (en) | 2006-11-27 | 2013-07-11 | Patrys Limited | Novel glycosylated peptide target in neoplastic cells |
| WO2008064884A1 (en) | 2006-11-28 | 2008-06-05 | U3 Pharma Gmbh | Activated her3 as a marker for predicting therapeutic efficacy |
| US8067179B2 (en) | 2006-11-30 | 2011-11-29 | Research Development Foundation | Immunoglobulin libraries |
| TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| PT2662091T (pt) | 2006-12-01 | 2018-12-03 | Novartis Ag | Anticorpos anti-p-selectina e métodos para os utilizar no tratamento de doenças inflamatórias |
| EP2099823B2 (en) | 2006-12-01 | 2022-02-09 | Seagen Inc. | Variant target binding agents and uses thereof |
| BRPI0717902A2 (pt) | 2006-12-01 | 2013-10-29 | Medarex Inc | "anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo" |
| US7858752B2 (en) | 2006-12-05 | 2010-12-28 | Abbott Laboratories | Recombinant antibodies against hepatitis C virus and methods of obtaining and using same |
| CN101678100A (zh) | 2006-12-06 | 2010-03-24 | 米迪缪尼有限公司 | 治疗系统性红斑狼疮的方法 |
| WO2008070780A1 (en) | 2006-12-07 | 2008-06-12 | Novartis Ag | Antagonist antibodies against ephb3 |
| US20080139790A1 (en) * | 2006-12-08 | 2008-06-12 | Jennings Philip A | Chimeric antibodies |
| EP2121751B1 (en) | 2006-12-08 | 2017-01-25 | Lexicon Pharmaceuticals, Inc. | Monoclonal antibodies against angptl3 |
| AU2007333098A1 (en) | 2006-12-14 | 2008-06-19 | Medarex, Inc. | Human antibodies that bind CD70 and uses thereof |
| CN101605814B (zh) | 2006-12-14 | 2014-02-19 | 默沙东公司 | 经工程改造的抗tslp抗体 |
| JP5386364B2 (ja) | 2006-12-18 | 2014-01-15 | ジェネンテック， インコーポレイテッド | 抗Ｎｏｔｃｈ３アンタゴニスト抗体とＮｏｔｃｈ３関連疾患の予防及び治療におけるその使用 |
| SG176448A1 (en) | 2006-12-19 | 2011-12-29 | Genentech Inc | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
| US20090186034A1 (en) * | 2006-12-19 | 2009-07-23 | Genetech, Inc. | Gene expression markers for inflammatory bowel disease |
| EP3124045A3 (en) | 2006-12-20 | 2017-05-03 | Xoma (Us) Llc | Treatment of il-1 beta related diseases |
| WO2008079302A2 (en) * | 2006-12-21 | 2008-07-03 | Millipore Corporation | Purification of proteins |
| US8569464B2 (en) | 2006-12-21 | 2013-10-29 | Emd Millipore Corporation | Purification of proteins |
| US8362217B2 (en) * | 2006-12-21 | 2013-01-29 | Emd Millipore Corporation | Purification of proteins |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| WO2008094370A2 (en) | 2006-12-22 | 2008-08-07 | University Of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
| AR064500A1 (es) * | 2006-12-22 | 2009-04-08 | Dow Agrosciences Llc | Vacunas del virus west nile (wnv) de plantas, vectores y secuencias optimizadas de codones de plantas |
| US20090068110A1 (en) * | 2006-12-22 | 2009-03-12 | Genentech, Inc. | Antibodies to insulin-like growth factor receptor |
| US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
| TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
| DK3345607T3 (da) | 2006-12-29 | 2022-11-21 | Ossifi Mab Llc | Fremgangsmåder til ændring af knoglevækst ved indgivelse af sost- eller wise-antagonist eller -agonist |
| WO2008086002A2 (en) | 2007-01-08 | 2008-07-17 | Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Slco1b3 genotype |
| US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| US20080171710A1 (en) | 2007-01-17 | 2008-07-17 | University Of Rochester | The Redox/Fyn/c-Cbl Pathway |
| AU2008207095B2 (en) | 2007-01-18 | 2013-08-29 | Merck Patent Gmbh | Specific therapy and medicament using integrin ligands for treating cancer |
| CA2675366A1 (en) * | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms predictive for dual tki therapy |
| KR101431856B1 (ko) | 2007-01-22 | 2014-08-27 | 제넨테크, 인크. | 항체의 고분자전해질 침전 및 정제 |
| US8309354B2 (en) * | 2007-01-22 | 2012-11-13 | Macrogenics West, Inc. | Human cancer stem cells |
| ES2564392T3 (es) | 2007-01-23 | 2016-03-22 | Shinshu University | Inhibidores de IL-6 para el tratamiento de rechazo crónico |
| WO2008092002A2 (en) * | 2007-01-24 | 2008-07-31 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
| MX2009007987A (es) * | 2007-01-25 | 2010-03-01 | Dana Farber Cancer Inst Inc | Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante. |
| EP2109670A1 (en) * | 2007-01-25 | 2009-10-21 | Danisco A/S | Production of a lipid acyltransferase from transformed bacillus licheniformis cells |
| WO2008094147A1 (en) * | 2007-01-29 | 2008-08-07 | Wyeth | Immunophilin ligands and methods for modulating immunophilin and calcium channel activity |
| FI20075059A0 (fi) | 2007-01-29 | 2007-01-29 | Valtion Teknillinen | Allergeeniä sitovat monoklonaaliset IgE-vasta-aineet ja hypoallergeenit:tyypin l lgE:n ja allergeenin immunokompleksivuorovaikutus |
| US8143046B2 (en) | 2007-02-07 | 2012-03-27 | Danisco Us Inc., Genencor Division | Variant Buttiauxella sp. phytases having altered properties |
| KR20090114443A (ko) | 2007-02-09 | 2009-11-03 | 제넨테크, 인크. | 항-Ｒｏｂｏ４ 항체 및 그의 용도 |
| EP1958645A1 (en) | 2007-02-13 | 2008-08-20 | Biomay AG | Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof |
| US7883705B2 (en) | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
| AR065368A1 (es) | 2007-02-15 | 2009-06-03 | Astrazeneca Ab | Anticuerpos para moleculas de ige |
| RS55636B1 (sr) | 2007-02-16 | 2017-06-30 | Genzyme Corp | Metode za prepoznavanje rizika od poremećaja štitne žlezde |
| ES2431940T3 (es) | 2007-02-16 | 2013-11-28 | Merrimack Pharmaceuticals, Inc. | Anticuerpos contra la ERBB3 y usos de los mismos |
| US8685666B2 (en) * | 2007-02-16 | 2014-04-01 | The Board Of Trustees Of Southern Illinois University | ARL-1 specific antibodies and uses thereof |
| WO2008103319A2 (en) | 2007-02-16 | 2008-08-28 | Ark Diagnostics, Inc. | Compounds and methods for use in detecting gabapentin |
| WO2008101184A2 (en) * | 2007-02-16 | 2008-08-21 | The Board Of Trustees Of Southern Illinois University | Arl-1 specific antibodies |
| US8603950B2 (en) | 2007-02-20 | 2013-12-10 | Anaptysbio, Inc. | Methods of generating libraries and uses thereof |
| KR20090122439A (ko) | 2007-02-21 | 2009-11-30 | 메다렉스, 인코포레이티드 | 단일 아미노산을 갖는 화학적 링커 및 이의 접합체 |
| DK2140021T3 (da) | 2007-02-22 | 2012-05-07 | Genentech Inc | Fremgangsmåder til detektion af inflammatorisk tarmsygdom. |
| EP2064242A1 (en) | 2007-02-23 | 2009-06-03 | Schering Corporation | Engineered anti-il-23p19 antibodies |
| EP2124988B1 (en) | 2007-02-23 | 2014-11-12 | The Trustees of Columbia University in the City of New York | Methods to activate or block the hla-e/qa-1 restricted cd8+ t cell regulatory pathway to treat immunological disease |
| EP2059534B1 (en) * | 2007-02-23 | 2012-04-25 | Schering Corporation | Engineered anti-il-23p19 antibodies |
| DK2447719T3 (en) | 2007-02-26 | 2016-10-10 | Oxford Biotherapeutics Ltd | proteins |
| WO2008104803A2 (en) | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
| US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| CN101675076B (zh) | 2007-02-28 | 2013-09-18 | 默沙东公司 | 工程化的抗il-23r抗体 |
| EP2918598B1 (en) | 2007-02-28 | 2019-01-30 | The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services | Brachyury polypeptides and methods for use |
| JP5337055B2 (ja) | 2007-02-28 | 2013-11-06 | メルク・シャープ・アンド・ドーム・コーポレーション | 免疫性障害の処置のための組合せ治療 |
| US8748371B2 (en) | 2007-02-28 | 2014-06-10 | Yeda Research And Development Co. Ltd. | Nuclear targeting sequences |
| EP2924113B1 (en) | 2007-03-02 | 2019-04-10 | Wyeth LLC | Use of copper and glutamate in cell culture for production of polypeptides |
| NZ578824A (en) | 2007-03-02 | 2012-03-30 | Genentech Inc | Predicting response to a her dimerisation inhibitor based on low her3 expression |
| AU2008222563A1 (en) | 2007-03-05 | 2008-09-12 | Cancer Care Ontario | Assessment of risk for colorectal cancer |
| US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
| TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| US20090081659A1 (en) | 2007-03-07 | 2009-03-26 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| NZ579478A (en) | 2007-03-08 | 2012-08-31 | Kalobios Pharmaceuticals Inc | Epha3 antibodies for the treatment of solid tumors |
| CL2008000719A1 (es) | 2007-03-12 | 2008-09-05 | Univ Tokushima Chugai Seiyaku | Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a |
| EP2134738A4 (en) | 2007-03-14 | 2010-04-21 | Univ Washington | METHODS OF IDENTIFYING DRUGS OF DIABETES AND OBESITY |
| EP2125898B1 (en) | 2007-03-14 | 2013-05-15 | Novartis AG | Apcdd1 inhibitors for treating, diagnosing or detecting cancer |
| CN101688229B (zh) | 2007-03-15 | 2013-06-12 | 路德维格癌症研究所 | 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途 |
| GB2447786C (en) * | 2007-03-22 | 2011-11-09 | Heptares Therapeutics Ltd | Mutant G-protein coupled receptor proteins and methods for selecting them |
| PL2125894T3 (pl) | 2007-03-22 | 2019-08-30 | Biogen Ma Inc. | Białka wiążące, w tym przeciwciała, pochodne przeciwciał i fragmenty przeciwciał, które swoiście wiążą się z CD154 i ich zastosowania |
| US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
| WO2008118324A2 (en) | 2007-03-26 | 2008-10-02 | Macrogenics, Inc. | Composition and method of treating cancer with an anti-uroplakin ib antibody |
| US20090068684A1 (en) * | 2007-03-26 | 2009-03-12 | Cell Signaling Technology, Inc. | Serine and threoninephosphorylation sites |
| KR101540822B1 (ko) | 2007-03-27 | 2015-07-30 | 씨 레인 바이오테크놀로지스, 엘엘씨 | 항체 대용물 경쇄 서열을 포함하는 구축물 및 라이브러리 |
| TW200902064A (en) * | 2007-03-28 | 2009-01-16 | Wyeth Corp | Methods and compositions for modulating IL-17F/IL-17A biological activity |
| GB0706070D0 (en) * | 2007-03-28 | 2007-05-09 | Scancell Ltd | Nucleic acids |
| US20080238709A1 (en) * | 2007-03-28 | 2008-10-02 | Faramarz Vaziri | One-way communication apparatus with dynamic key generation |
| WO2008120202A2 (en) | 2007-03-29 | 2008-10-09 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
| WO2008121391A2 (en) * | 2007-03-29 | 2008-10-09 | Fujirebio Diagnostics, Inc. | Use of he4 for assessment of breast cancers |
| BRPI0809674A2 (pt) | 2007-03-30 | 2014-10-07 | Medimmune Llc | Formulação aquosa estéril, estável, forma de dosagem unitária farmacêutica, recipiente selado, kit, método para prevenir, controlar, tratar ou melhorar uma doença ou distúrbio inflamatório, composição, processo para a preparação de uma composição, e, método para estabilizar um anticorpo 13h5 |
| EA036322B1 (ru) | 2007-04-02 | 2020-10-26 | Филоджен С.П.А. | Антитело, связывающееся с изоформой ed-a фибронектина, и его применение для лечения опухолевых метастазов |
| ATE501280T1 (de) * | 2007-04-04 | 2011-03-15 | Chimera Biotec Gmbh | Verfahren zum nachweis eines analyten in einer biologischen matrix |
| WO2008124176A2 (en) | 2007-04-10 | 2008-10-16 | The Administrators Of The Tulane Educational Fund | Soluble and membrane-anchored forms of lassa virus subunit proteins |
| US7807168B2 (en) * | 2007-04-10 | 2010-10-05 | Vaccinex, Inc. | Selection of human TNFα specific antibodies |
| PL2155248T3 (pl) | 2007-04-12 | 2015-12-31 | Brigham & Womens Hospital Inc | Celowanie w ABCB5 w terapii nowotworowej |
| BRPI0810118A8 (pt) * | 2007-04-18 | 2015-09-29 | Janssen Alzheimer Immunotherap | Método para tratar doença, método para efetuar profilaxia contra caa, uso de um agente, método para reduzir amilóide vascular em um paciente, e, kit para tratamento |
| US8003097B2 (en) * | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| EP1983002A3 (en) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
| EP1983003A3 (en) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
| US7977462B2 (en) | 2007-04-19 | 2011-07-12 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
| EP2140263B1 (en) * | 2007-04-20 | 2017-01-04 | The Board of Trustees of The University of Arkansas | Hapten compounds and compositions and uses thereof |
| TW200902708A (en) * | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
| CN101293916A (zh) | 2007-04-24 | 2008-10-29 | 上海国健生物技术研究院 | 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及用途 |
| EP2139916A1 (en) | 2007-04-26 | 2010-01-06 | Opsona Therapeutics Limited | Toll-like receptor binding epitope and compositions for binding thereto |
| US20080267977A1 (en) * | 2007-04-26 | 2008-10-30 | Friedrich-Alexander University Of Erlangen-Nuremberg | Combined immunological agent and sensitizing agent for the treatment of cancer |
| BRPI0810865A2 (pt) | 2007-04-28 | 2017-05-09 | Fraunhofer Usa Inc | antígenos de tripanossoma, composições vacinais, e métodos relacionados |
| CA2684998A1 (en) | 2007-04-30 | 2009-01-29 | Nanogen, Inc. | Multianalyte assay |
| EP2155789B1 (en) | 2007-05-01 | 2013-07-24 | Research Development Foundation | Immunoglobulin fc libraries |
| US20090053831A1 (en) | 2007-05-01 | 2009-02-26 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
| WO2009009215A2 (en) * | 2007-05-02 | 2009-01-15 | Emory University | Enhancement of glycoprotein incorporation into virus-like particles |
| BRPI0811466A2 (pt) | 2007-05-07 | 2014-10-14 | Medimmune Llc | Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica. |
| EP2162552A4 (en) | 2007-05-11 | 2010-06-30 | Univ Johns Hopkins | BIOMARKERS FOR MELANOMES |
| WO2008143797A1 (en) | 2007-05-11 | 2008-11-27 | Genzyme Corporation | Methods of producing a secreted protein |
| ES2433967T3 (es) | 2007-05-14 | 2013-12-13 | The University Of Chicago | Productos de fusión anticuerpo-LIGHT como productos terapéuticos de cáncer |
| KR101588061B1 (ko) | 2007-05-14 | 2016-01-25 | 메디뮨 엘엘씨 | 호산구 수준을 감소시키는 방법 |
| CA2689680C (en) | 2007-05-14 | 2017-11-07 | Novimmune Sa | Fc receptor-binding polypeptides with modified effector functions |
| ES2541051T3 (es) | 2007-05-17 | 2015-07-15 | Genentech, Inc. | Estructuras cristalinas de fragmentos de neuropilina y complejos neuropilina-anticuerpo |
| MX353428B (es) | 2007-05-21 | 2018-01-12 | Genentech Inc | Métodos y composiciones para identificar y tratar lupus. |
| HUE043782T2 (hu) | 2007-05-21 | 2019-09-30 | Alderbio Holdings Llc | IL-6 elleni antitestek és alkalmazásuk |
| US8158124B2 (en) | 2007-05-30 | 2012-04-17 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| PE20090329A1 (es) * | 2007-05-30 | 2009-03-27 | Abbott Lab | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos |
| US20110064744A1 (en) * | 2007-05-30 | 2011-03-17 | Sabbadini Roger A | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
| US8604172B2 (en) * | 2009-04-17 | 2013-12-10 | Lpath, Inc. | Humanized antibody compositions and methods for binding lysophosphatidic acid |
| CA2688275A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Stable igg4 antibodies |
| PE20090321A1 (es) | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
| KR101572700B1 (ko) | 2007-06-07 | 2015-11-30 | 제넨테크, 인크. | 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법 |
| US20100298156A1 (en) | 2007-06-08 | 2010-11-25 | Si Tuen Lee-Hoeflich | Gene expression markers of tumor resistance to her2 inhibitor treatment |
| WO2008154543A2 (en) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
| ES2528167T3 (es) * | 2007-06-15 | 2015-02-04 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Tratamiento de tumores usando anticuerpo anti-L1, específico. |
| WO2008154813A1 (en) | 2007-06-15 | 2008-12-24 | Xiamen University | Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof |
| US7580304B2 (en) * | 2007-06-15 | 2009-08-25 | United Memories, Inc. | Multiple bus charge sharing |
| SI2170959T1 (sl) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
| CA2691434C (en) | 2007-06-21 | 2020-07-21 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US20080317768A1 (en) * | 2007-06-21 | 2008-12-25 | Boeing Company | Bioconjugated nanoparticles |
| WO2009002562A2 (en) | 2007-06-27 | 2008-12-31 | Marine Polymer Technologies, Inc. | Complexes of il-15 and il-15ralpha and uses thereof |
| CL2008001887A1 (es) | 2007-06-29 | 2008-10-03 | Amgen Inc | Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. |
| AU2008272087B2 (en) * | 2007-06-29 | 2013-06-13 | Meiji Seika Kaisha, Ltd. | Pseudomonas aeruginosa outer membrane protein PA4710 |
| JP5931336B2 (ja) | 2007-07-02 | 2016-06-08 | オンコメッド ファーマシューティカルズ インコーポレイテッド | がんを処置および診断するための組成物および方法 |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| CA3113365A1 (en) | 2007-07-09 | 2009-01-15 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
| EP2178558B1 (en) | 2007-07-11 | 2014-04-30 | iBio, Inc. | Yersinia pestis antigens, vaccine compositions, and related methods |
| PT2175884T (pt) * | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2178442B1 (en) | 2007-07-12 | 2017-09-06 | Volcano Corporation | Catheter for in vivo imaging |
| WO2009009786A2 (en) * | 2007-07-12 | 2009-01-15 | Board Of Regents, The University Of Texas System | Magneto-motive ultrasound detection of magnetic nanoparticles |
| AU2008273813B2 (en) | 2007-07-12 | 2013-06-13 | Compugen Ltd. | Bioactive peptides and method of using same |
| WO2009009802A1 (en) | 2007-07-12 | 2009-01-15 | Volcano Corporation | Oct-ivus catheter for concurrent luminal imaging |
| JP5770471B2 (ja) | 2007-07-12 | 2015-08-26 | サンガモ バイオサイエンシーズ， インコーポレイテッド | α−１，６−フコシルトランスフェラーゼ（ＦＵＴ８）遺伝子発現を不活性化するための方法および組成物 |
| EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| CA2696833A1 (en) | 2007-07-15 | 2009-01-22 | Yitzchak Hillman | Disease treatment via antimicrobial peptides or their inhibitors |
| IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
| PE20090481A1 (es) | 2007-07-16 | 2009-05-18 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso |
| ES2579323T3 (es) | 2007-07-16 | 2016-08-09 | Genentech, Inc. | Anticuerpos anti-CD79B e inmunoconjugados y métodos de uso |
| WO2009013619A2 (en) | 2007-07-25 | 2009-01-29 | Philogen S.P.A | The ed-a antigen of fibrinogen is associated with the neovas culature of tumor metastases |
| CN101809033A (zh) | 2007-07-25 | 2010-08-18 | 日本国立感染症研究所 | 对丙型肝炎病毒(hcv)感染具有抑制活性的抗体和其用途 |
| WO2009014263A1 (ja) | 2007-07-26 | 2009-01-29 | Osaka University | インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤 |
| AU2008282218A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| EP2023144A1 (en) * | 2007-08-01 | 2009-02-11 | Sanofi-Aventis | Novel AS160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| AU2008299784B9 (en) * | 2007-08-02 | 2015-06-18 | Gilead Biologics, Inc. | LOX and LOXL2 inhibitors and uses thereof |
| US8992938B2 (en) | 2007-08-03 | 2015-03-31 | Matthew Bellgard | Genes and proteins of Brachyspira hyodysenteriae and uses thereof |
| US8734788B2 (en) | 2007-08-03 | 2014-05-27 | Opsona Therapeutics Ltd | Composition and method for treatment of reperfusion injury and tissue damage |
| WO2009020632A1 (en) | 2007-08-06 | 2009-02-12 | Burnham Institute For Medical Research | Znf206: a novel regulator of embryonic stem cell self-renewal and pluripotency |
| US20090038182A1 (en) * | 2007-08-09 | 2009-02-12 | Lans Maris J | Footwear with built-in scale |
| AU2008287427B2 (en) * | 2007-08-13 | 2014-10-09 | Vasgene Therapeutics, Inc. | Cancer treatment using humanized antibodies that bind to EphB4 |
| CN101896503B (zh) | 2007-08-14 | 2018-05-22 | 路德维格癌症研究所有限公司 | 靶向egf受体的单克隆抗体175及其衍生物和用途 |
| US7897139B2 (en) * | 2007-08-17 | 2011-03-01 | Biochrom Pharma, Inc. | PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease |
| WO2009026397A2 (en) * | 2007-08-20 | 2009-02-26 | Fraunhofer Usa, Inc. | Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods |
| WO2009026303A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Human c-fms antigen binding proteins |
| WO2009025847A2 (en) | 2007-08-21 | 2009-02-26 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
| CA2697032C (en) | 2007-08-22 | 2021-09-14 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| TW200920405A (en) | 2007-08-24 | 2009-05-16 | Oncotherapy Science Inc | PKIB and NAALADL2 for target genes of prostate cancer therapy and diagnosis |
| RU2010111120A (ru) | 2007-08-24 | 2011-09-27 | Онкотерапи Сайенс, Инк. (Jp) | Eb13, dlx5, nptx1 и cdkn3 в качестве генов-мишеней для терапии и диагностики рака легкого |
| EP2190985A4 (en) | 2007-08-24 | 2010-12-15 | Oncotherapy Science Inc | GENES RELATED TO CANCER, CDCA5, EPHA7, STK31 AND WDHD1 |
| JP2010537638A (ja) | 2007-08-28 | 2010-12-09 | ユーエービー リサーチ ファウンデーション | 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法 |
| DK2195331T3 (da) | 2007-08-28 | 2014-02-03 | Uab Research Foundation | Syntetiske polypeptider, der efterligner apolipoprotein e, og anvendelsesmetoder |
| MX2010002264A (es) | 2007-08-30 | 2010-08-02 | Curedm Inc | Composiciones y métodos para utilizar péptidos proislet y sus analogos. |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| ES2537580T3 (es) | 2007-09-04 | 2015-06-09 | Compugen Ltd. | Polipéptidos y polinucleótidos, y usos de los mismos como una diana farmacológica para producir fármacos y agentes biológicos |
| GB0717337D0 (en) | 2007-09-06 | 2007-10-17 | Ucb Pharma Sa | Method of treatment |
| EP2033971A1 (de) * | 2007-09-06 | 2009-03-11 | Abbott GmbH & Co. KG | Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung |
| AU2008299376B2 (en) | 2007-09-12 | 2013-02-28 | Glaxosmithkline Biologicals S.A. | GAS57 mutant antigens and GAS57 antibodies |
| US20100226925A1 (en) | 2007-09-14 | 2010-09-09 | Amgen Inc. | Homogeneous Antibody Populations |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| JP5933894B2 (ja) | 2007-09-14 | 2016-06-15 | アディマブ， エルエルシー | 合理的に設計された、合成抗体ライブラリおよびその使用 |
| CA2699394C (en) | 2007-09-17 | 2020-03-24 | The Regents Of The University Of California | Internalizing human monoclonal antibodies targeting prostate cancer cells in situ |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| US7951785B2 (en) | 2007-09-21 | 2011-05-31 | California Institute Of Technology | NFIA in glial fate determination, glioma therapy and astrocytoma treatment |
| US7695963B2 (en) * | 2007-09-24 | 2010-04-13 | Cythera, Inc. | Methods for increasing definitive endoderm production |
| ES2395548T3 (es) | 2007-09-24 | 2013-02-13 | Cornell University | Proteínas inmunogénicas de la membrana externa derivada de genoma de leptospira y composiciones y métodos basados en las mismas |
| GB0718843D0 (en) | 2007-09-26 | 2007-11-07 | Cancer Rec Tech Ltd | Materials and methods relating to modifying the binding of antibodies |
| EP4368721A2 (en) | 2007-09-26 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
| WO2009040562A1 (en) | 2007-09-26 | 2009-04-02 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| EP2199391B1 (en) | 2007-09-27 | 2015-11-11 | Japan Tobacco, Inc. | Factor involved in latent infection with herpesvirus, and use thereof |
| US8268783B2 (en) | 2007-09-28 | 2012-09-18 | Portola Pharmaceuticals, Inc. | Antidotes for factor Xa inhibitors and methods of using the same |
| BRPI0816837B1 (pt) | 2007-09-28 | 2022-10-18 | Portola Pharmaceuticals, Inc | Composições farmacêuticas, polipeptídeo isolado de duas cadeias e uso de uma composição farmacêutica |
| EP2196541B1 (en) | 2007-09-28 | 2012-11-07 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody having improved kinetics in plasma |
| EP2365333B1 (en) | 2007-10-01 | 2014-11-26 | The University Of British Columbia | Granzyme A diagnostics |
| WO2009046168A1 (en) | 2007-10-02 | 2009-04-09 | Avaxia Biologics, Inc. | Antibody therapy for use in the digestive tract |
| CA2699601A1 (en) | 2007-10-02 | 2009-04-09 | Genentech, Inc. | Nlrr-1 antagonists and uses thereof |
| US8529895B2 (en) | 2007-10-02 | 2013-09-10 | Chugai Seiyaku Kabushiki Kaisha | Method for suppressing the development of graft-versus-host-disease by administering interleukin 6 receptor antibodies |
| CA3042430C (en) | 2007-10-02 | 2022-10-11 | Theranos Ip Company, Llc | Modular point-of-care devices and uses thereof |
| WO2009046388A1 (en) | 2007-10-03 | 2009-04-09 | United States Medical Research & Material Command | Cr-2 binding peptide p28 as molecular adjuvant for dna vaccines |
| GB0719231D0 (en) | 2007-10-03 | 2007-11-14 | Oxford Genome Sciences Uk Ltd | Protein |
| AR068767A1 (es) * | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| DK2233149T3 (en) | 2007-10-16 | 2016-05-17 | Zymogenetics Inc | COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE |
| GB0720250D0 (en) | 2007-10-17 | 2007-11-28 | Univ Edinburgh | Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| ES2576650T3 (es) | 2007-10-18 | 2016-07-08 | Cell Signaling Technology, Inc. | Translocación y ROS quinasa mutante en el carcinoma pulmonar no microcítico humano |
| CA2702637A1 (en) * | 2007-10-22 | 2009-04-30 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| WO2009053442A1 (en) | 2007-10-23 | 2009-04-30 | Novartis Ag | Use of trkb antibodies for the treatment of respiratory disorders |
| US8143224B2 (en) | 2007-10-23 | 2012-03-27 | The Cleveland Clinic Foundation | Oxidant resistant apolipoprotein A-1 and mimetic peptides |
| FI20070808A0 (fi) | 2007-10-25 | 2007-10-25 | Mart Saarma | GDNF:n silmukointivariantit ja niiden käytöt |
| US8361465B2 (en) | 2007-10-26 | 2013-01-29 | Lpath, Inc. | Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents |
| US8663980B2 (en) * | 2007-10-26 | 2014-03-04 | Janssen Biotech, Inc. | Vectors, host cells, and methods of production and uses |
| ES2666170T3 (es) | 2007-10-30 | 2018-05-03 | Genentech, Inc. | Purificación de anticuerpos mediante cromatografía de intercambio catiónico |
| EP3783019A1 (en) | 2007-10-30 | 2021-02-24 | Philogen S.p.A. | An antigen associated with rheumatoid arthritis |
| US7888054B2 (en) | 2007-10-31 | 2011-02-15 | Idexx Laboratories, Inc. | Ehrlichia canis DIVA (differentiate infected from vaccinated animals) |
| WO2009086320A1 (en) | 2007-12-26 | 2009-07-09 | Xencor, Inc | Fc variants with altered binding to fcrn |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| JP5698534B2 (ja) | 2007-11-02 | 2015-04-08 | ノバルティス アーゲー | 改良されたｎｏｇｏ−ａ結合分子およびその医薬的使用 |
| CN101951954A (zh) | 2007-11-02 | 2011-01-19 | 诺瓦提斯公司 | 调节低密度脂蛋白受体相关蛋白6(lrp6)的分子和方法 |
| US8039212B2 (en) | 2007-11-05 | 2011-10-18 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof |
| NZ585064A (en) | 2007-11-05 | 2012-08-31 | Medimmune Llc | Methods of treating scleroderma |
| AU2008323770B2 (en) | 2007-11-07 | 2014-08-07 | Genentech, Inc. | Compositions and methods for treatment of microbial disorders |
| US20110123553A1 (en) * | 2007-11-08 | 2011-05-26 | Biogen Idec Ma Inc. | Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination |
| US20110033476A1 (en) * | 2007-11-12 | 2011-02-10 | Theraclone Sciences Inc. | Compositions and methods for the therapy and diagnosis of influenza |
| NZ585465A (en) | 2007-11-12 | 2012-12-21 | Monoclonal antibodies which bind to the extracellular domain of the axl receptor tyrosine kinase | |
| NZ585500A (en) | 2007-11-12 | 2012-06-29 | Theraclone Sciences Inc | Antibodies which bind to an epitope in the extracellular domain of the matrix 2 ectodomain polypeptide of an influenza virus |
| EP3211011A1 (en) | 2007-11-16 | 2017-08-30 | Nuvelo, Inc. | Antibodies to lrp6 |
| US8637435B2 (en) * | 2007-11-16 | 2014-01-28 | Merck Sharp & Dohme Corp. | Eukaryotic cell display systems |
| CA2705486C (en) | 2007-11-19 | 2019-04-02 | Celera Corporation | Lung cancer markers and uses thereof |
| EP2215238A2 (en) | 2007-11-20 | 2010-08-11 | Pioneer Hi-Bred International Inc. | Maize ethylene signaling genes and modulation of same for improved stress tolerance in plants |
| US8541543B2 (en) * | 2007-11-20 | 2013-09-24 | Academia Sinica | Peptides specific for hepatocellular carcinoma cells and applications thereof |
| EP2062920A3 (en) | 2007-11-21 | 2009-06-17 | Peter Hornbeck | Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways |
| AU2008334095A1 (en) | 2007-11-29 | 2009-06-11 | Genentech, Inc. | Gene expression markers for inflammatory bowel disease |
| BRPI0819018A2 (pt) | 2007-11-30 | 2015-05-05 | Bryan P Scheneider | "métodos para determinar se um paciente possui risco aumentado de desenvolver hipertensão, para determinar se um paciente possui maior probalidade de se beneficiar do tratamento com um antagonista de vegf e kits para determinar se um paciente possui risco aumentado de desenvolver hipertensão e para determinar se um paciente possui maior probabilidade de se beneficiar do tratamento com um antagonista de vegf" |
| TWI580694B (zh) * | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-ｖｅｇｆ抗體 |
| SG10201604258YA (en) | 2007-11-30 | 2016-07-28 | Abbvie Biotechnology Ltd | Anti-tnf antibody formulations |
| EP2215268B1 (en) | 2007-11-30 | 2018-08-29 | Siemens Healthcare Diagnostics Inc. | Adiponectin receptor fragments and methods of use |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| US8501912B2 (en) * | 2007-12-03 | 2013-08-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Filipil compositions and methods for treating cancer |
| US8815237B2 (en) | 2007-12-05 | 2014-08-26 | Massachusetts Institute Of Technology | Aglycosylated immunoglobulin mutants |
| DK2236604T3 (en) | 2007-12-05 | 2016-10-03 | Chugai Pharmaceutical Co Ltd | The anti-NR10 antibody and use thereof |
| GB0723797D0 (en) | 2007-12-05 | 2008-01-16 | Immunosolv Ltd | Method |
| EP3333187B1 (en) | 2007-12-06 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
| GB0724051D0 (en) * | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
| JPWO2009075344A1 (ja) | 2007-12-12 | 2011-04-28 | 独立行政法人国立がん研究センター | Ｍ−ｃｓｆ受容体を分子標的とするｍｌｌ白血病及びｍｏｚ白血病治療剤、およびその利用 |
| JP5591712B2 (ja) | 2007-12-14 | 2014-09-17 | ノボ・ノルデイスク・エー／エス | ヒトｎｋｇ２ｄに対する抗体とその使用 |
| CA2709135C (en) | 2007-12-17 | 2018-06-05 | Pfizer Limited | Treatment of interstitial cystitis |
| KR101672271B1 (ko) | 2007-12-18 | 2016-11-03 | 바이오얼라이언스 씨.브이. | 암세포에서 발현된 ｃｄ-43 및 ｃｅａ 상의 탄수화물 함유 에피토프를 인식하는 항체 및 그것의 사용 방법 |
| PT2227483T (pt) | 2007-12-19 | 2017-06-21 | Henry M Jackson Found Advancement Military Medicine Inc | Formas solúveis da glicoproteína f de vírus hendra e nipah e suas utilizações |
| GB0724860D0 (en) | 2007-12-20 | 2008-01-30 | Heptares Therapeutics Ltd | Screening |
| EP2391650B1 (en) | 2007-12-20 | 2014-10-15 | Xoma (Us) Llc | Methods for the treatment of gout |
| AU2008343855B2 (en) | 2007-12-21 | 2013-08-15 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
| AU2008339576B2 (en) | 2007-12-21 | 2014-05-22 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Ralpha) |
| RU2498994C2 (ru) | 2007-12-21 | 2013-11-20 | Новартис Аг | Мутантные формы стрептолизина о |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| US20100291070A1 (en) | 2007-12-25 | 2010-11-18 | Meiji Seika Kaisha, Ltd. | Type iii secretion system component protein pa1698 of pseudomonas aeruginosa |
| CN101932333A (zh) | 2007-12-26 | 2010-12-29 | 瓦西尼斯公司 | 抗c35抗体联合疗法和方法 |
| BRPI0821949B1 (pt) | 2007-12-28 | 2022-12-06 | University Of Tennessee Research Foundation | Anticorpos ou fragmentos de ligação ao antígeno destes, seus usos, seu método de preparação, suas composições farmacêuticas, e hibridomas |
| US7914785B2 (en) * | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| EP2077281A1 (en) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| HUE031207T2 (hu) | 2008-01-11 | 2017-07-28 | Adheron Therapeutics Inc | Cadherin-11 EC1 domén elleni antitestek gyulladásos ízületi rendellenességek kezeléséhez |
| EP2245156A4 (en) | 2008-01-11 | 2011-02-02 | Gene Techno Science Co Ltd | HUMANIZED ANTI-9 INTEGRIN ANTIBODIES AND USES THEREOF |
| WO2009091547A1 (en) | 2008-01-15 | 2009-07-23 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| EP2085095B1 (en) | 2008-01-17 | 2012-03-07 | Philogen S.p.A. | Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart |
| US8133488B2 (en) | 2008-01-18 | 2012-03-13 | Genentech, Inc. | Methods and compositions for targeting polyubiquitin |
| AU2009205995B2 (en) | 2008-01-18 | 2014-04-03 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
| WO2009093246A2 (en) * | 2008-01-22 | 2009-07-30 | Compugen Ltd. | Novel clusterin derived peptide |
| KR20100110864A (ko) | 2008-01-24 | 2010-10-13 | 노보 노르디스크 에이/에스 | 인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체 |
| BRPI0907640A2 (pt) | 2008-01-25 | 2015-11-03 | Univ Aarhus | inibição exosítio-seletiva da atividade de papp-a contra igfbp-4 |
| US9090875B2 (en) | 2008-01-29 | 2015-07-28 | Fred Hutchinson Cancer Research Center | Identifcation of CD8+ T cells that are CD161hi and/or IL18Rαhi and have rapid drug efflux capacity |
| US20090233295A1 (en) * | 2008-01-29 | 2009-09-17 | Elias Georges | Trim59 directed diagnostics for neoplastic disease |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| SI2657253T1 (sl) | 2008-01-31 | 2017-10-30 | Genentech, Inc. | Protitelesa proti CD79b in imunokonjugati in postopki za uporabo |
| EP2238170B1 (en) | 2008-01-31 | 2016-11-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
| US8039596B2 (en) | 2008-02-05 | 2011-10-18 | Bristol-Myers Squibb Company | Alpha 5-beta 1 antibodies and their uses |
| US20110059078A1 (en) | 2008-02-08 | 2011-03-10 | Medimmune, Llc | Anti-ifnar1 antibodies with reduced fc ligand affinity |
| GB0802474D0 (en) * | 2008-02-11 | 2008-03-19 | Heptares Therapeutics Ltd | Mutant proteins and methods for selecting them |
| JP2011511647A (ja) * | 2008-02-13 | 2011-04-14 | ダイアックス コーポレイション | 特異的結合対を作製するための改善された方法 |
| US8461310B2 (en) | 2008-02-14 | 2013-06-11 | Gene Techno Science Co., Ltd. | Anti-ADAM-15 antibodies and utilization of the same |
| US20090221620A1 (en) | 2008-02-20 | 2009-09-03 | Celera Corporation | Gentic polymorphisms associated with stroke, methods of detection and uses thereof |
| JO2913B1 (en) * | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| ES2553390T3 (es) | 2008-02-25 | 2015-12-09 | Nestec S.A. | Método para la detección de receptores truncados intracelulares |
| US20110003337A1 (en) * | 2008-02-29 | 2011-01-06 | Ramot At Tel-Aviv University Ltd. | Immunoglobulin compositions and methods of producing same |
| US20090220991A1 (en) * | 2008-02-29 | 2009-09-03 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
| US8962803B2 (en) * | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| CA2715212A1 (en) * | 2008-03-03 | 2009-09-11 | Glycofi, Inc. | Surface display of recombinant proteins in lower eukaryotes |
| US8293239B2 (en) | 2008-03-04 | 2012-10-23 | Pfizer Limited | Methods of treating chronic pain |
| WO2009111644A2 (en) * | 2008-03-05 | 2009-09-11 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating pancreatic cancer |
| US20110112037A1 (en) * | 2008-03-05 | 2011-05-12 | Heptares Therapeutics Limited BioPark | Crystal structure |
| EP2098536A1 (en) | 2008-03-05 | 2009-09-09 | 4-Antibody AG | Isolation and identification of antigen- or ligand-specific binding proteins |
| US20090226455A1 (en) * | 2008-03-06 | 2009-09-10 | Genentech, Inc. | Combination therapy with c-met and her antagonists |
| JP5544309B2 (ja) * | 2008-03-10 | 2014-07-09 | セラクローン サイエンシーズ， インコーポレイテッド | サイトメガロウイルス感染の治療および診断のための組成物および方法 |
| DK2265641T3 (en) | 2008-03-12 | 2018-04-23 | Otago Innovation Ltd | Biomarkers |
| US8507209B2 (en) | 2008-03-12 | 2013-08-13 | Otago Innovation Limited | Biomarkers |
| PT2271670E (pt) | 2008-03-14 | 2014-11-28 | Allergan Inc | Ensaio imunobaseado da atividade do serotipo a da toxina botulínica |
| NO2842575T3 (ja) | 2008-03-18 | 2018-02-24 | ||
| WO2009118300A1 (en) | 2008-03-25 | 2009-10-01 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by down-regulating frizzled-4 and/or frizzled-1 |
| EP2105742A1 (en) | 2008-03-26 | 2009-09-30 | Sanofi-Aventis | Use of cathepsin C |
| EP2271664A4 (en) | 2008-03-27 | 2011-11-23 | Prionics Ag | NEW SEQUENCES OF BRACHYSPIRA, IMMUNOGENIC COMPOSITION, METHOD OF MANUFACTURE AND APPLICATION THEREOF |
| DK2274008T3 (da) | 2008-03-27 | 2014-05-12 | Zymogenetics Inc | Sammensætninger og fremgangsmåder til hæmning af PDGFRBETA og VEGF-A |
| AU2009231733B2 (en) * | 2008-03-31 | 2015-12-24 | Genentech, Inc. | Compositions and methods for treating and diagnosing asthma |
| EP3498307A1 (en) | 2008-04-02 | 2019-06-19 | Georgia State University Research Foundation, Inc. | Contrast agents, methods for preparing contrast agents, and methods of imaging |
| US8669349B2 (en) | 2008-04-02 | 2014-03-11 | Macrogenics, Inc. | BCR-complex-specific antibodies and methods of using same |
| JP5555223B2 (ja) | 2008-04-02 | 2014-07-23 | マクロジェニクス，インコーポレーテッド | ＨＥＲ２／ｎｅｕ特異的抗体およびその使用方法 |
| CN102066552B (zh) | 2008-04-04 | 2014-03-12 | 麻省理工学院 | 细胞法产生葡糖二酸 |
| WO2009124294A2 (en) | 2008-04-05 | 2009-10-08 | Lpath, Inc. | Pharmaceutical compositions for binding sphingosine-1-phosphate |
| KR101855381B1 (ko) | 2008-04-09 | 2018-05-09 | 제넨테크, 인크. | 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법 |
| CA2718975A1 (en) | 2008-04-10 | 2009-10-15 | Cell Signaling Technology, Inc. | Compositions and methods for detecting egfr mutations in cancer |
| NZ621443A (en) | 2008-04-11 | 2015-09-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| MY195714A (en) | 2008-04-11 | 2023-02-07 | Chugai Pharmaceutical Co Ltd | Antigen-Binding Molecule Capable of Binding to Two or More Antigen Molecules Repeatedly |
| CA2721093A1 (en) | 2008-04-11 | 2009-10-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| AU2008201871A1 (en) * | 2008-04-16 | 2009-11-26 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Inhibition of angiogenesis and tumor metastasis |
| ES2836128T3 (es) | 2008-04-16 | 2021-06-24 | Univ Johns Hopkins | Método para determinar variantes del receptor de andrógenos en cáncer de próstata |
| GB0807018D0 (en) * | 2008-04-17 | 2008-05-21 | Fusion Antibodies Ltd | Antibodies and treatment |
| ES2922534T3 (es) | 2008-04-18 | 2022-09-16 | Massachusetts Gen Hospital | Inmunoterapias que emplean vacunas autoensamblantes |
| GB0807161D0 (en) * | 2008-04-18 | 2008-05-21 | Danisco | Process |
| WO2009131909A2 (en) | 2008-04-21 | 2009-10-29 | Bio-Rad Laboratories, Inc. | Recombinant deamidated gliadin antigen |
| AU2009238897B2 (en) | 2008-04-24 | 2015-03-19 | Gene Techno Science Co., Ltd. | Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof |
| US20090269786A1 (en) * | 2008-04-25 | 2009-10-29 | The Board Of Trustees Of The University Of Illinois | RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies |
| EP3449941A1 (en) | 2008-04-28 | 2019-03-06 | Humanigen, Inc. | Antibodies to granulocyte-macrophage colony-stimulating factor |
| CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| JP5646457B2 (ja) | 2008-04-29 | 2014-12-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| EP2280995A2 (en) * | 2008-04-29 | 2011-02-09 | Wyeth LLC | Methods for treating inflammation |
| WO2009133462A2 (en) | 2008-04-30 | 2009-11-05 | Danisco A/S | Proteins |
| FI20080326A0 (fi) | 2008-04-30 | 2008-04-30 | Licentia Oy | Neurotroofinen tekijä MANF ja sen käytöt |
| US20110229460A1 (en) * | 2008-05-01 | 2011-09-22 | Gtc Biotherapeutics, Inc. | anti-cd137 antibody as an agent in the treatment of inflammatory conditions |
| EP2282773B1 (en) | 2008-05-02 | 2014-01-15 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| EP2116261A1 (en) | 2008-05-07 | 2009-11-11 | Institut Pasteur | Sub-region of a plasmodium protein with improved vaccine potential and medical uses thereof |
| EP2116555A1 (en) | 2008-05-08 | 2009-11-11 | Bayer Schering Pharma Aktiengesellschaft | Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma |
| ES2354661B1 (es) | 2008-05-08 | 2012-02-01 | Consejo Superior De Investigaciones Científicas (Csic) | Método para generar anticuerpos monoclonales que reconocen antígenos de membrana de células progenitoras neurales, anticuerpos producidos por dicho método, y usos. |
| CA2723707C (en) | 2008-05-09 | 2016-08-23 | Akonni Biosystems | Microarray system |
| JP5890174B2 (ja) | 2008-05-09 | 2016-03-22 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | 終末糖化産物受容体（ｒａｇｅ）に対する抗体及びその使用 |
| US8680025B2 (en) * | 2008-05-09 | 2014-03-25 | Akonni Biosystems, Inc. | Microarray system |
| PT2119726E (pt) | 2008-05-14 | 2015-03-30 | Immatics Biotechnologies Gmbh | Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano |
| EP2297347B1 (en) | 2008-05-14 | 2017-03-08 | Millennium Pharmaceuticals, Inc. | Methods and kits for monitoring the effects of immunomodulators on adaptive immunity |
| EP2291536A4 (en) | 2008-05-15 | 2013-02-27 | Selexys Pharmaceuticals Corp | ANTI-PSGL-1 ANTIBODIES AND METHODS OF IDENTIFICATION AND USE THEREOF |
| DK2279004T3 (en) * | 2008-05-16 | 2015-02-02 | Hoffmann La Roche | USE OF biomarkers for assessment of treatment of gastrointestinal inflammatory disorders WITH beta7 integrin antagonists |
| ES2741730T3 (es) | 2008-05-19 | 2020-02-12 | Advaxis Inc | Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico |
| US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
| US9650639B2 (en) | 2008-05-19 | 2017-05-16 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
| US8093018B2 (en) | 2008-05-20 | 2012-01-10 | Otsuka Pharmaceutical Co., Ltd. | Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same |
| US8082730B2 (en) * | 2008-05-20 | 2011-12-27 | Caterpillar Inc. | Engine system having particulate reduction device and method |
| US20090291073A1 (en) * | 2008-05-20 | 2009-11-26 | Ward Keith W | Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same |
| WO2009148896A2 (en) | 2008-05-29 | 2009-12-10 | Nuclea Biotechnologies, LLC | Anti-phospho-akt antibodies |
| BRPI0913366A8 (pt) * | 2008-06-03 | 2017-07-11 | Abbott Lab | Imunoglobulinas de domínio variável duplo e seus usos |
| KR20110016958A (ko) | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| CA2726845C (en) | 2008-06-04 | 2017-09-26 | Macrogenics, Inc. | Antibodies with altered binding to fcrn and methods of using same |
| CN102256623A (zh) | 2008-06-05 | 2011-11-23 | 独立行政法人国立癌症研究中心 | 神经浸润抑制剂 |
| CA2726768C (en) | 2008-06-10 | 2016-09-06 | Sangamo Biosciences, Inc. | Methods and compositions for generation of bax- and bak-deficient cell lines |
| US8999702B2 (en) * | 2008-06-11 | 2015-04-07 | Emd Millipore Corporation | Stirred tank bioreactor |
| WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
| JP2011524179A (ja) | 2008-06-16 | 2011-09-01 | パトリス リミテッド | Ｌｍ−１抗体、機能性フラグメント、ｌｍ−１標的抗原、ならびにそれらを作製および使用するための方法 |
| WO2009154770A2 (en) | 2008-06-18 | 2009-12-23 | The Texas A & M University System | Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage |
| AU2009259959A1 (en) | 2008-06-20 | 2009-12-23 | Wyeth Llc | Compositions and methods of use of ORF1358 from beta-hemolytic streptococcal strains |
| US20110123542A1 (en) * | 2008-06-24 | 2011-05-26 | Hadasit Medical Research Services And Development Ltd. | Ccl20-specific antibodies for cancer therapy |
| EP2307042B1 (en) | 2008-06-25 | 2014-03-26 | H. Lundbeck A/S | Modulation of the trpv : vps10p-domain receptor system for the treatment of pain |
| WO2009158040A2 (en) * | 2008-06-26 | 2009-12-30 | University Of South Florida | Cancer platinum resistance detection and sensitization method |
| EP2671891A3 (en) | 2008-06-27 | 2014-03-05 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| EP2138511A1 (en) | 2008-06-27 | 2009-12-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | HER3 as a determinant for the prognosis of melanoma |
| US8685399B2 (en) * | 2008-06-30 | 2014-04-01 | Dako Denmark A/S | PAX 5 monoclonal antibody |
| NZ590619A (en) * | 2008-07-03 | 2012-08-31 | Pfenex Inc | High throughput screening method and use thereof to identify a production platform for a multifunctional binding protein |
| JP2011527579A (ja) | 2008-07-08 | 2011-11-04 | アボット・ラボラトリーズ | プロスタグランジンｅ２結合タンパク質およびこの使用 |
| FR2933702A1 (fr) * | 2008-07-08 | 2010-01-15 | Sanofi Aventis | Antagonistes specifiques du recepteur fgf-r4 |
| RU2011104348A (ru) * | 2008-07-08 | 2012-08-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение |
| MY155603A (en) | 2008-07-08 | 2015-11-13 | Oncomed Pharm Inc | Notch-binding agents and antagonists and methods of use thereof |
| US8067339B2 (en) * | 2008-07-09 | 2011-11-29 | Merck Sharp & Dohme Corp. | Surface display of whole antibodies in eukaryotes |
| US8216786B2 (en) | 2008-07-09 | 2012-07-10 | Celera Corporation | Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof |
| AU2009269099B2 (en) | 2008-07-09 | 2016-03-10 | Biogen Ma Inc. | Compositions comprising antibodies to LINGO or fragments thereof |
| US7981627B2 (en) * | 2008-07-17 | 2011-07-19 | Ramot At Tel-Aviv University Ltd. | Methods for diagnosing and monitoring liver diseases |
| US8148088B2 (en) * | 2008-07-18 | 2012-04-03 | Abgent | Regulation of autophagy pathway phosphorylation and uses thereof |
| AU2009274512A1 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of Colorado | Clip inhibitors and methods of modulating immune function |
| PE20110225A1 (es) | 2008-08-05 | 2011-04-05 | Novartis Ag | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 |
| WO2010016067A2 (en) | 2008-08-07 | 2010-02-11 | Yeda Research And Development Co. Ltd. | Affinity purification by cohesin-dockerin interaction |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010019702A2 (en) | 2008-08-12 | 2010-02-18 | Oncomed Pharmaceuticals, Inc. | Ddr1-binding agents and methods of use thereof |
| ES2527943T5 (es) | 2008-08-14 | 2019-03-07 | Genentech Inc | Métodos para eliminar un contaminante usando cromatografía de membrana de intercambio iónico de desplazamiento de proteínas |
| AU2009282234A1 (en) * | 2008-08-14 | 2010-02-18 | Merck Sharp & Dohme Corp. | Methods for purifying antibodies using protein a affinity chromatography |
| CA2734389A1 (en) | 2008-08-15 | 2010-02-18 | Vincent J. Hearing | S0x9, prostaglandin d2 and retinoic acid for treating pigmentary conditions and melanoma |
| TR201900975T4 (tr) | 2008-08-18 | 2019-02-21 | Mesoblast Inc | Yetişkin multipotansiyel mezenkimal prekürsör hücrelerin tanımlaması ve/veya zenginleştirmesi için markör olarak ısı şok proteini 90-beta'nın kullanımı. |
| EP2313515B1 (en) | 2008-08-22 | 2015-03-04 | Sangamo BioSciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
| WO2010027818A2 (en) | 2008-08-25 | 2010-03-11 | Dana-Farber Cancer Institute, Inc. | Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use |
| EP3339321B1 (en) | 2008-08-28 | 2021-04-28 | Taiga Biotechnologies, Inc. | Modulators of myc, methods of using the same and methods of identifying agents that modulate myc |
| US8790642B2 (en) | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
| TWI487712B (zh) | 2008-09-03 | 2015-06-11 | 建南德克公司 | 多重特異性抗體 |
| RU2478648C2 (ru) | 2008-09-07 | 2013-04-10 | Гликонекс Инк. | Антитело против удлиненного гликосфинголипида i типа, его производные и применение |
| EP2334702A2 (en) | 2008-09-10 | 2011-06-22 | Genentech, Inc. | Methods for inhibiting ocular angiogenesis |
| CA2734275A1 (en) | 2008-09-10 | 2010-03-18 | Genentech, Inc. | Compositions and methods for the prevention of oxidative degradation of proteins |
| AU2009290543B2 (en) * | 2008-09-12 | 2015-09-03 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| TWI445716B (zh) | 2008-09-12 | 2014-07-21 | Rinat Neuroscience Corp | Ｐｃｓｋ９拮抗劑類 |
| CA2736829C (en) | 2008-09-12 | 2018-02-27 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
| WO2010031749A1 (en) | 2008-09-17 | 2010-03-25 | Innate Pharma | Compositions and methods for detecting tlr3 |
| CN102159204B (zh) | 2008-09-19 | 2015-04-01 | 辉瑞公司 | 稳定的液体抗体制剂 |
| WO2010034007A2 (en) | 2008-09-22 | 2010-03-25 | Oregon Health & Science University | Methods for detecting a mycobacterium tuberculosis infection |
| US8937046B2 (en) | 2008-09-22 | 2015-01-20 | The Regents Of The University Of Colorado, A Body Corporate | Modulating the alternative complement pathway |
| CA2739357A1 (en) | 2008-09-23 | 2010-04-08 | Wyeth Llc | Methods for predicting production of activating signals by cross-linked binding proteins |
| WO2010034779A2 (en) * | 2008-09-24 | 2010-04-01 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Composition and method for treatment of preterm labor |
| EP3133086B1 (en) | 2008-09-26 | 2018-08-01 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof |
| WO2010037046A1 (en) | 2008-09-28 | 2010-04-01 | Fraunhofer Usa, Inc. | Humanized neuraminidase antibody and methods of use thereof |
| US9435811B2 (en) | 2008-09-30 | 2016-09-06 | Oriental Yeast Co., Ltd | Inducer of chondrocyte proliferation and differentiation |
| GB0817891D0 (en) | 2008-09-30 | 2008-11-05 | Medical Res Council | Antibodies against il-25 |
| ES2536465T3 (es) | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
| US8715654B2 (en) | 2008-10-02 | 2014-05-06 | Celtaxsys, Inc. | Methods of modulating the negative chemotaxis of immune cells |
| KR101455447B1 (ko) | 2008-10-06 | 2014-10-27 | 미네르바 바이오테크놀로지 코포레이션 | Ｍｕｃ１＊ 항체 |
| EP2355847A1 (en) | 2008-10-07 | 2011-08-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1) |
| WO2010040772A2 (en) * | 2008-10-07 | 2010-04-15 | Bracco Research Sa | Targeting construct comprising anti-polymer antibody and liposomes or microvesicles binding to the same |
| KR20160017117A (ko) | 2008-10-09 | 2016-02-15 | 미네르바 바이오테크놀로지 코포레이션 | 세포내에서 다능성을 유도하기 위한 방법 |
| PT2340038T (pt) | 2008-10-10 | 2018-02-21 | Beth Israel Deaconess Medical Ct Inc | Vacina de trímero de envelope para hiv-1 bioquimicamente estabilizada |
| WO2010042933A2 (en) | 2008-10-10 | 2010-04-15 | Northwestern University | Inhibition and treatment of prostate cancer metastasis |
| EP3524620A1 (en) | 2008-10-14 | 2019-08-14 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| ES2535734T3 (es) | 2008-10-20 | 2015-05-14 | Abbvie Inc. | Aislamiento y purificación de anticuerpos mediante cromatografía de afinidad con la proteína A |
| CA2741089A1 (en) | 2008-10-22 | 2010-04-29 | Genentech, Inc. | Modulation of axon degeneration |
| CA2741523C (en) | 2008-10-24 | 2022-06-21 | Jonathan S. Towner | Human ebola virus species and compositions and methods thereof |
| US8871202B2 (en) | 2008-10-24 | 2014-10-28 | Lpath, Inc. | Prevention and treatment of pain using antibodies to sphingosine-1-phosphate |
| EP2349335B1 (en) | 2008-10-24 | 2013-08-07 | ARK Diagnostics, Inc. | Levetiracetam immunoassays |
| CN104198712A (zh) | 2008-10-29 | 2014-12-10 | Bg医药股份有限公司 | 半乳凝素-3免疫测定法 |
| EP4104821A1 (en) | 2008-10-29 | 2022-12-21 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
| DK3199553T3 (da) | 2008-10-29 | 2019-07-22 | Circular Commitment Company | Fremgangsmåder og midler til diagnosticering og behandling af hepatocellulært carcinom |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| US8574582B2 (en) | 2008-10-31 | 2013-11-05 | Janssen Biotech, Inc. | Methods for mediating fibrotic response |
| KR20110081282A (ko) | 2008-11-05 | 2011-07-13 | 와이어쓰 엘엘씨 | 베타―용혈성 연쇄구균 (ｂｈｓ) 질환의 예방을 위한 다성분 면역원성 조성물 |
| CA2742899A1 (en) * | 2008-11-06 | 2010-05-14 | Glenmark Pharmaceuticals, S.A. | Treatment with anti-alpha2 integrin antibodies |
| EP2356251A1 (en) | 2008-11-07 | 2011-08-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Teneurin and cancer |
| LT2894165T (lt) | 2008-11-10 | 2023-03-10 | Alexion Pharmaceuticals, Inc. | Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui |
| LT2356462T (lt) | 2008-11-11 | 2017-03-10 | The Regents Of The University Of Michigan | Anti-cxcr1 kompozicijos ir būdai |
| US20110293605A1 (en) | 2008-11-12 | 2011-12-01 | Hasige Sathish | Antibody formulation |
| US8309306B2 (en) * | 2008-11-12 | 2012-11-13 | Nodality, Inc. | Detection composition |
| US8329188B2 (en) * | 2008-11-12 | 2012-12-11 | Theraclone Sciences, Inc. | Human M2e peptide immunogens |
| EP2349332B1 (en) | 2008-11-13 | 2019-10-23 | The General Hospital Corporation | Methods and compositions for regulating iron homeostasis by modulation bmp-6 |
| BRPI0921006A2 (pt) * | 2008-11-13 | 2015-12-15 | Emergent Product Dev Seattle | terapias imunoterapêuticas combinadas de cd37 e usos destas |
| CA2743853C (en) | 2008-11-14 | 2021-04-27 | Stephen M. Smith | Hiv-2 isolate |
| US20110229892A1 (en) | 2008-11-17 | 2011-09-22 | Yehuda G Assaraf | Method for predicting a patient's responsiveness to anti-folate therapy |
| WO2010055950A1 (ja) | 2008-11-17 | 2010-05-20 | 財団法人ヒューマンサイエンス振興財団 | 癌間質の構成因子に対して特異的結合能を有する物質と抗腫瘍性化合物との複合体による新規の癌ターゲティング治療 |
| WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| WO2010058396A1 (en) | 2008-11-19 | 2010-05-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | A cd44vra antibody and diagnostic and therapeutic methods using same |
| ATE523603T1 (de) | 2008-11-21 | 2011-09-15 | Chimera Biotec Gmbh | Konjugatkomplexe zum analytnachweis |
| EP2752189B1 (en) | 2008-11-22 | 2016-10-26 | F. Hoffmann-La Roche AG | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer |
| AU2009323009B2 (en) | 2008-11-25 | 2016-01-28 | Vitaeris Inc. | Antibodies to IL-6 and use thereof |
| CR20160443A (es) * | 2008-11-26 | 2016-11-08 | Amgen Inc | Variantes de polipéptidos receptores de activina iib y aplicaciones de éstos (divisional) |
| AU2009319772A1 (en) | 2008-11-26 | 2010-06-03 | Centocor Research & Development, Inc. | Compositions and methods for regulating collagen and smooth muscle actin expression by SERPINE2 |
| WO2010062857A1 (en) * | 2008-11-26 | 2010-06-03 | Allergan, Inc. | Klk-13 antibody inhibitor for treating dry eye |
| WO2010061393A1 (en) | 2008-11-30 | 2010-06-03 | Compugen Ltd. | He4 variant nucleotide and amino acid sequences, and methods of use thereof |
| US8545839B2 (en) | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| EP2370080A1 (en) | 2008-12-02 | 2011-10-05 | University of Utah Research Foundation | Pde1 as a target therapeutic in heart disease |
| AR074439A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
| BRPI0923249A2 (pt) | 2008-12-03 | 2016-01-26 | Inst Pasteur Ct Nat De La Rech Scient Cnrs | uso de modulinas solúveis em fenol no desenvolvimento de vacinas |
| US8431775B2 (en) | 2008-12-04 | 2013-04-30 | Pioneer Hi Bred International Inc | Methods and compositions for enhanced yield by targeted expression of knotted1 |
| US20120009123A1 (en) | 2008-12-05 | 2012-01-12 | Abraxis Bioscience, Llc | Albumin binding peptide-mediated disease targeting |
| US8401799B2 (en) | 2008-12-05 | 2013-03-19 | Lpath, Inc. | Antibody design using anti-lipid antibody crystal structures |
| KR101413480B1 (ko) | 2008-12-05 | 2014-07-10 | 아브락시스 바이오사이언스, 엘엘씨 | Ｓｐａｒｃ 결합 펩티드와 이들의 용도 |
| US20110044990A1 (en) * | 2008-12-05 | 2011-02-24 | Sabbadini Roger A | Antibody design using anti-lipid antibody crystal structures |
| AU2009325878B2 (en) | 2008-12-08 | 2014-01-16 | Compugen Ltd. | TMEM154 polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
| CN104479018B (zh) | 2008-12-09 | 2018-09-21 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
| WO2010074702A1 (en) | 2008-12-16 | 2010-07-01 | Millipore Corporation | Purification of proteins |
| JP2012511929A (ja) | 2008-12-16 | 2012-05-31 | イー・エム・デイー・ミリポア・コーポレイシヨン | 攪拌タンク反応器及び方法 |
| US20100151457A1 (en) | 2008-12-17 | 2010-06-17 | National Tsing Hua University | Detection of Unhealthy Cell and Uses Thereof |
| US20120027722A1 (en) | 2008-12-17 | 2012-02-02 | Medical Research Council | Hepatitis c virus combination therapy |
| SG10201407908VA (en) | 2008-12-19 | 2015-01-29 | Macrogenics Inc | Covalent diabodies and uses thereof |
| EP2379593A2 (en) | 2008-12-19 | 2011-10-26 | H. Lundbeck A/S | Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders |
| GB0823309D0 (en) | 2008-12-19 | 2009-01-28 | Univ Bath | Functionalising reagents and their uses |
| US20100159485A1 (en) * | 2008-12-19 | 2010-06-24 | Centre For Dna Fingerprinting And Diagnostics | Detection of mycobacterium tuberculosis |
| US8580267B2 (en) | 2008-12-19 | 2013-11-12 | Philogen S.P.A. | Immunocytokines for tumour therapy with chemotherapeutic agents |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| CN102264368B (zh) | 2008-12-22 | 2014-09-10 | 米伦纽姆医药公司 | 极光激酶抑制剂与抗cd20抗体的组合 |
| BRPI0918204A2 (pt) | 2008-12-23 | 2015-12-08 | Genentech Inc | igv variante composição farmaceutica e kit |
| US8753604B2 (en) * | 2008-12-23 | 2014-06-17 | Sanford-Burnham Medical Research Institute | Methods and compositions for synaphically-targeted treatment for cancer |
| JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| CN106008679A (zh) | 2008-12-24 | 2016-10-12 | 荷兰王国卫生福利和运动部国家公共卫生和环境研究所 | 修饰的肺炎链球菌溶血素(ply)多肽 |
| EP2376653A2 (en) | 2008-12-29 | 2011-10-19 | Yissum Research Development Company of The Hebrew University of Jerusalem | Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection |
| WO2010078376A2 (en) | 2008-12-30 | 2010-07-08 | Ventana Medical Systems, Inc. | Fc-specific polymer-conjugated antibodies and their diagnostic use |
| JP2012514458A (ja) | 2008-12-31 | 2012-06-28 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 抗リンホトキシン抗体 |
| US20110142836A1 (en) * | 2009-01-02 | 2011-06-16 | Olav Mella | B-cell depleting agents for the treatment of chronic fatigue syndrome |
| US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
| US9527907B2 (en) | 2009-01-07 | 2016-12-27 | Philogen S.P.A. | Antigens associated with endometriosis, psoriatic arthritis and psoriasis |
| WO2010078945A2 (en) | 2009-01-07 | 2010-07-15 | Philogen S.P.A. | Cancer treatment |
| WO2010080985A1 (en) | 2009-01-08 | 2010-07-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for induced brown fat differentiation |
| JP2012515158A (ja) | 2009-01-12 | 2012-07-05 | 武田薬品工業株式会社 | 癌の予防・治療剤 |
| CN106995495A (zh) | 2009-01-12 | 2017-08-01 | 希托马克斯医疗有限责任公司 | 修饰抗体组合物及其制备和使用方法 |
| WO2010083456A1 (en) | 2009-01-15 | 2010-07-22 | Imdaptive Inc. | Adaptive immunity profiling and methods for generation of monoclonal antibodies |
| US8940732B2 (en) * | 2009-01-16 | 2015-01-27 | Massachusetts Institute Of Technology | Diagnosis of autism spectrum disorders and its treatment with an antagonist or inhibitor of the 5-HT2c receptor signaling pathway |
| JP2012515532A (ja) | 2009-01-20 | 2012-07-12 | ラモット アット テル アビブ ユニバーシティ， リミテッド | Ｍｉｒ−２１プロモーター駆動性標的がん治療 |
| WO2010085510A1 (en) | 2009-01-20 | 2010-07-29 | Zadeh Homayoun H | Antibody mediated osseous regeneration |
| AU2010207552A1 (en) | 2009-01-21 | 2011-09-01 | Oxford Biotherapeutics Ltd. | PTA089 protein |
| WO2010085345A1 (en) | 2009-01-22 | 2010-07-29 | Ludwig Institute For Cancer Research Ltd. | Methods and compositions for diagnosis and treatment of malignant and non-malignant gammopathies |
| WO2010084327A2 (en) | 2009-01-26 | 2010-07-29 | Electrophoretics Limited | Methods |
| UA102722C2 (en) * | 2009-01-29 | 2013-08-12 | Эббви Инк. | Il-1 binding proteins |
| WO2010086382A1 (en) | 2009-01-30 | 2010-08-05 | Pronota N.V. | Target for treatment of acute heart failure |
| WO2010088522A2 (en) | 2009-01-30 | 2010-08-05 | Ab Biosciences, Inc. | Novel lowered affinity antibodies and uses therefor |
| WO2010086386A1 (en) | 2009-01-30 | 2010-08-05 | Pronota N.V. | Protein quantification methods and use thereof for candidate biomarker validation |
| WO2010086384A1 (en) | 2009-01-30 | 2010-08-05 | Pronota N.V. | Target for treatment of acute heart failure |
| WO2010087994A2 (en) | 2009-01-30 | 2010-08-05 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
| EP2391892B1 (en) | 2009-01-30 | 2017-01-18 | Mycartis N.V. | Biomarker for diagnosis of acute heart failure and uses thereof |
| WO2010086828A2 (en) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
| US8852608B2 (en) | 2009-02-02 | 2014-10-07 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
| US8309530B2 (en) * | 2009-02-04 | 2012-11-13 | Washington State University | Compositions and methods for modulating ghrelin-mediated conditions |
| EP2394159B1 (en) | 2009-02-04 | 2018-09-26 | Molecular Innovations | Assays for detecting prorenin, and antibodies used therein |
| WO2010091189A1 (en) | 2009-02-04 | 2010-08-12 | Kalobios Pharmaceuticals, Inc. | Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection |
| US9079942B2 (en) * | 2009-02-09 | 2015-07-14 | Epitomics, Inc. | CDR-anchored amplification method |
| EP3372591B1 (en) | 2009-02-09 | 2021-05-26 | Georgetown University | Cadherin-11 inhibitors and methods of use thereof |
| US20100233733A1 (en) * | 2009-02-10 | 2010-09-16 | Nodality, Inc., A Delaware Corporation | Multiple mechanisms for modulation of the pi3 kinase pathway |
| WO2010093465A1 (en) | 2009-02-11 | 2010-08-19 | Caris Mpi, Inc. | Molecular profiling of tumors |
| WO2010093814A1 (en) | 2009-02-11 | 2010-08-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a gm-csf antagonist |
| US20120165340A1 (en) | 2009-02-11 | 2012-06-28 | Ludwing Institute For Cancer Research Ltd. | Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis |
| DK2396652T3 (da) | 2009-02-11 | 2018-01-29 | Cedars Sinai Medical Center | Diagnose af inflammatorisk tarmsyndrom baseret på cytoletalt udspilende toksin |
| US20110014190A1 (en) | 2009-02-12 | 2011-01-20 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
| US9364477B2 (en) | 2009-02-12 | 2016-06-14 | Cell Signaling Technology, Inc. | Mutant ROS expression in human cancer |
| US9028833B2 (en) | 2012-12-13 | 2015-05-12 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| AU2010213568B2 (en) | 2009-02-16 | 2014-11-20 | Cerenis Therapeutics Holding Sa | Apolipoprotein A-I Mimics |
| WO2010096658A1 (en) | 2009-02-19 | 2010-08-26 | The Cleveland Clinic Foundation | Corin as a marker for heart failure |
| GB0902916D0 (en) | 2009-02-20 | 2009-04-08 | Fusion Antibodies Ltd | Antibody therapy |
| US8372639B2 (en) | 2009-02-23 | 2013-02-12 | Gene Techno Science Co., Ltd. | Anti-human α9 integrin antibody and use thereof |
| BRPI1011384A2 (pt) | 2009-02-23 | 2016-03-15 | Cytomx Therapeutics Inc | pro-proteinas e seus metodos de uso |
| US8030026B2 (en) | 2009-02-24 | 2011-10-04 | Abbott Laboratories | Antibodies to troponin I and methods of use thereof |
| EP2402033B1 (en) | 2009-02-24 | 2019-02-27 | University of Miyazaki | Cell adhesion inhibitor and use thereof |
| GB0903168D0 (en) | 2009-02-25 | 2009-04-08 | Fusion Antibodies Ltd | Diagnostic method and kit |
| US20120003695A1 (en) | 2009-02-25 | 2012-01-05 | Davidson Robert C | Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast pichia pastoris |
| GB0903151D0 (en) | 2009-02-25 | 2009-04-08 | Bioinvent Int Ab | Antibody uses and methods |
| US20100292443A1 (en) * | 2009-02-26 | 2010-11-18 | Sabbadini Roger A | Humanized platelet activating factor antibody design using anti-lipid antibody templates |
| ES2589769T3 (es) | 2009-02-27 | 2016-11-16 | Massachusetts Institute Of Technology | Proteínas modificadas con alta afinidad por quelatos de DOTA |
| JP5713923B2 (ja) | 2009-02-27 | 2015-05-07 | ジェネンテック， インコーポレイテッド | タンパク質標識方法及び組成物 |
| WO2010099472A2 (en) | 2009-02-27 | 2010-09-02 | The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services | Spanx-b polypeptides and their use |
| CA2754127C (en) | 2009-03-02 | 2017-04-18 | Stichting Top Institute Pharma | Antibodies against a proliferating inducing ligand (april) |
| US8716553B2 (en) | 2009-03-02 | 2014-05-06 | Pioneer Hi Bred International Inc | NAC transcriptional activators involved in abiotic stress tolerance |
| KR101579771B1 (ko) * | 2009-03-05 | 2015-12-28 | 애브비 인코포레이티드 | Ｉｌ-17 결합 단백질 |
| US20100227335A1 (en) | 2009-03-05 | 2010-09-09 | Becton, Dickinson And Company | Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer |
| EP2403875A1 (en) | 2009-03-06 | 2012-01-11 | Tripath Imaging, Inc. | Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer |
| US9599591B2 (en) | 2009-03-06 | 2017-03-21 | California Institute Of Technology | Low cost, portable sensor for molecular assays |
| JP5876728B2 (ja) | 2009-03-06 | 2016-03-02 | カロバイオス ファーマシューティカルズ インコーポレイティッド | ＥｐｈＡ３に対する抗体を用いた、白血病および慢性骨髄増殖性疾患の治療方法 |
| CA2754618A1 (en) | 2009-03-06 | 2010-09-10 | Novartis Ag | Chlamydia antigens |
| EP2405920A1 (en) | 2009-03-06 | 2012-01-18 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Novel therapy for anxiety |
| US20120004395A1 (en) | 2009-03-10 | 2012-01-05 | University Of Zurich | Use Of Serine Protease Inhibitors In The Treatment Of Neutropenia |
| JP5995442B2 (ja) | 2009-03-10 | 2016-09-21 | 株式会社ジーンテクノサイエンス | ヒト化ｋ３３ｎモノクローナル抗体の作製、発現及び解析 |
| JP2010213694A (ja) | 2009-03-12 | 2010-09-30 | Wyeth Llc | ＰＫＮ３／ＲｈｏＣ高分子複合体およびその使用方法 |
| GB0904355D0 (en) | 2009-03-13 | 2009-04-29 | Imp Innovations Ltd | Biological materials and uses thereof |
| KR101923847B1 (ko) | 2009-03-13 | 2018-11-29 | 알러간, 인코포레이티드 | 면역 기반 재표적화된 엔도펩티다제 활성 검정 |
| JP2010210772A (ja) | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| EP2230515B1 (en) * | 2009-03-16 | 2014-12-17 | Agilent Technologies, Inc. | Passivation of surfaces after ligand coupling |
| EP2408818A1 (en) | 2009-03-17 | 2012-01-25 | Université de la Méditerranée | Btla antibodies and uses thereof |
| SI3260136T1 (sl) | 2009-03-17 | 2021-05-31 | Theraclone Sciences, Inc. | Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa |
| US20100286762A1 (en) * | 2009-03-18 | 2010-11-11 | Musc Foundation For Research Development | Compositions and Methods for Ameliorating Clinical Electrical Disturbances |
| ES2486673T3 (es) | 2009-03-19 | 2014-08-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Uso de NKp46 para prevenir la diabetes tipo I |
| NZ594665A (en) | 2009-03-20 | 2013-08-30 | Genentech Inc | Bispecific anti-her antibodies |
| MY162752A (en) | 2009-03-20 | 2017-07-14 | Amgen Inc | Alpha-4-beta-7 heterodimer specific antagonist antibody |
| MX347295B (es) | 2009-03-20 | 2017-04-20 | Amgen Inc | Inmunoglobulinas portadoras y usos de las mismas. |
| CN201397956Y (zh) * | 2009-03-23 | 2010-02-03 | 富士康(昆山)电脑接插件有限公司 | 电连接器组件 |
| EP2411413B1 (en) | 2009-03-23 | 2016-05-11 | Quark Pharmaceuticals, Inc. | Compounds compositions and methods of treating cancer and fibrotic diseases |
| US8242248B2 (en) | 2009-03-23 | 2012-08-14 | Nodality, Inc. | Kits for multiparametric phospho analysis |
| US20120110684A1 (en) | 2009-03-24 | 2012-05-03 | INSERM (Institut National de la Sante st de la Recherche Medicale)- | Method for Diagnosing or Predicting a Non Syndromic Autosomal Recessive Optic Atrophy, or a Risk of a Non Syndromic Autosomal Recessive Optic Atrophy |
| CA2754393C (en) | 2009-03-24 | 2015-10-27 | Wyeth Llc | Membrane evaporation for generating highly concentrated protein therapeutics |
| CN102428103B (zh) | 2009-03-24 | 2015-04-08 | 泰华生物制药美国公司 | 抗light的人源化抗体及其使用 |
| SI3702371T1 (sl) | 2009-03-25 | 2023-01-31 | Genentech, Inc. | Protitelesa proti FGFR3 in postopki za uporabo le-teh |
| BRPI1006270B1 (pt) | 2009-03-25 | 2022-08-16 | Genentech, Inc | Anticorpo anti-a5ss1, imunoconjugado, composição farmacêutica, método in vitro ou ex vivo para detectar a proteína a5ss1, uso de um anticorpo e kit para detectar a proteína a5ss1 |
| JP2012522017A (ja) * | 2009-03-26 | 2012-09-20 | クアンタム イミュノロジクス， インコーポレイテッド | 診断適用および臨床適用のための癌胎児抗原／未熟ラミニン受容体抗体 |
| EP2411035A1 (en) * | 2009-03-26 | 2012-02-01 | Quantum Immunologics, Inc. | Oncofetal antigen/immature laminin receptor peptides for the sensitization of dendritic cells for cancer therapy |
| CN102448991B (zh) | 2009-03-30 | 2016-09-14 | 安迪穆生物科技有限公司 | 分离的激动剂型抗edar单克隆抗体的制备 |
| US20120020954A1 (en) | 2009-03-30 | 2012-01-26 | Anat Achiron | Methods of predicting clinical course and treating multiple sclerosis |
| WO2010112033A2 (en) | 2009-03-31 | 2010-10-07 | Østjysk Innovation A/S | Method for estimating the risk of having or developing multiple sclerosis using sequence polymorphisms in a specific region of chromosome x |
| AR075998A1 (es) | 2009-04-01 | 2011-05-11 | Genentech Inc | Tratamiento de trastornos resistentes a insulina.composicion farmaceutica. uso. kit |
| MA33256B1 (fr) | 2009-04-01 | 2012-05-02 | Genentech Inc | Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation |
| JP2012522762A (ja) | 2009-04-01 | 2012-09-27 | ザ メディカル リサーチ， インフラストラクチャー， アンド ヘルス サーヴィシーズ ファンド オブ ザ テル アヴィヴ メディカル センター | ケラチノサイトの増殖および分化を調節する方法 |
| WO2010112193A1 (en) | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
| WO2010112034A2 (en) | 2009-04-02 | 2010-10-07 | Aarhus Universitet | Compositions and methods for treatment and diagnosis of synucleinopathies |
| GB0905972D0 (en) | 2009-04-06 | 2009-05-20 | Medical Res Council | Antibodies against IL-17BR |
| WO2010116375A1 (en) | 2009-04-08 | 2010-10-14 | Yeda Research And Development Co. Ltd. | Isolated peptides for regulating apoptosis |
| WO2010117325A1 (en) | 2009-04-08 | 2010-10-14 | Olle Hernell | New methods for treatment of inflammatory diseases |
| US20120121706A1 (en) | 2009-04-10 | 2012-05-17 | Tufts Medical Center, Inc. | PAR-1 Activation by Metalloproteinase-1 (MMP-1) |
| EP2417984B1 (en) | 2009-04-10 | 2016-03-30 | Kyowa Hakko Kirin Co., Ltd. | Method for treatment of blood tumor using anti-tim-3 antibody |
| EP2241323A1 (en) | 2009-04-14 | 2010-10-20 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Tenascin-W and brain cancers |
| NZ612315A (en) | 2009-04-14 | 2014-10-31 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
| SG175181A1 (en) | 2009-04-16 | 2011-11-28 | Abbott Biotherapeutics Corp | ANTI-TNF-a ANTIBODIES AND THEIR USES |
| AU2010237046B2 (en) | 2009-04-17 | 2015-06-04 | New York University | Peptides targeting TNF family receptors and antagonizing TNF action, compositions, methods and uses thereof |
| AU2010236257A1 (en) * | 2009-04-17 | 2011-11-03 | Biogen Idec Ma Inc. | Compositions and methods to treat acute myelogenous leukemia |
| KR101787768B1 (ko) | 2009-04-18 | 2017-10-18 | 제넨테크, 인크. | 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 |
| FI20090161A0 (fi) | 2009-04-22 | 2009-04-22 | Faron Pharmaceuticals Oy | Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä |
| EP3248618A1 (en) | 2009-04-22 | 2017-11-29 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
| EP3444611A1 (en) | 2009-04-23 | 2019-02-20 | Siemens Healthcare Diagnostics Inc. | Monomeric and dimeric forms of adiponectin receptor fragments and methods of use |
| WO2010124113A1 (en) | 2009-04-23 | 2010-10-28 | Infinity Pharmaceuticals, Inc. | Anti-fatty acid amide hydrolase-2 antibodies and uses thereof |
| WO2010124163A2 (en) | 2009-04-23 | 2010-10-28 | Theraclone Sciences, Inc. | Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies |
| US20120294868A1 (en) | 2009-04-24 | 2012-11-22 | Edwards James R | Anti-tgf-beta induction of bone cell function and bone growth |
| WO2010125566A2 (en) | 2009-04-27 | 2010-11-04 | Technion Research And Development Foundation Ltd. | Markers for cancer detection |
| HUE025966T2 (en) | 2009-04-27 | 2016-05-30 | Kyowa Hakko Kirin Co Ltd | Anti-IL-3RA antibody for use in the treatment of blood cancer |
| US9074002B2 (en) | 2009-04-27 | 2015-07-07 | Cold Spring Harbor Laboratory | PTP1B inhibitors |
| NZ595235A (en) | 2009-04-27 | 2013-06-28 | Novartis Ag | Compositions and methods for increasing muscle growth |
| CA2759942A1 (en) | 2009-04-27 | 2010-10-07 | Novartis Ag | Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betai subunit |
| CN102459346B (zh) * | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| US8765916B2 (en) | 2009-04-29 | 2014-07-01 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | ERG monoclonal antibodies |
| AR076284A1 (es) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| BRPI1012162A2 (pt) * | 2009-04-29 | 2016-01-12 | Abbott Biotech Ltd | dispositivo de injeção automática |
| US8367350B2 (en) | 2009-04-29 | 2013-02-05 | Morehouse School Of Medicine | Compositions and methods for diagnosis, prognosis and management of malaria |
| US9018358B2 (en) | 2009-04-30 | 2015-04-28 | University Of Rochester | DC-STAMP antibodies |
| KR101875227B1 (ko) | 2009-04-30 | 2018-07-05 | 텔 하쇼머 메디컬 리서치 인프라스트럭쳐 앤드 서비시스 리미티드． | 항-ｃｅａｃａｍ1 항체들과 이를 이용하는 방법들 |
| PE20121540A1 (es) | 2009-05-04 | 2012-12-22 | Abbott Res Bv | Anticuerpos contra el factor de crecimiento nervioso (ngf) con estabilidad in vivo mejorada |
| RU2605318C2 (ru) | 2009-05-05 | 2016-12-20 | Новиммун С.А. | Анти-il-17f антитела и способы их применения |
| US8188040B2 (en) | 2009-05-05 | 2012-05-29 | Amgen Inc. | FGF21 mutants and uses thereof |
| WO2010128265A2 (fr) | 2009-05-07 | 2010-11-11 | Stallergenes S.A. | Utilisation d'immunoglobulines igg1 et/ou de ligands du récepteur cd32 pour le traitement de maladies et manifestations inflammatoires par voie mucosale |
| US9023767B2 (en) * | 2009-05-07 | 2015-05-05 | Memorial Sloan-Kettering Cancer Center | γ-Secretase substrates and methods of use |
| US9309325B2 (en) | 2009-05-07 | 2016-04-12 | The Regents Of The University Of California | Antibodies and methods of use thereof |
| US8187885B2 (en) * | 2009-05-07 | 2012-05-29 | Nodality, Inc. | Microbead kit and method for quantitative calibration and performance monitoring of a fluorescence instrument |
| EP2270053A1 (en) | 2009-05-11 | 2011-01-05 | U3 Pharma GmbH | Humanized AXL antibodies |
| EP3683317A3 (en) | 2009-05-13 | 2020-09-30 | Genzyme Corporation | Anti-human cd52 immunoglobulins |
| SG176074A1 (en) | 2009-05-15 | 2011-12-29 | Chugai Pharmaceutical Co Ltd | Anti-axl antibody |
| US20100291706A1 (en) | 2009-05-15 | 2010-11-18 | Millipore Corporation | Dye conjugates and methods of use |
| GB0908425D0 (en) | 2009-05-15 | 2009-06-24 | Medical Res Council | Medical use |
| CN102428177B (zh) | 2009-05-19 | 2015-01-14 | 杜邦营养生物科学有限公司 | 提高面包耐码垛性的方法及其产品 |
| CA2762302A1 (en) | 2009-05-20 | 2010-11-25 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
| WO2011019423A2 (en) | 2009-05-20 | 2011-02-17 | Schering Corporation | Modulation of pilr receptors to treat microbial infections |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| ES2545792T5 (es) * | 2009-05-20 | 2018-09-14 | Novimmune Sa | Bancos de polipéptidos sintéticos y métodos para generar variantes de polipéptidos diversificados de forma natural |
| AU2010252280A1 (en) | 2009-05-25 | 2012-01-19 | Merck Patent Gmbh | Continuous administration of cilengitide in cancer treatments |
| EP2435476A4 (en) | 2009-05-27 | 2013-04-17 | Synageva Biopharma Corp | ANTIBODIES OBTAINED FROM BIRDS |
| EP2435078A1 (en) | 2009-05-28 | 2012-04-04 | Yeda Research and Development Co. Ltd. | Methods of treating inflammation |
| US9989533B2 (en) | 2009-05-28 | 2018-06-05 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Anti-TNF induced apoptosis (ATIA) diagnostic markers and therapies |
| US8383358B2 (en) | 2009-05-28 | 2013-02-26 | Abraxis Bioscience, Llc | Use of 2 anti-SPARC antibodies to predict response to melanoma chemotherapy |
| US20120121586A1 (en) | 2009-05-29 | 2012-05-17 | Astrid Kiermaier | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| WO2010141630A1 (en) | 2009-06-03 | 2010-12-09 | University Of Southern California | Compositions and methods for treatment of cancer by disrupting the lh/lhr signaling pathway |
| WO2010144711A2 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
| US20100317539A1 (en) * | 2009-06-12 | 2010-12-16 | Guo-Liang Yu | Library of Engineered-Antibody Producing Cells |
| WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
| EP2443145A1 (en) * | 2009-06-17 | 2012-04-25 | Amgen, Inc | Chimeric fgf19 polypeptides and uses thereof |
| ES2534355T3 (es) | 2009-06-17 | 2015-04-21 | Abbvie Biotherapeutics Inc. | Anticuerpos anti-VEGF y sus usos |
| WO2010148117A1 (en) | 2009-06-17 | 2010-12-23 | Scantibodies Laboratory, Inc. | Therapeutic and diagnostic affinity purified specific polyclonal antibodies |
| SG176731A1 (en) | 2009-06-18 | 2012-01-30 | Pfizer | Anti notch-1 antibodies |
| EP2444492A4 (en) | 2009-06-18 | 2013-12-18 | Hiroshima Bio Medical Co Ltd | ANTI-LOX-1 ANTIBODY DERIVED FROM CHICKENS |
| GB0910620D0 (en) | 2009-06-19 | 2009-08-05 | Immunovia Ab | Agents and uses thereof |
| GB0910725D0 (en) | 2009-06-22 | 2009-08-05 | Heptares Therapeutics Ltd | Mutant proteins and methods for producing them |
| CN102802661B (zh) | 2009-06-22 | 2016-01-13 | 米迪缪尼有限公司 | 用于位点特异性偶联的工程改造的Fc区 |
| JP2012531423A (ja) | 2009-06-24 | 2012-12-10 | エルパス， インコーポレーテッド | リゾホスファチジン酸に対する抗体を用いたニューロン分化の増加法 |
| CA2766009A1 (en) | 2009-06-25 | 2010-12-29 | Danisco A/S | Variant lipolytic enzymes with improved expression, functionality and/or activity |
| KR101861547B1 (ko) | 2009-06-25 | 2018-07-02 | 크레알타 파마슈티칼스 엘엘씨 | 페길화된 유리카아제 치료 중에 혈청 요산을 모니터링하여 주입 반응의 위험성 및 반응의 항체매개 상실을 예측하는 방법 및 키트 |
| US20120101262A1 (en) | 2009-06-25 | 2012-04-26 | Bristol-Myers Squibb Company | Protein purification by caprylic acid (octanoic acid) precipitation |
| US8435961B2 (en) * | 2009-06-26 | 2013-05-07 | Massachusetts Institute Of Technology | Methods and compositions for increasing the activity of inhibitory RNA |
| US8268550B2 (en) * | 2009-06-26 | 2012-09-18 | Massachusetts Institute Of Technology | Compositions and methods for identification of PARP function, inhibitors, and activators |
| US20110097329A1 (en) | 2009-06-26 | 2011-04-28 | Massachusetts Institute Of Technology | Compositions and methods for treating cancer and modulating stress granule formation |
| WO2011001276A1 (en) | 2009-06-30 | 2011-01-06 | Philogen S.P.A. | Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer |
| CN102549016B (zh) * | 2009-06-30 | 2015-05-06 | 研究发展基金会 | 免疫球蛋白fc多肽 |
| EP2272979A1 (en) | 2009-06-30 | 2011-01-12 | Centre National de la Recherche Scientifique (CNRS) | Method for testing a subject thought to be predisposed to having cancer |
| ME01699B (me) | 2009-07-02 | 2014-09-20 | Musc Found For Res Dev | Metode za stimulaciju regeneracije jetre |
| EP2448596B1 (en) | 2009-07-02 | 2016-01-06 | Massachusetts Institute of Technology | Compositions and methods for diagnosing and/or treating influenza infection |
| KR101962476B1 (ko) | 2009-07-03 | 2019-03-26 | 아비펩 피티와이 리미티트 | 면역성 접합체 및 그 제조방법 |
| WO2011004899A1 (en) | 2009-07-06 | 2011-01-13 | Takeda Pharmaceutical Company Limited | Cancerous disease modifying antibodies |
| US10988511B2 (en) | 2009-07-07 | 2021-04-27 | Glaxosmithkline Biologicals Sa | Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens |
| WO2011006001A1 (en) | 2009-07-09 | 2011-01-13 | Genentech, Inc. | Animal model for the evaluation of adjuvant therapies of cancer |
| EP2451844B1 (en) | 2009-07-10 | 2015-04-22 | Innate Pharma | Tlr3 binding agents |
| CN102482715A (zh) | 2009-07-13 | 2012-05-30 | 霍夫曼-拉罗奇有限公司 | 用于癌症治疗的诊断方法和组合物 |
| WO2011008885A1 (en) | 2009-07-15 | 2011-01-20 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same |
| US20110117603A1 (en) * | 2009-07-15 | 2011-05-19 | Abbott Laboratories | Enhancement of cellular production through mechanotransduction |
| CN102639710A (zh) | 2009-07-20 | 2012-08-15 | 基因泰克公司 | 克罗恩病的基因表达标记 |
| US9409983B2 (en) | 2009-07-23 | 2016-08-09 | The Board Of Trustess Of The University Of Illinois | Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases |
| WO2011011689A2 (en) * | 2009-07-23 | 2011-01-27 | The Regents Of The University Of Michigan | Method for enzymatic production of decarboxylated polyketides and fatty acids |
| CA2767409C (en) | 2009-07-24 | 2018-10-30 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin |
| CA2767914C (en) | 2009-07-24 | 2020-02-25 | Geadic Biotec, Aie. | Markers for endometrial cancer |
| TW201106972A (en) | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| US20120183539A1 (en) | 2009-07-31 | 2012-07-19 | Shin Maeda | Cancer Metastasis Inhibitor |
| WO2011014775A1 (en) | 2009-07-31 | 2011-02-03 | The Brigham And Women's Hospital, Inc. | Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
| BR112012002083A2 (pt) | 2009-07-31 | 2016-11-08 | Genentech Inc | inibição de metaste tumoral |
| AU2010278959A1 (en) | 2009-07-31 | 2012-02-02 | Amgen Inc. | Polypeptides that bind tissue inhibitor of metalloproteinase type three (TIMP-3), compositions and methods |
| EA201270228A1 (ru) | 2009-07-31 | 2012-09-28 | Медарекс, Инк. | Полноценные человеческие антитела к btla |
| ES2640981T3 (es) | 2009-08-05 | 2017-11-07 | Philogen S.P.A. | Selección como diana de neovasculatura de médula ósea |
| US20110035843A1 (en) | 2009-08-05 | 2011-02-10 | Pioneer Hi-Bred International, Inc. | Novel eto1 genes and use of same for reduced ethylene and improved stress tolerance in plants |
| CN106905413A (zh) | 2009-08-06 | 2017-06-30 | 弗·哈夫曼-拉罗切有限公司 | 蛋白质纯化中提高病毒去除的方法 |
| JP5791602B2 (ja) * | 2009-08-07 | 2015-10-07 | イー・エム・デイー・ミリポア・コーポレイシヨン | 試料中の１つ以上の不純物から標的タンパク質を精製するための方法 |
| WO2011017294A1 (en) | 2009-08-07 | 2011-02-10 | Schering Corporation | Human anti-rankl antibodies |
| WO2011019620A1 (en) | 2009-08-10 | 2011-02-17 | Genentech, Inc. | Antibodies with enhanced adcc function |
| US8512983B2 (en) | 2009-08-11 | 2013-08-20 | Martin Gawlitzek | Production of proteins in glutamine-free cell culture media |
| US20110038871A1 (en) | 2009-08-11 | 2011-02-17 | Veena Viswanth | Ccr2 inhibitors for treating conditions of the eye |
| SG178335A1 (en) * | 2009-08-13 | 2012-03-29 | Crucell Holland Bv | Antibodies against human respiratory syncytial virus (rsv) and methods of use |
| AU2010282340B2 (en) | 2009-08-13 | 2016-12-22 | The Johns Hopkins University | Methods of modulating immune function |
| CN102575298A (zh) | 2009-08-14 | 2012-07-11 | 霍夫曼-拉罗奇有限公司 | 用于监测患者对vegf拮抗剂的响应的生物学标志物 |
| US20110053223A1 (en) | 2009-08-14 | 2011-03-03 | Robert Bayer | Cell culture methods to make antibodies with enhanced adcc function |
| MX336476B (es) | 2009-08-15 | 2016-01-20 | Genentech Inc | Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado. |
| KR20150089096A (ko) | 2009-08-17 | 2015-08-04 | 트라콘 파마수티칼즈, 인코포레이티드 | 항엔도글린 항체 및 항ｖｅｇｆ 제제를 사용한 암 치료를 위한 병용 요법 |
| US8221753B2 (en) * | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| US9163086B2 (en) | 2009-08-18 | 2015-10-20 | President And Fellows Of Harvard College | Methods and compositions for the treatment of proliferative and pathogenic diseases |
| GB0914446D0 (en) | 2009-08-18 | 2009-09-30 | King S College London | Bioconjugates and their uses in imaging |
| WO2011021146A1 (en) | 2009-08-20 | 2011-02-24 | Pfizer Inc. | Osteopontin antibodies |
| US20110044981A1 (en) * | 2009-08-21 | 2011-02-24 | Spangler Rhyannon | Methods and compositions for treatment of pulmonary fibrotic disorders |
| US20110207144A1 (en) * | 2009-08-21 | 2011-08-25 | Derek Marshall | In vitro screening assays |
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| SG2014004816A (en) * | 2009-08-21 | 2014-03-28 | Gilead Biologics Inc | Catalytic domains from lysyl oxidase and loxl2 |
| US20110044907A1 (en) * | 2009-08-21 | 2011-02-24 | Derek Marshall | In vivo screening assays |
| GB0914691D0 (en) | 2009-08-21 | 2009-09-30 | Lonza Biologics Plc | Immunoglobulin variants |
| RU2012110587A (ru) * | 2009-08-21 | 2013-09-27 | Джилид Байолоджикс, Инк. | Терапевтические способы и композиции |
| NZ599005A (en) | 2009-08-24 | 2014-11-28 | Phigenix Inc | Targeting pax2 for the treatment of breast cancer |
| RU2012111424A (ru) | 2009-08-26 | 2013-10-10 | Медицинише Хохшуле Ханновер | Средства и способы производства искусственных капсульных полисахаридов neisseria meningitidis |
| BR112012004464B8 (pt) | 2009-08-28 | 2021-05-25 | Labrys Biologics Inc | uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica |
| CN102002104A (zh) | 2009-08-28 | 2011-04-06 | 江苏先声药物研究有限公司 | 一种抗vegf的单克隆抗体及含有该抗体的药物组合物 |
| RU2570639C2 (ru) | 2009-08-29 | 2015-12-10 | Эббви Инк | Терапевтические dll4-связывающие белки |
| MX339608B (es) * | 2009-08-31 | 2016-05-31 | Roche Glycart Ag | Anticuerpos del antigeno carcinoembrionario (cea). |
| WO2011025542A1 (en) | 2009-08-31 | 2011-03-03 | Ludwig Institute For Cancer Research Ltd. | Seromic analysis of ovarian cancer |
| WO2011026122A2 (en) | 2009-08-31 | 2011-03-03 | Amplimmune, Inc. | B7-h4 fusion proteins and methods of use thereof |
| ES2787234T3 (es) | 2009-09-01 | 2020-10-15 | Hoffmann La Roche | Purificación de proteínas potenciada a través de una elución de proteína A modificada |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| EP2473522B1 (en) | 2009-09-02 | 2016-08-17 | Genentech, Inc. | Mutant smoothened and methods of using the same |
| US8178307B2 (en) | 2009-09-02 | 2012-05-15 | National Tsing Hua University | Methods and compositions for detection of lethal cell and uses thereof |
| JP5996429B2 (ja) | 2009-09-03 | 2016-09-21 | ジェネンテック， インコーポレイテッド | 関節リウマチの治療、診断及びモニターするための方法 |
| BR112012004823B1 (pt) | 2009-09-03 | 2021-11-30 | Merck Sharp & Dohme Corp | Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica |
| WO2011029823A1 (en) | 2009-09-09 | 2011-03-17 | Novartis Ag | Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells |
| WO2011031600A1 (en) | 2009-09-10 | 2011-03-17 | Schering Corporation | Use of il-33 antagonists to treat fibrotic disease |
| US8293483B2 (en) * | 2009-09-11 | 2012-10-23 | Epitomics, Inc. | Method for identifying lineage-related antibodies |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| AU2010292069B2 (en) | 2009-09-11 | 2015-08-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Improved Pseudomonas Exotoxin A with reduced immunogenicity |
| EP2475996A1 (en) | 2009-09-11 | 2012-07-18 | F. Hoffmann-La Roche AG | Method to identify a patient with an increased likelihood of responding to an anti-cancer agent |
| EP2477656B1 (en) | 2009-09-15 | 2017-03-29 | CSL Limited | Treatment of neurological conditions |
| SG10201408401RA (en) | 2009-09-16 | 2015-01-29 | Genentech Inc | Coiled coil and/or tether containing protein complexes and uses thereof |
| CA2772670A1 (en) | 2009-09-17 | 2011-03-24 | F. Hoffmann-La Roche Ag | Methods and compositions for diagnostics use in cancer patients |
| MX2012003287A (es) | 2009-09-18 | 2012-08-03 | Abraxis Bioscience Llc | Uso de la identificacion microambiental de sparc en el tratamiento del cancer. |
| EP2480573A1 (en) | 2009-09-22 | 2012-08-01 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mex-3 |
| WO2011037983A1 (en) | 2009-09-23 | 2011-03-31 | Medarex, Inc. | Cation exchange chromatography |
| TW201118166A (en) | 2009-09-24 | 2011-06-01 | Chugai Pharmaceutical Co Ltd | HLA class I-recognizing antibodies |
| JP2013506138A (ja) | 2009-09-25 | 2013-02-21 | オリジーン・テクノロジーズ・インコーポレイテツド | タンパク質アレイおよびその使用 |
| CN102597775A (zh) | 2009-09-25 | 2012-07-18 | 佐马技术有限公司 | 筛选方法 |
| US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
| GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| US20110076232A1 (en) | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| GB0917044D0 (en) | 2009-09-29 | 2009-11-18 | Cytoguide As | Agents, uses and methods |
| US8784819B2 (en) | 2009-09-29 | 2014-07-22 | Ibio Inc. | Influenza hemagglutinin antibodies, compositions and related methods |
| CN102630229B (zh) | 2009-09-30 | 2015-03-04 | 霍夫曼-拉罗奇有限公司 | 使用刻缺蛋白3拮抗剂来治疗刻缺蛋白1拮抗剂抗性癌症的方法 |
| WO2011038894A1 (en) | 2009-10-01 | 2011-04-07 | F. Hoffmann-La Roche Ag | Protein a chromatography |
| UY32914A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Anticuerpos que se usan específicamente al receptor epha2 |
| US20120278908A1 (en) | 2009-10-02 | 2012-11-01 | Eric Souied | Method for the diagnosis/prognosis of age-related macular degeneration |
| WO2011040973A2 (en) | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd. | Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof |
| AU2010301105A1 (en) | 2009-10-02 | 2012-04-19 | Ludwig Institute For Cancer Research Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| WO2011043980A1 (en) | 2009-10-07 | 2011-04-14 | Sanford Burnham Medical Research Institute | Methods and compositions related to clot-binding lipid compounds |
| ES2672121T3 (es) | 2009-10-07 | 2018-06-12 | Macrogenics, Inc. | Polipéptidos que contienen región Fc que presentan una función efectora mejorada debido a alteraciones del grado de fucosilación, y métodos para su uso |
| RU2016131167A (ru) | 2009-10-07 | 2018-12-07 | Дженентек, Инк. | Способы лечения, диагностики и мониторинга волчанки |
| US8518405B2 (en) | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| EP2949671A1 (en) | 2009-10-12 | 2015-12-02 | Pfizer Inc | Cancer treatment |
| EP2470569A1 (en) | 2009-10-13 | 2012-07-04 | Oxford Biotherapeutics Ltd. | Antibodies against epha10 |
| CN102666589B (zh) | 2009-10-14 | 2014-08-20 | 卡罗拜奥斯制药公司 | EphA3抗体 |
| EP2488640B1 (en) | 2009-10-14 | 2018-09-26 | Nanyang Technological University | Antiproliferative agent |
| WO2011045352A2 (en) | 2009-10-15 | 2011-04-21 | Novartis Forschungsstiftung | Spleen tyrosine kinase and brain cancers |
| WO2011047262A2 (en) | 2009-10-15 | 2011-04-21 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| EP2488202B1 (en) | 2009-10-15 | 2015-07-08 | Avaxia Biologics, Inc. | Antibody therapeutics with local activity in the digestive tract |
| RU2573896C2 (ru) * | 2009-10-15 | 2016-01-27 | Дженентек, Инк. | Химерные факторы роста фибробластов с измененной рецепторной специфичностью |
| US8883145B2 (en) | 2009-10-16 | 2014-11-11 | Oncomed Pharmaceuticals, Inc. | Methods of treatment with DLL4 antagonists and an anti-hypertensive agent |
| HUE026447T2 (en) | 2009-10-16 | 2016-05-30 | Novartis Ag | Pharmacodynamic tumor response biomarkers |
| WO2011047340A1 (en) | 2009-10-16 | 2011-04-21 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine |
| EP2489675A4 (en) | 2009-10-16 | 2013-06-05 | Univ Kyoto | ANTIBODIES WITH RECOGNITION OF THE INVERTED STRUCTURE IN AN AMYLOID ß |
| WO2011045080A2 (en) | 2009-10-16 | 2011-04-21 | Biorealites S.A.S. | Monoclonal antibodies to progastrin and their uses |
| ES2617920T3 (es) | 2009-10-16 | 2017-06-20 | Omeros Corporation | Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2 |
| US20110206704A1 (en) * | 2009-10-19 | 2011-08-25 | Genentech, Inc. | Methods and compositions for modulating hepatocyte growth factor activator |
| KR20120106940A (ko) * | 2009-10-19 | 2012-09-27 | 제넨테크, 인크. | 간세포 성장 인자 활성화제의 조절제 |
| HUE053489T2 (hu) | 2009-10-20 | 2021-06-28 | Abbvie Inc | Az anti-il-13 antitestek izolálása és tisztítása a protein A affinitás kromatográviával |
| CN102667478B (zh) | 2009-10-20 | 2018-06-01 | 雀巢产品技术援助有限公司 | 用于检测致癌融合蛋白的邻近介导试验 |
| US8658770B2 (en) | 2009-10-21 | 2014-02-25 | Hiroshima University | Integrin alpha 8-beta 1-specific monoclonal antibody |
| JP5714019B2 (ja) | 2009-10-21 | 2015-05-07 | マイカーティス エヌ．ヴェ．ＭｙＣａｒｔｉｓ ＮＶ | 急性心不全の診断、予知及び／又は予後用バイオマーカー及びその使用 |
| US20120263719A1 (en) | 2009-10-22 | 2012-10-18 | Yeda Research And Development Co., Ltd. | Compositions and methods for treating aspergillosis |
| US8435511B2 (en) | 2009-10-22 | 2013-05-07 | Genentech, Inc. | Anti-hepsin antibodies and methods using same |
| US8697386B2 (en) | 2009-10-22 | 2014-04-15 | Genentech, Inc. | Methods and compositions for modulating hepsin activation of macrophage-stimulating protein |
| TWI583394B (zh) | 2009-10-23 | 2017-05-21 | 千禧製藥公司 | 抗-ｇｃｃ抗體分子及其相關之組合物及方法 |
| WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
| WO2011056606A1 (en) * | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis |
| WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
| GB0922435D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | Method |
| US8771693B2 (en) | 2009-10-27 | 2014-07-08 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| GB0922434D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
| US9234037B2 (en) | 2009-10-27 | 2016-01-12 | Ucb Biopharma Sprl | Method to generate antibodies to ion channels |
| US20110098862A1 (en) | 2009-10-27 | 2011-04-28 | ExxonMobil Research Engineering Company Law Department | Multi-stage processes and control thereof |
| CN102781963B (zh) | 2009-10-27 | 2018-02-16 | Ucb医药有限公司 | 功能修饰性NAv1.7抗体 |
| CA2779223A1 (en) | 2009-10-27 | 2011-05-12 | Caris Mpi, Inc. | Molecular profiling for personalized medicine |
| UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US8389689B2 (en) | 2009-10-28 | 2013-03-05 | Janssen Biotech, Inc. | Anti-GLP-1R antibodies and their uses |
| US8658175B2 (en) | 2009-10-28 | 2014-02-25 | Abbvie Biotherapeutics Inc. | Anti-EGFR antibodies and their uses |
| CA2778568A1 (en) | 2009-10-30 | 2011-05-05 | Toray Industries, Inc. | Antibody having activity of inhibiting hepatitis c virus (hcv) infection and use thereof |
| EP2494072A1 (en) | 2009-10-30 | 2012-09-05 | The Regents of the University of California | Gna11 mutations in melanoma |
| TW201124535A (en) * | 2009-10-30 | 2011-07-16 | Abbott Lab | SORF constructs and multiple gene expression |
| US20120213801A1 (en) | 2009-10-30 | 2012-08-23 | Ekaterina Gresko | Phosphorylated Twist1 and cancer |
| US8420083B2 (en) | 2009-10-31 | 2013-04-16 | Abbvie Inc. | Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof |
| US20120282177A1 (en) | 2009-11-02 | 2012-11-08 | Christian Rohlff | ROR1 as Therapeutic and Diagnostic Target |
| EP2322149A1 (en) | 2009-11-03 | 2011-05-18 | Universidad del Pais Vasco | Methods and compositions for the treatment of ischemia |
| MY162511A (en) | 2009-11-04 | 2017-06-15 | Merck Sharp & Dohme | Engineered anti-tslp antibody |
| JP6007420B2 (ja) | 2009-11-04 | 2016-10-12 | ファブラス エルエルシー | 親和性成熟に基づく抗体最適化方法 |
| US20110165648A1 (en) | 2009-11-04 | 2011-07-07 | Menno Van Lookeren Campagne | Co-crystal structure of factor D and anti-factor D antibody |
| MX2012005168A (es) | 2009-11-05 | 2012-06-08 | Genentech Inc | Metodos y composicion para secrecion de polipeptidos heterologos. |
| WO2011057188A1 (en) | 2009-11-06 | 2011-05-12 | Idexx Laboratories, Inc. | Canine anti-cd20 antibodies |
| WO2011054359A2 (en) | 2009-11-06 | 2011-05-12 | University Of Copenhagen | Method for early detection of cancer |
| US20130045192A1 (en) | 2009-11-09 | 2013-02-21 | Alexion Pharmaceuticals, Inc. | Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders |
| GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| US9556272B2 (en) | 2009-11-11 | 2017-01-31 | The Trustees Of The University Of Pennsylvania | Anti-TEM1 antibodies and uses thereof |
| WO2011060272A2 (en) | 2009-11-13 | 2011-05-19 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 |
| PT2719708T (pt) | 2009-11-13 | 2018-01-16 | Daiichi Sankyo Europe Gmbh | Material e métodos para tratamento ou prevenção de doenças associadas a her-3 |
| RS56484B1 (sr) | 2009-11-17 | 2018-01-31 | Squibb & Sons Llc | Metode za poboljšanu proizvodnju proteina |
| EP3037435B1 (en) | 2009-11-17 | 2019-08-07 | MUSC Foundation for Research Development | Human monoclonal antibodies to human nucleolin |
| GB0920258D0 (en) | 2009-11-19 | 2010-01-06 | Alligator Bioscience Ab | New medical agents and use thereof |
| CN102713629B (zh) | 2009-11-20 | 2016-02-24 | 俄勒冈健康科学大学 | 用于检测结核分枝杆菌感染的方法 |
| JP5911805B2 (ja) | 2009-11-20 | 2016-04-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 上皮膜タンパク質−２（ｅｍｐ２）および増殖性硝子体網膜症（ｐｖｒ） |
| TW201129379A (en) | 2009-11-20 | 2011-09-01 | Amgen Inc | Anti-Orai1 antigen binding proteins and uses thereof |
| US20130183326A9 (en) | 2009-11-20 | 2013-07-18 | St. Jude Children's Research Hospital | Methods and compositions for modulating the activity of the interleukin-35 receptor complex |
| WO2011068870A2 (en) | 2009-12-01 | 2011-06-09 | President And Fellows Of Harvard College | Modulation of nk cell antigen specific effector activity by modulation of cxcr6 (cd186) |
| EP2507265B1 (en) | 2009-12-01 | 2016-05-11 | Compugen Ltd. | Antibody specific for heparanase splice variant T5 and its use. |
| US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US8372952B2 (en) * | 2009-12-02 | 2013-02-12 | Amgen Inc. | Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho |
| CA2781682A1 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
| US8324352B2 (en) | 2009-12-07 | 2012-12-04 | Decimmune Therapeutics, Inc. | Anti-inflammatory antibodies and uses therefor |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| EP2509997B1 (en) | 2009-12-07 | 2017-08-30 | i2 Pharmaceuticals, Inc. | Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties |
| MX2012006560A (es) * | 2009-12-08 | 2012-10-05 | Abbott Gmbh & Co Kg | Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal. |
| WO2011069528A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Lyophilization of nucleic acids in lactate-containing solutions |
| EP2332995A1 (en) | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
| EP2336171A1 (en) | 2009-12-11 | 2011-06-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel targets for the treatment of proliferative diseases |
| US8486397B2 (en) | 2009-12-11 | 2013-07-16 | Genentech, Inc. | Anti-VEGF-C antibodies and methods using same |
| US8758301B2 (en) * | 2009-12-15 | 2014-06-24 | Abbvie Biotechnology Ltd | Firing button for automatic injection device |
| JP2013514388A (ja) | 2009-12-16 | 2013-04-25 | フィリップ ボッシュ， | 間質性膀胱炎の処置の方法 |
| WO2011075725A1 (en) | 2009-12-18 | 2011-06-23 | Sanford-Burnham Medical Research Institute | Methods and compositions related to clot-binding compounds |
| RU2017102553A (ru) | 2009-12-21 | 2018-12-19 | Дженентек, Инк. | Состав, содержащий антитело |
| GB0922377D0 (en) | 2009-12-22 | 2010-02-03 | Arab Gulf University The | Mutant LDL receptor |
| RU2559542C2 (ru) | 2009-12-23 | 2015-08-10 | Дженентек, Инк. | Антитела против bv8 и их применение |
| WO2011076922A1 (en) | 2009-12-23 | 2011-06-30 | Synimmune Gmbh | Anti-flt3 antibodies and methods of using the same |
| GB0922553D0 (en) | 2009-12-23 | 2010-02-10 | Fusion Antibodies Ltd | Prognostic marker |
| CA2784610C (en) | 2009-12-23 | 2020-07-14 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
| SG181901A1 (en) | 2009-12-23 | 2012-08-30 | 4Antibody Ag | Binding members for human cytomegalovirus |
| WO2011079283A1 (en) * | 2009-12-23 | 2011-06-30 | Bioalliance C.V. | Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same |
| EP2338492A1 (en) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
| JP5728718B2 (ja) | 2009-12-28 | 2015-06-03 | オンコセラピー・サイエンス株式会社 | 抗ｃｄｈ３抗体およびその使用 |
| WO2011082345A2 (en) * | 2009-12-30 | 2011-07-07 | Brigham Young University | Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof |
| WO2011080322A1 (en) | 2009-12-30 | 2011-07-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method of prognosing the outcome of acquired hemophilia and of treatment of hemophilia |
| WO2011082187A1 (en) | 2009-12-30 | 2011-07-07 | Genentech, Inc. | Methods for modulating a pdgf-aa mediated biological response |
| WO2011084882A2 (en) | 2010-01-05 | 2011-07-14 | Contrafect Corporation | Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria |
| CA2787054A1 (en) * | 2010-01-11 | 2011-07-14 | Center For Molecular Medicine And Immunology | Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma |
| MX2012008085A (es) | 2010-01-13 | 2012-09-12 | Oncomed Pharm Inc | Agentes de union notch1 y metodos de uso de los mismos. |
| US20110177107A1 (en) | 2010-01-14 | 2011-07-21 | Haplomics, Inc. | Predicting and reducing alloimmunogenicity of protein therapeutics |
| CN102893154A (zh) | 2010-01-15 | 2013-01-23 | 加利福尼亚大学董事会 | 用于检测癌症的组合物和方法 |
| US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
| EP2525813B1 (en) | 2010-01-20 | 2017-01-04 | Merck Sharp & Dohme Corp. | Anti-ilt5 antibodies and ilt5-binding antibody fragments |
| CA2787755A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
| EP2526424A2 (en) | 2010-01-22 | 2012-11-28 | Dana-Farber Cancer Institute, Inc. | Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders |
| WO2011089211A1 (en) | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
| CA2787994C (en) | 2010-01-26 | 2021-01-12 | National Jewish Health | Diagnosis and prognosis of idiopathic interstitial pneumonia by rs35705950 snp in muc5b gene promoter |
| CA2787311C (en) | 2010-01-27 | 2017-08-15 | Yeda Research And Development Co. Ltd. | Antibodies that inhibit metalloproteins |
| WO2011094593A2 (en) | 2010-01-28 | 2011-08-04 | Ab Biosciences, Inc. | Novel lowered affinity antibodies and methods of marking the same |
| FR2955773B1 (fr) | 2010-02-01 | 2017-05-26 | Commissariat A L'energie Atomique | Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination |
| EP2531613A2 (en) | 2010-02-02 | 2012-12-12 | Abbott Biotechnology Ltd. | Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor |
| PL2531527T3 (pl) | 2010-02-04 | 2014-08-29 | Univ Miami | Przeciwciało monoklonalne przeciw CD44 do stosowania do leczenia raka płaskonabłonkowego głowy i szyi |
| TWI518325B (zh) | 2010-02-04 | 2016-01-21 | 自治醫科大學 | 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療 |
| NZ601615A (en) | 2010-02-04 | 2014-07-25 | Gilead Biologics Inc | Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor |
| EP2354159A1 (en) | 2010-02-05 | 2011-08-10 | RWTH Aachen | CCL17 inhibitors for use in T helper cell-driven diseases |
| ES2668645T3 (es) | 2010-02-08 | 2018-05-21 | Agensys, Inc. | Conjugados de fármaco y anticuerpo (ADC) que se unen a proteínas 161P2F10B |
| AR080154A1 (es) | 2010-02-10 | 2012-03-14 | Immunogen Inc | Anticuerpos cd20 y su utilizacion |
| BR112012019902A2 (pt) | 2010-02-10 | 2019-09-24 | Novartis Ag | "método e compostos para o crescimento muscular" |
| JP2013520173A (ja) | 2010-02-18 | 2013-06-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | インテグリンαｖβ８中和抗体 |
| CN102892779B (zh) | 2010-02-18 | 2016-12-21 | 基因泰克公司 | 神经调节蛋白拮抗剂及其在治疗癌症中的用途 |
| CA2790200A1 (en) | 2010-02-19 | 2011-08-25 | The Board Of Regents Of The University Of Oklahoma | Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof |
| US20110207789A1 (en) | 2010-02-19 | 2011-08-25 | Ye Fang | Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents |
| WO2011103471A1 (en) * | 2010-02-22 | 2011-08-25 | Duke University | Compositions and methods for the treatment of neurologic and psychiatric conditions |
| US10369189B2 (en) | 2010-02-22 | 2019-08-06 | Duke University | Compositions and methods for uncoupling TrkB receptor from PLC gamma 1 for the treatment of epilepsy and anxiety-like disorder |
| CA2787952C (en) | 2010-02-23 | 2016-07-26 | Genentech, Inc. | Anti-angiogenesis therapy for the treatment of ovarian cancer |
| EP2848632B1 (en) | 2010-02-23 | 2019-07-10 | Sanofi | Human igg1 fc with improved cdc and adcc activity |
| EP2538981B1 (en) | 2010-02-23 | 2017-12-20 | F. Hoffmann-La Roche AG | Compositions and methods for the diagnosis and treatment of tumor |
| TWI596114B (zh) | 2010-02-24 | 2017-08-21 | 雷那特神經科學股份有限公司 | 拮抗劑抗-ｉｌ-７受體抗體及方法 |
| KR20170085143A (ko) | 2010-02-24 | 2017-07-21 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
| CN102858949B (zh) | 2010-02-24 | 2016-07-06 | 默沙东公司 | 用于增加在巴氏毕赤酵母中生产的治疗性糖蛋白上的n-糖基化位点占据的方法 |
| GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
| WO2011106723A2 (en) * | 2010-02-26 | 2011-09-01 | Lpath, Inc. | Anti-paf antibodies |
| US9624491B2 (en) | 2010-02-26 | 2017-04-18 | Memorial Sloan Kettering Cancer Center | Methods and compositions for the detection and treatment of cancer involving miRNAs and miRNA inhibitors and targets |
| RU2012139181A (ru) | 2010-02-26 | 2014-04-10 | Ново Нордиск А/С | Стабильная композиция, содержащая антитело |
| EA032189B9 (ru) | 2010-03-01 | 2019-09-30 | БАЙЕР ХЕЛЬСКЕР ЛЛСи | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их |
| CA2789063A1 (en) * | 2010-03-02 | 2011-09-09 | F. Hoffmann-La Roche Ag | Expression vector |
| MY160628A (en) | 2010-03-02 | 2017-03-15 | Abbvie Inc | Therapeutic DLL4 Binding Proteins |
| WO2011106885A1 (en) | 2010-03-03 | 2011-09-09 | The University Of British Columbia | Oligomer-specific amyloid beta epitope and antibodies |
| US20110236386A1 (en) * | 2010-03-04 | 2011-09-29 | Zimering Mark B | Novel method for prediction of cardiovascular disease risk in type 2 diabetes |
| PH12018501083A1 (en) | 2010-03-04 | 2019-02-18 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| BR112012022338A2 (pt) | 2010-03-04 | 2017-02-14 | Vet Therapeutics Inc | anticorpos monoclonais direcionados a cd20 |
| US20130004516A1 (en) | 2010-03-04 | 2013-01-03 | Dainippon Sumitomo Pharma Co., Ltd. | Drug for inflammatory bowel disease |
| US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
| GB201003630D0 (en) | 2010-03-04 | 2010-04-21 | Novartis Ag | Avian rotavirus |
| JP5889181B2 (ja) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
| EP3260470A1 (en) | 2010-03-05 | 2017-12-27 | The John Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
| WO2011107586A1 (en) | 2010-03-05 | 2011-09-09 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, | Smoc1, tenascin-c and brain cancers |
| GB201003701D0 (en) | 2010-03-05 | 2010-04-21 | Cilian Ag | System for the expression of a protein |
| US20110223208A1 (en) | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| EP2630963A1 (en) | 2010-03-11 | 2013-08-28 | Abraxis BioScience, LLC | SPARC angiogenic domain and methods of use |
| SG10201507722QA (en) | 2010-03-11 | 2015-10-29 | Rinat Neuroscience Corp | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
| EP2368428A1 (en) | 2010-03-16 | 2011-09-28 | Institut National De La Recherche Agronomique | Obtention of a rex animal by molecular methods based on the alteration of the LIPH function |
| AR080685A1 (es) | 2010-03-17 | 2012-05-02 | Abbott Res Bv | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) |
| WO2011114251A1 (en) | 2010-03-18 | 2011-09-22 | Danisco A/S | Foodstuff |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| WO2011113118A1 (en) | 2010-03-19 | 2011-09-22 | Katholieke Universiteit Leuven | Drug tolerance/persistence of fungal biofilms |
| EP2550285B1 (en) | 2010-03-22 | 2017-07-19 | President and Fellows of Harvard College | Trioxacarcins and uses thereof |
| EP2550018B1 (en) | 2010-03-22 | 2019-02-27 | F.Hoffmann-La Roche Ag | Compositions and methods useful for stabilizing protein-containing formulations |
| WO2013040142A2 (en) | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| WO2011119484A1 (en) | 2010-03-23 | 2011-09-29 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| CA2791991A1 (en) | 2010-03-24 | 2011-09-29 | Genentech, Inc. | Anti-lrp6 antibodies |
| GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| TR201903279T4 (tr) | 2010-03-25 | 2019-03-21 | Ucb Biopharma Sprl | Disülfür stabilize edilmiş DVD-IG molekülleri. |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| WO2011120013A2 (en) | 2010-03-26 | 2011-09-29 | Trustees Of Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
| US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
| PT2552959T (pt) | 2010-03-26 | 2017-04-21 | Memorial Sloan Kettering Cancer Center | Anticorpos para muc16 e métodos de utilização dos mesmos |
| US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
| RU2012145183A (ru) | 2010-03-29 | 2014-05-10 | Займворкс, Инк. | Антитела с повышенной или пониженной эффекторной функцией |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| ES2665592T3 (es) | 2010-03-31 | 2018-04-26 | Boehringer Ingelheim International Gmbh | Anticuerpos anti-CD40 |
| GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
| EP2556374A1 (en) | 2010-04-05 | 2013-02-13 | Wyeth LLC | Biomarkers for p13k-driven cancer |
| EP2374816B1 (en) | 2010-04-07 | 2016-09-28 | Agency For Science, Technology And Research | Binding molecules against Chikungunya virus and uses thereof |
| US9441032B2 (en) | 2010-04-07 | 2016-09-13 | Agency For Science, Technology And Research | Binding molecules against Chikungunya virus and uses thereof |
| AR080873A1 (es) | 2010-04-09 | 2012-05-16 | Aveo Pharmaceuticals Inc | Anticuerpos contra factor de crecimiento epidermico (anti-erbb3 o anti-her3) |
| US8420785B2 (en) | 2010-04-09 | 2013-04-16 | Critical Care Diagnostics, Inc. | Soluble human ST-2 antibodies and assays |
| US10338069B2 (en) | 2010-04-12 | 2019-07-02 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
| GB201006096D0 (en) | 2010-04-13 | 2010-05-26 | Alligator Bioscience Ab | Novel compositions and uses thereof |
| JP2013524251A (ja) | 2010-04-13 | 2013-06-17 | プロノタ エヌ．ヴェ． | 妊娠高血圧疾患のバイオマーカー |
| CN104744591B (zh) | 2010-04-15 | 2022-09-27 | Abbvie德国有限责任两合公司 | β淀粉样蛋白结合蛋白 |
| WO2011130417A2 (en) | 2010-04-15 | 2011-10-20 | Amgen Inc. | HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS |
| EA024730B1 (ru) | 2010-04-15 | 2016-10-31 | Медимьюн Лимитед | Пирролбензодиазепиновые соединения, их конъюгаты, фармацевтические композиции, содержащие указанные конъюгаты, и применение указанных конъюгатов |
| US8383793B2 (en) | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
| LT3202789T (lt) | 2010-04-16 | 2020-06-10 | Biogen Ma Inc. | Antikūnai prieš vla-4 |
| WO2011133512A1 (en) | 2010-04-19 | 2011-10-27 | Research Development Foundation | Rtef-1 variants and uses thereof |
| US20110269735A1 (en) | 2010-04-19 | 2011-11-03 | Celera Corporation | Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof |
| EP2561076A1 (en) | 2010-04-19 | 2013-02-27 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Modulating xrn1 |
| KR102071212B1 (ko) | 2010-04-21 | 2020-01-30 | 애브비 바이오테크놀로지 리미티드 | 치료제의 제어된 전달을 위한 착용형 자동 주사 디바이스 |
| GB201006768D0 (en) | 2010-04-22 | 2010-06-09 | Cancer Rec Tech Ltd | Method for obtaining dendritic cells |
| WO2011133931A1 (en) | 2010-04-22 | 2011-10-27 | Genentech, Inc. | Use of il-27 antagonists for treating inflammatory bowel disease |
| CN102946906B (zh) | 2010-04-23 | 2015-07-15 | 弗·哈夫曼-拉罗切有限公司 | 生产异源多聚体蛋白质 |
| EP2563815A2 (en) | 2010-04-29 | 2013-03-06 | Nasvax Ltd. | Methods and compositions for treating hepatitis with anti-cd3 immune molecule therapy |
| EP2824111B1 (en) | 2010-04-30 | 2017-03-22 | Alexion Pharmaceuticals, Inc. | Anti-C5A Antibodies and Methods for Using the Antibodies |
| US20130266584A1 (en) | 2010-04-30 | 2013-10-10 | Detlef Schuppan | Methods and compositions for treating celiac disease |
| BR112012027828A2 (pt) | 2010-05-03 | 2016-08-09 | Genentech Inc | composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína |
| EP2566891B1 (en) | 2010-05-03 | 2016-11-02 | University Of Rochester | Anti-glucosaminidase passive immunization for staphylococcus aureus infections |
| JP2013533732A (ja) | 2010-05-03 | 2013-08-29 | ジェネンテック， インコーポレイテッド | 腫瘍の診断と治療のための組成物と方法 |
| EP2566517B1 (en) | 2010-05-04 | 2018-10-24 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| WO2011140151A1 (en) | 2010-05-04 | 2011-11-10 | Dyax Corp. | Antibodies against epidermal growth factor receptor (egfr) |
| RU2012151823A (ru) | 2010-05-04 | 2014-06-10 | Мерримак Фармасьютикалз, Инк. | Антитела против рецептора эпидермального фактора роста (egfr) и их применение |
| EP4234698A3 (en) | 2010-05-06 | 2023-11-08 | Novartis AG | Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies |
| DK2568976T3 (en) | 2010-05-10 | 2016-01-11 | Academia Sinica | Zanamivir-phosphonate congener with the anti-influenza activity, and determining the sensitivity oseltamivir in influenza viruses |
| TWI615405B (zh) | 2010-05-14 | 2018-02-21 | 艾伯維有限公司 | Ｉｌ-１結合蛋白 |
| EP3705133A3 (en) | 2010-05-14 | 2021-01-06 | Baxalta Incorporated | Ospa chimeras and use thereof in vaccines |
| EP2569337A1 (en) | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| US20110293629A1 (en) | 2010-05-14 | 2011-12-01 | Bastid Jeremy | Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists |
| WO2011146394A1 (en) | 2010-05-17 | 2011-11-24 | Millipore Corporation | Stimulus responsive polymers for the purification of biomolecules |
| US20110287018A1 (en) | 2010-05-19 | 2011-11-24 | Philip Bosch | Methods of Treating Interstitial Cystitis |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| SG185456A1 (en) | 2010-05-20 | 2012-12-28 | Hoffmann La Roche | Release reagent for vitamin d compounds |
| WO2011145085A2 (en) | 2010-05-21 | 2011-11-24 | Procognia (Israel) Ltd | Novel antibodies and methods of use for the treatment and diagnosis of cancer |
| GB201008541D0 (en) | 2010-05-21 | 2010-07-07 | Univ Geneve | Diagnostic methods |
| SG10201710439UA (en) | 2010-05-25 | 2018-01-30 | Genentech Inc | Methods of purifying polypeptides |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| WO2011150061A1 (en) | 2010-05-27 | 2011-12-01 | Centocor Ortho Biotech Inc. | Insulin-like growth factor 1 receptor binding peptides |
| ES2599412T3 (es) | 2010-05-28 | 2017-02-01 | F. Hoffmann-La Roche Ag | Disminución del nivel de lactato y aumento de la producción de polipéptidos regulando por disminución la expresión de la lactato deshidrogenasa y de la piruvato deshidrogenasa quinasa |
| WO2011149046A1 (ja) | 2010-05-28 | 2011-12-01 | 独立行政法人国立がん研究センター | 膵癌治療剤 |
| WO2011147921A1 (en) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
| RS63800B1 (sr) | 2010-05-28 | 2022-12-30 | Chugai Pharmaceutical Co Ltd | Poboljšanje antitumorskog odgovora t ćelije |
| US9169329B2 (en) | 2010-06-01 | 2015-10-27 | Ludwig Institute For Cancer Research | Antibodies directed to the receptor tyrosine kinase c-Met |
| EP3957653A1 (en) | 2010-06-02 | 2022-02-23 | Dana Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| US8858944B2 (en) | 2010-06-02 | 2014-10-14 | Sumitomo Dainippon Pharma Co., Ltd. | Treatment drug for autoimmune diseases and allergic diseases |
| EP2575863A4 (en) | 2010-06-03 | 2014-04-09 | Abraxis Bioscience Llc | USE OF SPARC MICROENVIRONMENT SIGNATURE IN THE TREATMENT OF CANCER |
| WO2011151833A1 (en) | 2010-06-03 | 2011-12-08 | Ramot At Tel-Aviv University Ltd. | Methods of treating diabetes and compositions capable of same |
| NZ701208A (en) | 2010-06-03 | 2016-05-27 | Genentech Inc | Immuno-pet imaging of antibodies and immunoconjugates and uses thereof |
| RS57543B1 (sr) | 2010-06-03 | 2018-10-31 | Abbvie Biotechnology Ltd | Primene i kompozicije za lečenje hidradenitis suppurativa (hs) |
| EP3845904A1 (en) | 2010-06-03 | 2021-07-07 | Idexx Laboratories, Inc. | Markers for renal disease |
| WO2011151076A2 (en) | 2010-06-04 | 2011-12-08 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS |
| GB201009455D0 (en) | 2010-06-04 | 2010-07-21 | King S College London | Nanoparticles and their uses in molecular imaging |
| US9000130B2 (en) | 2010-06-08 | 2015-04-07 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| WO2011156617A2 (en) | 2010-06-09 | 2011-12-15 | Aveo Pharmaceuticals, Inc. | Anti-egfr antibodies |
| WO2011154705A1 (en) | 2010-06-09 | 2011-12-15 | Queen Mary & Westfield College | Annexin 1 antibody |
| WO2011154485A1 (en) | 2010-06-10 | 2011-12-15 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mammalian sterile 20-like kinase 3 |
| GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
| US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
| KR20130088131A (ko) | 2010-06-16 | 2013-08-07 | 아비에 인코포레이티드 | 단백질 시료들의 비교 |
| TW201204388A (en) | 2010-06-18 | 2012-02-01 | Genentech Inc | Anti-Axl antibodies and methods of use |
| NZ702680A (en) | 2010-06-19 | 2016-07-29 | Sloan Kettering Inst Cancer | Anti-gd2 antibodies |
| CA2803391C (en) | 2010-06-22 | 2021-11-09 | Neogenix Oncology, Inc. | Npc1 antibodies that bind a muc5ac epitope |
| WO2011161119A1 (en) | 2010-06-22 | 2011-12-29 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
| US9815890B2 (en) | 2010-06-22 | 2017-11-14 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3d fragment of complement component 3 |
| CA2803029A1 (en) | 2010-06-23 | 2011-12-29 | Monash University | Constrained immunogenic compositions and uses therefor |
| EP2585045B1 (en) | 2010-06-24 | 2019-08-21 | F.Hoffmann-La Roche Ag | Compositions and methods containing alkylgycosides for stabilizing protein-containing formulations |
| EP3459558B1 (en) | 2010-06-25 | 2020-07-29 | Aston University | Glycoproteins having lipid mobilizing properties and therapeutic uses thereof |
| WO2012003493A2 (en) | 2010-07-01 | 2012-01-05 | The Regents Of The University Of California | Protein kinase ck2 gene mutations, amplifications and polymorphisms in human cancers and methods of use |
| WO2012003472A1 (en) | 2010-07-02 | 2012-01-05 | Aveo Pharmaceuticals, Inc. | Anti-notch1 antibodies |
| JP2013533746A (ja) | 2010-07-06 | 2013-08-29 | アベオ ファーマシューティカルズ， インコーポレイテッド | 抗ｒｏｎ抗体 |
| WO2012004565A1 (en) | 2010-07-06 | 2012-01-12 | Robert White | Cancer biomarker brf1 |
| AU2011275753A1 (en) | 2010-07-08 | 2013-01-10 | Pronota N.V. | Quiescin Q6 as biomarker for hypertensive disorders of pregnancy |
| WO2012006500A2 (en) | 2010-07-08 | 2012-01-12 | Abbott Laboratories | Monoclonal antibodies against hepatitis c virus core protein |
| GB201011513D0 (en) | 2010-07-08 | 2010-08-25 | Danisco | Method |
| AU2011275749C1 (en) | 2010-07-09 | 2015-09-17 | Aduro Biotech Holdings, Europe B.V. | Agonistic antibody to CD27 |
| WO2012006635A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Processable single chain molecules and polypeptides made using same |
| SG10201800717UA (en) | 2010-07-09 | 2018-02-27 | Janssen Vaccines & Prevention Bv | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
| UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| MX2013000083A (es) | 2010-07-09 | 2013-02-26 | Genentech Inc | Anticuerpos de anti-neuropilina y metodos de uso. |
| GB201011771D0 (en) | 2010-07-13 | 2010-08-25 | Bioinvent Int Ab | Biological material and particular uses thereof |
| EP2593128B1 (en) | 2010-07-15 | 2018-01-10 | Adheron Therapeutics, Inc. | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods |
| US20130189284A1 (en) | 2010-07-15 | 2013-07-25 | Technion Research & Development Foundation Ltd. | Antibodies with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides |
| WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
| EP2593476A2 (en) | 2010-07-16 | 2013-05-22 | Ablynx N.V. | Modified single domain antigen binding molecules and uses thereof |
| MX2013000667A (es) | 2010-07-19 | 2013-02-27 | Hoffmann La Roche | Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anticancer. |
| CN103140498B (zh) | 2010-07-19 | 2017-05-17 | 奥塔哥创新有限公司 | 信号生物标志物 |
| WO2012010550A1 (en) | 2010-07-19 | 2012-01-26 | F. Hoffmann-La Roche Ag | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| US9127057B2 (en) | 2010-07-20 | 2015-09-08 | Teva Pharmaceuticals Ausralia Pty Ltd | Anti-IL-23 heterodimer specific antibodies |
| WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
| WO2012011113A2 (en) | 2010-07-22 | 2012-01-26 | Shai Yarkoni | Regulatory immune cells with enhanced targeted cell death effect |
| WO2012012750A1 (en) | 2010-07-23 | 2012-01-26 | Trustees Of Boston University | ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY |
| EP2596025B1 (en) | 2010-07-23 | 2018-06-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for cancer management targeting co-029 |
| EP2412724A1 (en) | 2010-07-29 | 2012-02-01 | Centre National de la Recherche Scientifique (C.N.R.S) | Regulation of Glypican 4 activity to modulate the fate of stem cells and uses thereof |
| HUE051702T2 (hu) | 2010-07-30 | 2021-03-29 | Medimmune Llc | Tisztított aktív polipeptidek és immunkonjugátumok |
| JP2013533286A (ja) | 2010-07-30 | 2013-08-22 | セントルイス ユニバーシティ | 疼痛を治療する方法 |
| AU2011286024B2 (en) | 2010-08-02 | 2014-08-07 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| WO2012018771A1 (en) | 2010-08-03 | 2012-02-09 | Genentech, Inc. | Chronic lymphocytic leukemia (cll) biomarkers |
| CA2807014A1 (en) | 2010-08-03 | 2012-02-09 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
| RU2013106217A (ru) | 2010-08-05 | 2014-09-10 | Ф. Хоффманн-Ля Рош Аг | Гибридный белок из антитела против мнс и противовирусного цитокина |
| WO2012019061A2 (en) | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2011286407A1 (en) | 2010-08-06 | 2013-02-21 | Amgen | Use of HER3 binding agents in prostate treatment |
| US9465039B2 (en) | 2010-08-06 | 2016-10-11 | Mycartis Nv | Perlecan as a biomarker for renal dysfunction |
| US20120101108A1 (en) | 2010-08-06 | 2012-04-26 | Cell Signaling Technology, Inc. | Anaplastic Lymphoma Kinase In Kidney Cancer |
| SG187787A1 (en) | 2010-08-10 | 2013-03-28 | Amgen Inc | Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies |
| EP2603237A4 (en) | 2010-08-12 | 2014-05-21 | Theraclone Sciences Inc | ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE |
| EP2420250A1 (en) | 2010-08-13 | 2012-02-22 | Universitätsklinikum Münster | Anti-Syndecan-4 antibodies |
| US20130137627A1 (en) | 2010-08-12 | 2013-05-30 | Christophe Delacourt | Methods and kits for identifying a premature infant at risk of having or developing bronchopulmonary dysplasia |
| JP5841149B2 (ja) | 2010-08-13 | 2016-01-13 | ロシュ グリクアート アーゲー | 抗テネイシンｃａ２抗体及び使用の方法 |
| MX2013001267A (es) | 2010-08-13 | 2013-04-10 | Genentech Inc | ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD. |
| LT2603530T (lt) | 2010-08-13 | 2018-01-25 | Roche Glycart Ag | Anti-fap antikūnai ir jų naudojimo metodai |
| CN105348387B (zh) | 2010-08-14 | 2020-08-25 | Abbvie 公司 | β淀粉样蛋白结合蛋白 |
| WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
| NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
| CA3043423A1 (en) | 2010-08-17 | 2012-02-23 | F. Hoffmann-La Roche Ag | Anti-human igg1 antibody |
| KR101234807B1 (ko) | 2010-08-18 | 2013-02-19 | 한국원자력의학원 | 혈관신생 촉진용 약학 조성물 및 혈관신생 촉진용 활성물질을 스크리닝하는 방법 |
| WO2012024650A2 (en) | 2010-08-19 | 2012-02-23 | Abbott Laboratories | Anti-ngf antibodies and their use |
| WO2012022774A1 (en) | 2010-08-19 | 2012-02-23 | Roche Diagnostics Gmbh | An assay for measurement of antibodies binding to a therapeutic monoclonal antibody |
| US20130150554A1 (en) | 2010-08-20 | 2013-06-13 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
| GB201014033D0 (en) | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
| CN105037552B (zh) | 2010-08-20 | 2019-03-29 | 诺华股份有限公司 | 表皮生长因子受体3（her3)的抗体 |
| ES2850973T3 (es) | 2010-08-23 | 2021-09-01 | Wyeth Llc | Formulaciones estables de antígenos rLP2086 de Neisseria meningitidis |
| BR112013004266A8 (pt) | 2010-08-23 | 2018-01-02 | Univ Texas | anticorpos anti-ox40 e métodos de uso dos mesmos. |
| BR112013001847A2 (pt) | 2010-08-24 | 2016-05-31 | Hoffmann La Roche | anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica |
| ES2678145T3 (es) | 2010-08-24 | 2018-08-09 | Abbott Laboratories | Anticuerpos específicos contra la proteína del núcleo del VIH y usos de los mismos |
| WO2012027555A2 (en) | 2010-08-25 | 2012-03-01 | President And Fellows Of Harvard College | Glycated cd59 peptides, their preparation, and uses thereof |
| JP5813114B2 (ja) | 2010-08-25 | 2015-11-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｉｌ−１８ｒ１に対する抗体およびその使用 |
| RU2013113225A (ru) | 2010-08-26 | 2014-10-10 | Эббви Инк. | Иммуноглобулины с двумя вариабельными доменами и их применение |
| TR201910348T4 (tr) | 2010-08-27 | 2019-08-21 | Gilead Biologics Inc | Matriks metalloproteinaz 9 için antikorlar. |
| MX2013002255A (es) | 2010-08-27 | 2013-07-03 | Stem Centrx Inc | Moduladores de proteina de notum y metodos de uso. |
| CA2808236A1 (en) | 2010-08-31 | 2012-03-08 | Genentech, Inc. | Biomarkers and methods of treatment |
| SI3556396T1 (sl) | 2010-08-31 | 2022-09-30 | Theraclone Sciences, Inc. | Nevtralizacijska protitelesa proti virusu človeške imunske pomanjkljivosti (HIV) |
| ES2715177T3 (es) | 2010-09-01 | 2019-06-03 | Genzyme Corp | Tratamiento de infarto de miocardio usando antagonistas de tgf-beta |
| WO2013119964A2 (en) | 2012-02-08 | 2013-08-15 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| EP2426213A1 (en) | 2010-09-03 | 2012-03-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Marker for sunitnib resistance formation |
| EP2689787A1 (en) | 2010-09-03 | 2014-01-29 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| WO2012030512A1 (en) | 2010-09-03 | 2012-03-08 | Percivia Llc. | Flow-through protein purification process |
| CN103502466A (zh) | 2010-09-07 | 2014-01-08 | 斯隆－凯特林纪念癌症中心 | 用于γ-分泌酶测定的方法和组合物 |
| WO2012032043A1 (en) | 2010-09-07 | 2012-03-15 | Areva Med Llc | 212 pb imaging |
| PL2614082T3 (pl) | 2010-09-09 | 2019-02-28 | Pfizer Inc. | Cząsteczki wiążące 4-1BB |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| ES2728282T3 (es) | 2010-09-10 | 2019-10-23 | Wyeth Llc | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis |
| EP2614080A1 (en) | 2010-09-10 | 2013-07-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Phosphorylated twist1 and metastasis |
| US8999335B2 (en) | 2010-09-17 | 2015-04-07 | Compugen Ltd. | Compositions and methods for treatment of drug resistant multiple myeloma |
| NZ607750A (en) | 2010-09-20 | 2015-03-27 | Abbvie Inc | Purification of antibodies using simulated moving bed chromatography |
| CA2811023A1 (en) | 2010-09-21 | 2012-03-29 | Massachusetts Institute Of Technology | Influenza treatment and/or characterization; human-adapted ha polypeptides; vaccines |
| MX360946B (es) | 2010-09-22 | 2018-10-29 | Amgen Inc Star | Inmunoglobulinas portadoras y usos de las mismas. |
| JP6126991B2 (ja) | 2010-09-27 | 2017-05-10 | ヤンセン バイオテツク，インコーポレーテツド | ヒトｉｉ型コラーゲンに結合する抗体 |
| MX2013003561A (es) | 2010-09-27 | 2013-09-02 | Zestagen S A | Composiciones y métodos para tratar la neoplasia. |
| BR112013007309B1 (pt) | 2010-09-29 | 2021-07-06 | Agensys, Inc. | conjugado anticorpo-fármaco que compreende um anticorpo anti-191p4d12 conjugado a monometil auristatina e (mmae), seu uso, e composição farmacêutica |
| AU2011309028B2 (en) | 2010-09-29 | 2016-03-17 | Nb Health Laboratory Co. Ltd. | Antibody against human prostaglandin E2 receptor EP4 |
| US8530427B2 (en) | 2010-09-30 | 2013-09-10 | Mayo Foundation For Medical Education And Research | Methods for modulating resistance to apoptosis using KLK6 |
| US9675693B2 (en) | 2010-09-30 | 2017-06-13 | Riken | Methods and drugs targeting Eva1 or Ceacam1 gene expression for treatment and diagnosing of glioma |
| US9228023B2 (en) | 2010-10-01 | 2016-01-05 | Oxford Biotherapeutics Ltd. | Anti-ROR1 antibodies and methods of use for treatment of cancer |
| LT3590949T (lt) | 2010-10-01 | 2022-07-25 | Modernatx, Inc. | Ribonukleorūgštys, kurių sudėtyje yra n1-metil-pseudouracilų, ir jų naudojimas |
| EP2621527A4 (en) | 2010-10-01 | 2015-12-09 | Univ Pennsylvania | USE OF LISTERIA VACCINE VECTORS TO REVERSE VACCINE IMMUNITY IN PATIENTS WITH PARASITIC INFECTIONS |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| EP2624864B1 (en) | 2010-10-04 | 2017-12-06 | Massachusetts Institute of Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
| CN103154037A (zh) | 2010-10-05 | 2013-06-12 | 诺瓦提斯公司 | 抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途 |
| FR2965810B1 (fr) | 2010-10-06 | 2012-12-28 | Commissariat Energie Atomique | Anticorps antagoniste du sous-type b des recepteurs aux endothelines et ses utilisations |
| JP2013545969A (ja) | 2010-10-15 | 2013-12-26 | ユニヴェルシテ リブル ドゥ ブリュッセル | エストロゲン受容体αポリペプチド配列、並びにその診断および治療用途 |
| EP2630160B1 (en) | 2010-10-18 | 2016-11-09 | MediaPharma S.r.l. | Erbb3 binding antibody |
| AU2011318567B2 (en) | 2010-10-19 | 2017-02-09 | Mayo Foundation For Medical Education And Research | Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease |
| WO2012054565A1 (en) | 2010-10-20 | 2012-04-26 | Genentech, Inc. | Methods and compositions for modulating the wnt pathway |
| CN106563128B (zh) | 2010-10-22 | 2020-05-22 | 西雅图遗传学公司 | 以奥里斯他汀为主的抗体药物结合物和结合mTOR的抑制剂在制备治疗癌症药物中的用途 |
| WO2012061120A1 (en) | 2010-10-25 | 2012-05-10 | Regents Of The University Of Minnesota | Therapeutic composition for treatment of glioblastoma |
| EP3214442A1 (en) | 2010-10-25 | 2017-09-06 | F. Hoffmann-La Roche AG | Treatment of gastrointestinal inflammation and psoriasis and asthmainflammation and psoriasis a |
| CN103582494A (zh) | 2010-10-27 | 2014-02-12 | 纽约州立大学研究基金会 | 靶向e-钙粘着蛋白的可溶性细胞外结构域的组合物和用于癌症治疗的有关方法 |
| EP2632951B1 (en) | 2010-10-27 | 2017-08-02 | Amgen Inc. | Dkk1 antibodies and methods of use |
| ES2688457T3 (es) | 2010-10-28 | 2018-11-02 | Yeda Research And Development Co. Ltd. | Métodos de generación de anticuerpos contra metaloenzimas |
| AU2011323487B2 (en) | 2010-11-01 | 2016-08-11 | Genentech, Inc. | Predicting progression to advanced age-related macular degeneration using a polygenic score |
| US20120108651A1 (en) | 2010-11-02 | 2012-05-03 | Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) | Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof |
| GEP201706733B (en) | 2010-11-04 | 2017-09-25 | Boehringer Ingelheim Int | Anti-il-23 antibodies |
| MX352929B (es) | 2010-11-05 | 2017-12-13 | Zymeworks Inc | DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc. |
| SG189475A1 (en) | 2010-11-05 | 2013-05-31 | Transbio Ltd | Markers of endothelial progenitor cells and uses thereof |
| WO2012064743A2 (en) | 2010-11-08 | 2012-05-18 | The Johns Hopkins University | Methods for improving heart function |
| EP2638067A2 (en) | 2010-11-08 | 2013-09-18 | Genentech, Inc. | Subcutaneously administered anti-il-6 receptor antibody |
| KR20130133205A (ko) | 2010-11-10 | 2013-12-06 | 제넨테크, 인크. | 신경계 질환 면역요법을 위한 방법 및 조성물 |
| GB201019118D0 (en) | 2010-11-11 | 2010-12-29 | King S College | Conjugates and their uses in molecular imaging |
| US9297813B2 (en) | 2010-11-11 | 2016-03-29 | Agency For Science, Technology And Research | Targeting metabolic enzymes in human cancer |
| US20140093506A1 (en) | 2010-11-15 | 2014-04-03 | Marc Buehler | Anti-fungal-agents |
| WO2012099566A1 (en) | 2010-11-17 | 2012-07-26 | Sea Lane Biotechnologies, Llc | Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody |
| EP2640425A2 (en) | 2010-11-18 | 2013-09-25 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt) |
| JP5904468B2 (ja) | 2010-11-18 | 2016-04-13 | 国立大学法人 岡山大学 | ヒト型抗体を産生するｂ細胞の作製方法 |
| SG191716A1 (en) | 2010-11-19 | 2013-08-30 | Toshio Imai | Neutralizing anti-ccl20 antibodies |
| ES2742734T3 (es) | 2010-11-23 | 2020-02-17 | Pantheryx Inc | Composiciones y procedimientos para el tratamiento en aplicaciones clínicas de espectro general, no diferenciadas o mixtas |
| ES2847891T3 (es) | 2010-11-23 | 2021-08-04 | Vitaeris Inc | Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral |
| EP3369744A1 (en) | 2010-11-23 | 2018-09-05 | Glaxo Group Limited | Antigen binding proteins to oncostatin m (osm) |
| US20130245233A1 (en) | 2010-11-24 | 2013-09-19 | Ming Lei | Multispecific Molecules |
| CN103415615B (zh) | 2010-11-24 | 2015-11-25 | 高红 | 扩增造血干细胞 |
| KR102385507B1 (ko) | 2010-11-30 | 2022-04-12 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
| WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
| WO2012075173A2 (en) | 2010-12-01 | 2012-06-07 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
| EP2646468B1 (en) | 2010-12-01 | 2018-07-25 | AlderBio Holdings LLC | Anti-ngf compositions and use thereof |
| WO2012075333A2 (en) | 2010-12-02 | 2012-06-07 | Prometheus Laboratories Inc. | Her2delta16 peptides |
| CN103415769B (zh) | 2010-12-06 | 2017-04-12 | 迈卡蒂斯股份有限公司 | 用于妊娠性高血压疾病的生物标志物和参数 |
| BR112013014321A2 (pt) | 2010-12-08 | 2019-09-24 | Stem Centrx Inc | moduladores inovadores e métodos de uso |
| US10202615B2 (en) | 2010-12-10 | 2019-02-12 | Vanderbilt University | Mammalian genes involved in toxicity and infection |
| WO2012080769A1 (en) | 2010-12-15 | 2012-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd277 antibodies and uses thereof |
| CA2821130C (en) | 2010-12-15 | 2017-11-07 | Wyeth Llc | Anti-notch1 antibodies |
| KR101615420B1 (ko) | 2010-12-16 | 2016-04-26 | 제넨테크, 인크. | Th2 억제에 관한 진단 및 치료 |
| TW201241179A (en) | 2010-12-17 | 2012-10-16 | Sanofi Sa | MiRNAs in joint disease |
| TW201239097A (en) | 2010-12-17 | 2012-10-01 | Sanofi Sa | MiRNAs in joint disease |
| TW201238974A (en) | 2010-12-17 | 2012-10-01 | Sanofi Sa | MiRNAs in joint disease |
| TW201238973A (en) | 2010-12-17 | 2012-10-01 | Sanofi Sa | MiRNAs in joint disease |
| JP2014508511A (ja) | 2010-12-20 | 2014-04-10 | メドイミューン・リミテッド | 抗ｉｌ−１８抗体およびそれらの使用 |
| PH12018500046A1 (en) | 2010-12-20 | 2019-04-08 | Genentech Inc | Anti-mesothelin antibodies and immunoconjugates |
| WO2012087928A2 (en) | 2010-12-20 | 2012-06-28 | The Rockefeller University | Modulating agonistic tnfr antibodies |
| WO2012088265A1 (en) | 2010-12-21 | 2012-06-28 | Selexys Pharmaceuticals Corporation | Anti-p-selectin antibodies and methods of their use and identification |
| WO2012088094A2 (en) | 2010-12-21 | 2012-06-28 | Abbott Laboratories | Il-1 binding proteins |
| US9631002B2 (en) | 2010-12-21 | 2017-04-25 | The University Of North Carolina At Chapel Hill | Methods and compositions for producing active vitamin K-dependent proteins |
| EP2654789B1 (en) | 2010-12-22 | 2018-05-30 | Orega Biotech | Antibodies against human cd39 and use thereof |
| AU2011349049B2 (en) | 2010-12-22 | 2016-08-11 | Teva Pharmaceuticals Australia Pty Ltd | Modified antibody with improved half-life |
| US11141063B2 (en) | 2010-12-23 | 2021-10-12 | Philips Image Guided Therapy Corporation | Integrated system architectures and methods of use |
| WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| CN103582651A (zh) | 2010-12-27 | 2014-02-12 | 公益财团法人日本健康科学振兴财团 | 识别人类乳突病毒(hpv)l2蛋白质的单克隆抗体及使用其的测定hpv中和抗体的效价的方法 |
| WO2012090939A1 (ja) | 2010-12-27 | 2012-07-05 | 国立大学法人名古屋大学 | 受容体型チロシンキナーゼが仲介する癌細胞の生存促進性シグナルを抑制する方法 |
| EP2471554A1 (en) | 2010-12-28 | 2012-07-04 | Hexal AG | Pharmaceutical formulation comprising a biopharmaceutical drug |
| US11040140B2 (en) | 2010-12-31 | 2021-06-22 | Philips Image Guided Therapy Corporation | Deep vein thrombosis therapeutic methods |
| WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
| WO2012092374A2 (en) | 2010-12-31 | 2012-07-05 | Short Jay M | Express humanization of antibodies |
| EP2659270A4 (en) * | 2010-12-31 | 2014-05-21 | Bioatla Llc | GENERATION OF WHOLE MONOCLONAL ANTIBODIES |
| KR20130113493A (ko) | 2011-01-03 | 2013-10-15 | 에프. 호프만-라 로슈 아게 | 항―ｄｉｇ 항체 및 펩티드에 접합되어 있는 디그옥시게닌의 복합체의 약학적 조성물 |
| US20120171195A1 (en) | 2011-01-03 | 2012-07-05 | Ravindranath Mepur H | Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use |
| EP2662385A4 (en) | 2011-01-07 | 2015-11-11 | Chugai Pharmaceutical Co Ltd | METHOD FOR IMPROVING THE PHYSICAL PROPERTIES OF ANTIBODIES |
| WO2012093340A2 (en) | 2011-01-07 | 2012-07-12 | Bioscience Slovakia | Viral diagnostics |
| ES2808529T3 (es) | 2011-01-10 | 2021-03-01 | Univ Michigan Regents | Inhibidor del factor de células madre |
| ES2704685T3 (es) | 2011-01-11 | 2019-03-19 | Governing Council Univ Toronto | Método para la detección de proteínas |
| CA2824313A1 (en) | 2011-01-12 | 2012-07-19 | Innate Pharma | Tlr3 binding agents |
| EP2663578A2 (en) | 2011-01-14 | 2013-11-20 | Five Prime Therapeutics, Inc. | Il-27 antagonists for treating inflammatory diseases |
| EP3567121B1 (en) | 2011-01-17 | 2023-08-30 | Life Technologies Corporation | Workflow for detection of ligands using nucleic acids |
| CA2823707A1 (en) | 2011-01-18 | 2012-07-26 | Amgen Inc. | Nav1.7 knockout mice and uses thereof |
| EP3508498A1 (en) | 2011-01-19 | 2019-07-10 | Cantargia AB | Novel agents and uses thereof |
| CN106248582B (zh) | 2011-01-21 | 2020-10-20 | 拉布拉多诊断有限责任公司 | 样品使用最大化的系统和方法 |
| SG192119A1 (en) | 2011-01-24 | 2013-08-30 | Abbvie Biotechnology Ltd | Automatic injection devices having overmolded gripping surfaces |
| WO2012101125A1 (en) | 2011-01-24 | 2012-08-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Specific antibodies against human cxcl4 and uses thereof |
| WO2012103165A2 (en) | 2011-01-26 | 2012-08-02 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
| US20140050728A1 (en) | 2011-01-28 | 2014-02-20 | Board Of Regents Of The University Of Nebraska | Methods and compositions for inhibiting cyclophilin d for the treatment and prevention of obesity and kidney indications |
| US9669092B2 (en) | 2011-02-02 | 2017-06-06 | Emory University | Antagonism of the VIP signaling pathway |
| AU2012212075A1 (en) | 2011-02-02 | 2013-07-18 | Amgen Inc. | Methods and compositons relating to inhibition of IGF-1R |
| JP6161541B2 (ja) | 2011-02-03 | 2017-07-12 | ゾーマ テクノロジー リミテッド | 細菌中の機能的タンパク質発現を向上させるための方法および物質 |
| US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
| CA2825064C (en) | 2011-02-04 | 2022-08-30 | Genentech, Inc. | Fc variants and methods for their production |
| US20120201752A1 (en) | 2011-02-04 | 2012-08-09 | Xiaojiang Cui | Foxc1 antibodies and methods of their use |
| JP6228014B2 (ja) | 2011-02-07 | 2017-11-08 | リサーチ ディベロップメント ファウンデーション | 操作された免疫グロブリンＦｃポリペプチド |
| RU2440142C1 (ru) | 2011-02-07 | 2012-01-20 | Общество С Ограниченной Ответственностью "Онкомакс" | Антитело, останавливающее или замедляющее рост опухоли (варианты), способ подавления роста опухоли, способ диагностики злокачественных образований |
| EP2487242A1 (en) | 2011-02-09 | 2012-08-15 | Ruprecht-Karls-Universität Heidelberg | B-type plexin antagonists and uses thereof |
| WO2012107416A2 (en) | 2011-02-10 | 2012-08-16 | Roche Glycart Ag | Improved immunotherapy |
| JP2014506580A (ja) | 2011-02-14 | 2014-03-17 | セラクローン サイエンシーズ， インコーポレイテッド | インフルエンザの治療および診断のための組成物および方法 |
| WO2012112842A2 (en) | 2011-02-17 | 2012-08-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for treating poliovirus |
| WO2012110843A1 (en) | 2011-02-18 | 2012-08-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis |
| WO2012110824A1 (en) | 2011-02-18 | 2012-08-23 | Astrazeneca Ab | Binding agents with specificity for a nucleic acid modification |
| SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
| WO2012113718A1 (en) | 2011-02-21 | 2012-08-30 | Roche Diagnostics Gmbh | A diagnostic method for type ii diabetes |
| US20130330349A1 (en) | 2011-02-23 | 2013-12-12 | Rappaport Family Institute For Research In The Medical Sciences | High affinity molecules capable of binding a type a plexin receptor and uses of same |
| FR2972006B1 (fr) | 2011-02-24 | 2016-03-25 | Centre Nat Rech Scient | Nouveaux fragments d'il-33 superactifs et leurs utilisations |
| CA2827923C (en) | 2011-02-25 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Fc.gamma.riib-specific fc antibody |
| BR112013020338A2 (pt) | 2011-02-28 | 2016-10-18 | Hoffmann La Roche | proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira |
| MX353143B (es) | 2011-02-28 | 2017-12-20 | Genentech Inc | Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b. |
| CA2828405A1 (en) | 2011-02-28 | 2012-09-07 | Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale | Apoptosis-inducing molecules and uses therefor |
| MX2013010011A (es) | 2011-03-01 | 2014-10-24 | Amgen Inc | Agentes de unión biespecífica. |
| SI2681244T1 (en) | 2011-03-02 | 2018-03-30 | Roche Glycart Ag | PROTITELESA CEA |
| CN107273712B (zh) | 2011-03-02 | 2021-12-03 | 博格有限责任公司 | 基于细胞的探询式分析及其应用 |
| AU2012223365B2 (en) | 2011-03-03 | 2016-11-10 | Quark Pharmaceuticals, Inc. | Compositions and methods for treating lung disease and injury |
| WO2012119989A2 (en) | 2011-03-04 | 2012-09-13 | Oryzon Genomics, S.A. | Methods and antibodies for the diagnosis and treatment of cancer |
| WO2012119999A1 (en) | 2011-03-07 | 2012-09-13 | F. Hoffmann-La Roche Ag | Means and methods for in vivo testing of therapeutic antibodies |
| EP2683413A1 (en) | 2011-03-07 | 2014-01-15 | F.Hoffmann-La Roche Ag | In vivo selection of therapeutically active antibodies |
| US9061006B2 (en) | 2011-03-08 | 2015-06-23 | Ramot At Tel-Aviv University Ltd. | Compositions and methods for diagnosing and treating phenylketonuria (PKU) |
| KR20190107761A (ko) | 2011-03-09 | 2019-09-20 | 셀 시그널링 테크놀러지, 인크. | 모노클로날 항체를 생성하는 방법 및 시약 |
| US10139420B2 (en) | 2011-03-09 | 2018-11-27 | ISNERM (Institut National de la Sante et de la Recherche Medicale) | Methods for treating vaso-occlusive crisis using non-modified annexin V |
| US20140056897A1 (en) | 2011-03-10 | 2014-02-27 | Hco Antibody, Inc. | Bispecific three-chain antibody-like molecules |
| WO2012122512A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
| SI2683406T1 (sl) | 2011-03-11 | 2019-10-30 | Beth Israel Deconess Medical Center Inc | Protitelesa ANTI-CD40 in njihova uporaba |
| EP2683400A4 (en) | 2011-03-11 | 2014-09-17 | Advaxis | ADJUVANZIA ON LISTERIA BASE |
| US9624294B2 (en) | 2011-03-14 | 2017-04-18 | Cellmid Limited | Antibody recognizing N-domain of midkine |
| KR20140012131A (ko) | 2011-03-15 | 2014-01-29 | 테라클론 사이언시스, 아이엔씨. | 인플루엔자의 치료 및 진단을 위한 조성물 및 방법 |
| WO2012125735A1 (en) | 2011-03-15 | 2012-09-20 | Abott Laboratories | An integrated approach to the isolation and purification of antibodies |
| EP2686014A1 (en) | 2011-03-16 | 2014-01-22 | Sanofi | Uses of a dual v region antibody-like protein |
| KR20140019385A (ko) | 2011-03-17 | 2014-02-14 | 라모트 앳 텔-아비브 유니버시티 리미티드 | 이중특이성 및 단일특이성, 비대칭성 항체 및 이의 제조방법 |
| ES2699532T3 (es) | 2011-03-23 | 2019-02-11 | Univ California | Métodos y composiciones para mejorar la terapia antiangiogénica con anti-integrinas |
| EP2689250A1 (en) | 2011-03-23 | 2014-01-29 | AbbVie Inc. | Methods and systems for the analysis of protein samples |
| US9555108B2 (en) | 2011-03-24 | 2017-01-31 | Texas Tech University System | TCR mimic antibodies as vascular targeting tools |
| US9051619B2 (en) | 2011-03-25 | 2015-06-09 | Florida Agricultural and Mechanical University (FAMU) | Methods and compositions for prostate cancer metastasis |
| CN103582700B (zh) | 2011-03-25 | 2016-08-17 | 弗·哈夫曼一拉罗切有限公司 | 新的蛋白质纯化方法 |
| US8969526B2 (en) | 2011-03-29 | 2015-03-03 | Roche Glycart Ag | Antibody Fc variants |
| MX361242B (es) | 2011-03-30 | 2018-11-30 | Ablynx Nv | Anticuerpos de dominio sencillo contra tnf-alfa y usos de los mismos. |
| EP2692359B1 (en) | 2011-03-31 | 2017-06-07 | Oriental Yeast Co., Ltd. | Cancer immunopotienting agent containing rankl antagonist |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| JP6220774B2 (ja) | 2011-03-31 | 2017-10-25 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｉｃｏｓに対する抗体及びその使用 |
| CN103608038A (zh) | 2011-03-31 | 2014-02-26 | 弗·哈夫曼-拉罗切有限公司 | 施用β7整联蛋白拮抗剂的方法 |
| MX356426B (es) | 2011-04-04 | 2018-05-29 | Univ Iowa Res Found | Metodos para mejorar inmunogenicidad de vacuna. |
| WO2012138941A1 (en) | 2011-04-05 | 2012-10-11 | Longevity Biotech, Inc. | Compositions comprising glucagon analogs and methods of making and using the same |
| EP2696898A4 (en) | 2011-04-07 | 2014-10-01 | Univ Emory | COMPOSITIONS COMPRISING SACCHARIDE BINDING FRACTIONS AND METHODS FOR TARGETED THERAPY |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US20140031272A1 (en) | 2011-04-08 | 2014-01-30 | Danisco Us Inc. | Compositions |
| AU2012239961A1 (en) | 2011-04-08 | 2013-10-24 | Biogen Ma Inc. | Biomarkers predictive of therapeutic responsiveness to IFNbeta and uses thereof |
| WO2012142164A1 (en) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii |
| EP2511293A1 (en) | 2011-04-13 | 2012-10-17 | LEK Pharmaceuticals d.d. | A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins |
| NZ713461A (en) | 2011-04-15 | 2017-02-24 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
| US20140178368A1 (en) | 2011-04-19 | 2014-06-26 | Leslie Lynne SHARP | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
| RU2625034C2 (ru) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Антитела и другие молекулы, которые связывают в7-н1 и pd-1 |
| KR101589135B1 (ko) | 2011-04-20 | 2016-01-29 | 주식회사 셀앤바이오 | 인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도 |
| EP3699286A1 (en) | 2011-04-20 | 2020-08-26 | The Trustees of the University of Pennsylvania | Regimens and compositions for aav-mediated passive immunization of airborne pathogens |
| BR112013027119A8 (pt) | 2011-04-21 | 2018-03-06 | Seattle Genetics Inc | novos conjugados ligante-droga (adcs) e uso dos mesmos |
| WO2012145746A1 (en) | 2011-04-21 | 2012-10-26 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for the treatment of neuromyelitis optica |
| MX336427B (es) | 2011-04-21 | 2016-01-18 | Univ Rockefeller | Lisinas de bacteriofago de estreptococcus para la deteccion y tratamiento de bacterias gram positivas. |
| JP6066995B2 (ja) | 2011-04-21 | 2017-01-25 | アッヴィ・インコーポレイテッド | 装着型自動注射装置 |
| CN103619877B (zh) | 2011-04-21 | 2018-01-02 | 加文医学研究所 | 修饰的可变结构域分子及其产生和使用方法b |
| KR102007444B1 (ko) | 2011-04-25 | 2019-08-06 | 어드밴스드 바이오사이언스 라보라토리즈, 인코포레이티드 | 절단형 hiv 피막 단백질(env), 이와 관련된 방법 및 조성물 |
| EP2518157A1 (en) | 2011-04-26 | 2012-10-31 | Sanofi | Test Systems and methods for identifying a compound altering cellular DDR activity |
| GB2490655A (en) | 2011-04-28 | 2012-11-14 | Univ Aston | Modulators of tissue transglutaminase |
| US20140056912A1 (en) | 2011-04-29 | 2014-02-27 | Novartis Ag | Methods of treating squamous cell carcinoma |
| CN103619880A (zh) | 2011-04-29 | 2014-03-05 | 百时美施贵宝公司 | Ip-10抗体剂量递增方法 |
| WO2012146630A1 (en) | 2011-04-29 | 2012-11-01 | F. Hoffmann-La Roche Ag | N-terminal acylated polypeptides, methods for their production and uses thereof |
| CN108969761A (zh) | 2011-05-02 | 2018-12-11 | 米伦纽姆医药公司 | 抗α4β7抗体的制剂 |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| WO2012151317A1 (en) | 2011-05-03 | 2012-11-08 | Genentech, Inc. | Vascular disruption agents and uses thereof |
| US8889427B2 (en) | 2011-05-04 | 2014-11-18 | Pop Test, Llc | Diagnostic device |
| CA3131223C (en) | 2011-05-04 | 2024-01-30 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement activation |
| GB201107467D0 (en) | 2011-05-05 | 2011-06-15 | Univ Leuven Kath | Novel treatment of pain |
| MX2013012905A (es) | 2011-05-06 | 2014-04-25 | Us Gov Health & Human Serv | Inmunotoxina recombinante dirigida a la mesotelina. |
| CA2835576C (en) | 2011-05-08 | 2021-01-05 | Legochem Biosciences, Inc. | Protein-active agent conjugates and method for preparing the same |
| WO2012154889A1 (en) | 2011-05-09 | 2012-11-15 | The Cleveland Clinic Foundation | Serum s100b and uses thereof |
| CN103534272B (zh) | 2011-05-09 | 2016-05-11 | 株式会社英仙蛋白质科学 | 能够特异性识别转铁蛋白受体的抗体 |
| CA2833212C (en) | 2011-05-12 | 2020-06-09 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides |
| EP2707389B1 (en) | 2011-05-12 | 2019-10-30 | The Johns Hopkins University | Assay reagents for a neurogranin diagnostic kit |
| JP6400470B2 (ja) | 2011-05-16 | 2018-10-03 | ジェネロン（シャンハイ）コーポレイション リミテッド | 多重特異性Ｆａｂ融合タンパク質および使用法 |
| DK2710035T3 (en) | 2011-05-16 | 2017-06-19 | Hoffmann La Roche | FGFR1 agonists and methods of use |
| EP2524699A1 (en) | 2011-05-17 | 2012-11-21 | Trion Research GmbH | Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties |
| AU2012255266B2 (en) | 2011-05-17 | 2017-05-25 | California Institute Of Technology | Human immunodeficiency virus neutralizing antibodies and methods of use thereof |
| WO2012156430A1 (en) | 2011-05-17 | 2012-11-22 | Trion Research Gmbh | Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties |
| WO2012159079A1 (en) | 2011-05-18 | 2012-11-22 | The Parkinson's Institute | Assay to determine lrrk2 activity in parkinson's disease |
| WO2012156447A1 (en) | 2011-05-18 | 2012-11-22 | Pronota N.V. | New biomarker for the classification of ovarian tumours |
| JP2014516960A (ja) | 2011-05-19 | 2014-07-17 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | 抗ヒトｈｅｒ３抗体及びその使用 |
| EP2710037B1 (en) | 2011-05-19 | 2019-07-31 | The Regents of The University of Michigan | Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation |
| SG194974A1 (en) | 2011-05-20 | 2013-12-30 | Alderbio Holdings Llc | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
| CA3048709A1 (en) | 2011-05-20 | 2012-11-29 | Alderbio Holdings Llc | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
| HUE055505T2 (hu) | 2011-05-20 | 2021-11-29 | H Lundbeck As | Anti-CGRP készítmények és alkalmazásuk |
| CA2836873C (en) | 2011-05-21 | 2019-10-22 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use for extending serum half-life |
| MY173899A (en) | 2011-05-21 | 2020-02-26 | Macrogenics Inc | Cd3-binding molecules capable of binding to human and non-human cd3 |
| AU2012258637B2 (en) | 2011-05-24 | 2017-07-20 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| MX347514B (es) | 2011-05-25 | 2017-04-28 | Innate Pharma Sa | Anticuerpos anti-receptores tipo inmunoglobulina citoliticos (kir) para el tratamiento de trastornos inflamatorios. |
| AR086543A1 (es) | 2011-05-25 | 2014-01-08 | Bg Medicine Inc | Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica |
| JP6263467B2 (ja) | 2011-05-27 | 2018-01-17 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）結合タンパク質 |
| WO2012163848A1 (en) | 2011-05-27 | 2012-12-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of crohn's disease |
| CA2837546A1 (en) | 2011-06-02 | 2012-12-06 | Tufts University | Dsrna/dna hybrid genome replication intermediate of metakaryotic stem cells |
| EP2530089A1 (en) | 2011-06-03 | 2012-12-05 | Bayer Pharma Aktiengesellschaft | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| EA201990698A1 (ru) | 2011-06-03 | 2019-12-30 | Ксома Текнолоджи Лтд. | Антитела, специфические к tgf-бета |
| US9574002B2 (en) | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
| US9181553B2 (en) | 2011-06-06 | 2015-11-10 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Method of treatment of breast cancers over-expressing the SHP2 signature genes |
| JP6305919B2 (ja) | 2011-06-06 | 2018-04-04 | プロセナ バイオサイエンシーズ リミテッド | Ｍｃａｍアンタゴニスト及び治療の方法 |
| WO2012170740A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
| US9561274B2 (en) | 2011-06-07 | 2017-02-07 | University Of Hawaii | Treatment and prevention of cancer with HMGB1 antagonists |
| EP2717913A4 (en) | 2011-06-08 | 2014-11-26 | Univ Indiana Res & Tech Corp | MONOCLONAL ANTIBODIES AND ANTIGENS FOR DIAGNOSING AND TREATING PULMONARY DISEASE AND INJURY |
| WO2012168399A1 (en) | 2011-06-08 | 2012-12-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting, treating and modelling hormone resistance |
| BR112013031262A2 (pt) | 2011-06-09 | 2016-11-22 | Us Health | "exotoxinas a de pseudomonas com menos epítopos imunogênicos de célula b e t, e seu uso no tratamento e prevenção de câncer, bem como molécula quimérica, ácido nucleico, vetor de expressão, células, composição farmacêutica e métodos para inibir crescimento de célula-alvo e de produção de endotoxinas a de pseudomonas e de molécula quimérica". |
| GB201109966D0 (en) | 2011-06-10 | 2011-07-27 | Cancer Res Inst Royal | Materials and methods for treating pten mutated or deficient cancer |
| EP2717898B1 (en) | 2011-06-10 | 2018-12-19 | Bioverativ Therapeutics Inc. | Pro-coagulant compounds and methods of use thereof |
| AU2012266241B2 (en) | 2011-06-10 | 2016-04-28 | Bone Therapeutics Sa | Markers for impaired bone fracture healing |
| WO2012170607A2 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Use of pcsk9 antagonists |
| WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| CA2838490A1 (en) | 2011-06-10 | 2012-12-13 | Universite Libre De Bruxelles | Targets and agents for the treatment of impaired bone fracture healing |
| KR102111171B1 (ko) | 2011-06-10 | 2020-05-14 | 메디뮨 엘엘씨 | 항슈도모나스 ｐｓｌ 결합 분자 및 그의 용도 |
| GB201109965D0 (en) | 2011-06-10 | 2011-07-27 | Cancer Res Inst Royal | Materials and methods for treating estrogen receptor alpher(ER) positive cancer |
| BR112013031943B1 (pt) | 2011-06-13 | 2021-10-13 | Csl Limited | Composição que compreende proteínas e anticorpos contra g-csfr |
| WO2012172495A1 (en) | 2011-06-14 | 2012-12-20 | Novartis Ag | Compositions and methods for antibodies targeting tem8 |
| EP2720720B1 (en) | 2011-06-14 | 2018-02-28 | Yeda Research and Development Co. Ltd. | Combination therapy to prevent dcis formation and progression to breast cancer |
| AU2012269075B2 (en) | 2011-06-15 | 2015-05-21 | F. Hoffmann-La Roche Ag | Anti-human EPO receptor antibodies and methods of use |
| MX2013014847A (es) | 2011-06-17 | 2015-01-12 | Amgen Inc | Metodo para tratar o aminorar trastornos metabolicos udando clec-2. |
| WO2012175613A1 (en) | 2011-06-21 | 2012-12-27 | Innate Pharma | NKp46-MEDIATED NK CELL TUNING |
| JP6120833B2 (ja) | 2011-06-22 | 2017-04-26 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） | 抗Ａｘｌ抗体及びその使用 |
| AU2012273954A1 (en) | 2011-06-22 | 2014-01-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-Axl antibodies and uses thereof |
| PL2723773T3 (pl) | 2011-06-22 | 2018-07-31 | F.Hoffmann-La Roche Ag | Eliminacja komórek docelowych przez obecne w krążeniu, swoiste dla wirusa, cytotoksyczne limfocyty T z wykorzystaniem kompleksów zawierających MHC klasy I |
| EP2537532A1 (en) | 2011-06-22 | 2012-12-26 | J. Stefan Institute | Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use |
| WO2013003625A2 (en) | 2011-06-28 | 2013-01-03 | Oxford Biotherapeutics Ltd. | Antibodies |
| ES2615256T3 (es) | 2011-06-28 | 2017-06-06 | Oxford Biotherapeutics Ltd. | Objetivo terapéutico y de diagnóstico |
| TW201306866A (zh) | 2011-06-30 | 2013-02-16 | Genentech Inc | 抗－ｃ－ｍｅｔ抗體調配物 |
| CN109517059B (zh) | 2011-06-30 | 2023-03-28 | 中外制药株式会社 | 异源二聚化多肽 |
| WO2013001517A1 (en) | 2011-06-30 | 2013-01-03 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
| EP2726101B1 (en) | 2011-06-30 | 2018-08-08 | Genzyme Corporation | Inhibitors of t-cell activation |
| EP2727937A4 (en) | 2011-06-30 | 2015-03-18 | Immuno Biological Lab Co Ltd | SOLUBLE MUTANT OF INEGRINE ALPHA-4 |
| WO2013006437A1 (en) | 2011-07-01 | 2013-01-10 | Novartis Ag | Method for treating metabolic disorders |
| JP2013040160A (ja) | 2011-07-01 | 2013-02-28 | Genentech Inc | 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用 |
| CN102268089A (zh) | 2011-07-05 | 2011-12-07 | 上海交通大学 | Agr2阻断抗体及其用途 |
| EP2543677A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
| EP2543679A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
| EP2543678A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
| DK2732021T3 (da) | 2011-07-08 | 2020-07-27 | Emd Millipore Corp | Forbedrede dybdefiltre til bioteknologiske engangsfremgangsmåder |
| ES2670621T3 (es) | 2011-07-11 | 2018-05-31 | Glenmark Pharmaceuticals S.A. | Anticuerpos que se unen a OX40 y sus usos |
| US9057728B2 (en) | 2011-07-12 | 2015-06-16 | Epitomics, Inc. | FACS-based method for obtaining an antibody sequence |
| CN103857411A (zh) | 2011-07-13 | 2014-06-11 | 阿布维公司 | 使用抗il-13抗体治疗哮喘的方法和组合物 |
| WO2013010170A1 (en) | 2011-07-14 | 2013-01-17 | Lovell Mark A | Process for detection of alzheimer's disease from a serum sample |
| EP2731970B1 (en) | 2011-07-15 | 2018-11-28 | MorphoSys AG | Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt) |
| US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
| CN106167526A (zh) | 2011-07-15 | 2016-11-30 | 昂考梅德药品有限公司 | Rspo结合剂和其应用 |
| EP2548891A1 (en) | 2011-07-18 | 2013-01-23 | Universiteit Maastricht | Human monoclonal antibody against the gamma subunit of the acetylcholine receptor for use in the treatment of rhabdomyosarcoma. |
| CA2842195A1 (en) | 2011-07-18 | 2013-01-24 | Immunomedics, Inc. | Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death |
| US9156911B2 (en) | 2011-07-18 | 2015-10-13 | Amgen Inc. | Apelin antigen-binding proteins and uses thereof |
| WO2013011072A1 (en) | 2011-07-20 | 2013-01-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Carbapenemase and antibacterial treatment |
| WO2013015821A1 (en) | 2011-07-22 | 2013-01-31 | The Research Foundation Of State University Of New York | Antibodies to the b12-transcobalamin receptor |
| US20130022551A1 (en) | 2011-07-22 | 2013-01-24 | Trustees Of Boston University | DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS |
| US9120858B2 (en) | 2011-07-22 | 2015-09-01 | The Research Foundation Of State University Of New York | Antibodies to the B12-transcobalamin receptor |
| US20150125533A1 (en) | 2011-07-25 | 2015-05-07 | American University In Cairo | Single-domain antibodies and graphene coated magnetic metal nanoparticles conjugate and methods for using the same |
| EP2738252B1 (en) | 2011-07-26 | 2019-07-10 | National Institute of Advanced Industrial Science And Technology | Antibody for detecting epithelial ovarian cancer marker and method for diagnosing epithelial ovarian cancer |
| JP5857334B2 (ja) | 2011-07-26 | 2016-02-10 | 国立研究開発法人産業技術総合研究所 | 上皮性卵巣癌マーカー検出用抗体及び上皮性卵巣癌判定方法 |
| US20140308275A1 (en) | 2011-07-27 | 2014-10-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale | Methods for diagnosing and treating myhre syndrome |
| CA2842053C (en) | 2011-07-27 | 2018-01-16 | Philogen S.P.A. | Il-12 immunoconjugate |
| EP2736928B1 (en) | 2011-07-28 | 2019-01-09 | i2 Pharmaceuticals, Inc. | Sur-binding proteins against erbb3 |
| CN104010494B (zh) | 2011-07-28 | 2017-07-04 | 霍夫曼-拉罗奇有限公司 | Pik3ca h1047r敲入非人动物乳腺癌模型 |
| KR102049817B1 (ko) | 2011-08-01 | 2019-12-02 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법 |
| WO2013017656A1 (en) | 2011-08-02 | 2013-02-07 | Medizinische Universität Wien | Antagonists of ribonucleases for treating obesity |
| WO2013019817A1 (en) | 2011-08-03 | 2013-02-07 | Quidel Corporation | N-acetyl-d-glucosamine for enhanced specificity of strep a immunoassay |
| WO2013017691A1 (en) | 2011-08-04 | 2013-02-07 | Medizinische Universität Innsbruck | Cahgt1p inhibitors for use in the treatment of candidiasis |
| US8663637B2 (en) | 2011-08-05 | 2014-03-04 | Research Development Foundation | Methods and compositions for modulation of Olfml3 mediated angiogenesis |
| WO2013021228A1 (en) | 2011-08-10 | 2013-02-14 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Early childhood membranous nephropathy due to cationic bovine serum albumin |
| WO2013023994A1 (en) | 2011-08-12 | 2013-02-21 | Pronota N.V. | New biomarker for the classification of ovarian tumours |
| EP2743699A4 (en) | 2011-08-12 | 2015-04-08 | Nat Inst Infectious Diseases | METHOD FOR THE TEST, PREVENTION AND TREATMENT OF ASPERGILLUS FUMIGATUS INFECTIOUS DISEASE, AND COMPOSITION |
| EP2741777B1 (en) | 2011-08-12 | 2017-01-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| EP2756094B1 (en) | 2011-08-15 | 2017-12-27 | Medlmmune, LLC | Anti-b7-h4 antibodies and their uses |
| WO2013025479A1 (en) | 2011-08-16 | 2013-02-21 | Emory University | Jaml specific binding agents, antibodies, and uses related thereto |
| WO2013025944A1 (en) | 2011-08-17 | 2013-02-21 | Genentech, Inc. | Inhibition of angiogenesis in refractory tumors |
| JP6093360B2 (ja) | 2011-08-17 | 2017-03-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | インテグリンα−ｖβ−８と結合する抗体 |
| CN103890246A (zh) | 2011-08-18 | 2014-06-25 | 亲和生物科学公司 | 可溶性多肽 |
| WO2013028330A2 (en) | 2011-08-19 | 2013-02-28 | Emd Millipore Corporation | Methods of reducing level of one of more impurities in a sample during protein purification |
| KR20140078633A (ko) | 2011-08-22 | 2014-06-25 | 캔진코포레이션 | 클로스트리듐 디피실리균 항체 |
| SG10201606991RA (en) | 2011-08-23 | 2016-10-28 | Foundation Medicine Inc | Novel kif5b-ret fusion molecules and uses thereof |
| KR101870555B1 (ko) | 2011-08-23 | 2018-06-22 | 로슈 글리카트 아게 | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 |
| JP2014534806A (ja) | 2011-08-23 | 2014-12-25 | ロシュ グリクアート アーゲー | 抗ｍｃｓｐ抗体 |
| AR087601A1 (es) | 2011-08-23 | 2014-04-03 | Roche Glycart Ag | Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de utilizacion |
| US8822651B2 (en) | 2011-08-30 | 2014-09-02 | Theraclone Sciences, Inc. | Human rhinovirus (HRV) antibodies |
| GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
| US9360630B2 (en) | 2011-08-31 | 2016-06-07 | Volcano Corporation | Optical-electrical rotary joint and methods of use |
| MY166152A (en) | 2011-09-01 | 2018-06-06 | Eisai R&D Man Co Ltd | Anti-human xcr1 antibodies |
| EP2751562B1 (en) | 2011-09-02 | 2015-09-16 | Nestec S.A. | Profiling of signal pathway proteins to determine therapeutic efficacy |
| US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
| EP2753359B1 (en) | 2011-09-06 | 2018-02-28 | Translational Sciences Inc. | Serpinf2-binding molecules and methods of use |
| EP2749641B1 (en) | 2011-09-07 | 2021-06-02 | Chugai Seiyaku Kabushiki Kaisha | Cancer stem cell isolation |
| SG11201400100SA (en) | 2011-09-09 | 2014-06-27 | Univ Osaka | Dengue-virus serotype neutralizing antibodies |
| US20140378537A1 (en) | 2011-09-09 | 2014-12-25 | Genentech, Inc. | Treatment of th17 mediated inflammatory diseases |
| WO2013036799A2 (en) | 2011-09-09 | 2013-03-14 | Fred Hutchinson Cancer Research Center | Methods and compositions involving nkg2d inhibitors and cancer |
| KR20140075708A (ko) | 2011-09-12 | 2014-06-19 | 얀센 바이오테크 인코포레이티드 | 대사 및 심혈관 질환의 치료를 위한 톨-유사 수용체 3 길항제 |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US20140170735A1 (en) | 2011-09-25 | 2014-06-19 | Elizabeth A. Holmes | Systems and methods for multi-analysis |
| US9268915B2 (en) | 2011-09-25 | 2016-02-23 | Theranos, Inc. | Systems and methods for diagnosis or treatment |
| US8475739B2 (en) | 2011-09-25 | 2013-07-02 | Theranos, Inc. | Systems and methods for fluid handling |
| US8435738B2 (en) | 2011-09-25 | 2013-05-07 | Theranos, Inc. | Systems and methods for multi-analysis |
| US8840838B2 (en) | 2011-09-25 | 2014-09-23 | Theranos, Inc. | Centrifuge configurations |
| US9632102B2 (en) | 2011-09-25 | 2017-04-25 | Theranos, Inc. | Systems and methods for multi-purpose analysis |
| US9619627B2 (en) | 2011-09-25 | 2017-04-11 | Theranos, Inc. | Systems and methods for collecting and transmitting assay results |
| WO2013039996A1 (en) | 2011-09-13 | 2013-03-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for brown fat induction and activity using fndc5 |
| US9664702B2 (en) | 2011-09-25 | 2017-05-30 | Theranos, Inc. | Fluid handling apparatus and configurations |
| US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
| WO2013038412A2 (en) | 2011-09-15 | 2013-03-21 | Vaxil Bio Therapeutics Ltd. | Antibodies directed against signal peptides, methods and uses thereof |
| WO2013040433A1 (en) | 2011-09-15 | 2013-03-21 | Genentech, Inc. | Methods of promoting differentiation |
| CA2846608C (en) | 2011-09-16 | 2023-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pseudomonas exotoxin a with less immunogenic b cell epitopes |
| RU2014114617A (ru) | 2011-09-19 | 2015-10-27 | Дженентек, Инк. | Комбинированные виды лечения, содержащие антагонисты с-мет и антагонисты b-raf |
| PT2760463T (pt) | 2011-09-20 | 2019-02-27 | Univ North Carolina Chapel Hill | Regulação de canais de sódio por proteínas plunc |
| BR112014006405A2 (pt) | 2011-09-21 | 2017-04-04 | Fujirebio Kk | anticorpo, conjunto, e, método para medir um complexo de afinidade |
| AU2012311492A1 (en) | 2011-09-23 | 2014-03-06 | Amgen Research (Munich) Gmbh | Bispecific binding molecules for 5T4 and CD3 |
| TWI583699B (zh) | 2011-09-23 | 2017-05-21 | 安可美德藥物股份有限公司 | Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途 |
| JP2014530001A (ja) | 2011-09-23 | 2014-11-17 | テクノファージ， インベスティガサン エデセンボルビメント エム ビオテクノロジア，エスエー | 抗腫瘍壊死因子−α剤及びその使用 |
| US10012664B2 (en) | 2011-09-25 | 2018-07-03 | Theranos Ip Company, Llc | Systems and methods for fluid and component handling |
| US9250229B2 (en) | 2011-09-25 | 2016-02-02 | Theranos, Inc. | Systems and methods for multi-analysis |
| US9810704B2 (en) | 2013-02-18 | 2017-11-07 | Theranos, Inc. | Systems and methods for multi-analysis |
| ES2762179T3 (es) | 2011-09-26 | 2020-05-22 | Philogen Spa | Terapia de combinación de inmunocitocinas |
| US20140234307A1 (en) | 2011-09-27 | 2014-08-21 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis |
| GB2495113A (en) | 2011-09-29 | 2013-04-03 | Bioinvent Int Ab | Anti-ICAM-1 antibody for treating multiple-myeloma-related disorders |
| CA2850178C (en) | 2011-09-30 | 2020-02-25 | Sarcotein Diagnostics, Llc | Bin1 expression as a marker of cancer |
| TW201326209A (zh) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| PL2760471T3 (pl) | 2011-09-30 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Peptydy terapeutyczne |
| CA2850549C (en) | 2011-09-30 | 2023-03-14 | Teva Pharmaceuticals Australia Pty Ltd. | Antibodies against tl1a and uses thereof |
| WO2013047748A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| MX354267B (es) | 2011-10-03 | 2018-02-21 | Moderna Therapeutics Inc Star | Nucléosidos, nucleótidos, y ácidos nucleicos modificados, y usos de los mismos. |
| TW201329105A (zh) | 2011-10-04 | 2013-07-16 | Thr Trustees Of Columbia University In The City Of New York | 人類ｎｏｔｃｈ１引誘物 |
| US20150299313A1 (en) | 2011-10-05 | 2015-10-22 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain |
| BR112014008212A2 (pt) | 2011-10-05 | 2017-06-13 | Genentech Inc | método para tratar uma condição hepática, método de indução por diferenciação hepática e método de redução de proliferação anormal do ducto biliar |
| WO2013050441A1 (en) | 2011-10-05 | 2013-04-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation |
| AU2012318609B2 (en) | 2011-10-05 | 2018-02-08 | The Rockefeller University | Dimeric bacteriophage lysins |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| US9575073B2 (en) | 2011-10-10 | 2017-02-21 | Rutgers, The State University Of New Jersey | Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma |
| WO2013053767A1 (en) | 2011-10-10 | 2013-04-18 | Medimmune Limited | Treatment for rheumatoid arthritis |
| WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| EP3418306B1 (en) | 2011-10-11 | 2023-12-06 | F. Hoffmann-La Roche AG | Improved assembly of bispecific antibodies |
| EP2766037A4 (en) | 2011-10-12 | 2015-08-05 | Scripps Research Inst | HIV-1 GP-120 MINI-V3 LOOP AND USES THEREOF |
| EP2766041B1 (en) | 2011-10-12 | 2018-12-05 | Children's Medical Center Corporation | Combinatorial compositions and methods of treating hemoglobinopathies |
| CN104039351A (zh) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | 用于治疗血管渗漏综合征和癌症的方法 |
| EP3501536A1 (en) | 2011-10-13 | 2019-06-26 | Aerpio Therapeutics, Inc. | Treatment of ocular disease |
| US20140302509A1 (en) | 2011-10-14 | 2014-10-09 | Pronota N.V. | Procathepsin l and cathepsin l as biomarkers for ischemia |
| PE20142363A1 (es) | 2011-10-14 | 2015-01-30 | Genentech Inc | Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab |
| WO2013056054A2 (en) | 2011-10-14 | 2013-04-18 | Genentech, Inc | Peptide inhibitors of bace1 |
| US10378060B2 (en) | 2011-10-14 | 2019-08-13 | Dana-Farber Cancer Institute, Inc. | ZNF365/ZFP365 biomarker predictive of anti-cancer response |
| EP2581388A1 (en) | 2011-10-14 | 2013-04-17 | Centre National de la Recherche Scientifique (CNRS) | Anti-sPLA2-V antibodies and uses thereof |
| PL2766393T3 (pl) | 2011-10-14 | 2018-11-30 | F.Hoffmann-La Roche Ag | PRZECIWCIAŁA PRZECIW HtrA1 I SPOSOBY ZASTOSOWANIA |
| WO2013054307A2 (en) | 2011-10-14 | 2013-04-18 | Novartis Ag | Antibodies and methods for wnt pathway-related diseases |
| CA2852244C (en) | 2011-10-17 | 2023-10-17 | Minerva Biotechnologies Corporation | Media for stem cell proliferation and induction |
| WO2013059531A1 (en) | 2011-10-20 | 2013-04-25 | Genentech, Inc. | Anti-gcgr antibodies and uses thereof |
| US20140248284A1 (en) | 2011-10-20 | 2014-09-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the detection and the treatment of cardiac remodeling |
| EP2768944B2 (en) | 2011-10-21 | 2023-11-22 | Pfizer Inc. | Addition of iron to improve cell culture |
| JP6316195B2 (ja) | 2011-10-26 | 2018-04-25 | エランコ ティーアゲズンタイト アーゲー | モノクローナル抗体および使用の方法 |
| KR20140090997A (ko) | 2011-10-26 | 2014-07-18 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | B-세포 만성 림프구성 백혈병 및 다른 혈액학적 악성종양의 치료를 위한 cd44 단일클론 항체 |
| EP2771464B1 (en) | 2011-10-27 | 2018-03-21 | Yeda Research and Development Co. Ltd. | Methods of treating cancer |
| WO2013062083A1 (ja) | 2011-10-28 | 2013-05-02 | ファーマロジカルズ・リサーチ プライベート リミテッド | 癌幹細胞特異的分子 |
| MX2014004991A (es) | 2011-10-28 | 2014-05-22 | Genentech Inc | Combinaciones terapeuticas y metodos para tratar el melanoma. |
| WO2013063419A2 (en) | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
| WO2013063496A1 (en) | 2011-10-28 | 2013-05-02 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to nae inhibitors |
| KR102232811B1 (ko) | 2011-10-28 | 2021-03-29 | 프레닥스 에이비 | 치료제 및 이의 용도 |
| WO2013059886A1 (en) | 2011-10-28 | 2013-05-02 | Patrys Limited | Pat-lm1 epitopes and methods for using same |
| BR112014010257A2 (pt) | 2011-10-31 | 2017-04-18 | Chugai Pharmaceutical Co Ltd | molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves |
| CN116077644A (zh) | 2011-10-31 | 2023-05-09 | 弗·哈夫曼-拉罗切有限公司 | 抗体制剂 |
| AU2012332587B2 (en) | 2011-11-01 | 2017-02-23 | Bionomics, Inc. | Antibodies and methods of treating cancer |
| AU2012332588B2 (en) | 2011-11-01 | 2017-09-07 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
| WO2013067057A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Anti-gpr49 antibodies |
| US9221907B2 (en) | 2011-11-01 | 2015-12-29 | Bionomics Inc. | Anti-GPR49 monoclonal antibodies |
| US9487577B2 (en) | 2011-11-02 | 2016-11-08 | University Of Rochester | Anti-glucosaminidase passive immunization for Staphylococcus aureus infections |
| EP3257564B2 (en) | 2011-11-02 | 2024-05-29 | F. Hoffmann-La Roche AG | Overload and elute chromatography |
| ES2861435T3 (es) | 2011-11-03 | 2021-10-06 | Univ Pennsylvania | Composiciones específicas de B7-H4 aisladas y métodos de uso de las mismas |
| PT2773671T (pt) | 2011-11-04 | 2021-12-14 | Zymeworks Inc | Geração de anticorpo heterodimérico estável com mutações no domínio fc |
| CN104136042B (zh) | 2011-11-07 | 2017-08-18 | 米迪缪尼有限公司 | 使用抗假单胞菌Psl和PcrV结合分子的联合治疗 |
| US9757451B2 (en) | 2011-11-07 | 2017-09-12 | UNIVERSITé LAVAL | Use of RANK/RANKL antagonists for treating muscular dystrophy |
| EP2776838A1 (en) | 2011-11-08 | 2014-09-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Early diagnostic of neurodegenerative diseases |
| EP2592103A1 (en) | 2011-11-08 | 2013-05-15 | Adriacell S.p.A. | Polymer aldehyde derivatives |
| WO2013070468A1 (en) | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| EP2776022A1 (en) | 2011-11-08 | 2014-09-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
| WO2013071233A1 (en) | 2011-11-10 | 2013-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for detecting infectious agents and a novel virus detected thereby |
| CA2954166A1 (en) | 2011-11-11 | 2013-05-16 | Rinat Neuroscience Corp. | Antibodies specific for trop-2 and their uses |
| IN2014DN03451A (ja) | 2011-11-11 | 2015-06-05 | Ucb Pharma Sa | |
| CN104126017A (zh) | 2011-11-11 | 2014-10-29 | 米伦纽姆医药公司 | 对蛋白酶体抑制剂的反应的生物标记 |
| US9920373B2 (en) | 2011-11-11 | 2018-03-20 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| US9023995B2 (en) | 2011-11-16 | 2015-05-05 | Boehringer Ingelheim International Gmbh | Anti IL-36R antibodies |
| DK2780039T3 (en) | 2011-11-17 | 2018-01-15 | Pfizer | Cytotoxic peptides and antibody-drug conjugates thereof |
| CN103946710B (zh) | 2011-11-18 | 2015-08-26 | 霍夫曼-拉罗奇有限公司 | 维生素d化合物的释放制剂 |
| AU2012340826A1 (en) | 2011-11-21 | 2014-05-29 | Genentech, Inc. | Purification of anti-c-met antibodies |
| WO2013078122A1 (en) | 2011-11-22 | 2013-05-30 | President And Fellows Of Harvard College | Diabetes diagnosis through the detection of glycated proteins in urine |
| WO2013076194A1 (en) | 2011-11-22 | 2013-05-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing airway hyperresponse |
| MX350957B (es) | 2011-11-23 | 2017-09-27 | Medimmune Llc | Moleculas de union especificas para her3 y usos de las mismas. |
| BR112014012590A8 (pt) | 2011-11-23 | 2017-12-19 | Igenica Inc | Anticorpos anti-cd98 e métodos de uso dos mesmos |
| EA036814B9 (ru) | 2011-11-28 | 2021-12-27 | Мерк Патент Гмбх | Антитело против pd-l1 (варианты), композиция, содержащая это антитело, и их применение |
| JP6082402B2 (ja) | 2011-11-28 | 2017-02-15 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 加齢に伴う機能障害の処置に使用するための薬学的組成物 |
| CA2854042A1 (en) | 2011-11-29 | 2013-06-06 | Genentech, Inc. | Compositions and methods for prostate cancer analysis |
| EP2599496A1 (en) | 2011-11-30 | 2013-06-05 | Kenta Biotech AG | Novel targets of Acinetobacter baumannii |
| US20150147274A1 (en) | 2011-12-02 | 2015-05-28 | Cancer Research Technology Limited | Antibodies against hgf - receptor and uses |
| US20130273029A1 (en) | 2011-12-05 | 2013-10-17 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
| WO2013085893A1 (en) | 2011-12-05 | 2013-06-13 | Immunomedics, Inc. | Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
| US9757458B2 (en) | 2011-12-05 | 2017-09-12 | Immunomedics, Inc. | Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells |
| TWI591074B (zh) | 2011-12-05 | 2017-07-11 | Ｘ 染色體有限公司 | ＰＤＧＦ受體β結合多肽 |
| US20140335084A1 (en) | 2011-12-06 | 2014-11-13 | Hoffmann-La Roche Inc. | Antibody formulation |
| EP2602265A1 (en) | 2011-12-07 | 2013-06-12 | Centre National de la Recherche Scientifique (CNRS) | Antibodies anti-sPLA2-X and uses thereof |
| MX368200B (es) | 2011-12-08 | 2019-09-24 | Amgen Inc | Proteinas de union al antigeno lecitin colesterol aciltransferasas humanas agonistas y su uso en terapia. |
| JP2015500988A (ja) | 2011-12-09 | 2015-01-08 | ミカーティス エヌ．ブイ． | 肺障害のバイオマーカーとしてのｌｔｂｐ２ |
| GB201121301D0 (en) | 2011-12-12 | 2012-01-25 | Novartis Ag | Method |
| WO2013088136A1 (en) | 2011-12-12 | 2013-06-20 | Ahrens Susan | Ligand for dngr-1 receptor |
| AU2012352168C1 (en) | 2011-12-14 | 2018-01-25 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
| EP2790731A2 (de) | 2011-12-14 | 2014-10-22 | Seattle Genetics, Inc. | Fgfr-binder-wirkstoff konjugate und ihre verwendung |
| CN104136462B (zh) | 2011-12-14 | 2017-06-09 | 艾伯维德国有限责任两合公司 | 用于诊断和治疗铁相关病症的组合物和方法 |
| GB201121564D0 (en) | 2011-12-14 | 2012-01-25 | Queen Mary & Westfield College | Use of antibody |
| EP2790730B1 (en) | 2011-12-15 | 2019-01-23 | The University of Chicago | Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors |
| US20130156849A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
| EP3050900A1 (en) | 2011-12-19 | 2016-08-03 | Xoma (Us) Llc | Methods for treating acne |
| CA3234629A1 (en) | 2011-12-20 | 2013-06-27 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
| GB201121891D0 (en) | 2011-12-20 | 2012-02-01 | Bakhiet Abdelmoiz | Applications of an immune system-released activating agent (ISRAA) |
| BR112014015111A2 (pt) | 2011-12-21 | 2017-06-13 | Novartis Ag | composições e processos para anticorpos que se direcionam ao fator p |
| RU2756106C2 (ru) | 2011-12-22 | 2021-09-28 | Ф. Хоффманн-Ля Рош Аг | Строение экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов |
| WO2013096828A1 (en) | 2011-12-22 | 2013-06-27 | Sea Lane Biotechnologies, Llc | Surrogate binding proteins |
| CN107119073A (zh) | 2011-12-22 | 2017-09-01 | 弗·哈夫曼-拉罗切有限公司 | 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途 |
| AU2012355356B2 (en) | 2011-12-22 | 2017-10-12 | Genentech, Inc. | Ion exchange membrane chromatography |
| MX2014007644A (es) | 2011-12-22 | 2014-09-26 | Rinat Neuroscience Corp | Anticuerpos antagonistas del receptor de hormona de crecimiento humana y metodos para su uso. |
| JP2015503907A (ja) | 2011-12-22 | 2015-02-05 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 真核細胞のための全長抗体提示システムおよびその使用 |
| WO2013093693A1 (en) | 2011-12-22 | 2013-06-27 | Rinat Neuroscience Corp. | Staphylococcus aureus specific antibodies and uses thereof |
| WO2013091903A1 (en) | 2011-12-22 | 2013-06-27 | Novo Nordisk A/S | Anti-crac channel antibodies |
| FR2984750B1 (fr) | 2011-12-23 | 2014-01-10 | Lfb Biotechnologies | Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii |
| CA2858806A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
| GB201122325D0 (en) | 2011-12-23 | 2012-02-01 | Cytoguide As | Novel formulations |
| EP3539982A3 (en) | 2011-12-23 | 2020-01-15 | Pfizer Inc | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| WO2013096812A1 (en) | 2011-12-23 | 2013-06-27 | Genentech, Inc. | Articles of manufacture and methods for co-administration of antibodies |
| US9823246B2 (en) | 2011-12-28 | 2017-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescence enhancing plasmonic nanoscopic gold films and assays based thereon |
| EP2797955A2 (en) | 2011-12-30 | 2014-11-05 | AbbVie Inc. | Dual variable domain immunoglobulins against il-13 and/or il-17 |
| SG11201403756PA (en) | 2012-01-01 | 2014-11-27 | Qbi Entpr Ltd | Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents |
| JP2015505368A (ja) | 2012-01-06 | 2015-02-19 | ビージー メディシン， インコーポレイテッド | 妊娠高血圧腎症および関連状態のリスク評価および検出のためのガレクチン−３の使用 |
| EP3663314A1 (en) | 2012-01-09 | 2020-06-10 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
| AU2013208003B2 (en) | 2012-01-09 | 2017-12-14 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
| PT2802606T (pt) | 2012-01-10 | 2018-07-13 | Biogen Ma Inc | Melhoramento do transporte de moléculas terapêuticas através da barreira hematoencefálica |
| CN102571433B (zh) | 2012-01-11 | 2014-07-30 | 华为技术有限公司 | 呈现网络路径的方法和装置 |
| US20130177574A1 (en) | 2012-01-11 | 2013-07-11 | Paul I. Terasaki Foundation Laboratory | ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE |
| US10800847B2 (en) | 2012-01-11 | 2020-10-13 | Dr. Mepur Ravindranath | Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use |
| WO2013104798A1 (en) | 2012-01-12 | 2013-07-18 | Cemm - Center For Molecular Medicine Of The Austrian Academy Of Sciences | Modulators of immune responses |
| KR20140114415A (ko) | 2012-01-13 | 2014-09-26 | 제넨테크, 인크. | Vegf 길항제로의 치료를 위한 환자를 확인하기 위한 생물학적 마커 |
| SG11201406762QA (en) | 2012-01-20 | 2014-11-27 | Genzyme Corp | Anti-cxcr3 antibodies |
| JP2015508156A (ja) | 2012-01-25 | 2015-03-16 | ディーエヌエートリックス インコーポレイテッド | バイオマーカーならびに腫瘍溶解性ウイルスと免疫調節法とを用いる併用療法 |
| MX352772B (es) | 2012-01-27 | 2017-12-07 | Abbvie Deutschland | Composición y método para el diagnóstico y tratamiento de enfermedades asociadas con la degeneración de neuritas. |
| WO2013113755A1 (en) | 2012-01-30 | 2013-08-08 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Reagents and methods for the treatment of diseases based on the inhibition of calcineurin - nfat signalling pathway |
| KR20140119777A (ko) | 2012-01-31 | 2014-10-10 | 제넨테크, 인크. | 항-ig-e m1'' 항체 및 그의 사용 방법 |
| BR112014018481A2 (pt) | 2012-02-01 | 2017-07-04 | Compugen Ltd | anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso |
| WO2013116750A1 (en) | 2012-02-02 | 2013-08-08 | Conicet | HaHB11 PROVIDES IMPROVED PLANT YIELD AND TOLERANCE TO ABIOTIC STRESS |
| HUE13746964T2 (hu) | 2012-02-06 | 2020-01-28 | Inhibrx Inc | CD47 antitestek és alkalmazási eljárásaik |
| WO2013119419A1 (en) | 2012-02-08 | 2013-08-15 | North Carolina State University | Treatment of allergic diseases with recombinant antibodies |
| US20150210763A1 (en) | 2012-02-09 | 2015-07-30 | Chugai Seiyaku Kabushiki Kaisha | MODIFIED Fc REGION OF ANTIBODY |
| CA2864092C (en) | 2012-02-10 | 2021-06-29 | Seattle Genetics, Inc. | Detection and treatment of cd30+ cancers |
| CN104718220A (zh) | 2012-02-11 | 2015-06-17 | 霍夫曼-拉罗奇有限公司 | R-spondin易位及其使用方法 |
| RU2624128C2 (ru) | 2012-02-15 | 2017-06-30 | Ф. Хоффманн-Ля Рош Аг | Аффинная хроматография с применением fc-рецепторов |
| ES2640268T3 (es) | 2012-02-15 | 2017-11-02 | Novo Nordisk A/S | Anticuerpos que se unen a y bloquean un receptor desencadenante expresado en células mieloides 1 (TREM-1) |
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| US9663568B2 (en) | 2012-02-15 | 2017-05-30 | Novo Nordisk A/S | Antibodies that bind peptidoglycan recognition protein 1 |
| CA2864702A1 (en) | 2012-02-22 | 2013-08-29 | Amgen Inc. | Autologous mammalian models derived from induced pluripotent stem cells and related methods |
| GB201203071D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| SG10201806867VA (en) | 2012-02-24 | 2018-09-27 | Abbvie Stemcentrx Llc | Dll3 modulators and methods of use |
| MD20140108A2 (ro) | 2012-02-29 | 2015-03-31 | Gilead Biologics, Inc. | Anticorpi împotriva metaloproteinazei 9 matriciale |
| MD20140107A2 (ro) | 2012-02-29 | 2015-03-31 | Gilead Biologics, Inc. | Anticorpi împotriva metaloproteinazei 9 din matrice |
| US20150037334A1 (en) | 2012-03-01 | 2015-02-05 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
| EP3483184A1 (en) | 2012-03-07 | 2019-05-15 | Yeda Research and Development Co. Ltd | Compositions for inhibition of quiescinsulfhydryl oxidase (qsox1) and uses of same |
| US20150132339A1 (en) | 2012-03-07 | 2015-05-14 | Novartis Ag | Adjuvanted formulations of streptococcus pneumoniae antigens |
| MY166045A (en) | 2012-03-08 | 2018-05-22 | Hoffmann La Roche | Abeta antibody formulation |
| JP5925342B2 (ja) | 2012-03-09 | 2016-05-25 | ファイザー・インク | 髄膜炎菌（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）組成物およびその方法 |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| US10058599B2 (en) | 2012-03-12 | 2018-08-28 | Advaxis, Inc. | Suppressor cell function inhibition following Listeria vaccine treatment |
| DK2825558T3 (da) | 2012-03-13 | 2019-07-22 | Hoffmann La Roche | Kombinationsterapi til behandling af ovariecancer |
| CA2867444C (en) | 2012-03-16 | 2021-04-13 | University Health Network | Compositions containing soluble toso protein and uses thereof |
| EP2828282B1 (en) | 2012-03-20 | 2017-12-27 | Otago Innovation Limited | Biomarkers |
| EP2828291A1 (en) | 2012-03-21 | 2015-01-28 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Peptides derived from the d1-domain of nkp46 |
| WO2013139956A1 (en) | 2012-03-22 | 2013-09-26 | Thrombogenics Nv | Antibodies abrogating cell binding to lactadherin |
| EP2641916A1 (en) | 2012-03-23 | 2013-09-25 | Centre National de la Recherche Scientifique (C.N.R.S) | Novel antibodies anti-sPLA2-IIA and uses thereof |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| US20130259867A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
| WO2013148232A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis |
| SG10201912877SA (en) | 2012-03-27 | 2020-02-27 | Genentech Inc | Improved harvest operations for recombinant proteins |
| DK2831113T3 (en) | 2012-03-28 | 2018-06-25 | Sanofi Sa | ANTIBODIES AGAINST BRADYKININ-B1 RECEPTOR LIGANDS |
| EP2832368B1 (en) | 2012-03-28 | 2021-11-10 | Hiroshima University | Fibrosis suppression by inhibiting integrin alpha8beta1 function |
| US9139659B2 (en) | 2012-03-28 | 2015-09-22 | Genentech, Inc. | Idiotypic antibodies and uses thereof |
| US20150266961A1 (en) | 2012-03-29 | 2015-09-24 | Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute | Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer |
| CN104540851B (zh) | 2012-03-29 | 2017-09-15 | 诺夫免疫股份有限公司 | 抗tlr4抗体及其用途 |
| AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| WO2013149219A2 (en) | 2012-03-30 | 2013-10-03 | Sorrento Therapeutics Inc. | Fully human antibodies that bind to vegfr2 |
| EP2830661A4 (en) | 2012-03-30 | 2016-05-18 | Hoffmann La Roche | DIAGNOSTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER |
| EP2833900B1 (en) | 2012-04-01 | 2018-09-19 | Technion Research & Development Foundation Limited | Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies |
| WO2013152011A1 (en) | 2012-04-02 | 2013-10-10 | Ab Biosciences, Inc. | Novel human control antibodies and uses therefor |
| EA038600B1 (ru) | 2012-04-02 | 2021-09-21 | Берг Ллк | Основанные на клетках перекрестные анализы и их применение |
| CA2868996A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| WO2013151649A1 (en) | 2012-04-04 | 2013-10-10 | Sialix Inc | Glycan-interacting compounds |
| US9566329B2 (en) | 2012-04-06 | 2017-02-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Live, attenuated rubella vector to express vaccine antigens |
| US9493744B2 (en) | 2012-06-20 | 2016-11-15 | Genentech, Inc. | Methods for viral inactivation and other adventitious agents |
| EP2836605A1 (en) | 2012-04-11 | 2015-02-18 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Method for diagnosing a skeletal ciliopathy |
| US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
| EP2839011B1 (en) | 2012-04-17 | 2016-09-14 | F. Hoffmann-La Roche AG | Method for the expression of polypeptides using modified nucleic acids |
| US9914767B2 (en) | 2012-04-17 | 2018-03-13 | Arsanis Biosciences Gmbh | Cross-reactive Staphylococcus aureus antibody |
| EP2838562B1 (en) | 2012-04-17 | 2017-08-30 | Mayo Foundation for Medical Education and Research | Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions |
| PT2838998T (pt) | 2012-04-18 | 2018-01-16 | Cell Signaling Technology Inc | Egfr e ros1 cinase no cancro |
| US10114023B2 (en) | 2012-04-18 | 2018-10-30 | Massachusetts Institute Of Technology | Method of enhancing the efficacy of anti-hepatocyte growth factor receptor breast cancer therapy by administering an inhibitor of menaINV |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
| KR102171431B1 (ko) | 2012-04-20 | 2020-10-30 | 메뤼스 엔.페. | Ig-유사 분자의 제조방법 및 제조수단 |
| WO2013158275A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Cell culture methods to reduce acidic species |
| CA2871417C (en) | 2012-04-23 | 2021-08-31 | Genefrontier Corporation | Anti-human cd69 antibody, and use thereof for medical purposes |
| AU2013254690B2 (en) | 2012-04-24 | 2017-12-07 | Thrombogenics N.V. | Anti-PDGF-C antibodies |
| US20130281355A1 (en) | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
| US10279026B2 (en) | 2012-04-26 | 2019-05-07 | Glaxosmithkline Biologicals Sa | Antigens and antigen combinations |
| US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
| EP2841096B1 (en) | 2012-04-26 | 2020-09-30 | GlaxoSmithKline Biologicals SA | Antigens and antigen combinations |
| PT2841456T (pt) | 2012-04-27 | 2018-10-19 | Novo Nordisk As | Proteinas de ligação ao antigénio do ligando de cd30 humano |
| WO2013162748A1 (en) | 2012-04-27 | 2013-10-31 | The Trustees Of The University Of Pennsylvania | Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof |
| SG11201407106XA (en) | 2012-05-01 | 2014-11-27 | Genentech Inc | Anti-pmel17 antibodies and immunoconjugates |
| CN104428000A (zh) | 2012-05-02 | 2015-03-18 | 纽约大学 | 治疗和预防金黄色葡萄球菌感染和相关病状的方法 |
| EP3326649B1 (en) | 2012-05-03 | 2022-02-09 | Boehringer Ingelheim International GmbH | Anti-il-23p19 antibodies |
| WO2013166290A1 (en) | 2012-05-04 | 2013-11-07 | Abbvie Biotherapeutics Inc. | P21 biomarker assay |
| CA2871751C (en) | 2012-05-04 | 2021-08-24 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
| US20140315283A1 (en) | 2012-05-09 | 2014-10-23 | David A. Calderwood | Sample cartridge and sample stage |
| KR102122618B1 (ko) | 2012-05-10 | 2020-06-29 | 메사츄세츠 인스티튜트 어브 테크놀로지 | 인플루엔자 중화를 위한 작용제 |
| PL2847228T3 (pl) | 2012-05-10 | 2019-03-29 | Bayer Pharma Aktiengesellschaft | Przeciwciała zdolne do wiązania się z czynnikiem krzepnięcia XI i/lub jego aktywowaną postacią, czynnikiem Xla oraz ich zastosowanie |
| WO2013167681A1 (en) | 2012-05-10 | 2013-11-14 | Georg-August-Universität Göttingen | CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST Αβ OLIGOMERS |
| JP2013235003A (ja) | 2012-05-10 | 2013-11-21 | Fujita Gakuen | 細胞におけるｄｎａ損傷の検出方法及びｄｎａ鎖切断応答性細胞表面抗原に対する抗体 |
| BR112014028013A2 (pt) | 2012-05-11 | 2018-02-27 | Five Prime Therapeutics Inc | métodos para tratar uma condição associada com artrite reumatoide, artrite reumatoide, lesões de pele, nefrite lúpica, lúpus, uma condição inflamatória, distúrbio de cd16+, método para reduzir o número de monócitos cd16+, métodos para desacelerar a progressão de uma condição renal,de formação de panos e de perda óssea |
| WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
| EP2848633B1 (en) | 2012-05-11 | 2019-02-06 | Microbial Chemistry Research Foundation | Anti-cxadr antibody |
| WO2013170977A1 (en) | 2012-05-14 | 2013-11-21 | Novo Nordisk A/S | Stabilised protein solutions |
| NZ702178A (en) | 2012-05-14 | 2017-01-27 | Biogen Ma Inc | Lingo-2 antagonists for treatment of conditions involving motor neurons |
| NZ630870A (en) | 2012-05-15 | 2016-10-28 | Seattle Genetics Inc | Self-stabilizing linker conjugates |
| EP2850207B1 (en) | 2012-05-16 | 2017-01-04 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the diagnosis and the treatment of familial thoracic aortic aneurysms caused by tgfb2 loss of function mutations |
| US9289507B2 (en) | 2012-05-17 | 2016-03-22 | Extend Biosciences, Inc. | Carriers for improved drug delivery |
| US20150168398A1 (en) | 2012-05-17 | 2015-06-18 | The Johns Hopkins University | Methods for identifying patterns of ifn induced expression and use in diagnosis, monitoring and therapy |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| TW201348247A (zh) | 2012-05-21 | 2013-12-01 | Abbvie Inc | 利用蛋白質ａ親和性層析之非人類抗體之新穎純化 |
| KR102115438B1 (ko) | 2012-05-21 | 2020-05-27 | 제넨테크, 인크. | 혈액-뇌 장벽 수송의 안전성을 개선하는 방법 |
| US9844582B2 (en) | 2012-05-22 | 2017-12-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents |
| EP2852679A1 (en) | 2012-05-22 | 2015-04-01 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for diagnosing and treating focal segmental glomerulosclerosis |
| EP3605090A1 (en) | 2012-05-23 | 2020-02-05 | F. Hoffmann-La Roche AG | Selection method for therapeutic agents |
| WO2013175276A1 (en) | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
| WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
| MX369626B (es) | 2012-05-24 | 2019-11-13 | Mountgate Group Ltd | Composiciones y metodos relacionados con la prevencion y el tratamiento de infecciones por rabia. |
| WO2013177386A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Biotherapeutics Inc. | Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy |
| EP2856172A4 (en) | 2012-05-25 | 2016-03-02 | Univ Vermont | COMPOSITIONS AND METHODS FOR TESTING THROMBOCYTE REACTIVITY AND TREATMENT SELECTION |
| WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| US20130315891A1 (en) | 2012-05-25 | 2013-11-28 | Matthew Charles | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
| ES2695151T3 (es) | 2012-05-31 | 2019-01-02 | Innate Pharma | Agentes de ligación a TLR3 |
| MY186099A (en) | 2012-05-31 | 2021-06-22 | Genentech Inc | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
| WO2013181755A1 (en) | 2012-06-04 | 2013-12-12 | Diamedica Inc. | Human tissue kallikrein 1 glycosylation isoforms |
| WO2013184871A1 (en) | 2012-06-06 | 2013-12-12 | Zoetis Llc | Caninized anti-ngf antibodies and methods thereof |
| MX2014014951A (es) | 2012-06-06 | 2015-03-13 | Oncomed Pharm Inc | Agentes aglutinantes que modulan la trayectoria hippo y sus usos. |
| WO2013185114A2 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Chimeric clotting factors |
| PE20150212A1 (es) | 2012-06-08 | 2015-02-27 | Glenmark Pharmaceuticals Sa | Anticuerpos anti-trka con propiedades inhibitorias mejoradas y sus derivados |
| AU2013270682A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Procoagulant compounds |
| AU2013270684B2 (en) | 2012-06-08 | 2018-04-19 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| KR101944263B1 (ko) | 2012-06-11 | 2019-02-01 | 시아먼 유니버시티 | 에이치비브이 감염 및 관련 질병의 치료를 위한 폴리펩타이드 및 항체 |
| CN104540961A (zh) | 2012-06-11 | 2015-04-22 | 安姆根公司 | 双重受体拮抗性抗原结合蛋白及其用途 |
| US20130330761A1 (en) | 2012-06-12 | 2013-12-12 | Celcuity, LLC | Whole cell assays and methods |
| US10155987B2 (en) | 2012-06-12 | 2018-12-18 | Dana-Farber Cancer Institute, Inc. | Methods of predicting resistance to JAK inhibitor therapy |
| CN104822704B (zh) | 2012-06-14 | 2020-02-14 | 医疗生物科学有限公司 | 针对分化簇3(cd3)的人源化的抗体 |
| WO2013187495A1 (ja) | 2012-06-14 | 2013-12-19 | 中外製薬株式会社 | 改変されたFc領域を含む抗原結合分子 |
| CA2876706A1 (en) | 2012-06-14 | 2013-12-19 | Ambrx, Inc. | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides |
| EP3786183A3 (en) | 2012-06-15 | 2021-06-09 | Imaginab, Inc. | Antigen binding constructs to cd3 |
| AU2013277309B2 (en) | 2012-06-18 | 2018-03-29 | Omeros Corporation | Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders |
| JP2015531748A (ja) | 2012-06-21 | 2015-11-05 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | 改変ｆｃエフェクター機能を有するインクレチン受容体リガンドポリペプチドｆｃ領域融合ポリペプチド及び複合物 |
| US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
| AU2013277051B2 (en) | 2012-06-22 | 2018-06-07 | King's College London | Novel VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
| WO2014004586A1 (en) | 2012-06-25 | 2014-01-03 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
| WO2014001368A1 (en) | 2012-06-25 | 2014-01-03 | Orega Biotech | Il-17 antagonist antibodies |
| EP2867253B1 (en) | 2012-06-27 | 2016-09-14 | F. Hoffmann-La Roche AG | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
| BR112014028368A2 (pt) | 2012-06-27 | 2017-11-14 | Hoffmann La Roche | método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica |
| US9457071B2 (en) | 2012-06-28 | 2016-10-04 | Hiroshima University | Histamine releaser contained in human sweat |
| JP6182210B2 (ja) | 2012-06-29 | 2017-08-16 | イー・エム・デイー・ミリポア・コーポレイシヨン | タンパク質精製プロセス中のウイルスの不活性化方法 |
| US20150218238A1 (en) | 2012-06-29 | 2015-08-06 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear | Treating diseases by modulating a specific isoform of mkl1 |
| EP2682168A1 (en) | 2012-07-02 | 2014-01-08 | Millipore Corporation | Purification of biological molecules |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| WO2014008263A2 (en) | 2012-07-02 | 2014-01-09 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Paramyxovirus and methods of use |
| ES2600154T3 (es) | 2012-07-04 | 2017-02-07 | F. Hoffmann-La Roche Ag | Anticuerpos antiteofilina y métodos de uso |
| EP2870180A1 (en) | 2012-07-04 | 2015-05-13 | F. Hoffmann-La Roche AG | Anti-biotin antibodies and methods of use |
| BR112014029403A2 (pt) | 2012-07-04 | 2018-10-09 | F. Hoffmann-La Roche Ag | conjugados, anticorpo e formulação farmacêutica |
| EP2870242A1 (en) | 2012-07-05 | 2015-05-13 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
| EP3608401A1 (en) | 2012-07-05 | 2020-02-12 | Ohio State Innovation Foundation | Compositions and methods related to viral vaccines |
| US10656156B2 (en) | 2012-07-05 | 2020-05-19 | Mepur Ravindranath | Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E |
| WO2014008391A1 (en) | 2012-07-05 | 2014-01-09 | Genentech, Inc. | Expression and secretion system |
| US20150224190A1 (en) | 2012-07-06 | 2015-08-13 | Mohamed Bentires-Alj | Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction |
| US11180572B2 (en) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Dimeric protein with triple mutations |
| KR20150030698A (ko) | 2012-07-09 | 2015-03-20 | 제넨테크, 인크. | 항-cd79b 항체를 포함하는 면역접합체 |
| TW201406785A (zh) | 2012-07-09 | 2014-02-16 | Genentech Inc | 抗ｃｄ２２抗體及免疫結合物 |
| EP2684896A1 (en) | 2012-07-09 | 2014-01-15 | International-Drug-Development-Biotech | Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
| WO2014011908A1 (en) | 2012-07-11 | 2014-01-16 | Esperion Therapeutics, Inc. | Apolipoprotein mixtures |
| TW201402608A (zh) | 2012-07-12 | 2014-01-16 | Abbvie Inc | Ｉｌ－１結合蛋白質 |
| WO2014009465A1 (en) | 2012-07-13 | 2014-01-16 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| EP2872894B1 (en) | 2012-07-13 | 2019-04-17 | Innate Pharma | Screening of conjugated antibodies |
| EP2872526B1 (en) | 2012-07-13 | 2020-04-01 | The Trustees of the University of Pennsylvania | Enhancing activity of car t cells by co-introducing a bispecific antibody |
| US20140024015A1 (en) | 2012-07-18 | 2014-01-23 | Idexx Laboratories, Inc. | Boone Cardiovirus |
| EP2875049B1 (en) | 2012-07-18 | 2018-12-26 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for preventing and treating chronic kidney disease (ckd) |
| MX2015000789A (es) | 2012-07-19 | 2015-05-07 | Zoetis Llc | Composiciones de virus de la gripe bovina. |
| US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
| ES2817897T3 (es) | 2012-07-23 | 2021-04-08 | La Jolla Inst Allergy & Immunology | PTPRS y proteoglicanos en enfermedad autoinmune |
| US9023367B2 (en) | 2012-07-27 | 2015-05-05 | Baxter International Inc. | Compositions comprising chimeric OSPA molecules and methods of use thereof |
| WO2014018724A1 (en) | 2012-07-27 | 2014-01-30 | Zoetis Llc | Tick toxin compositions |
| WO2014020293A1 (en) | 2012-07-31 | 2014-02-06 | Imperial Innovations Limited | Assay |
| DK2880053T3 (da) | 2012-08-01 | 2020-05-11 | Ikaika Therapeutics Llc | Lindring af vævsskade og fibrose via anti-LTBP4-antistof |
| GB201213652D0 (en) | 2012-08-01 | 2012-09-12 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| EP2879710B1 (en) | 2012-08-03 | 2019-11-13 | Dana-Farber Cancer Institute, Inc. | Medical uses of agents that modulate immune cell activation and corresponding screening methods |
| RU2015104001A (ru) | 2012-08-07 | 2016-09-27 | Дженентек, Инк. | Комбинированная терапия для лечения глиобластомы |
| CA2872195A1 (en) | 2012-08-07 | 2014-02-13 | Roche Glycart Ag | Composition comprising two antibodies engineered to have reduced and increased effector function |
| FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| US20150210758A1 (en) | 2012-08-14 | 2015-07-30 | Nanyang Technological University | Angiopoietin-like 4 antibody and a method of its use in cancer treatment |
| MX359817B (es) | 2012-08-16 | 2018-10-11 | Ipierian Inc | Anticuerpos que se enlazan a tau. |
| WO2014027626A1 (ja) | 2012-08-17 | 2014-02-20 | 国立大学法人広島大学 | 汗アレルギー抗原蛋白質に結合するモノクローナルIgE抗体 |
| WO2014028939A2 (en) | 2012-08-17 | 2014-02-20 | California Institute Of Technology | Targeting phosphofructokinase and its glycosylation form for cancer |
| US9914956B2 (en) | 2012-08-18 | 2018-03-13 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
| US20140056901A1 (en) | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
| CA2882745C (en) | 2012-08-23 | 2022-03-29 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to 158p1d7 proteins |
| KR102273985B1 (ko) | 2012-08-24 | 2021-07-06 | 추가이 세이야쿠 가부시키가이샤 | ＦｃγＲＩＩｂ 특이적 Ｆｃ영역 개변체 |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| EP3260464A1 (en) | 2012-08-28 | 2017-12-27 | Novartis AG | Methods for purification of antibodies using aliphatic alcohols |
| JP6219956B2 (ja) | 2012-08-29 | 2017-10-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 血液脳関門シャトル |
| US20150202287A1 (en) | 2012-08-30 | 2015-07-23 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
| WO2014034700A1 (ja) | 2012-08-30 | 2014-03-06 | 国立大学法人広島大学 | BBF2H7(BBF2 human homologue on chromosome7)部分アミノ酸配列を有するペプチドまたはそれに結合する抗体を含む細胞増殖調節用組成物 |
| RS60217B1 (sr) | 2012-08-31 | 2020-06-30 | Immunogen Inc | Dijagnostički testovi i kompleti za detekciju folatnog receptora 1 |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| KR20150047593A (ko) | 2012-08-31 | 2015-05-04 | 파이브 프라임 테라퓨틱스, 인크. | 집락 자극 인자 1 수용체(csf1r)에 결합하는 항체로 질환을 치료하는 방법 |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US9695247B2 (en) | 2012-09-03 | 2017-07-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies directed against ICOS for treating graft-versus-host disease |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| WO2014039675A2 (en) | 2012-09-05 | 2014-03-13 | University Of Virginia Patent Foundation | Target peptides for colorectal cancer therapy and diagnostics |
| PT2892560T (pt) | 2012-09-06 | 2019-10-18 | Adelaide Research&Innovation Pty Ltd | Métodos e produtos para prevenção e/ou tratamento do cancro metastático |
| JOP20200308A1 (ar) | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
| US9381244B2 (en) | 2012-09-07 | 2016-07-05 | King's College London | VISTA modulators for diagnosis and treatment of cancer |
| FR2995214B1 (fr) | 2012-09-10 | 2014-11-21 | Adocia | Solution a viscosite reduite de proteine a concentration elevee |
| TW201922795A (zh) | 2012-09-10 | 2019-06-16 | 愛爾蘭商尼歐托普生物科學公司 | 抗ｍｃａｍ抗體及相關使用方法 |
| EP2892555B1 (en) | 2012-09-10 | 2020-03-25 | International Aids Vaccine Initiative | Immunogens of hiv-1 broadly neutralizing antibodies, methods of generation and uses thereof |
| EP2895197B1 (en) | 2012-09-12 | 2020-02-26 | Ramot at Tel-Aviv University Ltd. | Immunoparticles and methods of generating and using same |
| EP2895191B1 (en) | 2012-09-14 | 2019-06-05 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Brachyury protein, adenoviral vectors encoding brachyury protein, and their use |
| DK178233B1 (en) | 2012-09-17 | 2015-09-14 | Novartis Tiergesundheit Ag | Fiskevaccine |
| WO2014047342A1 (en) | 2012-09-19 | 2014-03-27 | Dana-Farber Cancer Institute, Inc. | Dynamic bh3 profiling |
| US9651555B2 (en) | 2012-09-24 | 2017-05-16 | Ventana Medical Systems, Inc. | Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (ALK) as a marker |
| WO2014051022A1 (ja) | 2012-09-27 | 2014-04-03 | 中外製薬株式会社 | Fgfr3融合遺伝子およびそれを標的とする医薬 |
| CN111621507A (zh) | 2012-09-28 | 2020-09-04 | 北卡罗来纳-查佩尔山大学 | 靶向少突胶质细胞的aav载体 |
| WO2014055442A2 (en) | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
| US10662477B2 (en) | 2012-10-01 | 2020-05-26 | Millennium Pharmaceuticals, Inc. | Biomarkers and methods to predict response to inhibitors and uses thereof |
| NO2760138T3 (ja) | 2012-10-01 | 2018-08-04 | ||
| US20140094383A1 (en) | 2012-10-02 | 2014-04-03 | Ohio State Innovation Foundation | Tethered Lipoplex nanoparticle Biochips And Methods Of Use |
| EP2903629B1 (en) | 2012-10-03 | 2019-07-10 | Philogen S.p.A. | Antibody conjugate for use in treating inflammatory bowel disease |
| JP6581505B2 (ja) | 2012-10-03 | 2019-09-25 | ザイムワークス，インコーポレイテッド | 重鎖および軽鎖ポリペプチドの対を定量化する方法 |
| CA3139031A1 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| US9324141B2 (en) | 2012-10-05 | 2016-04-26 | Volcano Corporation | Removal of A-scan streaking artifact |
| US9286673B2 (en) | 2012-10-05 | 2016-03-15 | Volcano Corporation | Systems for correcting distortions in a medical image and methods of use thereof |
| US9307926B2 (en) | 2012-10-05 | 2016-04-12 | Volcano Corporation | Automatic stent detection |
| US10070827B2 (en) | 2012-10-05 | 2018-09-11 | Volcano Corporation | Automatic image playback |
| US9367965B2 (en) | 2012-10-05 | 2016-06-14 | Volcano Corporation | Systems and methods for generating images of tissue |
| US9858668B2 (en) | 2012-10-05 | 2018-01-02 | Volcano Corporation | Guidewire artifact removal in images |
| US11272845B2 (en) | 2012-10-05 | 2022-03-15 | Philips Image Guided Therapy Corporation | System and method for instant and automatic border detection |
| WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| EP2904671B1 (en) | 2012-10-05 | 2022-05-04 | David Welford | Systems and methods for amplifying light |
| WO2014055824A1 (en) | 2012-10-05 | 2014-04-10 | Genentech, Inc. | Methods for diagnosing and treating inflammatory bowel disease |
| US9292918B2 (en) | 2012-10-05 | 2016-03-22 | Volcano Corporation | Methods and systems for transforming luminal images |
| EP3677310A1 (en) | 2012-10-08 | 2020-07-08 | St. Jude Children's Research Hospital | Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis |
| CN104704004B (zh) | 2012-10-08 | 2019-12-31 | 罗切格利卡特公司 | 包含两个Fab片段的无Fc的抗体及使用方法 |
| CN104870014A (zh) | 2012-10-09 | 2015-08-26 | 比奥根Ma公司 | 联合治疗及用于治疗脱髓鞘病症的用途 |
| US11105809B2 (en) | 2012-10-09 | 2021-08-31 | Ramot At Tel-Aviv University Ltd. | Methods and kits for predicting prognosis of cancer using soluble mortalin in blood |
| EP2906598A1 (en) | 2012-10-09 | 2015-08-19 | Igenica Biotherapeutics, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
| PT2766048E (pt) | 2012-10-12 | 2015-02-25 | Spirogen Sarl | Pirrolobenzodiazepinas e conjugados das mesmas |
| NZ707543A (en) | 2012-10-12 | 2018-09-28 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| SI2906253T1 (sl) | 2012-10-12 | 2018-11-30 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo proti PSMA |
| ES2649990T3 (es) | 2012-10-12 | 2018-01-16 | Medimmune Limited | Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas |
| KR101995619B1 (ko) | 2012-10-12 | 2019-07-03 | 에이디씨 테라퓨틱스 에스에이 | 피롤로벤조디아제핀-항체 컨주게이트 |
| EP2906250B1 (en) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| SI2906248T1 (sl) | 2012-10-12 | 2019-02-28 | Medimmune Limited | Pirolobenzodiazepini in njihovi konjugati |
| EP2906241B1 (en) | 2012-10-12 | 2020-01-08 | The Brigham and Women's Hospital, Inc. | Enhancement of the immune response |
| JP6367204B2 (ja) | 2012-10-12 | 2018-08-01 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | 結合用のピロロベンゾジアゼピン誘導体の合成および中間体 |
| ES2660029T3 (es) | 2012-10-12 | 2018-03-20 | Medimmune Limited | Conjugados de anticuerpo-pirrolobenzodiazepinas |
| SI2906597T1 (sl) | 2012-10-15 | 2020-08-31 | Medimmune Limited | Protitelesa za amiloid beta |
| SI2908912T1 (sl) | 2012-10-18 | 2021-03-31 | The Rockefeller University | Široko nevtralizirajoča protitelesa proti HIV |
| US10226744B2 (en) | 2012-10-19 | 2019-03-12 | Danisco Us Inc | Stabilization of biomimetic membranes |
| US9395369B2 (en) | 2012-10-19 | 2016-07-19 | Regents Of The University Of Minnesota | Guinea pig cytomegalovirus (CIDMTR strain) |
| US9840734B2 (en) | 2012-10-22 | 2017-12-12 | Raindance Technologies, Inc. | Methods for analyzing DNA |
| WO2014066328A1 (en) | 2012-10-23 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
| US9803014B2 (en) | 2012-10-24 | 2017-10-31 | Research Development Foundation | JAM-C antibodies and methods for treatment of cancer |
| US20150246146A1 (en) | 2012-10-25 | 2015-09-03 | Life Technologies Corporation | Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins |
| CA3124553A1 (en) | 2012-10-25 | 2014-05-01 | Bioverativ Usa Inc. | Anti-complement c1s antibodies and uses thereof |
| US9751931B2 (en) | 2012-10-26 | 2017-09-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hepatitis C virus neutralizing antibodies and methods |
| EP2912194B1 (en) | 2012-10-26 | 2019-05-08 | Memorial Sloan-Kettering Cancer Center | Androgen receptor variants and methods for making and using |
| US10253107B2 (en) | 2012-10-26 | 2019-04-09 | The University Of Queensland | Use of endocytosis inhibitors and antibodies for cancer therapy |
| WO2014064203A1 (en) | 2012-10-26 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis |
| WO2014070786A1 (en) | 2012-10-29 | 2014-05-08 | The University Of North Carolina At Chapel Hill | Compositions and methods for inhibiting pathogen infection |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res (Munich) Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| US9833410B2 (en) | 2012-10-31 | 2017-12-05 | Takeda Gmbh | Lyophilized formulation comprising GM-CSF neutralizing compound |
| CA2889638A1 (en) | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a dll4 antagonist |
| EP3508503B1 (en) | 2012-11-01 | 2022-11-02 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Antibody against cd269 (bcma) |
| TW202210507A (zh) | 2012-11-01 | 2022-03-16 | 美商艾伯維有限公司 | 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途 |
| JP6543572B2 (ja) | 2012-11-02 | 2019-07-10 | バイオベラティブ・ユーエスエイ・インコーポレイテッド | 抗補体Ｃ１ｓ抗体とそれらの用途 |
| US9809863B2 (en) | 2012-11-02 | 2017-11-07 | Elanco Tiergesundheit Ag | Flavivirus associated with Theiler's disease |
| EP2914621B1 (en) | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
| PL2917195T3 (pl) | 2012-11-05 | 2018-04-30 | Pfizer Inc. | Analogi spliceostatyny |
| CN104902923A (zh) | 2012-11-05 | 2015-09-09 | 建新公司 | 用于治疗蛋白质病的组合物和方法 |
| WO2014072897A1 (en) | 2012-11-07 | 2014-05-15 | Pfizer Inc. | Anti-notch3 antibodies and antibody-drug conjugates |
| JP6445446B2 (ja) | 2012-11-08 | 2018-12-26 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 骨転移の治療のための方法及び医薬組成物 |
| JP6302476B2 (ja) | 2012-11-08 | 2018-03-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｈｅｒ３のベータヘアピンに結合するｈｅｒ３抗原結合タンパク質 |
| AU2013342163B2 (en) | 2012-11-08 | 2018-08-16 | F. Hoffmann-La Roche Ltd | IL-6 antagonists and uses thereof |
| RS57696B1 (sr) | 2012-11-08 | 2018-12-31 | Univ Miyazaki | Antitelo sposobno da specifično prepozna transferinski receptor |
| EP3473718A1 (en) | 2012-11-09 | 2019-04-24 | GeneFrontier Corporation | Anti-adam28 antibody for treating cancer |
| CN105026426A (zh) | 2012-11-09 | 2015-11-04 | 辉瑞公司 | 血小板衍生生长因子b之特异性抗体及其组合物和用途 |
| WO2014072482A1 (en) | 2012-11-09 | 2014-05-15 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
| CN104884056A (zh) | 2012-11-12 | 2015-09-02 | 雷德伍德生物科技股份有限公司 | 用于制备缀合物的化合物和方法 |
| EA201892509A1 (ru) | 2012-11-13 | 2019-04-30 | Дженентек, Инк. | Антитела к гемагглютинину и способы применения |
| EP2733153A1 (en) | 2012-11-15 | 2014-05-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the preparation of immunoconjugates and uses thereof |
| BR112015011011A2 (pt) | 2012-11-15 | 2019-12-17 | Genentech Inc | cromatografia por troca de íon com gradiente de ph mediada por força iônica |
| DK3660033T5 (da) | 2012-11-15 | 2022-06-27 | Apellis Pharmaceuticals Inc | Langtidsvirkende compstatinanaloger og tilhørende sammensætninger og fremgangsmåder |
| CA2890906A1 (en) | 2012-11-16 | 2014-05-22 | The Regents Of The University Of California | Pictet-spengler ligation for protein chemical modification |
| US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
| KR102408660B1 (ko) | 2012-11-20 | 2022-06-15 | 사노피 | 항-ceacam5 항체 및 이의 용도 |
| EP2735874A1 (en) | 2012-11-21 | 2014-05-28 | Fundación Para La Investigación Biomédica Del Hospital Universitario Puerta De Hierro | Methods of diagnosing and therapeutic agents for use in the treatment of prostate cancer |
| GB201220924D0 (en) | 2012-11-21 | 2013-01-02 | Cancer Res Inst Royal | Materials and methods for determining susceptibility or predisposition to cancer |
| WO2014080251A1 (en) | 2012-11-24 | 2014-05-30 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
| JP6408478B2 (ja) | 2012-11-26 | 2018-10-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | トリオキサカルシン、トリオキサカルシン−抗体複合体、およびその用途 |
| FR2998579B1 (fr) | 2012-11-27 | 2015-06-19 | Commissariat Energie Atomique | Methode pour obtenir des anticorps humains specifiques d'un antigene par immunisation in vitro |
| US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| EP2925779A1 (en) | 2012-11-30 | 2015-10-07 | Institut Pasteur | Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock |
| US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
| US10407503B2 (en) | 2012-11-30 | 2019-09-10 | The Regents Of The University Of California | Fully human antibodies and fragments recognizing human c-Met |
| WO2014084859A1 (en) | 2012-11-30 | 2014-06-05 | Novartis Ag | Molecules and methods for modulating tmem16a activities |
| CA3155275A1 (en) | 2012-12-03 | 2014-06-12 | Novimmune S.A. | Anti-cd47 antibodies and methods of use thereof |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| AP2015008365A0 (en) | 2012-12-05 | 2015-04-30 | Novartis Ag | Compositions and methods for antibodies targeting epo |
| UA118255C2 (uk) | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
| US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| EP2929021A1 (en) | 2012-12-07 | 2015-10-14 | Danisco US Inc. | Compositions and methods of use |
| US9383357B2 (en) | 2012-12-07 | 2016-07-05 | Northwestern University | Biomarker for replicative senescence |
| WO2014093417A1 (en) | 2012-12-12 | 2014-06-19 | University Of Virginia Patent Foundation | Compositions and methods for regulating erythropoiesis |
| BR112015013647A2 (pt) | 2012-12-12 | 2017-11-14 | Danisco Us Inc | variante isolada de uma enzima celobio-hidrolase (cbh) parental, polinucleotídeo isolado, vetor, célula hospedeira, composição detergente, aditivo alimentar, método para hidrolisar um substrato celulósico, sobrenadante de cultura celular, métodos de produção de um polipeptídeo cbh variante e sobrenadante de cultura celular |
| AU2013359001A1 (en) | 2012-12-13 | 2015-07-23 | The Board Of Regents Of The University Of Oklahoma | Target peptides for ovarian cancer therapy and diagnostics |
| ES2819573T3 (es) | 2012-12-13 | 2021-04-16 | Immunomedics Inc | Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A |
| US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| US10206918B2 (en) | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
| US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| US10413539B2 (en) | 2012-12-13 | 2019-09-17 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
| WO2014096672A1 (fr) | 2012-12-17 | 2014-06-26 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
| US20140186350A1 (en) | 2012-12-18 | 2014-07-03 | Novartis Ag | Compositions and methods for long acting molecules |
| KR20150100716A (ko) | 2012-12-19 | 2015-09-02 | 앰플리뮨, 인크. | 항 인간 b7-h4 항체 및 이의 용도 |
| EP2934602B1 (en) | 2012-12-19 | 2019-02-27 | Genentech, Inc. | Methods and compositions for radiohalogen protein labeling |
| ES2737649T3 (es) | 2012-12-19 | 2020-01-15 | Aveo Pharmaceuticals Inc | Anticuerpos anti-Notch3 |
| US10939826B2 (en) | 2012-12-20 | 2021-03-09 | Philips Image Guided Therapy Corporation | Aspirating and removing biological material |
| US9730613B2 (en) | 2012-12-20 | 2017-08-15 | Volcano Corporation | Locating intravascular images |
| US11406498B2 (en) | 2012-12-20 | 2022-08-09 | Philips Image Guided Therapy Corporation | Implant delivery system and implants |
| EP2934311B1 (en) | 2012-12-20 | 2020-04-15 | Volcano Corporation | Smooth transition catheters |
| JP2016504589A (ja) | 2012-12-20 | 2016-02-12 | ナサニエル ジェイ． ケンプ， | 異なる撮像モード間で再構成可能な光コヒーレンストモグラフィシステム |
| US10942022B2 (en) | 2012-12-20 | 2021-03-09 | Philips Image Guided Therapy Corporation | Manual calibration of imaging system |
| ES2929876T3 (es) | 2012-12-20 | 2022-12-02 | Medimmune Ltd | Replegamiento y purificación de moxetumomab pasudotox |
| WO2014100602A1 (en) | 2012-12-20 | 2014-06-26 | Hospital For Special Surgery | Treatment of egf-receptor dependent pathologies |
| US10166003B2 (en) | 2012-12-21 | 2019-01-01 | Volcano Corporation | Ultrasound imaging with variable line density |
| WO2014096365A1 (en) | 2012-12-21 | 2014-06-26 | Spirogen Sàrl | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
| CA2896091C (en) | 2012-12-21 | 2018-06-19 | Amplimmune, Inc. | Anti-h7cr antibodies |
| US10058284B2 (en) | 2012-12-21 | 2018-08-28 | Volcano Corporation | Simultaneous imaging, monitoring, and therapy |
| US9612105B2 (en) | 2012-12-21 | 2017-04-04 | Volcano Corporation | Polarization sensitive optical coherence tomography system |
| RU2015129800A (ru) | 2012-12-21 | 2017-01-30 | Биоэллаенс К. В. | Гидрофильные саморазрушающиеся линкеры и их конъюгаты |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| US9486143B2 (en) | 2012-12-21 | 2016-11-08 | Volcano Corporation | Intravascular forward imaging device |
| US10332228B2 (en) | 2012-12-21 | 2019-06-25 | Volcano Corporation | System and method for graphical processing of medical data |
| JP2016507892A (ja) | 2012-12-21 | 2016-03-10 | デイビッド ウェルフォード， | 光の波長放出を狭幅化するためのシステムおよび方法 |
| JP2016501623A (ja) | 2012-12-21 | 2016-01-21 | アンドリュー ハンコック， | 画像信号のマルチ経路処理のためのシステムおよび方法 |
| GB201223172D0 (en) | 2012-12-21 | 2013-02-06 | Immunocore Ltd | Method |
| US10413317B2 (en) | 2012-12-21 | 2019-09-17 | Volcano Corporation | System and method for catheter steering and operation |
| WO2014096368A1 (en) | 2012-12-21 | 2014-06-26 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014100542A1 (en) | 2012-12-21 | 2014-06-26 | Abbvie, Inc. | High-throughput antibody humanization |
| EP2934584B1 (en) | 2012-12-21 | 2020-02-19 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| EA201591219A1 (ru) | 2012-12-27 | 2015-12-30 | Санофи | Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение |
| DK2940135T5 (da) | 2012-12-27 | 2021-09-20 | Chugai Pharmaceutical Co Ltd | Heterodimeriseret polypeptid |
| ES2639559T3 (es) | 2012-12-28 | 2017-10-27 | Ventana Medical Systems, Inc. | Análisis de imágenes para el pronóstico de cáncer de mama |
| TR201815254T4 (tr) | 2013-01-02 | 2018-11-21 | Glenmark Pharmaceuticals Sa | Tl1a'ya bağlanan anti̇korlar ve bunlarin kullanimlari |
| WO2014107739A1 (en) | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
| GB201300346D0 (en) | 2013-01-09 | 2013-02-20 | Biolnvent Internat Ab | BiologIcal materials and uses thereof |
| WO2014108854A1 (en) | 2013-01-09 | 2014-07-17 | Fusimab Ltd. | Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies |
| MX2019001795A (es) | 2013-01-17 | 2022-07-26 | X4 Pharmaceuticals Austria Gmbh | Anticuerpo específico contra e. coli mdr. |
| EP2945942B1 (en) | 2013-01-18 | 2018-05-09 | ARK Diagnostics, Inc. | Voriconazole immunoassays |
| WO2014113729A2 (en) | 2013-01-18 | 2014-07-24 | Foundation Mecicine, Inc. | Methods of treating cholangiocarcinoma |
| WO2014116749A1 (en) | 2013-01-23 | 2014-07-31 | Genentech, Inc. | Anti-hcv antibodies and methods of using thereof |
| JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
| US9834610B2 (en) | 2013-01-31 | 2017-12-05 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector T cells |
| WO2014118705A1 (en) | 2013-01-31 | 2014-08-07 | Novartis Ag | Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists |
| EP3626743A1 (en) | 2013-02-01 | 2020-03-25 | Kira Biotech Pty Limited | Anti-cd83 antibodies and use thereof |
| JP2016508606A (ja) | 2013-02-01 | 2016-03-22 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | トリプルネガティブ乳ガンにおける転移を予測及び予防するための方法 |
| AU2014212014A1 (en) | 2013-02-01 | 2015-08-27 | Amgen Inc. | Administration of an anti-activin-A compound to a subject |
| EP2762497A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP2762496A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
| US10077315B2 (en) | 2013-02-05 | 2018-09-18 | Engmab Sàrl | Bispecific antibodies against CD3 and BCMA |
| US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| CN105101997B (zh) | 2013-02-06 | 2018-11-09 | 印希彼有限合伙公司 | 不减少血小板和不减少血红细胞的cd47抗体及其使用方法 |
| JP6545105B2 (ja) | 2013-02-07 | 2019-07-17 | シーエスエル、リミテッド | Ｉｌ−１１ｒ結合タンパク質及びその使用 |
| EP3936137A1 (en) | 2013-02-07 | 2022-01-12 | The General Hospital Corporation | Methods for expansion or depletion of t-regulatory cells |
| WO2014124319A2 (en) | 2013-02-07 | 2014-08-14 | Massachusetts Institute Of Technology | Human adaptation of h5 influenza |
| EP2953645A4 (en) | 2013-02-07 | 2016-12-28 | Immunomedics Inc | PRO-MEDICINE FORM (P2PDOX) OF HIGHLY POWERFUL 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED CANCER THERAPY |
| JP2016514091A (ja) | 2013-02-08 | 2016-05-19 | ミスフォールディング ダイアグノスティクス， インコーポレイテッド | トランスサイレチン抗体およびその使用 |
| JP6084708B2 (ja) | 2013-02-08 | 2017-02-22 | ノバルティス アーゲー | 抗ｉｌ−１７ａ抗体ならびに自己免疫性および炎症性障害の処置におけるその使用 |
| CA2900529A1 (en) | 2013-02-08 | 2014-08-14 | Institute For Myeloma & Bone Cancer Research | Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma |
| JP6357113B2 (ja) | 2013-02-08 | 2018-07-11 | 株式会社医学生物学研究所 | ヒトｎｒｇ１タンパク質に対する抗体 |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| EP2956444B1 (en) | 2013-02-13 | 2018-05-30 | ARK Diagnostics, Inc. | Posaconazole immunoassays |
| CA2900909A1 (en) | 2013-02-13 | 2014-08-21 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Highly galactosylated anti-tnf-.alpha. antibodies and uses thereof |
| AR094778A1 (es) | 2013-02-13 | 2015-08-26 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteínas con glicosilación modificada y métodos para producirlas |
| DK3255062T3 (da) | 2013-02-14 | 2019-10-07 | Innate Pharma | Anti-nkp46-antistof til diagnosticering af et ikke-kutant perifert t-cellelymfom (ptcl) |
| ES2760023T3 (es) | 2013-02-20 | 2020-05-12 | Univ Pennsylvania | Tratamiento del cáncer utilizando receptor de antígeno quimérico anti-EGFRvIII humanizado |
| TW201446794A (zh) | 2013-02-20 | 2014-12-16 | Novartis Ag | 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向 |
| JP6360077B2 (ja) | 2013-02-20 | 2018-07-18 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 末梢ｔ細胞リンパ腫の処置における使用のためのｋｉｒ３ｄｌ２に特異的に結合する化合物 |
| MX2015010791A (es) | 2013-02-22 | 2015-11-26 | Hoffmann La Roche | Metodos para tratar el cancer y prevenir la resistencia a farmacos. |
| MX2015010682A (es) | 2013-02-22 | 2016-05-31 | Stemcentrx Inc | Nuevos conjugados de anticuerpos y usos de los mismos. |
| CA2897858A1 (en) | 2013-02-22 | 2014-08-28 | Curevac Gmbh | Combination of vaccination and inhibition of the pd-1 pathway |
| DK3292873T3 (da) | 2013-02-22 | 2019-06-03 | Curevac Ag | Kombination af vaccination og hæmning af PD-1-vejen |
| MX2015010789A (es) | 2013-02-26 | 2015-11-26 | Roche Glycart Ag | Anticuerpos anti-pcsm. |
| US9429584B2 (en) | 2013-02-28 | 2016-08-30 | National Cancer Center | Antibody against insoluble fibrin |
| CN105143470B (zh) | 2013-02-28 | 2020-06-09 | 德克萨斯大学系统董事会 | 用于将癌症分类为易感于tmepai定向疗法以及治疗所述癌症的方法 |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| EP2964260A2 (en) | 2013-03-06 | 2016-01-13 | F. Hoffmann-La Roche AG | Methods of treating and preventing cancer drug resistance |
| EP2965263B1 (en) | 2013-03-07 | 2022-07-20 | Bernhard Sturm | Multimodal segmentation in intravascular images |
| US10226597B2 (en) | 2013-03-07 | 2019-03-12 | Volcano Corporation | Guidewire with centering mechanism |
| US9802987B2 (en) | 2013-03-08 | 2017-10-31 | Pfizer Inc. | Immunogenic fusion polypeptides |
| WO2014164472A1 (en) | 2013-03-10 | 2014-10-09 | The Board Of Regents Of The University Of Texas System | Biomarkers for chagas disease related cardiomyopathy |
| EP2778176A1 (en) | 2013-03-12 | 2014-09-17 | Sanofi | Compositions and methods for analyzing histidine phosphorylation |
| WO2014164696A1 (en) | 2013-03-12 | 2014-10-09 | Collins Donna | Systems and methods for diagnosing coronary microvascular disease |
| US11084860B2 (en) | 2013-03-12 | 2021-08-10 | The General Hospital Corporation | Modified Mullerian inhibiting substance (MIS) proteins and uses thereof for the treatment of diseases |
| US20140276923A1 (en) | 2013-03-12 | 2014-09-18 | Volcano Corporation | Vibrating catheter and methods of use |
| US9023353B2 (en) | 2013-03-13 | 2015-05-05 | The Board Of Trustees Of The University Of Arkansas | Anti-(+)—methamphetamine monoclonal antibodies |
| AU2014249243C1 (en) | 2013-03-13 | 2019-08-08 | Imaginab, Inc. | Antigen binding constructs to CD8 |
| RS57813B1 (sr) | 2013-03-13 | 2018-12-31 | Hoffmann La Roche | Formulacije sa smanjenom oksidacijom |
| US9301687B2 (en) | 2013-03-13 | 2016-04-05 | Volcano Corporation | System and method for OCT depth calibration |
| JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
| WO2014160497A1 (en) | 2013-03-13 | 2014-10-02 | Genentech, Inc. | Formulations with reduced oxidation |
| US10023608B1 (en) | 2013-03-13 | 2018-07-17 | Amgen Inc. | Protein purification methods to remove impurities |
| ES2808565T3 (es) | 2013-03-13 | 2021-03-01 | Sanofi Sa | Composiciones que comprenden anticuerpos anti-CD38 y carfilzomib |
| US10653779B2 (en) | 2013-03-13 | 2020-05-19 | Genentech, Inc. | Formulations with reduced oxidation |
| WO2014159819A1 (en) | 2013-03-13 | 2014-10-02 | Jinhyoung Park | System and methods for producing an image from a rotational intravascular ultrasound device |
| US11026591B2 (en) | 2013-03-13 | 2021-06-08 | Philips Image Guided Therapy Corporation | Intravascular pressure sensor calibration |
| US20140314778A1 (en) | 2013-03-13 | 2014-10-23 | Genentech, Inc. | Formulations with reduced oxidation |
| EP2968596B1 (en) | 2013-03-13 | 2019-03-06 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| AR095396A1 (es) | 2013-03-13 | 2015-10-14 | Genentech Inc | Formulaciones de anticuerpo |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| SG11201507477XA (en) | 2013-03-14 | 2015-10-29 | Genentech Inc | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
| KR20150127720A (ko) | 2013-03-14 | 2015-11-17 | 유니버시티 오브 매릴랜드, 발티모어 | 안드로겐 수용체 하향 조절제 및 그의 용도 |
| US10219887B2 (en) | 2013-03-14 | 2019-03-05 | Volcano Corporation | Filters with echogenic characteristics |
| BR112015022790A8 (pt) | 2013-03-14 | 2020-01-21 | Univ Duke | molécula biespecífica, composição farmacêutica, método de tratamento de uma infecção por vírus latente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus persistente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus inativo em um indivíduo em necessidade de tal tratamento, método para exterminar uma célula que contém um genoma viral, e, método para exterminar uma célula que expressa uma proteína viral |
| WO2014159554A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Low acidic species compositions and methods for producing the same using displacement chromatography |
| CA2905070A1 (en) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
| WO2014152365A2 (en) | 2013-03-14 | 2014-09-25 | Volcano Corporation | Filters with echogenic characteristics |
| WO2014159961A1 (en) | 2013-03-14 | 2014-10-02 | Beth Israel Deaconess Medical Center, Inc. | Measurement of fgf21 as a biomarker of fructose metabolism and metabolic disease |
| KR20150129033A (ko) | 2013-03-14 | 2015-11-18 | 애브비 인코포레이티드 | 저 산성 종 조성물 및 이의 제조 및 사용 방법 |
| US20160185853A1 (en) | 2013-03-14 | 2016-06-30 | Parkash Gill | Cancer treatment using antibodies that bind cell surface grp78 |
| WO2014151917A1 (en) | 2013-03-14 | 2014-09-25 | Ffe Therapeutics Llc | Compositions and methods for treating angiogenesis-related disorders |
| EP3495505A1 (en) | 2013-03-14 | 2019-06-12 | Translate Bio, Inc. | Quantitative assessment for cap efficiency of messenger rna |
| US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| WO2014159835A1 (en) | 2013-03-14 | 2014-10-02 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
| WO2014159239A2 (en) | 2013-03-14 | 2014-10-02 | Novartis Ag | Antibodies against notch 3 |
| US10292677B2 (en) | 2013-03-14 | 2019-05-21 | Volcano Corporation | Endoluminal filter having enhanced echogenic properties |
| CN113549148A (zh) | 2013-03-14 | 2021-10-26 | 雅培制药有限公司 | Hcv核心脂质结合结构域单克隆抗体 |
| AU2014244444A1 (en) | 2013-03-14 | 2015-09-24 | Amgen Inc. | CHRDL-1 antigen binding proteins and methods of treatment |
| US9469686B2 (en) | 2013-03-15 | 2016-10-18 | Abbott Laboratories | Anti-GP73 monoclonal antibodies and methods of obtaining the same |
| MX2015012551A (es) | 2013-03-15 | 2016-10-26 | Abbvie Biotechnology Ltd | Anticuerpos anti-cd25 y sus usos. |
| SI2970449T1 (sl) | 2013-03-15 | 2019-11-29 | Amgen Res Munich Gmbh | Enoverižne vezavne molekule, ki vsebujejo N-terminalni ABP |
| BR112015022167A2 (pt) | 2013-03-15 | 2017-07-18 | Theranos Inc | dispositivos, sistemas e métodos para preparação de amostras |
| EP2971042B1 (en) | 2013-03-15 | 2020-01-15 | Dana-Farber Cancer Institute, Inc. | Flavivirus neutralizing antibodies and methods of use thereof |
| EP4079760A3 (en) | 2013-03-15 | 2023-01-25 | Sanofi Pasteur Inc. | Antibodies against clostridium difficile toxins and methods of using the same |
| US10611824B2 (en) | 2013-03-15 | 2020-04-07 | Innate Pharma | Solid phase TGase-mediated conjugation of antibodies |
| CA2906960C (en) | 2013-03-15 | 2021-07-20 | Xiamen University | Epitope of rsv fusion protein and antibody recognizing the epitope |
| MX360779B (es) | 2013-03-15 | 2018-11-16 | Genentech Inc | Composiciones de cultivo celular con antioxidantes y métodos para la producción de polipéptidos. |
| US9062108B2 (en) | 2013-03-15 | 2015-06-23 | Abbvie Inc. | Dual specific binding proteins directed against IL-1 and/or IL-17 |
| ES2835716T3 (es) | 2013-03-15 | 2021-06-23 | Beth Israel Deaconess Medical Ct Inc | Procedimientos y composiciones para la generación y el uso de anticuerpos específicos de conformación |
| TW201511770A (zh) | 2013-03-15 | 2015-04-01 | Genentech Inc | 診斷及治療肝癌之組合物及方法 |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
| WO2014145718A2 (en) | 2013-03-15 | 2014-09-18 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
| EP2968541A4 (en) | 2013-03-15 | 2017-02-08 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| AU2014233494B2 (en) | 2013-03-15 | 2018-10-04 | Genentech, Inc. | IL-22 polypeptides and IL-22 Fc fusion proteins and methods of use |
| EA032830B1 (ru) | 2013-03-15 | 2019-07-31 | Эмджен Инк. | Антитела к pac1 человека и их применение для лечения головной боли |
| US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
| BR112015021521A2 (pt) | 2013-03-15 | 2017-10-10 | Genentech Inc | anticorpos anti-crth2 e métodos para seu uso |
| DK2968503T3 (en) | 2013-03-15 | 2018-12-03 | Intrinsic Lifesciences Llc | ANTI-HEPCIDIN ANTIBODIES AND APPLICATIONS THEREOF |
| PL2968440T3 (pl) | 2013-03-15 | 2019-12-31 | Zymeworks Inc. | Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania |
| MX2015011899A (es) | 2013-03-15 | 2016-05-05 | Genentech Inc | Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer. |
| CA2905798C (en) | 2013-03-15 | 2023-01-24 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
| US9505849B2 (en) | 2013-03-15 | 2016-11-29 | Amgen Research (Munich) Gmbh | Antibody constructs for influenza M2 and CD3 |
| AU2014233503A1 (en) | 2013-03-15 | 2015-09-24 | Abbvie Biotechnology Ltd. | Anti-CD25 antibodies and their uses |
| WO2014152030A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Removal of dna fragments in mrna production process |
| RU2661111C2 (ru) | 2013-03-15 | 2018-07-11 | Ац Иммуне С.А. | Антитела к тау и способы применения |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3623380A1 (en) | 2013-03-15 | 2020-03-18 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| US9850297B2 (en) | 2013-03-15 | 2017-12-26 | Amgen Inc. | Secreted frizzle-related protein 5 (SFRP5) binding proteins |
| ES2779398T3 (es) | 2013-03-15 | 2020-08-17 | Dana-Farber Cancer Institute Inc | Péptidos terapéuticos |
| US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
| JP6591961B2 (ja) | 2013-03-15 | 2019-10-16 | ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター | 真菌病原体および細菌病原体を処置するための組成物および方法 |
| WO2014144960A2 (en) | 2013-03-15 | 2014-09-18 | Abbvie Biotherapeutics Inc. | Fc variants |
| US9023357B2 (en) | 2013-03-15 | 2015-05-05 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| EP2976362B1 (en) | 2013-03-19 | 2019-10-23 | Beijing Shenogen Pharma Group Ltd. | Antibodies and methods for treating estrogen receptor-associated diseases |
| IL225380A (en) | 2013-03-21 | 2014-04-30 | Savyon Diagnostics Ltd | Bacterial training test and kit |
| US9447193B2 (en) | 2013-03-24 | 2016-09-20 | Development Center For Biotechnology | Methods for suppressing cancer by inhibition of TMCC3 |
| CN105143876B (zh) | 2013-03-27 | 2018-04-20 | 豪夫迈·罗氏有限公司 | 生物标志物用于评估用β7整联蛋白拮抗剂治疗胃肠炎性病症的用途 |
| US20160084839A1 (en) | 2013-04-02 | 2016-03-24 | Marisa Dolled-Filhart | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| CN113621057A (zh) | 2013-04-02 | 2021-11-09 | 中外制药株式会社 | Fc区变体 |
| EP2982691B1 (en) | 2013-04-02 | 2020-05-06 | Xiamen University | Broad spectrum monoclonal antibody identifying ha1 structural domain of influenza virus hemagglutinin proteins |
| WO2014165818A2 (en) | 2013-04-05 | 2014-10-09 | T Cell Therapeutics, Inc. | Compositions and methods for preventing and treating prostate cancer |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| EP2983710B1 (en) | 2013-04-09 | 2019-07-31 | Annexon, Inc. | Methods of treatment for neuromyelitis optica |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| WO2014172434A1 (en) | 2013-04-16 | 2014-10-23 | The Johns Hopkins University | Diagnostic and prognostic test for sturge-weber syndrome, klippel-trenaunay-weber syndrome, and port-wine stains (pwss) |
| JP2016518126A (ja) | 2013-04-19 | 2016-06-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ローンスターウイルス |
| WO2014174596A1 (ja) | 2013-04-23 | 2014-10-30 | 株式会社医学生物学研究所 | ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体 |
| SG10201800492PA (en) | 2013-04-29 | 2018-03-28 | Hoffmann La Roche | Human fcrn-binding modified antibodies and methods of use |
| CN105164157B (zh) | 2013-04-29 | 2024-05-28 | 豪夫迈·罗氏有限公司 | Fc-受体结合的修饰的非对称抗体及使用方法 |
| TWI653243B (zh) | 2013-04-29 | 2019-03-11 | 赫孚孟拉羅股份公司 | 遏止ＦｃＲｎ結合之抗ＩＧＦ－１Ｒ抗體及其治療血管性眼疾之用途 |
| US10501802B2 (en) | 2013-04-30 | 2019-12-10 | Universite De Montreal | Biomarkers for acute myeloid leukemia |
| SG10201800800YA (en) | 2013-05-06 | 2018-03-28 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
| AU2014264295A1 (en) | 2013-05-07 | 2015-10-29 | Rinat Neuroscience Corp. | Anti-glucagon receptor antibodies and methods of use thereof |
| GB201308259D0 (en) | 2013-05-08 | 2013-06-12 | Iles Raymond K | Cancer diagnosis and monitoring |
| US9989540B2 (en) | 2013-05-10 | 2018-06-05 | The Regents Of The University Of California | Diagnostic and monitoring system for Huntington's disease |
| EP4119662A1 (en) | 2013-05-10 | 2023-01-18 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| CN105264381B (zh) | 2013-05-16 | 2018-06-01 | 国立大学法人京都大学 | 用于确定癌症预后的方法 |
| WO2014183885A1 (en) | 2013-05-17 | 2014-11-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of the btla/hvem interaction for use in therapy |
| SG11201509284VA (en) | 2013-05-17 | 2015-12-30 | Centre Nat Rech Scient | Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications |
| CN105358578B (zh) | 2013-05-20 | 2021-08-06 | 豪夫迈·罗氏有限公司 | 运铁蛋白受体的抗体及其使用方法 |
| EP2999713A2 (en) | 2013-05-21 | 2016-03-30 | ARSANIS Biosciences GmbH | Generation of highly potent antibodies neutralizing the lukgh (lukab) toxin of staphylococcus aureus |
| EA201591993A1 (ru) | 2013-05-23 | 2016-05-31 | Шир Хьюман Дженетик Терапис, Инк. | Лечение склеродермии с применением комбинированной терапии антителами анти-ccl2 и анти-loxl2 |
| EP3004068A2 (en) | 2013-05-24 | 2016-04-13 | Nestec S.A. | Pathway specific assays for predicting irritable bowel syndrome diagnosis |
| KR20160129698A (ko) | 2013-05-24 | 2016-11-09 | 메디뮨 엘엘씨 | 항-b7-h5 항체 및 이의 용도 |
| WO2014190441A1 (en) | 2013-05-31 | 2014-12-04 | Zymeworks Inc. | Heteromultimers with reduced or silenced effector function |
| WO2014197723A2 (en) | 2013-06-05 | 2014-12-11 | Massachusetts Institute Of Technology | Human adaptation of h7 ha |
| WO2014197369A1 (en) | 2013-06-06 | 2014-12-11 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms |
| WO2014197866A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
| NZ714765A (en) | 2013-06-06 | 2021-12-24 | Pf Medicament | Anti-c10orf54 antibodies and uses thereof |
| EP3003372B1 (en) | 2013-06-07 | 2019-10-09 | Duke University | Inhibitors of complement factor h |
| MX370723B (es) | 2013-06-10 | 2019-12-20 | Ipierian Inc | Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatía. |
| WO2014201118A2 (en) | 2013-06-11 | 2014-12-18 | Sanford-Burnham Medical Research Institute | Compositions and methods for targeted endometriosis treatment |
| EP3009518B1 (en) | 2013-06-11 | 2020-08-12 | National Center of Neurology and Psychiatry | Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy |
| US9587032B2 (en) | 2013-06-12 | 2017-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | IgE antibodies for the inhibition of tumor metastasis |
| US20160130661A1 (en) | 2013-06-13 | 2016-05-12 | University Of South Australia | Methods for detecting prostate cancer |
| US9428748B2 (en) | 2013-06-17 | 2016-08-30 | Hong Gao | Method of expanding hematopoietic stem cells |
| WO2014205187A1 (en) | 2013-06-20 | 2014-12-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor |
| WO2014202773A1 (en) | 2013-06-20 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
| EP3011334A1 (en) | 2013-06-20 | 2016-04-27 | The Trustees Of The University Of Pennsylvania | Methods for diagnosing pancreatic cancer |
| AR096601A1 (es) | 2013-06-21 | 2016-01-20 | Novartis Ag | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso |
| KR20160042871A (ko) | 2013-06-21 | 2016-04-20 | 이나뜨 파르마, 에스.아. | 폴리펩티드의 효소적 콘쥬게이션 |
| US10086054B2 (en) | 2013-06-26 | 2018-10-02 | Academia Sinica | RM2 antigens and use thereof |
| EP3013347B1 (en) | 2013-06-27 | 2019-12-11 | Academia Sinica | Glycan conjugates and use thereof |
| EP2818484A1 (en) | 2013-06-28 | 2014-12-31 | Universitat Autònoma de Barcelona | Synergistic combination of an anti-IgE antibody and an EP2 receptor agonist |
| US10221239B2 (en) | 2013-06-28 | 2019-03-05 | Singapore Health Services Pte Ltd | TRPM4 channel inhibitors for stroke treatment |
| WO2015001049A1 (en) | 2013-07-04 | 2015-01-08 | Novartis Ag | O-mannosyltransferase deficient filamentous fungal cells and methods of use thereof |
| EP3016973A1 (en) | 2013-07-05 | 2016-05-11 | INSERM - Institut National de la Santé et de la Recherche Médicale | Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof |
| WO2015006507A1 (en) | 2013-07-09 | 2015-01-15 | Annexon, Inc. | Methods of treatment for alzheimer's disease and huntington's disease |
| WO2015006554A1 (en) | 2013-07-10 | 2015-01-15 | The Regents Of The University Of Michigan | Therapeutic antibodies and uses thereof |
| EP3019522B1 (en) | 2013-07-10 | 2017-12-13 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| CN105339388B (zh) | 2013-07-12 | 2021-06-15 | Emd密理博公司 | 确定利用活性炭从包含靶蛋白的样品去除病毒的方法 |
| TR201818966T4 (tr) | 2013-07-12 | 2019-01-21 | Hoffmann La Roche | İyon değişim kromatografisi girdi optimizasyonunun açıklaması. |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| KR20220042248A (ko) | 2013-07-16 | 2022-04-04 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법 |
| EP3022224A2 (en) | 2013-07-18 | 2016-05-25 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
| WO2015010100A2 (en) | 2013-07-18 | 2015-01-22 | Fabrus, Inc. | Humanized antibodies with ultralong complementarity determining regions |
| MX2016001042A (es) | 2013-07-23 | 2017-01-05 | Biocon Ltd | Metodos para controlar los niveles de fucosilacion en proteinas. |
| WO2015015489A1 (en) | 2013-07-30 | 2015-02-05 | Biolinerx Ltd. | Antibody for treating diabetes and autoimmune diseases |
| JP6521959B2 (ja) | 2013-07-31 | 2019-05-29 | ライナット ニューロサイエンス コーポレイション | 操作されたポリペプチドコンジュゲート |
| EP3027225B1 (en) | 2013-07-31 | 2021-03-24 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating thermogenesis using transforming growth factor alpha |
| EP3027220A1 (en) | 2013-08-01 | 2016-06-08 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to cd37 proteins |
| HUE058243T2 (hu) | 2013-08-01 | 2022-07-28 | Five Prime Therapeutics Inc | Afukozilált, FGFR2IIIB elleni antitestek |
| EP3786187A1 (en) | 2013-08-01 | 2021-03-03 | Université catholique de Louvain | Antibody binding a complex of human glycoprotein a repetitions predominant (garp) and latent tgf-beta-1 |
| KR101809072B1 (ko) | 2013-08-02 | 2017-12-14 | 화이자 인코포레이티드 | 항-cxcr4 항체 및 항체-약물 접합체 |
| BR112016001420A2 (pt) | 2013-08-02 | 2018-01-23 | Aduro Biotech Holdings Europe B V | combinação de agonistas de cd27 e inibição pontual imune para estimulação imune |
| TWI777195B (zh) | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（三） |
| US20160178610A1 (en) | 2013-08-07 | 2016-06-23 | Friedrich Miescher Institute For Biomedical Research | New screening method for the treatment Friedreich's ataxia |
| AU2014305111B2 (en) | 2013-08-07 | 2019-05-30 | Fertilitypro Aps | Antibodies, compounds and derivatives thereof for use in the treatment of male infertility |
| EP3030268B1 (en) | 2013-08-09 | 2022-07-27 | The Trustees Of The University Of Pennsylvania | Combination of ifn-gamma with anti-erbb antibody for the treatment of cancers |
| CR20160132A (es) | 2013-08-12 | 2016-08-25 | Genentech Inc | Composiciones y método para tratar condiciones asociadas con el complemento |
| CA2918139A1 (en) | 2013-08-12 | 2015-02-19 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
| JP6696899B2 (ja) | 2013-08-13 | 2020-05-20 | サノフイＳａｎｏｆｉ | プラスミノーゲン活性化因子阻害剤−１（ｐａｉ−１）に対する抗体及びその使用 |
| AU2014306564B2 (en) | 2013-08-14 | 2019-10-17 | Modmab Therapeutics Corporation | Antibodies against frizzled proteins and methods of use thereof |
| AU2014307589A1 (en) | 2013-08-14 | 2016-02-11 | Novartis Ag | Methods of treating sporadic inclusion body myositis |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| CN106659909B (zh) | 2013-08-21 | 2022-01-11 | 德克萨斯州大学系统董事会 | 用于靶向连接蛋白半通道的组合物和方法 |
| BR112016004242A8 (pt) | 2013-08-28 | 2018-06-12 | Stemcentrx Inc | Métodos para conjugação sítio-específica de anticorpos e composições |
| JP6736464B2 (ja) | 2013-08-29 | 2020-08-05 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | 細胞透過性コンジュゲート及びその使用の方法 |
| HUE055856T2 (hu) | 2013-08-30 | 2021-12-28 | Immunogen Inc | Antitestek és vizsgálatok a folsavreceptor 1 kimutatására |
| EP3039039B1 (en) | 2013-08-30 | 2021-03-10 | Takeda GmbH | Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| US20160251410A1 (en) | 2013-09-03 | 2016-09-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for expressing recombinant polypeptides |
| WO2015035044A2 (en) | 2013-09-04 | 2015-03-12 | Abbvie Biotherapeutics Inc. | Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY |
| CA2922830A1 (en) | 2013-09-05 | 2015-04-16 | Igm Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies |
| KR20160050062A (ko) | 2013-09-05 | 2016-05-10 | 제넨테크, 인크. | 크로마토그래피 재사용 방법 |
| EP3041868A2 (en) | 2013-09-05 | 2016-07-13 | Aduro Biotech Holdings, Europe B.V. | Cd70-binding peptides and method, process and use relating thereto |
| CN105682666B (zh) | 2013-09-06 | 2021-06-01 | 中央研究院 | 使用醣脂激活人类iNKT细胞 |
| MX356055B (es) | 2013-09-06 | 2018-05-11 | Theranos Ip Co Llc | Sistemas y métodos para detectar enfermedades infecciosas. |
| BR112016004463A2 (pt) | 2013-09-08 | 2017-10-17 | Pfizer | composições de neisseria meningitidis e métodos das mesmas |
| CA2923844C (en) | 2013-09-11 | 2022-07-26 | Arsia Therapeutics, Inc. | Liquid protein formulations containing organophosphates |
| US20150071923A1 (en) | 2013-09-12 | 2015-03-12 | Ge Wei | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
| TWI688401B (zh) | 2013-09-13 | 2020-03-21 | 美商安進公司 | 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合 |
| WO2015038884A2 (en) | 2013-09-13 | 2015-03-19 | Genentech, Inc. | Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products |
| CA2921999C (en) | 2013-09-13 | 2023-03-21 | Genentech, Inc. | Methods and compositions comprising an anti-il13 antibody and residual hamster phospholipase b-like 2 |
| WO2015037009A1 (en) | 2013-09-16 | 2015-03-19 | Plexicure Ltd. | Isolated proteins capable of binding plexin-a4 and methods of producing and using same |
| EP3046940B1 (en) | 2013-09-17 | 2019-07-03 | F.Hoffmann-La Roche Ag | Methods of using anti-lgr5 antibodies |
| AU2014324043B2 (en) | 2013-09-17 | 2019-05-09 | University Health Network (Uhn): Technology Development And Commercialization | Agents directed against a cis RGMa/Neogenin interaction or lipid rafts and use of the same in methods of treatment |
| US10739333B2 (en) | 2013-09-19 | 2020-08-11 | Dana-Farber Cancer Institute, Inc. | Methods of BH3 profiling |
| JP6615100B2 (ja) | 2013-09-24 | 2019-12-04 | ザ ファインスタイン インスティチュート フォー メディカル リサーチ | 低温誘導性ｒｎａ結合タンパク質活性を阻害するペプチド |
| WO2015048531A1 (en) | 2013-09-26 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Inhibition of sgk1 in the treatment of heart conditions |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| SG11201602261VA (en) | 2013-09-27 | 2016-04-28 | Chugai Pharmaceutical Co Ltd | Method for producing polypeptide heteromultimer |
| EP3049437A1 (en) | 2013-09-27 | 2016-08-03 | F. Hoffmann-La Roche AG | Thermus thermophilus slyd fkbp domain specific antibodies |
| SG10201708542RA (en) | 2013-09-27 | 2017-12-28 | Genentech Inc | Anti-pdl1 antibody formulations |
| GB201317207D0 (en) | 2013-09-27 | 2013-11-13 | Univ Glasgow | Materials and methods for modulating disc1 turnover |
| US9243294B2 (en) | 2013-09-30 | 2016-01-26 | Hadasit Medical Research Services And Development Ltd. | Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD) |
| WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052131B1 (en) | 2013-10-01 | 2018-12-05 | Mayo Foundation for Medical Education and Research | Methods for treating cancer in patients with elevated levels of bim |
| WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
| SG11201602522VA (en) | 2013-10-02 | 2016-04-28 | Medimmune Llc | Neutralizing anti-influenza a antibodies and uses thereof |
| RU2687143C2 (ru) | 2013-10-06 | 2019-05-07 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Модифицированный экзотоксин а псевдомонад |
| RS59644B1 (sr) | 2013-10-08 | 2020-01-31 | Immunogen Inc | Režimi doziranja imunokonjugata anti-folr1 |
| JP2016534152A (ja) | 2013-10-09 | 2016-11-04 | ユニバーシティ オブ マイアミ | 感染性疾患及び腸の炎症の薬剤標的としてのパーフォリン−２活性化剤及び阻害剤 |
| AU2014331909B2 (en) | 2013-10-10 | 2020-03-12 | Beth Israel Deaconess Medical Center, Inc. | TM4SF1 binding proteins and methods of using same |
| WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| MX2016003593A (es) | 2013-10-11 | 2016-06-02 | Hoffmann La Roche | Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico. |
| MX365742B (es) | 2013-10-11 | 2019-06-12 | Oxford Biotherapeutics Ltd | Anticuerpos conjugados contra ly75 para el tratamiento del cancer. |
| EP3054983B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| EP3055328A1 (en) | 2013-10-11 | 2016-08-17 | F. Hoffmann-La Roche AG | Nsp4 inhibitors and methods of use |
| EP2860243A1 (en) | 2013-10-14 | 2015-04-15 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Reprogramming bone endothelial cells for bone angiogenesis and osteogenesis |
| KR20240034882A (ko) | 2013-10-15 | 2024-03-14 | 씨젠 인크. | 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커 |
| WO2015056808A1 (en) | 2013-10-15 | 2015-04-23 | Genefrontier Corporation | Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases |
| WO2015055796A1 (en) | 2013-10-16 | 2015-04-23 | Université Libre de Bruxelles | Formulations useful in the treatment of proliferative diseases affecting the respiratory tract |
| MX2016004928A (es) | 2013-10-17 | 2016-07-11 | Arsanis Biosciences Gmbh | Secuencias de anticuerpos con reaccion cruzada para staphylococcus aureus. |
| MX2016005017A (es) | 2013-10-17 | 2016-11-07 | Omeros Corp | Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2. |
| CA3120508A1 (en) | 2013-10-28 | 2015-05-07 | Dots Technology Corp. | Allergen detection |
| GB201319374D0 (en) | 2013-11-01 | 2013-12-18 | Univ Nottingham | Glycans as functional cancer targets abd antibodies thereto |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| JPWO2015068781A1 (ja) | 2013-11-06 | 2017-03-09 | 国立大学法人大阪大学 | インフルエンザウイルスａ型のグループ１に対して広域な中和活性を有する抗体 |
| EP3094973B1 (en) | 2013-11-07 | 2020-07-29 | Diagnodus Limited | Biomarkers |
| EP2871189A1 (en) | 2013-11-07 | 2015-05-13 | Institut Pasteur | High-affinity monoclonal anti-strep-tag antibody |
| EP3066121A1 (en) | 2013-11-07 | 2016-09-14 | AbbVie Inc. | Isolation and purification of dvd-igs |
| ES2865196T3 (es) | 2013-11-07 | 2021-10-15 | Inst Nat Sante Rech Med | Anticuerpos anti-HER3 humana alostéricos de neuregulina |
| US10584147B2 (en) | 2013-11-08 | 2020-03-10 | Biovertiv Therapeutics Inc. | Procoagulant fusion compound |
| US20170002064A1 (en) | 2013-11-08 | 2017-01-05 | The Board Of Regents Of The University Of Texas System | Vh4 antibodies against gray matter neuron and astrocyte |
| EP3070168A4 (en) | 2013-11-11 | 2017-06-28 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified antibody variable region |
| WO2015070207A2 (en) | 2013-11-11 | 2015-05-14 | The Government Of The United States, As Represented By The Secretary Of The Army | Ama-1 epitopes, antibodies, compositions, and methods of making and using the same |
| JP6740126B2 (ja) | 2013-11-13 | 2020-08-12 | ファイザー・インコーポレイテッド | 腫瘍壊死因子様リガンド１ａ特異的抗体ならびにその組成物および使用 |
| GB201320061D0 (en) | 2013-11-13 | 2013-12-25 | Electrophoretics Ltd | Materials nad methods for diagnosis and prognosis of liver cancer |
| AU2014348552A1 (en) | 2013-11-13 | 2016-06-02 | Zymeworks Inc. | Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof |
| JP2016538286A (ja) | 2013-11-15 | 2016-12-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 膵臓癌を処置するための方法及び医薬組成物 |
| CA2928014A1 (en) | 2013-11-15 | 2015-05-21 | Institut Pasteur | Method for detecting a molecular marker of plasmodium falciparum artemisinin resistance |
| KR102238133B1 (ko) | 2013-11-15 | 2021-04-09 | 제넨테크, 인크. | 환경-친화적 세제를 사용한 바이러스 불활성화 방법 |
| EP2873740A1 (en) | 2013-11-19 | 2015-05-20 | Oncodiag | Methods for the surveillance, diagnosis and screening of bladder cancer |
| LT3071595T (lt) | 2013-11-19 | 2019-05-10 | Fredax Ab | Humanizuotas anti-kalikreino-2 antikūnas |
| PL3071597T3 (pl) | 2013-11-21 | 2020-11-30 | F.Hoffmann-La Roche Ag | Przeciwciała przeciwko alfa-synukleinie i sposoby stosowania |
| EP3763387B1 (en) | 2013-11-25 | 2024-03-27 | FameWave Ltd | Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy |
| JP6620094B2 (ja) | 2013-11-26 | 2019-12-11 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 免疫応答を調節するための組成物および方法 |
| US9493413B2 (en) | 2013-11-27 | 2016-11-15 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
| RU2737882C2 (ru) * | 2013-11-27 | 2020-12-04 | Займворкс Инк. | Биспецифические антигенсвязывающие конструкции против her2 |
| WO2015081085A2 (en) | 2013-11-27 | 2015-06-04 | Ipierian, Inc. | Methods of treating a tauopathy |
| WO2015077845A1 (en) | 2013-11-28 | 2015-06-04 | Csl Limited | Method of treating nephropathy |
| CN105899528B (zh) | 2013-12-02 | 2020-09-01 | 贝勒医学院 | 用于维持最佳体重和血糖的新的多肽激素的鉴定 |
| KR20160092006A (ko) | 2013-12-03 | 2016-08-03 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 임신성 당뇨병의 평가를 위한 방법 및 시약 |
| US9321834B2 (en) | 2013-12-05 | 2016-04-26 | Leidos, Inc. | Anti-malarial compositions |
| MX371187B (es) | 2013-12-06 | 2020-01-22 | Dana Farber Cancer Inst Inc | Péptidos terapéuticos. |
| EP3076963A4 (en) | 2013-12-06 | 2017-09-13 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd30 antibodies |
| EP3077417A1 (en) | 2013-12-08 | 2016-10-12 | Peptcell Limited | Hiv antigens and antibodies and compositions, methods and uses thereof |
| US9644023B2 (en) | 2013-12-09 | 2017-05-09 | New York University | Compositions and methods for phagocyte delivery of anti-staphylococcal agents |
| CN105916519B (zh) | 2013-12-09 | 2021-10-22 | 爱乐科斯公司 | 抗Siglec-8抗体及其使用方法 |
| WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
| CN105979780A (zh) | 2013-12-11 | 2016-09-28 | 斯隆-凯特林癌症研究院 | 治疗前列腺癌的糖皮质激素抑制剂 |
| CA2933335A1 (en) | 2013-12-11 | 2015-06-18 | The General Hospital Corporation | Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation |
| WO2015089380A2 (en) | 2013-12-12 | 2015-06-18 | Celcuity Llc | Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent |
| EP3461845B1 (en) | 2013-12-13 | 2020-09-16 | Genentech, Inc. | Anti-cd33 antibodies and immunoconjugates |
| US9944694B2 (en) | 2013-12-13 | 2018-04-17 | Rijksuniversiteit Groningen | Antibodies against Staphylococcus aureus and uses therof |
| CN106030310B (zh) | 2013-12-13 | 2019-01-04 | 通用医疗公司 | 可溶性高分子量(hmw)tau种类及其应用 |
| MX2016007578A (es) | 2013-12-16 | 2016-10-03 | Genentech Inc | Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento. |
| EP2883883A1 (en) | 2013-12-16 | 2015-06-17 | Cardio3 Biosciences S.A. | Therapeutic targets and agents useful in treating ischemia reperfusion injury |
| CR20160271A (es) | 2013-12-16 | 2016-12-02 | Genentech Inc | Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco |
| AU2014365838B2 (en) | 2013-12-16 | 2021-01-14 | The University Of North Carolina At Chapel Hill | Depletion of plasmacytoid dendritic cells |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
| BR112016013963A2 (pt) | 2013-12-17 | 2017-10-10 | Genentech Inc | terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1 |
| IL302303A (en) | 2013-12-17 | 2023-06-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| EP3084003A4 (en) | 2013-12-17 | 2017-07-19 | Merck Sharp & Dohme Corp. | Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists |
| WO2015091653A2 (en) | 2013-12-17 | 2015-06-25 | Westfaelische Wilhelms-Universitaet Muenster | Means and methods for treating a pruritus-like skin-disease |
| US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
| ES2763429T5 (es) | 2013-12-17 | 2023-06-21 | Hoffmann La Roche | Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos |
| US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| EP3082860B1 (en) | 2013-12-18 | 2020-11-25 | CSL Limited | Method of treating wounds |
| US9982229B2 (en) | 2013-12-19 | 2018-05-29 | Danisco Us Inc. | Use of hydrophobins to increase gas transfer in aerobic fermentation processes |
| WO2015095868A1 (en) | 2013-12-20 | 2015-06-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
| US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| AU2014368696A1 (en) | 2013-12-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Humanized anti-Tau(pS422) antibodies and methods of use |
| RU2732032C2 (ru) | 2013-12-20 | 2020-09-10 | Дженентек, Инк. | Антитела с двойной специфичностью |
| CN117603354A (zh) | 2013-12-20 | 2024-02-27 | 英特维特国际股份有限公司 | 具有经修饰的ch2-ch3序列的犬抗体 |
| CN106029087A (zh) | 2013-12-20 | 2016-10-12 | 印第安纳大学研究及科技有限公司 | 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽 |
| NZ720736A (en) | 2013-12-23 | 2020-08-28 | Bayer Pharma AG | Antibody drug conjugates (adcs) with kinesin spindel protein (ksp) |
| TWI670283B (zh) | 2013-12-23 | 2019-09-01 | 美商建南德克公司 | 抗體及使用方法 |
| EP2960252A1 (en) | 2014-06-26 | 2015-12-30 | Institut Pasteur | Phospholipase for treatment of immunosuppression |
| SG10201805933TA (en) | 2013-12-24 | 2018-08-30 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
| US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
| EP3088890B1 (en) | 2013-12-24 | 2020-09-23 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring soluble gpc3 protein |
| BR112016013347B1 (pt) | 2013-12-26 | 2023-12-12 | Mitsubishi Tanabe Pharma Corporation | Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos |
| RU2729194C2 (ru) | 2013-12-27 | 2020-08-05 | Займворкс Инк. | Сульфонамидсодержащие связывающие системы для лекарственных конъюгатов |
| EP3088001B1 (en) | 2013-12-27 | 2020-02-12 | National University Corporation Kochi University | Anti-lipolysis stimulated liporotein receptor antibodies for treatment of ovarian cancer |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| US10391081B2 (en) | 2013-12-27 | 2019-08-27 | Chugai Seiyaku Kabushiki Kaisha | FGFR gatekeeper mutant gene and drug targeting same |
| CN106062005A (zh) | 2013-12-30 | 2016-10-26 | 医药生命融合研究团 | 抗krs单克隆抗体及其用途 |
| RU2682754C2 (ru) | 2014-01-03 | 2019-03-21 | Ф. Хоффманн-Ля Рош Аг | Конъюгаты полипептидного токсина и антитела, соединенных ковалентной связью |
| CN105899540B (zh) | 2014-01-03 | 2020-02-07 | 豪夫迈·罗氏有限公司 | 双特异性抗-半抗原/抗-血脑屏障受体的抗体、其复合物及它们作为血脑屏障穿梭物的应用 |
| US10188650B2 (en) | 2014-01-03 | 2019-01-29 | The Regents Of The University Of Michigan | Treatment of neurological disorders |
| CN105873615B (zh) | 2014-01-03 | 2020-12-25 | 豪夫迈·罗氏有限公司 | 共价连接的helicar-抗helicar抗体缀合物及其用途 |
| CN111057147B (zh) | 2014-01-06 | 2023-11-10 | 豪夫迈·罗氏有限公司 | 单价血脑屏障穿梭模块 |
| AU2015205327B2 (en) | 2014-01-09 | 2019-02-14 | Hadasit Medical Research Services And Development Ltd. | Improved cell compositions and methods for cancer therapy |
| JP2017504622A (ja) | 2014-01-14 | 2017-02-09 | ザ メディカル カレッジ オブ ウィスコンシン インクＴｈｅ Ｍｅｄｉｃａｌ Ｃｏｌｌｅｇｅ Ｏｆ Ｗｉｓｃｏｎｓｉｎ， Ｉｎｃ． | 癌の処置および予防のためのｃｌｐｔｍ１ｌ標的化 |
| KR20160107190A (ko) | 2014-01-15 | 2016-09-13 | 에프. 호프만-라 로슈 아게 | 변형된 FcRn-결합 및 유지된 단백질 A-결합 성질을 갖는 Fc-영역 변이체 |
| US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| CN106459920B (zh) | 2014-01-16 | 2020-10-30 | 中央研究院 | 治疗及检测癌症的组合物及方法 |
| EP2896400A1 (en) | 2014-01-17 | 2015-07-22 | Université Catholique De Louvain | Method for increasing the bioavailability of inhaled compounds |
| WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
| EP3097117B1 (en) | 2014-01-21 | 2023-10-04 | Novartis Ag | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| US20170043034A1 (en) | 2014-01-24 | 2017-02-16 | Genentech, Inc. | Methods of using anti-steap1 antibodies and immunoconjugates |
| ES2808340T3 (es) | 2014-01-24 | 2021-02-26 | Ngm Biopharmaceuticals Inc | Anticuerpos que se unen al dominio de beta klotho 2 y procedimientos de uso de los mismos |
| ES2722103T3 (es) | 2014-01-27 | 2019-08-07 | Pfizer | Agentes citotóxicos bifuncionales |
| EP3100054B1 (en) | 2014-01-28 | 2022-02-23 | Quest Diagnostics Investments Incorporated | Method and compositions for detecting an adenoma-adenocarcinoma transition in cancer |
| US10059775B2 (en) | 2014-01-29 | 2018-08-28 | Dana-Farber Cancer Institute, Inc. | Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD) |
| WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
| WO2016039801A1 (en) | 2014-01-31 | 2016-03-17 | Boehringer Ingelheim International Gmbh | Novel anti-baff antibodies |
| AU2015212341A1 (en) | 2014-02-03 | 2016-09-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Use of Casein kinase I inhibitors for depleting stem cells |
| CA2938566A1 (en) | 2014-02-04 | 2015-08-13 | Incyte Corporation | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer |
| BR112016018082A2 (pt) | 2014-02-04 | 2018-02-20 | Contrafect Corporation | ?anticorpos úteis na imunização passiva de influenza e composições, combinações e métodos para uso dos mesmos? |
| BR112016017256A2 (pt) | 2014-02-04 | 2017-10-17 | Merck Sharp & Dohme | combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer |
| SG10201901076WA (en) | 2014-02-08 | 2019-03-28 | Genentech Inc | Methods of treating alzheimer's disease |
| KR20230056800A (ko) | 2014-02-08 | 2023-04-27 | 제넨테크, 인크. | 알츠하이머 질환을 치료하는 방법 |
| CN105992772A (zh) | 2014-02-10 | 2016-10-05 | Igm生命科学股份有限公司 | IgA多特异性结合分子 |
| EP4190809A1 (en) | 2014-02-11 | 2023-06-07 | Seagen Inc. | Selective reduction of proteins |
| WO2015122995A1 (en) | 2014-02-11 | 2015-08-20 | Visterra, Inc. | Antibody moleules to dengue virus and uses thereof |
| WO2015121383A1 (en) | 2014-02-12 | 2015-08-20 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
| ES2885686T3 (es) | 2014-02-17 | 2021-12-15 | Seagen Inc | Conjugados anticuerpo-fármaco hidrófilos |
| WO2015124588A1 (en) | 2014-02-18 | 2015-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway |
| WO2015124570A1 (en) | 2014-02-18 | 2015-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of influenza a virus infection |
| CA2939034A1 (en) | 2014-02-19 | 2015-08-27 | Cangene Corporation | Methods of modulating an immune response |
| EP4008726A1 (en) | 2014-02-20 | 2022-06-08 | Allergan, Inc. | Complement component c5 antibodies |
| EA201691683A1 (ru) | 2014-02-21 | 2017-04-28 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме |
| AU2015218631A1 (en) | 2014-02-21 | 2016-08-11 | Genentech, Inc. | Anti-IL-13/IL-17 bispecific antibodies and uses thereof |
| WO2015130805A1 (en) | 2014-02-26 | 2015-09-03 | Arizona Board Of Regents On Behalf Of Arizona State University | Dna gridiron compositions and methods |
| SG11201606546VA (en) | 2014-02-27 | 2016-09-29 | Gilead Sciences Inc | Antibodies to matrix metalloproteinase 9 and methods of use thereof |
| AU2015223567B2 (en) | 2014-02-28 | 2020-09-10 | Merus N.V. | Antibody that binds ErbB-2 and ErbB-3 |
| FI3122757T3 (fi) | 2014-02-28 | 2023-10-10 | Hangzhou Dac Biotech Co Ltd | Varautuneita linkkereitä ja niiden konjugointikäyttötapoja |
| US10183996B2 (en) | 2014-02-28 | 2019-01-22 | Allakos Inc. | Methods and compositions for treating Siglec-8 associated diseases |
| NZ724013A (en) | 2014-02-28 | 2019-11-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| GB201403815D0 (en) | 2014-03-04 | 2014-04-16 | Mologic Ltd | Assay |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| WO2015132675A2 (en) | 2014-03-07 | 2015-09-11 | University Health Network | Methods and compositions for modifying the immune response |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| EP3116535B1 (en) | 2014-03-12 | 2019-08-07 | CureVac AG | Combination of vaccination and ox40 agonists |
| SG11201607519VA (en) | 2014-03-14 | 2016-10-28 | Genentech Inc | Methods and compositions for secretion of heterologous polypeptides |
| US9738702B2 (en) | 2014-03-14 | 2017-08-22 | Janssen Biotech, Inc. | Antibodies with improved half-life in ferrets |
| AU2015229009B2 (en) | 2014-03-14 | 2019-08-22 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring NKG2D pathway function against cancers |
| BR122024001145A2 (pt) | 2014-03-14 | 2024-02-27 | Novartis Ag | Molécula de anticorpo isolada capaz de se ligar a lag-3, seu método de produção, composição farmacêutica, ácidos nucleicos, vetor de expressão, método para detecção de lag-3 em uma amostra biológica, e uso das referidas molécula de anticorpo e composição |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| WO2015142661A1 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Regulatable chimeric antigen receptor |
| CA2940196C (en) | 2014-03-19 | 2023-03-07 | Wayne Marasco | Immunogenetic restriction on elicitation of antibodies |
| US10544395B2 (en) | 2014-03-19 | 2020-01-28 | Pfizer Inc. | Method of cell culture |
| US9884895B2 (en) | 2014-03-20 | 2018-02-06 | The University Of North Carolina At Chapel Hill | Methods and compositions for chimeric coronavirus spike proteins |
| FI3119431T3 (fi) | 2014-03-21 | 2024-03-20 | Teva Pharmaceuticals Int Gmbh | Kalsitoniinigeeniin liittyvää peptidiä vastaan suunnattuja antagonisti-vasta-aineita ja menetelmiä niiden käyttämiseksi |
| AU2015231155B2 (en) | 2014-03-21 | 2020-11-12 | X-Body, Inc. | Bi-specific antigen-binding polypeptides |
| US20170107294A1 (en) | 2014-03-21 | 2017-04-20 | Nordlandssykehuset Hf | Anti-cd14 antibodies and uses thereof |
| MA39776A (fr) | 2014-03-24 | 2017-02-01 | Hoffmann La Roche | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf |
| MY178060A (en) | 2014-03-25 | 2020-09-30 | Genentech Inc | Methods of preparing a poloxamer for use in cell culture medium |
| DK3483593T3 (da) | 2014-03-26 | 2021-07-19 | Siemens Healthcare Diagnostics Inc | Luminescent-oxygen-channeling-immunoassay ved anvendelse af tre antistoffer og fremgangsmåder til fremstilling og anvendelse deraf |
| JP7054990B2 (ja) | 2014-03-27 | 2022-04-15 | ジェネンテック， インコーポレイテッド | 炎症性腸疾患の診断及び治療のための方法 |
| WO2015145449A2 (en) | 2014-03-27 | 2015-10-01 | Yeda Research And Development Co. Ltd. | T-cell receptor cdr3 peptides and antibodies |
| JP6562942B2 (ja) | 2014-03-27 | 2019-08-28 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | 反応性標識化合物およびその使用 |
| KR20160138494A (ko) | 2014-03-31 | 2016-12-05 | 데비오팜 인터네셔날 에스 에이 | Fgfr 융합물 |
| CR20160500A (es) | 2014-03-31 | 2016-12-14 | Genentech Inc | Anticuerpos anti-ox40 y métodos de uso |
| RU2016142476A (ru) | 2014-03-31 | 2018-05-07 | Дженентек, Инк. | Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40 |
| WO2015152908A1 (en) | 2014-04-02 | 2015-10-08 | U.S. Army Medical Research Institute Of Infectious Diseases | Rapid dual direct fluorescent antibody assay for the identification of bacillus anthracis |
| SG11201608054YA (en) | 2014-04-02 | 2016-10-28 | Hoffmann La Roche | Method for detecting multispecific antibody light chain mispairing |
| SI3126383T1 (sl) | 2014-04-03 | 2019-05-31 | Igm Biosciences, Inc. | Modificirana veriga J |
| CN111514283A (zh) | 2014-04-07 | 2020-08-11 | 诺华股份有限公司 | 使用抗cd19嵌合抗原受体治疗癌症 |
| WO2015157238A2 (en) | 2014-04-08 | 2015-10-15 | Medimmune, Llc | Binding molecules specific for il-21 and uses thereof |
| CN106456727B (zh) | 2014-04-10 | 2020-11-27 | 台湾浩鼎生技股份有限公司 | 抗体、产生所述抗体的杂交瘤、及其用途 |
| WO2015157592A1 (en) | 2014-04-11 | 2015-10-15 | Medimmune, Llc | Bispecific her2 antibodies |
| GB201406767D0 (en) | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
| WO2015158851A1 (en) | 2014-04-16 | 2015-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the prevention or the treatment of bleeding episodes |
| EP2933640A1 (en) | 2014-04-17 | 2015-10-21 | eXcorLab GmbH | Diagnosis of chronic kidney disease by quantitative analysis of post-translational modifications of plasma proteins |
| WO2015158898A2 (en) | 2014-04-17 | 2015-10-22 | Medizinische Hochschule Hannover | Means and methods for producing neisseria meningitidis capsular polysaccharides of low dispersity |
| BR112016024319B1 (pt) | 2014-04-18 | 2024-01-23 | Acceleron Pharma Inc | USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME |
| EP3134439B1 (en) | 2014-04-21 | 2018-12-26 | Millennium Pharmaceuticals, Inc. | Anti-psyk antibody molecules and use of same for syk-targeted therapy |
| GB201407132D0 (en) | 2014-04-23 | 2014-06-04 | Velgene Biotechnology | Marker for neurodegenerative disorders |
| WO2015164743A2 (en) | 2014-04-24 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| TW201622746A (zh) | 2014-04-24 | 2016-07-01 | 諾華公司 | 改善或加速髖部骨折術後身體復原之方法 |
| WO2015164615A1 (en) | 2014-04-24 | 2015-10-29 | University Of Oslo | Anti-gluten antibodies and uses thereof |
| WO2015162563A1 (en) | 2014-04-25 | 2015-10-29 | Rinat Neuroscience Corp. | Antibody-drug conjugates with high drug loading |
| EP3804745A1 (en) | 2014-04-25 | 2021-04-14 | The Brigham and Women's Hospital, Inc. | Methods to manipulate alpha-fetoprotein (afp) |
| US20170045528A1 (en) | 2014-04-25 | 2017-02-16 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating subjects with immune-mediated diseases |
| EP3134111B1 (en) | 2014-04-25 | 2022-06-08 | Dana-Farber Cancer Institute, Inc. | Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof |
| US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
| KR102452349B1 (ko) | 2014-04-27 | 2022-10-11 | 페임웨이브 리미티드 | Ceacam1에 대한 인간화 항체 |
| US10087259B1 (en) | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
| US9753036B2 (en) | 2014-04-29 | 2017-09-05 | Edp Biotech Corporation | Methods and compositions for screening and detecting biomarkers |
| PL3137114T3 (pl) | 2014-04-30 | 2021-06-28 | Pfizer Inc. | Koniugaty przeciwciało anty-ptk7-lek |
| US9388239B2 (en) | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
| BR112016025312A2 (pt) | 2014-05-01 | 2017-10-17 | Genentech Inc | variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem |
| AU2015252805B2 (en) | 2014-05-02 | 2018-05-10 | Research Institute At Nationwide Children's Hospital | Compositions and methods for anti-LYST immunomodulation |
| AU2015254558B2 (en) | 2014-05-02 | 2021-02-25 | Medimmune Limited | Ion channel modulators and uses thereof |
| EP2942627A1 (en) | 2014-05-05 | 2015-11-11 | MicroBPlex, Inc. | Media elaborated with newly synthesized antibodies (mensa) from recently proliferated antibody secreting cells (asc) and uses thereof |
| MX2016014409A (es) | 2014-05-06 | 2017-01-20 | Genentech Inc | Produccion de proteinas heteromultimericas usando celulas de mamifero. |
| WO2015171723A1 (en) | 2014-05-06 | 2015-11-12 | Research Development Foundation | Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy |
| EA201691883A1 (ru) | 2014-05-07 | 2017-05-31 | Такеда Гмбх | Жидкая композиция, содержащая соединение, нейтрализующее gm-csf |
| GB201408255D0 (en) | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| CA2946606C (en) | 2014-05-13 | 2023-06-06 | Bavarian Nordic A/S | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist of tim-3 |
| FR3020947B1 (fr) | 2014-05-14 | 2018-08-31 | Adocia | Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations |
| US10058559B2 (en) | 2014-05-15 | 2018-08-28 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Treatment or prevention of an intestinal disease or disorder |
| JP6832709B2 (ja) | 2014-05-16 | 2021-02-24 | メディミューン，エルエルシー | 新生児Ｆｃ受容体結合が改変されて治療および診断特性が強化された分子 |
| US9903868B2 (en) | 2014-05-16 | 2018-02-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for the detection and quantitation of biomarkers |
| CA2949237C (en) | 2014-05-16 | 2022-08-23 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
| ES2841400T3 (es) | 2014-05-19 | 2021-07-08 | Pfizer | Compuestos sustituidos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol como agentes diana de ASGPR |
| EP3146081B1 (en) | 2014-05-19 | 2020-10-28 | The Johns Hopkins University | Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer |
| WO2015179236A1 (en) | 2014-05-21 | 2015-11-26 | Pfizer Inc. | Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer |
| CA2945822A1 (en) | 2014-05-21 | 2015-11-26 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer with anti bip or anti mica antibodies |
| RU2016150370A (ru) | 2014-05-22 | 2018-06-26 | Дженентек, Инк. | Антитела и иммуноконъюгаты против GPC3 |
| WO2015179654A1 (en) | 2014-05-22 | 2015-11-26 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti b7-h1 antibodies |
| KR20170005016A (ko) | 2014-05-23 | 2017-01-11 | 제넨테크, 인크. | MiT 바이오마커 및 그의 사용 방법 |
| US10695406B2 (en) | 2014-05-27 | 2020-06-30 | The University Of Queensland | Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent |
| CA2950415A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Anti-cd20 glycoantibodies and uses thereof |
| EP4116329A1 (en) | 2014-05-27 | 2023-01-11 | Academia Sinica | Anti-her2 glycoantibodies and uses thereof |
| CN106661562A (zh) | 2014-05-27 | 2017-05-10 | 中央研究院 | 得自类杆菌属的岩藻糖苷酶及其用途 |
| US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| KR102494193B1 (ko) | 2014-05-28 | 2023-01-31 | 아카데미아 시니카 | 항-ｔｎｆ-알파 글리코항체 및 이의 용도 |
| MA47849A (fr) | 2014-05-28 | 2020-01-29 | Agenus Inc | Anticorps anti-gitr et leurs procédés d'utilisation |
| TWI707872B (zh) | 2014-05-29 | 2020-10-21 | 美商宏觀基因股份有限公司 | 特異性結合多種癌症抗原的三特異性結合分子和其使用方法 |
| ES2905777T3 (es) | 2014-05-30 | 2022-04-12 | Shanghai Henlius Biotech Inc | Anticuerpos anti-receptor del factor de crecimiento epidérmico (EGFR) |
| WO2015186129A1 (en) | 2014-06-02 | 2015-12-10 | Technion Research & Development Foundation Limited. | Compositions and methods of selectively inhibiting irp1 and treating inflammation |
| WO2015187499A1 (en) | 2014-06-03 | 2015-12-10 | Gilead Sciences, Inc. | Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor |
| CA2947484C (en) | 2014-06-06 | 2023-05-09 | Redwood Bioscience, Inc. | Anti-her2 antibody-maytansine conjugates and methods of use thereof |
| DK3151921T3 (da) | 2014-06-06 | 2019-12-02 | Bristol Myers Squibb Co | Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf |
| WO2015191615A2 (en) | 2014-06-09 | 2015-12-17 | Biomed Valley Discoveries, Inc. | Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents |
| US10758613B2 (en) | 2014-06-09 | 2020-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Intstitutes Of Health | Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells |
| WO2015191590A2 (en) | 2014-06-09 | 2015-12-17 | Biomed Valley Discoveries, Inc. | Combination therapies targeting tumor-associated stroma or tumor cells and microtubules |
| US10758526B2 (en) | 2014-06-09 | 2020-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health | Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways |
| US10758614B2 (en) | 2014-06-09 | 2020-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health | Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase |
| AU2015275128C1 (en) | 2014-06-09 | 2020-02-13 | Kyowa Kirin Co., Ltd. | The effective and efficient control of serum phosphate for optimal bone formation |
| WO2015191596A1 (en) | 2014-06-09 | 2015-12-17 | Biomed Valley Discoveries, Inc. | Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells |
| AU2015274987A1 (en) | 2014-06-11 | 2016-11-24 | Gilead Sciences, Inc. | Methods for treating cardiovascular diseases |
| MX2016016310A (es) | 2014-06-11 | 2017-10-20 | A Green Kathy | Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral. |
| CN106459202A (zh) | 2014-06-11 | 2017-02-22 | 豪夫迈·罗氏有限公司 | 抗LgR5抗体及其用途 |
| US20230190750A1 (en) | 2014-06-13 | 2023-06-22 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
| EP2957571B1 (en) | 2014-06-17 | 2018-08-15 | Centre National De La Recherche Scientifique (Cnrs) | Monoclonal anti-pvhl antibodies and uses thereof |
| US20170129955A1 (en) | 2014-06-17 | 2017-05-11 | The Regents Of The University Of California | Alpha-v beta-8 antibodies |
| GB201411037D0 (en) | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
| MX2016016490A (es) | 2014-06-20 | 2017-07-28 | Bioalliance Cv | Conjugados de farmaco-anticuerpo anti-receptor de folato alfa (fra) y metodos de uso de los mismos. |
| US20170137505A1 (en) | 2014-06-20 | 2017-05-18 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
| SG11201610672YA (en) | 2014-06-23 | 2017-01-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| WO2015198320A1 (en) | 2014-06-24 | 2015-12-30 | Insight Biopharmaceuticals Ltd. | Methods of purifying antibodies |
| WO2015199976A1 (en) | 2014-06-24 | 2015-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Target activated microdissection |
| EP3161001A2 (en) | 2014-06-25 | 2017-05-03 | Novartis AG | Antibodies specific for il-17a fused to hyaluronan binding peptide tags |
| WO2015198243A2 (en) | 2014-06-25 | 2015-12-30 | Novartis Ag | Compositions and methods for long acting proteins |
| WO2015198240A2 (en) | 2014-06-25 | 2015-12-30 | Novartis Ag | Compositions and methods for long acting proteins |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| TW201628647A (zh) | 2014-06-27 | 2016-08-16 | 賽諾菲公司 | 抗－ｉｌ４－ｉｌ１３雙特異性抗體 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| TW201623329A (zh) | 2014-06-30 | 2016-07-01 | 亞佛瑞司股份有限公司 | 針對骨調素截斷變異體的疫苗及單株抗體暨其用途 |
| WO2016001830A1 (en) | 2014-07-01 | 2016-01-07 | Friedrich Miescher Institute For Biomedical Research | Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma |
| BR112016030740A2 (pt) | 2014-07-01 | 2018-02-20 | Pfizer Inc. | diacorpos heterodiméricos biespecíficos e seus usos |
| CN114306605A (zh) | 2014-07-03 | 2022-04-12 | 耶鲁大学 | Dickkopf2(Dkk2)抑制作用抑制肿瘤形成 |
| WO2016004383A1 (en) | 2014-07-03 | 2016-01-07 | City Of Hope | Tumor-selective ctla-4 antagonists |
| ES2763526T3 (es) | 2014-07-03 | 2020-05-29 | Hoffmann La Roche | Sistemas de expresión de polipéptidos |
| KR20170026624A (ko) * | 2014-07-07 | 2017-03-08 | 알러간, 인코포레이티드 | 조직 샘플에서 절단된 snap25를 검출하는 방법 |
| US20160000791A1 (en) | 2014-07-07 | 2016-01-07 | Mayo Foundation For Medical Education And Research | Par1 modulation to alter myelination |
| EP3777535A1 (en) | 2014-07-09 | 2021-02-17 | F. Hoffmann-La Roche AG | Ph adjustment to improve thaw recovery of cell banks |
| CN106604933B (zh) | 2014-07-11 | 2021-08-10 | 文塔纳医疗系统公司 | 抗pd-l1抗体及其诊断用途 |
| CN106460067A (zh) | 2014-07-14 | 2017-02-22 | 豪夫迈·罗氏有限公司 | 诊断方法和用于治疗成胶质细胞瘤的组合物 |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| EP3169343B1 (en) | 2014-07-15 | 2020-03-25 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Isolated polypeptides of cd44 and uses thereof |
| KR20170026630A (ko) | 2014-07-15 | 2017-03-08 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 mek 저해제를 사용하는 암의 치료용 조성물 |
| US20170227541A1 (en) | 2014-07-17 | 2017-08-10 | The Trustees Of The University Of Pennsylvania | Methods for using exosomes to monitor transplanted organ status |
| SG11201700250WA (en) | 2014-07-17 | 2017-02-27 | Novo Nordisk As | Site directed mutagenesis of trem-1 antibodies for decreasing viscosity |
| BR112017001242A2 (pt) | 2014-07-21 | 2017-12-05 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico a cd33 |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| MX2017001011A (es) | 2014-07-21 | 2018-05-28 | Novartis Ag | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. |
| EP3172233B1 (en) | 2014-07-22 | 2019-09-11 | Sutro Biopharma, Inc. | Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies |
| EP3172238B1 (en) | 2014-07-23 | 2020-09-23 | Ohio State Innovation Foundation | Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (tag-72) |
| US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
| EP3172339A1 (en) | 2014-07-24 | 2017-05-31 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
| WO2018140026A1 (en) | 2017-01-27 | 2018-08-02 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
| WO2016012623A1 (en) | 2014-07-25 | 2016-01-28 | Theravectys | Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule |
| US20170348402A1 (en) | 2014-07-30 | 2017-12-07 | The Research Foundation For The State University Of New York | System and method for delivering genetic material or protein to cells |
| UY36245A (es) | 2014-07-31 | 2016-01-29 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
| AU2015298263B2 (en) | 2014-07-31 | 2020-05-14 | Anji Pharmaceuticals, Inc. | ApoE mimetic peptides and higher potency to clear plasma cholesterol |
| US20170209492A1 (en) | 2014-07-31 | 2017-07-27 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
| TW201609812A (zh) | 2014-07-31 | 2016-03-16 | 安美基研究（慕尼黑）公司 | 最佳化之跨物種特異性雙特異性單鏈抗體構築體 |
| CA2952540C (en) | 2014-07-31 | 2022-06-21 | Amgen Research (Munich) Gmbh | Bispecific single chain antibody construct with enhanced tissue distribution |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| CN107002087B (zh) | 2014-08-01 | 2021-09-28 | 约翰·霍普金斯大学 | 检测假性过敏药物反应和鉴别阻断剂以预防不良反应的基于mrgprx2/mrgprb2表达细胞的试验 |
| US10426735B2 (en) | 2014-08-01 | 2019-10-01 | Massachusetts Institute Of Technology | Modified alginates for anti-fibrotic materials and applications |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| US10072097B2 (en) | 2014-08-04 | 2018-09-11 | Academia Sinica | Compositions and methods for detection of protein S-nitrosylation and oxidation |
| US9982052B2 (en) | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| ES2847311T3 (es) | 2014-08-05 | 2021-08-02 | MabQuest SA | Reactivos inmunológicos que se unen a PD-1 |
| GB201413913D0 (en) | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| TW201613977A (en) | 2014-08-07 | 2016-04-16 | Novartis Ag | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use |
| DK3177642T3 (da) | 2014-08-07 | 2022-02-21 | Novartis Ag | Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf |
| EP3177321B1 (en) | 2014-08-08 | 2020-11-25 | Oncoquest Pharmaceuticals Inc. | Tumor antigen specific antibodies and tlr3 stimulation to enhance the performance of checkpoint interference therapy of cancer |
| IL279606B (en) | 2014-08-08 | 2022-08-01 | Alector Llc | Anti-trem2 antibodies and methods of using them |
| CN111388672A (zh) | 2014-08-08 | 2020-07-10 | 美国政府(由卫生和人类服务部的部长所代表) | 在体内和在体外的靶标的光控移除 |
| US10457721B2 (en) | 2014-08-11 | 2019-10-29 | University Of Massachusetts | Anti-OSPA antibodies and methods of use |
| US20170216403A1 (en) | 2014-08-12 | 2017-08-03 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
| US10278986B2 (en) | 2014-08-14 | 2019-05-07 | The Regents Of The University Of Colorado, A Body Corporate | Antibody-siRNA conjugates and uses therefor |
| CA2958200A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using a gfr alpha-4 chimeric antigen receptor |
| IL250583B (en) | 2014-08-19 | 2022-07-01 | Merck Sharp & Dohme | Anti-tigit antibodies |
| BR112017003104A2 (pt) | 2014-08-19 | 2017-12-05 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico anti-cd123 |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| US20170362304A1 (en) * | 2014-08-20 | 2017-12-21 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring viscosity of protein solution |
| EP3183002B1 (en) | 2014-08-21 | 2021-03-03 | Walter Reed Army Institute of Research | Monoclonal antibodies for treatment of microbial infections |
| WO2016026143A1 (en) | 2014-08-22 | 2016-02-25 | Huiru Wang | Saccharide-based biomarkers and therapeutics |
| WO2016026978A1 (en) | 2014-08-22 | 2016-02-25 | Universite Nice Sophia Antipolis | Methods and pharmaceutical compositions for treating drug addiction |
| EP3186393A4 (en) | 2014-08-25 | 2018-01-10 | The Johns Hopkins University | Methods and compositions related to prostate cancer therapeutics |
| WO2016032927A1 (en) | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| WO2016030488A1 (en) | 2014-08-27 | 2016-03-03 | Innate Pharma | Treatment of celiac disease |
| BR112017003835A2 (pt) | 2014-08-28 | 2018-04-10 | Bioatla Llc | receptor de antígeno quimérico, vetor de expressão, célula citotóxica engenheirada geneticamente, composição farmacêutica, e, métodos para produção de um receptor de antígeno quimérico e para tratamento de uma doença em um indivíduo. |
| PT3186281T (pt) | 2014-08-28 | 2019-07-10 | Halozyme Inc | Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica |
| PT3185908T (pt) | 2014-08-28 | 2020-06-18 | Rinat Neuroscience Corp | Ligantes de modulação de estabilidade para utilização com conjugados de anticorpo e fármaco |
| TW201617368A (zh) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
| US10526416B2 (en) | 2014-09-08 | 2020-01-07 | Yeda Research And Development Co. Ltd. | Anti-HER3 antibodies and uses of same |
| EP3191523B1 (en) | 2014-09-08 | 2019-08-07 | Yeda Research and Development Co., Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
| WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| CN113698485A (zh) | 2014-09-12 | 2021-11-26 | 基因泰克公司 | 抗-b7-h4抗体及免疫缀合物 |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| WO2016040767A2 (en) | 2014-09-12 | 2016-03-17 | Amgen Inc. | Chrdl-1 epitopes and antibodies |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| TW201625690A (zh) | 2014-09-12 | 2016-07-16 | 建南德克公司 | 抗－ｃｌｌ－１抗體及免疫結合物 |
| WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
| CA2957354A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| WO2016040882A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of egfr inhibitors |
| IL234638A0 (en) | 2014-09-14 | 2014-12-02 | Yeda Res & Dev | NMDA receptor antagonists for the treatment of Gaucher disease |
| CN106794247B (zh) | 2014-09-15 | 2022-12-02 | 豪夫迈·罗氏有限公司 | 抗体配制剂 |
| CA2944085C (en) | 2014-09-16 | 2018-04-10 | Ease Charm Limited | Anti-egfr antibody and uses of same |
| WO2016043577A1 (en) | 2014-09-16 | 2016-03-24 | Academisch Medisch Centrum | Ig-like molecules binding to bmp4 |
| CN114621969A (zh) | 2014-09-17 | 2022-06-14 | 诺华股份有限公司 | 用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞 |
| EP3194421B1 (en) | 2014-09-17 | 2021-11-03 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| BR112017004953A2 (pt) | 2014-09-17 | 2017-12-05 | Genentech Inc | imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| US10080790B2 (en) | 2014-09-19 | 2018-09-25 | The Regents Of The University Of Michigan | Staphylococcus aureus materials and methods |
| WO2016049036A1 (en) | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| EP3197557A1 (en) | 2014-09-24 | 2017-08-02 | Friedrich Miescher Institute for Biomedical Research | Lats and breast cancer |
| PL3197493T3 (pl) | 2014-09-25 | 2021-08-23 | Aveo Pharmaceuticals Inc. | Sposoby odwracania kacheksji i przedłużania przeżycia obejmujące podanie modulatora gdf15 i środka przeciwnowotworowego |
| AP2017009823A0 (en) | 2014-09-26 | 2017-03-31 | Macrogenics Inc | Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| AU2015323860B2 (en) | 2014-09-29 | 2021-05-27 | Duke University | Bispecific molecules comprising an HIV-1 envelope targeting arm |
| JP6875275B2 (ja) | 2014-09-30 | 2021-05-19 | ドイチェス クレブスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェンレヒツ | Ｌ１ｃａｍ（ｃｄ１７）と結合する抗体などの結合分子 |
| US20170211053A1 (en) | 2014-09-30 | 2017-07-27 | Danisco Us Inc. | Compositions comprising beta mannanase and methods of use |
| US20170233707A1 (en) | 2014-09-30 | 2017-08-17 | Danisco Us Inc | Compositions comprising beta-mannanase and methods of use |
| WO2016054176A1 (en) | 2014-09-30 | 2016-04-07 | Danisco Us Inc | Compositions comprising beta-mannanase and methods of use |
| EP3201330A1 (en) | 2014-09-30 | 2017-08-09 | Danisco US Inc. | Compositions comprising beta mannanase and methods of use |
| EP3200804A4 (en) | 2014-10-01 | 2018-04-18 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| US10365280B2 (en) | 2014-10-02 | 2019-07-30 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating malignancies |
| CN107106687A (zh) | 2014-10-03 | 2017-08-29 | 诺华股份有限公司 | 组合治疗 |
| CN114634571A (zh) | 2014-10-06 | 2022-06-17 | 达纳－法伯癌症研究所公司 | 人源化cc趋化因子受体4 (ccr4)抗体及其使用方法 |
| US20170248603A1 (en) | 2014-10-06 | 2017-08-31 | Dana-Farber Cancer Institute, Inc. | Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response |
| US9921230B2 (en) | 2014-10-08 | 2018-03-20 | Rhode Island Hospital | Methods for diagnosis and treatment of concussion or brain injury |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| CA2963602A1 (en) | 2014-10-09 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Multiple-variable il-2 dose regimen for treating immune disorders |
| ES2850325T3 (es) | 2014-10-09 | 2021-08-27 | Engmab Sarl | Anticuerpos biespecíficos contra CD3epsilon y ROR1 |
| CR20170143A (es) | 2014-10-14 | 2017-06-19 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| EP3722433B1 (en) | 2014-10-15 | 2023-07-26 | Amgen Inc. | Promoter and regulatory elements for improved expression of heterologous genes in host cells |
| JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック， インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
| EP3207061A1 (en) | 2014-10-18 | 2017-08-23 | Pfizer Inc | Anti-il-7r antibody compositions |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
| US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
| EP3209697A4 (en) | 2014-10-23 | 2018-05-30 | La Trobe University | Fn14-binding proteins and uses thereof |
| US10870704B2 (en) | 2014-10-23 | 2020-12-22 | Kira Biotech Pty Limited | CD83 binding proteins and uses thereof |
| US20180295858A1 (en) | 2014-10-24 | 2018-10-18 | Dupont Nutrition Biosciences Aps | Method |
| BR112017007949A2 (pt) | 2014-10-24 | 2018-01-23 | Danisco Us Inc | método para produção de álcool pelo uso de uma tripeptidil-peptidase |
| WO2016065329A1 (en) | 2014-10-24 | 2016-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance |
| GB201419108D0 (en) | 2014-10-27 | 2014-12-10 | Glythera Ltd | Materials and methods relating to linkers for use in antibody drug conjugates |
| SG11201702723VA (en) | 2014-10-29 | 2017-05-30 | Five Prime Therapeutics Inc | Combination therapy for cancer |
| JP2017537893A (ja) | 2014-10-31 | 2017-12-21 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | 抗ｃｓ１抗体および抗体薬結合体 |
| EP3217989B1 (en) | 2014-10-31 | 2022-01-05 | The Trustees of the University of Pennsylvania | Compositions and methods of stimulating and expanding t cells |
| EP3015475A1 (en) | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
| EP4219725A3 (en) | 2014-10-31 | 2023-08-30 | The Trustees of the University of Pennsylvania | Altering gene expression in modified t cells and uses thereof |
| WO2016073401A1 (en) | 2014-11-03 | 2016-05-12 | Bristol-Myers Squibb Company | Use of caprylic acid precipitation for protein purification |
| KR20170074246A (ko) | 2014-11-03 | 2017-06-29 | 제넨테크, 인크. | Ox40 효능제 치료의 효능 예측 및 평가용 방법 및 바이오마커 |
| CN106796235B (zh) | 2014-11-03 | 2021-01-29 | 豪夫迈·罗氏有限公司 | 用于检测t细胞免疫子集的测定法及其使用方法 |
| WO2016073184A1 (en) | 2014-11-04 | 2016-05-12 | Dana Farber Cancer Institute, Inc. | Compositions and methods for treating multiple myeloma |
| CN107110851B (zh) | 2014-11-05 | 2019-10-22 | 纳迈达斯生物科技中心 | 用于增强成像的金属复合物 |
| ES2819256T3 (es) | 2014-11-05 | 2021-04-15 | Genentech Inc | Métodos para producir proteínas bicatenarias en bacterias |
| CA2966558C (en) | 2014-11-05 | 2024-03-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
| KR102626877B1 (ko) | 2014-11-05 | 2024-01-19 | 애넥슨, 인코포레이티드 | 인간화 항-보체 인자 c1q 항체 및 이의 용도 |
| CA2961439A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
| KR20170076697A (ko) | 2014-11-06 | 2017-07-04 | 에프. 호프만-라 로슈 아게 | 개질된 FCRN-결합 특성 및 단백질 A-결합 특성을 가진 Fc-영역 변이체 |
| UA122673C2 (uk) | 2014-11-07 | 2020-12-28 | Елевен Байотерапьютікс, Інк. | Антитіло, що специфічно зв'язується з людським il-6 |
| WO2016075099A1 (en) | 2014-11-10 | 2016-05-19 | Medimmune Limited | Binding molecules specific for cd73 and uses thereof |
| EP3217787B1 (en) | 2014-11-10 | 2019-04-17 | F.Hoffmann-La Roche Ag | Animal model for nephropathy and agents for treating the same |
| JP6929771B2 (ja) | 2014-11-10 | 2021-09-01 | ジェネンテック， インコーポレイテッド | 抗インターロイキン−３３抗体及びその使用 |
| GB2538120A (en) | 2014-11-11 | 2016-11-09 | Medimmune Ltd | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof |
| CA2966905A1 (en) | 2014-11-12 | 2016-05-19 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| DK3218005T3 (da) | 2014-11-12 | 2023-03-27 | Seagen Inc | Glycan-interagerende forbindelser og anvendelsesfremgangsmåder |
| US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| WO2016081455A1 (en) | 2014-11-17 | 2016-05-26 | Pelican Therapeutics, Inc. | Human tnfrsf25 antibody |
| AU2015350242A1 (en) | 2014-11-17 | 2017-06-29 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
| US20180042994A1 (en) | 2014-11-17 | 2018-02-15 | Yeda Research And Development Co. Ltd. | Methods of treating diseases related to mitochondrial function |
| AU2015350190B2 (en) | 2014-11-18 | 2021-08-05 | Janssen Pharmaceutica Nv | CD47 antibodies, methods, and uses |
| US10882920B2 (en) | 2014-11-19 | 2021-01-05 | Genentech, Inc. | Antibodies against BACE1 and use thereof for neural disease immunotherapy |
| BR112017010498A2 (pt) | 2014-11-19 | 2017-12-26 | Axon Neuroscience Se | anticorpos tau humanizados em doença de alzheimer |
| CN107257805A (zh) | 2014-11-19 | 2017-10-17 | 雀巢产品技术援助有限公司 | 抗血清素、色氨酸和犬尿氨酸代谢产物的抗体及其用途 |
| CN107250158B (zh) | 2014-11-19 | 2022-03-25 | 基因泰克公司 | 抗转铁蛋白受体/抗bace1多特异性抗体和使用方法 |
| MY192999A (en) | 2014-11-20 | 2022-09-20 | Hoffmann La Roche | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| WO2016081808A1 (en) | 2014-11-20 | 2016-05-26 | The Regents Of The University Of California | Compositions and methods related to hematologic recovery |
| RU2727015C2 (ru) | 2014-11-21 | 2020-07-17 | Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл | Векторы aav, нацеленные на центральную нервную систему |
| WO2016080510A1 (ja) | 2014-11-21 | 2016-05-26 | アステラス製薬株式会社 | 新規二重特異的抗体フォーマット |
| ME03806B (me) | 2014-11-21 | 2021-04-20 | Bristol Myers Squibb Co | Antitela protiv cd73 i njihova upotreba |
| GB201420852D0 (en) | 2014-11-24 | 2015-01-07 | Genevillage Kft | Method |
| JP6701217B2 (ja) | 2014-11-25 | 2020-05-27 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 生物学的製剤の１８ｆ−放射性標識方法および組成物 |
| EP3224276B1 (en) | 2014-11-25 | 2020-06-17 | Technion Research & Development Foundation Limited | Novel epitope as a target for therapy of inflammatory autoimmune diseases and graft rejection |
| US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| JP2017537105A (ja) | 2014-11-26 | 2017-12-14 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 瘻孔を伴うクローン病の治療用ベドリズマブ |
| KR101760467B1 (ko) | 2014-12-01 | 2017-07-24 | 중앙대학교 산학협력단 | 수태능력 관련 단백질 마커를 이용한 동물의 산자수 예측 방법과 클로르테트라사이클린 염색법을 이용한 동물의 정액 품질 및 산자수의 예측 방법 |
| WO2016087514A1 (en) | 2014-12-02 | 2016-06-09 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| WO2016087889A1 (en) | 2014-12-03 | 2016-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions using orexins (oxa, oxb) for the treatment of prostate cancers |
| JP6721590B2 (ja) | 2014-12-03 | 2020-07-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 多重特異性抗体 |
| CA2969730A1 (en) | 2014-12-05 | 2016-06-09 | Immunext, Inc. | Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators |
| EP3227328B1 (en) | 2014-12-05 | 2022-10-05 | Merck Patent GmbH | Domain-exchanged antibody |
| CR20170230A (es) | 2014-12-05 | 2017-11-07 | Genentech Inc | Anticuerpos anti-cd79b y métodos de uso |
| WO2016094273A1 (en) | 2014-12-08 | 2016-06-16 | Dana-Farber Cancer Institute, Inc. | Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents |
| EP3031822A1 (en) | 2014-12-08 | 2016-06-15 | Novartis AG | Cytomegalovirus antigens |
| EP4242329A3 (en) | 2014-12-08 | 2023-10-25 | Berg LLC | Use of markers including filamin a in the diagnosis and treatment of prostate cancer |
| WO2016094505A1 (en) | 2014-12-09 | 2016-06-16 | Abbvie Inc. | Antibody drug conjugates with cell permeable bcl-xl inhibitors |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| CA2970155A1 (en) | 2014-12-09 | 2016-06-16 | Abbvie Inc. | Bcl-xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same |
| BR112017011234A2 (pt) | 2014-12-10 | 2018-03-27 | Genentech Inc | anticorpos contra receptor da barreira hematoencefálica e métodos de uso |
| CA2970352A1 (en) | 2014-12-11 | 2016-06-16 | Pierre Fabre Medicament | Anti-c10orf54 antibodies and uses thereof |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| KR20170093182A (ko) | 2014-12-11 | 2017-08-14 | 인바이오모션 에스.엘. | 인간 c-maf에 대한 결합 구성원 |
| EP3230736B1 (en) | 2014-12-12 | 2020-03-11 | Celcuity Inc. | Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients |
| CN107635586B (zh) | 2014-12-15 | 2021-09-24 | 拜耳医药股份有限公司 | Ksp抑制剂与无糖基化抗-tweakr抗体的抗体-药物缀合物(adc) |
| EP3234119A1 (en) | 2014-12-18 | 2017-10-25 | Danisco US Inc. | Engineered multifunctional enzymes and methods of use |
| HUE056489T2 (hu) | 2014-12-19 | 2022-02-28 | Chugai Pharmaceutical Co Ltd | Anti-C5 antitestek és alkalmazási eljárások |
| US10047157B2 (en) | 2014-12-19 | 2018-08-14 | Alder Biopharmaceuticals, Inc. | Humanized anti-ACTH antibodies and use thereof |
| UY36449A (es) | 2014-12-19 | 2016-07-29 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a bmp6 |
| EP3233120A4 (en) | 2014-12-19 | 2018-05-30 | Monash University | Il-21 antibodies |
| DK3234599T3 (da) | 2014-12-19 | 2020-05-04 | Inst Nat Sante Rech Med | Fremgangsmåder til forudsigelse af transplantatforandringer |
| EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
| CA2969341C (en) | 2014-12-22 | 2023-07-04 | Five Prime Therapeutics, Inc. | Anti-csf1r antibodies for treating pvns |
| DK3237446T3 (en) | 2014-12-22 | 2021-07-26 | Pd 1 Acquisition Group Llc | Anti-PD-1-antistoffer |
| EP3789039A1 (en) | 2014-12-22 | 2021-03-10 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
| AR103172A1 (es) | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
| RS56854B1 (sr) | 2014-12-23 | 2018-04-30 | 4D Pharma Res Ltd | Soj bacteroides thetaiotaomicron i njegova upotreba u smanjenju inflamacije |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| EP3237000A1 (en) | 2014-12-23 | 2017-11-01 | Pfizer Inc | Stable aqueous antibody formulation for anti tnf alpha antibodies |
| CN113813386A (zh) | 2014-12-31 | 2021-12-21 | 查克美特制药公司 | 组合肿瘤免疫疗法 |
| WO2016111947A2 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| EP3242893A1 (en) | 2015-01-08 | 2017-11-15 | Biogen MA Inc. | Lingo-1 antagonists and uses for treatment of demyelinating disorders |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| EP3244911B1 (en) | 2015-01-12 | 2019-10-23 | Rigshospitalet, Copenhagen University Hospital | A method for determining a likely effect of a treatment to improve male infertility |
| WO2016115275A1 (en) | 2015-01-13 | 2016-07-21 | City Of Hope | Ctla4-binding protein peptide-linker masks |
| CA2973978A1 (en) | 2015-01-14 | 2016-07-21 | The Brigham And Women's Hospital, Inc. | Treatment of cancer with anti-lap monoclonal antibodies |
| EP3244924B1 (en) | 2015-01-15 | 2021-04-07 | Oncoquest Pharmaceuticals Inc. | Methods of increasing delivery of anti-cancer agents to targets |
| US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
| EP3048114A1 (en) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| NZ734803A (en) | 2015-01-23 | 2023-03-31 | Sanofi Sa | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
| EP3047856A1 (en) | 2015-01-23 | 2016-07-27 | Novartis AG | Cmv antigens and uses thereof |
| KR20170104617A (ko) | 2015-01-24 | 2017-09-15 | 아카데미아 시니카 | 신규한 글리칸 콘주게이트 및 이를 사용하는 방법 |
| EP3248013B1 (en) | 2015-01-24 | 2020-07-15 | Academia Sinica | Cancer markers and methods of use thereof |
| SG11201706024YA (en) | 2015-01-26 | 2017-08-30 | Macrogenics Inc | Multivalent molecules comprising dr5-binding domains |
| EP3250184A1 (en) | 2015-01-27 | 2017-12-06 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
| WO2016120753A1 (en) | 2015-01-28 | 2016-08-04 | Pfizer Inc. | Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation |
| CN107407677B (zh) | 2015-01-28 | 2020-07-17 | 豪夫迈·罗氏有限公司 | 多发性硬化的基因表达标志和治疗 |
| US10654917B2 (en) | 2015-01-29 | 2020-05-19 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders |
| AU2016211176B2 (en) | 2015-01-30 | 2021-01-28 | Academia Sinica; | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| US10539572B2 (en) | 2015-01-30 | 2020-01-21 | Salk Institute For Biological Studies | Compositions and methods for treating age-related diabetes and related disorders |
| ES2947589T3 (es) | 2015-01-31 | 2023-08-11 | Univ Pennsylvania | Composiciones y métodos para el suministro de moléculas terapéuticas a linfocitos T |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| CN104593416A (zh) * | 2015-02-02 | 2015-05-06 | 上海交通大学 | pHAb-FAST人源抗体表达载体系统及其使用方法 |
| WO2016124558A1 (en) | 2015-02-03 | 2016-08-11 | Ventana Medical Systems, Inc. | Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1) |
| WO2016125017A1 (en) | 2015-02-03 | 2016-08-11 | Universite Catholique De Louvain | Anti-garp protein and uses thereof |
| US20160222102A1 (en) | 2015-02-04 | 2016-08-04 | Boehringer Ingelheim International Gmbh | Methods of treating inflammatory diseases |
| JP2018512597A (ja) | 2015-02-04 | 2018-05-17 | ジェネンテック， インコーポレイテッド | 突然変異体スムースンド及びその使用方法 |
| EP3253778A1 (en) | 2015-02-05 | 2017-12-13 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| US10266584B2 (en) | 2015-02-09 | 2019-04-23 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies specific to glycoprotein (GP) of Ebolavirus and uses for the treatment and diagnosis of ebola virus infection |
| CA2976236A1 (en) | 2015-02-09 | 2016-08-18 | Research Development Foundation | Engineered immunoglobulin fc polypeptides displaying improved complement activation |
| CN105461809B (zh) | 2015-02-11 | 2018-10-12 | 康融东方（广东）医药有限公司 | Pcsk9抗体、其药物组合物及其用途 |
| EP3256148A1 (en) | 2015-02-12 | 2017-12-20 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
| JP6987638B2 (ja) | 2015-02-17 | 2022-01-05 | エックスフォー・ファーマシューティカルズ（オーストリア）ゲーエムべーハー | クレブシエラ・ニューモニエのガラクタンベースのｏ抗原をターゲティングする抗体 |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| EP3865139B1 (en) | 2015-02-18 | 2023-05-03 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US10888611B2 (en) | 2015-02-19 | 2021-01-12 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| EP3261670A4 (en) | 2015-02-24 | 2018-08-01 | Rpeptide, LLC | Anti-tau antibodies |
| CA2977499C (en) | 2015-02-25 | 2023-10-03 | Vanderbilt University | Antibody-mediated neutralization of marburg virus |
| CA2977607A1 (en) | 2015-02-26 | 2016-09-01 | Jacob Schneiderman | Methods and compositions relating to leptin antagonists |
| SG10201810615VA (en) | 2015-02-26 | 2019-01-30 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| EP3262072A1 (en) | 2015-02-26 | 2018-01-03 | F. Hoffmann-La Roche AG | Integrin beta7 antagonists and methods of treating crohn's disease |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| KR101892883B1 (ko) | 2015-02-27 | 2018-10-05 | 추가이 세이야쿠 가부시키가이샤 | Il-6 관련 질환 치료용 조성물 |
| EP3265491A1 (en) | 2015-03-03 | 2018-01-10 | Xoma (Us) Llc | Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery |
| WO2016140799A1 (en) | 2015-03-03 | 2016-09-09 | Ark Diagnostics, Inc. | Pregabalin immunoassays |
| FI3265123T3 (fi) | 2015-03-03 | 2023-01-31 | Vasta-aineita, käyttöjä & menetelmiä | |
| KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| KR20170122810A (ko) | 2015-03-04 | 2017-11-06 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합 |
| EP3265474A1 (en) | 2015-03-05 | 2018-01-10 | Sirenas LLC | Cyclic peptide analogs and conjugates thereof |
| BR112017018468A2 (pt) | 2015-03-06 | 2018-04-17 | Csl Behring Recombinant Facility Ag | fator de von willebrand modificado com meia-vida aumentada |
| MA41636A (fr) | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
| JP6369922B2 (ja) | 2015-03-06 | 2018-08-08 | 公立大学法人横浜市立大学 | 新規抗ｐａｄ４抗体 |
| US10073098B2 (en) | 2015-03-06 | 2018-09-11 | Genentech, Inc. | Ultrapurified DsbA and DsbC and methods of making and using the same |
| EP3265825A4 (en) | 2015-03-06 | 2018-08-08 | Dana-Farber Cancer Institute, Inc. | Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers |
| GB201503967D0 (en) | 2015-03-09 | 2015-04-22 | Univ Glasgow | Biocompatible implants for use in tendon therapy |
| WO2016145258A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| WO2016142385A1 (en) | 2015-03-11 | 2016-09-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for diagnosing ocular anterior chamber dysgenesis |
| EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
| KR102490956B1 (ko) | 2015-03-13 | 2023-01-19 | 브리스톨-마이어스 스큅 컴퍼니 | 불순물을 제거하기 위한 크로마토그래피 동안의 알칼리성 세척의 용도 |
| KR20170127011A (ko) | 2015-03-16 | 2017-11-20 | 제넨테크, 인크. | Il-13을 검출 및 정량화하는 방법 및 th2-연관 질환의 진단 및 치료에서의 용도 |
| EP4190817A1 (en) | 2015-03-17 | 2023-06-07 | Memorial Sloan Kettering Cancer Center | Anti-muc16 antibodies and uses thereof |
| US10722592B2 (en) | 2015-03-18 | 2020-07-28 | Seattle Genetics, Inc. | CD48 antibodies and conjugates thereof |
| EP3271401A4 (en) | 2015-03-18 | 2018-11-21 | Immunobiochem Corporation | Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens |
| IL237852A0 (en) | 2015-03-19 | 2016-03-24 | Yeda Res & Dev | Antibodies against amphigoline, medical preparations containing them and their use |
| WO2016153983A1 (en) | 2015-03-20 | 2016-09-29 | Bristol-Myers Squibb Company | Use of dextran for protein purification |
| US20180105554A1 (en) | 2015-03-20 | 2018-04-19 | Bristol-Myers Squibb Company | Use of dextran sulfate to enhance protein a affinity chromatography |
| AU2016238551B2 (en) | 2015-03-20 | 2020-01-02 | Pfizer Inc. | Bifunctional cytotoxic agents containing the CTI pharmacophore |
| WO2016154177A2 (en) | 2015-03-23 | 2016-09-29 | Jounce Therapeutics, Inc. | Antibodies to icos |
| US20180087087A1 (en) | 2015-03-25 | 2018-03-29 | Alexion Pharmaceuticals, Inc. | A method for measuring the protease activity of c3 and c5 convertase of the alternative complement pathway |
| EP3274724A1 (en) | 2015-03-25 | 2018-01-31 | Alexion Pharmaceuticals, Inc. | A method for measuring the protease activity of factor d of the alternative complement pathway |
| US20180064748A1 (en) | 2015-03-27 | 2018-03-08 | Yeda Research And Development Co. Ltd. | Methods of treating motor neuron diseases |
| EP3277712A4 (en) | 2015-03-30 | 2018-09-26 | City of Hope | Mechanically interlocking complexes |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| WO2016157195A1 (en) | 2015-04-01 | 2016-10-06 | Hadasit Medical Research Services And Development Ltd. | Inhibitors of neuroligin 4 - neurexin 1-beta protein-protein interaction for treatment of liver disorders |
| PT3277722T (pt) | 2015-04-02 | 2021-10-06 | Intervet Int Bv | Anticorpos para recetor alfa da interleucina-4 canina |
| KR20170134525A (ko) | 2015-04-02 | 2017-12-06 | 메모리얼 슬로안-케터링 캔서 센터 | Tnfrsf14 / hvem 단백질 및 이의 이용 방법 |
| US11279768B1 (en) | 2015-04-03 | 2022-03-22 | Precision Biologics, Inc. | Anti-cancer antibodies, combination therapies, and uses thereof |
| RU2021124437A (ru) | 2015-04-03 | 2021-09-29 | Еурека Терапьютикс, Инк. | Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования |
| EP3770171A1 (en) | 2015-04-03 | 2021-01-27 | XOMA Technology Ltd. | Treatment of cancer using inhibitors of tgf-beta and pd-1 |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| LT3280440T (lt) | 2015-04-06 | 2023-02-27 | Bioverativ Usa Inc. | Humanizuoti antikūnai prieš c1s ir jų panaudojimo būdai |
| KR20180026370A (ko) | 2015-04-06 | 2018-03-12 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 비-골수제거적 컨디셔닝을 위한 조성물 및 방법 |
| EP3280435B1 (en) | 2015-04-06 | 2021-06-02 | Acceleron Pharma Inc. | Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof |
| JP6999421B2 (ja) | 2015-04-07 | 2022-02-04 | アレクトル エルエルシー | 抗ソルチリン抗体及びその使用方法 |
| WO2016162368A1 (en) | 2015-04-07 | 2016-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Non-invasive imaging of tumor pd-l1 expression |
| WO2016164608A1 (en) | 2015-04-07 | 2016-10-13 | Alector Llc | Methods of screening for sortilin binding antagonists |
| PL3280401T3 (pl) | 2015-04-07 | 2022-02-14 | Ela Pharma Ltd | Kompozycje do leczenia i/lub zapobiegania martwicy komórek lub tkanek specjalnie ukierunkowane na katepsynę C i/lub CELA1 i/lub CELA3A i/lub strukturalnie związane z nimi enzymy |
| CA2981183A1 (en) | 2015-04-07 | 2016-10-13 | Greg Lazar | Antigen binding complex having agonistic activity and methods of use |
| CA2981969C (en) | 2015-04-08 | 2023-12-05 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
| CN114958764A (zh) | 2015-04-08 | 2022-08-30 | 诺华股份有限公司 | Cd20疗法、cd22疗法和与cd19嵌合抗原受体（car）表达细胞的联合疗法 |
| WO2016164815A1 (en) | 2015-04-10 | 2016-10-13 | Applied Proteomics, Inc. | Protein biomarker panels for detecting colorectal cancer and advanced adenoma |
| WO2016166629A1 (en) | 2015-04-13 | 2016-10-20 | Pfizer Inc. | Therapeutic antibodies and their uses |
| US10851176B2 (en) | 2015-04-13 | 2020-12-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods of administering neutralizing anti-protease nexin-1 antibodies to treat hemophilia A |
| CA2925589A1 (en) | 2015-04-13 | 2016-10-13 | Pfizer Inc. | Chimeric antigen receptors targeting b-cell maturation antigen |
| WO2016168149A1 (en) | 2015-04-13 | 2016-10-20 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| EP3283109A1 (en) | 2015-04-14 | 2018-02-21 | Boehringer Ingelheim International GmbH | Methods of treating diseases |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| ES2945313T3 (es) | 2015-04-17 | 2023-06-30 | Amgen Res Munich Gmbh | Construcciones de anticuerpos biespecificos para CDH3 y CD3 |
| CA2978855A1 (en) | 2015-04-17 | 2016-10-20 | Arsanis Biosciences Gmbh | Anti-staphylococcus aureus antibody combination preparation |
| EP3839510A3 (en) | 2015-04-17 | 2021-08-25 | Merck Sharp & Dohme Corp. | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists |
| MX2017013383A (es) | 2015-04-20 | 2017-12-07 | Tolero Pharmaceuticals Inc | Prediccion de respuesta a alvocidib mediante perfilado mitocondrial. |
| JP6815331B2 (ja) | 2015-04-21 | 2021-01-20 | ジェネンテック， インコーポレイテッド | 前立腺がんの分析のための組成物及び方法 |
| WO2016170022A1 (en) | 2015-04-21 | 2016-10-27 | Institut Gustave Roussy | Therapeutic methods, products and compositions inhibiting znf555 |
| CA2982452A1 (en) | 2015-04-21 | 2016-10-27 | Enlivex Therapeutics Ltd. | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| CA2979313A1 (en) | 2015-04-22 | 2016-10-27 | Nestec S.A. | Biomarkers for predicting degree of weight loss in female subjects |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| WO2016169806A1 (en) | 2015-04-22 | 2016-10-27 | Nestec S.A. | Biomarkers for predicting degree of weight loss in male subjects |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| AU2016252773B2 (en) | 2015-04-24 | 2022-06-02 | Genentech, Inc. | Multispecific antigen-binding proteins |
| JOP20200116A1 (ar) | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
| SI3286315T1 (sl) | 2015-04-24 | 2021-09-30 | F. Hoffmann-La Roche Ag | Postopek identifikacije bakterij, ki obsegajo vezavne polipeptide |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| EP3289094B1 (en) | 2015-04-27 | 2024-06-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for assessing toxicity using dynamic bh3 profiling |
| KR20170140318A (ko) | 2015-04-29 | 2017-12-20 | 리제너론 파마슈티칼스 인코포레이티드 | 진행성 골화성 섬유이형성증의 치료 |
| WO2016178779A1 (en) | 2015-05-01 | 2016-11-10 | Dana-Farber Cancer Institute, Inc. | Methods of mediating cytokine expression with anti ccr4 antibodies |
| EP3288981A1 (en) | 2015-05-01 | 2018-03-07 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
| WO2016179194A1 (en) | 2015-05-04 | 2016-11-10 | Jounce Therapeutics, Inc. | Lilra3 and method of using the same |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| CA2985125A1 (en) | 2015-05-06 | 2016-11-10 | Janssen Biotech, Inc. | Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof |
| MX2017014188A (es) | 2015-05-07 | 2018-04-10 | Agenus Inc | Anticuerpos anti-ox40 y metodos para su uso. |
| US20160346387A1 (en) | 2015-05-11 | 2016-12-01 | Genentech, Inc. | Compositions and methods of treating lupus nephritis |
| US20180161300A1 (en) | 2015-05-11 | 2018-06-14 | Yeda Research And Development Co., Ltd. | Citrin inhibitors for the treatment of cancer |
| LT3294770T (lt) | 2015-05-12 | 2020-12-28 | F. Hoffmann-La Roche Ag | Vėžio gydymo ir diagnostikos būdai |
| US20160333087A1 (en) | 2015-05-12 | 2016-11-17 | Bioven 3 Limited | Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors |
| EP3307310A2 (en) | 2015-05-13 | 2018-04-18 | The Trustees Of The University Of Pennsylvania | Aav-mediated expression of anti-influenza antibodies and methods of use thereof |
| CA2985816A1 (en) | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| PL3294764T3 (pl) | 2015-05-15 | 2021-06-28 | City Of Hope | Kompozycje chimerycznego receptora antygenowego |
| WO2016187349A1 (en) | 2015-05-18 | 2016-11-24 | Tcr2, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| DK3527574T3 (da) | 2015-05-18 | 2022-06-27 | Sumitomo Pharma Oncology Inc | Alvocidib-prodrugs, der har øget biotilgængelighed |
| WO2016185457A1 (en) | 2015-05-19 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Methods of promoting lymphangiogenesis |
| WO2016185481A2 (en) | 2015-05-20 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Method of targeting senescent cells |
| IL293719B2 (en) | 2015-05-21 | 2023-07-01 | Harpoon Therapeutics Inc | Trispecific binding proteins and methods of use |
| AU2016267059B2 (en) | 2015-05-22 | 2020-08-13 | Translational Drug Development Llc | Benzamide and active compound compositions and methods of use |
| WO2016189091A1 (en) | 2015-05-26 | 2016-12-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas |
| WO2016189118A1 (en) | 2015-05-28 | 2016-12-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of prognosis and treatment of patients suffering from acute myeloid leukemia |
| MX2017015011A (es) | 2015-05-28 | 2018-03-23 | Genentech Inc | Ensayo a base de celulas para detectar homodimeros anti-cd3. |
| CA2984003A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| MX2017014735A (es) | 2015-05-29 | 2018-03-23 | Genentech Inc | Metilacion de promotor pd-l1 en cancer. |
| EP3303395B1 (en) | 2015-05-29 | 2019-12-11 | AbbVie Inc. | Anti-cd40 antibodies and uses thereof |
| JP6893608B2 (ja) | 2015-05-29 | 2021-06-23 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がんの処置のためのＰＤ−１アンタゴニストとＣｐＧ−Ｃ型オリゴヌクレオチドの併用 |
| KR102492532B1 (ko) | 2015-05-29 | 2023-01-30 | 아게누스 인코포레이티드 | 항-ctla-4 항체 및 이의 사용 방법 |
| JP2018080114A (ja) | 2015-05-29 | 2018-05-24 | 株式会社アールテック・ウエノ | 抗ヒトｖａｐ−１モノクローナル抗体 |
| WO2016196343A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Humanized anti-ebola virus glycoprotein antibodies and methods of use |
| TW201717975A (zh) | 2015-06-01 | 2017-06-01 | 美國芝加哥州立大學 | 藉由控制共生微生物叢來治療癌症 |
| MX2017015189A (es) | 2015-06-01 | 2018-04-13 | Medimmune Llc | Neutralizacion de moleculas de union anti-influenza y usos de las mismas. |
| AU2016269839B2 (en) | 2015-06-03 | 2021-07-08 | The University Of Queensland | Mobilizing agents and uses therefor |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| IL300670A (en) | 2015-06-05 | 2023-04-01 | Genentech Inc | Anti-tau antibodies and methods of use |
| US20170000885A1 (en) | 2015-06-08 | 2017-01-05 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| TW201709932A (zh) | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | Ｃｄ１２３抗體及其共軛物 |
| CA2988982A1 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| JP2018518491A (ja) | 2015-06-12 | 2018-07-12 | アレクトル エルエルシー | 抗ｃｄ３３抗体及びその使用方法 |
| TW201709929A (zh) | 2015-06-12 | 2017-03-16 | 宏觀基因股份有限公司 | 治療癌症的聯合療法 |
| WO2016201282A2 (en) | 2015-06-12 | 2016-12-15 | Ludwig Institute For Cancer Research Ltd | TGF-β3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF |
| CN108064246A (zh) | 2015-06-15 | 2018-05-22 | 基因泰克公司 | 抗体和免疫结合物 |
| NZ737752A (en) | 2015-06-15 | 2022-02-25 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| SG10201912324XA (en) | 2015-06-15 | 2020-02-27 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| CA2988693A1 (en) | 2015-06-15 | 2016-12-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| EP3916018A1 (en) | 2015-06-16 | 2021-12-01 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| PL3310814T3 (pl) | 2015-06-16 | 2023-12-11 | F. Hoffmann-La Roche Ag | Humanizowane i wykazujące dojrzałe powinowactwo przeciwciała przeciwko FcRH5 i sposoby stosowania |
| TW201718647A (zh) | 2015-06-16 | 2017-06-01 | 建南德克公司 | 抗-cll-1抗體及使用方法 |
| WO2016205531A2 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Anti-her2 antibodies and methods of use |
| AU2016280070B2 (en) | 2015-06-17 | 2022-09-15 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists and taxanes |
| EP3954394A1 (en) | 2015-06-19 | 2022-02-16 | Centurion BioPharma Corporation | Delivery systems for controlled drug release |
| CN108025084A (zh) | 2015-06-22 | 2018-05-11 | 拜耳医药股份有限公司 | 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc） |
| CA2990394A1 (en) | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies |
| WO2016207104A1 (de) | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-b7h3-antikörpern |
| CN114805576A (zh) | 2015-06-24 | 2022-07-29 | 詹森药业有限公司 | 抗vista抗体和片段 |
| CN107810196B (zh) | 2015-06-24 | 2021-11-05 | 豪夫迈·罗氏有限公司 | 人源化的抗-Tau(pS422)抗体和使用方法 |
| ES2908009T3 (es) | 2015-06-24 | 2022-04-27 | Hoffmann La Roche | Anticuerpos anti-receptor de transferrina con afinidad adaptada |
| GB201511196D0 (en) | 2015-06-25 | 2015-08-12 | Cytosystems Ltd | Monoclonal antibodies |
| US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
| CN107849595A (zh) | 2015-06-26 | 2018-03-27 | 杜邦营养生物科学有限公司 | 用于蛋白水解产物的氨肽酶 |
| JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| WO2017004079A1 (en) | 2015-06-29 | 2017-01-05 | Biomed Valley Discoveries, Inc. | Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment |
| EP3313884B9 (en) | 2015-06-29 | 2021-05-19 | ImmunoGen, Inc. | Anti-cd123 antibodies and conjugates and derivatives thereof |
| JP2018520153A (ja) | 2015-06-29 | 2018-07-26 | ジェネンテック， インコーポレイテッド | 臓器移植における使用のためのｉｉ型抗ｃｄ２０抗体 |
| EA201890162A1 (ru) | 2015-06-29 | 2018-07-31 | Бристол-Маерс Сквибб Компани | Антитела к cd40 с повышенной агонистической активностью |
| EP3514174B1 (en) | 2015-06-29 | 2021-03-31 | Ventana Medical Systems, Inc. | Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| PE20180499A1 (es) | 2015-07-06 | 2018-03-09 | Ucb Biopharma Sprl | Anticuerpos de union a tau |
| UA124616C2 (uk) | 2015-07-06 | 2021-10-20 | Юсб Біофарма Срл | Зв'язуюче тау-білок антитіло |
| BR112017028363A2 (pt) | 2015-07-06 | 2018-08-28 | Immatics Biotechnologies Gmbh | peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de esôfago e outros cânceres |
| EP3319990A1 (en) | 2015-07-07 | 2018-05-16 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Antibodies having specificity to myosin 18a and uses thereof |
| JP7010811B2 (ja) | 2015-07-10 | 2022-02-10 | メルス ナムローゼ フェンノートシャップ | ヒトｃｄ３結合抗体 |
| US10287338B2 (en) | 2015-07-10 | 2019-05-14 | Miran NERSISSIAN | Factor VIII protein compositions and methods of treating of hemophilia A |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| CN111375066B (zh) | 2015-07-16 | 2023-04-25 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| US10877045B2 (en) | 2015-07-21 | 2020-12-29 | Saint Louis University | Compositions and methods for diagnosing and treating endometriosis-related infertility |
| US11066481B2 (en) | 2015-07-23 | 2021-07-20 | The Regents Of The University Of California | Antibodies to coagulation factor XIa and uses thereof |
| SI3124976T1 (sl) | 2015-07-28 | 2018-12-31 | F. Hoffmann-La Roche Ag | Izboljšan test bakterijskih endotoksinov za določanje endotoksinov |
| EP3317301B1 (en) | 2015-07-29 | 2021-04-07 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| PE20231958A1 (es) | 2015-07-30 | 2023-12-06 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
| TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究（慕尼黑）公司 | Ｃｄ７０及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI793062B (zh) | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| EP3331536A4 (en) | 2015-08-03 | 2019-03-27 | The Regents of The University of California | COMPOSITIONS AND METHODS FOR MODULATING ABHD2 ACTIVITY |
| PL3331910T3 (pl) | 2015-08-03 | 2020-05-18 | Engmab Sàrl | Przeciwciała monoklonalne przeciwko ludzkiemu antygenowi dojrzewania limfocytów B (BCMA) |
| CA2993659A1 (en) | 2015-08-03 | 2017-02-09 | Tolero Pharmaceuticals, Inc. | Combination therapies for treatment of cancer |
| WO2017024171A1 (en) | 2015-08-04 | 2017-02-09 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
| TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| CN108289939B (zh) | 2015-08-05 | 2022-08-12 | 艾科迪科尔生物技术公司 | 抗人gpvi抗体及其用途 |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| AU2016304588A1 (en) | 2015-08-06 | 2018-02-15 | Xoma (Us) Llc | Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia |
| US11254744B2 (en) | 2015-08-07 | 2022-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| AU2016306907A1 (en) | 2015-08-07 | 2018-03-29 | Merck Patent Gmbh | A transglutamine tag for efficient site-specific bioconjugation |
| MA45352A (fr) | 2015-08-07 | 2018-06-13 | Univ Birmingham | Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer |
| EP3331569A1 (en) | 2015-08-07 | 2018-06-13 | Gamamabs Pharma | Antibodies, antibody drug conjugates and methods of use |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| HRP20221440T1 (hr) | 2015-08-14 | 2023-02-03 | Zoetis Services Llc | Pripravci bakterije mycoplasma bovis |
| JP6720293B2 (ja) | 2015-08-19 | 2020-07-08 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | 安定な抗ｉｆｎａｒ１製剤 |
| EP3337822A1 (en) | 2015-08-19 | 2018-06-27 | Rutgers, The State University of New Jersey | Novel methods of generating antibodies |
| JP6979941B2 (ja) | 2015-08-20 | 2021-12-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Ｐｅｇ化分析物特異的結合剤を用いた粒子に基づくイムノアッセイ |
| GB201514928D0 (en) | 2015-08-21 | 2015-10-07 | King S College London | PDD compounds |
| CN108135932A (zh) | 2015-08-28 | 2018-06-08 | 宾夕法尼亚大学董事会 | 表达嵌合细胞内信号传导分子的细胞的方法和组合物 |
| EP3341411A1 (en) | 2015-08-28 | 2018-07-04 | Alector LLC | Anti-siglec-7 antibodies and methods of use thereof |
| EP3340998B1 (en) | 2015-08-28 | 2023-01-11 | The Trustees of the University of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| EP3344656A1 (en) | 2015-09-01 | 2018-07-11 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
| DK3344655T3 (da) | 2015-09-01 | 2023-10-09 | Boehringer Ingelheim Int | Brug af anti-cd40-antistoffer til behandling af lupus nefritis |
| CN108137691B (zh) | 2015-09-02 | 2021-10-19 | 耶路撒冷希伯来大学伊萨姆研究发展有限公司 | 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体 |
| CN108699145A (zh) | 2015-09-02 | 2018-10-23 | 伊缪泰普有限公司 | 抗lag-3抗体 |
| US10407484B2 (en) | 2015-09-02 | 2019-09-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for modulating T-cell mediated immune response |
| EP3344806A4 (en) | 2015-09-04 | 2019-03-20 | OBI Pharma, Inc. | GLYCAN NETWORKS AND METHODS OF USE |
| SI3307322T1 (sl) | 2015-09-04 | 2021-08-31 | Primatope Therapeutics Inc. | Humanizirana protitelesa proti CD40 in njihove uporabe |
| EP3347377B1 (en) | 2015-09-09 | 2021-02-17 | Novartis AG | Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies |
| US10775389B2 (en) | 2015-09-09 | 2020-09-15 | Medizinische Hochschule Hannover | Method for detecting plasminogen activator inhibitor-1 in a sample |
| WO2017042814A1 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd. | Use of perforin positive immature dendritic cells in disease treatment |
| SI3350220T1 (sl) | 2015-09-15 | 2021-12-31 | Scholar Rock, Inc. | Protitelesa proti pro/latentnemu miostatinu in uporabe le-teh |
| US20190330290A1 (en) | 2015-09-17 | 2019-10-31 | Histide Ag | Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof |
| PL3349776T3 (pl) | 2015-09-17 | 2021-08-02 | Histide Ag | Związek farmaceutyczny agonisty receptora czynnika wzrostu i inhibitora białka adhezyjnego do przekształcania komórki nowotworowej w komórkę nienowotworową i jego zastosowanie |
| CR20180217A (es) | 2015-09-18 | 2018-05-03 | Chugai Pharmaceutical Co Ltd | Anticuerpos que se unen a interleucina 8 (il-8) y sus usos |
| MX2018003308A (es) | 2015-09-18 | 2018-11-09 | The General Hospital Corp Dba Massacsetts General Hospital | Suministro localizado de agente anti-fuctactico para tratamiento del cancer. |
| TWI733695B (zh) | 2015-09-18 | 2021-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
| MX2018003445A (es) | 2015-09-22 | 2018-08-01 | Genentech Inc | Expresion de proteinas que contienen fc. |
| AU2016328357B2 (en) | 2015-09-22 | 2023-03-02 | Ventana Medical Systems, Inc. | Anti-OX40 antibodies and diagnostic uses thereof |
| CA2999160A1 (en) | 2015-09-23 | 2017-03-30 | Oncomed Pharmaceuticals, Inc. | Methods and compositions for treatment of cancer |
| CA2992602A1 (en) | 2015-09-23 | 2017-03-30 | Genentech, Inc. | Optimized variants of anti-vegf antibodies |
| CA2999224C (en) | 2015-09-23 | 2023-10-24 | Pfizer Inc. | Cells and method of cell culture |
| US11142565B2 (en) | 2015-09-24 | 2021-10-12 | Abvitro Llc | Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope |
| KR102279524B1 (ko) | 2015-09-25 | 2021-07-20 | 제넨테크, 인크. | 항-tigit 항체 및 이의 이용 방법 |
| JP6936230B2 (ja) | 2015-09-25 | 2021-09-15 | キアゲン サイエンシス リミテッド ライアビリティ カンパニー | ライム病を診断するためのおよび治療後のライム病スピロヘータ除去を予測するための組成物および方法 |
| RU2638457C2 (ru) | 2015-09-28 | 2017-12-13 | Общество С Ограниченной Ответственностью "Онкомакс" | Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител |
| WO2017055484A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for determining the metabolic status of lymphomas |
| BR112018006237A2 (pt) | 2015-09-29 | 2018-10-09 | Celgene Corp | proteínas de ligação a pd-1 e métodos de uso das mesmas |
| US11266730B2 (en) | 2015-09-29 | 2022-03-08 | The General Hospital Corporation | Methods of treating and diagnosing disease using biomarkers for BCG therapy |
| AU2016329197B2 (en) | 2015-09-30 | 2021-01-21 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| CA3000386A1 (en) | 2015-09-30 | 2017-04-06 | Merck Patent Gmbh | Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer |
| WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
| CA3000697A1 (en) | 2015-10-01 | 2017-04-06 | Amgen Inc. | Treatment of bile acid disorders |
| LT3356404T (lt) | 2015-10-02 | 2021-11-10 | F. Hoffmann-La Roche Ag | Pd1 antikūnai ir jų naudojimo metodai |
| EP3150636A1 (en) | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
| CR20180161A (es) | 2015-10-02 | 2018-05-25 | Hoffmann La Roche | Anticuerpos biespecíficos para pd1 y tim3 |
| MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
| MA43023A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| US10800826B2 (en) | 2015-10-05 | 2020-10-13 | Merck Sharp & Dohme Corp. | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors |
| CA2997960A1 (en) | 2015-10-06 | 2017-04-13 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| AU2016335842A1 (en) | 2015-10-07 | 2018-04-12 | Obi Pharma, Inc. | Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof |
| RU2018116846A (ru) | 2015-10-08 | 2019-11-08 | Займворкс Инк. | Антигенсвязывающие полипептидные конструкции, содержащие легкие цепи каппа и лямбда, и их применения |
| CN108136010A (zh) | 2015-10-08 | 2018-06-08 | 宏观基因有限公司 | 用于治疗癌症的联合疗法 |
| WO2017060397A1 (en) | 2015-10-09 | 2017-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of subjects suffering from melanoma metastases |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| AU2016334401A1 (en) | 2015-10-10 | 2018-04-26 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
| WO2017064034A1 (en) | 2015-10-12 | 2017-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An agent capable of depleting cd8 t cells for the treatment of myocardial infarction or acute myocardial infarction |
| WO2017064716A1 (en) | 2015-10-13 | 2017-04-20 | Rappaport Family Institute For Research | Heparanase-neutralizing monoclonal antibodies |
| EP3365027B1 (en) | 2015-10-14 | 2022-03-30 | Research Institute at Nationwide Children's Hospital | Hu specific antibodies and their use in inhibiting biofilm |
| US20180305458A1 (en) | 2015-10-16 | 2018-10-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases |
| KR20180084793A (ko) | 2015-10-16 | 2018-07-25 | 알사니스 바이오사이언시스 게엠베하 | 폐렴 간균(Klebsiella pneumoniae)을 타겟으로 하는 살균성 단일클론 항체 |
| WO2017066561A2 (en) | 2015-10-16 | 2017-04-20 | President And Fellows Of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
| WO2017067944A1 (en) | 2015-10-19 | 2017-04-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of subjects suffering from triple negative breast cancer |
| MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
| SI3370515T1 (sl) | 2015-10-21 | 2022-06-30 | Redcoat Solutions,Inc | Naprava za odkrivanje posteljnih stenic |
| GB201518675D0 (en) | 2015-10-21 | 2015-12-02 | Cellcap Technologies Ltd | Detection of structural forms of proteins |
| HRP20231035T1 (hr) | 2015-10-21 | 2023-12-22 | Redcoat Solutions, Inc. | Monoklonska antitijela protiv krevetnih stjenica i postupci njihove proizvodnje i uporabe |
| US20170114127A1 (en) | 2015-10-22 | 2017-04-27 | Massachusetts Institute Of Technology | Vegf-a-binding proteins and her2-binding proteins with enhanced stability against aggregation |
| US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
| CN108350505A (zh) | 2015-10-22 | 2018-07-31 | 震动疗法股份有限公司 | 用于测定icos表达的基因标志 |
| MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
| TW201722989A (zh) | 2015-10-23 | 2017-07-01 | 輝瑞大藥廠 | 抗il-2抗體及其組合物及用途 |
| RU2767209C2 (ru) | 2015-10-23 | 2022-03-16 | Еурека Терапьютикс, Инк. | Химерные конструкции антитело/т-клеточный рецептор и их применения |
| US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| US20180348224A1 (en) | 2015-10-28 | 2018-12-06 | Friedrich Miescher Institute For Biomedical Resear Ch | Tenascin-w and biliary tract cancers |
| US11267875B2 (en) | 2015-10-28 | 2022-03-08 | Yale University | Humanized anti-DKK2 antibody and uses thereof |
| JO3555B1 (ar) | 2015-10-29 | 2020-07-05 | Merck Sharp & Dohme | جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري |
| AU2016344665C1 (en) | 2015-10-29 | 2023-07-27 | F. Hoffmann-La Roche Ag | Anti-variant Fc-region antibodies and methods of use |
| US20210106661A1 (en) | 2015-10-29 | 2021-04-15 | Dana-Farber Cancer Institute, Inc. | Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids |
| AU2016343987B2 (en) | 2015-10-29 | 2023-11-23 | Alector Llc | Anti-Siglec-9 antibodies and methods of use thereof |
| WO2017075252A1 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibody variant conjugates and uses thereof |
| EP3368074A2 (en) | 2015-10-30 | 2018-09-05 | Hoffmann-La Roche AG | Anti-factor d antibodies and conjugates |
| US10421821B2 (en) | 2015-10-30 | 2019-09-24 | Genentech, Inc. | Anti-HtrA1 antibodies and methods of use thereof |
| KR20180069906A (ko) | 2015-10-30 | 2018-06-25 | 제넨테크, 인크. | 항-인자 d 항체 제제 |
| ES2904553T3 (es) | 2015-10-30 | 2022-04-05 | Hoffmann La Roche | Fragmentos de anticuerpo modificados con bisagra y procedimientos de preparación |
| WO2017075045A2 (en) | 2015-10-30 | 2017-05-04 | Mayo Foundation For Medical Education And Research | Antibodies to b7-h1 |
| DK3368085T3 (da) | 2015-11-01 | 2024-04-02 | Massachusetts Inst Technology | Modificerede alginater til anti-fibrotiske materialer og anvendelser |
| AU2016350732A1 (en) | 2015-11-02 | 2018-04-05 | Genentech, Inc. | Methods of making fucosylated and afucosylated forms of a protein |
| JP6412906B2 (ja) | 2015-11-03 | 2018-10-24 | 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | 化合物、リンカー−薬物およびリガンド−薬物複合体 |
| JP2019503985A (ja) | 2015-11-03 | 2019-02-14 | グリコミメティクス， インコーポレイテッド | モノクローナル抗体、造血幹細胞の産生のための方法および組成物、ならびにそれらを使用する方法 |
| WO2017079419A1 (en) | 2015-11-05 | 2017-05-11 | The Regents Of The University Of California | Cells labelled with lipid conjugates and methods of use thereof |
| JP6998869B2 (ja) | 2015-11-08 | 2022-02-04 | ジェネンテック， インコーポレイテッド | 多重特異性抗体のスクリーニング方法 |
| GEP20237574B (en) | 2015-11-09 | 2023-12-25 | Univ Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
| AU2016354440B2 (en) | 2015-11-09 | 2023-09-28 | The Children's Hospital Of Philadelphia | Glypican 2 as a cancer marker and therapeutic target |
| MX2018005541A (es) | 2015-11-10 | 2018-08-01 | Medimmune Llc | Moleculas de union especificas para transportador 2 con preferencia a alanina, serina y cistenia (asct2) y usos de las mismas. |
| CA3004790A1 (en) | 2015-11-10 | 2017-05-18 | Visterra, Inc. | Lipopolysaccharide binding antibody-antimicrobial peptide conjugates and uses thereof |
| IL258768B2 (en) | 2015-11-12 | 2023-11-01 | Siamab Therapeutics Inc | Compounds interacting with glycans and methods of use |
| EP3377533A2 (en) | 2015-11-19 | 2018-09-26 | Sutro Biopharma, Inc. | Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies |
| BR112018010172A2 (pt) | 2015-11-19 | 2018-11-21 | Bristol Myers Squibb Co | anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| NZ742787A (en) | 2015-11-20 | 2020-02-28 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520545D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
| GB201520536D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520557D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201607534D0 (en) | 2016-04-29 | 2016-06-15 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520558D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520565D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520563D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520566D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520603D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520548D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520595D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520542D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201604468D0 (en) | 2016-03-16 | 2016-04-27 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520546D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| WO2017089786A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
| GB201520541D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520579D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520544D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520539D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520562D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520592D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201607535D0 (en) | 2016-04-29 | 2016-06-15 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520543D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520564D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520567D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520597D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| GB201520589D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520559D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| KR20180096645A (ko) | 2015-11-23 | 2018-08-29 | 악셀레론 파마 인코포레이티드 | 눈 질환의 치료 방법 |
| RU2745707C2 (ru) | 2015-11-23 | 2021-03-30 | Файв Прайм Терапьютикс, Инк. | Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака |
| GB201520575D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520583D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520570D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| CN117244076A (zh) | 2015-11-25 | 2023-12-19 | 乐高化学生物科学股份有限公司 | 包含自降解基团的缀合物及其相关方法 |
| MX2018006385A (es) | 2015-11-25 | 2019-09-11 | Visterra Inc | Moleculas de anticuerpo contra april y usos de las mismas. |
| CN108602885B (zh) | 2015-11-30 | 2022-05-24 | 百时美施贵宝公司 | 抗人ip-10抗体及其用途 |
| JP2019500327A (ja) | 2015-11-30 | 2019-01-10 | アッヴィ・インコーポレイテッド | 抗ｈｕＬＲＲＣ１５抗体薬物コンジュゲート及びその使用方法 |
| WO2017096017A1 (en) | 2015-12-02 | 2017-06-08 | Stsciences, Inc. | Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator) |
| EP3176183A1 (en) | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki) |
| CN114470194A (zh) | 2015-12-02 | 2022-05-13 | 斯特库伯株式会社 | 与btn1a1免疫特异性结合的抗体和分子及其治疗用途 |
| MX2018006218A (es) | 2015-12-04 | 2018-09-05 | Seattle Genetics Inc | Conjugados de compuestos de tubulisina cuaternizada. |
| CN108602870A (zh) | 2015-12-04 | 2018-09-28 | 诺华股份有限公司 | 抗体细胞因子嫁接组合物及用于免疫调节的方法 |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| US20180271998A1 (en) | 2015-12-04 | 2018-09-27 | Merrimack Pharmaceuticals, Inc. | Disulfide-stabilized fabs |
| CN108779168A (zh) | 2015-12-05 | 2018-11-09 | 沃迪奥斯大学医院中心 | Hiv结合剂 |
| EP3387015B1 (en) | 2015-12-09 | 2021-10-27 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
| EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
| TW202208440A (zh) | 2015-12-14 | 2022-03-01 | 美商宏觀基因股份有限公司 | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 |
| MX2018006925A (es) | 2015-12-15 | 2018-08-01 | Oncoimmune Inc | Anticuerpos monoclonales anti-ctla4 humano quimericos y humanizados y sus usos. |
| EP3399989B1 (en) | 2015-12-16 | 2023-08-09 | Merck Sharp & Dohme LLC | Anti-lag3 antibodies and antigen-binding fragments |
| EP3389712B1 (en) | 2015-12-17 | 2024-04-10 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
| WO2017106566A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders |
| JP6797203B2 (ja) | 2015-12-17 | 2020-12-09 | ザ・ジョンズ・ホプキンス・ユニバーシティー | デスレセプターアゴニストによる全身性硬化症の改善 |
| CA3007421A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof |
| US10588953B2 (en) | 2015-12-18 | 2020-03-17 | Agilvax, Inc. | Compositions and methods related to xCT peptides |
| EP3389711A1 (en) | 2015-12-18 | 2018-10-24 | Novartis AG | Antibodies targeting cd32b and methods of use thereof |
| EP3390442B1 (en) | 2015-12-18 | 2023-11-08 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
| GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| EP3184544A1 (en) | 2015-12-23 | 2017-06-28 | Julius-Maximilians-Universität Würzburg | Glycoprotein v inhibitors for use as coagulants |
| JP6948330B2 (ja) | 2015-12-23 | 2021-10-13 | アムジエン・インコーポレーテツド | 胃抑制ペプチド受容体（ｇｉｐｒ）に対する結合タンパク質をｇｌｐ−１アゴニストと組み合わせて使用する、代謝障害の治療方法または寛解方法 |
| WO2017112917A1 (en) | 2015-12-24 | 2017-06-29 | Corvus Pharmaceuticals, Inc. | Methods of treating cancer |
| US10561706B2 (en) | 2015-12-28 | 2020-02-18 | B. G. Negev Technologies And Applications | Isolated polypeptide and compositions comprising same |
| RU2744860C2 (ru) | 2015-12-30 | 2021-03-16 | Кодиак Сайенсиз Инк. | Антитела и их конъюгаты |
| IL299759A (en) | 2015-12-30 | 2023-03-01 | Genentech Inc | Formulations with reduced polysorbate dissolution |
| US20170239355A1 (en) | 2015-12-30 | 2017-08-24 | Genentech, Inc. | Use of tryptophan derivatives for protein formulations |
| WO2017118634A1 (en) | 2016-01-04 | 2017-07-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma |
| GEP20217290B (en) | 2016-01-05 | 2021-09-10 | Univ Leicester | Masp-2 antibodies for inhibiting fibrosis |
| CN107531795B (zh) | 2016-01-05 | 2021-01-19 | 江苏恒瑞医药股份有限公司 | Pcsk9抗体、其抗原结合片段及其医药用途 |
| CN108697907A (zh) | 2016-01-06 | 2018-10-23 | 耶达研究及发展有限公司 | 用于治疗恶性疾病、自身免疫疾病和炎性疾病的组合物和方法 |
| JP7183042B2 (ja) | 2016-01-07 | 2022-12-05 | ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド | 眼の免疫炎症性疾患のための治療法 |
| US10472422B2 (en) | 2016-01-08 | 2019-11-12 | Abgenomics International Inc. | Tetravalent anti-PSGL-1 antibodies and uses thereof |
| CA3006529A1 (en) | 2016-01-08 | 2017-07-13 | F. Hoffmann-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
| AU2017206089B2 (en) | 2016-01-09 | 2020-04-16 | Arbele Pty Ltd | Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment |
| WO2017122098A2 (en) | 2016-01-10 | 2017-07-20 | Neotx Therapeutics Ltd. | Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy. |
| EP3403091B1 (en) | 2016-01-11 | 2021-12-22 | Technion Research & Development Foundation Limited | Methods of determining prognosis of sepsis and treating same |
| ES2898329T3 (es) | 2016-01-12 | 2022-03-07 | Oncotracker Inc | Métodos mejorados para supervisar el estado inmunitario de un sujeto |
| US20190309060A1 (en) | 2016-01-15 | 2019-10-10 | Philogen S.P.A. | Intestinal antigens for pharmacodelivery applications |
| CN114019170A (zh) | 2016-01-20 | 2022-02-08 | 基因泰克公司 | 用于阿尔茨海默氏病的高剂量治疗 |
| JP2019506398A (ja) | 2016-01-21 | 2019-03-07 | ファイザー・インク | 上皮増殖因子受容体変異体ｉｉｉおよびｃｄ３の単一および二重特異性抗体およびそれらの使用 |
| ES2847155T3 (es) | 2016-01-21 | 2021-08-02 | Novartis Ag | Moléculas multiespecíficas que fijan como objetivo CLL-1 |
| KR102479606B1 (ko) | 2016-01-21 | 2022-12-21 | 화이자 인코포레이티드 | 상피 성장 인자 수용체 변이체 iii을 표적화하는 키메라 항원 수용체 |
| CA3012075A1 (en) | 2016-01-22 | 2017-07-27 | MabQuest SA | Immunological reagents |
| US11214617B2 (en) | 2016-01-22 | 2022-01-04 | MabQuest SA | Immunological reagents |
| US10053515B2 (en) | 2016-01-22 | 2018-08-21 | Merck Sharp & Dohme Corp. | Anti-coagulation factor XI antibodies |
| AU2017211540B2 (en) | 2016-01-25 | 2020-04-30 | Pfizer Inc. | Combination of an OX40 agonist and a 4-1BB agonist monoclonal antibody for treating cancer |
| WO2017129558A1 (en) | 2016-01-25 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis |
| US11513127B2 (en) | 2016-01-25 | 2022-11-29 | Genentech, Inc. | Methods for assaying T-cell dependent bispecific antibodies |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| CA3011455A1 (en) | 2016-01-27 | 2017-08-03 | Sutro Biopharma, Inc. | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates |
| WO2017129763A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
| WO2017129790A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of cancer |
| EP3407916B1 (en) | 2016-01-29 | 2023-12-20 | Merck Sharp & Dohme LLC | Phosphonate linkers and their use to facilitate cellular retention of compounds |
| JP2019507126A (ja) | 2016-02-01 | 2019-03-14 | ファイザー・インク | ツブリシン類似体およびこれらの調製のための方法 |
| MX2018009304A (es) | 2016-02-01 | 2019-01-10 | Prevencio Inc | Metodos de diagnostico y pronostico para episodios y enfermedades cardiovasculares. |
| AU2017216237B2 (en) | 2016-02-03 | 2024-04-04 | Amgen Research (Munich) Gmbh | PSMA and CD3 bispecific T cell engaging antibody constructs |
| EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| WO2017136685A1 (en) | 2016-02-03 | 2017-08-10 | President And Fellows Of Harvard College | Methods of treating of inflammatory bowel disease and parasite infection |
| BR112018015715A2 (pt) | 2016-02-03 | 2019-02-05 | Amgen Inc | construtos de anticorpo de engate de célula t biespecífica bcma e cd3 |
| EP3202788A1 (en) | 2016-02-05 | 2017-08-09 | MediaPharma S.r.l. | Endosialin-binding antibody |
| WO2017136676A1 (en) | 2016-02-05 | 2017-08-10 | Nanoview Diagnostics Inc. | Detection of exosomes having surface markers |
| US10465003B2 (en) | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
| US11780934B2 (en) | 2016-02-05 | 2023-10-10 | Institut Pasteur | Use of inhibitors of ADAM12 as adjuvants in tumor therapies |
| US20170224837A1 (en) | 2016-02-10 | 2017-08-10 | Immunomedics, Inc. | Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| AU2017218767A1 (en) | 2016-02-10 | 2018-08-02 | Pfizer Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
| WO2017137830A1 (en) | 2016-02-12 | 2017-08-17 | Janssen Pharmaceutica Nv | Anti-vista (b7h5) antibodies |
| US20190046497A1 (en) | 2016-02-14 | 2019-02-14 | Yeda Research And Development Co., Ltd. | Methods of modulating protein exocytosis and uses of same in therapy |
| EP3416688B1 (en) | 2016-02-15 | 2022-08-17 | INSERM - Institut National de la Santé et de la Recherche Médicale | Apelin for use in the treatment of post-operative cognitive dysfunction |
| WO2017140803A1 (en) | 2016-02-16 | 2017-08-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Modulators of tumor immune resistance for the treatment of cancer |
| EP3416641A1 (en) | 2016-02-16 | 2018-12-26 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Modulators of ccr9 for treating tumor resistance to immune responses |
| JP7152309B2 (ja) | 2016-02-17 | 2022-10-12 | シージェン インコーポレイテッド | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| US20170233472A1 (en) | 2016-02-17 | 2017-08-17 | Macrogenics, Inc. | ROR1-Binding Molecules, and Methods of Use Thereof |
| EP3207937A1 (en) | 2016-02-17 | 2017-08-23 | Royal College of Surgeons in Ireland | A method of treating or preventing sepsis |
| US11730761B2 (en) | 2016-02-18 | 2023-08-22 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| WO2017139975A1 (en) | 2016-02-19 | 2017-08-24 | Huiru Wang | Antibodies against n-acetylglucosamine and n-acetyl-galactosamine |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| GB201603002D0 (en) | 2016-02-22 | 2016-04-06 | Univ Manchester | Inflammation biomarker |
| EP3420097A1 (en) | 2016-02-25 | 2019-01-02 | DuPont Nutrition Biosciences ApS | Method for producing a protein hydrolysate employing an aspergillus fumigatus tripeptidyl peptidase |
| CN108699154A (zh) | 2016-02-26 | 2018-10-23 | 国家医疗保健研究所 | 对btla具有特异性的抗体及其用途 |
| EP3423488A4 (en) | 2016-02-29 | 2019-11-06 | Foundation Medicine, Inc. | METHOD FOR THE TREATMENT OF CANCER |
| CN116375797A (zh) | 2016-03-01 | 2023-07-04 | 伊玛提克斯生物技术有限公司 | 用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物 |
| ES2903280T3 (es) | 2016-03-01 | 2022-03-31 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Anticuerpos específicos del receptor de poliovirus humano (RPH) |
| CA3016163A1 (en) | 2016-03-02 | 2017-09-08 | Idexx Laboratories, Inc. | Methods and compositions for the detection and diagnosis of renal disease and periodontal disease |
| EP3824909A1 (en) | 2016-03-02 | 2021-05-26 | Eisai R&D Management Co., Ltd. | Eribulin-based antibody-drug conjugates and methods of use |
| WO2017151176A1 (en) | 2016-03-04 | 2017-09-08 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
| US20190284293A1 (en) | 2016-03-04 | 2019-09-19 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| KR102010207B1 (ko) | 2016-03-04 | 2019-08-12 | 4디 파마 피엘씨 | 세균 균주를 포함하는 조성물 |
| JP7023853B2 (ja) | 2016-03-04 | 2022-02-22 | アレクトル エルエルシー | 抗ｔｒｅｍ１抗体及びその使用方法 |
| SG11201807489PA (en) | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| US20190216891A1 (en) | 2016-03-06 | 2019-07-18 | Yeda Research And Development Co., Ltd. | Method for modulating myelination |
| US10443054B2 (en) | 2016-03-06 | 2019-10-15 | Massachusetts Institute Of Technology | Methods for identifying and treating invasive/metastatic breast cancers |
| US11078274B2 (en) | 2016-03-08 | 2021-08-03 | Innate Pharma | Siglec neutralizing antibodies |
| CA3016170A1 (en) | 2016-03-08 | 2017-09-14 | Academia Sinica | Methods for modular synthesis of n-glycans and arrays thereof |
| US11014088B2 (en) | 2016-03-09 | 2021-05-25 | The Board Of Regents Of The University Of Texas System | Sensitive ELISA for disease diagnosis on surface modified poly(methyl methacrylate) (PMMA) microfluidic microplates |
| WO2017156263A1 (en) | 2016-03-09 | 2017-09-14 | Memorial Sloan-Kettering Cancer Center | Enigma and cdh18 as companion diagnostics for cdk4 inhibitors |
| AU2017230091B2 (en) | 2016-03-10 | 2022-04-07 | Acceleron Pharma Inc. | Activin type 2 receptor binding proteins and uses thereof |
| EP3426289A4 (en) | 2016-03-10 | 2019-08-07 | Aperisys, Inc. | ANTIGEN-BINDING FUSION PROTEINS WITH MODIFIED HSP70 DOMAINS |
| WO2017156500A1 (en) | 2016-03-11 | 2017-09-14 | Scholar Rock, Inc. | Tgfb1-binding immunoglobulins and use thereof |
| WO2017158421A1 (en) | 2016-03-14 | 2017-09-21 | University Of Oslo | Anti-viral engineered immunoglobulins |
| US11319383B2 (en) | 2016-03-14 | 2022-05-03 | Universitetet | Oslo | Engineered immunoglobulins with altered FcRn binding |
| JP7034489B2 (ja) | 2016-03-15 | 2022-03-14 | アイタブメッド （エイチケイ） リミテッド | 多重特異性Ｆａｂ融合タンパクおよびその使用 |
| ES2904286T3 (es) | 2016-03-15 | 2022-04-04 | Chugai Pharmaceutical Co Ltd | Métodos de tratamiento de cánceres que emplean antagonistas que se unen al eje PD-1 y anticuerpos anti-GPC3 |
| EP3779447B1 (en) | 2016-03-15 | 2023-02-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to activate the anti-tumoral cd8+t cell response of a patient affected with a cancer |
| MX2018011204A (es) | 2016-03-15 | 2019-03-07 | Mersana Therapeutics Inc | Conjugados de anticuerpo-farmaco dirigidos a napi2b y sus metodos de uso. |
| WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
| KR20170108203A (ko) | 2016-03-16 | 2017-09-27 | 주식회사 피플바이오 | 응집형-형성 폴리펩타이드의 응집형을 검출하는 방법 |
| WO2017158396A1 (en) | 2016-03-16 | 2017-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cytidine deaminase inhibitors for the treatment of pancreatic cancer |
| RS61374B1 (sr) | 2016-03-17 | 2021-02-26 | Tillotts Pharma Ag | Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti |
| SI3219727T1 (sl) | 2016-03-17 | 2021-04-30 | Tillotts Pharma Ag | Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti |
| US11186641B2 (en) | 2016-03-17 | 2021-11-30 | Oslo Universitetssykehus Hf | Fusion proteins targeting tumour associated macrophages for treating cancer |
| CN109153718B (zh) | 2016-03-17 | 2022-02-08 | 努玛治疗有限公司 | 抗TNFα抗体及其功能片段 |
| EP3433615A1 (en) | 2016-03-21 | 2019-01-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for diagnosis and treatment of solar lentigo |
| CA3016563A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| CN108697799A (zh) | 2016-03-22 | 2018-10-23 | 生态学有限公司 | 抗lgr5单克隆抗体的施用 |
| US11059905B2 (en) | 2016-03-23 | 2021-07-13 | Prothix B.V. | Monoclonal antibodies against the active site of factor XI and uses thereof |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| CN108779180B (zh) | 2016-03-23 | 2020-10-16 | 迈博斯生物医药(苏州)有限公司 | 新型抗-pd-l1抗体 |
| EP3432934B1 (de) | 2016-03-24 | 2022-02-23 | Bayer Pharma Aktiengesellschaft | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
| BR112018069273A2 (pt) | 2016-03-25 | 2019-01-22 | Seattle Genetics Inc | métodos para preparação de um composto e para tratamento de um indivíduo com uma malignidade hematológica, composto, composição, e, intermediário ligante de fármaco ou composto ligante de fármaco |
| CN108700598A (zh) | 2016-03-25 | 2018-10-23 | 豪夫迈·罗氏有限公司 | 多路总抗体和抗体缀合的药物量化测定法 |
| US20170274076A1 (en) | 2016-03-25 | 2017-09-28 | Visterra, Inc. | Formulations of antibody molecules to dengue virus |
| AU2017239637A1 (en) | 2016-03-29 | 2018-11-15 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| WO2017172517A1 (en) | 2016-03-29 | 2017-10-05 | Stcube & Co., Inc. | Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins |
| EP3943508B1 (en) | 2016-03-29 | 2024-01-10 | Board Of Regents, The University Of Texas System | Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof |
| US11046782B2 (en) | 2016-03-30 | 2021-06-29 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination |
| WO2017173327A1 (en) | 2016-03-31 | 2017-10-05 | The Schepens Eye Research Institute, Inc. | Endomucin inhibitor as an anti-angiogenic agent |
| US10870708B2 (en) | 2016-03-31 | 2020-12-22 | University Of Leicester | Methods for inhibiting angiogenesis in a subject in need thereof |
| EA201892225A1 (ru) | 2016-04-04 | 2019-09-30 | БИОВЕРАТИВ ЮЭсЭй ИНК. | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ |
| MA43764A (fr) | 2016-04-05 | 2021-06-02 | Baliopharm Ag | Inhibiteur monovalent de l'interaction hutnfr1 |
| JP7253923B2 (ja) | 2016-04-05 | 2023-04-07 | ファイザー・インク | 細胞培養プロセス |
| EP3439659A1 (en) | 2016-04-06 | 2019-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases |
| SG11201808627RA (en) | 2016-04-06 | 2018-10-30 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers |
| EP3440468B1 (en) | 2016-04-06 | 2021-12-01 | Nestle Sa | BIOMARKERS TO PREDICT THE DEGREE OF WEIGHT LOSS |
| CN109195620B (zh) | 2016-04-07 | 2022-06-28 | 约翰霍普金斯大学 | 用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法 |
| US11168145B2 (en) | 2016-04-08 | 2021-11-09 | Zielbio, Inc. | Plectin-1 binding antibodies and uses thereof |
| US20170319688A1 (en) | 2016-04-14 | 2017-11-09 | Genentech, Inc. | Anti-rspo3 antibodies and methods of use |
| JP7184751B2 (ja) | 2016-04-15 | 2022-12-06 | イミュネクスト インコーポレイテッド | 抗ヒトｖｉｓｔａ抗体およびその使用 |
| CA3021086C (en) | 2016-04-15 | 2023-10-17 | Bioatla, Llc | Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof |
| IL262321B1 (en) | 2016-04-15 | 2024-05-01 | Novartis Ag | Preparations and methods for selective protein expression |
| US20170298119A1 (en) | 2016-04-15 | 2017-10-19 | Visterra, Inc. | Antibody molecules to zika virus and uses thereof |
| MX2018012492A (es) | 2016-04-15 | 2019-06-06 | Genentech Inc | Métodos para monitorear y tratar el cáncer. |
| EP3974451A3 (en) | 2016-04-15 | 2022-07-06 | Boehringer Ingelheim International GmbH | Methods of treating inflammatory diseases |
| US10961311B2 (en) | 2016-04-15 | 2021-03-30 | Macrogenics, Inc. | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
| EP3443120A2 (en) | 2016-04-15 | 2019-02-20 | H. Hoffnabb-La Roche Ag | Methods for monitoring and treating cancer |
| SG10202109691UA (en) | 2016-04-15 | 2021-10-28 | Alder Biopharmaceuticals Inc | Anti-pacap antibodies and uses thereof |
| JOP20170091B1 (ar) | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية |
| US11230591B2 (en) | 2016-04-20 | 2022-01-25 | Merck Sharp & Dohme Corp. | CMV neutralizing antigen binding proteins |
| EP3445788B1 (en) | 2016-04-22 | 2022-01-19 | Alligator Bioscience AB | Novel bispecific polypeptides against cd137 |
| WO2017182609A1 (en) | 2016-04-22 | 2017-10-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency |
| MY200886A (en) | 2016-04-22 | 2024-01-22 | Obi Pharma Inc | Cancer Immunotherapy by Immune Activation or Immune Modulation Via Globo Series Antigens |
| CA3016917A1 (en) | 2016-04-27 | 2017-11-02 | Immunomedics, Inc. | Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
| US11514331B2 (en) | 2016-04-27 | 2022-11-29 | Massachusetts Institute Of Technology | Sequence-controlled polymer random access memory storage |
| US11410746B2 (en) | 2016-04-27 | 2022-08-09 | Massachusetts Institute Of Technology | Stable nanoscale nucleic acid assemblies and methods thereof |
| EP3448391B1 (en) | 2016-04-27 | 2024-05-29 | AbbVie Manufacturing Management Unlimited Company | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CR20180509A (es) | 2016-05-02 | 2019-02-15 | Hoffmann La Roche | Contorsbody - un ligante de diana monocatenario |
| ES2912453T3 (es) | 2016-05-06 | 2022-05-26 | Inst Nat Sante Rech Med | Composiciones farmacéuticas para el tratamiento de la leucemia mieloide aguda (LMA) quimiorresistente |
| SG11201809793UA (en) | 2016-05-09 | 2018-12-28 | Bristol Myers Squibb Co | Tl1a antibodies and uses thereof |
| SG11201809959PA (en) | 2016-05-10 | 2018-12-28 | Genentech Inc | Methods of decreasing trisulfide bonds during recombinant production of polypeptides |
| EP3454863A1 (en) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
| EP3454884B1 (en) | 2016-05-10 | 2023-07-12 | Sorbonne Université | Agents that activate cd47 and their use in the treatment of inflammation |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| ES2914118T3 (es) | 2016-05-11 | 2022-06-07 | Amgen Inc | Selección directa de células que expresan niveles altos de proteínas heterodiméricas usando vectores de complementación intragénica de glutamina sintetasa |
| EP3455252B1 (en) | 2016-05-11 | 2022-02-23 | F. Hoffmann-La Roche AG | Modified anti-tenascin antibodies and methods of use |
| SI3455261T1 (sl) | 2016-05-13 | 2023-01-31 | Bioatla, Inc. | Protitelesa proti ROR2, fragmenti protitelesa, njihovi imunokonjugati in uporabe le-teh |
| EP3455262A4 (en) | 2016-05-13 | 2020-04-08 | The General Hospital Corporation | ANTAGONISTIC ANTI-TUMOR NECROSE FACTOR RECEPTOR SUPER FAMILY ANTIBODIES |
| EP3458853B1 (en) | 2016-05-16 | 2022-09-07 | Onco Tracker, Inc. | Improved methods for monitoring immune status of a subject |
| SG11201810034XA (en) | 2016-05-17 | 2018-12-28 | Abbvie Biotherapeutics Inc | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
| JP7359547B2 (ja) | 2016-05-17 | 2023-10-11 | ジェネンテック， インコーポレイテッド | 免疫療法における診断及び使用のための間質遺伝子シグネチャー |
| CN107400165A (zh) | 2016-05-18 | 2017-11-28 | 上海开拓者生物医药有限公司 | 一种il‑13抗体及其制备方法和应用 |
| KR102530742B1 (ko) | 2016-05-20 | 2023-05-09 | 하푼 테라퓨틱스, 인크. | 단일 도메인 혈청 알부민 결합 단백질 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| PL3458101T3 (pl) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
| WO2017202813A1 (en) | 2016-05-24 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections |
| US20190292259A1 (en) | 2016-05-24 | 2019-09-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd) |
| WO2017202814A1 (en) | 2016-05-24 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons |
| IL245861A0 (en) | 2016-05-25 | 2016-09-04 | Yeda Res & Dev | Use of substances to treat drug-resistant tumors |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| CN117230193A (zh) | 2016-05-25 | 2023-12-15 | 生物运动有限公司 | 基于c-maf状态的乳腺癌治疗性治疗 |
| WO2017203051A1 (en) | 2016-05-26 | 2017-11-30 | University College Cork - National University Of Ireland, Cork | An engineered gram positive bacterium |
| LT3464361T (lt) | 2016-05-27 | 2022-01-10 | Abbvie Biotherapeutics Inc. | Anti-cd40 antikūnai ir jų panaudojimas |
| WO2017205745A1 (en) | 2016-05-27 | 2017-11-30 | Abbvie Biotherapeutics Inc. | Anti-4-1bb antibodies and their uses |
| EP3465221B1 (en) | 2016-05-27 | 2020-07-22 | H. Hoffnabb-La Roche Ag | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
| MY195089A (en) | 2016-05-27 | 2023-01-10 | Agenus Inc | Anti-Tim-3 Antibodies and Methods of use thereof |
| WO2017202890A1 (en) | 2016-05-27 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating myeloma |
| US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
| TW201902512A (zh) | 2016-06-02 | 2019-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療方法 |
| US20210177896A1 (en) | 2016-06-02 | 2021-06-17 | Novartis Ag | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| ES2877548T3 (es) | 2016-06-02 | 2021-11-17 | Abbvie Inc | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo |
| JP2019517499A (ja) | 2016-06-02 | 2019-06-24 | イムノコア リミテッド | ｇｐ１００特異的ＴＣＲ−抗ＣＤ３ ｓｃＦｖ融合タンパク質の投薬レジメン |
| US10851159B2 (en) | 2016-06-02 | 2020-12-01 | Bloom Diagnostics Ag | Antibodies that bind to human anti-Müllerian hormone (AMH) and their uses |
| AU2017276604B2 (en) | 2016-06-06 | 2020-02-27 | F. Hoffmann-La Roche Ag | Fusion proteins for ophthalmology with increased eye retention |
| JP7043425B2 (ja) | 2016-06-06 | 2022-03-29 | ジェネンテック， インコーポレイテッド | シルベストロール抗体－薬物コンジュゲート及び使用方法 |
| US20190307797A1 (en) | 2016-06-07 | 2019-10-10 | Maax-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
| CN109562168A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗cd98抗体及抗体药物偶联物 |
| WO2017214456A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| CN109641962A (zh) | 2016-06-08 | 2019-04-16 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
| RS61828B1 (sr) | 2016-06-08 | 2021-06-30 | Abbvie Inc | Anti-b7-h3 antitela i antitelske konjugacije lekova |
| AU2017277288B2 (en) | 2016-06-09 | 2024-05-16 | Omeros Corporation | Monoclonal antibodies, compositions and methods for detecting mucin -like protein (MLP) as a biomarker for ovarian and pancreatic cancer |
| IL263406B2 (en) | 2016-06-09 | 2023-09-01 | Pelican Therapeutics Inc | Anti-tnfrs25 antibodies |
| CA3027286A1 (en) | 2016-06-12 | 2017-12-21 | Millennium Pharmaceuticals, Inc. | Method of treating inflammatory bowel disease |
| KR102218714B1 (ko) | 2016-06-14 | 2021-02-24 | 머크 샤프 앤드 돔 코포레이션 | 항응고 인자 xi 항체 |
| MA45235A (fr) | 2016-06-14 | 2019-04-17 | Regeneron Pharma | Anticorps anti-c5 et leurs utilisations |
| US11098107B2 (en) | 2016-06-15 | 2021-08-24 | Sutro Biopharma, Inc. | Antibodies with engineered CH2 domains, compositions thereof and methods of using the same |
| KR102492057B1 (ko) | 2016-06-15 | 2023-01-26 | 노파르티스 아게 | 골 형태형성 단백질 6(ｂｍｐ6)의 억제제를 사용한 질병의 치료 방법 |
| EP3471776B1 (en) | 2016-06-15 | 2022-05-04 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies |
| WO2017218891A1 (en) | 2016-06-17 | 2017-12-21 | Life Technologies Corporation | Site-specific crosslinking of antibodies |
| JP2019521986A (ja) | 2016-06-17 | 2019-08-08 | ジェネンテック， インコーポレイテッド | 多重特異性抗体の精製 |
| PT3472207T (pt) | 2016-06-20 | 2021-03-31 | F Star Delta Ltd | Moléculas ligantes que se ligam a pd-l1 e lag-3 |
| US11780924B2 (en) | 2016-06-21 | 2023-10-10 | University Of Oslo | HLA binding vaccine moieties and uses thereof |
| SG11201811490XA (en) | 2016-06-21 | 2019-01-30 | Teneobio Inc | Cd3 binding antibodies |
| WO2017221255A1 (en) | 2016-06-23 | 2017-12-28 | Memed Diagnostics Ltd. | Measuring trail by lateral flow immunoassay |
| JP7133477B2 (ja) | 2016-06-24 | 2022-09-08 | ジェネンテック， インコーポレイテッド | 抗ポリユビキチン多重特異性抗体 |
| FR3053042B1 (fr) | 2016-06-24 | 2018-08-10 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Anticorps dirige contre le sous-type b des recepteurs aux endothelines et ses utilisations |
| WO2018001844A1 (en) | 2016-06-28 | 2018-01-04 | Nestec S.A. | Biomarkers of blood-brain barrier dysfunction |
| GB201611530D0 (en) | 2016-07-01 | 2016-08-17 | Alligator Bioscience Ab | Novel polypeptides |
| CN109641967A (zh) | 2016-07-01 | 2019-04-16 | 戊瑞治疗有限公司 | 用GITR激动剂和CpG的组合的抗肿瘤疗法 |
| WO2018007314A1 (en) | 2016-07-04 | 2018-01-11 | F. Hoffmann-La Roche Ag | Novel antibody format |
| EA038617B1 (ru) * | 2016-07-06 | 2021-09-23 | Онкоиммьюн, Инк. | Химерные и гуманизированные античеловеческие ctla-4 моноклональные антитела и их использование |
| US20180024132A1 (en) | 2016-07-07 | 2018-01-25 | Berg Llc | Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer |
| KR20190039937A (ko) | 2016-07-08 | 2019-04-16 | 스태튼 바이오테크놀로지 비.브이. | 항-ApoC3 항체 및 이의 사용 방법 |
| WO2018011691A1 (en) | 2016-07-12 | 2018-01-18 | Nestec S.A. | Competitive immunoassay methods |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| CN109862911A (zh) | 2016-07-13 | 2019-06-07 | 比奥根Ma公司 | Lingo-1拮抗剂的剂量方案和用于治疗脱髓鞘病症的用途 |
| AU2017295704B2 (en) | 2016-07-13 | 2023-07-13 | President And Fellows Of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
| PE20190418A1 (es) | 2016-07-14 | 2019-03-19 | Bristol Myers Squibb Co | Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos |
| EP3484455A2 (en) | 2016-07-15 | 2019-05-22 | Novartis AG | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| BR112019000790A2 (pt) | 2016-07-15 | 2019-07-02 | Acceleron Pharma Inc | composições e métodos para tratar hipertensão pulmonar |
| WO2018015881A1 (en) | 2016-07-18 | 2018-01-25 | Ramot At Tel-Aviv University Ltd. | Modular platform for targeted therapeutics |
| KR20190031299A (ko) | 2016-07-20 | 2019-03-25 | 주식회사 에스티큐브 | 글리코실화된 pd-l1에 결합하는 항체의 조합을 사용하는 암 치료 방법 |
| CA3031542A1 (en) | 2016-07-20 | 2018-01-25 | University Of Utah Research Foundation | Cd229 car t cells and methods of use thereof |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| WO2018017814A1 (en) | 2016-07-20 | 2018-01-25 | President And Fellows Of Harvard College | Peptidoglycan glycosyltransferase inhibitors of sed proteins for treating bacterial infections |
| IL296127A (en) | 2016-07-22 | 2022-11-01 | Dana Farber Cancer Inst Inc | Antibodies to the glucocorticoid-induced tumor necrosis factor receptor and methods of using them |
| JP2019531332A (ja) | 2016-07-22 | 2019-10-31 | ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー．ファウ．（デーツェットエンエー） | Ｔｒｅｍ２切断モジュレーター及びその使用 |
| WO2018018082A1 (en) | 2016-07-26 | 2018-02-01 | The Australian National University | Immunostimulatory compositions and uses therefor |
| EP3490582A4 (en) | 2016-07-27 | 2020-04-01 | Acceleron Pharma Inc. | METHOD AND COMPOSITIONS FOR TREATING MYELOFIBROSE |
| JP2019527690A (ja) | 2016-07-27 | 2019-10-03 | オービーアイ ファーマ，インコーポレイテッド | 免疫原性／治療用グリカン組成物およびその使用 |
| NL2017267B1 (en) | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
| WO2018023121A1 (en) | 2016-07-29 | 2018-02-01 | Obi Pharma, Inc. | Human antibodies, pharmaceutical compositions and methods |
| KR20230107408A (ko) | 2016-07-29 | 2023-07-14 | 주노 쎄러퓨티크스 인코퍼레이티드 | 항-cd19 항체에 대한 항-이디오타입 항체 |
| AU2017303205A1 (en) | 2016-07-29 | 2019-01-17 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody exhibiting increased alternative FVIII-cofactor-function activity |
| GB201613167D0 (en) | 2016-07-29 | 2016-09-14 | Univ Southampton | Cancer and b-cell related disease therapy |
| WO2018020000A1 (en) | 2016-07-29 | 2018-02-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies targeting tumor associated macrophages and uses thereof |
| JOP20170154B1 (ar) | 2016-08-01 | 2023-03-28 | Omeros Corp | تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة |
| KR20190036551A (ko) | 2016-08-01 | 2019-04-04 | 노파르티스 아게 | Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료 |
| US10519250B2 (en) | 2016-08-01 | 2019-12-31 | Xoma (Us) Llc | Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof |
| AU2017325654A1 (en) | 2016-08-02 | 2019-02-14 | Visterra, Inc. | Engineered polypeptides and uses thereof |
| AU2017306432A1 (en) | 2016-08-02 | 2019-03-21 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
| CA3032559C (en) | 2016-08-03 | 2022-04-19 | Pfizer Inc. | Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates |
| CN109862910A (zh) | 2016-08-03 | 2019-06-07 | 小利兰·斯坦福大学托管委员会 | 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效 |
| AU2017305073B2 (en) | 2016-08-05 | 2024-02-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for prevention or treatment of IL-8 related diseases |
| JP7161266B2 (ja) | 2016-08-05 | 2022-10-26 | メディミューン，エルエルシー | 抗ｏ２抗体およびその使用 |
| CN109963871A (zh) | 2016-08-05 | 2019-07-02 | 豪夫迈·罗氏有限公司 | 具有激动活性的多价及多表位抗体以及使用方法 |
| JP2019528312A (ja) | 2016-08-07 | 2019-10-10 | ノバルティス アーゲー | ｍＲＮＡ媒介性の免疫化方法 |
| WO2018029124A1 (en) | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
| EA201990470A1 (ru) | 2016-08-09 | 2019-09-30 | Сиэтл Дженетикс, Инк. | Конъюгаты лекарственного средства с самостабилизирующимися линкерами, имеющие улучшенные физико-химические свойства |
| EP3497237B1 (en) | 2016-08-10 | 2022-05-04 | Institut Pasteur | Methods and reagents for detecting piperaquine-resistant plasmodium falciparum malaria |
| EP3496763A1 (en) | 2016-08-11 | 2019-06-19 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
| JP2019524820A (ja) | 2016-08-12 | 2019-09-05 | ジェネンテック， インコーポレイテッド | Ｍｅｋ阻害剤、ｐｄ−１軸阻害剤及びｖｅｇｆ阻害剤での組合せ療法 |
| EP3497125A1 (en) | 2016-08-12 | 2019-06-19 | ARSANIS Biosciences GmbH | Anti-galactan ii monoclonal antibodies targeting klebsiella pneumoniae |
| US10759848B2 (en) | 2016-08-12 | 2020-09-01 | Arsanis Biosciences Gmbh | Klebsiella pneumoniae O3 specific antibodies |
| JP2019530646A (ja) | 2016-08-12 | 2019-10-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | タンパク質精製法 |
| ES2954259T3 (es) | 2016-08-15 | 2023-11-21 | Novartis Ag | Regímenes y métodos de tratamiento de la esclerosis múltiple utilizando ofatumumab |
| SG11201901228QA (en) | 2016-08-15 | 2019-03-28 | Genentech Inc | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide |
| WO2018035364A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute Inc. | Product and methods useful for modulating and evaluating immune responses |
| US11225689B2 (en) | 2016-08-17 | 2022-01-18 | The Broad Institute, Inc. | Method for determination and identification of cell signatures and cell markers |
| CN106938051B (zh) | 2016-08-22 | 2019-10-11 | 复旦大学 | 靶向于组织因子的抗体-药物偶联物 |
| EP3502250B1 (en) | 2016-08-22 | 2024-04-24 | Chugai Seiyaku Kabushiki Kaisha | Gene-modified rodent expressing human gpc3 polypeptide |
| KR102588027B1 (ko) | 2016-08-22 | 2023-10-12 | 초 파마 인크. | 항체, 결합 단편 및 사용 방법 |
| WO2018037001A1 (en) | 2016-08-23 | 2018-03-01 | Medimmune Limited | Anti-vegf-a antibodies and uses thereof |
| CN106967172B (zh) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| SG11201901355SA (en) | 2016-08-30 | 2019-03-28 | Regeneron Pharma | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling |
| GB201614627D0 (en) | 2016-08-30 | 2016-10-12 | Glaxosmithkline Ip Dev Ltd | Antigen binding proteins |
| EP3508576A4 (en) | 2016-08-31 | 2020-04-22 | Onco Therapy Science, Inc. | MONOCLONAL ANTIBODIES AGAINST MILK AND USE THEREOF |
| US10870694B2 (en) | 2016-09-02 | 2020-12-22 | Dana Farber Cancer Institute, Inc. | Composition and methods of treating B cell disorders |
| WO2018045245A1 (en) | 2016-09-02 | 2018-03-08 | Sirenas Llc | Cyclic peptide analogs and conjugates thereof |
| WO2018045210A1 (en) | 2016-09-02 | 2018-03-08 | Therapeutics Lp 180 | Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody |
| EP3506920A4 (en) | 2016-09-02 | 2020-05-27 | 180 Therapeutics LP | METHOD OF TREATING SYSTEMIC FIBROSIS USING A BISPECIFIC ANTIBODY AGAINST IL-33 AND TNF |
| BR112019004214A2 (pt) | 2016-09-06 | 2019-05-28 | Dana Farber Cancer Inst Inc | métodos para tratar ou prevenir infecção pelo vírus zika |
| EP3510046A4 (en) | 2016-09-07 | 2020-05-06 | The Regents of the University of California | ANTIBODIES AGAINST OXIDATION-SPECIFIC EPITOPES |
| EP3510047A1 (en) | 2016-09-07 | 2019-07-17 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Anti-nkp46 antibodies and therapeutic use of same |
| WO2018049248A1 (en) | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus equipped with bispecific engager molecules |
| EP3293271A1 (en) | 2016-09-12 | 2018-03-14 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | Marker and target as a diagnostic variable and target for therapy of metastatic cancer |
| EP3512883A1 (en) | 2016-09-13 | 2019-07-24 | Humanigen, Inc. | Epha3 antibodies for the treatment of pulmonary fibrosis |
| PE20191102A1 (es) | 2016-09-14 | 2019-08-23 | Abbvie Biotherapeutics Inc | Anticuerpos anti-pd-1 y sus usos |
| WO2018053142A2 (en) | 2016-09-14 | 2018-03-22 | President And Fellows Of Harvard College | Methods and compositions for modulating erythropoiesis |
| BR122022002481A8 (pt) | 2016-09-14 | 2023-02-07 | Teneobio Inc | Anticorpos biespecíficos de ligação específica para cd3delta-epsilon |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| AU2017327828B2 (en) | 2016-09-16 | 2023-11-16 | Shanghai Henlius Biotech, Inc. | Anti-PD-1 antibodies |
| KR102257154B1 (ko) | 2016-09-19 | 2021-05-28 | 셀진 코포레이션 | Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법 |
| PL3328887T3 (pl) | 2016-09-19 | 2021-12-27 | I-Mab Biopharma (Hangzhou) Co., Ltd. | Przeciwciała anty-gm-csf i ich zastosowania |
| US10766958B2 (en) | 2016-09-19 | 2020-09-08 | Celgene Corporation | Methods of treating vitiligo using PD-1 binding antibodies |
| CN109689682B (zh) | 2016-09-19 | 2022-11-29 | 豪夫迈·罗氏有限公司 | 基于补体因子的亲和层析 |
| CA3037230A1 (en) | 2016-09-20 | 2018-03-29 | Merck Patent Gmbh | Diagnostic anti-pd-l1 antibody and use thereof |
| US11136409B2 (en) | 2016-09-20 | 2021-10-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators |
| DK3515478T3 (da) | 2016-09-21 | 2024-05-21 | Nextcure Inc | Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf |
| EP4360714A2 (en) | 2016-09-21 | 2024-05-01 | Nextcure, Inc. | Antibodies for siglec-15 and methods of use thereof |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| US11525008B2 (en) | 2016-09-22 | 2022-12-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of lung cancer |
| CN109952314A (zh) | 2016-09-23 | 2019-06-28 | 泰瓦制药国际有限公司 | 治疗难治性偏头痛 |
| EP3515488A1 (en) | 2016-09-23 | 2019-07-31 | Teva Pharmaceuticals International GmbH | Treating cluster headache |
| CA3036564A1 (en) | 2016-09-23 | 2018-03-29 | Elstar Therapeutics, Inc. | Multispecific antibody molecules comprising lambda and kappa light chains |
| EP3516390A1 (en) | 2016-09-23 | 2019-07-31 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Manipulation of immune activity by modulation of expression |
| CA3034105A1 (en) | 2016-09-23 | 2018-03-29 | Csl Limited | Coagulation factor binding proteins and uses thereof |
| AU2017330405B2 (en) | 2016-09-23 | 2024-02-01 | Genentech, Inc. | Uses of IL-13 antagonists for treating atopic dermatitis |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| WO2018064190A1 (en) | 2016-09-27 | 2018-04-05 | Epicentrx, Inc. | Immunomodulatory fusion proteins |
| JP2019534710A (ja) | 2016-09-28 | 2019-12-05 | ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー | インターロイキン２に結合する抗体およびその使用 |
| CA3036232A1 (en) | 2016-09-29 | 2018-04-05 | The Regents Of The University Of California | Neutralizing antibodies to the .alpha.v.beta.8 integrin complex for immunotherapy |
| TW201815419A (zh) | 2016-09-29 | 2018-05-01 | 美商建南德克公司 | Mek抑制劑、 pd-1軸抑制劑及紫杉烷之組合療法 |
| CA3038909A1 (en) | 2016-09-29 | 2018-04-05 | Amgen Inc. | Low-viscosity antigen binding proteins and methods of making them |
| CN110249226B (zh) | 2016-10-03 | 2023-08-25 | 雅培实验室 | 评估患者样品中gfap状态的改进方法 |
| JP7050770B2 (ja) | 2016-10-05 | 2022-04-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
| AU2017340633B2 (en) | 2016-10-05 | 2024-01-11 | University Of Central Florida Research Foundation, Inc. | Methods and compositions related to NK cell and anti-PDL1 cancer therapies |
| CN116650622A (zh) | 2016-10-05 | 2023-08-29 | 艾科赛扬制药股份有限公司 | 用于治疗肾脏疾病的组合物和方法 |
| TWI762516B (zh) | 2016-10-06 | 2022-05-01 | 日商腫瘤療法 科學股份有限公司 | 針對ｆｚｄ１０之單株抗體及其用途 |
| CA3038712A1 (en) | 2016-10-06 | 2018-04-12 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| EP3522923A1 (en) | 2016-10-06 | 2019-08-14 | Pfizer Inc | Dosing regimen of avelumab for the treatment of cancer |
| US20200016202A1 (en) | 2016-10-07 | 2020-01-16 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| MX2019003886A (es) | 2016-10-07 | 2019-08-05 | Novartis Ag | Receptores de antigenos quimericos para el tratamiento del cancer. |
| DK3445787T3 (da) | 2016-10-07 | 2021-03-01 | Tcr2 Therapeutics Inc | Sammensætninger og fremgangsmåder til omprogrammering af t-cellereceptorer under anvendelse af fusionsproteiner |
| WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| KR20230133934A (ko) | 2016-10-11 | 2023-09-19 | 아게누스 인코포레이티드 | 항-lag-3 항체 및 이의 사용 방법 |
| US20190233512A1 (en) | 2016-10-12 | 2019-08-01 | Sutro Biopharma, Inc. | Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies |
| CN110300520B (zh) | 2016-10-12 | 2022-10-04 | 美国比奥维拉迪维股份有限公司 | 抗C1s抗体及其使用方法 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| CN110072552A (zh) | 2016-10-14 | 2019-07-30 | 默沙东公司 | 用于治疗尿路上皮癌的pd-1拮抗剂和艾立布林的组合 |
| CA3040687A1 (en) | 2016-10-14 | 2018-04-19 | Childrens' Medical Center Corporation | Compositions and methods for treating diseases and disorders of the central nervous system |
| US20180105588A1 (en) | 2016-10-14 | 2018-04-19 | Boehringer Ingelheim International Gmbh | Methods of treating diseases |
| WO2018075564A1 (en) | 2016-10-17 | 2018-04-26 | University Of Maryland, College Park | Multispecific antibodies targeting human immunodeficiency virus and methods of using the same |
| MX2019004046A (es) | 2016-10-18 | 2019-08-21 | Seattle Genetics Inc | Administracion dirigida de inhibidores de la via de rescate de nicotinamida adenina dinucleotido. |
| EP3529268A1 (en) | 2016-10-19 | 2019-08-28 | The Scripps Research Institute | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
| KR20190064636A (ko) | 2016-10-19 | 2019-06-10 | 메디뮨 엘엘씨 | 항-o1 항체 및 이의 용도 |
| TW202300515A (zh) | 2016-10-20 | 2023-01-01 | 法商賽諾菲公司 | 抗ｃｈｉｋｖ抗體及其用途 |
| WO2018073363A1 (en) | 2016-10-21 | 2018-04-26 | Innate Pharma | Treatment with anti-kir3dl2 agents |
| CN110291102A (zh) | 2016-10-21 | 2019-09-27 | 国立卫生和医学研究所 | 促进t细胞应答的方法 |
| AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
| CA3080270A1 (en) | 2016-10-25 | 2018-05-03 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Monoclonal antibodies binding to the cd160 transmembrane isoform |
| WO2018081531A2 (en) | 2016-10-28 | 2018-05-03 | Ariad Pharmaceuticals, Inc. | Methods for human t-cell activation |
| EP3532496A1 (en) | 2016-10-28 | 2019-09-04 | Banyan Biomarkers, Inc. | Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods |
| JP7267914B2 (ja) | 2016-11-02 | 2023-05-02 | エンクマフ エスアーエールエル | Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
| AR110017A1 (es) | 2016-11-02 | 2019-02-13 | Jounce Therapeutics Inc | Anticuerpos de pd-1 y usos de estos |
| KR20190107656A (ko) | 2016-11-02 | 2019-09-20 | 이뮤노젠 아이엔씨 | 항체-약물 콘주게이트 및 parp 억제제로 병용 치료 |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| WO2018144097A1 (en) | 2016-11-04 | 2018-08-09 | Akeagen Llc | Genetically modified non-human animals and methods for producing heavy chain-only antibodies |
| WO2018083535A1 (en) | 2016-11-04 | 2018-05-11 | Novimmune Sa | Anti-cd19 antibodies and methods of use thereof |
| JP7045724B2 (ja) | 2016-11-07 | 2022-04-01 | ニューラクル サイエンス カンパニー リミテッド | 配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途 |
| EP3535288A1 (en) | 2016-11-07 | 2019-09-11 | Immunocore Limited | Peptides |
| WO2018087172A1 (en) | 2016-11-09 | 2018-05-17 | Philogen S.P.A | Il2 and tnf mutant immunoconjugates |
| EP3538558A4 (en) | 2016-11-09 | 2020-07-15 | North Carolina State University | TREATMENT OF ALLERGIC DISEASES WITH A CHIMERAL PROTEIN |
| EP3321280B8 (en) | 2016-11-10 | 2021-03-10 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Immune modulators for reducing immune-resistance in melanoma and other proliferative diseases |
| US20190263906A1 (en) | 2016-11-10 | 2019-08-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Immune modulators for reducing immune-resistance in melanoma and other proliferative diseases |
| US11008325B2 (en) | 2016-11-14 | 2021-05-18 | Virginia Commonwealth University | Inhibitors of cancer invasion, attachment, and/or metastasis |
| WO2018093797A1 (en) | 2016-11-15 | 2018-05-24 | The Schepens Eye Research Institute, Inc. | Compositions and methods for the treatment of aberrant angiogenesis |
| US11208474B2 (en) | 2016-11-16 | 2021-12-28 | Janssen Biotech, Inc. | Method of treating psoriasis with anti-IL23 specific antibody |
| WO2018094143A1 (en) | 2016-11-17 | 2018-05-24 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| JOP20190100A1 (ar) | 2016-11-19 | 2019-05-01 | Potenza Therapeutics Inc | بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها |
| GB201619648D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
| TWI822055B (zh) | 2016-11-21 | 2023-11-11 | 台灣浩鼎生技股份有限公司 | 共軛生物分子、醫藥組成物及方法 |
| WO2018091724A1 (en) | 2016-11-21 | 2018-05-24 | Cureab Gmbh | Anti-gp73 antibodies and immunoconjugates |
| CN116327963A (zh) | 2016-11-21 | 2023-06-27 | 济世-伊沃泰克生物制品有限公司 | 一种眼科制剂及其用途 |
| WO2018091720A1 (en) | 2016-11-21 | 2018-05-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the prophylactic treatment of metastases |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| JP6812551B2 (ja) | 2016-11-23 | 2021-01-13 | ハープーン セラピューティクス，インク． | 前立腺特異的膜抗原結合タンパク質 |
| CR20190297A (es) | 2016-11-23 | 2019-11-01 | Bioverativ Therapeutics Inc | Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x |
| AU2017363302A1 (en) | 2016-11-23 | 2019-06-27 | Harpoon Therapeutics, Inc. | PSMA targeting trispecific proteins and methods of use |
| US10780080B2 (en) | 2016-11-23 | 2020-09-22 | Translational Drug Development, Llc | Benzamide and active compound compositions and methods of use |
| EP3544628A4 (en) | 2016-11-23 | 2020-11-18 | Immunoah Therapeutics, Inc. | 4-1BB BINDING PROTEINS AND THEIR USES |
| US10759855B2 (en) | 2016-12-02 | 2020-09-01 | Rigel Pharmaceuticals, Inc. | Antigen binding molecules to TIGIT |
| WO2018100190A1 (en) | 2016-12-02 | 2018-06-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for diagnosing renal cell carcinoma |
| US11198723B2 (en) | 2016-12-05 | 2021-12-14 | The Administrators Of The Tulane Educational Fund | Arenavirus monoclonal antibodies and uses |
| PE20191135A1 (es) | 2016-12-07 | 2019-09-02 | Genentech Inc | Anticuerpos antitau y metodos de uso |
| ES2963226T3 (es) | 2016-12-07 | 2024-03-26 | Agenus Inc | Anticuerpos ANTI-CTLA-4 y métodos de uso de los mismos |
| WO2018106776A2 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| AU2017373945A1 (en) | 2016-12-07 | 2019-06-20 | Agenus Inc. | Antibodies and methods of use thereof |
| EP4252629A3 (en) | 2016-12-07 | 2023-12-27 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| WO2018112032A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8 |
| CA3045475A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device |
| US10980739B2 (en) | 2016-12-14 | 2021-04-20 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| KR20190097107A (ko) | 2016-12-14 | 2019-08-20 | 프로제너티, 인크. | Jak 저해제로의 위장관 질환의 치료 및 장치 |
| WO2018112235A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor |
| WO2018112237A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor |
| MX2019006864A (es) | 2016-12-14 | 2019-10-15 | Progenity Inc | Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de factor de necrosis tumoral (tnf). |
| WO2018112256A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor |
| JP7150723B2 (ja) | 2016-12-14 | 2022-10-11 | ビオラ・セラピューティクス・インコーポレイテッド | 消化管疾病のインテグリン阻害薬による治療 |
| US11426566B2 (en) | 2016-12-14 | 2022-08-30 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a TLR modulator |
| JP7244987B2 (ja) | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | 多剤抗体薬物コンジュゲート |
| HUE050399T2 (hu) | 2016-12-15 | 2020-12-28 | Abbvie Biotherapeutics Inc | Anti-OX40 antitestek és alkalmazásuk |
| WO2018112407A1 (en) | 2016-12-15 | 2018-06-21 | Duke University | Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors |
| WO2018112364A1 (en) | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating melanoma |
| WO2018112360A1 (en) | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating cancer |
| US10132797B2 (en) | 2016-12-19 | 2018-11-20 | Tolero Pharmaceuticals, Inc. | Profiling peptides and methods for sensitivity profiling |
| US20200157190A1 (en) | 2016-12-19 | 2020-05-21 | Abcam Plc | Monovalent and divalent binding proteins |
| CA3047522A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (adcs) having ksp inhibitors |
| CA3045970A1 (en) | 2016-12-21 | 2018-06-28 | F. Hoffmann-La Roche Ag | Method for in vitro glycoengineering of antibodies |
| WO2018114878A1 (en) | 2016-12-21 | 2018-06-28 | F. Hoffmann-La Roche Ag | Re-use of enzymes in in vitro glycoengineering of antibodies |
| EP3558388A1 (de) | 2016-12-21 | 2019-10-30 | Bayer Pharma Aktiengesellschaft | Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen |
| WO2018114798A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
| GB201621806D0 (en) | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
| CN106519034B (zh) | 2016-12-22 | 2020-09-18 | 鲁南制药集团股份有限公司 | 抗pd-1抗体及其用途 |
| EP3559037A1 (en) | 2016-12-22 | 2019-10-30 | Wake Forest University Health Sciences | Sirp-gamma targeted agents for use in the treatment of cancer |
| EP3559039A1 (en) | 2016-12-22 | 2019-10-30 | Università Degli Studi Magna Graecia Catanzaro | A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43 |
| JOP20190134A1 (ar) | 2016-12-23 | 2019-06-02 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها |
| JP7062669B2 (ja) | 2016-12-23 | 2022-05-06 | ブリストル－マイヤーズ スクイブ カンパニー | 改善されたバイオアナリシス特性およびバイオプロセシング特性のための、治療用免疫グロブリンｇ４の設計 |
| BR112019013096A2 (pt) | 2016-12-23 | 2019-12-17 | Visterra Inc | polipeptídeos ligantes e métodos de preparo dos mesmos |
| AR110424A1 (es) | 2016-12-23 | 2019-03-27 | Macrogenics Inc | Moléculas de unión a adam9 y métodos de uso de las mismas |
| RS63154B1 (sr) | 2016-12-23 | 2022-05-31 | Immunogen Inc | Imunokonjugati koji ciljano deluju na adam9 i postupci za njihovu upotrebu |
| WO2018116255A1 (en) | 2016-12-23 | 2018-06-28 | Novartis Ag | Factor xi antibodies and methods of use |
| JP6901562B2 (ja) | 2016-12-27 | 2021-07-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規のビオチン特異的モノクローナル抗体およびその使用 |
| WO2018122205A2 (en) | 2016-12-27 | 2018-07-05 | F. Hoffmann-La Roche Ag | Novel biotin-specific monoclonal antibody and use thereof |
| WO2018122249A1 (en) | 2016-12-28 | 2018-07-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer |
| KR102085798B1 (ko) | 2016-12-28 | 2020-03-06 | 주식회사 인투셀 | 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물 |
| JP6888764B2 (ja) | 2016-12-29 | 2021-06-16 | ディヴェロップメント センター フォー バイオテクノロジー | 糖タンパク質−薬物コンジュゲートを調製する方法 |
| WO2018129092A1 (en) | 2017-01-04 | 2018-07-12 | Research Institute At Nationwide Children's Hospital | Antibody fragments for the treatment of biofilm-related disorders |
| AU2018206552A1 (en) | 2017-01-04 | 2019-07-18 | Research Institute At Nationwide Children's Hospital | DNABII vaccines and antibodies with enhanced activity |
| WO2018129039A1 (en) | 2017-01-04 | 2018-07-12 | President And Fellows Of Harvard College | Modulating nudix homology domain (nhd) with nicotinamide mononucleotide analogs and derivatives of same |
| EP3609536B1 (en) | 2017-01-05 | 2022-03-09 | Innovative Cellular Therapeutics Holdings, Ltd. | Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor |
| US11155611B2 (en) | 2017-01-06 | 2021-10-26 | Scholar Rock, Inc. | Compositions and methods for making and using anti-myostatin antibodies |
| EP3567054A4 (en) | 2017-01-06 | 2021-03-10 | ABL Bio Inc. | ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF |
| US11390685B2 (en) | 2017-01-06 | 2022-07-19 | Biosion, Inc. | ErbB2 antibodies and uses therefore |
| WO2018127585A1 (en) | 2017-01-06 | 2018-07-12 | Txcell | Monospecific regulatory t cell population with cytotoxicity for b cells |
| CA3049005A1 (en) | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | Isoform-specific, context-permissive tgf.beta.1 inhibitors and use thereof |
| WO2018129395A1 (en) | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
| GB201700345D0 (en) | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
| WO2018132597A1 (en) | 2017-01-12 | 2018-07-19 | Eureka Therapeutics, Inc. | Constructs targeting histone h3 peptide/mhc complexes and uses thereof |
| WO2018132768A1 (en) | 2017-01-13 | 2018-07-19 | Sanna Pietro P | Methods and compositions for treating hpa hyperactivity |
| CN110913872B (zh) | 2017-01-17 | 2023-08-04 | 儿童医疗中心有限公司 | 治疗溶酶体贮积疾病及病症的组合物和方法 |
| DK3570884T3 (da) | 2017-01-17 | 2020-11-30 | Genentech Inc | Subkutane HER2-antistofformuleringer |
| JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
| CN110167967B (zh) | 2017-01-18 | 2022-08-05 | 豪夫迈·罗氏有限公司 | 针对抗pd-l1抗体的独特型抗体及其用途 |
| US11890319B2 (en) | 2017-01-18 | 2024-02-06 | Visterra, Inc. | Antibody molecule-drug conjugates and uses thereof |
| CN110291109B (zh) | 2017-01-20 | 2023-01-31 | 大有华夏生物医药集团有限公司 | 人程序性死亡受体pd-1的单克隆抗体及其片段 |
| MX2019008758A (es) | 2017-01-24 | 2019-09-11 | I Mab | Anticuerpos anti-cd37 y usos de los mismos. |
| KR20190111086A (ko) | 2017-01-24 | 2019-10-01 | 화이자 인코포레이티드 | 칼리키아마이신 유도체 및 이의 항체 약물 접합체 |
| US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
| SG10202108219QA (en) | 2017-01-27 | 2021-08-30 | A Clip Institute Co | Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease |
| TWI796314B (zh) | 2017-01-27 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物 |
| WO2018140121A1 (en) | 2017-01-30 | 2018-08-02 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis |
| CN110582509A (zh) | 2017-01-31 | 2019-12-17 | 诺华股份有限公司 | 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症 |
| IL303108B1 (en) | 2017-01-31 | 2024-03-01 | Pfizer | NEISSERIA MENINGITIDIS preparations and methods therefor |
| AU2018214946A1 (en) | 2017-01-31 | 2019-08-08 | Vanderbilt University | Generation of human allergen-and helminth-specific IgE monoclonal antibodies for diagnostic and therapeutic use |
| JP7068323B2 (ja) | 2017-02-02 | 2022-05-16 | エフ．ホフマン－ラ ロシュ アーゲー | 少なくとも２種のペグ化された分析物特異的結合剤を使用する免疫アッセイ |
| JOP20190189A1 (ar) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t |
| MX2019007984A (es) | 2017-02-02 | 2019-10-15 | Merck Patent Gmbh | Apareamiento preferido de dominios de anticuerpos. |
| AU2018214222C1 (en) | 2017-02-03 | 2021-08-05 | Acticor Biotech | Inhibition of platelet aggregation using anti-human GPVI antibodies |
| US20180221476A1 (en) | 2017-02-06 | 2018-08-09 | Oncoquest Nc. | Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant |
| WO2018141959A1 (en) | 2017-02-06 | 2018-08-09 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
| CA3052911A1 (en) | 2017-02-08 | 2018-08-16 | Novartis Ag | Fgf21 mimetic antibodies and uses thereof |
| JP6671555B2 (ja) | 2017-02-08 | 2020-03-25 | アーデーセー セラピューティクス ソシエテ アノニム | ピロロベンゾジアゼピン抗体複合体 |
| HRP20211640T1 (hr) | 2017-02-08 | 2022-02-04 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin - protutijelo |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| EP3579879A4 (en) | 2017-02-09 | 2020-12-16 | Memorial Sloan Kettering Cancer Center | ANTI-BODY ANTI-KIR3DL1 |
| EP3579872A1 (en) | 2017-02-10 | 2019-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
| US10738131B2 (en) | 2017-02-10 | 2020-08-11 | Genentech, Inc. | Anti-tryptase antibodies, compositions thereof, and uses thereof |
| US20200291089A1 (en) | 2017-02-16 | 2020-09-17 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| JP7136790B2 (ja) | 2017-02-17 | 2022-09-13 | ブリストル－マイヤーズ スクイブ カンパニー | アルファ－シヌクレインに対する抗体およびその使用 |
| WO2018156785A1 (en) | 2017-02-22 | 2018-08-30 | Sutro Biopharma, Inc. | Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
| SG11201907753TA (en) | 2017-02-24 | 2019-09-27 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| JP6949131B2 (ja) | 2017-02-28 | 2021-10-13 | サノフイＳａｎｏｆｉ | 治療用ｒｎａ |
| CN110573523A (zh) | 2017-02-28 | 2019-12-13 | 宾夕法尼亚州大学信托人 | 基于aav载体的流感疫苗 |
| EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| JP7455579B2 (ja) | 2017-02-28 | 2024-03-26 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 新規アデノ随伴ウイルス（ａａｖ）クレードｆベクター及びその用途 |
| WO2018159549A1 (ja) | 2017-03-01 | 2018-09-07 | 株式会社膠原病研究所 | 自己免疫疾患の予防および／または治療剤、並びに、ワクチン |
| EP3589754B1 (en) | 2017-03-01 | 2023-06-28 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for cancer |
| WO2018160897A1 (en) | 2017-03-02 | 2018-09-07 | Beth Israel Deaconess Medical Center, Inc. | Preventing post-ictal headaches |
| US11685776B2 (en) | 2017-03-02 | 2023-06-27 | Novartis Ag | Engineered heterodimeric proteins |
| EP3589654A1 (en) | 2017-03-02 | 2020-01-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
| CN116850283A (zh) | 2017-03-02 | 2023-10-10 | 豪夫迈·罗氏有限公司 | Her2阳性乳腺癌的辅助治疗 |
| KR20240044544A (ko) | 2017-03-03 | 2024-04-04 | 씨젠 인크. | 글리칸-상호작용 화합물 및 사용 방법 |
| US11198735B2 (en) | 2017-03-03 | 2021-12-14 | Rinat Neuroscience Corp. | Anti-GITR antibodies and methods of use thereof |
| EP3592377A4 (en) | 2017-03-09 | 2021-02-17 | Diamedica Inc. | DOSAGE FORMS OF TISSUE KALLIKREIN 1 |
| EP3592350A4 (en) | 2017-03-10 | 2020-12-23 | Embera NeuroTherapeutics, Inc. | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF |
| JP7021245B2 (ja) | 2017-03-10 | 2022-02-16 | エフ．ホフマン－ラ ロシュ アーゲー | 多重特異性抗体を生産するための方法 |
| GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
| TW201842931A (zh) | 2017-03-14 | 2018-12-16 | 美商生物維瑞提夫美國公司 | 用於治療補體介導之疾病及病症之方法 |
| KR102619015B1 (ko) | 2017-03-15 | 2023-12-28 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
| CN114940713B (zh) | 2017-03-15 | 2024-04-30 | 清华大学 | 抗trkb抗体 |
| AU2018236271B2 (en) | 2017-03-15 | 2023-12-21 | Research Institute At Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
| WO2018167312A1 (en) | 2017-03-16 | 2018-09-20 | Université Libre de Bruxelles | Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker |
| JOP20180021A1 (ar) | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
| US11578136B2 (en) | 2017-03-16 | 2023-02-14 | Innate Pharma | Compositions and methods for treating cancer |
| JP2020514370A (ja) | 2017-03-17 | 2020-05-21 | キュアバック アーゲー | 組合せ抗癌療法のためのｒｎａワクチン及び免疫チェックポイント阻害剤 |
| WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
| CA3049472A1 (en) | 2017-03-20 | 2018-09-27 | Celcuity Inc. | Methods of measuring signaling pathway activity for selection of therapeutic agents |
| EP3378872A1 (en) | 2017-03-20 | 2018-09-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antibodies against the human fshr extracellular domain |
| TWI808963B (zh) | 2017-03-22 | 2023-07-21 | 法商賽諾菲公司 | 使用人類化抗ｃｘｃｒ５抗體治療狼瘡 |
| TW201842936A (zh) | 2017-03-22 | 2018-12-16 | 美商建南德克公司 | 水凝膠交聯化的玻尿酸前藥組合物及方法 |
| JP7227151B2 (ja) | 2017-03-22 | 2023-02-21 | ジェネンテック， インコーポレイテッド | 眼障害の治療のために最適化された抗体組成物 |
| CA3052513A1 (en) | 2017-03-23 | 2018-09-27 | Abbott Laboratories | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1 |
| KR20240014600A (ko) | 2017-03-24 | 2024-02-01 | 노바르티스 아게 | 심장질환 예방 및 치료 방법 |
| EP3600427A1 (en) | 2017-03-24 | 2020-02-05 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating melanoma |
| CA3057808A1 (en) | 2017-03-24 | 2018-09-27 | Zenyaku Kogyo Co., Ltd. | Anti-igm/b cell surface antigen bispecific antibody |
| US20200132673A1 (en) | 2017-03-24 | 2020-04-30 | The Regents Of The University Of California | Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom |
| WO2018178029A1 (en) | 2017-03-27 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases |
| WO2018178030A1 (en) | 2017-03-27 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases |
| SG11201908678XA (en) | 2017-03-27 | 2019-10-30 | Celgene Corp | Methods and compositions for reduction of immunogenicity |
| JP2020512344A (ja) | 2017-03-27 | 2020-04-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗ｉｌ−３６ｒ抗体併用治療 |
| CA3054159A1 (en) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor |
| WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
| EP4108183A1 (en) | 2017-03-30 | 2022-12-28 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| JP7022328B2 (ja) | 2017-03-30 | 2022-02-18 | 日油株式会社 | 自壊性アセタールリンカーを有する親水性ポリマー誘導体及びそれを用いた複合体 |
| CN110869514A (zh) | 2017-03-30 | 2020-03-06 | 小利兰·斯坦福大学托管委员会 | 多重同型特异性抗体检测 |
| EP3600308A1 (en) | 2017-03-30 | 2020-02-05 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of mitochondrial genetic diseases |
| KR20190135017A (ko) | 2017-03-30 | 2019-12-05 | 더 유니버서티 어브 퀸슬랜드 | 키메라 분자 및 그의 용도 |
| EP3601531B1 (en) | 2017-03-30 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with live biotherapeutics |
| JOP20190203A1 (ar) | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها |
| WO2018182422A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
| US20200031944A1 (en) | 2017-03-31 | 2020-01-30 | Five Prime Therapeutics, Inc. | Combination therapy for cancer using anti-gitr antibodies |
| US20190048055A1 (en) | 2017-03-31 | 2019-02-14 | Altor Bioscience Corporation | Alt-803 in combination with anti-cd38 antibody for cancer therapies |
| CN110352201A (zh) | 2017-04-03 | 2019-10-18 | 免疫医疗公司 | 用于癌症疗法的抗体药物缀合物的皮下施用 |
| WO2018187191A1 (en) | 2017-04-03 | 2018-10-11 | Jounce Therapeutics, Inc | Compositions and methods for the treatment of cancer |
| JP2020515637A (ja) | 2017-04-03 | 2020-05-28 | オンコロジー、インコーポレイテッド | 免疫腫瘍剤を伴うｐｓ標的化抗体を用いる癌の治療方法 |
| WO2018185516A1 (en) | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy |
| EP3606955A1 (en) | 2017-04-05 | 2020-02-12 | H. Hoffnabb-La Roche Ag | Bispecific antibodies specifically binding to pd1 and lag3 |
| JP6871415B2 (ja) | 2017-04-05 | 2021-05-12 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｌａｇ３抗体 |
| TWI796329B (zh) | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗－ilt4抗體及抗原結合片段 |
| KR20190139931A (ko) | 2017-04-07 | 2019-12-18 | 아펠리스 파마슈티컬스 인코포레이티드 | 투여 요법 및 관련 조성물 및 방법 |
| CN111647062A (zh) | 2017-04-10 | 2020-09-11 | 伊玛提克斯生物技术有限公司 | 用于癌症免疫治疗的肽及其肽组合物 |
| TW201841937A (zh) | 2017-04-10 | 2018-12-01 | 德商英麥提克生物技術股份有限公司 | 用於白血病和其他癌症免疫治療的新穎肽和肽組合物 |
| TW201841934A (zh) | 2017-04-10 | 2018-12-01 | 德商英麥提克生物技術股份有限公司 | 用於治療癌症免疫治療的新穎肽及其肽組合物 |
| CA3059542A1 (en) | 2017-04-12 | 2018-10-18 | Pfizer Inc. | Antibodies having conditional affinity and methods of use thereof |
| US20210115407A1 (en) | 2017-04-12 | 2021-04-22 | The Broad Institute, Inc. | Respiratory and sweat gland ionocytes |
| JOP20190243A1 (ar) | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
| JP2020516638A (ja) | 2017-04-13 | 2020-06-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんを処置する方法における使用のための、インターロイキン２イムノコンジュゲート、ｃｄ４０アゴニスト、および任意選択のｐｄ−１軸結合アンタゴニスト |
| SG11201908813QA (en) | 2017-04-13 | 2019-10-30 | Aduro Biotech Holdings Europe B V | Anti-sirp alpha antibodies |
| US20200088732A1 (en) | 2017-04-13 | 2020-03-19 | INSERM (Institut National de la Santé et de la Recherche Mèdicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
| JP7297672B2 (ja) | 2017-04-13 | 2023-06-26 | アジェナス インコーポレイテッド | 抗ｃｄ１３７抗体およびその使用方法 |
| WO2018189381A1 (en) | 2017-04-14 | 2018-10-18 | Gamamabs Pharma | Amhrii-binding compounds for preventing or treating lung cancers |
| BR112019021472A8 (pt) | 2017-04-14 | 2023-05-02 | Inst Curie | Compostos de ligação ao amhrii para prevenção ou tratamento de cânceres |
| US10993936B2 (en) | 2017-04-14 | 2021-05-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method of treating one or more symptoms of pulmonary fibrosis by administering inhibitors of nicotinamide phosphoribotransferase |
| CA3059938A1 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
| BR112019021612A2 (pt) | 2017-04-15 | 2020-05-12 | Abbott Laboratories | Métodos para auxiliar o diagnóstico hiperagudo e determinação de traumatismo crânioencefálico em um indivíduo humano com o uso de biomarcadores precoces |
| RU2665790C1 (ru) | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело к pd-l1 |
| US20200033347A1 (en) | 2017-04-18 | 2020-01-30 | Universite Libre De Bruxelles | Biomarkers And Targets For Proliferative Diseases |
| WO2018192944A1 (en) | 2017-04-18 | 2018-10-25 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| WO2018192407A1 (zh) | 2017-04-19 | 2018-10-25 | 四川科伦博泰生物医药股份有限公司 | 细胞毒素和偶联物、其用途和制备方法 |
| WO2018195283A1 (en) | 2017-04-19 | 2018-10-25 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| BR112019021680A2 (pt) | 2017-04-20 | 2020-05-12 | Adc Therapeutics Sa | Terapia de combinação com conjugado anticorpo-fármaco anti-cd25?? |
| EP3612234B1 (en) | 2017-04-20 | 2024-03-13 | ADC Therapeutics SA | Combination therapy with an anti-axl antibody-drug conjugate |
| JP2020517242A (ja) | 2017-04-21 | 2020-06-18 | スターテン・バイオテクノロジー・ベー・フェー | 抗ＡｐｏＣ３抗体およびその使用方法 |
| US11203629B2 (en) | 2017-04-22 | 2021-12-21 | Immunomic Therapeutics, Inc. | LAMP constructs |
| EP3396378A1 (en) | 2017-04-24 | 2018-10-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | A method for determining myeloid natural killer (nk)-cells and use thereof |
| EP3615569A1 (en) | 2017-04-25 | 2020-03-04 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of epstein barr virus infection |
| JP2020517287A (ja) | 2017-04-26 | 2020-06-18 | ユーリカ セラピューティックス， インコーポレイテッド | キメラ抗体／ｔ細胞受容体構築物及びその使用 |
| CA3059820A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
| US20230140818A1 (en) | 2017-04-27 | 2023-05-04 | The University Of Hong Kong | Use of hcn inhibitors for treatment of cancer |
| KR20230164219A (ko) | 2017-04-27 | 2023-12-01 | 주노 테라퓨틱스 게엠베하 | 올리고머 입자 시약 및 이의 사용 방법 |
| CA3060206A1 (en) | 2017-04-27 | 2018-11-01 | Seattle Genetics, Inc. | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
| MA48461A (fr) | 2017-04-28 | 2020-03-04 | Amgen Inc | Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation |
| WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| US20200308299A1 (en) | 2017-04-28 | 2020-10-01 | National University Corporation Kochi University | Anti-gpc-1 antibody |
| EP3615566B1 (en) | 2017-04-28 | 2023-12-20 | Marengo Therapeutics, Inc. | Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof |
| AU2018260777A1 (en) | 2017-04-28 | 2019-10-17 | Amgen Inc. | Biomarkers for cancer therapeutics |
| BR112019022476A2 (pt) | 2017-04-28 | 2020-05-12 | Abbott Laboratories | Métodos para o auxílio no diagnóstico e determinação hiperagudos de lesão cerebral traumática usando biomarcadores iniciais em pelo menos duas amostras a partir do mesmo ser humano |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| MA50957A (fr) | 2017-05-01 | 2020-10-14 | Agenus Inc | Anticorps anti-tigit et leurs méthodes d'utilisation |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| US11845798B2 (en) | 2017-05-02 | 2023-12-19 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| AU2018263923A1 (en) | 2017-05-02 | 2019-10-31 | Immunomic Therapeutics, Inc. | LAMP (lysosomal associated membrane protein) constructs comprising cancer antigens |
| JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| WO2018204876A1 (en) | 2017-05-04 | 2018-11-08 | City Of Hope | Antibody variable domains and antibody constructs |
| US10865238B1 (en) | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
| EP3618864A1 (en) | 2017-05-05 | 2020-03-11 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
| WO2018204868A1 (en) | 2017-05-05 | 2018-11-08 | Allakos Inc. | Methods and compositions for treating allergic ocular diseases |
| IL252151A0 (en) | 2017-05-07 | 2017-07-31 | Fainzilber Michael | Treatment of stress disorders |
| WO2018207184A2 (en) | 2017-05-10 | 2018-11-15 | Ariel Scientific Innovations Ltd. | Methods of purifying antibodies |
| US20190016810A1 (en) | 2017-05-11 | 2019-01-17 | Cytodyn Inc. | Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agents |
| US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| GB201707561D0 (en) | 2017-05-11 | 2017-06-28 | Argenx Bvba | GARP-TGF-beta antibodies |
| US11467160B2 (en) | 2017-05-11 | 2022-10-11 | Inserm (Institut Naitonal De La Santé Et De La Recherche Médicale) | Method of therapy selection for patient suffering from glioblastoma |
| WO2018209175A2 (en) | 2017-05-12 | 2018-11-15 | The Trustees Of The University Of Pennsylvania | Fully humanized anti-platelet factor 4 antibodies that treat heparin-induced thrombocytopenia |
| AU2018265860B2 (en) | 2017-05-12 | 2022-08-11 | Harpoon Therapeutics, Inc. | MSLN targeting trispecific proteins and methods of use |
| CN113896792A (zh) | 2017-05-12 | 2022-01-07 | 哈普恩治疗公司 | 间皮素结合蛋白质 |
| EP3623368A4 (en) | 2017-05-12 | 2021-04-07 | Riken | CLASS A GPCR BINDING COMPOUND MODIFIER |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| EP3625251A1 (en) | 2017-05-15 | 2020-03-25 | University Of Rochester | Broadly neutralizing anti-influenza monoclonal antibody and uses thereof |
| WO2018213316A1 (en) | 2017-05-16 | 2018-11-22 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
| KR20200005659A (ko) | 2017-05-16 | 2020-01-15 | 신톤 바이오파머슈티칼즈 비.브이. | 항-SIRPα 항체 |
| US10646569B2 (en) | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| SG10202112636SA (en) | 2017-05-16 | 2021-12-30 | Five Prime Therapeutics Inc | Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment |
| EP3403649A1 (en) | 2017-05-16 | 2018-11-21 | Bayer Pharma Aktiengesellschaft | Inhibitors and antagonists of gpr84 for the treatment of endometriosis |
| KR102582297B1 (ko) | 2017-05-19 | 2023-09-25 | 필립모리스 프로덕츠 에스.에이. | 대상체의 흡연 상태를 구별하기 위한 진단 테스트 |
| WO2018215760A1 (en) | 2017-05-22 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10914729B2 (en) | 2017-05-22 | 2021-02-09 | The Trustees Of Princeton University | Methods for detecting protein binding sequences and tagging nucleic acids |
| KR20200010491A (ko) | 2017-05-23 | 2020-01-30 | 신톤 바이오파머슈티칼즈 비.브이. | 항체-약물 접합체를 제조하기 위한 이중 접합 방법 |
| US20200172604A1 (en) | 2017-05-23 | 2020-06-04 | Technion Research & Development Foundation Limited | Agents which inhibit gads dimerization and methods of use thereof |
| EP3630292A2 (en) | 2017-05-24 | 2020-04-08 | Sutro Biopharma, Inc. | Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
| US20200270334A1 (en) | 2017-05-24 | 2020-08-27 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
| JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
| JP6978514B2 (ja) | 2017-05-24 | 2021-12-08 | フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited | 細菌株を含む組成物 |
| WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
| WO2018215938A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use |
| EP3406253A1 (en) | 2017-05-24 | 2018-11-28 | Bayer Aktiengesellschaft | Inhibitors and antagonists of human pycr1 |
| JP7416625B2 (ja) | 2017-05-25 | 2024-01-17 | アボット・ラボラトリーズ | 早期バイオマーカーを使用する、頭部への損傷を負ったヒト対象又は負った可能性があるヒト対象に対して、イメージングを実施するかどうかの決定の一助となるための方法 |
| US11260117B2 (en) | 2017-05-26 | 2022-03-01 | Novimmune Sa | Anti-CD47 x anti-mesothelin antibodies and methods of use thereof |
| JP7269183B2 (ja) | 2017-05-30 | 2023-05-08 | アボット・ラボラトリーズ | 心臓トロポニンｉを使用する、ヒト対象における軽度外傷性脳損傷を診断及び査定する一助となるための方法 |
| EP3630834A1 (en) | 2017-05-31 | 2020-04-08 | STCube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1 |
| KR20200015602A (ko) | 2017-05-31 | 2020-02-12 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도 |
| JP2020522254A (ja) | 2017-05-31 | 2020-07-30 | エルスター セラピューティクス， インコーポレイテッド | 骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用 |
| JOP20190259A1 (ar) | 2017-05-31 | 2019-10-31 | Amgen Inc | بروتينات ربط مولد ضد مضادة لـ jagged1 |
| KR102505349B1 (ko) | 2017-06-02 | 2023-03-02 | 화이자 인코포레이티드 | Flt3에 특이적인 항체 및 이의 용도 |
| US11638728B2 (en) | 2017-06-05 | 2023-05-02 | The University Of Chicago | Microbiome biomarkers immunotherapy responsiveness: diagnostic, prognostic and therapeutic uses thereof |
| CN110997724A (zh) | 2017-06-06 | 2020-04-10 | 斯特库伯株式会社 | 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法 |
| EP3634496A4 (en) | 2017-06-06 | 2021-09-08 | Dana-Farber Cancer Institute, Inc. | METHOD FOR RISING AWARENESS IN CANCER CELLS AGAINST T-CELL-MEDIATED KILLING BY MODULATING MOLECULAR SIGNAL PATHS |
| AU2018281871B2 (en) | 2017-06-07 | 2022-07-28 | Philogen S.P.A. | Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins |
| US10793634B2 (en) | 2017-06-09 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Anti-TrkB antibodies |
| WO2018232020A1 (en) | 2017-06-13 | 2018-12-20 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US11635435B2 (en) | 2017-06-13 | 2023-04-25 | Oncotracker, Inc. | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
| CN107271674B (zh) | 2017-06-13 | 2019-05-07 | 首都医科大学附属北京地坛医院 | 一种用于脂肪性肝炎检测的靶标志物gp73及检测应用方法 |
| EP3600364B1 (en) | 2017-06-14 | 2020-08-05 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus megasphaera and uses thereof |
| JP7145891B2 (ja) | 2017-06-14 | 2022-10-03 | アーデーセー セラピューティクス ソシエテ アノニム | 抗ｃｄ１９ ａｄｃを投与するための投与レジメ |
| JP2020523383A (ja) | 2017-06-14 | 2020-08-06 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｂ細胞成熟抗原（ｂｃｍａ）指向性ナノ粒子 |
| SI3638271T1 (sl) | 2017-06-14 | 2021-01-29 | 4D Pharma Research Limited | Sestavki, ki vsebujejo bakterijske seve |
| WO2018228875A1 (en) | 2017-06-15 | 2018-12-20 | Nestec S.A. | Micro-rna biomarkers of blood-brain barrier dysfunction |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| US11325957B2 (en) | 2017-06-19 | 2022-05-10 | Cell Design Labs, Inc. | Methods and compositions for reducing the immunogenicity of chimeric notch receptors |
| CA3070991C (en) | 2017-06-19 | 2023-10-17 | Massachusetts Institute Of Technology | Automated methods for scalable, parallelized enzymatic biopolymer synthesis and modification using microfluidic devices |
| WO2018237037A2 (en) | 2017-06-20 | 2018-12-27 | Teneobio, Inc. | HEAVY CHAIN ANTIBODY ONLY ANTI-BCMA |
| WO2018237010A2 (en) | 2017-06-20 | 2018-12-27 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE |
| EP3642239A1 (en) | 2017-06-20 | 2020-04-29 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
| CA3065951A1 (en) | 2017-06-20 | 2018-12-27 | Teneoone, Inc. | Anti-bcma heavy chain-only antibodies |
| SG11201912473PA (en) | 2017-06-22 | 2020-01-30 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| EP3645742A4 (en) | 2017-06-25 | 2021-07-14 | Systimmune, Inc. | ANTI-ROR1 ANTIBODIES AND METHOD FOR MANUFACTURING AND USING THEREOF |
| EP3645037A1 (en) | 2017-06-27 | 2020-05-06 | Novartis AG | Dosage regimens for anti-tim-3 antibodies and uses thereof |
| WO2019000223A1 (en) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF |
| WO2019003104A1 (en) | 2017-06-28 | 2019-01-03 | Novartis Ag | METHOD FOR PREVENTING AND TREATING URINARY INCONTINENCE |
| US20210145828A1 (en) | 2017-06-29 | 2021-05-20 | Rutgers, The State University Of New Jersey | Compositions And Methods Targeting G12 Signaling For Bronchodilator Therapy |
| WO2019002548A1 (en) | 2017-06-29 | 2019-01-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TREATMENT OF MIGRAINE WITH TREK1, TREK2 AGONIZATION OR HETEROMERS COMPRISING SAME |
| CA3068041A1 (en) | 2017-07-03 | 2019-01-10 | Abbott Laboratories | Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood |
| CN110785183A (zh) | 2017-07-07 | 2020-02-11 | 伊玛提克斯生物技术有限公司 | 用于肺癌(包括nsclc、sclc和其他癌症)免疫治疗的新型肽和肽组合物 |
| US10800823B2 (en) | 2017-07-07 | 2020-10-13 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
| RU2020104749A (ru) | 2017-07-10 | 2021-08-10 | Байер Фарма Акциенгезельшафт | Антитело к рецептору пролактина при мужском и женском типах выпадения волос |
| JP2020527144A (ja) | 2017-07-10 | 2020-09-03 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 癌を処置するためのヒトｓｉｇｌｅｃ−９に対する抗体およびヒトｎｋｇ２ａに対する抗体を使用する組み合わせ療法 |
| JP7293188B2 (ja) | 2017-07-10 | 2023-06-19 | イナート・ファルマ・ソシエテ・アノニム | Ｓｉｇｌｅｃ－９中和抗体 |
| EP3431496A1 (en) | 2017-07-19 | 2019-01-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti- isoasp7 amyloid beta antibodies and uses thereof |
| CN111094334A (zh) | 2017-07-19 | 2020-05-01 | 美国卫生与公众服务部 | 用于诊断和治疗乙肝病毒感染的抗体和方法 |
| WO2019018729A1 (en) | 2017-07-20 | 2019-01-24 | Dana-Farber Cancer Institute, Inc. | COMPOSITIONS AND METHODS FOR IDENTIFICATION AND TREATMENT OF NEUROENDOCRINE METASTATIC TUMORS OF INTESTINAL HAIL |
| WO2019018647A1 (en) | 2017-07-20 | 2019-01-24 | Pfizer Inc. | ANTI-GD3 ANTIBODIES AND CONJUGATES ANTIBODY-MEDICATION |
| WO2019018730A1 (en) | 2017-07-20 | 2019-01-24 | Novartis Ag | DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF |
| EP3655034A1 (en) | 2017-07-21 | 2020-05-27 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| EP3658581A1 (en) | 2017-07-24 | 2020-06-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies and peptides to treat hcmv related diseases |
| WO2019020593A1 (en) | 2017-07-25 | 2019-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF MONOCYTOPOISIS |
| US20200207859A1 (en) | 2017-07-26 | 2020-07-02 | Sutro Biopharma, Inc. | Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma |
| PL3658589T3 (pl) | 2017-07-26 | 2024-03-18 | Forty Seven, Inc. | Przeciwciała anty-sirp-alfa i powiązane sposoby |
| JP2020528936A (ja) | 2017-07-27 | 2020-10-01 | ノモキャン ファーマシューティカルズ エルエルシー | Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用 |
| WO2020159504A1 (en) | 2019-01-30 | 2020-08-06 | Nomocan Pharmaceuticals Llc | Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer |
| CN116271012A (zh) | 2017-07-27 | 2023-06-23 | 瑞颂医药公司 | 高浓度抗c5抗体制剂 |
| MA49690A (fr) | 2017-07-28 | 2021-05-19 | Scholar Rock Inc | Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations |
| US11285149B2 (en) | 2017-07-28 | 2022-03-29 | Dana-Farber Cancer Institute, Inc. | Enhanced immunotherapy of cancer using targeted transcriptional modulators |
| WO2019020807A1 (en) | 2017-07-28 | 2019-01-31 | Gene Signal International Sa | CD9P-1 TARGETING ANTIBODIES AND USES THEREOF |
| CN117050176A (zh) | 2017-07-31 | 2023-11-14 | 豪夫迈·罗氏有限公司 | 基于三维结构的人源化方法 |
| CN110662765B (zh) | 2017-08-03 | 2023-09-29 | 艾利妥 | 抗cd33抗体及其使用方法 |
| WO2019028292A1 (en) | 2017-08-03 | 2019-02-07 | Alector Llc | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| JP2020529986A (ja) | 2017-08-04 | 2020-10-15 | アムジエン・インコーポレーテツド | Ｃｙｓ−ｍａｂのコンジュゲーション方法 |
| CA3070297A1 (en) | 2017-08-11 | 2019-02-14 | Genentech, Inc. | Anti-cd8 antibodies and uses thereof |
| WO2019036363A1 (en) | 2017-08-14 | 2019-02-21 | Progenity Inc. | TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF |
| TWI818919B (zh) | 2017-08-15 | 2023-10-21 | 美商歐米諾斯公司 | 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法 |
| EP3444275A1 (en) | 2017-08-16 | 2019-02-20 | Exiris S.r.l. | Monoclonal antibody anti-fgfr4 |
| US20200256880A1 (en) | 2017-08-16 | 2020-08-13 | The Broad Institute, Inc. | Neuronal Assay Method Involving Calcineurin |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CA3067735A1 (en) | 2017-08-17 | 2019-02-21 | Just Biotherapeutics, Inc. | Method of purifying glycosylated protein from host cell galectins and other contaminants |
| EA039276B1 (ru) | 2017-08-18 | 2021-12-27 | Медимьюн Лимитед | Пирролобензодиазепиновые конъюгаты |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | ANTI-CD137 MOLECULES AND THEIR USE |
| KR20230119260A (ko) | 2017-08-21 | 2023-08-16 | 아다진 인크. | 동적 인간 항체 경쇄 라이브러리 |
| WO2019036842A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | DYNAMIC LIBRARIES OF HUMAN HEAVY CHAIN ANTIBODIES |
| WO2019040471A1 (en) | 2017-08-22 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING |
| US11672877B2 (en) | 2017-08-23 | 2023-06-13 | Wayne State University | In vivo immunoimaging of interferon-gamma |
| KR20200039783A (ko) | 2017-08-23 | 2020-04-16 | 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 | Cxcr5에 결합하는 키메라 항원 수용체 및 car-t 세포 |
| AU2018323470A1 (en) | 2017-08-28 | 2020-03-19 | Angiex, Inc. | Anti-TM4SF1 antibodies and methods of using same |
| WO2019046600A1 (en) | 2017-08-30 | 2019-03-07 | Amgen Inc. | INSULIN-RELATED GROWTH FACTOR 1 RECEPTOR BINDING PROTEINS (IGF-1R) AND METHODS OF USE |
| US11085929B2 (en) | 2017-08-31 | 2021-08-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Nanoshell-structured material as co-matrix for peptide characterization in mass spectrometry |
| IL272864B2 (en) | 2017-08-31 | 2024-03-01 | Mitsubishi Tanabe Pharma Corp | A therapeutic agent containing an IL-33 antagonist for the treatment of endometriosis |
| EP3677267A4 (en) | 2017-09-01 | 2021-06-02 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF TUMORS, METHOD AND USES THEREOF |
| JP2020532991A (ja) | 2017-09-07 | 2020-11-19 | オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド | プログラム細胞死タンパク質１に対する抗体 |
| IL302614A (en) | 2017-09-08 | 2023-07-01 | Maverick Therapeutics Inc | Binding proteins are activated under limited conditions |
| WO2019050362A2 (ko) | 2017-09-08 | 2019-03-14 | 주식회사 와이바이오로직스 | 인간 dlk1에 대한 항체 및 이의 용도 |
| US20200209241A1 (en) | 2017-09-15 | 2020-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
| US11464784B2 (en) | 2017-09-15 | 2022-10-11 | The Regents Of The University Of California | Inhibition of aminocylase 3 (AA3) in the treatment of cancer |
| WO2019055796A1 (en) | 2017-09-15 | 2019-03-21 | Bristol-Myers Squibb Company | ONLINE BIOMASS CAPACITY MONITORING DURING LARGE SCALE PRODUCTION OF POLYPEPTIDES OF INTEREST |
| EP3684814A1 (en) | 2017-09-18 | 2020-07-29 | Sutro Biopharma, Inc. | Anti-folate receptor alpha antibody conjugates and their uses |
| EP3684471A1 (en) | 2017-09-20 | 2020-07-29 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and pharmaceutical compositions for modulating autophagy |
| CN111448216B (zh) | 2017-09-20 | 2023-11-07 | 英属哥伦比亚大学 | 新的抗hla-a2抗体及其用途 |
| US20200216542A1 (en) | 2017-09-20 | 2020-07-09 | Chugai Seiyaku Kabushiki Kaisha | Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent |
| MX2020003214A (es) | 2017-09-20 | 2020-07-28 | Mersana Therapeutics Inc | Composiciones y metodos para predecir la respuesta a la terapia dirigida al napi2b. |
| KR20200133323A (ko) | 2017-09-21 | 2020-11-27 | 임체크 테라퓨틱스 에스에이에스 | Ｂｔｎ２에 대해 특이성을 갖는 항체 및 이의 용도 |
| CA3075450A1 (en) | 2017-09-22 | 2019-03-28 | F. Hoffmann-La Roche Ag | Multivalent mono- or bispecific recombinant antibodies for analytic purpose |
| TW201922780A (zh) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法 |
| US11897917B2 (en) | 2017-09-27 | 2024-02-13 | The University Of York | Bioconjugation of polypeptides |
| WO2019067592A1 (en) | 2017-09-27 | 2019-04-04 | University Of Georgia Research Foundation | TREATMENT AND DETECTION OF INFECTION AND DISEASE ASSOCIATED WITH DIFFERENT FUNGAL PATHOGENS |
| SG11202002826VA (en) | 2017-09-27 | 2020-04-29 | Epicentrx Inc | Immunomodulatory fusion proteins |
| US11180541B2 (en) | 2017-09-28 | 2021-11-23 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
| WO2019067792A1 (en) | 2017-09-28 | 2019-04-04 | Celularity, Inc. | TUMOR CONTROL WITH INTERMEDIATE NATURAL KILLER CELLS DERIVED FROM HUMAN PLACENTA (PINK) IN COMBINATION WITH ANTIBODY |
| US20200354452A1 (en) | 2017-09-29 | 2020-11-12 | City Of Hope | Cars and bispecific antibodies for treatment of mantle cell lymphoma |
| CN111108202A (zh) | 2017-09-29 | 2020-05-05 | 中外制药株式会社 | 具有凝血因子viii(fviii)辅因子功能替代活性的多特异性抗原结合分子及含有所述分子作为活性成分的药物制剂 |
| SG11202002248TA (en) | 2017-10-02 | 2020-04-29 | Visterra Inc | Antibody molecules to cd138 and uses thereof |
| EP3461841B1 (en) | 2017-10-02 | 2019-09-11 | Certest Biotec, S.L. | Anti-dps antibodies and test devices for the detection of bacteria of the genus campylobacter |
| RU2698048C2 (ru) | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
| EA039662B1 (ru) | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Антитела, специфичные к cd47 и pd-l1 |
| JP2021500873A (ja) | 2017-10-03 | 2021-01-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | システイン操作された抗原結合分子 |
| AU2018344859A1 (en) | 2017-10-04 | 2020-04-30 | Hesperix SA | Articles and methods directed to personalized therapy of cancer |
| EP3691662A4 (en) | 2017-10-06 | 2021-05-12 | The University of Chicago | T-LYMPHOCYTES SCREENING FOR CANCER-SPECIFIC ANTIGENS |
| EP3694558B1 (en) | 2017-10-10 | 2024-04-10 | Medicenna Therapeutics Inc. | Il-4-fusion formulations for treatment of central nervous system (cns) tumors |
| US11230601B2 (en) | 2017-10-10 | 2022-01-25 | Tilos Therapeutics, Inc. | Methods of using anti-lap antibodies |
| WO2019075097A1 (en) | 2017-10-11 | 2019-04-18 | Board Of Regents, The University Of Texas System | PD-L1 HUMAN ANTIBODIES AND METHODS OF USE |
| US11912754B2 (en) | 2017-10-12 | 2024-02-27 | Immunowake Inc. | VEGFR-antibody light chain fusion protein |
| CA3078799A1 (en) | 2017-10-13 | 2019-04-18 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
| BR112020006371A2 (pt) | 2017-10-13 | 2020-09-29 | Merck Patent Gmbh | combinação de um inibidor de parp e um antagonista de ligação de eixo de pd-1 |
| WO2019075366A1 (en) | 2017-10-13 | 2019-04-18 | Merck Sharp & Dohme Corp. | COMPOSITIONS AND METHODS FOR TREATING DIFFUSED LYMPHOMA WITH LARGE B CELLS |
| BR112020007196A2 (pt) | 2017-10-13 | 2020-12-01 | Harpoon Therapeutics, Inc. | proteínas triespecíficas e métodos de uso |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| CA3072634A1 (en) | 2017-10-18 | 2019-04-25 | Sabine Rauth | Human serum albumin variants and uses thereof |
| CN111655725A (zh) | 2017-10-19 | 2020-09-11 | 德比奥药物国际股份有限公司 | 用于治疗癌症的组合产品 |
| WO2019078344A1 (ja) | 2017-10-20 | 2019-04-25 | 学校法人兵庫医科大学 | 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物 |
| WO2019077164A1 (en) | 2017-10-20 | 2019-04-25 | Institut Curie | CROCHET FUSION PROTEIN FOR REGULATING THE CELLULAR TRAFFIC OF A TARGET PROTEIN |
| WO2019077165A1 (en) | 2017-10-20 | 2019-04-25 | Institut Curie | DAP10 / 12-BASED CHIMERIC ANTIGENIC RECEPTORS (CAR) ADAPTED FOR RUSH |
| KR101966362B1 (ko) * | 2017-10-20 | 2019-04-05 | 주식회사 녹십자 | 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| US11826414B2 (en) | 2017-10-23 | 2023-11-28 | Cz Biohub Sf, Llc | Measurement of afucosylated IgG Fc glycans and related vaccination methods |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| EP3700933A1 (en) | 2017-10-25 | 2020-09-02 | Novartis AG | Antibodies targeting cd32b and methods of use thereof |
| WO2019084460A1 (en) | 2017-10-26 | 2019-05-02 | The Regents Of The University Of California | INHIBITION OF OXIDATION-SPECIFIC EPITOPES TO TREAT ISCHEMIC REPERFUSION INJURY |
| AU2018355519A1 (en) | 2017-10-27 | 2020-03-26 | Amgen Inc. | Compositions and methods for treating liver cancer |
| CA3078676A1 (en) | 2017-10-30 | 2019-05-09 | F. Hoffmann-La Roche Ag | Method for in vivo generation of multispecific antibodies from monospecific antibodies |
| JP7039694B2 (ja) | 2017-10-31 | 2022-03-22 | スターテン・バイオテクノロジー・ベー・フェー | 抗ａｐｏｃ３抗体およびその使用方法 |
| WO2019088658A1 (ko) | 2017-10-31 | 2019-05-09 | 주식회사 컴워스파마 | Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도 |
| WO2019089594A1 (en) | 2017-10-31 | 2019-05-09 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and cytarabine |
| WO2019086394A1 (en) | 2017-11-01 | 2019-05-09 | F. Hoffmann-La Roche Ag | The compbody - a multivalent target binder |
| WO2019086499A1 (en) | 2017-11-01 | 2019-05-09 | F. Hoffmann-La Roche Ag | Novel tnf family ligand trimer-containing antigen binding molecules |
| CN111278856A (zh) | 2017-11-01 | 2020-06-12 | 豪夫迈·罗氏有限公司 | 三Fab-康特斯体 |
| US11673963B2 (en) | 2017-11-02 | 2023-06-13 | Oxford Biotherapeutics Ltd | CRTAM antibodies and methods of treating cancer |
| CN111587123A (zh) | 2017-11-09 | 2020-08-25 | 品通治疗有限公司 | 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物 |
| EP3707150A1 (en) | 2017-11-10 | 2020-09-16 | Massachusetts Institute Of Technology | Microbial production of pure single stranded nucleic acids |
| MX2020004935A (es) | 2017-11-14 | 2020-09-25 | Arcellx Inc | Terapias con celulas inmunitarias multifuncionales. |
| IL255664A0 (en) | 2017-11-14 | 2017-12-31 | Shachar Idit | Hematopoietic stem cells with enhanced properties |
| JP7416700B2 (ja) | 2017-11-14 | 2024-01-17 | ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド | 増殖性硝子体網膜症および上皮間葉転換と関連付けられる状態の治療のためのｒｕｎｘ１阻害の方法 |
| WO2019099374A2 (en) | 2017-11-14 | 2019-05-23 | University Of Virginia Patent Foundation | Compositions and methods for making and using bispecific antibodies |
| RU2020119578A (ru) | 2017-11-16 | 2021-12-17 | Новартис Аг | Комбинированные терапии |
| JP7194481B2 (ja) | 2017-11-17 | 2022-12-22 | メルク・シャープ・アンド・ドーム・エルエルシー | 免疫グロブリン様転写産物３（ｉｌｔ３）に特異的な抗体およびその使用 |
| KR20200089282A (ko) | 2017-11-20 | 2020-07-24 | 저스트-에보텍 바이오로직스, 아이엔씨. | 등장화제로서 라이신 염을 함유하는 아플리베르셉트 제제 및 그것의 용도 |
| CN111565725A (zh) | 2017-11-22 | 2020-08-21 | 生物运动有限公司 | 基于c-maf状态的乳腺癌的治疗性处理 |
| WO2019102456A1 (en) | 2017-11-27 | 2019-05-31 | University Of Rijeka Faculty Of Medicine | Immunotoxins for treating cancer |
| WO2019101995A1 (en) | 2017-11-27 | 2019-05-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for cardiac regeneration |
| CA3083345A1 (en) | 2017-11-27 | 2019-05-31 | Purdue Pharma L.P. | Humanized antibodies targeting human tissue factor |
| CA3083346A1 (en) | 2017-11-28 | 2019-06-06 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule having adjustable ligand-binding activity |
| ES2939461T3 (es) | 2017-11-29 | 2023-04-24 | Csl Ltd | Método para tratar o prevenir la lesión por isquemia-reperfusión |
| CN111918876B (zh) | 2017-11-30 | 2024-02-02 | 豪夫迈·罗氏有限公司 | 抗pd-l1抗体及使用其检测pd-l1的方法 |
| JP7442821B2 (ja) | 2017-11-30 | 2024-03-05 | センチュリオン バイオファーマ コーポレイション | メイタンシノイド系薬物送達システム |
| JP7359449B2 (ja) | 2017-11-30 | 2023-10-11 | センチュリオン バイオファーマ コーポレイション | オーリスタチンｅ誘導体のアルブミン結合プロドラッグ |
| WO2019106126A1 (en) | 2017-12-01 | 2019-06-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mdm2 modulators for the diagnosis and treatment of liposarcoma |
| WO2019113464A1 (en) | 2017-12-08 | 2019-06-13 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| WO2019110706A1 (en) | 2017-12-08 | 2019-06-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of developing a sepsis or a systemic inflammatory response syndrome (sirs) |
| JP7379165B2 (ja) | 2017-12-09 | 2023-11-14 | アボット・ラボラトリーズ | Ｇｆａｐとｕｃｈ－ｌ１との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法 |
| EP3721233A2 (en) | 2017-12-09 | 2020-10-14 | Abbott Laboratories | Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1) |
| KR20200098590A (ko) | 2017-12-12 | 2020-08-20 | 마크로제닉스, 인크. | 이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도 |
| WO2019118318A1 (en) | 2017-12-12 | 2019-06-20 | Calico Biolabs, Inc. | Recombinant antibody comprising heavy chain genetically fused to signature peptide and uses thereof |
| EP3724226A1 (en) | 2017-12-13 | 2020-10-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
| CN113698414A (zh) | 2017-12-15 | 2021-11-26 | 四川科伦博泰生物医药股份有限公司 | 生物活性物偶联物及其制备方法和用途 |
| EP3498293A1 (en) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Treatment of monogenic diseases with an anti-cd45rc antibody |
| TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
| SG11202005618WA (en) | 2017-12-19 | 2020-07-29 | Akouos Inc | Aav-mediated delivery of therapeutic antibodies to the inner ear |
| EP3502139A1 (en) | 2017-12-19 | 2019-06-26 | Philogen S.p.A. | Antibodies to tumour antigens |
| EP3541837A4 (en) | 2017-12-19 | 2020-05-13 | The Rockefeller University | HUMANE IGG FC DOMAIN VARIANTS WITH IMPROVED EFFECT FUNCTION |
| DK3710484T3 (da) | 2017-12-20 | 2023-11-27 | Harbour Biomed Shanghai Co Ltd | Ctla-4-bindende antistoffer og anvendelser deraf |
| WO2019120527A1 (en) | 2017-12-20 | 2019-06-27 | Michael Heneka | Novel means and methods for treating neurodegenerative diseases |
| US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
| EP3728639B1 (en) | 2017-12-20 | 2023-05-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of selection of an ire1-inhibitor therapy for patient suffering from cancer |
| US11192957B2 (en) | 2017-12-21 | 2021-12-07 | Hoffmann-La Roche Inc. | Antibodies binding to HLA-A2/WT1 |
| CA3087166A1 (en) | 2017-12-22 | 2019-06-27 | Jounce Therapeutics, Inc. | Antibodies to lilrb2 |
| CR20200322A (es) | 2017-12-22 | 2021-01-12 | Teneobio Inc | Anticuerpos de cadena pesada que se unen a cd22 |
| US20190211098A1 (en) | 2017-12-22 | 2019-07-11 | Genentech, Inc. | Use of pilra binding agents for treatment of a disease |
| CN115925943A (zh) | 2017-12-27 | 2023-04-07 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
| CA3087061A1 (en) | 2017-12-27 | 2019-07-04 | Teneobio, Inc. | Cd3-delta/epsilon heterodimer specific antibodies |
| WO2019129137A1 (zh) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
| WO2019129136A1 (zh) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
| SG11202004158QA (en) | 2017-12-28 | 2020-06-29 | Nanjing Legend Biotech Co Ltd | Single-domain antibodies and variants thereof against tigit |
| AU2018396964A1 (en) | 2017-12-28 | 2020-08-06 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against PD-L1 |
| JP7490565B2 (ja) | 2017-12-29 | 2024-05-27 | アレクトル エルエルシー | 抗ｔｍｅｍ１０６ｂ抗体及びその使用方法 |
| JP2021508471A (ja) | 2017-12-29 | 2021-03-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｖｅｇｆ抗体のｖｅｇｆ受容体遮断選択性を改善する方法 |
| TW201940518A (zh) | 2017-12-29 | 2019-10-16 | 美商安進公司 | 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體 |
| EP3735319B1 (en) | 2018-01-03 | 2024-05-22 | Albert-Ludwigs-Universität Freiburg | Single-channel multianalyte biosensor |
| WO2019134946A1 (en) | 2018-01-04 | 2019-07-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma resistant |
| SG11202006348VA (en) | 2018-01-05 | 2020-07-29 | Ac Immune Sa | Misfolded tdp-43 binding molecules |
| US11951129B2 (en) | 2018-01-09 | 2024-04-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Compositions and methods for targeting CLEC12A-expressing cancers |
| CN111886255A (zh) | 2018-01-12 | 2020-11-03 | 百时美施贵宝公司 | 抗tim3抗体及其用途 |
| AU2019207915A1 (en) | 2018-01-12 | 2020-07-16 | Amgen Inc. | PAC1 antibodies and uses thereof |
| MX2020007543A (es) | 2018-01-15 | 2020-09-09 | Pfizer | Metodos para administrar inmunoterapia de receptor de antigeno quimerico en combinacion con agonista 4-1bb. |
| CN111699200B (zh) | 2018-01-15 | 2023-05-26 | 南京传奇生物科技有限公司 | 针对pd-1的单域抗体和其变体 |
| US20200339686A1 (en) | 2018-01-16 | 2020-10-29 | Lakepharma, Inc. | Bispecific antibody that binds cd3 and another target |
| WO2019147822A2 (en) | 2018-01-24 | 2019-08-01 | Northwestern University | Inhibiting tumor cell migration by inhibition of kinesin light chain 1, variant 1 (klc1c) |
| EP3743096A1 (en) | 2018-01-25 | 2020-12-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonists of il-33 for use in methods for preventing ischemia reperfusion injury in an organ |
| WO2019147824A1 (en) | 2018-01-26 | 2019-08-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| PL3638698T3 (pl) | 2018-01-26 | 2021-09-06 | Regeneron Pharmaceuticals, Inc. | Przeciwciała i fragmenty wiążące antygen anty-TMPRSS2 |
| WO2019147579A1 (en) | 2018-01-28 | 2019-08-01 | Enable Biosciences Inc. | Reagents and methods for blocking non-specific interactions with nucleic acids |
| TWI822728B (zh) | 2018-01-31 | 2023-11-21 | 加藤元一 | 含有il-6抑制劑的哮喘治療劑 |
| US11472874B2 (en) | 2018-01-31 | 2022-10-18 | Alector Llc | Anti-MS4A4A antibodies and methods of use thereof |
| AU2019215075A1 (en) | 2018-02-01 | 2020-08-20 | Pfizer Inc. | Antibodies specific for CD70 and their uses |
| PE20211299A1 (es) | 2018-02-01 | 2021-07-20 | Pfizer | Receptores de antigeno quimericos dirigidos a cd70 |
| JP7438953B2 (ja) | 2018-02-01 | 2024-02-27 | イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド | 完全ヒト化抗ｂ細胞成熟抗原（ｂｃｍａ）の単鎖抗体およびその応用 |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2019150309A1 (en) | 2018-02-02 | 2019-08-08 | Hammack Scott | Modulators of gpr68 and uses thereof for treating and preventing diseases |
| FR3077574B1 (fr) | 2018-02-07 | 2022-04-01 | Commissariat Energie Atomique | Anticorps dirige contre le sous-type a des recepteurs aux endothelines et ses utilisations. |
| EP3749361A1 (en) | 2018-02-08 | 2020-12-16 | F. Hoffmann-La Roche AG | Bispecific antigen-binding molecules and methods of use |
| CA3226165A1 (en) | 2018-02-09 | 2019-08-15 | Genentech, Inc. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
| WO2019155474A1 (en) | 2018-02-12 | 2019-08-15 | Hadasit Medical Research Services & Development Ltd. | Modulation of slamf6 splice variants for cancer therapy |
| WO2019157772A1 (zh) | 2018-02-13 | 2019-08-22 | 和元生物技术（上海）股份有限公司 | 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途 |
| WO2019158512A1 (en) | 2018-02-13 | 2019-08-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the prognosis and the treatment of glioblastoma |
| EP3752530A1 (en) | 2018-02-14 | 2020-12-23 | ABBA Therapeutics AG | Anti-human pd-l2 antibodies |
| MX2020008479A (es) | 2018-02-14 | 2020-11-24 | Viela Bio Inc | Anticuerpos frente al ligando del receptor de tirosina cinasa 3 similar al sarcoma de mcdonough felino (fms) (flt3l) y tratamiento de enfermedades autoinmunes e inflamatorias. |
| AU2019222666A1 (en) | 2018-02-15 | 2020-09-03 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
| SG11202007540SA (en) | 2018-02-20 | 2020-09-29 | Seattle Genetics Inc | Hydrophobic auristatin f compounds and conjugates thereof |
| EP3755712A1 (en) | 2018-02-21 | 2020-12-30 | Cell Design Labs, Inc. | Chimeric transmembrane receptors and uses thereof |
| EA202091974A1 (ru) | 2018-02-21 | 2020-12-08 | Селджин Корпорейшн | Связывающие bcma антитела и их применение |
| CN111757751A (zh) | 2018-02-21 | 2020-10-09 | 豪夫迈·罗氏有限公司 | 用于使用IL-22 Fc融合蛋白的治疗的剂量方案 |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| EP3530282A1 (en) | 2018-02-27 | 2019-08-28 | Diaccurate | Therapeutic methods |
| JP2021516045A (ja) | 2018-02-28 | 2021-07-01 | ファイザー・インク | Ｉｌ−１５バリアントおよびその使用 |
| US20210002373A1 (en) | 2018-03-01 | 2021-01-07 | Nextcure, Inc. | KLRG1 Binding Compositions and Methods of Use Thereof |
| EP3760722A4 (en) | 2018-03-01 | 2021-11-24 | Hiroshima University | MONOCLONAL ANTI-INTEGRIN ALPHA11 ANTIBODY AND ASSOCIATED USE |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| US11702464B2 (en) | 2018-03-02 | 2023-07-18 | The University Of Chicago | Methods and composition for neutralization of influenza |
| NL2020520B1 (en) | 2018-03-02 | 2019-09-12 | Labo Bio Medical Invest B V | Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders |
| CA3093200A1 (en) | 2018-03-05 | 2019-09-12 | Janssen Pharmaceutica Nv | Anti-phf-tau antibodies and uses thereof |
| JP2021515770A (ja) | 2018-03-05 | 2021-06-24 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｉｌ−２３特異的抗体を用いたクローン病の治療方法 |
| EA202092087A1 (ru) | 2018-03-05 | 2020-11-17 | Янссен Фармацевтика Нв | Анализы для выявления нейродегенеративных заболеваний |
| WO2019170131A1 (zh) | 2018-03-07 | 2019-09-12 | 复旦大学 | 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途 |
| KR102594028B1 (ko) | 2018-03-07 | 2023-10-24 | 화이자 인코포레이티드 | 항-pd-1 항체 조성물 |
| EP3737384B1 (en) | 2018-03-08 | 2023-10-25 | Purepharm Inc. | Methods and compositions for preventing and treating conditions related to alpha-synuclein |
| JP2021517461A (ja) | 2018-03-12 | 2021-07-26 | ゾエティス・サービシーズ・エルエルシー | 抗ｎｇｆ抗体およびその方法 |
| AU2019234468A1 (en) | 2018-03-12 | 2020-10-01 | Memorial Sloan Kettering Cancer Center | Bispecific binding agents and uses thereof |
| EP3766917B1 (en) | 2018-03-13 | 2023-04-19 | NOF Corporation | Heterobifunctional compound having monodispersed polyethylene glycol in main chain or side chain |
| CA3092345A1 (en) | 2018-03-13 | 2019-09-19 | The Regents Of The University Of California | Inhibitors of integrin alpha 2 beta 1 and methods of use |
| US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
| JP7404256B2 (ja) | 2018-03-14 | 2023-12-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用 |
| US20210009711A1 (en) | 2018-03-14 | 2021-01-14 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| CN110272490B (zh) | 2018-03-14 | 2021-05-14 | 上海开拓者生物医药有限公司 | 靶向ctla-4抗体、其制备方法和用途 |
| US20210238280A1 (en) | 2018-03-14 | 2021-08-05 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| AU2019235033A1 (en) | 2018-03-14 | 2020-07-30 | Beijing Xuanyi Pharmasciences Co., Ltd. | Anti-claudin 18.2 antibodies |
| JP7377590B2 (ja) | 2018-03-14 | 2023-11-10 | ノビミューン エスアー | 抗ｃｄ３イプシロン抗体およびそれを使用する方法 |
| CN112074539A (zh) | 2018-03-15 | 2020-12-11 | 比昂生物制剂公司 | 降低可溶性免疫受体cd28的方法和组合物 |
| KR20200133240A (ko) | 2018-03-16 | 2020-11-26 | 브리스톨-마이어스 스큅 컴퍼니 | 단백질 생산 동안의 대사 효소 활성 및 디술피드 결합 환원 |
| BR112020018927A2 (pt) | 2018-03-21 | 2021-01-05 | ALX Oncology Inc. | Anticorpos contra proteína alfa reguladora de sinal e métodos de uso |
| WO2019182896A1 (en) | 2018-03-23 | 2019-09-26 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor |
| EP4163295A1 (en) | 2018-03-23 | 2023-04-12 | Université Libre de Bruxelles | Wnt signaling agonist molecules |
| WO2019180272A1 (en) | 2018-03-23 | 2019-09-26 | Fundación Instituto De Investigación Sanitaria De Santiago De Compostela | Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases |
| BR112020018539A2 (pt) | 2018-03-23 | 2020-12-29 | Bristol-Myers Squibb Company | Anticorpos contra mica e/ou micb e usos dos mesmos |
| US11993658B2 (en) | 2018-03-26 | 2024-05-28 | Sutro Biopharma, Inc. | Anti-BCMA antibodies and treatment methods |
| AU2019246007A1 (en) | 2018-03-26 | 2020-09-10 | Glycanostics S.R.O. | Means and methods for glycoprofiling of a protein |
| US20210047696A1 (en) | 2018-03-28 | 2021-02-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
| WO2019185792A1 (en) | 2018-03-29 | 2019-10-03 | Philogen S.P.A | Cancer treatment using immunoconjugates and immune check-point inhibitors |
| WO2019191416A1 (en) | 2018-03-29 | 2019-10-03 | Bristol-Myers Squibb Company | Methods of purifying monomeric monoclonal antibodies |
| CN111886254B (zh) | 2018-03-30 | 2023-12-08 | 南京传奇生物科技有限公司 | 针对lag-3的单结构域抗体及其用途 |
| US11840568B2 (en) | 2018-04-02 | 2023-12-12 | Mab-Venture Biopharm Co., Ltd. | Lymphocyte activation gene-3 (LAG-3) binding antibody and use thereof |
| KR20200139219A (ko) | 2018-04-02 | 2020-12-11 | 브리스톨-마이어스 스큅 컴퍼니 | 항-trem-1 항체 및 이의 용도 |
| CN110343178B (zh) | 2018-04-03 | 2022-07-22 | 上海开拓者生物医药有限公司 | 抗人lag-3单克隆抗体及其应用 |
| TW202011029A (zh) | 2018-04-04 | 2020-03-16 | 美商建南德克公司 | 偵測及定量fgf21之方法 |
| WO2019193375A1 (en) | 2018-04-04 | 2019-10-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fzd7 inhibitors for the treatment of retinal neovascularization |
| CN112334485A (zh) | 2018-04-06 | 2021-02-05 | 百进生物科技公司 | 抗-四次穿膜蛋白33药剂及其组合物以及制备和使用方法 |
| US10640576B2 (en) | 2018-04-10 | 2020-05-05 | Y-Biologics Inc. | Cell engaging binding molecules |
| EP3552620A1 (en) | 2018-04-11 | 2019-10-16 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Methods of treatment for candida auris infections |
| CN112004558A (zh) | 2018-04-12 | 2020-11-27 | 米迪亚制药有限责任公司 | Lgals3bp抗体-药物-偶联物及其用于癌症的治疗的用途 |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| JP2021521445A (ja) | 2018-04-13 | 2021-08-26 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 前立腺癌又は乳癌を患っている患者の転帰を予測するための及び処置のための方法 |
| WO2019197678A1 (en) | 2018-04-13 | 2019-10-17 | Sangamo Therapeutics France | Chimeric antigen receptor specific for interleukin-23 receptor |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| WO2019201904A1 (en) | 2018-04-16 | 2019-10-24 | Merck Patent Gmbh | Viscosity reduction of highly concentrated protein formulations |
| CN108623687A (zh) | 2018-04-17 | 2018-10-09 | 中山康方生物医药有限公司 | 神经生长因子的单克隆抗体及其编码基因和应用 |
| AR115052A1 (es) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | Anticuerpos multiespecíficos y utilización de los mismos |
| AR114789A1 (es) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
| CN112189018A (zh) | 2018-04-20 | 2021-01-05 | 汉诺威医学院 | 结合疱疹病毒抗原的嵌合抗原受体和car-t细胞 |
| CN108373505B (zh) | 2018-04-20 | 2019-08-20 | 北京智仁美博生物科技有限公司 | 抗il-4r抗体及其用途 |
| WO2019209952A2 (en) | 2018-04-23 | 2019-10-31 | Emory University | Vip antagonists and uses in treating cancer |
| IT201800004853A1 (it) | 2018-04-24 | 2019-10-24 | Metodi per trattare il cancro | |
| WO2019206095A1 (zh) | 2018-04-24 | 2019-10-31 | 安源医药科技（上海）有限公司 | 针对tim-3的抗体及其用途 |
| WO2019207030A1 (en) | 2018-04-26 | 2019-10-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer |
| WO2019207066A1 (en) | 2018-04-26 | 2019-10-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for the treatment of sjögren's syndrome |
| EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
| WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| US20210171610A1 (en) | 2018-05-02 | 2021-06-10 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection |
| WO2019211370A1 (en) | 2018-05-03 | 2019-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
| WO2019211369A1 (en) | 2018-05-03 | 2019-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
| US11958895B2 (en) | 2018-05-03 | 2024-04-16 | University Of Rochester | Anti-influenza neuraminidase monoclonal antibodies and uses thereof |
| EP3790900A1 (en) | 2018-05-09 | 2021-03-17 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Antibodies specific to human nectin4 |
| US10647755B2 (en) | 2018-05-09 | 2020-05-12 | The Hong Kong University Of Science And Technology | Photoresponsive protein hydrogels and methods and uses thereof |
| KR20240056644A (ko) | 2018-05-10 | 2024-04-30 | 주식회사 뉴라클사이언스 | 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법 |
| CA3100005A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| EP3794024B1 (en) | 2018-05-14 | 2023-05-10 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| CN110483639A (zh) | 2018-05-15 | 2019-11-22 | 复旦大学 | 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途 |
| KR20210013091A (ko) | 2018-05-16 | 2021-02-03 | 시에스엘 리미티드 | 가용성 보체 수용체 1형 변이체 및 이의 용도 |
| WO2019224715A1 (en) | 2018-05-23 | 2019-11-28 | Pfizer Inc. | Antibodies specific for cd3 and uses thereof |
| US11525010B2 (en) | 2018-05-23 | 2022-12-13 | Pfizer Inc. | Antibodies specific for GUCY2c and uses thereof |
| WO2019225787A1 (ko) | 2018-05-24 | 2019-11-28 | 에이비엘바이오 주식회사 | 항-b7-h3 항체 및 그 용도 |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| CN112218893A (zh) | 2018-05-25 | 2021-01-12 | 艾利妥 | 抗-sirpa抗体及其使用方法 |
| US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| EP3575320A1 (en) | 2018-05-29 | 2019-12-04 | Heinrich-Pette-Institut Leibniz-Institut für Experimentelle Virologie | New therapy for treating graft-versus-host-disease |
| UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| WO2019230868A1 (ja) | 2018-05-30 | 2019-12-05 | 中外製薬株式会社 | 単ドメイン抗体含有リガンド結合分子 |
| CN110551215A (zh) | 2018-05-30 | 2019-12-10 | 中山康方生物医药有限公司 | 抗白细胞介素-17a抗体、其药物组合物及其用途 |
| CN112533948A (zh) | 2018-05-31 | 2021-03-19 | 台湾醣联生技医药股份有限公司 | 与双触角Lewis B以及Lewis Y抗原结合的治疗性抗体 |
| GB201808927D0 (en) | 2018-05-31 | 2018-07-18 | Institute Of Cancer Res Royal Cancer Hospital | Materials and methods for monitoring the development of resistance of cancers to treatment |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| WO2019232321A1 (en) | 2018-06-01 | 2019-12-05 | NanoView Biosciences, Inc. | Compositions, systems, and methods for enhanced label-free and fluorescence - based detection of nanoparticles |
| TW202016136A (zh) | 2018-06-01 | 2020-05-01 | 瑞士商諾華公司 | 針對ｂｃｍａ之結合分子及其用途 |
| US20210230300A1 (en) | 2018-06-04 | 2021-07-29 | Bayer Aktiengesellschaft | Inhibitors of shp2 |
| WO2019234099A1 (en) | 2018-06-06 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction |
| EP3804759A4 (en) | 2018-06-06 | 2022-07-20 | Osaka University | METHODS OF TREATMENT OF DANDRUFF OR PREVENTION OF GNASE 1 SECONDARY DISEASES |
| WO2019236965A1 (en) | 2018-06-08 | 2019-12-12 | Alector Llc | Anti-siglec-7 antibodies and methods of use thereof |
| KR102480493B1 (ko) | 2018-06-08 | 2022-12-21 | 크리스탈 바이오사이언스 주식회사 | 동일한 경쇄 i을 갖는 다양한 항체를 생산하기 위한 트랜스제닉 동물 |
| WO2019234221A1 (en) | 2018-06-08 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia |
| GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
| WO2019245269A1 (ko) | 2018-06-18 | 2019-12-26 | 연세대학교 산학협력단 | Flt3 억제제를 유효성분으로 포함하는 만성 골수성 백혈병 약물 내성 억제용 조성물 |
| TW202016142A (zh) | 2018-06-18 | 2020-05-01 | 法商天賜製藥公司 | 用於治療癌症之組合物及方法 |
| CA3103327A1 (en) | 2018-06-18 | 2019-12-26 | Bayer Aktiengesellschaft | Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile |
| JP2021526844A (ja) | 2018-06-18 | 2021-10-11 | ユーリカ セラピューティックス， インコーポレイテッド | 前立腺特異的膜抗原（ｐｓｍａ）を標的とする構築物及びその使用 |
| MA52969A (fr) | 2018-06-19 | 2021-04-28 | Atarga Llc | Molécules d'anticorps se liant au composant du complément 5 et leurs utilisations |
| EP3810268A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
| EP3810085A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| EP3810094A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
| WO2019246313A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
| JP7084057B2 (ja) | 2018-06-20 | 2022-06-14 | 株式会社ファーマフーズ | 新規抗ｐａｄ２抗体 |
| EP3810777A4 (en) | 2018-06-21 | 2022-03-30 | Yumanity Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS |
| WO2019244107A1 (en) | 2018-06-21 | 2019-12-26 | Daiichi Sankyo Company, Limited | Compositions including cd3 antigen binding fragments and uses thereof |
| TW202016081A (zh) | 2018-06-21 | 2020-05-01 | 英商克拉德夫製藥有限公司 | 人類ｓｔｉｎｇ之小分子調節劑、結合物及治療應用 |
| BR112020025504A2 (pt) | 2018-06-22 | 2021-03-16 | Junten Bio Co., Ltd. | Anticorpo que induz a imunotolerância, linfócito induzido, e agente de terapia celular método terapêutico usando o linfócito induzido |
| TWI832869B (zh) | 2018-06-22 | 2024-02-21 | 日商順天生化股份有限公司 | 使用具有複合狀態之細胞混合物之誘導免疫耐受之抗體、及被誘導之淋巴球、以及使用被誘導之淋巴球之細胞治療劑及治療法 |
| AU2019288728A1 (en) | 2018-06-23 | 2021-01-14 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
| TWI831797B (zh) | 2018-06-26 | 2024-02-11 | 美商伊繆諾金公司 | 靶向adam9之免疫接合物及其使用方法 |
| TW202035444A (zh) | 2018-06-27 | 2020-10-01 | 台灣浩鼎生技股份有限公司 | 用於糖蛋白工程的糖苷合成酶變體及其使用方法 |
| BR112020024078A2 (pt) | 2018-06-29 | 2021-02-17 | Boehringer Ingelheim International Gmbh | anticorpos anti-cd40 para uso no tratamento de doença autoimune |
| US11884729B2 (en) | 2018-06-29 | 2024-01-30 | ApitBio, Inc | Anti-L1CAM antibodies and uses thereof |
| WO2020006568A1 (en) | 2018-06-29 | 2020-01-02 | City Of Hope | Cd6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders |
| AU2019293589A1 (en) | 2018-06-29 | 2021-01-21 | Alector Llc | Anti-SIRP-beta1 antibodies and methods of use thereof |
| JP2021529762A (ja) | 2018-06-29 | 2021-11-04 | ノース・キャロライナ・ステイト・ユニヴァーシティ | 術後治療用ｉｎ ｓｉｔｕ噴霧生体応答性免疫療法ゲル |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| EP3817762A4 (en) | 2018-07-03 | 2022-04-13 | Catalent Pharma Solutions, LLC | MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND THEIR USE |
| WO2020007898A1 (en) | 2018-07-04 | 2020-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating brain injury or neurodegenerative disease |
| WO2020008083A1 (es) | 2018-07-05 | 2020-01-09 | Consejo Superior De Investigaciones Científicas | Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas |
| WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| PT3677278T (pt) | 2018-07-11 | 2022-02-03 | Scholar Rock Inc | Inibidores seletivos da isoforma tgfbeta1 e sua utilização |
| GB201811364D0 (en) | 2018-07-11 | 2018-08-29 | Adc Therapeutics Sa | Combination therapy |
| TW202019957A (zh) | 2018-07-11 | 2020-06-01 | 美商供石公司 | TGFβ1抑制劑及其用途 |
| CN112996535A (zh) | 2018-07-11 | 2021-06-18 | 供石公司 | 高亲和性、亚型选择性TGFβ1抑制剂及其用途 |
| AU2019301206A1 (en) | 2018-07-12 | 2021-03-04 | F-Star Therapeutics Limited | Antibody molecules that bind CD137 and OX40 |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| US20220049007A1 (en) | 2018-07-12 | 2022-02-17 | F-Star Beta Limited | Antibody molecules that bind pd-l1 and cd137 |
| PE20210186A1 (es) | 2018-07-13 | 2021-02-02 | Alector Llc | Anticuerpos anti-sortilina y metodos para su uso |
| JP7447388B2 (ja) | 2018-07-13 | 2024-03-12 | ナンジン レジェンド バイオテック カンパニー，リミテッド | 感染性疾患の治療のための共受容体システム |
| WO2020012435A1 (en) | 2018-07-13 | 2020-01-16 | Lausanne University Hospital | Hiv binding agents |
| EP3823989A2 (en) | 2018-07-16 | 2021-05-26 | Regeneron Pharmaceuticals, Inc. | Anti-il36r antibodies |
| JP2021530502A (ja) | 2018-07-18 | 2021-11-11 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト、代謝拮抗剤、及びプラチナ製剤で肺がんを治療する方法 |
| MA53160A (fr) | 2018-07-20 | 2021-05-26 | Pf Medicament | Récepteur pour vista |
| EP3823673A4 (en) | 2018-07-20 | 2022-05-11 | Surface Oncology, Inc. | ANTI-CD112R COMPOSITIONS AND METHODS |
| WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
| EA202190183A1 (ru) | 2018-07-27 | 2021-05-18 | Алектор Ллс | Антитела к siglec-5 и способы их применения |
| JP7182308B2 (ja) | 2018-07-27 | 2022-12-02 | 国立大学法人大阪大学 | 老化の抑制、加齢性の疾患もしくは症状の予防、改善、もしくは治療、または寿命の延長のための組成物 |
| TW202021616A (zh) | 2018-07-30 | 2020-06-16 | 美商安進公司 | 結合至ｃｄ３３和ｃｄ３的雙特異性抗體構建體之延長投與 |
| KR20210073489A (ko) | 2018-07-31 | 2021-06-18 | 어센테지 파마 (쑤저우) 컴퍼니 리미티드 | Iap 억제제와 면역 체크포인트 분자 조절제의 병용에 의한 암 치료 방법 |
| TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| AU2019315226A1 (en) | 2018-08-03 | 2021-03-18 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing two antigen-binding domains that are linked to each other |
| US11692031B2 (en) | 2018-08-03 | 2023-07-04 | Amgen Research (Munich) Gmbh | Antibody constructs for CLDN18.2 and CD3 |
| BR112021002145A2 (pt) | 2018-08-07 | 2021-12-14 | In3Bio Ltd | Métodos e composições para inibição da via egf/egfr em combinação com inibidores da quinase de linfoma anaplásico |
| CN112770775A (zh) | 2018-08-08 | 2021-05-07 | 豪夫迈·罗氏有限公司 | 色氨酸衍生物和l-蛋氨酸用于蛋白制剂的用途 |
| EP3833446A2 (en) | 2018-08-10 | 2021-06-16 | Sangamo Therapeutics France | New car constructs comprising tnfr2 domains |
| CA3108369A1 (en) | 2018-08-10 | 2020-02-13 | Tomoyuki Igawa | Anti-cd137 antigen-binding molecule and utilization thereof |
| IL261156A (en) | 2018-08-14 | 2020-02-27 | Fass Deborah | Chimeric quiescin sulfhydryl oxidase (qsox1) antibodies and uses of same |
| CN110818793A (zh) | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| BR112021002747A2 (pt) | 2018-08-17 | 2021-08-10 | Mersana Therapeutics, Inc. | conjugados de anticorpo-fármaco e polímero direcionados a napi2b e métodos de uso dos mesmos |
| SG11202012148RA (en) | 2018-08-21 | 2021-01-28 | Albert Einstein College Of Medicine | Monoclonal antibodies against human tim-3 |
| JP7177543B2 (ja) | 2018-08-21 | 2022-11-24 | エービーエル バイオ インコーポレイテッド | 抗ｐｄ－ｌ１／抗ｌａｇ３二重特異性抗体およびその使用 |
| US11548938B2 (en) | 2018-08-21 | 2023-01-10 | Quidel Corporation | DbpA antibodies and uses thereof |
| MA53434A (fr) | 2018-08-23 | 2021-12-01 | Seagen Inc | Anticorps anti-tigit |
| CN113227359A (zh) | 2018-08-24 | 2021-08-06 | 耶达研究及发展有限公司 | 调节m2巨噬细胞极化的方法及其在治疗中的用途 |
| WO2020041758A1 (en) | 2018-08-24 | 2020-02-27 | City Of Hope | Masked cytokine conjugates |
| CN109053895B (zh) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| US20210253666A1 (en) | 2018-08-30 | 2021-08-19 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2020047345A1 (en) | 2018-08-31 | 2020-03-05 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| EP3843748A1 (en) | 2018-08-31 | 2021-07-07 | ADC Therapeutics SA | Combination therapy |
| EA202190235A1 (ru) | 2018-08-31 | 2021-07-02 | Алектор Ллс | Антитела к cd33 и способы их применения |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| EP3847650A1 (en) | 2018-09-06 | 2021-07-14 | The Broad Institute, Inc. | Nucleic acid assemblies for use in targeted delivery |
| WO2020048607A1 (en) | 2018-09-07 | 2020-03-12 | Université Libre de Bruxelles | Srsf2 as rna epigenetic factor |
| CN112823167A (zh) | 2018-09-07 | 2021-05-18 | 辉瑞大药厂 | 抗-αvβ8抗体和组合物及其用途 |
| EP3849545A1 (en) | 2018-09-10 | 2021-07-21 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of neurofibromatosis |
| EP3849602A1 (en) | 2018-09-10 | 2021-07-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of her2/neu antibody with heme for treating cancer |
| US20220048995A1 (en) | 2018-09-10 | 2022-02-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of an inhibitor of ntsr1 activation or expression for preventing weight loss, muscle loss, and protein blood level decrease in subjects in need thereof |
| US20220105176A1 (en) | 2018-09-12 | 2022-04-07 | Acm Biolabs Pte Ltd | Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof |
| WO2020053808A1 (en) | 2018-09-12 | 2020-03-19 | Georg Dewald | Method of diagnosing vasoregulatory disorders |
| US10899826B1 (en) | 2018-09-13 | 2021-01-26 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for an anti-CGRP antagonist antibody |
| GB201815041D0 (en) | 2018-09-14 | 2018-10-31 | Scancell Ltd | Epitopes |
| JP7407723B2 (ja) | 2018-09-14 | 2024-01-04 | 田辺三菱製薬株式会社 | ヒト抗ｉｌ－３３モノクローナル抗体含有医薬用組成物 |
| TW202028224A (zh) | 2018-09-17 | 2020-08-01 | 德商英麥提克生物技術股份有限公司 | B*44限制肽在抗癌免疫治療的用途和相關方法 |
| JP2022500454A (ja) | 2018-09-17 | 2022-01-04 | ストロ バイオファーマ インコーポレーテッド | 抗葉酸受容体抗体コンジュゲートによる併用療法 |
| TW202024121A (zh) | 2018-09-18 | 2020-07-01 | 德商英麥提克生物技術股份有限公司 | A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法 |
| CN113056487A (zh) | 2018-09-18 | 2021-06-29 | 梅里麦克制药股份有限公司 | 抗tnfr2抗体及其用途 |
| KR20210063330A (ko) | 2018-09-19 | 2021-06-01 | 제넨테크, 인크. | 방광암에 대한 치료 및 진단 방법 |
| CN113015746A (zh) | 2018-09-19 | 2021-06-22 | 拉荷亚免疫研究所 | 在类风湿性关节炎中的ptprs和蛋白聚糖 |
| US20220073638A1 (en) | 2018-09-19 | 2022-03-10 | INSERM (Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy |
| EP3626265A1 (en) | 2018-09-21 | 2020-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-human cd45rc antibodies and uses thereof |
| WO2020059847A1 (ja) | 2018-09-21 | 2020-03-26 | 国立大学法人 東京医科歯科大学 | ヒトｈｍｇｂ１に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物 |
| EP3857230B1 (en) | 2018-09-21 | 2023-06-07 | F. Hoffmann-La Roche AG | Diagnostic methods for triple-negative breast cancer |
| AU2019343952A1 (en) | 2018-09-21 | 2021-04-22 | Mucommune, Llc | Synthetic binding agents for limiting permeation through mucus |
| CA3114038A1 (en) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| WO2020068557A1 (en) | 2018-09-25 | 2020-04-02 | BioLegend, Inc. | Anti-tlr9 agents and compositions and methods for making and using the same |
| EP3856772A1 (en) | 2018-09-25 | 2021-08-04 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma |
| MX2021003263A (es) | 2018-09-26 | 2021-05-12 | Merck Patent Gmbh | Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer. |
| CN113286812A (zh) | 2018-09-27 | 2021-08-20 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| EP3856206A1 (en) | 2018-09-27 | 2021-08-04 | Phosphogam, Inc. | Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells |
| AR116526A1 (es) | 2018-09-27 | 2021-05-19 | Tizona Therapeutics | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anticuerpos anti-hla-g |
| CN113164777A (zh) | 2018-09-27 | 2021-07-23 | 马伦戈治疗公司 | Csf1r/ccr2多特异性抗体 |
| CN112771071A (zh) | 2018-09-28 | 2021-05-07 | 麻省理工学院 | 胶原蛋白定位的免疫调节分子及其方法 |
| US20210347851A1 (en) | 2018-09-28 | 2021-11-11 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
| WO2020069405A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
| MA53732A (fr) | 2018-09-28 | 2022-01-05 | Amgen Inc | Anticorps dirigés contre bcma soluble |
| AU2019349958A1 (en) | 2018-09-28 | 2021-05-06 | Kyowa Kirin Co., Ltd. | IL-36 antibodies and uses thereof |
| WO2020070062A1 (en) | 2018-10-01 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma |
| WO2020070678A2 (en) | 2018-10-03 | 2020-04-09 | Staten Biotechnology B.V. | Antibodies specific for human and cynomolgus apoc3 and methods of use thereof |
| WO2020070240A1 (en) | 2018-10-04 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of mucosal inflammatory diseases |
| CA3113818A1 (en) | 2018-10-05 | 2020-04-09 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist |
| JP2022512580A (ja) | 2018-10-05 | 2022-02-07 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 細菌バイオフィルムの酵素的破壊のための組成物および方法 |
| WO2020074937A1 (en) | 2018-10-09 | 2020-04-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of alpha-v-integrin (cd51) inhibitors for the treatment of cardiac fibrosis |
| TW202028244A (zh) | 2018-10-09 | 2020-08-01 | 美商建南德克公司 | 用於確定突觸形成之方法及系統 |
| WO2020076969A2 (en) | 2018-10-10 | 2020-04-16 | Tilos Therapeutics, Inc. | Anti-lap antibody variants and uses thereof |
| US20210340277A1 (en) | 2018-10-11 | 2021-11-04 | The Scripps Research Institute | Antibody compounds with reactive arginine and related antibody drug conjugates |
| CN113518647A (zh) | 2018-10-11 | 2021-10-19 | 印希比股份有限公司 | 5t4单域抗体及其治疗性组合物 |
| EP3864049A1 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
| EP3864045A2 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| WO2020077212A1 (en) | 2018-10-11 | 2020-04-16 | Amgen Inc. | Downstream processing of bispecific antibody constructs |
| US11674961B2 (en) | 2018-10-12 | 2023-06-13 | Quidel Corporation | Extraction reagent for use in an assay for detection of group A Streptococcus |
| CN113164447A (zh) | 2018-10-15 | 2021-07-23 | 默克专利股份公司 | 利用dna烷化剂和atr抑制剂的组合疗法 |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
| JP2022504468A (ja) | 2018-10-17 | 2022-01-13 | バイオラインアールエックス・リミテッド | 転移性膵臓腺癌の処置 |
| US20210353750A1 (en) | 2018-10-18 | 2021-11-18 | Jounce Therapeutics, Inc. | Methods of Treating Cancer |
| WO2020079164A1 (en) | 2018-10-18 | 2020-04-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor |
| MX2021004348A (es) | 2018-10-18 | 2021-05-28 | Genentech Inc | Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide. |
| EP3866856A1 (en) | 2018-10-19 | 2021-08-25 | MedImmune Limited | Pyrrolobenzodiazepine conjugates |
| WO2020082209A1 (zh) | 2018-10-22 | 2020-04-30 | 上海吉倍生物技术有限公司 | 抗cldn18.2抗体及其用途 |
| BR112021007765A2 (pt) | 2018-10-23 | 2021-08-03 | Scholar Rock, Inc. | inibidores seletivos de rgmc e uso dos mesmos |
| AU2019365238A1 (en) | 2018-10-24 | 2021-05-13 | F. Hoffmann-La Roche Ag | Conjugated chemical inducers of degradation and methods of use |
| WO2020086802A1 (en) | 2018-10-24 | 2020-04-30 | Jounce Therapeutics, Inc. | Methods and compositions for the treatment of cancer and infectious diseases |
| TWI824043B (zh) | 2018-10-25 | 2023-12-01 | 西班牙商瑪製藥股份有限公司 | 藥物抗體共軛物 |
| EP3870299A1 (en) | 2018-10-26 | 2021-09-01 | Jounce Therapeutics, Inc. | Methods of treating cancer |
| CA3100232A1 (en) | 2018-10-26 | 2020-04-30 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
| KR20200047937A (ko) | 2018-10-26 | 2020-05-08 | 재단법인 목암생명과학연구소 | Ids를 포함하는 융합 단백질 및 이의 용도 |
| US20220170097A1 (en) | 2018-10-29 | 2022-06-02 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
| RU2724469C2 (ru) | 2018-10-31 | 2020-06-23 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело, которое специфически связывается с cd20 |
| CA3117112A1 (en) | 2018-10-31 | 2020-05-07 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Biomarkers and methods of use for radiation-induced lung injury |
| MX2021004819A (es) | 2018-11-02 | 2021-06-08 | Annexon Inc | Composiciones y metodos para tratar lesiones cerebrales. |
| EP4219550A1 (en) | 2018-11-02 | 2023-08-02 | Oklahoma Medical Research Foundation | Monoclonal antibodies to eltd1 and uses thereof |
| CN113613726A (zh) | 2018-11-05 | 2021-11-05 | 路德维格癌症研究所有限公司 | 人源化和变体TGF-β3特异性抗体及其方法和用途 |
| CN113613725A (zh) | 2018-11-05 | 2021-11-05 | 路德维格癌症研究所有限公司 | 人源化和变体TGF-β1特异性抗体及其方法和用途 |
| EP3877407A1 (en) | 2018-11-05 | 2021-09-15 | F. Hoffmann-La Roche AG | Methods of producing two chain proteins in prokaryotic host cells |
| WO2020094609A1 (en) | 2018-11-06 | 2020-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells |
| EP3878869A4 (en) | 2018-11-07 | 2023-04-19 | Shanghai Hyamab Biotech Co., Ltd. | NKG2A ANTIBODY, METHOD FOR PREPARATION AND USE |
| CA3117945A1 (en) | 2018-11-09 | 2020-05-14 | University Of Massachusetts | Anti-cfae antibodies and methods of use |
| SG11202104431PA (en) | 2018-11-15 | 2021-05-28 | Byondis Bv | HUMANIZED ANTI-SIRPα ANTIBODIES |
| CN113366022A (zh) | 2018-11-16 | 2021-09-07 | 纪念斯隆凯特琳癌症中心 | 针对粘蛋白-16的抗体及其使用方法 |
| US20220000762A1 (en) | 2018-11-16 | 2022-01-06 | S-biomedic N.v. | Compositions for treating oxidative stress-associated skin diseases and skin ageing and diagnosis of oxidative stress-associated skin diseases |
| EP3883635A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| US11548941B2 (en) | 2018-11-20 | 2023-01-10 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-IL-23 specific antibody |
| MX2021005560A (es) | 2018-11-20 | 2021-06-23 | Bavarian Nordic As | Terapia para el tratamiento del cancer con administracion intratumoral y/o intravenosa de un virus vaccinia ankara (mva) recombinante que codifica ligando 4-1bbl (cd137l) y/o ligando del cumulo o grupo de diferenciacion 40 (cd40l). |
| US20220017629A1 (en) | 2018-11-20 | 2022-01-20 | Shanghai Pharmaexplorer Co., Ltd. | Ox40 antibody, preparation method thereof and use thereof |
| CN111196851B (zh) | 2018-11-20 | 2021-11-16 | 厦门万泰凯瑞生物技术有限公司 | 针对人抗缪勒管激素的特异性抗体及其应用 |
| WO2020104705A2 (en) | 2018-11-23 | 2020-05-28 | Katholieke Universiteit Leuven | Predicting a treatment response in inflammatory bowel disease |
| WO2020109251A1 (en) | 2018-11-29 | 2020-06-04 | Adc Therapeutics Sa | Dosage regime |
| CN111234018A (zh) | 2018-11-29 | 2020-06-05 | 上海开拓者生物医药有限公司 | 全人抗gitr抗体及其制备方法 |
| WO2020117627A1 (en) | 2018-12-03 | 2020-06-11 | Bristol-Myers Squibb Company | Anti-ido antibody and uses thereof |
| CN113166257B (zh) | 2018-12-03 | 2023-05-30 | 上海开拓者生物医药有限公司 | Cd47抗体及其制备方法和应用 |
| CN113490499A (zh) | 2018-12-04 | 2021-10-08 | 大日本住友制药肿瘤公司 | 用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物 |
| US20220098310A1 (en) | 2018-12-06 | 2022-03-31 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
| EP3891292A1 (en) | 2018-12-06 | 2021-10-13 | Pfizer Inc. | Cells with reduced inhibitor production and methods of use thereof |
| WO2020117257A1 (en) | 2018-12-06 | 2020-06-11 | Genentech, Inc. | Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody |
| WO2020115261A1 (en) | 2018-12-07 | 2020-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| KR102433184B1 (ko) | 2018-12-07 | 2022-08-17 | 서울대학교 산학협력단 | 항 c-Met 아고니스트 항체 및 이의 용도 |
| BR112021010026A2 (pt) | 2018-12-07 | 2021-08-17 | Jiangsu Hengrui Medicine Co., Ltd. | anticorpo cd3 e seu uso farmacêutico |
| US20220026445A1 (en) | 2018-12-07 | 2022-01-27 | Georgia Tech Research Corporation | Antibodies that bind to natively folded myocilin |
| KR102396194B1 (ko) | 2018-12-07 | 2022-05-10 | 서울대학교 산학협력단 | 항 c-Met 아고니스트 항체 및 이의 용도 |
| JP2022513198A (ja) | 2018-12-10 | 2022-02-07 | ジェネンテック， インコーポレイテッド | Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド |
| US20220010008A1 (en) | 2018-12-12 | 2022-01-13 | Shanghai Pharmaexplorer Co., Ltd. | Anti-human interleukin 5(il-5) monoclonal antibody and use thereof |
| CN111303283A (zh) | 2018-12-12 | 2020-06-19 | 上海君实生物医药科技股份有限公司 | 抗il-17a抗体及其应用 |
| KR20210102274A (ko) | 2018-12-13 | 2021-08-19 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 헤르복시디엔 항체-약물 접합체 및 사용 방법 |
| WO2020120786A1 (en) | 2018-12-14 | 2020-06-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs |
| GB201820554D0 (en) | 2018-12-17 | 2019-01-30 | Univ Oxford Innovation Ltd | BTLA antibodies |
| GB201820547D0 (en) | 2018-12-17 | 2019-01-30 | Oxford Univ Innovation | Modified antibodies |
| CN113677703A (zh) | 2018-12-17 | 2021-11-19 | 鳄鱼生物科学公司 | 多肽 |
| TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
| CN113557244A (zh) | 2018-12-18 | 2021-10-26 | 弹射器治疗有限公司 | 预防或治疗移植物抗宿主病(GvHD)的抗CCR7 mAb的用途 |
| GB201820725D0 (en) | 2018-12-19 | 2019-01-30 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine resistance |
| WO2020128863A1 (en) | 2018-12-19 | 2020-06-25 | Novartis Ag | Anti-tnf-alpha antibodies |
| CA3123356A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer |
| AR117327A1 (es) | 2018-12-20 | 2021-07-28 | 23Andme Inc | Anticuerpos anti-cd96 y métodos de uso de estos |
| AU2019402163A1 (en) | 2018-12-20 | 2021-07-08 | Kyowa Kirin Co., Ltd. | Fn14 antibodies and uses thereof |
| AR117453A1 (es) | 2018-12-20 | 2021-08-04 | Genentech Inc | Fc de anticuerpos modificados y métodos para utilizarlas |
| WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
| EP3898673A1 (en) | 2018-12-21 | 2021-10-27 | 23Andme, Inc. | Anti-il-36 antibodies and methods of use thereof |
| GB201820983D0 (en) | 2018-12-21 | 2019-02-06 | Pirbright Inst | Virus |
| WO2020132231A1 (en) | 2018-12-21 | 2020-06-25 | Genentech, Inc. | Methods of producing polypeptides using a cell line resistant to apoptosis |
| NL2024544B1 (en) | 2018-12-21 | 2021-03-15 | Aim Immunotech Inc | Compositions And Methods For Cancer Therapy |
| JP2022514362A (ja) | 2018-12-21 | 2022-02-10 | エフ．ホフマン－ラ ロシュ アーゲー | 抗ｖｅｇｆ抗体のｖｅｇｆ－ｒ１への結合阻害を改善する方法 |
| WO2020132557A1 (en) | 2018-12-21 | 2020-06-25 | Compass Therapeutics Llc | Transgenic mouse expressing common human light chain |
| WO2020127885A1 (en) | 2018-12-21 | 2020-06-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions for treating cancers and resistant cancers |
| BR112021012022A2 (pt) | 2018-12-21 | 2021-11-03 | Hoffmann La Roche | Anticorpo que se liga ao vegf e à il-1beta e métodos de uso |
| AU2019412489A1 (en) | 2018-12-26 | 2021-06-10 | Innate Pharma | Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies |
| JP2022516503A (ja) | 2018-12-26 | 2022-02-28 | シティ・オブ・ホープ | 活性化可能なマスクされた抗ｃｔｌａ４結合タンパク質 |
| BR112021010789A2 (pt) | 2018-12-27 | 2021-08-31 | Boehringer Ingelheim International Gmbh | Anticorpos anti-il-36r para o tratamento de pustulose palmoplantar |
| JP2022519340A (ja) | 2018-12-27 | 2022-03-23 | アケソ・バイオファーマ・インコーポレイテッド | ヒトｉｌ４ｒａに対する抗体及びその使用 |
| CN111378045B (zh) | 2018-12-28 | 2022-08-02 | 长春金赛药业有限责任公司 | 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物 |
| WO2020136060A1 (en) | 2018-12-28 | 2020-07-02 | F. Hoffmann-La Roche Ag | A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response |
| WO2020139956A1 (en) | 2018-12-28 | 2020-07-02 | Sparx Therapeutics Inc. | Binding molecules specific for claudin 18.2, compositons and methods thereof, for treatment of cancer and other diseases |
| JP2022515318A (ja) | 2018-12-28 | 2022-02-18 | 四川科倫博泰生物医薬股▲フン▼有限公司 | 抗体及びその用途 |
| CN113272327A (zh) | 2018-12-30 | 2021-08-17 | 豪夫迈·罗氏有限公司 | 抗兔cd19抗体及其使用方法 |
| WO2020141199A1 (en) | 2019-01-03 | 2020-07-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer |
| KR20210113265A (ko) | 2019-01-07 | 2021-09-15 | 인히브릭스, 인크. | 변형된 il-2 폴리펩타이드를 포함하는 폴리펩타이드 및 이의 용도 |
| CN111434688A (zh) | 2019-01-11 | 2020-07-21 | 上海开拓者生物医药有限公司 | Cd73抗体及其制备方法和应用 |
| MX2021008094A (es) | 2019-01-11 | 2021-09-21 | Omeros Corp | Metodos y composiciones para el tratamiento del cancer. |
| AU2020207664A1 (en) | 2019-01-13 | 2021-07-22 | University Of Rijeka Faculty Of Medicine | Antibodies specific to human Nectin-2 |
| WO2020148206A1 (en) | 2019-01-14 | 2020-07-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and kits for generating and selecting a variant of a binding protein with increased binding affinity and/or specificity |
| EP3911678A1 (en) | 2019-01-14 | 2021-11-24 | Genentech, Inc. | Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine |
| BR112021013903A2 (pt) | 2019-01-15 | 2021-09-21 | Janssen Biotech, Inc. | Composições e métodos de anticorpos anti-tnf para o tratamento da artrite idiopática juvenil |
| CN109762067B (zh) | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| CN113347980A (zh) | 2019-01-18 | 2021-09-03 | 天主教鲁汶大学 | 病毒组合物 |
| US11008395B2 (en) | 2019-01-22 | 2021-05-18 | Bristol Myers-Squibb Company | Antibodies against IL-7R alpha subunit and uses thereof |
| KR20210118881A (ko) | 2019-01-22 | 2021-10-01 | 제넨테크, 인크. | 면역글로불린 a 항체 및 생산과 이용의 방법 |
| WO2020152081A1 (en) | 2019-01-22 | 2020-07-30 | Innate Pharma | Treatment of t cell lymphoma |
| US11235032B2 (en) | 2019-01-23 | 2022-02-01 | Massachusetts Institute Of Technology | Combination immunotherapy dosing regimen for immune checkpoint blockade |
| CA3127748A1 (en) | 2019-01-23 | 2020-07-30 | Janssen Biotech, Inc. | Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis |
| KR20210119448A (ko) | 2019-01-23 | 2021-10-05 | 앙세파 | Cd31 경쟁인자(competitor) 및 이의 용도 |
| BR112021014481A2 (pt) | 2019-01-23 | 2021-10-13 | Genentech, Inc. | Método para produzir um polipeptídeo multimérico, método para produzir um anticorpo biespecífico, pluralidade de polipeptídeos multiméricos, células hospedeiras eucarióticas recombinantes, método para identificar uma combinação de sequências e kit de polinucleotídeos |
| WO2020154595A1 (en) | 2019-01-24 | 2020-07-30 | Massachusetts Institute Of Technology | Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom |
| CN113329770A (zh) | 2019-01-24 | 2021-08-31 | 中外制药株式会社 | 新型癌抗原及所述抗原的抗体 |
| JP2022518796A (ja) | 2019-01-28 | 2022-03-16 | メイプル バイオテック エルエルシー | 肺、腎臓、または肝臓の線維症疾患の処置に使用するためのｐｓｍｐアンタゴニスト |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| GB201901305D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Specific binding molecules |
| CN113366317A (zh) | 2019-02-01 | 2021-09-07 | 纳诺韦尔生物科学有限公司 | 用于囊泡货物标记和检测的系统和方法 |
| CN113474370A (zh) | 2019-02-01 | 2021-10-01 | 瑞泽恩制药公司 | 抗IL2受体γ抗原结合蛋白 |
| EP3693063A1 (en) | 2019-02-06 | 2020-08-12 | Diaccurate | Methods and compositions for treating cancer |
| IL264768A (en) | 2019-02-10 | 2020-08-31 | Sagi Irit | ANTI-MATRIX METALLOPROTEINASE 7 (MMP-7) inhibitory antibody and its use |
| KR20220007584A (ko) | 2019-02-11 | 2022-01-18 | 주무토르 바이오로직스 인코포레이티드 | 항-clec2d 항체 및 이의 사용 방법 |
| EP3924739A1 (en) | 2019-02-12 | 2021-12-22 | Biogen MA Inc. | Biomarkers of progressive multifocal leukoencephalopathy |
| MA54955A (fr) | 2019-02-15 | 2021-12-22 | Integral Molecular Inc | Anticorps anti-claudine 6 et leurs utilisations |
| KR20210127947A (ko) | 2019-02-15 | 2021-10-25 | 저스트-에보텍 바이오로직스, 아이엔씨. | 자동화된 바이오 제조 시스템, 설비 및 공정 |
| KR20210125034A (ko) | 2019-02-15 | 2021-10-15 | 우시 바이올로직스 아일랜드 리미티드 | 동질성이 개선된 항체-약물 콘쥬게이트의 제조방법 |
| JP2022520632A (ja) | 2019-02-15 | 2022-03-31 | インテグラル・モレキュラー・インコーポレイテッド | 共通軽鎖を含む抗体及びその使用 |
| US10871640B2 (en) | 2019-02-15 | 2020-12-22 | Perkinelmer Cellular Technologies Germany Gmbh | Methods and systems for automated imaging of three-dimensional objects |
| WO2020169472A2 (en) | 2019-02-18 | 2020-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of inducing phenotypic changes in macrophages |
| JP7150999B2 (ja) | 2019-02-18 | 2022-10-11 | エーティービー セラピューティクス | 植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法 |
| AU2020224680A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders |
| JP2022523197A (ja) | 2019-02-21 | 2022-04-21 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| EP3927746A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| JP2022521411A (ja) | 2019-02-21 | 2022-04-07 | トリシュラ セラピューティクス， インコーポレイテッド | 抗ｃｄ３９抗体および抗ｐｄ－１または抗ｐｄ－ｌ１抗体を伴う併用療法 |
| JP2022521751A (ja) | 2019-02-21 | 2022-04-12 | マレンゴ・セラピューティクス，インコーポレーテッド | 抗ｔｃｒ抗体分子およびその使用 |
| CN112703013B (zh) | 2019-02-22 | 2022-09-30 | 武汉友芝友生物制药股份有限公司 | Cd3抗原结合片段及其应用 |
| EP3927371A1 (en) | 2019-02-22 | 2021-12-29 | Novartis AG | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
| US20220118089A1 (en) | 2019-02-25 | 2022-04-21 | The University Of Chicago | Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents |
| EP3930847B1 (en) | 2019-02-26 | 2024-02-14 | Inspirna, Inc. | High-affinity anti-mertk antibodies and uses thereof |
| AU2020228383A1 (en) | 2019-02-27 | 2021-09-23 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-CD20 or anti-CD38 antibodies |
| CN113677994A (zh) | 2019-02-27 | 2021-11-19 | 外延轴治疗股份有限公司 | 用于评估t细胞功能和预测对疗法的应答的方法和药剂 |
| MX2021010441A (es) | 2019-03-01 | 2021-09-21 | Allogene Therapeutics Inc | Receptores antigenicos quimericos y agentes de union dirigidos a dll3. |
| CN113874083A (zh) | 2019-03-01 | 2021-12-31 | 梅里麦克制药股份有限公司 | 抗-tnfr2抗体及其用途 |
| WO2020178193A1 (en) | 2019-03-01 | 2020-09-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of treatment of sarcoidosis |
| US11685780B2 (en) | 2019-03-05 | 2023-06-27 | Takeda Pharmaceutical Company Limited | Single domain antigen binding domains that bind human Trop2 |
| WO2020181058A1 (en) | 2019-03-05 | 2020-09-10 | Massachusetts Institute Of Technology | Dna launched rna replicon system (drep) and uses thereof |
| US20220339291A1 (en) | 2019-03-06 | 2022-10-27 | Legochem Biosciences, Inc. | Antibody-drug conjugates that target dlk1 and uses thereof |
| CN113784990A (zh) | 2019-03-08 | 2021-12-10 | 丹尼斯科美国公司 | 融合多肽 |
| MX2021010565A (es) | 2019-03-08 | 2021-10-13 | Genentech Inc | Metodos para detectar y cuantificar proteinas asociadas a la membrana en vesiculas extracelulares. |
| CN114949201A (zh) | 2019-03-12 | 2022-08-30 | 哈佛大学校长及研究员协会 | 治疗癌症的方法和组合物 |
| CN113518923A (zh) | 2019-03-13 | 2021-10-19 | 默克专利股份公司 | 用于脂质化蛋白质结构的制备的方法 |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
| CN113825769A (zh) | 2019-03-14 | 2021-12-21 | 詹森生物科技公司 | 用于产生抗tnf抗体组合物的方法 |
| JP2022524860A (ja) | 2019-03-14 | 2022-05-10 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｔｎｆ抗体組成物を産生するための方法 |
| EP3938384A4 (en) | 2019-03-14 | 2022-12-28 | Janssen Biotech, Inc. | METHODS OF MANUFACTURING FOR PRODUCING ANTI-IL12/IL23 ANTIBODY COMPOSITIONS |
| US20220169732A1 (en) | 2019-03-14 | 2022-06-02 | Biond Biologics Ltd. | Small shedding blocking agents |
| CN113840838A (zh) | 2019-03-14 | 2021-12-24 | 詹森生物科技公司 | 用于产生抗tnf抗体组合物的制造方法 |
| SG11202109424RA (en) | 2019-03-14 | 2021-09-29 | Genentech Inc | Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab |
| AU2020242747A1 (en) | 2019-03-15 | 2021-09-16 | Medimmune Limited | Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer |
| CN113853385A (zh) | 2019-03-18 | 2021-12-28 | 詹森生物科技公司 | 用抗il12/il23抗体治疗儿科受试者的银屑病的方法 |
| AU2020240072A1 (en) | 2019-03-18 | 2021-10-28 | Glaxosmithkline Biologicals S.A. | Bioconjugates of E. coli O-antigen polysaccharides, methods of production thereof, and methods of use thereof |
| JP2022525535A (ja) | 2019-03-19 | 2022-05-17 | アルベルト・アインシュタイン・カレッジ・オブ・メディシン | 単純ヘルペスウイルス感染の予防及び処置のためのモノクローナル抗体 |
| US20220153875A1 (en) | 2019-03-19 | 2022-05-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain |
| BR112021018611A2 (pt) | 2019-03-20 | 2021-11-23 | Imcheck Therapeutics Sas | Anticorpos tendo especificidade para btn2 e usos dos mesmos |
| CN113490502A (zh) | 2019-03-21 | 2021-10-08 | 艾洛基治疗公司 | 用于提高TCRαβ+细胞耗竭效率的方法 |
| WO2020198009A1 (en) | 2019-03-22 | 2020-10-01 | Regeneron Pharmaceuticals, Inc. | EGFR x CD28 MULTISPECIFIC ANTIBODIES |
| WO2020193628A1 (en) | 2019-03-25 | 2020-10-01 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Enhancement of cytolytic t-cell activity by inhibiting ebag9 |
| JP2022526334A (ja) | 2019-03-25 | 2022-05-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 新たなタウ種を標的化することによるタウオパチー障害の処置の方法 |
| EP3947454A1 (en) | 2019-03-27 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Recombinant proteins with cd40 activating properties |
| US20220169706A1 (en) | 2019-03-28 | 2022-06-02 | Danisco Us Inc | Engineered antibodies |
| KR102498681B1 (ko) | 2019-03-29 | 2023-02-09 | 메디뮨 리미티드 | 화합물 및 이의 접합체 |
| SG11202110732XA (en) | 2019-03-29 | 2021-10-28 | Atarga Llc | Anti fgf23 antibody |
| AU2020254582A1 (en) | 2019-04-01 | 2021-09-30 | Genentech, Inc. | Compositions and methods for stabilizing protein-containing formulations |
| EP3947737A2 (en) | 2019-04-02 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| GB201904717D0 (en) | 2019-04-03 | 2019-05-15 | Univ London Queen Mary | Treatment and diagnosis of mental disorders |
| WO2020206063A1 (en) | 2019-04-03 | 2020-10-08 | Genzyme Corporation | Anti-alpha beta tcr binding polypeptides with reduced fragmentation |
| JP2022527345A (ja) | 2019-04-03 | 2022-06-01 | オレガ・バイオテック | Ｐｄ１阻害剤及びｉｌ－１７ｂ阻害剤に基づく複合療法 |
| TW202102544A (zh) | 2019-04-04 | 2021-01-16 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
| WO2020201195A2 (en) | 2019-04-04 | 2020-10-08 | Bayer Aktiengesellschaft | Agonists of adiponectin |
| PE20220142A1 (es) | 2019-04-05 | 2022-01-27 | Teneobio Inc | Anticuerpos de cadena pesada que se unen al psma |
| KR20210150506A (ko) | 2019-04-09 | 2021-12-10 | 압큐로, 인크. | 킬러 세포 렉틴 유사-수용체 서브패밀리 G 구성원 1(KLRGl) 고갈 항체 |
| SG11202109901TA (en) | 2019-04-09 | 2021-10-28 | Hospital For Special Surgery | Protein binders for irhom2 |
| CA3136691A1 (en) | 2019-04-12 | 2020-10-15 | Geltor, Inc. | Recombinant elastin and production thereof |
| CA3136602A1 (en) | 2019-04-15 | 2020-10-22 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
| CN113474374A (zh) | 2019-04-16 | 2021-10-01 | 四川科伦博泰生物医药股份有限公司 | 抗FXI/FXIa抗体及其用途 |
| MX2021012163A (es) | 2019-04-17 | 2022-01-31 | Univ Hiroshima | Agente terapeutico para cancer urologico que se caracteriza por ser administrado con un inhibidor de il-6 y un inhibidor de ccr2 en combinacion. |
| KR20210148349A (ko) | 2019-04-17 | 2021-12-07 | 브리스톨-마이어스 스큅 컴퍼니 | 크로마토그래피 수지의 재생 방법 |
| JP2022528804A (ja) | 2019-04-18 | 2022-06-15 | ジェネンテック， インコーポレイテッド | 抗体力価試験 |
| JP2022529344A (ja) | 2019-04-18 | 2022-06-21 | エイシー イミューン ソシエテ アノニム | 治療及び診断のための新規分子 |
| CA3134522A1 (en) | 2019-04-19 | 2020-10-22 | Genentech, Inc. | Anti-mertk antibodies and their methods of use |
| MX2021012506A (es) | 2019-04-19 | 2022-01-24 | Chugai Pharmaceutical Co Ltd | Receptor quimerico que reconoce un sitio modificado geneticamente en anticuerpo. |
| RU2734432C1 (ru) | 2019-04-23 | 2020-10-16 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело, которое специфически связывается с GITR |
| SG11202110287QA (en) | 2019-04-24 | 2021-10-28 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| CN113748201A (zh) | 2019-04-26 | 2021-12-03 | 艾洛基治疗公司 | 制备同种异体car t细胞的方法 |
| WO2020221796A1 (en) | 2019-04-30 | 2020-11-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| US20220289854A1 (en) | 2019-04-30 | 2022-09-15 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents |
| US20220226496A1 (en) | 2019-05-02 | 2022-07-21 | Legochem Biosciences, Inc. | Ligand-drug conjugate including linker having tris structure |
| AU2020270407A1 (en) | 2019-05-03 | 2021-12-02 | Celgene Corporation | Anti-BCMA antibody conjugate, compositions comprising the same, and methods of making and using the same |
| AU2020268896A1 (en) | 2019-05-03 | 2021-09-30 | F. Hoffmann-La Roche Ag | Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform |
| EP3962947A2 (en) | 2019-05-03 | 2022-03-09 | F. Hoffmann-La Roche AG | Methods of treating cancer with an anti-pd-l1 antibody |
| EP3962951A1 (en) | 2019-05-03 | 2022-03-09 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
| US20200347139A1 (en) | 2019-05-04 | 2020-11-05 | Inhibrx, Inc. | CLEC12a Binding Polypeptides and Uses Thereof |
| EP3966239A1 (en) | 2019-05-09 | 2022-03-16 | Boehringer Ingelheim International GmbH | Anti-sema3a antibodies and their uses for treating eye or ocular diseases |
| GB201906578D0 (en) | 2019-05-09 | 2019-06-26 | Cancer Research Tech Ltd | Detection of fusion protein |
| KR20220005568A (ko) | 2019-05-09 | 2022-01-13 | 제넨테크, 인크. | 항체의 제조 방법 |
| SG11202112541RA (en) | 2019-05-14 | 2021-12-30 | Werewolf Therapeutics Inc | Separation moieties and methods and use thereof |
| JP2022536602A (ja) | 2019-05-14 | 2022-08-18 | ジェネンテック， インコーポレイテッド | 濾胞性リンパ腫を処置するための抗ｃｄ７９ｂ免疫複合体の使用方法 |
| AU2020275142A1 (en) | 2019-05-15 | 2021-12-16 | Neotx Therapeutics Ltd. | Cancer treatment |
| EP3969906A1 (en) | 2019-05-16 | 2022-03-23 | ProciseDx Inc. | Assay detection methods for vcam-1 and calprotectin |
| JP2022533400A (ja) | 2019-05-20 | 2022-07-22 | ノバルティス アーゲー | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
| WO2020234399A1 (en) | 2019-05-20 | 2020-11-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel anti-cd25 antibodies |
| WO2020236797A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Variant cd58 domains and uses thereof |
| EP3972998A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Cd19 binding molecules and uses thereof |
| CN114008073A (zh) | 2019-05-23 | 2022-02-01 | Ac免疫有限公司 | 抗tdp-43结合分子及其用途 |
| US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
| CN113874073A (zh) | 2019-05-23 | 2021-12-31 | 詹森生物科技公司 | 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法 |
| CA3141673A1 (en) | 2019-05-23 | 2020-11-26 | Xiamen University | Anti-hepatitis b virus antibodies and use thereof |
| WO2020236528A1 (en) | 2019-05-23 | 2020-11-26 | Procisedx Inc. | Assay methods for the detection of human serum albumin, vitamin d, c-reactive protein, and anti-transglutaminase autoantibody |
| WO2020234632A1 (en) | 2019-05-23 | 2020-11-26 | Ichorlabs, D.O.O | Method for removal of nucleic acids impurities from liquid composition comprising genetically engineered particles or proteins |
| JP2022533833A (ja) | 2019-05-24 | 2022-07-26 | ファイザー・インク | Ｃｄｋ阻害剤を使用した組合せ療法 |
| EP3976181A1 (en) | 2019-05-24 | 2022-04-06 | Sanofi | Methods for treating systemic sclerosis |
| CN113874036A (zh) | 2019-05-24 | 2021-12-31 | 辉瑞公司 | 使用cdk抑制剂的联合治疗 |
| CA3140406A1 (en) | 2019-05-28 | 2020-12-03 | Shanghaitech University | Composition and methods to treat ectodermal dysplasia 2, clouston type |
| EP3976648A1 (en) | 2019-06-03 | 2022-04-06 | Janssen Biotech, Inc. | Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis |
| CN114173873A (zh) | 2019-06-03 | 2022-03-11 | 詹森生物科技公司 | 用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法 |
| WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| GB201908128D0 (en) | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| US20220305132A1 (en) | 2019-06-10 | 2022-09-29 | Adc Therapeutics Sa | Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent |
| EP3980423A1 (en) | 2019-06-10 | 2022-04-13 | Sutro Biopharma, Inc. | 5h-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof |
| KR20220031616A (ko) | 2019-06-11 | 2022-03-11 | 알렉터 엘엘씨 | 치료요법에 사용하기 위한 항-소르틸린 항체 |
| US20210038684A1 (en) | 2019-06-11 | 2021-02-11 | Alkermes Pharma Ireland Limited | Compositions and Methods for Cancer Immunotherapy |
| WO2020252257A1 (en) | 2019-06-12 | 2020-12-17 | President And Fellows Of Harvard College | Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism |
| TW202112816A (zh) | 2019-06-12 | 2021-04-01 | 瑞士商諾華公司 | 利鈉肽受體1抗體及使用方法 |
| TW202045711A (zh) | 2019-06-13 | 2020-12-16 | 美商安進公司 | 生物製品製造中基於生物量之自動灌注控制 |
| WO2020252366A1 (en) | 2019-06-14 | 2020-12-17 | Teneobio, Inc. | Multispecific heavy chain antibodies binding to cd22 and cd3 |
| JP2022536800A (ja) | 2019-06-17 | 2022-08-18 | ストロ バイオファーマ インコーポレーテッド | Ｔｏｌｌ様受容体（ｔｌｒ）７／８アゴニストとしての１－（４－（アミノメチル）ベンジル）－２－ブチル－２ｈ－ピラゾロ［３，４－ｃ］キノリン－４－アミン誘導体および関連化合物、ならびにがん療法および診断に使用するためのその抗体薬物コンジュゲート |
| EP3983442A2 (en) | 2019-06-17 | 2022-04-20 | Visterra, Inc. | Humanized antibody molecules to cd138 and uses thereof |
| WO2020254861A1 (en) | 2019-06-19 | 2020-12-24 | Ovatrition Ltd. | Antibody-mediated neutralization of beta-lactamases |
| KR20220044490A (ko) | 2019-06-21 | 2022-04-08 | 백시넥스 인코포레이티드 | 세마포린-4d 차단(sema4d) 및 dc1 요법을 사용한 조합 요법 |
| GB201909135D0 (en) | 2019-06-25 | 2019-08-07 | Institute Of Cancer Res Royal Cancer Hospital | Means and methods for treating cancer |
| CN114041055A (zh) | 2019-06-25 | 2022-02-11 | 阿克托姆有限责任公司 | 用于以双组分体系测量分析物的方法和试剂盒及其用途 |
| US11905532B2 (en) | 2019-06-25 | 2024-02-20 | Massachusetts Institute Of Technology | Compositions and methods for molecular memory storage and retrieval |
| EP3990922A1 (en) | 2019-06-25 | 2022-05-04 | ProciseDx Inc. | Detection of anti-tnf alpha drug biologics and anti-drug antibodies |
| EP3990491A1 (en) | 2019-06-26 | 2022-05-04 | Massachusetts Institute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
| AU2020306672B2 (en) | 2019-06-26 | 2023-08-24 | F. Hoffmann-La Roche Ag | Mammalian cell lines with SIRT-1 gene knockout |
| TW202115112A (zh) | 2019-06-27 | 2021-04-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-angpt2抗體 |
| WO2020264384A1 (en) | 2019-06-28 | 2020-12-30 | Amgen Inc. | Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins |
| WO2020264300A1 (en) | 2019-06-28 | 2020-12-30 | Genentech, Inc. | Composition and methods for stabilizing liquid protein formulations |
| GB201909393D0 (en) | 2019-06-28 | 2019-08-14 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
| CN113993888A (zh) | 2019-06-28 | 2022-01-28 | 豪夫迈·罗氏有限公司 | 产生抗体的方法 |
| JP2022538674A (ja) | 2019-07-01 | 2022-09-05 | トニックス ファーマ リミテッド | 抗ｃｄ１５４抗体およびその使用 |
| BR112021024997A2 (pt) | 2019-07-03 | 2022-01-25 | Oxford Biotherapeutics Ltd | Anticorpos, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, métodos e uso |
| EP3998081A4 (en) | 2019-07-05 | 2023-07-12 | Ono Pharmaceutical Co., Ltd. | TREATMENT OF BLOOD CANCER WITH PD-1/CD3 DUAL SPECIFICITY PROTEIN |
| GB2585252A (en) | 2019-07-05 | 2021-01-06 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
| US20220273810A1 (en) | 2019-07-08 | 2022-09-01 | Imcare Biotech, Llc | Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use |
| US20220251518A1 (en) | 2019-07-08 | 2022-08-11 | Terumo Kabushik Kaisha | Hybridoma, method for making the same, monoclonal antibody, and method for making the same |
| CN114401986A (zh) | 2019-07-08 | 2022-04-26 | 国家儿童医院研究所 | 破坏生物膜的抗体组合物 |
| CN114539419A (zh) | 2019-07-11 | 2022-05-27 | 南京友博迪生物技术有限公司 | 四价对称双特异性抗体 |
| AR119382A1 (es) | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
| MX2022000586A (es) | 2019-07-15 | 2022-03-04 | Shanghai Junshi Biosciences Co Ltd | Anticuerpos anti-tigit y aplicacion de los mismos. |
| WO2021009697A2 (en) | 2019-07-15 | 2021-01-21 | Lausanne University Hospital | Hiv binding agents |
| WO2021009187A1 (en) | 2019-07-15 | 2021-01-21 | Intervet International B.V. | Caninized antibodies against canine ctla-4 |
| AR119393A1 (es) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
| IL268111A (en) | 2019-07-16 | 2021-01-31 | Fainzilber Michael | Methods of treating pain |
| WO2021009740A1 (en) | 2019-07-16 | 2021-01-21 | Ramot At Tel-Aviv University Ltd. | Compositions and methods for the treatment of tuberculosis |
| US20220268787A1 (en) | 2019-07-18 | 2022-08-25 | Jw Bioscience | Antibody specifically binding to wrs protein, and use thereof |
| JP2022541538A (ja) | 2019-07-19 | 2022-09-26 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | グリピカン２結合ドメインを含有するキメラ抗原受容体 |
| WO2021014385A1 (en) | 2019-07-24 | 2021-01-28 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
| BR112021005478A2 (pt) | 2019-07-24 | 2021-06-15 | H. Lundbeck A/S | anticorpos anti-mglur5 e uso dos mesmos |
| KR20220044753A (ko) | 2019-07-25 | 2022-04-11 | 큐라데브 파마 프라이버트 리미티드 | 아세틸 조효소 a 신테타제 단쇄 2(acss2)의 소분자 억제제 |
| CN112300279A (zh) | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
| WO2021021606A1 (en) | 2019-07-26 | 2021-02-04 | Visterra, Inc. | Interleukin-2 agents and uses thereof |
| JP2022541652A (ja) | 2019-07-26 | 2022-09-26 | ヴァンダービルト ユニバーシティ | エンテロウイルスｄ６８に対するヒトモノクローナル抗体 |
| CA3147575A1 (en) | 2019-07-29 | 2021-02-04 | Yeda Research And Development Co. Ltd. | Methods of treating and diagnosing lung cancer |
| CA3145909A1 (en) | 2019-07-30 | 2021-02-04 | Yu Xia | Anti-human p40 protein domain antibody and use thereof |
| CN114174343A (zh) | 2019-07-30 | 2022-03-11 | 小野药品工业株式会社 | 双特异性抗体 |
| WO2021022304A2 (en) | 2019-07-30 | 2021-02-04 | Qlsf Biotherapeutics, Inc. | MULTISPECIFIC BINDING COMPOUNDS THAT BIND TO LRRC15 AND CD3ε |
| GB201910899D0 (en) | 2019-07-31 | 2019-09-11 | Scancell Ltd | Binding members |
| MX2022001260A (es) | 2019-07-31 | 2022-04-18 | Alector Llc | Anticuerpos anti-ms4a4a y metodos de uso de los mismos. |
| WO2021026028A1 (en) | 2019-08-02 | 2021-02-11 | Cytodyn Inc. | Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents |
| WO2021023644A1 (en) | 2019-08-02 | 2021-02-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Neutralizing granzyme b for providing cardioprotection in a subject who experienced a myocardial infarction |
| JP2022543259A (ja) | 2019-08-02 | 2022-10-11 | オレガ・バイオテック | 新規ｉｌ－１７ｂ抗体 |
| BR112022002013A2 (pt) | 2019-08-02 | 2022-03-29 | Akeso Pharmaceuticals Inc | Anticorpo biespecífico anti-ctla4/anti-pd-1 e uso do mesmo |
| KR102509648B1 (ko) | 2019-08-06 | 2023-03-15 | 아프리노이아 테라퓨틱스 리미티드 | 병리학적 타우 종에 결합하는 항체 및 이의 용도 |
| WO2021023860A1 (en) | 2019-08-07 | 2021-02-11 | Db Biotech, As | Improved horseradish peroxidase polypeptides |
| WO2021028921A1 (en) | 2019-08-12 | 2021-02-18 | Biond Biologics Ltd. | Antibodies against ilt2 and use thereof |
| US20210047425A1 (en) | 2019-08-12 | 2021-02-18 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells |
| KR20220047826A (ko) | 2019-08-16 | 2022-04-19 | 리제너론 파마슈티칼스 인코포레이티드 | 고 농도의 항-c5 제형 |
| WO2021035170A1 (en) | 2019-08-21 | 2021-02-25 | Precision Biosciences, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
| CN114585644A (zh) | 2019-08-30 | 2022-06-03 | 艾吉纳斯公司 | 抗cd96抗体及其使用方法 |
| EP3789401A1 (en) | 2019-09-03 | 2021-03-10 | Gamamabs Pharma | Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers |
| GB201912657D0 (en) | 2019-09-03 | 2019-10-16 | Scancell Ltd | Binding members |
| KR20220053665A (ko) | 2019-09-03 | 2022-04-29 | 아케소 바이오파마, 인크. | 항-cd47 단일클론 항체 및 이의 용도 |
| CN114616250A (zh) | 2019-09-04 | 2022-06-10 | 豪夫迈·罗氏有限公司 | Cd8结合剂及其用途 |
| WO2021044009A1 (en) | 2019-09-04 | 2021-03-11 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | Herv inhibitors for use in treating tauopathies |
| EP4025253B1 (en) | 2019-09-05 | 2024-03-20 | Pharma Mar, S.A. | Drug antibody conjugates |
| GB201912882D0 (en) | 2019-09-06 | 2019-10-23 | Scancell Ltd | Ssea-4 binding members |
| CA3152946A1 (en) | 2019-09-10 | 2021-03-18 | Amgen Inc. | Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity |
| WO2021048292A1 (en) | 2019-09-11 | 2021-03-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| EP4028053A1 (en) | 2019-09-11 | 2022-07-20 | Bausch Health Ireland Limited | Methods of treating nonalcoholic fatty liver disease (nafld) using il-17ra antibody |
| MX2022002963A (es) | 2019-09-12 | 2022-04-06 | Genentech Inc | Composiciones y metodos para tratar nefritis lupica. |
| EP3792632A1 (en) | 2019-09-16 | 2021-03-17 | Vito NV | Immunotherapy markers |
| KR20220063222A (ko) | 2019-09-17 | 2022-05-17 | 메르크 파텐트 게엠베하 | 고농축 단백질 제형에서 점도 감소제로서의 캄포술폰산 및 양이온성 부형제와 이의 조합 |
| CR20220156A (es) | 2019-09-18 | 2022-05-23 | Genentech Inc | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso |
| TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與ｅｎｔｐｄ２抗體之組合療法 |
| US20220348651A1 (en) | 2019-09-18 | 2022-11-03 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| US11918649B2 (en) | 2019-09-18 | 2024-03-05 | Molecular Templates, Inc. | PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds |
| BR112022004863A2 (pt) | 2019-09-19 | 2022-06-07 | Seagen Inc | Composição conjugado de ligante fármaco, compostos conjugado de ligante-fármaco e conector de fármaco, e, formulação farmaceuticamente aceitável |
| WO2021054778A1 (ko) | 2019-09-20 | 2021-03-25 | 경북대학교 산학협력단 | Cox2 단백질의 아세틸화 검출용 항체 및 이의 용도 |
| WO2021055694A1 (en) | 2019-09-20 | 2021-03-25 | Genentech, Inc. | Dosing for anti-tryptase antibodies |
| TW202126685A (zh) | 2019-09-24 | 2021-07-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗nrp1a抗體及其用於治療眼或眼部疾病之用途 |
| CN114450324B (zh) | 2019-09-26 | 2024-02-27 | 日油株式会社 | 具有肽连接子的异双官能单分散聚乙二醇 |
| US20220411511A1 (en) | 2019-09-26 | 2022-12-29 | Stcube & Co. | Antibodies specific to glycosylated ctla-4 and methods of use thereof |
| US20220281997A1 (en) | 2019-09-27 | 2022-09-08 | Nanjing GenScript Biotech Co., Ltd. | Anti-VHH Domain Antibodies and Use Thereof |
| CN114450304B (zh) | 2019-09-27 | 2023-12-12 | 国家医疗保健研究所 | 抗苗勒管抑制物质抗体及其用途 |
| WO2021059075A1 (en) | 2019-09-27 | 2021-04-01 | Janssen Biotech, Inc. | Anti-ceacam antibodies and uses thereof |
| WO2021058729A1 (en) | 2019-09-27 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof |
| CA3155930A1 (en) | 2019-09-27 | 2021-04-01 | Starkage Therapeutics | SENESCENT CELL-ASSOCIATED ANTIGEN-BINDING DOMAINS, ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS COMPRISING THEM, AND USES THEREOF |
| WO2021058744A1 (en) | 2019-09-27 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of müllerian inhibiting substance inhibitors for treating cancer |
| CR20220127A (es) | 2019-09-27 | 2022-05-27 | Genentech Inc | Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1 |
| WO2021063968A1 (en) | 2019-09-30 | 2021-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and composition for diagnosing chronic obstructive pulmonary disease |
| EP4039704A4 (en) | 2019-09-30 | 2023-09-20 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | ANTI-PD-1 ANTIBODIES AND ITS USE |
| AU2020360849A1 (en) | 2019-09-30 | 2022-04-14 | New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery | Protein binders to iRhom2 epitopes |
| EP3800201A1 (en) | 2019-10-01 | 2021-04-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd28h stimulation enhances nk cell killing activities |
| WO2021067550A1 (en) | 2019-10-02 | 2021-04-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
| AU2020357550A1 (en) | 2019-10-04 | 2022-05-05 | Tae Life Sciences, Llc | Antibody compositions comprising Fc mutations and site-specific conjugation properties |
| EP4037717A1 (en) | 2019-10-04 | 2022-08-10 | Seagen Inc. | Camptothecin peptide conjugates |
| WO2021064079A1 (en) | 2019-10-04 | 2021-04-08 | Merck Patent Gmbh | Purification of proteins and viral inactivation |
| EP4037710A1 (en) | 2019-10-04 | 2022-08-10 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer |
| WO2021067820A1 (en) | 2019-10-04 | 2021-04-08 | Seagen Inc. | Formulation of antibody-drug conjugate |
| WO2021064066A1 (en) | 2019-10-04 | 2021-04-08 | Merck Patent Gmbh | Elution of monoclonal antibodies in protein a affinity chromatography |
| JP2022552282A (ja) | 2019-10-09 | 2022-12-15 | エスティーキューブ アンド カンパニー | グリコシル化ｌａｇ３に対して特異的な抗体およびその使用方法 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| EP3808766A1 (en) | 2019-10-15 | 2021-04-21 | Sangamo Therapeutics France | Chimeric antigen receptor specific for interleukin-23 receptor |
| WO2021076930A1 (en) | 2019-10-18 | 2021-04-22 | The Regents Of The University Of California | Plxdc activators and their use in the treatment of blood vessel disorders |
| GB201915163D0 (en) | 2019-10-18 | 2019-12-04 | Univ Southampton | Cancer vaccine |
| CN114641306A (zh) | 2019-10-18 | 2022-06-17 | 免疫治疗有限公司 | 包含癌抗原的改良lamp构建物 |
| MX2022004443A (es) | 2019-10-18 | 2022-05-02 | Genentech Inc | Metodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes. |
| MX2022004769A (es) | 2019-10-21 | 2022-05-16 | Novartis Ag | Inhibidores de tim-3 y sus usos. |
| BR112022007376A2 (pt) | 2019-10-21 | 2022-07-05 | Novartis Ag | Terapias de combinação com venetoclax e inibidores de tim-3 |
| EP3812008A1 (en) | 2019-10-23 | 2021-04-28 | Gamamabs Pharma | Amh-competitive antagonist antibody |
| WO2021080608A1 (en) | 2019-10-25 | 2021-04-29 | Medimmune, Llc | Branched moiety for use in conjugates |
| CN115052889A (zh) | 2019-10-25 | 2022-09-13 | 瑞泽恩制药公司 | 用于治疗或预防c5相关疾病的给药方案 |
| BR112022007971A8 (pt) | 2019-10-29 | 2023-02-07 | Eisai R&D Man Co Ltd | Combinação de antagonista do pd-1, inibidor da tirosina quinase vegfr/fgfr/ret e inibidor da cbp/beta-catenina para o tratamento do câncer |
| IL292613A (en) | 2019-11-01 | 2022-07-01 | Ares Trading Sa | Combined inhibition of pd-1, tgf-beta and atm along with radiotherapy for cancer treatment |
| US20220409642A1 (en) | 2019-11-04 | 2022-12-29 | Astrazeneca Ab | Combination therapy for treating cancer |
| IL292757A (en) | 2019-11-05 | 2022-07-01 | Merck Patent Gmbh | Tigit antibodies and their uses |
| EP4054633A1 (en) | 2019-11-05 | 2022-09-14 | Merck Patent GmbH | Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer |
| CN114787188A (zh) | 2019-11-05 | 2022-07-22 | 震动疗法股份有限公司 | 用抗pd-1抗体治疗癌症的方法 |
| AU2020378330A1 (en) | 2019-11-06 | 2022-05-12 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for treatment of hematologic cancers |
| PE20230467A1 (es) | 2019-11-07 | 2023-03-14 | Eisai Randd Man Co Ltd | Conjugados de anticuerpo y farmaco de eribulina anti-mesotelina y metodos de uso |
| US20220378891A1 (en) | 2019-11-07 | 2022-12-01 | In3Bio Ltd. | Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors |
| CA3156683A1 (en) | 2019-11-13 | 2021-05-20 | Amgen Inc. | METHOD FOR REDUCING AGGREGATE FORMATION IN DOWNSTREAM PROCESSING OF BI-SPECIFIC ANTIGEN-BINDING MOLECULES |
| EP4058466A1 (en) | 2019-11-13 | 2022-09-21 | Amunix Pharmaceuticals, Inc. | Barcoded xten polypeptides and compositions thereof, and methods for making and using the same |
| JP2023503851A (ja) | 2019-11-15 | 2023-02-01 | プライアント・セラピューティクス・インコーポレイテッド | インテグリン活性化のための組成物および方法 |
| EP3825330A1 (en) | 2019-11-19 | 2021-05-26 | International-Drug-Development-Biotech | Anti-cd117 antibodies and methods of use thereof |
| IL293009A (en) | 2019-11-20 | 2022-07-01 | Bavarian Nordic As | Recombinant mva viruses for intratumoral and/or intravenous administration for cancer treatment |
| US11774451B2 (en) | 2019-11-21 | 2023-10-03 | The Board Of Trustees Of The Leland Stanford Junior University | Molecular vibrational spectroscopic markers for detection of cancer |
| JP2023503429A (ja) | 2019-11-22 | 2023-01-30 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 白血病幹細胞を根絶することによる、急性骨髄性白血病の処置のための、アドレノメデュリン阻害剤 |
| WO2021104302A1 (zh) | 2019-11-25 | 2021-06-03 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双特异性抗体、其药物组合物及其用途 |
| GB201917254D0 (en) | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
| WO2021110796A1 (en) | 2019-12-04 | 2021-06-10 | Bayer Aktiengesellschaft | Inhibitors of shp2 |
| KR20220110537A (ko) | 2019-12-05 | 2022-08-08 | 알렉터 엘엘씨 | 항-trem2 항체 사용 방법 |
| US11897950B2 (en) | 2019-12-06 | 2024-02-13 | Augusta University Research Institute, Inc. | Osteopontin monoclonal antibodies |
| KR20220122653A (ko) | 2019-12-06 | 2022-09-02 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｂｃｍａ-표적 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법 |
| CN115335399A (zh) | 2019-12-06 | 2022-11-11 | 朱诺治疗学股份有限公司 | 针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法 |
| EP4069374A1 (en) | 2019-12-06 | 2022-10-12 | Thoas Fioretos | Novel agents and uses thereof |
| EP4069264A1 (en) | 2019-12-06 | 2022-10-12 | Regeneron Pharmaceuticals, Inc. | Vegf mini-traps and methods of use thereof |
| US20230040928A1 (en) | 2019-12-09 | 2023-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to her4 and uses thereof |
| CA3158987A1 (en) | 2019-12-09 | 2021-06-17 | Genentech, Inc. | Anti-pd-l1 antibody formulations |
| WO2021119056A1 (en) | 2019-12-09 | 2021-06-17 | Celcuity Inc. | Methods of treating cancer patients with ras node or rtk targeted therapeutic agents |
| BR112022011337A2 (pt) | 2019-12-12 | 2022-08-23 | Alector Llc | Método para tratar e/ou retardar a progressão de uma doença ou lesão em um indivíduo |
| KR20220127252A (ko) | 2019-12-13 | 2022-09-19 | 알렉터 엘엘씨 | 항-mertk 항체 및 이의 사용 방법 |
| CA3163950A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
| IL293926A (en) | 2019-12-17 | 2022-08-01 | Pfizer | Antibodies unique to d47, pd-l1 and their uses |
| EP4077391A1 (en) | 2019-12-18 | 2022-10-26 | Teneofour, Inc. | Heavy chain antibodies binding to cd38 |
| TW202135858A (zh) | 2019-12-20 | 2021-10-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體和檢查點抑制劑用於治療增殖性疾病之用途 |
| AU2020409583A1 (en) | 2019-12-20 | 2022-06-09 | Intervet International B.V. | Canine interleukin-4 receptor alpha antibodies |
| CN115135671A (zh) | 2019-12-20 | 2022-09-30 | 新石生物制药有限公司 | 抗白介素-23 p19的抗体及其使用方法 |
| US11926672B2 (en) | 2019-12-20 | 2024-03-12 | Amgen Inc. | Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors |
| JP2023506922A (ja) | 2019-12-20 | 2023-02-20 | インターベット インターナショナル ベー． フェー． | アトピー性皮膚炎を処置するための二重特異性イヌ化抗体 |
| WO2021132166A1 (ja) | 2019-12-23 | 2021-07-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | エリブリンをベースとする抗体－薬物コンジュゲートの製造方法 |
| CA3165504A1 (en) | 2019-12-23 | 2021-07-01 | Genentech, Inc. | Apolipoprotein l1-specific antibodies and methods of use |
| JPWO2021132427A1 (ja) | 2019-12-27 | 2021-07-01 | ||
| AU2020414409A1 (en) | 2019-12-27 | 2022-06-16 | Affimed Gmbh | Method for the production of bispecific FcyRIIl x CD30 antibody construct |
| TW202138388A (zh) | 2019-12-30 | 2021-10-16 | 美商西根公司 | 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法 |
| WO2021138454A1 (en) | 2019-12-30 | 2021-07-08 | City Of Hope | Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers |
| WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| KR20220139886A (ko) | 2020-01-08 | 2022-10-17 | 리제너론 파아마슈티컬스, 인크. | 진행성 골화성 섬유이형성증의 치료 |
| JP2023509760A (ja) | 2020-01-08 | 2023-03-09 | シンシス セラピューティクス，インコーポレイテッド | Ａｌｋ５阻害剤複合体およびその使用 |
| CN110818795B (zh) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | 抗tigit抗体和使用方法 |
| AU2021205433A1 (en) | 2020-01-11 | 2022-08-18 | Scholar Rock, Inc. | Tgfß inhibitors and use thereof |
| EP4087659A2 (en) | 2020-01-11 | 2022-11-16 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| WO2021146303A1 (en) | 2020-01-13 | 2021-07-22 | Jounce Therapeutics, Inc. | Methods for the treatment of cancer |
| TW202140553A (zh) | 2020-01-13 | 2021-11-01 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| WO2021144657A1 (en) | 2020-01-17 | 2021-07-22 | Novartis Ag | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
| WO2021144426A1 (en) | 2020-01-17 | 2021-07-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| CN113138276B (zh) | 2020-01-19 | 2022-09-16 | 厦门万泰凯瑞生物技术有限公司 | 用于检测HBcAg的方法及抗体 |
| TW202140076A (zh) | 2020-01-22 | 2021-11-01 | 英商梅迪繆思有限公司 | 化合物及其軛合物 |
| WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
| WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
| KR20220133243A (ko) | 2020-01-27 | 2022-10-04 | 제넨테크, 인크. | 항 tigit 길항제 항체를 이용한 암의 치료 방법 |
| WO2021151974A1 (en) | 2020-01-28 | 2021-08-05 | Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis | Interfering with mrna splicing to enhance response to checkpoint immunotherapies. |
| KR20220148175A (ko) | 2020-01-29 | 2022-11-04 | 인히브릭스, 인크. | Ｃｄ28 단일 도메인 항체 및 이의 다가 및 다중특이적 구조체 |
| IL272390A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Cancer treatment methods |
| WO2021152587A1 (en) | 2020-01-30 | 2021-08-05 | Yeda Research And Development Co. Ltd. | Treating acute liver disease with tlr-mik inhibitors |
| IL272389A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Kits containing antibodies to PD-L1 and their uses in therapy |
| JP2023512654A (ja) | 2020-01-31 | 2023-03-28 | ジェネンテック， インコーポレイテッド | Ｐｄ－１軸結合アンタゴニストおよびｒｎａワクチンを用いてネオエピトープ特異的ｔ細胞を誘導する方法 |
| AU2021213421A1 (en) | 2020-01-31 | 2022-06-23 | Innate Pharma | Treatment of cancer |
| AU2021214795A1 (en) | 2020-01-31 | 2022-08-18 | The Cleveland Clinic Foundation | Anti-Müllerian Hormone Receptor 2 antibodies and methods of use |
| BR102020002165A2 (pt) | 2020-01-31 | 2021-11-30 | Fundação Oswaldo Cruz | Anticorpo, seu uso, composição farmacêutica o compreendendo, método de diagnóstico de infecções fúngicas, kit de diagnóstico de infecções fúngicas e método para tratamento de infecções fúngicas. |
| JP2023512684A (ja) | 2020-02-03 | 2023-03-28 | ヴィア・バイオテクノロジー・インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２に対する抗体およびそれを使用する方法 |
| CA3167027A1 (en) | 2020-02-05 | 2021-08-12 | Larimar Therapeutics, Inc. | Tat peptide binding proteins and uses thereof |
| WO2021156329A1 (en) | 2020-02-05 | 2021-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of treatment of cancer disease by targeting an epigenetic factor |
| CA3167349A1 (en) | 2020-02-10 | 2021-08-19 | Qing Zhou | Claudin 18.2 antibody and use thereof |
| CN115427453A (zh) | 2020-02-10 | 2022-12-02 | 上海诗健生物科技有限公司 | Cldn18.2抗体及其用途 |
| IL295310A (en) | 2020-02-11 | 2022-10-01 | Univ Vanderbilt | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
| TW202144395A (zh) | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
| EP4103605A1 (en) | 2020-02-13 | 2022-12-21 | Amgen Inc. | Treatment of atopic dermatitis with anti-tslp antibody |
| UY39083A (es) | 2020-02-13 | 2021-08-31 | Amgen Inc | Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria |
| CN113248611A (zh) | 2020-02-13 | 2021-08-13 | 湖南华康恒健生物技术有限公司 | 抗bcma抗体、其药物组合物及应用 |
| EP4103285A2 (en) | 2020-02-14 | 2022-12-21 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| US20230106973A1 (en) | 2020-02-17 | 2023-04-06 | Board Of Regents, The University Of Texas System | Methods for expansion of tumor infiltrating lymphocytes and use thereof |
| KR20220143730A (ko) | 2020-02-19 | 2022-10-25 | 에린 테라퓨틱스 | 단백질을 표적화하는 분자 |
| CA3171925A1 (en) | 2020-02-19 | 2021-08-26 | Aelin Therapeutics | Molecules targeting ras protein |
| BR112022016550A2 (pt) | 2020-02-21 | 2022-11-16 | Harpoon Therapeutics Inc | Proteínas de ligação a flt3 e métodos de uso |
| WO2021164722A1 (zh) | 2020-02-21 | 2021-08-26 | 江苏恒瑞医药股份有限公司 | 抗il-2抗体、其抗原结合片段及其医药用途 |
| EP4110402A1 (en) | 2020-02-25 | 2023-01-04 | Mediboston, Inc. | Camptothecin derivatives and conjugates thereof |
| IL295801A (en) | 2020-02-26 | 2022-10-01 | Vir Biotechnology Inc | Antibodies against sars-cov-2 and methods of using them |
| US20230105029A1 (en) | 2020-02-27 | 2023-04-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Antibodies binding il4r and uses thereof |
| JP2023516945A (ja) | 2020-02-28 | 2023-04-21 | 上海復宏漢霖生物技術股▲フン▼有限公司 | 抗ｃｄ１３７コンストラクト及びその使用 |
| KR20220145859A (ko) | 2020-02-28 | 2022-10-31 | 상하이 헨리우스 바이오테크, 인크. | 항cd137 작제물, 다중 특이적 항체 및 그 용도 |
| EP4110404A1 (en) | 2020-02-28 | 2023-01-04 | Genzyme Corporation | Modified binding polypeptides for optimized drug conjugation |
| TW202146056A (zh) | 2020-02-28 | 2021-12-16 | 美商泰勒克療法公司 | 轉穀胺醯胺酶介導之結合 |
| CA3168070A1 (en) | 2020-03-03 | 2021-09-10 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
| CA3174064A1 (en) | 2020-03-03 | 2021-09-10 | Array Biopharma Inc. | Methods to treat cancer using (r)-n-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1h-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide |
| WO2021175954A1 (en) | 2020-03-04 | 2021-09-10 | Imcheck Therapeutics Sas | Antibodies having specificity for btnl8 and uses thereof |
| AU2021232625A1 (en) | 2020-03-05 | 2022-09-29 | Umc Utrecht Holding B.V. | Membrane ubiquitin ligases to target protein degradation |
| EP4114860A1 (en) | 2020-03-06 | 2023-01-11 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| WO2021177980A1 (en) | 2020-03-06 | 2021-09-10 | Genentech, Inc. | Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist |
| CA3174908A1 (en) | 2020-03-09 | 2021-09-16 | Pfizer Inc. | Fusion proteins and uses thereof |
| AU2021232853A1 (en) | 2020-03-10 | 2022-09-22 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of NPM1c-positive cancer |
| CA3169827A1 (en) | 2020-03-10 | 2021-09-16 | Kunwar Shailubhai | Compositions of il-6/il-6r antibodies and methods of use thereof |
| GB202003632D0 (en) | 2020-03-12 | 2020-04-29 | Harbour Antibodies Bv | SARS-Cov-2 (SARS2, COVID-19) antibodies |
| EP4118113A1 (en) | 2020-03-12 | 2023-01-18 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
| MX2022011156A (es) | 2020-03-13 | 2022-10-13 | Genentech Inc | Anticuerpos anti-interleucina-33 y usos de estos. |
| EP4121163A1 (en) | 2020-03-19 | 2023-01-25 | Genentech, Inc. | Isoform-selective anti-tgf-beta antibodies and methods of use |
| WO2021188851A1 (en) | 2020-03-19 | 2021-09-23 | Amgen Inc. | Antibodies against mucin 17 and uses thereof |
| US20230192833A1 (en) | 2020-03-20 | 2023-06-22 | Centre National De La Recherche (Cnrs) | New anti-VEGFC antibodies and uses thereof |
| GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
| EP4107184A1 (en) | 2020-03-23 | 2022-12-28 | Genentech, Inc. | Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist |
| CN115867577A (zh) | 2020-03-23 | 2023-03-28 | 基因泰克公司 | 用于预测covid-19肺炎中对il-6拮抗剂反应的生物标志物 |
| JP2023518812A (ja) | 2020-03-23 | 2023-05-08 | ジェネンテック， インコーポレイテッド | Ｃｏｖｉｄ１９肺炎を治療するための、トシリズマブとレムデシビルとの組み合わせ |
| WO2021194913A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Tie2-binding agents and methods of use |
| CN113444171A (zh) | 2020-03-25 | 2021-09-28 | 兴盟生物医药(苏州)有限公司 | 金黄色葡萄球菌α-毒素特异性抗体及其应用 |
| US11345741B2 (en) | 2020-03-26 | 2022-05-31 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| WO2021195385A1 (en) | 2020-03-26 | 2021-09-30 | Vanderbilt University | HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2) |
| EP4127153A2 (en) | 2020-03-26 | 2023-02-08 | Genentech, Inc. | Modified mammalian cells having reduced host cell proteins |
| US11045546B1 (en) | 2020-03-30 | 2021-06-29 | Cytodyn Inc. | Methods of treating coronavirus infection |
| CN115348971A (zh) | 2020-03-30 | 2022-11-15 | 国立研究开发法人国立癌症研究中心 | 抗体-药物缀合物 |
| US20230203191A1 (en) | 2020-03-30 | 2023-06-29 | Danisco Us Inc | Engineered antibodies |
| WO2021197340A1 (zh) | 2020-03-31 | 2021-10-07 | 百奥泰生物制药股份有限公司 | 用于治疗冠状病毒的抗体、融合蛋白及其应用 |
| CN115335410A (zh) | 2020-03-31 | 2022-11-11 | 中外制药株式会社 | 生产多特异性抗原结合分子的方法 |
| CN116075525A (zh) | 2020-03-31 | 2023-05-05 | 艾莱克特有限责任公司 | 抗mertk抗体及其使用方法 |
| US20210311054A1 (en) | 2020-04-01 | 2021-10-07 | Institut Pasteur | Severe acute respiratory syndrome (sars) - associated coronavirus diagnostics |
| EP4126934A1 (en) | 2020-04-01 | 2023-02-08 | University of Rochester | Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses |
| US11815513B2 (en) | 2020-04-01 | 2023-11-14 | Institut Pasteur | Severe acute respiratory syndrome (SARS)-associated coronavirus diagnostics |
| CN115380210A (zh) | 2020-04-02 | 2022-11-22 | 中外制药株式会社 | 含多特异性抗原结合分子的组合物中的杂质分子的分析方法 |
| WO2021045836A1 (en) | 2020-04-02 | 2021-03-11 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
| JP2023520516A (ja) | 2020-04-03 | 2023-05-17 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体の使用方法 |
| WO2021198511A1 (en) | 2020-04-03 | 2021-10-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of sars-cov-2 infection |
| CN115698717A (zh) | 2020-04-03 | 2023-02-03 | 基因泰克公司 | 癌症的治疗和诊断方法 |
| EP4126064A1 (en) | 2020-04-03 | 2023-02-08 | Visterra, Inc. | Antibody molecule-drug conjugates and uses thereof |
| CN115768467A (zh) | 2020-04-06 | 2023-03-07 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 用于治疗癌症和感染的针对NKp46的抗体及其构建体 |
| WO2021207348A1 (en) | 2020-04-07 | 2021-10-14 | Albert Einstein College Of Medicine | Method of treating and preventing ocular disease with hsv-2 delta gd |
| WO2021205325A1 (en) | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
| US20230272056A1 (en) | 2020-04-09 | 2023-08-31 | Merck Sharp & Dohme Llc | Affinity matured anti-lap antibodies and uses thereof |
| WO2021207662A1 (en) | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
| CN115955980A (zh) | 2020-04-10 | 2023-04-11 | 思进公司 | 电荷可变接头 |
| EP4136459A1 (en) | 2020-04-13 | 2023-02-22 | Abbott Laboratories | Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample |
| EP4135846A1 (en) | 2020-04-14 | 2023-02-22 | VIR Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
| AU2021257848A1 (en) | 2020-04-15 | 2022-12-01 | Voyager Therapeutics, Inc. | Tau binding compounds |
| WO2021209824A1 (en) | 2020-04-17 | 2021-10-21 | Institut Pasteur | Methods and products for serological analysis of sars-cov-2 infection |
| CN113527485A (zh) | 2020-04-17 | 2021-10-22 | 上海麦济生物技术有限公司 | 抗人白细胞介素-4受体α抗体及其制备方法和应用 |
| GB2594084A (en) | 2020-04-17 | 2021-10-20 | Bertrand Marie Rene Joseph | Medical methods and medical uses |
| AU2021257355A1 (en) | 2020-04-17 | 2022-11-03 | Zoetis Services Llc | Feline antibody variants |
| CA3173134A1 (en) | 2020-04-20 | 2021-10-28 | Jounce Therapeutics, Inc. | Compositions and methods for vaccination and the treatment of infectious diseases |
| GB202005779D0 (en) | 2020-04-21 | 2020-06-03 | Scancell Ltd | Anti-tumour immune responses |
| JP2023522259A (ja) | 2020-04-21 | 2023-05-29 | ファルマ、マール、ソシエダード、アノニマ | 薬物抗体コンジュゲート |
| MX2022013402A (es) | 2020-04-24 | 2022-11-14 | Sanofi Sa | Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5 y folfiri. |
| EP4139349A1 (en) | 2020-04-24 | 2023-03-01 | F. Hoffmann-La Roche AG | Enzyme and pathway modulation with sulfhydryl compounds and their derivatives |
| JP2023522393A (ja) | 2020-04-24 | 2023-05-30 | サノフイ | 抗ｃｅａｃａｍ５抗体コンジュゲートおよびセツキシマブを含有する抗腫瘍組み合わせ |
| EP4139363A1 (en) | 2020-04-24 | 2023-03-01 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| AU2021258464A1 (en) | 2020-04-24 | 2023-01-05 | Sanofi | Antitumor combinations containing anti-CEACAM5 antibody conjugates, trifluridine and tipiracil |
| IL297541A (en) | 2020-04-24 | 2022-12-01 | Genentech Inc | Methods for using anti-cd79b immunoconjugates |
| JP2023522395A (ja) | 2020-04-24 | 2023-05-30 | サノフイ | 抗ｃｅａｃａｍ５抗体コンジュゲートおよびフォルフォックスを含有する抗腫瘍組み合わせ |
| GB202006072D0 (en) | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
| WO2021222181A2 (en) | 2020-04-27 | 2021-11-04 | The Regents Of The University Of California | Isoform-independent antibodies to lipoprotein(a) |
| JP2023523450A (ja) | 2020-04-28 | 2023-06-05 | ジェネンテック， インコーポレイテッド | 非小細胞肺がん免疫療法のための方法及び組成物 |
| JP2023523480A (ja) | 2020-04-28 | 2023-06-06 | ザ ロックフェラー ユニバーシティー | 中和抗ｓａｒｓ－ｃｏｖ－２抗体およびその使用方法 |
| BR112022024483A2 (pt) | 2020-04-29 | 2023-02-07 | Teneoone Inc | Métodos para tratar mieloma múltiplo |
| CA3176792A1 (en) | 2020-04-29 | 2021-11-04 | Katherine HARRIS | Anti-cd3 and anti-bcma bispecific antibodies wth modified heavy chain constant regions |
| UY39191A (es) | 2020-04-29 | 2021-11-30 | Teneobio Inc | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas |
| CR20220598A (es) | 2020-04-30 | 2023-01-17 | Genentech Inc | Anticuerpos específicos para kras y sus usos |
| WO2021222533A1 (en) | 2020-04-30 | 2021-11-04 | Procisedx Inc. | Methods of detecting antibodies to sars-cov-2 |
| EP4143227A2 (en) | 2020-04-30 | 2023-03-08 | Sairopa B.V. | Anti-cd103 antibodies |
| JP2023523794A (ja) | 2020-05-01 | 2023-06-07 | ノバルティス アーゲー | 人工操作免疫グロブリン |
| WO2021222789A1 (en) | 2020-05-01 | 2021-11-04 | The Regents Of The University Of California | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof |
| WO2021220218A1 (en) | 2020-05-01 | 2021-11-04 | Novartis Ag | Immunoglobulin variants |
| WO2021225961A1 (en) | 2020-05-04 | 2021-11-11 | Inhibrx, Inc. | Canine pd-1-binding polypeptides and uses thereof |
| WO2021224401A1 (en) | 2020-05-07 | 2021-11-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for determining a reference range of β-galactose exposure platelet |
| US11850421B2 (en) | 2020-05-08 | 2023-12-26 | Novocure Gmbh | Compositions and methods of applying alternating electric fields to pluripotent stem cells |
| EP3909601A1 (en) | 2020-05-11 | 2021-11-17 | LeukoCom GmbH | A novel antibody binding specifically to human ceacam1/3/5 and use thereof |
| US20230272086A1 (en) | 2020-05-12 | 2023-08-31 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | St2 antigen binding protein |
| US20230312739A1 (en) | 2020-05-12 | 2023-10-05 | Biotheus Inc. | Anti-cd73 antibody and use thereof |
| EP4149558A1 (en) | 2020-05-12 | 2023-03-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas |
| CA3182887A1 (en) | 2020-05-13 | 2021-11-18 | Pfizer Inc. | Methods, therapies and uses for treating cancer |
| JP2023520249A (ja) | 2020-05-15 | 2023-05-16 | エフ． ホフマン－ラ ロシュ アーゲー | 非経口タンパク質溶液中の可視粒子形成の防止方法 |
| WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
| JP2023527293A (ja) | 2020-05-19 | 2023-06-28 | アムジエン・インコーポレーテツド | Ｍａｇｅｂ２結合構築物 |
| JP2023525898A (ja) | 2020-05-19 | 2023-06-19 | エフ． ホフマン－ラ ロシュ アーゲー | 非経口タンパク質溶液における可視粒子の形成を防止するためのキレート剤の使用 |
| WO2021233962A1 (en) | 2020-05-19 | 2021-11-25 | Institut Curie | Methods for the diagnosis and treatment of cytokine release syndrome |
| JP7352040B2 (ja) | 2020-05-22 | 2023-09-27 | フィロジェン エッセ．ピー．アー． | 脳腫瘍の治療のためのＴＮＦα免疫コンジュゲート療法 |
| EP4157343A2 (en) | 2020-05-26 | 2023-04-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes |
| WO2021239666A1 (en) | 2020-05-26 | 2021-12-02 | Diaccurate | Therapeutic methods |
| CA3181776A1 (en) | 2020-05-26 | 2021-12-02 | Boehringer Ingelheim International Gmbh | Anti-pd-1 antibodies |
| KR20230017815A (ko) | 2020-05-26 | 2023-02-06 | 리제너론 파아마슈티컬스, 인크. | 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편 |
| EP3915641A1 (en) | 2020-05-27 | 2021-12-01 | International-Drug-Development-Biotech | Anti-cd5 antibodies and methods of use thereof |
| CN113993900B (zh) | 2020-05-27 | 2023-08-04 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别神经生长因子的抗体及其用途 |
| FR3110838B1 (fr) | 2020-05-28 | 2022-06-24 | Commissariat Energie Atomique | Complexe immunomodulateur et ses applications pour la thérapie |
| AU2021281417A1 (en) | 2020-05-29 | 2022-12-08 | 23Andme, Inc. | Anti-CD200R1 antibodies and methods of use thereof |
| CN116529260A (zh) | 2020-06-02 | 2023-08-01 | 当康生物技术有限责任公司 | 抗cd93构建体及其用途 |
| CN113754766A (zh) | 2020-06-02 | 2021-12-07 | 明慧医药（上海）有限公司 | 抗b7-h3抗体及其制备和应用 |
| WO2021247769A1 (en) | 2020-06-02 | 2021-12-09 | Dynamicure Biotechnology Llc | Anti-cd93 constructs and uses thereof |
| WO2021247925A1 (en) | 2020-06-03 | 2021-12-09 | Vir Biotechnology, Inc. | Structure-guided immunotherapy against sars-cov-2 |
| EP4161653A1 (en) | 2020-06-03 | 2023-04-12 | Bionecure Therapeutics, Inc. | Trophoblast cell-surface antigen-2 (trop-2) antibodies |
| JP2023527578A (ja) | 2020-06-05 | 2023-06-29 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 眼疾患を処置するための方法及び医薬組成物 |
| US20220081486A1 (en) | 2020-06-05 | 2022-03-17 | Eisai R&D Management Co., Ltd. | Anti-bcma antibody-drug conjugates and methods of use |
| KR20230020975A (ko) | 2020-06-08 | 2023-02-13 | 에프. 호프만-라 로슈 아게 | 항-hbv 항체 및 사용 방법 |
| EP4186526A1 (en) | 2020-06-08 | 2023-05-31 | Y'S AC Co., Ltd. | Agent for reversing resistance to anticancer drugs |
| US20220119513A1 (en) | 2020-06-08 | 2022-04-21 | Zoetis Services Llc | Anti-tgfb antibodies and therapeutic uses thereof |
| GB202008651D0 (en) | 2020-06-09 | 2020-07-22 | Univ Newcastle | Method of identifying complement modulators |
| WO2021249969A1 (en) | 2020-06-10 | 2021-12-16 | Merck Patent Gmbh | Combination product for the treatment of cancer diseases |
| IL298473A (en) | 2020-06-11 | 2023-01-01 | Novartis Ag | zbtb32 inhibitors and uses thereof |
| GB202008860D0 (en) | 2020-06-11 | 2020-07-29 | Univ Oxford Innovation Ltd | BTLA antibodies |
| US20240148889A1 (en) | 2020-06-11 | 2024-05-09 | President And Fellows Of Harvard College | Stabilized trioxacarcin antibody drug conjugates and uses thereof |
| WO2021251459A1 (ja) | 2020-06-11 | 2021-12-16 | 国立大学法人高知大学 | ヒト化抗ｇｐｃ－１抗体 |
| CA3180477A1 (en) | 2020-06-12 | 2021-12-16 | Elizabeth Alexander | Antibody therapies for sars-cov-2 infection |
| US20210388064A1 (en) | 2020-06-15 | 2021-12-16 | Sarepta Therapeutics, Inc. | Adeno-associated virus antibodies and fragments thereof |
| MX2022015877A (es) | 2020-06-16 | 2023-01-24 | Genentech Inc | Metodos y composiciones para tratar cancer de mama triple negativo. |
| JP2023529853A (ja) | 2020-06-17 | 2023-07-12 | ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー | キメラ抗原受容体（ｃａｒ）ｔ細胞療法を増強するための組成物および方法 |
| CA3178265A1 (en) | 2020-06-18 | 2021-12-23 | Umc Utrecht Holding B.V. | Screening method for effective target - e3 ligase combinations |
| AU2021293507A1 (en) | 2020-06-18 | 2023-02-02 | F. Hoffmann-La Roche Ag | Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists |
| WO2021262765A1 (en) | 2020-06-22 | 2021-12-30 | The Board Of Trustees Of The Leland Stanford Junior University | Tsp-1 inhibitors for the treatment of aged, atrophied or dystrophied muscle |
| WO2021259880A1 (en) | 2020-06-22 | 2021-12-30 | Almirall, S.A. | Anti-il-36 antibodies and methods of use thereof |
| WO2021259963A1 (en) | 2020-06-23 | 2021-12-30 | Pandora Endocrine Innovation B.V. | Immunization against wnt4 for treatment and prophylaxis of breast cancer |
| MX2022016591A (es) | 2020-06-24 | 2023-04-20 | Visterra Inc | Moléculas de anticuerpo contra april y usos de las mismas. |
| CN116723856A (zh) | 2020-06-25 | 2023-09-08 | 默沙东有限责任公司 | 靶向丝氨酸413处磷酸化的tau的高亲和力抗体 |
| EP4172193A1 (en) | 2020-06-29 | 2023-05-03 | Zoetis Services LLC | Feline antibody variants for improving stability |
| KR20230030621A (ko) | 2020-06-29 | 2023-03-06 | 제넨테크, 인크. | 퍼투주맙 + 트라스투주맙 고정 용량 조합 |
| WO2022006316A1 (en) | 2020-06-30 | 2022-01-06 | Teneobio, Inc. | Multi-specific antibodies binding to bcma |
| WO2022003554A1 (en) | 2020-07-01 | 2022-01-06 | Pfizer Inc. | Biomarkers for pd-1 axis binding antagonist therapy |
| EP3933035A1 (en) | 2020-07-03 | 2022-01-05 | Aarhus Universitet | Compositions comprising extracellular vesicles and sting stimulatory agents |
| WO2022006562A1 (en) | 2020-07-03 | 2022-01-06 | Dana-Farber Cancer Institute, Inc. | Multispecific coronavirus antibodies |
| EP4175650A1 (en) | 2020-07-06 | 2023-05-10 | Kiromic BioPharma, Inc. | Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof |
| EP4178529A1 (en) | 2020-07-07 | 2023-05-17 | F. Hoffmann-La Roche AG | Alternative surfactants as stabilizers for therapeutic protein formulations |
| EP4178624A2 (en) | 2020-07-07 | 2023-05-17 | Bionecure Therapeutics, Inc. | Maytansinoids as adc payloads and their use for the treatment of cancer |
| WO2022008699A1 (en) | 2020-07-09 | 2022-01-13 | F. Hoffmann-La Roche Ag | Concentrated compositions of proteins, their preparation and use thereof |
| EP4178985A1 (en) | 2020-07-10 | 2023-05-17 | F. Hoffmann-La Roche AG | Antibodies which bind to cancer cells and target radionuclides to said cells |
| CN116600824A (zh) | 2020-07-10 | 2023-08-15 | 巴斯德研究所 | Gdf11诊断和治疗焦虑症和抑郁症的用途 |
| CN116096416A (zh) | 2020-07-13 | 2023-05-09 | 上海君实生物医药科技股份有限公司 | 抗cldn-18.2抗体及其用途 |
| AU2021308283A1 (en) | 2020-07-14 | 2023-02-02 | F. Hoffmann-La Roche Ag | Assays for fixed dose combinations |
| WO2022013328A1 (en) | 2020-07-15 | 2022-01-20 | Université Libre de Bruxelles | Method for determining sensitivity to an antineoplastic agent |
| CN116323664A (zh) | 2020-07-16 | 2023-06-23 | 诺华股份有限公司 | 抗β细胞素抗体、其片段和多特异性结合分子 |
| JP2023533793A (ja) | 2020-07-17 | 2023-08-04 | ファイザー・インク | 治療用抗体およびそれらの使用 |
| BR112023000839A2 (pt) | 2020-07-17 | 2023-02-07 | Genentech Inc | Anticorpos isolados, ácido nucleico isolado, célula hospedeira, métodos para produzir um anticorpo que se liga a notch2 humano, para tratar um indivíduo com uma doença pulmonar muco-obstrutiva e para reduzir o número de células secretoras em um indivíduo, composição farmacêutica, anticorpo, anticorpo para uso e uso do anticorpo |
| EP4182475A2 (en) | 2020-07-17 | 2023-05-24 | Onena Medicines S.L. | Antibodies against lefty proteins |
| AU2021312225A1 (en) | 2020-07-21 | 2023-02-16 | Genentech, Inc. | Antibody-conjugated chemical inducers of degradation of BRM and methods thereof |
| AU2021311701A1 (en) | 2020-07-21 | 2023-02-16 | Shanghai Junshi Biosciences Co., Ltd. | Anti-CTLA-4 antibody and use thereof |
| US20230293512A1 (en) | 2020-07-23 | 2023-09-21 | Erasmus University Medical Center Rotterdam | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms |
| TW202219067A (zh) | 2020-07-24 | 2022-05-16 | 瑞士商赫孚孟拉羅股份公司 | 用於表現抗體多聚體融合之方法 |
| WO2022026592A2 (en) | 2020-07-28 | 2022-02-03 | Celltas Bio, Inc. | Antibody molecules to coronavirus and uses thereof |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
| WO2022023379A1 (en) | 2020-07-28 | 2022-02-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for preventing and treating a cancer |
| MX2023001083A (es) | 2020-07-29 | 2023-04-10 | Dynamicure Biotechnology Llc | Construcciones anti grupo de diferenciacion 93 (cd93) y usos de las mismas. |
| JP2023537331A (ja) | 2020-07-31 | 2023-08-31 | バイオ－テラ ソリュ－ションズ，エルティーディー． | Ｃｄ４７抗体及びその応用 |
| CA3190109A1 (en) | 2020-07-31 | 2022-02-03 | Genentech, Inc. | Anti-integrin beta7 antibody formulations and devices |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| EP4189121A1 (en) | 2020-08-03 | 2023-06-07 | Genentech, Inc. | Diagnostic and therapeutic methods for lymphoma |
| CA3188349A1 (en) | 2020-08-04 | 2022-02-10 | A. Scott Muerhoff | Improved methods and kits for detecting sars-cov-2 protein in a sample |
| WO2022029494A1 (en) | 2020-08-04 | 2022-02-10 | Abbott Rapid Diagnostics International Unlimited Company | Assays for detecting sars-cov-2 |
| US20230324408A1 (en) | 2020-08-05 | 2023-10-12 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods |
| BR112023001942A2 (pt) | 2020-08-06 | 2023-02-28 | Bioverativ Usa Inc | Citocinas inflamatórias e fadiga em indivíduo com doença mediada por complemento |
| TW202214698A (zh) | 2020-08-07 | 2022-04-16 | 大陸商百奧泰生物製藥股份有限公司 | 抗pd-l1抗體及其應用 |
| EP4192942A1 (en) | 2020-08-07 | 2023-06-14 | Genentech, Inc. | T cell-based methods for predicting polypeptide immunogenicity |
| US20230303695A1 (en) | 2020-08-10 | 2023-09-28 | Tengfei XIAO | Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8 |
| CA3190634A1 (en) | 2020-08-12 | 2022-02-17 | Biond Biologics Ltd. | Antibodies against ilt2 and use thereof |
| CN116615452A (zh) | 2020-08-14 | 2023-08-18 | Ac免疫有限公司 | 人源化抗tdp-43结合分子及其用途 |
| EP4196223A1 (en) | 2020-08-14 | 2023-06-21 | F. Hoffmann-La Roche AG | Methods for treating multiple sclerosis with ocrelizumab |
| EP4197555A1 (en) | 2020-08-17 | 2023-06-21 | Akeso Biopharma, Inc. | Anti-cd73 antibody and use thereof |
| IL300701A (en) | 2020-08-17 | 2023-04-01 | Atb Therapeutics | Immunotoxin-containing immunotoxin-containing or renase |
| CN116348593A (zh) | 2020-08-21 | 2023-06-27 | 上海吉倍生物技术有限公司 | 特异性结合糖基化ceacam5的抗体 |
| US20230321242A1 (en) | 2020-08-24 | 2023-10-12 | Charité - Universitätsmedizin Berlin | Chimeric antigen receptor (car)-expressing cells recognizing cea |
| WO2022043315A1 (en) | 2020-08-24 | 2022-03-03 | Charité - Universitätsmedizin Berlin | A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6 |
| JP2023540248A (ja) | 2020-08-26 | 2023-09-22 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔｒｂｃ１またはｔｒｂｃ２を検出する方法 |
| EP4204096A2 (en) | 2020-08-26 | 2023-07-05 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| CN114106173A (zh) | 2020-08-26 | 2022-03-01 | 上海泰槿生物技术有限公司 | 抗ox40抗体、其药物组合物及应用 |
| WO2022044010A1 (en) | 2020-08-26 | 2022-03-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections |
| CA3190755A1 (en) | 2020-08-26 | 2022-03-03 | Andreas Loew | Multifunctional molecules that bind to calreticulin and uses thereof |
| EP4204448A2 (en) | 2020-08-27 | 2023-07-05 | cureab GmbH | Anti-golph2 antibodies for macrophage and dendritic cell differentiation |
| CN116648507A (zh) | 2020-08-28 | 2023-08-25 | 基因泰克公司 | 宿主细胞蛋白的CRISPR/Cas9多重敲除 |
| US20230321285A1 (en) | 2020-08-31 | 2023-10-12 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| WO2022047359A1 (en) | 2020-08-31 | 2022-03-03 | Berg Llc | Protein biomarkers for pancreatic cancer |
| US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| AU2021336734A1 (en) | 2020-09-01 | 2023-03-09 | Merck Patent Gmbh | NKp30 binders |
| EP4215211A1 (en) | 2020-09-02 | 2023-07-26 | The University of Tokyo | Tumor immune microenvironment regulator, and preventive, diagnostic or therapeutic use thereof |
| EP4208482A1 (en) | 2020-09-02 | 2023-07-12 | Pharmabcine Inc. | Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer |
| EP4208481A1 (en) | 2020-09-04 | 2023-07-12 | Merck Patent GmbH | Anti-ceacam5 antibodies and conjugates and uses thereof |
| EP4208197A1 (en) | 2020-09-04 | 2023-07-12 | Rutgers, The State University of New Jersey | Sars-cov-2 vaccines and antibodies |
| KR102528412B1 (ko) | 2020-09-08 | 2023-05-04 | 클립스비엔씨 주식회사 | 신규한 포도상구균 감염 질환의 예방 또는 치료용 조성물 |
| AR123480A1 (es) | 2020-09-11 | 2022-12-07 | Medimmune Ltd | Moléculas de unión terapéuticas |
| IL301264A (en) | 2020-09-12 | 2023-05-01 | Medimmune Ltd | A scoring method for anti-B7H4 antibody-drug therapy |
| EP4211165A1 (en) | 2020-09-14 | 2023-07-19 | Ichnos Sciences SA | Antibodies that bind to il1rap and uses thereof |
| US20230340137A1 (en) | 2020-09-14 | 2023-10-26 | Pfizer Inc. | Methods, therapies and uses for treating cancer |
| TW202227505A (zh) | 2020-09-15 | 2022-07-16 | 德商拜耳廠股份有限公司 | 新穎抗a2ap抗體及其用途 |
| CA3195231A1 (en) | 2020-09-16 | 2022-03-24 | President And Fellows Of Harvard College | Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy |
| EP3970752A1 (en) | 2020-09-17 | 2022-03-23 | Merck Patent GmbH | Molecules with solubility tag and related methods |
| CN116685351A (zh) | 2020-09-17 | 2023-09-01 | 基因泰克公司 | Empacta的结果：一项用于评估托珠单抗在患有covid-19肺炎的住院患者中的功效和安全性的随机、双盲、安慰剂对照、多中心研究 |
| CN114195900B (zh) | 2020-09-17 | 2024-02-23 | 普米斯生物技术(珠海)有限公司 | 一种抗4-1bb/pd-l1双特异性抗体及其用途 |
| EP4213939A1 (en) | 2020-09-21 | 2023-07-26 | Boehringer Ingelheim International GmbH | Use of anti-cd40 antibodies for treatment of inflammatory conditions |
| EP4214223A1 (en) | 2020-09-21 | 2023-07-26 | Theravectys | High throughput methods and products for sars-cov-2 sero-neutralization assay |
| US11225508B1 (en) | 2020-09-23 | 2022-01-18 | The University Of North Carolina At Chapel Hill | Mouse-adapted SARS-CoV-2 viruses and methods of use thereof |
| WO2022066973A1 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting pbk or oip5 antigens |
| KR20230068415A (ko) | 2020-09-24 | 2023-05-17 | 에프. 호프만-라 로슈 아게 | 유전자 녹아웃을 갖는 포유류 세포주 |
| EP4217387A2 (en) | 2020-09-24 | 2023-08-02 | Fred Hutchinson Cancer Center | Immunotherapy targeting sox2 antigens |
| US20230365692A1 (en) | 2020-09-24 | 2023-11-16 | Merck Sharp & Dohme Llc | Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof |
| GB202015226D0 (en) | 2020-09-25 | 2020-11-11 | Adc Therapeutics S A | Pyrrol obenzodiazepine-antibody conugates and uses thereof |
| WO2022067233A2 (en) | 2020-09-28 | 2022-03-31 | Zoetis Services Llc | Canine antibody variants |
| TW202229312A (zh) | 2020-09-29 | 2022-08-01 | 德商英麥提克生物技術股份有限公司 | 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物 |
| DE102020125465A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| PE20240110A1 (es) | 2020-09-29 | 2024-01-22 | Zoetis Services Llc | Variantes de anticuerpos felinos |
| WO2022072431A1 (en) | 2020-09-30 | 2022-04-07 | Zoetis Services Llc | Novel pasteurella multocida strains and vaccines having hyac and nanp deletions |
| WO2022073915A1 (en) | 2020-10-05 | 2022-04-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Gdf3 as biomarker and biotarget in post-ischemic cardiac remodeling |
| EP4225443A1 (en) | 2020-10-05 | 2023-08-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| CA3198362A1 (en) | 2020-10-07 | 2022-04-14 | Zoetis Services Llc | Anti-ngf antibodies and methods of use thereof |
| GB202015916D0 (en) | 2020-10-07 | 2020-11-18 | Adc Therapeutics Sa | Combination therapy |
| US20230365709A1 (en) | 2020-10-08 | 2023-11-16 | Affimed Gmbh | Trispecific binders |
| EP3981789A1 (en) | 2020-10-12 | 2022-04-13 | Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives | Anti-lilrb antibodies and uses thereof |
| CA3198456A1 (en) | 2020-10-14 | 2022-04-21 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
| US20230382978A1 (en) | 2020-10-15 | 2023-11-30 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods |
| US20230414700A1 (en) | 2020-10-15 | 2023-12-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tg2 inhibitors for improving mucociliary clearance in respiratory diseases |
| MX2023004438A (es) | 2020-10-15 | 2023-05-08 | Intervet Int Bv | Anticuerpos de rata caninizados para el receptor alfa de interleucina-31 canino. |
| EP4228697A1 (en) | 2020-10-16 | 2023-08-23 | Invisishield Technologies Ltd. | Compositions for preventing or treating viral and other microbial infections |
| JP2023554215A (ja) | 2020-10-16 | 2023-12-27 | ユニバーシティー オブ ジョージア リサーチ ファウンデーション，インコーポレイテッド | 糖共役体 |
| WO2022079297A1 (en) | 2020-10-16 | 2022-04-21 | Ac Immune Sa | Antibodies binding to alpha-synuclein for therapy and diagnosis |
| WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
| KR20230091871A (ko) | 2020-10-20 | 2023-06-23 | 에프. 호프만-라 로슈 아게 | Pd-1 축 결합 길항제 및 lrrk2 억제제의 병용 요법 |
| WO2022084300A1 (en) | 2020-10-20 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosis and monitoring form of coronavirus infection |
| WO2022086957A1 (en) | 2020-10-20 | 2022-04-28 | Genentech, Inc. | Peg-conjugated anti-mertk antibodies and methods of use |
| US20230416346A1 (en) | 2020-10-21 | 2023-12-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | C-terminal sparc fragments for treating cancer |
| WO2022087274A1 (en) | 2020-10-21 | 2022-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that neutralize type-i interferon (ifn) activity |
| WO2022084531A1 (en) | 2020-10-23 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating glioma |
| US20220127344A1 (en) | 2020-10-23 | 2022-04-28 | Boehringer Ingelheim International Gmbh | Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina |
| IL302182A (en) | 2020-10-23 | 2023-06-01 | Akeso Biopharma Inc | Anti-CD73 antibody and its use |
| CA3199806A1 (en) | 2020-10-26 | 2022-05-05 | Janssen Pharmaceutica Nv | Methods of reducing tau in human subjects |
| EP4232472A1 (en) | 2020-10-26 | 2023-08-30 | JANSSEN Pharmaceutica NV | Method of safe administration of anti-tau antibody |
| CN114478769B (zh) | 2020-10-26 | 2023-03-28 | 中山康方生物医药有限公司 | 抗tigit抗体、其药物组合物及用途 |
| WO2022093981A1 (en) | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists |
| WO2022093641A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2a agents and compositions and methods for making and using the same |
| WO2022094116A1 (en) | 2020-10-30 | 2022-05-05 | Genentech, Inc. | Purification platforms for obtaining pharmaceutical compositions having a reduced hydrolytic enzyme activity rate |
| US20230406909A1 (en) | 2020-11-02 | 2023-12-21 | Roche Diagnostics Operations, Inc. | Sars-cov-2 nucleocapsid antibodies |
| CA3196557A1 (en) | 2020-11-02 | 2022-05-05 | Ada SALA-HOJMAN | Combination treatment of cancer |
| KR20230095119A (ko) | 2020-11-04 | 2023-06-28 | 제넨테크, 인크. | 항-cd20/항-cd3 이중특이적 항체를 사용한 치료를 위한 투약 |
| IL302217A (en) | 2020-11-04 | 2023-06-01 | Genentech Inc | Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies and anti-CD79B drug antibody conjugates |
| AR123997A1 (es) | 2020-11-04 | 2023-02-01 | Univ Rockefeller | ANTICUERPOS NEUTRALIZANTES CONTRA EL SARS-CoV-2 |
| KR20230100732A (ko) | 2020-11-04 | 2023-07-05 | 제넨테크, 인크. | 항-cd20/항-cd3 이중특이성 항체의 피하 투여 |
| EP4240761A1 (en) | 2020-11-05 | 2023-09-13 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of il-6 inhibitors for the treatment of acute chest syndrome in patients suffering from sickle cell disease |
| CA3199976A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Research (Munich) Gmbh | Polypeptide constructs selectively binding to cldn6 and cd3 |
| CN114437212B (zh) | 2020-11-06 | 2023-03-14 | 上海麦济生物技术有限公司 | 抗人胸腺基质淋巴细胞生成素抗体及其制备方法和应用 |
| CA3199839A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies |
| MX2023005353A (es) | 2020-11-06 | 2023-05-22 | Novartis Ag | Moleculas de union a cd19 y usos de las mismas. |
| UY39508A (es) | 2020-11-06 | 2022-05-31 | Amgen Res Munich Gmbh | Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada |
| EP4240767A1 (en) | 2020-11-06 | 2023-09-13 | Amgen Inc. | Polypeptide constructs binding to cd3 |
| EP4242232A1 (en) | 2020-11-06 | 2023-09-13 | Bio-Thera Solutions, Ltd. | Bispecific antibody and use thereof |
| IL302402A (en) | 2020-11-08 | 2023-06-01 | Seagen Inc | Combined treatment |
| US20220168330A1 (en) | 2020-11-09 | 2022-06-02 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
| WO2022101302A1 (en) | 2020-11-12 | 2022-05-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes |
| WO2022104061A1 (en) | 2020-11-13 | 2022-05-19 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
| EP4244248A1 (en) | 2020-11-16 | 2023-09-20 | F. Hoffmann-La Roche AG | Fab high mannose glycoforms |
| EP4244391A1 (en) | 2020-11-16 | 2023-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating uveal melanoma |
| WO2022108627A1 (en) | 2020-11-18 | 2022-05-27 | Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. | Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules |
| TW202233684A (zh) | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | 結合於葉酸受體α之重鏈抗體 |
| EP4247496A1 (en) | 2020-11-20 | 2023-09-27 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Anti-cd25 antibodies |
| US20230416410A1 (en) | 2020-11-20 | 2023-12-28 | Zoetis Services Llc | Bovine antibody variants |
| GB202105804D0 (en) | 2020-11-20 | 2021-06-09 | Univ Cape Town | Use of microvirin in the identification of mycobacterium tuberculosis mannose-capped lipoarabinomannan |
| AU2021380966A1 (en) | 2020-11-20 | 2023-06-22 | Alderaan Biotechnology | Anti-cd25 antibodies |
| CA3199429A1 (en) | 2020-11-23 | 2022-05-27 | Davide Corti | Anti-influenza antibodies and combinations thereof |
| GB202018395D0 (en) | 2020-11-23 | 2021-01-06 | Scancell Ltd | Immunotherapy |
| WO2022106726A2 (en) | 2020-11-23 | 2022-05-27 | Norimun As | IgY ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CORONA VIRUS CAUSED DISEASES |
| JP2023551668A (ja) | 2020-11-23 | 2023-12-12 | ヴィア・バイオテクノロジー・インコーポレイテッド | インフルエンザのノイラミニダーゼに対する広域中和抗体 |
| EP4247844A1 (en) | 2020-11-23 | 2023-09-27 | VIR Biotechnology, Inc. | Antibodies against influenza a viruses |
| IL303048A (en) | 2020-11-24 | 2023-07-01 | Novartis Ag | BCL-XL inhibitor antibody-drug conjugates and methods of using them |
| EP4251208A1 (en) | 2020-11-24 | 2023-10-04 | Novartis AG | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| WO2022115486A1 (en) | 2020-11-25 | 2022-06-02 | Vir Biotechnology, Inc. | Antibodies that bind to multiple betacoronaviruses |
| AU2021387795A1 (en) | 2020-11-25 | 2023-06-01 | Innate Pharma | Treatment of cancer |
| WO2022112469A1 (en) | 2020-11-27 | 2022-06-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosis and monitoring of toxic epidermal necrolysis |
| JP2023554589A (ja) | 2020-11-27 | 2023-12-28 | ジェネラル ナノセラピューティクス エルエルシー | 免疫媒介性疾患の治療のための方法及び組成物 |
| CA3198161A1 (en) | 2020-12-01 | 2022-06-09 | Beth MCQUISTON | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
| WO2022120352A1 (en) | 2020-12-02 | 2022-06-09 | Alector Llc | Methods of use of anti-sortilin antibodies |
| EP4255496A1 (en) | 2020-12-02 | 2023-10-11 | Westfälische Wilhelms-Universität Münster | Electrostatic nanoparticles and use thereof |
| KR20230117385A (ko) | 2020-12-04 | 2023-08-08 | 퀴아젠 사이언시스, 엘엘씨 | SARS-CoV-2 (COVID-19)를 진단하고 SARS-CoV-2-특이적면역 기억을 모니터링하기 위한 조성물 및 방법 |
| MX2023006599A (es) | 2020-12-04 | 2023-06-19 | Visterra Inc | Metodos de uso de agentes de interleucina-2. |
| US20230416357A1 (en) | 2020-12-07 | 2023-12-28 | UCB Biopharma SRL | Antibodies against interleukin-22 |
| TW202237638A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法 |
| TW202237639A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法 |
| US20240025985A1 (en) | 2020-12-09 | 2024-01-25 | National University Corporation Tokyo Medical And Dental University | Agent for Preventing or Treating Frontotemporal Lobar Degeneration |
| US20240052042A1 (en) | 2020-12-14 | 2024-02-15 | Novartis Ag | Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof |
| JP2023553634A (ja) | 2020-12-14 | 2023-12-25 | アロジーン セラピューティクス，インコーポレイテッド | 治療用のｃａｒ ｔ細胞を特徴付けるための方法および試薬 |
| WO2022130206A1 (en) | 2020-12-16 | 2022-06-23 | Pfizer Inc. | TGFβr1 INHIBITOR COMBINATION THERAPIES |
| MX2023007181A (es) | 2020-12-16 | 2023-08-30 | Voyager Therapeutics Inc | Compuestos de union a tau. |
| IL303656A (en) | 2020-12-17 | 2023-08-01 | Hoffmann La Roche | ANTI-HLA-G antibodies and their use |
| JP2024503212A (ja) | 2020-12-18 | 2024-01-25 | ゾエティス・サービシーズ・エルエルシー | ネコ科動物抗体の定常領域における変異 |
| CN112500491B (zh) | 2020-12-18 | 2022-04-08 | 深圳市迈加瑞生物技术有限公司 | 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途 |
| JP2024500237A (ja) | 2020-12-23 | 2024-01-05 | アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） | 抗原提示細胞に対するｍｏｍｐ ｖｓ４抗原の標的化に基づくクラミジアワクチン |
| WO2022136569A1 (en) | 2020-12-23 | 2022-06-30 | Cantargia Ab | Anti-il1rap antibody |
| WO2022140797A1 (en) | 2020-12-23 | 2022-06-30 | Immunowake Inc. | Immunocytokines and uses thereof |
| WO2022147147A1 (en) | 2020-12-30 | 2022-07-07 | Abbott Laboratories | Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample |
| CN114685669A (zh) | 2020-12-30 | 2022-07-01 | 和铂医药(苏州)有限公司 | 结合trop2的抗体及其用途 |
| CN114685660A (zh) | 2020-12-30 | 2022-07-01 | 百奥泰生物制药股份有限公司 | 抗cldn18.2抗体及其制备方法和应用 |
| EP4274587A1 (en) | 2021-01-06 | 2023-11-15 | Tonix Pharma Limited | Methods of inducing immune tolerance with modified anti-cd154 antibodies |
| IL304067A (en) | 2021-01-06 | 2023-08-01 | Hoffmann La Roche | Combined treatment using PD1-LAG3 bispecific antibody and CD20 T cell bispecific antibody |
| KR20230131204A (ko) | 2021-01-12 | 2023-09-12 | 에프. 호프만-라 로슈 아게 | 암 세포에 결합하여 방사성핵종을 상기 세포에 표적화하는분할 항체 |
| CN114763381A (zh) | 2021-01-13 | 2022-07-19 | 博生吉医药科技(苏州)有限公司 | B7-h3嵌合抗原受体修饰的t细胞及其应用 |
| CN117425501A (zh) | 2021-01-13 | 2024-01-19 | 纪念斯隆凯特琳癌症中心 | 抗体-吡咯并苯二氮䓬衍生物缀合物 |
| WO2022153195A1 (en) | 2021-01-13 | 2022-07-21 | Memorial Sloan Kettering Cancer Center | Anti-dll3 antibody-drug conjugate |
| US20220227844A1 (en) | 2021-01-15 | 2022-07-21 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies |
| KR20230133331A (ko) | 2021-01-15 | 2023-09-19 | 씨젠 인크. | 면역조절 항체-약물 컨쥬게이트 |
| CA3208934A1 (en) | 2021-01-20 | 2022-07-28 | Visterra, Inc. | Interleukin-2 mutants and uses thereof |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| CA3208974A1 (en) | 2021-01-20 | 2022-07-28 | Bioentre Llc | Ctla4-binding proteins and methods of treating cancer |
| JP2024512824A (ja) | 2021-01-22 | 2024-03-19 | ロイヤル カレッジ オブ サージャンズ イン アイルランド | コロナウイルスの治療 |
| EP4281484A1 (en) | 2021-01-22 | 2023-11-29 | Bionecure Therapeutics, Inc. | Anti-her-2/trop-2 constructs and uses thereof |
| WO2022159842A1 (en) | 2021-01-25 | 2022-07-28 | Vir Biotechnology, Inc. | Antibody combination therapies for sars-cov-2 infection |
| WO2022162587A1 (en) | 2021-01-27 | 2022-08-04 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection |
| WO2022165067A2 (en) | 2021-01-28 | 2022-08-04 | Zoetis Services Llc | Mutations in canine antibody constant regions |
| GB2603166A (en) | 2021-01-29 | 2022-08-03 | Thelper As | Therapeutic and Diagnostic Agents and Uses Thereof |
| WO2022162177A1 (en) | 2021-01-29 | 2022-08-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes |
| WO2022165001A1 (en) | 2021-01-29 | 2022-08-04 | Merck Sharp & Dohme Llc | Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof |
| EP4284510A1 (en) | 2021-01-29 | 2023-12-06 | Novartis AG | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
| JP2024509695A (ja) | 2021-02-03 | 2024-03-05 | ジェネンテック， インコーポレイテッド | 多重特異性結合タンパク質分解プラットフォームおよび使用方法 |
| CN113501878B (zh) | 2021-02-03 | 2022-12-02 | 北京智仁美博生物科技有限公司 | 针对人tslp的多种抗体及其用途 |
| TW202245811A (zh) | 2021-02-03 | 2022-12-01 | 美商異基因治療有限公司 | 用於ｃａｒ ｔ細胞藥物產品的調配物與製程 |
| EP4288457A2 (en) | 2021-02-05 | 2023-12-13 | Boehringer Ingelheim International GmbH | Anti-il1rap antibodies |
| WO2022173745A1 (en) | 2021-02-09 | 2022-08-18 | Humabs Biomed Sa | Antibodies against respiratory syncytial virus, human metapneumovirus and pneumonia virus of mice and methods of using the same |
| JP2024508081A (ja) | 2021-02-09 | 2024-02-22 | メディリンク セラピューティクス（スーチョウ）カンパニー，リミティド | 生物活性物質コンジュゲート、その調製方法及びその使用 |
| JP2024506626A (ja) | 2021-02-09 | 2024-02-14 | 上海君▲実▼生物医▲薬▼科技股▲分▼有限公司 | 抗ｃｄ１１２ｒ抗体及びその用途 |
| CN116829591A (zh) | 2021-02-11 | 2023-09-29 | 奈克汀治疗有限公司 | 针对cd112r的抗体及其用途 |
| BR112023016717A2 (pt) | 2021-02-19 | 2023-10-31 | Seoul Nat Univ R&Db Foundation | Anticorpo biespecífico que se liga biespecificamente ao ligante 1 de morte programada e agrupamento de diferenciação 47, molécula de ácido nucleico, e, uso do anticorpo biespecífico que se liga biespecificamente ao ligante 1 de morte programada e agrupamento de diferenciação 47 |
| WO2022177393A1 (ko) | 2021-02-19 | 2022-08-25 | (주)샤페론 | Pd-l1에 대한 단일 도메인 항체 및 이의 용도 |
| CA3208641A1 (en) | 2021-02-19 | 2022-08-25 | Ashraf AMANULLAH | Formulations of dr5 binding polypeptides |
| WO2022182872A2 (en) | 2021-02-24 | 2022-09-01 | Alladapt Immunotherapeutics, Inc. | Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies |
| EP4298129A1 (en) | 2021-02-26 | 2024-01-03 | Teneobio, Inc. | Anti-muc1-c antibodies and car-t structures |
| CN117157317A (zh) | 2021-02-26 | 2023-12-01 | 拜耳公司 | 用于治疗异常子宫出血的IL-11或IL-11Ra的抑制剂 |
| CA3209364A1 (en) | 2021-03-01 | 2022-09-09 | Jennifer O'neil | Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer |
| AU2022229740A1 (en) | 2021-03-01 | 2023-08-24 | New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery | Humanized antibodies against irhom2 |
| IL305575A (en) | 2021-03-02 | 2023-10-01 | Dana Farber Cancer Inst Inc | Methods for treating red blood cell disorders |
| AU2022230300A1 (en) | 2021-03-02 | 2023-09-21 | Cgrp Diagnostics Gmbh | Treatment and/or reduction of occurrence of migraine |
| JP2024509169A (ja) | 2021-03-03 | 2024-02-29 | ソレント・セラピューティクス・インコーポレイテッド | 抗ｂｃｍａ抗体を含む抗体－薬物コンジュゲート |
| CA3209006A1 (en) | 2021-03-04 | 2022-09-09 | Boehringer Ingelheim International Gmbh | Methods for the treatment of gpp |
| WO2022187591A1 (en) | 2021-03-05 | 2022-09-09 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| WO2022187626A1 (en) | 2021-03-05 | 2022-09-09 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments |
| JP2024509191A (ja) | 2021-03-05 | 2024-02-29 | ダイナミキュア バイオテクノロジー エルエルシー | 抗ｖｉｓｔａ構築物およびその使用 |
| CN114933649B (zh) | 2021-03-10 | 2023-04-21 | 北京智仁美博生物科技有限公司 | 抗水痘-带状疱疹病毒的抗体及其用途 |
| IL305758A (en) | 2021-03-10 | 2023-11-01 | Immunowake Inc | Immunomodulatory compounds and their uses |
| EP4305061A1 (en) | 2021-03-12 | 2024-01-17 | Janssen Biotech, Inc. | Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody |
| EP4304732A1 (en) | 2021-03-12 | 2024-01-17 | Genentech, Inc. | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use |
| EP4305062A1 (en) | 2021-03-12 | 2024-01-17 | Janssen Biotech, Inc. | Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody |
| KR20230156368A (ko) | 2021-03-12 | 2023-11-14 | 추가이 세이야쿠 가부시키가이샤 | 중증 근무력증의 치료 또는 예방용의 의약 조성물 |
| BR112023018621A2 (pt) | 2021-03-15 | 2023-10-24 | Hoffmann La Roche | Métodos para tratar nefrite lúpica, esgotar células b periféricas, kits para tratar nefrite lúpica e anticorpos anti-cd20 tipo ii |
| US20220306700A1 (en) | 2021-03-17 | 2022-09-29 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
| GB202103706D0 (en) | 2021-03-17 | 2021-04-28 | Ucl Business Ltd | CD160 binding domain |
| WO2022195051A1 (en) | 2021-03-18 | 2022-09-22 | Université De Genève | Peptides and use thereof for diagnosing and treating antiphospholipid syndrome |
| JP2024511373A (ja) | 2021-03-18 | 2024-03-13 | ノバルティス アーゲー | がんのためのバイオマーカーおよびその使用 |
| US20230091653A1 (en) | 2021-03-18 | 2023-03-23 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| JP2024516769A (ja) | 2021-03-18 | 2024-04-17 | メドイミューン・リミテッド | 治療用結合分子 |
| CN116981696A (zh) | 2021-03-18 | 2023-10-31 | 艾莱克特有限责任公司 | 抗tmem106b抗体及其使用方法 |
| JP2024511360A (ja) | 2021-03-18 | 2024-03-13 | シージェン インコーポレイテッド | 生体活性化合物の内部移行複合体からの選択的薬物放出 |
| WO2022195504A1 (en) | 2021-03-19 | 2022-09-22 | Pfizer Inc. | Method of treating osteoarthritis pain with an anti ngf antibody |
| KR20230159851A (ko) | 2021-03-22 | 2023-11-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 치료 세포 조성물의 효력을 결정하는 방법 |
| EP4314280A1 (en) | 2021-03-22 | 2024-02-07 | Juno Therapeutics, Inc. | Method to assess potency of viral vector particles |
| US20220315654A1 (en) | 2021-03-22 | 2022-10-06 | Novimmune Sa | Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof |
| AU2022245196A1 (en) | 2021-03-22 | 2023-09-21 | Novimmune S.A. | Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof |
| US20240175873A1 (en) | 2021-03-23 | 2024-05-30 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of t cell-lymphomas |
| GB202104037D0 (en) | 2021-03-23 | 2021-05-05 | Bergenbio Asa | Combination therapy |
| US20240166738A1 (en) | 2021-03-23 | 2024-05-23 | Alector Llc | Anti-tmem106b antibodies for treating and preventing coronavirus infections |
| WO2022204202A1 (en) | 2021-03-23 | 2022-09-29 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
| EP4314049A1 (en) | 2021-03-25 | 2024-02-07 | Dynamicure Biotechnology LLC | Anti-igfbp7 constructs and uses thereof |
| AU2022246164A1 (en) | 2021-03-26 | 2023-09-28 | Abcuro, Inc. | Anti-klrg1 antibodies |
| WO2022204529A1 (en) | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
| CA3214440A1 (en) | 2021-03-26 | 2022-09-29 | Rupesh Nanjunda | Humanized antibodies against paired helical filament tau and uses thereof |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| WO2022207652A1 (en) | 2021-03-29 | 2022-10-06 | Scirhom Gmbh | Methods of treatment using protein binders to irhom2 epitopes |
| CN117396504A (zh) | 2021-03-30 | 2024-01-12 | 拜耳公司 | 抗Sema3A抗体及其用途 |
| JP2024514306A (ja) | 2021-03-31 | 2024-04-01 | エフ． ホフマン－ラ ロシュ アーゲー | 混合モードクロマトグラフィーによる抗体の精製 |
| CN117241828A (zh) | 2021-03-31 | 2023-12-15 | 美国比奥维拉迪维股份有限公司 | 减少冷凝集素病患者的手术相关溶血 |
| WO2022212836A1 (en) | 2021-04-01 | 2022-10-06 | Pyxis Oncology, Inc. | Gpnmb antibodies and methods of use |
| TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗ｉｌ－２ｒ抗體及使用方法 |
| AR125290A1 (es) | 2021-04-02 | 2023-07-05 | Amgen Inc | Construcciones de unión a mageb2 |
| WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| CN117157401A (zh) | 2021-04-05 | 2023-12-01 | 公立大学法人大阪 | 针对胰腺癌干细胞的抗体 |
| WO2022216846A1 (en) | 2021-04-06 | 2022-10-13 | Berg Llc | Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer |
| IL307528A (en) | 2021-04-06 | 2023-12-01 | Bpgbio Inc | Protein markers for the prognosis of breast cancer progression |
| WO2022216841A1 (en) | 2021-04-06 | 2022-10-13 | Berg Llc | Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AU2022255506A1 (en) | 2021-04-08 | 2023-11-09 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
| AU2022254104A1 (en) | 2021-04-08 | 2023-10-26 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds |
| WO2022214681A1 (en) | 2021-04-09 | 2022-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of anaplastic large cell lymphoma |
| JP2024513246A (ja) | 2021-04-09 | 2024-03-22 | ジェネンテック， インコーポレイテッド | Ｒａｆ阻害剤及びｐｄ－１軸阻害剤を用いた併用治療 |
| BR112023020662A2 (pt) | 2021-04-09 | 2024-02-06 | Seagen Inc | Métodos de tratamento de câncer com anticorpos anti-tigit |
| GB202105187D0 (en) | 2021-04-12 | 2021-05-26 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| WO2022218998A1 (en) | 2021-04-13 | 2022-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating hepatitis b and d virus infection |
| BR112023021297A2 (pt) | 2021-04-14 | 2023-12-12 | Villaris Therapeutics Inc | Anticorpos anti-cd122 e usos dos mesmos |
| EP4190816A1 (en) | 2021-04-14 | 2023-06-07 | Akeso Biopharma, Inc. | Anti-cd47 monoclonal antibody and use thereof |
| AR125344A1 (es) | 2021-04-15 | 2023-07-05 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-c1s |
| CN115215937B (zh) | 2021-04-15 | 2023-05-26 | 上海麦济生物技术有限公司 | 抗人masp-2抗体及其制备方法和应用 |
| CR20230525A (es) | 2021-04-16 | 2024-02-19 | Teneobio Inc | Anticuerpos anti-cd20 y estructuras car-t |
| WO2022221767A1 (en) | 2021-04-16 | 2022-10-20 | Tiziana Life Sciences Plc | Subcutaneous administration of antibodies for the treatment of disease |
| EP4326871A1 (en) | 2021-04-19 | 2024-02-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of splice switching oligonucleotides for exon skipping-mediated knockdown of pim2 |
| TW202305122A (zh) | 2021-04-19 | 2023-02-01 | 美商建南德克公司 | 經修飾之哺乳動物細胞 |
| CA3212610A1 (en) | 2021-04-20 | 2022-10-27 | Philip MOQUIST | Modulation of antibody-dependent cellular cytotoxicity |
| PE20240068A1 (es) | 2021-04-23 | 2024-01-11 | Amgen Inc | Composiciones de anticuerpos anti-tslp y usos de las mismas |
| CA3216700A1 (en) | 2021-04-23 | 2022-10-27 | Amgen Inc. | Modified anti-tslp antibodies |
| AU2022266934A1 (en) | 2021-04-26 | 2023-10-26 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-nectin-4 antibody and anti-nectin-4 antibody-drug conjugate, and medicinal user thereof |
| KR20240004659A (ko) | 2021-04-30 | 2024-01-11 | 셀진 코포레이션 | 감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법 |
| CA3217803A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
| CA3218933A1 (en) | 2021-05-03 | 2022-11-10 | UCB Biopharma SRL | Antibodies |
| EP4333900A2 (en) | 2021-05-03 | 2024-03-13 | Merck Patent GmbH | Her2 targeting fc antigen binding fragment-drug conjugates |
| US20220372168A1 (en) | 2021-05-04 | 2022-11-24 | Regeneron Pharmaceuticals, Inc. | Multispecific fgf21 receptor agonists and their uses |
| EP4334343A2 (en) | 2021-05-06 | 2024-03-13 | The Rockefeller University | Neutralizing anti-sars- cov-2 antibodies and methods of use thereof |
| CN117279947A (zh) | 2021-05-06 | 2023-12-22 | 安进研发（慕尼黑）股份有限公司 | 用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子 |
| WO2022241057A1 (en) | 2021-05-12 | 2022-11-17 | Applied Biomedical Science Institute | Binding polypeptides against sars cov-2 and uses thereof |
| CA3218170A1 (en) | 2021-05-12 | 2022-11-17 | Jamie Harue HIRATA | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
| JP2023546368A (ja) | 2021-05-14 | 2023-11-02 | ジェネンテック， インコーポレイテッド | モスネツズマブおよびポラツズマブベドチンを用いたｃｄ２０陽性増殖性障害の処置のための方法 |
| KR20240007928A (ko) | 2021-05-14 | 2024-01-17 | 제넨테크, 인크. | Trem2의 효능제 |
| BR112023024169A2 (pt) | 2021-05-18 | 2024-02-06 | Abbott Lab | Métodos para avaliar lesão cerebral em um indivíduo pediátrico |
| KR20240012502A (ko) | 2021-05-21 | 2024-01-29 | 세바스티안 보이머 | 프로타민 기반 나노입자의 표적 화합물로서의 항체-프로타민 융합 |
| EP4341385A1 (en) | 2021-05-21 | 2024-03-27 | Genentech, Inc. | Modified cells for the production of a recombinant product of interest |
| AU2022280767A1 (en) | 2021-05-24 | 2024-01-18 | Humabs Biomed Sa | Engineered polypeptides |
| AU2022280341A1 (en) | 2021-05-25 | 2024-01-04 | Merck Patent Gmbh | Egfr targeting fc antigen binding fragment-drug conjugates |
| WO2022248268A1 (en) | 2021-05-28 | 2022-12-01 | Adc Therapeutics Sa | Combination therapy |
| GB202107706D0 (en) | 2021-05-28 | 2021-07-14 | Adc Therapeutics S A | Combination therapy |
| GB202107709D0 (en) | 2021-05-28 | 2021-07-14 | Adc Therapeutics S A | Combination therapy |
| WO2022251446A1 (en) | 2021-05-28 | 2022-12-01 | Alexion Pharmaceuticals, Inc. | Methods for detecting cm-tma biomarkers |
| WO2022251850A1 (en) | 2021-05-28 | 2022-12-01 | Seagen Inc. | Anthracycline antibody conjugates |
| EP4347647A1 (en) | 2021-06-01 | 2024-04-10 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of b cell depleting agents for the treatment of rheumatic heart disease |
| WO2022253991A1 (en) | 2021-06-02 | 2022-12-08 | Inotrem | Anti-trem-1 antibodies |
| US20230036592A1 (en) | 2021-06-03 | 2023-02-02 | Surface Oncology, Inc. | Methods of treating cancer with an anti-cd39 antibody and pembrolizumab |
| EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| WO2022256534A1 (en) | 2021-06-03 | 2022-12-08 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab |
| JP7436711B2 (ja) | 2021-06-04 | 2024-02-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗ｓｉｒｐ－アルファ抗体 |
| GB202108055D0 (en) | 2021-06-04 | 2021-07-21 | Univ Court Of The Univ Of Aberdeen | Antibodies and methods for generating the same |
| JP2024520261A (ja) | 2021-06-04 | 2024-05-24 | 中外製薬株式会社 | 抗ｄｄｒ２抗体およびその使用 |
| JP2024520764A (ja) | 2021-06-07 | 2024-05-24 | アレス トレーディング ソシエテ アノニム | 癌の組み合わせ処置 |
| WO2022261183A2 (en) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating and/or identifying an agent for treating intestinal cancers |
| IL308015A (en) | 2021-06-09 | 2023-12-01 | Hoffmann La Roche | A combination of a specific BRAF inhibitor (paradox breaker) and a PD-1 spindle-binding antagonist for use in cancer treatment |
| AU2022293389A1 (en) | 2021-06-14 | 2024-01-04 | Abbott Laboratories | Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind |
| CA3218481A1 (en) | 2021-06-14 | 2022-12-22 | argenx BV | Anti-il-9 antibodies and methods of use thereof |
| WO2022266223A1 (en) | 2021-06-16 | 2022-12-22 | Alector Llc | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
| WO2022266221A1 (en) | 2021-06-16 | 2022-12-22 | Alector Llc | Monovalent anti-mertk antibodies and methods of use thereof |
| WO2022266660A1 (en) | 2021-06-17 | 2022-12-22 | Amberstone Biosciences, Inc. | Anti-cd3 constructs and uses thereof |
| EP4355771A1 (en) | 2021-06-17 | 2024-04-24 | Genentech, Inc. | Anti-ubiquitination antibodies and methods of use |
| WO2022263638A1 (en) | 2021-06-17 | 2022-12-22 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection |
| BR112023026429A2 (pt) | 2021-06-18 | 2024-03-05 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Anticorpo anti-il-36r isolado ou um fragmento de ligação ao antígeno deste, imunoconjugado ou molécula multiespecífica, composição farmacêutica, método para inibir a transdução de sinal de il-36/il-36r e método para tratar doenças e condições relacionadas mediadas por il-36/il-36r em um sujeito em necessidade |
| EP4329794A2 (en) | 2021-06-18 | 2024-03-06 | Nammi Therapeutics, Inc. | Fusion protein composition(s) comprising masked type i interferons (ifn? and ifn?) for use in the treatment of cancer and methods thereof |
| EP4355780A1 (en) | 2021-06-18 | 2024-04-24 | Alligator Bioscience AB | Novel combination therapies and uses thereof |
| WO2022269473A1 (en) | 2021-06-23 | 2022-12-29 | Janssen Biotech, Inc. | Materials and methods for hinge regions in functional exogenous receptors |
| WO2022271867A1 (en) | 2021-06-23 | 2022-12-29 | Scholar Rock, Inc. | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
| WO2022269605A1 (en) | 2021-06-24 | 2022-12-29 | Yeda Research And Development Co. Ltd. | Combination therapy for the treatment of cancer comprising an anti-egfr antibody and an axl-inhibitor |
| BR112023022992A2 (pt) | 2021-06-25 | 2024-01-23 | Chugai Pharmaceutical Co Ltd | Anticorpo anti-ctla-4 |
| US20240165229A1 (en) | 2021-06-29 | 2024-05-23 | Seagen Inc. | Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist |
| AU2022304258A1 (en) | 2021-07-02 | 2024-02-15 | Merck Patent Gmbh | Anti-protac antibodies and complexes |
| CN115558023A (zh) | 2021-07-02 | 2023-01-03 | 安源医药科技（上海）有限公司 | 抗cd3抗体及其用途 |
| CN118103397A (zh) | 2021-07-08 | 2024-05-28 | 舒泰神(加州)生物科技有限公司 | 特异性识别tnfr2的抗体及其用途 |
| IL309996A (en) | 2021-07-09 | 2024-03-01 | Janssen Biotech Inc | Production methods for the production of anti-TNF antibody compositions |
| CN117616048A (zh) | 2021-07-09 | 2024-02-27 | 先声再明医药有限公司 | Cd19抗体及其应用 |
| EP4367138A1 (en) | 2021-07-09 | 2024-05-15 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-il12/il23 antibody compositions |
| WO2023281462A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
| EP4370550A1 (en) | 2021-07-12 | 2024-05-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of il-36 inhibitors for the treatment of netherton syndrome |
| EP4370545A1 (en) | 2021-07-12 | 2024-05-22 | Genentech, Inc. | Structures for reducing antibody-lipase binding |
| EP4371125A1 (en) | 2021-07-13 | 2024-05-22 | Genentech, Inc. | Multi-variate model for predicting cytokine release syndrome |
| WO2023285620A2 (en) | 2021-07-14 | 2023-01-19 | Alchemab Therapeutics Ltd. | Compositions and methods for targeting viral proteins |
| KR20240034234A (ko) | 2021-07-14 | 2024-03-13 | 2세븐티 바이오, 인코포레이티드 | 항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체 |
| KR20240046322A (ko) | 2021-07-14 | 2024-04-08 | 리제너론 파아마슈티컬스, 인크. | 항-sars-cov-2-스파이크 당단백질 항체 및 항원-결합 단편 |
| EP4370647A1 (en) | 2021-07-15 | 2024-05-22 | Just-Evotec Biologics, Inc. | Bidirectional tangential flow filtration (tff) perfusion system |
| TW202309102A (zh) | 2021-07-20 | 2023-03-01 | 美商英伊布里克斯公司 | 靶向cd8之經修飾il-2多肽及其用途 |
| CA3225092A1 (en) | 2021-07-20 | 2023-01-26 | John C. Timmer | Cd8-binding polypeptides and uses thereof |
| WO2023004386A1 (en) | 2021-07-22 | 2023-01-26 | Genentech, Inc. | Brain targeting compositions and methods of use thereof |
| CN117730102A (zh) | 2021-07-22 | 2024-03-19 | 豪夫迈·罗氏有限公司 | 异二聚体Fc结构域抗体 |
| WO2023001303A1 (zh) | 2021-07-23 | 2023-01-26 | 中山康方生物医药有限公司 | 药物组合物及用途 |
| WO2023004197A1 (en) | 2021-07-23 | 2023-01-26 | Teneoten, Inc. | Heavy chain antibodies binding to hepatitis b surface antigen |
| GB202110726D0 (en) | 2021-07-26 | 2021-09-08 | Cambridge Entpr Ltd | Conjugating reagents and conjugates thereof |
| EP4378951A1 (en) | 2021-07-26 | 2024-06-05 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | General affinity epitope polypeptide for human rhinovirus, and antibody and uses thereof |
| AU2022320627A1 (en) | 2021-07-26 | 2024-02-08 | Abcuro, Inc. | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies |
| WO2023007374A1 (en) | 2021-07-27 | 2023-02-02 | Pfizer Inc. | Method of treatment of cancer pain with tanezumab |
| WO2023010060A2 (en) | 2021-07-27 | 2023-02-02 | Novab, Inc. | Engineered vlrb antibodies with immune effector functions |
| WO2023006919A1 (en) | 2021-07-29 | 2023-02-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | HUMANIZED ANTI-HUMAN βIG-H3 PROTEIN AND USES THEREOF |
| KR20240038768A (ko) | 2021-07-30 | 2024-03-25 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키메라 단백질 및 면역치료 방법 |
| AU2022324456A1 (en) | 2021-08-05 | 2024-02-15 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
| CA3227511A1 (en) | 2021-08-06 | 2023-02-09 | Lætitia LINARES | Methods for the treatment of cancer |
| AU2022327511A1 (en) | 2021-08-09 | 2024-03-07 | Biotheus Inc. | Anti-tigit antibody and use thereof |
| WO2023019239A1 (en) | 2021-08-13 | 2023-02-16 | Genentech, Inc. | Dosing for anti-tryptase antibodies |
| AU2022330225A1 (en) | 2021-08-18 | 2024-02-29 | Biotheus Inc. | Bispecific antibody and use thereof |
| CN117858905A (zh) | 2021-08-19 | 2024-04-09 | 豪夫迈·罗氏有限公司 | 多价抗变体fc区抗体及使用方法 |
| WO2023021170A2 (en) | 2021-08-20 | 2023-02-23 | Intervet International B.V. | Fusion proteins for treating atopic dermatitis |
| CA3227716A1 (en) | 2021-08-20 | 2023-02-23 | Intervet International B.V. | Antibodies and igg fusion proteins with an extended half-life |
| WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
| TW202327642A (zh) | 2021-08-25 | 2023-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種含融合蛋白的醫藥組成物 |
| KR20240043818A (ko) | 2021-08-26 | 2024-04-03 | 글리카노스틱스 에스.알.오. | 암 진단을 위한 당단백질 바이오마커 |
| WO2023025303A1 (zh) | 2021-08-26 | 2023-03-02 | 上海君实生物医药科技股份有限公司 | 抗cldn-18.2抗体药物偶联物及其用途 |
| AU2022333323A1 (en) | 2021-08-27 | 2024-02-29 | H. Lundbeck A/S | Treatment of cluster headache using anti-cgrp antibodies |
| IL310382A (en) | 2021-08-27 | 2024-03-01 | Genentech Inc | Methods for treating tau pathologies |
| JPWO2023032955A1 (ja) | 2021-08-31 | 2023-03-09 | ||
| WO2023034866A1 (en) | 2021-09-01 | 2023-03-09 | Vir Biotechnology, Inc. | Antibody therapies for sars-cov-2 infection in pediatric subjects |
| WO2023034871A1 (en) | 2021-09-01 | 2023-03-09 | Vir Biotechnology, Inc. | High concentration antibody therapies for sars-cov-2 infection |
| IL310773A (en) | 2021-09-02 | 2024-04-01 | Deutsches Krebsforschungszentrum Stiftung Des ?Ffentlichen Rechts | Anti-CECAM6 antibodies with reduced side effects |
| WO2023034571A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
| EP4148067A1 (en) | 2021-09-08 | 2023-03-15 | F. Hoffmann-La Roche AG | Method for the expression of an antibody-multimer-fusion |
| WO2023039442A1 (en) | 2021-09-08 | 2023-03-16 | Vir Biotechnology, Inc. | Broadly neutralizing antibody combination therapies for sars-cov-2 infection |
| GB202112935D0 (en) | 2021-09-10 | 2021-10-27 | Harbour Antibodies Bv | Sars-cov-2 (sars2, covid-19) heavy chain only antibodies |
| WO2023036982A1 (en) | 2021-09-10 | 2023-03-16 | Harbour Antibodies Bv | Anti-sars2-s antibodies |
| CA3231761A1 (en) | 2021-09-13 | 2023-03-16 | Qiong Wang | Anti-human cd3 antibody and use thereof |
| KR20240053007A (ko) | 2021-09-14 | 2024-04-23 | 글리카노스틱스 에스.알.오. | 유방암 진단을 위한 당단백질 바이오마커 |
| WO2023044094A1 (en) | 2021-09-20 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof |
| WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2023048111A1 (ja) | 2021-09-21 | 2023-03-30 | 国立研究開発法人 農業・食品産業技術総合研究機構 | 無莢膜株を抗原として含むワクチン |
| CN115925929A (zh) | 2021-09-22 | 2023-04-07 | 上海康岱生物医药技术股份有限公司 | 抗tnfr2单克隆抗体及其应用 |
| CN115838424A (zh) | 2021-09-22 | 2023-03-24 | 上海康岱生物医药技术股份有限公司 | 靶向tigit的单克隆抗体 |
| GB202113904D0 (en) | 2021-09-29 | 2021-11-10 | Alligator Bioscience Ab | Methods and compositions |
| WO2023051621A1 (zh) | 2021-09-29 | 2023-04-06 | 中山康方生物医药有限公司 | 抗lag3抗体、药物组合物及用途 |
| WO2023053282A1 (ja) | 2021-09-29 | 2023-04-06 | 中外製薬株式会社 | がんの治療に用いるための細胞傷害誘導治療剤 |
| WO2023056268A1 (en) | 2021-09-30 | 2023-04-06 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
| CN115894689A (zh) | 2021-09-30 | 2023-04-04 | 百奥泰生物制药股份有限公司 | 抗b7-h3抗体及其应用 |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| WO2023052541A1 (en) | 2021-09-30 | 2023-04-06 | Imcheck Therapeutics | Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| US11879010B2 (en) | 2021-09-30 | 2024-01-23 | The Charlotte Mecklenburg Hospital Authority | Methods and compositions for pretargeted immunotherapy |
| US20230190807A1 (en) | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Tcr compounds, compositions, and methods of treating |
| AR127269A1 (es) | 2021-10-08 | 2024-01-03 | Chugai Pharmaceutical Co Ltd | Formulación de anticuerpo anti-hla-dq2.5 |
| CA3234966A1 (en) | 2021-10-14 | 2023-04-20 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
| CA3234995A1 (en) | 2021-10-14 | 2023-04-20 | Latticon (Suzhou) Biopharmaceuticals Co., Ltd. | Novel antibody-cytokine fusion protein, preparation method therefor and use thereof |
| WO2023064942A1 (en) | 2021-10-14 | 2023-04-20 | Tiziana Life Sciences Plc | Methods of suppressing microglial activation |
| CA3234162A1 (en) | 2021-10-15 | 2023-04-20 | Michele Fiscella | Antibodies and methods of using thereof |
| WO2023069919A1 (en) | 2021-10-19 | 2023-04-27 | Alector Llc | Anti-cd300lb antibodies and methods of use thereof |
| CA3234598A1 (en) | 2021-10-27 | 2023-05-04 | Daniel Olive | Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders |
| CA3236522A1 (en) | 2021-10-28 | 2023-05-04 | In3Bio Ltd. | Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors |
| WO2023077053A2 (en) | 2021-10-28 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-related methods and compositions for knocking out c5 |
| TW202334221A (zh) | 2021-11-03 | 2023-09-01 | 德商安富美德有限公司 | 雙特異性cd16a結合劑 |
| CA3237018A1 (en) | 2021-11-03 | 2023-05-11 | Joachim Koch | Bispecific cd16a binders |
| WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
| CA3237463A1 (en) | 2021-11-05 | 2023-05-11 | Alligator Bioscience Ab | Novel peptides |
| WO2023079058A1 (en) | 2021-11-05 | 2023-05-11 | Yokogawa Insilico Biotechnology Gmbh | Cell culture with reduced production of lactate |
| TW202333797A (zh) | 2021-11-05 | 2023-09-01 | 法商賽諾菲公司 | 含有抗ceacam5抗體-藥物接合物及抗vegfr-2抗體之抗腫瘤組合 |
| CA3237090A1 (en) | 2021-11-05 | 2023-05-11 | Dana-Farber Cancer Institute, Inc. | Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof |
| AU2022379952A1 (en) | 2021-11-05 | 2024-05-16 | American Diagnostics & Therapy, Llc (Adxrx) | Monoclonal antibodies against carcinoembryonic antigens, and their uses |
| WO2023081486A1 (en) | 2021-11-08 | 2023-05-11 | Nurix Therapeutics, Inc. | Toll-like receptor therapy combinations with cbl-b inhibitor compounds |
| WO2023081925A1 (en) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
| WO2023086835A1 (en) | 2021-11-09 | 2023-05-19 | Sensei Biotherapeutics, Inc. | Anti-vista antibodies and uses thereof |
| EP4180061A1 (en) | 2021-11-10 | 2023-05-17 | Nerviano Medical Sciences S.r.l. | Anthracycline derivative linker reagents, antibody-drug conjugates and methods |
| WO2023086807A1 (en) | 2021-11-10 | 2023-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| US20230151087A1 (en) | 2021-11-15 | 2023-05-18 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
| TW202334202A (zh) | 2021-11-16 | 2023-09-01 | 瑞士商Ａｃ免疫有限公司 | 用於治療和診斷的新分子 |
| CA3238660A1 (en) | 2021-11-17 | 2023-05-25 | Institut National De La Sante Et De La Recherche Medicale | Universal sarbecovirus vaccines |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2023089314A1 (en) | 2021-11-18 | 2023-05-25 | Oxford Biotherapeutics Limited | Pharmaceutical combinations |
| WO2023089032A1 (en) | 2021-11-19 | 2023-05-25 | Institut Curie | Methods for the treatment of hrd cancer and brca-associated cancer |
| TW202323301A (zh) | 2021-11-19 | 2023-06-16 | 英商米羅比奧有限公司 | 經工程改造之ｐｄ－１抗體及其用途 |
| US20230159633A1 (en) | 2021-11-23 | 2023-05-25 | Janssen Biotech, Inc. | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody |
| WO2023096904A2 (en) | 2021-11-24 | 2023-06-01 | President And Fellows Of Harvard College | C-16 modified trioxacarcins, antibody drug conjugates, and uses thereof |
| WO2023097254A1 (en) | 2021-11-24 | 2023-06-01 | Visterra, Inc. | Engineered antibody molecules to cd138 and uses thereof |
| WO2023097119A2 (en) | 2021-11-29 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
| TW202333772A (zh) | 2021-12-01 | 2023-09-01 | 美商威特拉公司 | 使用介白素-2藥劑之方法 |
| WO2023102077A1 (en) | 2021-12-01 | 2023-06-08 | Sutro Biopharma, Inc. | Anti-folate receptor conjugate cancer therapy |
| WO2023099763A1 (en) | 2021-12-03 | 2023-06-08 | Institut Curie | Sirt6 inhibitors for use in treating resistant hrd cancer |
| WO2023104904A2 (en) | 2021-12-08 | 2023-06-15 | Genclis | The sars-cov-2 and variants use two independent cell receptors to replicate |
| GB202117928D0 (en) | 2021-12-11 | 2022-01-26 | Cancer Research Tech Ltd | Immunotherapy for cancer |
| WO2023105528A1 (en) | 2021-12-12 | 2023-06-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to ceacam1 |
| WO2023110937A1 (en) | 2021-12-14 | 2023-06-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling |
| TW202334405A (zh) | 2021-12-15 | 2023-09-01 | 美商英特瑞斯生物療法公司 | 假型分型之病毒顆粒、包含其之組合物及其用途 |
| WO2023111153A1 (en) | 2021-12-16 | 2023-06-22 | Intervet International B.V. | Caninized antibodies to human ngf |
| WO2023111148A1 (en) | 2021-12-16 | 2023-06-22 | Intervet International B.V. | Caninized antibodies to canine interleukin-31 receptor alpha 1 |
| WO2023114978A1 (en) | 2021-12-17 | 2023-06-22 | Abbott Laboratories | Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples |
| WO2023114543A2 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Platform for antibody discovery |
| WO2023114544A1 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Antibodies and uses thereof |
| CA3223956A1 (en) | 2021-12-20 | 2023-06-29 | Vetoquinol Sa | Anti-canine interleukine-31-receptor a (il-31ra) antibodies and the uses thereof |
| WO2023122573A1 (en) | 2021-12-20 | 2023-06-29 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab |
| WO2023118165A1 (en) | 2021-12-21 | 2023-06-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| WO2023117325A1 (en) | 2021-12-21 | 2023-06-29 | F. Hoffmann-La Roche Ag | Method for the determination of hydrolytic activity |
| TW202342515A (zh) | 2021-12-22 | 2023-11-01 | 瑞士商Ｃｄｒ生命股份有限公司 | 抗c3抗體及其抗原結合片段及其用於治療眼疾病之用途 |
| WO2023118508A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| US20230213536A1 (en) | 2021-12-28 | 2023-07-06 | Abbott Laboratories | Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan |
| TW202334233A (zh) | 2022-01-05 | 2023-09-01 | 美商英伊布里克斯公司 | 結合γδ T細胞之多肽及其用途 |
| WO2023133393A1 (en) | 2022-01-05 | 2023-07-13 | Inhibrx, Inc. | Gamma delta t-cell-targeted modified il-2 polypeptides and uses thereof |
| TW202340251A (zh) | 2022-01-19 | 2023-10-16 | 美商建南德克公司 | 抗ｎｏｔｃｈ２抗體及結合物及其使用方法 |
| US20230295348A1 (en) | 2022-01-24 | 2023-09-21 | Novimmune Sa | Composition and methods for the selective activation of cytokine signaling pathways |
| AR128331A1 (es) | 2022-01-26 | 2024-04-17 | Genentech Inc | Inductores químicos de degradación conjugados con anticuerpos y métodos de estos |
| WO2023144235A1 (en) | 2022-01-27 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for monitoring and treating warburg effect in patients with pi3k-related disorders |
| WO2023147399A1 (en) | 2022-01-27 | 2023-08-03 | The Rockefeller University | Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof |
| GB202201137D0 (en) | 2022-01-28 | 2022-03-16 | Thelper As | Therapeutic and diagnostic agents and uses thereof |
| WO2023144665A1 (en) | 2022-01-28 | 2023-08-03 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
| WO2023150181A1 (en) | 2022-02-01 | 2023-08-10 | President And Fellows Of Harvard College | Methods and compositions for treating cancer |
| WO2023148598A1 (en) | 2022-02-02 | 2023-08-10 | Pfizer Inc. | Cysteine prototrophy |
| WO2023150623A2 (en) | 2022-02-02 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease |
| WO2023150652A1 (en) | 2022-02-04 | 2023-08-10 | Abbott Laboratories | Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample |
| TW202342548A (zh) | 2022-02-07 | 2023-11-01 | 美商威特拉公司 | 抗獨特型(anti-idiotype)抗體分子及其用途 |
| WO2023152637A1 (en) | 2022-02-08 | 2023-08-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Neutralization of acyl-coa binding protein confers autophagy-dependent organ protection |
| WO2023154780A1 (en) | 2022-02-09 | 2023-08-17 | Martell Diagnostic Laboratories, Inc. | Anti-her2/neu antibodies and methods of use |
| WO2023152633A1 (en) | 2022-02-09 | 2023-08-17 | Janssen Biotech, Inc. | Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes |
| CN114181310B (zh) | 2022-02-14 | 2022-07-05 | 中山康方生物医药有限公司 | 抗tigit抗体、其药物组合物及用途 |
| TW202342519A (zh) | 2022-02-16 | 2023-11-01 | 瑞士商Ａｃ 免疫有限公司 | 人源化抗ｔｄｐ－４３結合分子及其用途 |
| TW202348252A (zh) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | 用治療性結合分子治療癌症的組合療法 |
| WO2023156634A1 (en) | 2022-02-17 | 2023-08-24 | Atb Therapeutics | Recombinant immunotoxin comprising a ribosome inactivating protein |
| EP4230222A1 (en) | 2022-02-17 | 2023-08-23 | Oxsonics Limited | Combination therapy with an anti-axl antibody-pbd conjugate and nanocups |
| WO2023156587A1 (en) | 2022-02-18 | 2023-08-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance |
| WO2023155902A1 (en) | 2022-02-18 | 2023-08-24 | Chongqing Mingdao Haoyue Biotechnology Co., Ltd. | Intranasal formulations and anti-sars-cov-2-spike protein antibodies |
| WO2023156683A1 (en) | 2022-02-21 | 2023-08-24 | Acticor Biotech | Treatment of cardiovascular diseases using anti-human gpvi antibodies |
| WO2023164516A1 (en) | 2022-02-23 | 2023-08-31 | Alector Llc | Methods of use of anti-trem2 antibodies |
| WO2023161412A1 (en) | 2022-02-25 | 2023-08-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for preventing the cleavage of cd95l by metalloproteases |
| WO2023166420A1 (en) | 2022-03-03 | 2023-09-07 | Pfizer Inc. | Multispecific antibodies and uses thereof |
| US20240002544A1 (en) | 2022-03-07 | 2024-01-04 | Novimmune Sa | Cd28 bispecific antibodies for targeted t cell activation |
| WO2023172968A1 (en) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof |
| WO2023170207A1 (en) | 2022-03-09 | 2023-09-14 | Alderaan Biotechnology | Anti-cd160 transmembrane isoform antibodies |
| WO2023170240A1 (en) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Anti-ceacam5 antibodies and conjugates and uses thereof |
| WO2023173026A1 (en) | 2022-03-10 | 2023-09-14 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
| WO2023170216A1 (en) | 2022-03-11 | 2023-09-14 | Astrazeneca Ab | A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY |
| WO2023170434A1 (en) | 2022-03-11 | 2023-09-14 | Macomics Limited | Compositions and methods for modulation of macrophage activity |
| GB202203588D0 (en) | 2022-03-15 | 2022-04-27 | Argonaut Therapeutics Ltd | Cancer diagnostic |
| TW202400137A (zh) | 2022-03-17 | 2024-01-01 | 美商思進公司 | 喜樹鹼偶聯物 |
| WO2023178357A1 (en) | 2022-03-18 | 2023-09-21 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules and methods of use thereof |
| TW202346365A (zh) | 2022-03-23 | 2023-12-01 | 瑞士商赫孚孟拉羅股份公司 | 抗ｃｄ２０／抗ｃｄ３雙特異性抗體及化學療法之組合治療 |
| TW202402790A (zh) | 2022-03-25 | 2024-01-16 | 英商梅迪繆思有限公司 | 減少呼吸系統感染之方法 |
| WO2023192872A1 (en) | 2022-03-28 | 2023-10-05 | Massachusetts Institute Of Technology | Rna scaffolded wireframe origami and methods thereof |
| US20230312703A1 (en) | 2022-03-30 | 2023-10-05 | Janssen Biotech, Inc. | Method of Treating Psoriasis with IL-23 Specific Antibody |
| TW202405009A (zh) | 2022-03-30 | 2024-02-01 | 瑞士商諾華公司 | 使用抗利尿鈉肽受體１（ｎｐｒ１）抗體治療障礙之方法 |
| GB202204813D0 (en) | 2022-04-01 | 2022-05-18 | Bradcode Ltd | Human monoclonal antibodies and methods of use thereof |
| WO2023192622A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides |
| WO2023187176A1 (en) | 2022-04-01 | 2023-10-05 | Trince bv | Method for delivering a cargo into cell |
| US20230357851A1 (en) | 2022-04-06 | 2023-11-09 | Larimar Therapeutics, Inc. | Frataxin-sensitive markers for monitoring frataxin-replacement therapy |
| WO2023194565A1 (en) | 2022-04-08 | 2023-10-12 | Ac Immune Sa | Anti-tdp-43 binding molecules |
| TW202404636A (zh) | 2022-04-08 | 2024-02-01 | 美商英伊布里克斯公司 | Dr5促效劑及plk1抑制劑或cdk抑制劑之組合療法 |
| EP4257609A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Combination therapies based on pd-1 inhibitors and sik3 inhibitors |
| WO2023193239A1 (en) | 2022-04-08 | 2023-10-12 | Peter Peizhi Luo | Anti-cd28 antibodies and methods of use thereof |
| WO2023201201A1 (en) | 2022-04-10 | 2023-10-19 | Immunomic Therapeutics, Inc. | Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof |
| WO2023198648A1 (en) | 2022-04-11 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of t-cell malignancies |
| TW202400243A (zh) | 2022-04-12 | 2024-01-01 | 日商衛材R&D企管股份有限公司 | 基於艾日布林的抗體–藥物軛合物及其使用方法 |
| TW202406571A (zh) | 2022-04-13 | 2024-02-16 | 美商建南德克公司 | 莫蘇妥珠單抗之醫藥組成物及其使用方法 |
| US20230406930A1 (en) | 2022-04-13 | 2023-12-21 | Genentech, Inc. | Pharmaceutical compositions of therapeutic proteins and methods of use |
| WO2023198874A1 (en) | 2022-04-15 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of t cell-lymphomas |
| WO2023212518A1 (en) | 2022-04-25 | 2023-11-02 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| WO2023209716A1 (en) | 2022-04-25 | 2023-11-02 | Biond Biologics Ltd. | Anti-ilt3 antibodies and use thereof |
| WO2023209568A1 (en) | 2022-04-26 | 2023-11-02 | Novartis Ag | Multispecific antibodies targeting il-13 and il-18 |
| WO2023212294A1 (en) | 2022-04-29 | 2023-11-02 | Broadwing Bio Llc | Angiopoietin-related protein 7-specific antibodies and uses thereof |
| WO2023212298A1 (en) | 2022-04-29 | 2023-11-02 | Broadwing Bio Llc | Bispecific antibodies and methods of treating ocular disease |
| TW202406934A (zh) | 2022-05-03 | 2024-02-16 | 美商建南德克公司 | 抗Ｌｙ６Ｅ抗體、免疫結合物及其用途 |
| WO2023215810A1 (en) | 2022-05-05 | 2023-11-09 | Inhibrx, Inc. | Albumin-binding polypeptides and uses thereof |
| WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
| WO2023215740A1 (en) | 2022-05-06 | 2023-11-09 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
| US20240059799A1 (en) | 2022-05-11 | 2024-02-22 | Pfizer Inc. | Anti-tl1a antibodies and methods of use thereof |
| TW202402810A (zh) | 2022-05-11 | 2024-01-16 | 瑞士商赫孚孟拉羅股份公司 | 與ｖｅｇｆ—ａ及ｉｌ６結合之抗體及其使用方法 |
| WO2023218320A1 (en) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Anti-lymphotoxin beta receptor antibodies and methods of use thereof |
| TW202346368A (zh) | 2022-05-12 | 2023-12-01 | 德商安美基研究（慕尼黑）公司 | 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子 |
| WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| US20230374122A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody |
| WO2023223092A1 (en) | 2022-05-18 | 2023-11-23 | Institut Pasteur | Identification of a human circovirus |
| WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| WO2023225336A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| WO2023222886A1 (en) | 2022-05-20 | 2023-11-23 | Depth Charge Ltd | Antibody-cytokine fusion proteins |
| EP4279090A1 (en) | 2022-05-20 | 2023-11-22 | ADC Therapeutics SA | Composition comprising a pyrrolobenzodiazepine-based antibody drug conjugate |
| WO2023230448A1 (en) | 2022-05-23 | 2023-11-30 | Vir Biotechnology, Inc. | Combination immunotherapy for influenza |
| WO2023230445A2 (en) | 2022-05-23 | 2023-11-30 | Humabs Biomed Sa | Broadly neutralizing antibodies against influenza neuraminidase |
| WO2023230432A1 (en) | 2022-05-23 | 2023-11-30 | Inhibrx, Inc. | Dr5 agonist and iap antagonist combination therapy |
| WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
| GB202207691D0 (en) | 2022-05-25 | 2022-07-06 | Cambridge Entpr Ltd | Quinone protected forms and conjugates |
| WO2023228082A1 (en) | 2022-05-26 | 2023-11-30 | Pfizer Inc. | Anti-tnfr2 antibodies and methods of use thereof |
| WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
| US20240083991A1 (en) | 2022-05-31 | 2024-03-14 | Pfizer Inc. | Anti-bmp9 antibodies and methods of use thereof |
| WO2023235415A1 (en) | 2022-06-01 | 2023-12-07 | Genentech, Inc. | Method to identify a patient with an increased likelihood of chemotherapy-induced peripheral neuropathy |
| WO2023237431A1 (en) | 2022-06-07 | 2023-12-14 | Esocap Ag | Drug delivery system comprising an agent effective in the treatment or prevention of an esophageal disease for the application to esophageal mucous membranes |
| WO2023240201A1 (en) | 2022-06-08 | 2023-12-14 | Larimar Therapeutics, Inc. | Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome |
| WO2023239803A1 (en) | 2022-06-08 | 2023-12-14 | Angiex, Inc. | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same |
| WO2023240218A1 (en) | 2022-06-09 | 2023-12-14 | Allogene Therapeutics Inc. | Methods for detecting genomic abnormalities in cells |
| WO2023237663A1 (en) | 2022-06-09 | 2023-12-14 | Institut National de la Santé et de la Recherche Médicale | Use of the f359l missense irf4 variant for increasing the stability of regulatory t cells |
| WO2023240287A1 (en) | 2022-06-10 | 2023-12-14 | Bioentre Llc | Combinations of ctla4 binding proteins and methods of treating cancer |
| WO2023240216A1 (en) | 2022-06-11 | 2023-12-14 | Inhibrx, Inc. | Fcrn-binding polypeptides and uses thereof |
| WO2023245008A1 (en) | 2022-06-13 | 2023-12-21 | Genentech, Inc. | Methods of delaying or preventing the onset of alzheimer's disease using crenezumab |
| WO2023245048A1 (en) | 2022-06-15 | 2023-12-21 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
| WO2023245105A1 (en) | 2022-06-17 | 2023-12-21 | Genentech, Inc. | Use of kosmotropes to enhance yield of an affinity chromatography purification step |
| WO2023242769A1 (en) | 2022-06-17 | 2023-12-21 | Pfizer Inc. | Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof |
| WO2023250388A1 (en) | 2022-06-22 | 2023-12-28 | Voyager Therapeutics, Inc. | Tau binding compounds |
| WO2023246247A1 (zh) | 2022-06-22 | 2023-12-28 | 中山康方生物医药有限公司 | 药物组合物及其用途 |
| US20240043553A1 (en) | 2022-06-22 | 2024-02-08 | Genentech, Inc. | Methods for treatment of previously untreated follicular lymphoma with mosunetuzumab and lenalidomide |
| EP4296279A1 (en) | 2022-06-23 | 2023-12-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-transthyretin (ttr) binding proteins and uses thereof |
| WO2023250507A1 (en) | 2022-06-24 | 2023-12-28 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases |
| WO2024006876A1 (en) | 2022-06-29 | 2024-01-04 | Abbott Laboratories | Magnetic point-of-care systems and assays for determining gfap in biological samples |
| WO2024003114A1 (en) | 2022-06-29 | 2024-01-04 | Actome Gmbh | Detection of biomolecules in single cells |
| WO2024003310A1 (en) | 2022-06-30 | 2024-01-04 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of acute lymphoblastic leukemia |
| WO2024006472A1 (en) | 2022-06-30 | 2024-01-04 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
| WO2024006961A1 (en) | 2022-07-01 | 2024-01-04 | Neoleukin Therapeutics, Inc. | Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells |
| WO2024008274A1 (en) | 2022-07-04 | 2024-01-11 | Universiteit Antwerpen | T regulatory cell modification |
| WO2024008799A1 (en) | 2022-07-06 | 2024-01-11 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of proliferative glomerulonephritis |
| WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| WO2024013727A1 (en) | 2022-07-15 | 2024-01-18 | Janssen Biotech, Inc. | Material and methods for improved bioengineered pairing of antigen-binding variable regions |
| WO2024015993A1 (en) | 2022-07-15 | 2024-01-18 | Fibrogen, Inc. | Modified anti-galectin-9 antibody and uses thereof |
| WO2024015953A1 (en) | 2022-07-15 | 2024-01-18 | Danisco Us Inc. | Methods for producing monoclonal antibodies |
| WO2024020051A1 (en) | 2022-07-19 | 2024-01-25 | BioLegend, Inc. | Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same |
| WO2024018426A1 (en) | 2022-07-22 | 2024-01-25 | Janssen Biotech, Inc. | Enhanced transfer of genetic instructions to effector immune cells |
| EP4309733A1 (en) | 2022-07-22 | 2024-01-24 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Neutralization of acyl-coa binding protein for the treatment of cardiac dysfunction |
| WO2024018046A1 (en) | 2022-07-22 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Garp as a biomarker and biotarget in t-cell malignancies |
| US20240132622A1 (en) | 2022-07-22 | 2024-04-25 | Bristol-Myers Squibb Company | Antibodies Binding to Human PAD4 and Uses Thereof |
| WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
| WO2024026358A1 (en) | 2022-07-27 | 2024-02-01 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
| WO2024026411A1 (en) | 2022-07-27 | 2024-02-01 | Humabs Biomed Sa | Broadly neutralizing antibodies against rsv and mpv paramyxoviruses |
| US20240108744A1 (en) | 2022-07-27 | 2024-04-04 | Mediboston Limited | Auristatin derivatives and conjugates thereof |
| GB202210965D0 (en) | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
| WO2024023246A1 (en) | 2022-07-28 | 2024-02-01 | Philogen S.P.A. | Antibody binding to pd1 |
| WO2024026470A2 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:payload fusions and methods of use thereof |
| WO2024026447A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Anti-gpnmb antibodies and methods of use thereof |
| WO2024023283A1 (en) | 2022-07-29 | 2024-02-01 | Institut National de la Santé et de la Recherche Médicale | Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas |
| WO2024028794A1 (en) | 2022-08-02 | 2024-02-08 | Temple Therapeutics BV | Methods for treating endometrial and ovarian hyperproliferative disorders |
| WO2024030982A2 (en) | 2022-08-02 | 2024-02-08 | Diadem Spa | Device for detection and prognostic assessment of neurodegenerative disorders |
| WO2024030976A2 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
| WO2024030577A1 (en) | 2022-08-03 | 2024-02-08 | Seagen Inc. | Immunostimulatory anti-pd-l1-drug conjugates |
| WO2024028773A1 (en) | 2022-08-03 | 2024-02-08 | Pfizer Inc. | Anti- il27r antibodies and methods of use thereof |
| WO2024028732A1 (en) | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Cd98 binding constructs for treating brain tumors |
| WO2024033362A1 (en) | 2022-08-08 | 2024-02-15 | Atb Therapeutics | Humanized antibodies against cd79b |
| WO2024036139A2 (en) | 2022-08-09 | 2024-02-15 | Qlsf Biotherapeutics, Inc. | Antibodies binding to clec12a |
| WO2024033400A1 (en) | 2022-08-10 | 2024-02-15 | Institut National de la Santé et de la Recherche Médicale | Sk2 inhibitor for the treatment of pancreatic cancer |
| WO2024033399A1 (en) | 2022-08-10 | 2024-02-15 | Institut National de la Santé et de la Recherche Médicale | Sigmar1 ligand for the treatment of pancreatic cancer |
| EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
| WO2024039670A1 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against cldn4 and methods of use thereof |
| WO2024039672A2 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
| WO2024040090A1 (en) | 2022-08-16 | 2024-02-22 | Allogene Therapeutics Inc. | In vitro method for inhibiting hhv-6 infection |
| WO2024038183A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
| WO2024038165A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Ltd | T cell receptor fusion proteins specific for mage a4 |
| WO2024040114A2 (en) | 2022-08-18 | 2024-02-22 | BioLegend, Inc. | Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same |
| WO2024038186A1 (en) | 2022-08-19 | 2024-02-22 | Medimmune Limited | Treatment of acute respiratory failure |
| WO2024040216A2 (en) | 2022-08-19 | 2024-02-22 | Fibrogen, Inc. | Anti-ccr8 antibodies and uses thereof |
| WO2024044687A1 (en) | 2022-08-26 | 2024-02-29 | Valo Health, Inc. | Biomarker combinations for prognosis and management of diabetic retinopathy |
| WO2024047110A1 (en) | 2022-08-31 | 2024-03-07 | Institut National de la Santé et de la Recherche Médicale | Method to generate more efficient car-t cells |
| WO2024049949A1 (en) | 2022-09-01 | 2024-03-07 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
| WO2024050524A1 (en) | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
| WO2024052318A1 (en) | 2022-09-06 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies |
| WO2024054929A1 (en) | 2022-09-07 | 2024-03-14 | Dynamicure Biotechnology Llc | Anti-vista constructs and uses thereof |
| CN117679505A (zh) | 2022-09-09 | 2024-03-12 | 中山康方生物医药有限公司 | 药物组合及用途 |
| WO2024056668A1 (en) | 2022-09-12 | 2024-03-21 | Institut National de la Santé et de la Recherche Médicale | New anti-itgb8 antibodies and its uses thereof |
| WO2024059183A1 (en) | 2022-09-14 | 2024-03-21 | President And Fellows Of Harvard College | Methods and compositions for modulation of piezo1 in the treatment of cancer |
| WO2024059675A2 (en) | 2022-09-14 | 2024-03-21 | Amgen Inc. | Bispecific molecule stabilizing composition |
| WO2024059739A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
| WO2024062019A1 (en) | 2022-09-21 | 2024-03-28 | Synabs | Anti-ccr8 antibodies and uses thereof |
| US20240101691A1 (en) | 2022-09-21 | 2024-03-28 | Sanofi Biotechnology | Humanized anti-il-1r3 antibody and methods of use |
| WO2024062420A1 (en) | 2022-09-22 | 2024-03-28 | Pfizer Inc. | METHODS OF TREATMENT WITH IFNß ANTIBODIES |
| WO2024068996A1 (en) | 2022-09-30 | 2024-04-04 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection |
| WO2024074498A1 (en) | 2022-10-04 | 2024-04-11 | Imcheck Therapeutics | Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer |
| WO2024074571A1 (en) | 2022-10-05 | 2024-04-11 | Institut National de la Santé et de la Recherche Médicale | Dc-targeting vaccine against nipah virus infection |
| WO2024074649A1 (en) | 2022-10-05 | 2024-04-11 | Alcea Therapeutics, Inc. | Notch4 antibodies, compositions, and methods for treating airway inflammation |
| WO2024077044A1 (en) | 2022-10-05 | 2024-04-11 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
| WO2024077239A1 (en) | 2022-10-07 | 2024-04-11 | Genentech, Inc. | Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies |
| WO2024079192A1 (en) | 2022-10-12 | 2024-04-18 | Institut National de la Santé et de la Recherche Médicale | Cd81 as a biomarker and biotarget in t-cell malignancies |
| GB202215115D0 (en) | 2022-10-13 | 2022-11-30 | Univ Nottingham | VEGF antibodies |
| WO2024079310A1 (en) | 2022-10-14 | 2024-04-18 | Ebbil, Ltd. | Sil-6r and ctgf binding proteins and methods of use thereof |
| WO2024086796A1 (en) | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
| WO2024084052A1 (en) | 2022-10-21 | 2024-04-25 | Novimmune Sa | Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation |
| WO2024089417A1 (en) | 2022-10-24 | 2024-05-02 | Memorial Sloan-Kettering Cancer Center | Tumour stratification for responsiveness to an immune checkpoint inhibitor |
| WO2024089418A1 (en) | 2022-10-24 | 2024-05-02 | Cancer Research Technology Limited | Tumour sensitisation to checkpoint inhibitors with redox status modifier |
| WO2024089551A1 (en) | 2022-10-25 | 2024-05-02 | Janssen Biotech, Inc. | Msln and cd3 binding agents and methods of use thereof |
| WO2024091991A1 (en) | 2022-10-25 | 2024-05-02 | Genentech, Inc. | Therapeutic and diagnostic methods for multiple myeloma |
| WO2024091437A1 (en) | 2022-10-25 | 2024-05-02 | Merck Sharp & Dohme Llc | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof |
| WO2024089180A1 (en) | 2022-10-26 | 2024-05-02 | Eximmium Biotechnologies Gmbh | Method to determine extracellular vesicle recovery |
| WO2024097796A1 (en) | 2022-11-02 | 2024-05-10 | Kira Pharmaceuticals (Us) Llc | Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases |
| WO2024097441A1 (en) | 2022-11-02 | 2024-05-10 | Kira Pharmaceuticals (Us) Llc | Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases |
| WO2024098002A1 (en) | 2022-11-04 | 2024-05-10 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
| WO2024102734A1 (en) | 2022-11-08 | 2024-05-16 | Genentech, Inc. | Compositions and methods of treating childhood onset idiopathic nephrotic syndrome |
| WO2024100200A1 (en) | 2022-11-09 | 2024-05-16 | Cis Pharma Ag | Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications |
| US20240173426A1 (en) | 2022-11-14 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
| US20240158515A1 (en) | 2022-11-14 | 2024-05-16 | Regeneron Pharmaceuticals, Inc. | Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof |
| WO2024105205A1 (en) | 2022-11-17 | 2024-05-23 | Bayer Aktiengesellschaft | Antibody-drug conjugates (a2dcs) with enzymatically cleavable groups |
| WO2024105244A1 (en) | 2022-11-18 | 2024-05-23 | Universiteit Antwerpen | Igfbp2 as biomarker for thoracic aortic aneurysm and dissections |
| WO2024108178A1 (en) | 2022-11-18 | 2024-05-23 | Genentech, Inc. | Signal amplification and multiplexing using mass tags for ia-lc-ms/ms based assays |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6050089A (ja) * | 1983-08-27 | 1985-03-19 | 浅山 金吾 | ２輪車用ブレ−キ装置 |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
| GB1594097A (en) | 1976-12-16 | 1981-07-30 | Int Inst Of Differentiation | Production of specific immune nucleic acids cell dialysates and antibodies |
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US5583013A (en) | 1977-11-08 | 1996-12-10 | Genentech, Inc. | Method and means for microbial polypeptide expression |
| US5420020A (en) | 1977-11-08 | 1995-05-30 | Genentech, Inc. | Method and means for microbial polypeptide expression |
| US4704362A (en) * | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4366246A (en) | 1977-11-08 | 1982-12-28 | Genentech, Inc. | Method for microbial polypeptide expression |
| US4565785A (en) | 1978-06-08 | 1986-01-21 | The President And Fellows Of Harvard College | Recombinant DNA molecule |
| US4342832A (en) | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
| US4431740A (en) | 1979-09-12 | 1984-02-14 | The Regents Of The University Of California | DNA Transfer vector and transformed microorganism containing human proinsulin and pre-proinsulin genes |
| US4418149A (en) | 1980-01-10 | 1983-11-29 | President And Fellows Of Harvard College | Fused hybrid gene |
| GB2068969B (en) | 1980-02-05 | 1983-07-27 | Upjohn Co | Gene expression |
| US6455275B1 (en) | 1980-02-25 | 2002-09-24 | The Trustees Of Columbia University In The City Of New York | DNA construct for producing proteinaceous materials in eucaryotic cells |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4348376A (en) | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
| US4370417A (en) | 1980-04-03 | 1983-01-25 | Abbott Laboratories | Recombinant deoxyribonucleic acid which codes for plasminogen activator |
| NZ196706A (en) | 1980-04-03 | 1988-01-08 | Biogen Nv | Dna sequences, recombinant dna molecules and processes for producing fibroblast interferon-like polypeptides; pharmaceutical and veterinary compositions |
| ZA811895B (en) | 1980-04-07 | 1982-04-28 | Univ California | Expression of hormone genomic clones |
| US4338397A (en) | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
| US4510244A (en) | 1980-04-17 | 1985-04-09 | The Board Of Trustees Of The Leland Stanford Jr. University | Cell labeling with antigen-coupled microspheres |
| GR74282B (ja) | 1980-06-06 | 1984-06-21 | Biogen Nv | |
| JPS57502090A (ja) | 1980-07-18 | 1982-11-25 | ||
| US4668629A (en) | 1980-07-18 | 1987-05-26 | The Board Of Trustees Of Leland Stanford Jr. University | Human hybridomas, precursors and products |
| US4403036A (en) | 1980-12-02 | 1983-09-06 | University Of Iowa Research Foundation | Genetic reagents for generating plasmids containing multiple copies of DNA segments |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ199391A (en) | 1981-01-02 | 1985-12-13 | Genentech Inc | Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin |
| EP0057107A3 (en) * | 1981-01-28 | 1982-11-10 | Coats Patons Plc | Method of manufacturing monoclonal antibodies and cells capable of manufacturing such antibodies |
| NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US5137721A (en) | 1981-03-09 | 1992-08-11 | Cetus Corporation | Employing strains of E. coli expressing non-indigenous adhesins and toxoids of E. coli |
| US4495280A (en) | 1981-05-20 | 1985-01-22 | The Board Of Trustees Of The Leland Stanford Jr. University | Cloned high signal strength promoters |
| US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4792447A (en) | 1981-07-23 | 1988-12-20 | Board Of Regents, The University Of Texas System | Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors |
| ZW18282A1 (en) * | 1981-08-31 | 1983-03-23 | Genentech Inc | Preparation of polypeptides in vertebrate cell culture |
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4444878A (en) * | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| DE3382317D1 (de) | 1982-03-15 | 1991-07-25 | Schering Corp | Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer. |
| US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| AR241654A1 (es) | 1982-05-05 | 1992-10-30 | Genentech Inc | Procedimiento para producir activador de plasminogeno de tejido humano. |
| US4500637A (en) | 1982-07-19 | 1985-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | Prevention of graft versus host disease following bone marrow transplantation |
| JPS5944399A (ja) | 1982-09-07 | 1984-03-12 | Takeda Chem Ind Ltd | 新規ｄｎａ |
| US4599197A (en) | 1982-12-22 | 1986-07-08 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4511502A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4512922A (en) * | 1982-12-22 | 1985-04-23 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4965196A (en) | 1983-01-19 | 1990-10-23 | Genentech, Inc. | Polycistronic expression vector construction |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) * | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| EP0196864A3 (en) | 1985-03-25 | 1988-03-23 | Cetus Corporation | Alkaline phosphatase-mediated processing and secretion of recombinant proteins, dna sequences for use therein and cells transformed using such sequences |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
| DE3689123T2 (de) * | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| JPS62201581A (ja) | 1986-02-28 | 1987-09-05 | Rikagaku Kenkyusho | 新規プラスミド、微生物細胞及びヒト免疫グロブリンＧ Ｆｃ領域蛋白質の製造方法 |
| EP0234592A1 (en) | 1986-02-28 | 1987-09-02 | Teijin Limited | Plasmid containing DNA fragment coding for human immunoglobulin G Fc region protein and use thereof for production of said protein |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| NO873164L (no) | 1986-07-30 | 1988-02-01 | Teijin Ltd | Muse-humane kimaere antistoffer. |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| CA1341235C (en) | 1987-07-24 | 2001-05-22 | Randy R. Robinson | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| DE3744595A1 (de) | 1987-12-31 | 1989-07-13 | Andreas Dr Plueckthun | Verfahren zur gentechnischen herstellung von antikoerpern |
| US5965405A (en) | 1988-04-16 | 1999-10-12 | Celltech Limited | Method for producing Fv fragments in eukaryotic cells |
| JP2935520B2 (ja) | 1988-10-19 | 1999-08-16 | ザ ダウ ケミカル カンパニー | ガン治療に用いられる新規高親和性改変抗体系統群 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5098833A (en) | 1989-02-23 | 1992-03-24 | Genentech, Inc. | DNA sequence encoding a functional domain of a lymphocyte homing receptor |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5081235A (en) | 1989-07-26 | 1992-01-14 | City Of Hope | Chimeric anti-cea antibody |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| JPH06508133A (ja) | 1991-05-31 | 1994-09-14 | ジェネンテク，インコーポレイテッド | Ｈｉｖに関連した免疫性の血小板減少性紫斑病の治療 |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| WO1994009363A1 (en) | 1992-10-14 | 1994-04-28 | Board Of Regents, The University Of Texas System | Cancer diagnosis and therapy |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| EP0714409A1 (en) * | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| US5561053A (en) | 1994-08-05 | 1996-10-01 | Genentech, Inc. | Method for selecting high-expressing host cells |
| US6979556B2 (en) | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
-
1983
- 1983-04-08 US US06/483,457 patent/US4816567A/en not_active Expired - Lifetime
- 1983-04-28 KR KR1019830001806A patent/KR840008264A/ko not_active Application Discontinuation
-
1984
- 1984-04-04 NZ NZ222543A patent/NZ222543A/en unknown
- 1984-04-04 NZ NZ207746A patent/NZ207746A/en unknown
- 1984-04-04 AU AU26429/84A patent/AU598441B2/en not_active Expired
- 1984-04-04 NZ NZ222542A patent/NZ222542A/en unknown
- 1984-04-05 ZA ZA842583A patent/ZA842583B/xx unknown
- 1984-04-05 DK DK198401796A patent/DK174048B1/da not_active IP Right Cessation
- 1984-04-05 IE IE840/84A patent/IE57198B1/en not_active IP Right Cessation
- 1984-04-06 DE DE8484302368T patent/DE3484664D1/de not_active Expired - Lifetime
- 1984-04-06 KR KR1019840001806A patent/KR840008693A/ko not_active Application Discontinuation
- 1984-04-06 JP JP06987484A patent/JP3162055B2/ja not_active Expired - Lifetime
- 1984-04-06 ES ES531372A patent/ES531372A0/es active Granted
- 1984-04-06 IL IL7145584A patent/IL71455A/en not_active IP Right Cessation
- 1984-04-06 AT AT84302368T patent/ATE64151T1/de not_active IP Right Cessation
- 1984-04-06 EP EP84302368A patent/EP0125023B2/en not_active Expired - Lifetime
- 1984-04-09 CA CA000451580A patent/CA1218613A/en not_active Expired
-
1988
- 1988-06-10 US US07/205,419 patent/US6331415B1/en not_active Expired - Lifetime
-
1990
- 1990-03-20 AU AU52013/90A patent/AU639910B2/en not_active Expired
-
1992
- 1992-10-15 DK DK126292A patent/DK170895B1/da not_active IP Right Cessation
-
1994
- 1994-10-05 JP JP6241576A patent/JPH07194384A/ja active Pending
- 1994-10-05 JP JP24156594A patent/JP3559795B2/ja not_active Expired - Lifetime
- 1994-11-17 HK HK129394A patent/HK129394A/xx not_active IP Right Cessation
-
1995
- 1995-02-17 CY CY179395A patent/CY1793A/xx unknown
- 1995-04-13 US US08/422,187 patent/US7923221B1/en not_active Expired - Fee Related
-
2001
- 2001-04-03 JP JP2001104856A patent/JP2001346591A/ja active Pending
- 2001-04-03 JP JP2001104857A patent/JP2001346592A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6050089A (ja) * | 1983-08-27 | 1985-03-19 | 浅山 金吾 | ２輪車用ブレ−キ装置 |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010539911A (ja) * | 2007-09-24 | 2010-12-24 | ウーデ ゲゼルシャフト ミット ベシュレンクテル ハフツング | アミンでの発酵及び抽出により乳酸を製造する方法 |
| WO2009119794A1 (ja) | 2008-03-27 | 2009-10-01 | タカラバイオ株式会社 | 感染症予防、治療剤 |
| WO2010013498A1 (ja) | 2008-08-01 | 2010-02-04 | 学校法人聖マリアンナ医科大学 | 変形性関節症治療剤又は予防剤 |
| WO2011093081A1 (ja) | 2010-01-29 | 2011-08-04 | Ａｘｉｓ株式会社 | 変形性関節症治療剤を含有する注射剤 |
| WO2011093082A1 (ja) | 2010-01-29 | 2011-08-04 | Ａｘｉｓ株式会社 | 変形性関節症治療剤または予防剤を製造するための使用 |
| WO2011093083A1 (ja) | 2010-01-29 | 2011-08-04 | Ａｘｉｓ株式会社 | 変形性関節症治療又は予防用医薬組成物及びその製造方法 |
| US9200077B2 (en) | 2010-01-29 | 2015-12-01 | Axis, Inc. | Injectable solution containing therapeutic agent for osteoarthritis |
| WO2012005076A1 (ja) | 2010-07-08 | 2012-01-12 | 本田技研工業株式会社 | 高周波加熱用コイル |
| WO2014021339A1 (ja) | 2012-07-30 | 2014-02-06 | 国立大学法人名古屋大学 | ヒトミッドカインに対するモノクローナル抗体 |
| WO2014042251A1 (ja) | 2012-09-13 | 2014-03-20 | 中外製薬株式会社 | 遺伝子ノックイン非ヒト動物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH07194384A (ja) | 免疫グロブリンｄｎａ含有発現ベクター及び組換え宿主細胞 | |
| JP2882775B2 (ja) | ヒトーグリア由来神経突起因子 | |
| EP0521996B1 (en) | Catalytic antibody components | |
| JPH03505397A (ja) | インスリン様成長因子結合タンパク質の製造 | |
| HU196842B (en) | Process for producing hybrid dna and bonding composition comprising the same | |
| EP0365997B1 (en) | A novel family of high affinity, modified antibodies for cancer treatment | |
| JPH06502762A (ja) | フレームワーク変異抗体およびそれらの調製物 | |
| JP2637393B2 (ja) | プロインシュリンおよびプレプロインシュリン産生暗号を有するヒト遺伝子 | |
| JPH07504802A (ja) | 遺伝子操作抗体 | |
| US5658753A (en) | Catalytic antibody components | |
| EP0227110B1 (en) | Human immunoglobulin g fc region protein and production thereof | |
| JP2753274B2 (ja) | モチリン様ポリペプチドの製法並びにそのための組換えｄｎａ及び発現用プラスミド | |
| JPH05317050A (ja) | Ｐｚｐ−４遺伝子及び避妊ワクチン | |
| IL99507A (en) | Preparation of antigen-specific immunoglobulins known in a transformed host cell, vectors and transformed cells using it | |
| FI103477B (fi) | Menetelmä terapeuttisesti käyttökelpoisen vasta-aineen tai vasta-ainef ragmentin valmistamiseksi | |
| WO1996003434A1 (fr) | Facteur de differenciation/proliferation de megacaryocytes | |
| JPS62190083A (ja) | ポリペプチド発現ベクタ−、該ベクタ−で形質転換した宿主及び該宿主によるポリペプチドの製造法 | |
| HU210608A9 (hu) | Inzulinszerű növekedési faktort kötő protein, valamint a proteint tartalmazó gyógyszerkészítmények Az átmeneti oltalom az 1-7. igénypontokra vonatkozik. | |
| KR890002397A (ko) | 하이브리드 인터페론 및 그의 제조방법 |